<SEC-DOCUMENT>0001558370-21-011244.txt : 20210811
<SEC-HEADER>0001558370-21-011244.hdr.sgml : 20210811
<ACCEPTANCE-DATETIME>20210811114609
ACCESSION NUMBER:		0001558370-21-011244
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210811
DATE AS OF CHANGE:		20210811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		211162604

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>gmab-20210630x6k.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7811.37134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/11/2021 3:41:08 PM -->
      <!-- iXBRL Library version: 1.0.7811.37150 -->
      <!-- iXBRL Service Job ID: 4358e0f9-a190-49df-a10e-3a169892d159 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:gmab="http://www.genmab.com/20210630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:EntityCentralIndexKey" id="Tc_lachAVH9CEeZhg1Q7RLNrw_2_1">0001434265</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:CurrentFiscalYearEndDate" id="Tc_rZOD-FyHd02Q1btUTgGilA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:DocumentFiscalYearFocus" id="Tc_7BjP4jCIvUaRrOhjSivKwg_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:DocumentFiscalPeriodFocus" id="Tc_K0PRgFc-BEmJkGA7aau2hw_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:AmendmentFlag" id="Tc_qqTsQ23MYUmJaV9f9Q0RAw_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:EntityRegistrantName" id="Tc_19P3lYK10U2_hHkCJUFi-w_7_1">Genmab A/S</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:DocumentType" id="Tc_FrVqi3K7m06yn_PA2gcWEw_8_1">6-K</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="dei:DocumentPeriodEndDate" id="Tc_ilA1Dtog2EOMdcDD0DdZkQ_9_1">2021-06-30</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="gmab-20210630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember__kp1XyJRaEqpMiDAX0T8vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_AqtNH3bYz0emLMQ_xHz5lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_YxEM9iziHkO-obYvfBGHEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_Vnp4zSnt40qzvspJ2EGkFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_PwANnCyzn0C5MUS8nwx1Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_Jx4QuMwJkUqCuFfiBGwvYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_ZaPHCufkHU64vY8arktfIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_l8NTH0WDpEq0wlqXAMBCwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_qY9lpk9pk02Tfs4Fh-iqBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_VCedgugRDUuAx52NFUHvig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_BPVE7vPNz0u0Ekx3yAqzWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_VeITHDP1a0WhA62xDHpgQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_Tn5RwvlkRUSHrBhAtsMlIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_DYo9Pa8mmEeHldxkY2EtIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_uqBDRnrgSEiaSoEvBB_vhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_D2_7lyccvkaTuObCOVPGJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_lb_1v3MJVUOVzAmVqtUJ_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:OtherCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_m1JCpHXO-kyYxFku-zvTnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_n6OJ6Akl1USS7Gay7gozVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_NrXt0j_za0WkwizDvCEL2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_rRkDJdMjTUWStzjCszxcAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_r5jbLSw0x0GSS0r6RF8nrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_XoWF9GDwvkauQCs4eAuD6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_i0YAdPafokSkZiDf9ElCYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_XkMrksxnsESH9AlVnJk8Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_OY8O9iGctkKqyFaG0cKc5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_mh6YfnyyLUOtHNXoweh8Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:BoltBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_oRQeDeA0OUCUPKU1Y5V9-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hGOPQ12jT0ecOSLSOn671A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L6h4ixqJq0SJo8Qw1UTTOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_l6TS3ZYOmUeez0G-_bZVGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Y6PESuh_w0ChCcbF0c5LwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_iIgp3bLrT0WdC_XUJJoNxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_EgSoxPtT_kqpSjaUbjg4YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_HrDvCApT5Uq1RhvNtNXV-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_fnkpZL-bskSS4uB8m0uSdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_DodsJRF0NEOqpd0-8JQNgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Rqd-AfD3wEytE2ZCSjiHNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_8tHM7VtXkUuk3JpNpYCVqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_c3PLtVVYzU-uGuMkstgoXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember__pM2AyC5skGhYxOaXLPg1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fAcxKfHxzk-3GSCXEGeVWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1qraLfsZLEOjAsD-dxenzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4NLivLW-z0mqDErSzXuYzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_CtJaR3tu706WU9cIhYOn4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_-07AYjBjOk67K2am_lv-cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SgqnYnfln0me5bps_X9-Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_mais4ePNskeTkgOGq_-lGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_A0Jfc6FGgUWtNsve74S7sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_qA8435Q28E6nAiBn6iJsFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_NmzONsVw20-JjLot4LBL5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_TKZcta72hkC3Gvhut1vakg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L4KIMTzqKkag3QB7vZbfEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_PAZySbIZoEaim7Pchrrdtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1TQAORpB002CwFlwkSY-8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_p1Fn9MmXZ0mJDu3DNDH-CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_arkOpJJSzEOXHp0JsMegrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8pQrFQMD0keUvx5gLpDr7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_OIs20y9YdUCpESyQhSl9AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8DR9RGN4mk6fMGFsM-lTeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_AXjT64eEiUCHnI3_V_FM8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_UJmiHgLlu06muPRZ5PWz-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_A_sHaM7Ykki3oxBQqJ10GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_3MA1mpKA4kSpw8AfLI3utA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_eRyWOdr0U0arOAxOzCgi-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-10</xbrli:startDate><xbrli:endDate>2020-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2021_To_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_J6YNADjInUKuD19rDW3Jyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-23</xbrli:startDate><xbrli:endDate>2021-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_sribKozRAUu_07Nu947Axw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_K2gHqglzhkiiSSYKd-yiaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_b1nEv0AoyUCoV8jNBI30Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_OZ08P4IEB0-J1srEa0iG7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_lu3v55zbDES12yHJmhVJ7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gmab:TripleaRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_MCTqYNYF1kymMnq9M9KqFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_qlEizQljAU-i-kzexaRMsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_p0VWrcAFBkKEYD1w7sMfZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_FGZXpaWuR0uGlP1dW_5pEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_wD9EUBzhJkWAnxVwt1BN_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_YXgvtwoFbEya6zUeGSPkMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_S4o242eUzEC8Lsv54F5WNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_XnjM0c4Pf0-AfdDAV6Byxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_YbHFH-aRiUOdag_c24OEXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2016_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_ESq4TWsOUU-_fQutYyImDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_tqrSzrvaIkWs3_xaEgi0Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_x8IPZU4fukqM5g_XH7UpIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_ifrs-full_PerformanceObligationsAxis_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_ilvsRwJsmUW_LnWzSnv9Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-10</xbrli:startDate><xbrli:endDate>2020-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ"><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ"><xbrli:measure>gmab:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_MZ_DR3Sd-0iNndMFiKqHcQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA"><xbrli:measure>gmab:EquityInstruments</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_2aa72704_f794_4e83_b8e3_8844b70c4c7b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#xA0;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#x200B;</span><br /></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#xA0;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#xA0;13a-16 OR&#xA0;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#xA0;MONTH OF AUGUST 2021</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S<br /></b><span style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Exact name of Registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Kalvebod Brygge 43</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1560 Copenhagen V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28<br /></b><span style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">(Address of principal executive offices)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#xA0;20-F or&#xA0;Form&#xA0;40-F.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#xA0;20-F&#xA0;</span><span style="font-family:'Times New Roman';">&#x2327;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#xA0;40-F&#xA0;</span><span style="font-family:'Times New Roman';font-size:10pt;">&#x25FB;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#xA0;6-K in paper as permitted by Regulation&#xA0;S-T Rule&#xA0;101(b)(1)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#xA0;</span><span style="font-family:'Times New Roman';font-size:10pt;">&#x25FB;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#xA0;</span><span style="font-family:'Times New Roman';">&#x2327;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#xA0;6-K in paper as permitted by Regulation&#xA0;S-T Rule&#xA0;101(b)(7)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#xA0;</span><span style="font-family:'Times New Roman';font-size:10pt;">&#x25FB;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#xA0;</span><span style="font-family:'Times New Roman';">&#x2327;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;">Exhibit 99.1 to this report on Form&#xA0;6-K&#xA0;shall be deemed to be&#xA0;</span>incorporated by reference<span style="background-color:#ffffff;">&#xA0;in Genmab A/S&#x2019;s registration statement on&#xA0;</span><span style="background-color:#ffffff;">Form&#xA0;S-8</span><span style="background-color:#ffffff;">&#xA0;(File&#xA0;No.&#xA0;333-232693)&#xA0;and in the outstanding prospectus contained in such registration statement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_ae1b4f6e_5931_4918_b39a_881d28f4f8e4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">BY:</span></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: August 11, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p><a id="_d6085548_b2d0_4d3b_9bf4_f8438f4b8ef5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#xA0;INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:96.42%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">A</b></p></div></div></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';text-decoration:underline;text-decoration-color:#000000;">Exhibit</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';text-decoration:underline;text-decoration-color:#000000;">Description of Exhibit</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">99.1</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Interim Report Dated August 11, 2021</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.INS</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Instance Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.SCH</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Schema Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.CAL</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.DEF</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Definition Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.LAB</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Labels Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.PRE</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gmab-20210630xex991d85adb.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7811.37134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/11/2021 3:41:22 PM -->
      <!-- iXBRL Library version: 1.0.7811.37150 -->
      <!-- iXBRL Service Job ID: 4358e0f9-a190-49df-a10e-3a169892d159 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:gmab="http://www.genmab.com/20210630" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="gmab-20210630.xsd"></link:schemaRef></ix:references><ix:resources></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#xA0;99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Genmab Announces Financial Results for the First Half of 2021 </b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_Hlk45803746"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="color:#029c93;font-weight:bold;">August 11, 2021; Copenhagen, Denmark; </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim Report for the First Half of 2021</p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Highlights</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application (BLA), for patients with recurrent or metastatic cervical cancer</b></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;text-align:left;top:0pt;vertical-align:top;">&#xAE;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;"> net sales increased 52% compared to the first half of 2020 to USD 2,798 million, resulting in royalty income of DKK 2,360 million </b></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Following a positive CHMP opinion, Janssen-Cilag International NV received European Marketing Authorization for DARZALEX SC (daratumumab and hyaluronidase-fihj) for adult patients with newly diagnosed light-chain (AL) amyloidosis </b></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Genmab improves its 2021 financial guidance</b></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#x201C;Genmab&#x2019;s antibody expertise and innovation were on display during the second quarter of 2021 with the U.S. FDA&#x2019;s acceptance for priority review of the BLA for tisotumab vedotin, which we are developing with Seagen, and with the approval of Janssen&#x2019;s RYBREVANT&#x2122; (amivantamab-vmjw), the first regulatory approval for a product created using Genmab&#x2019;s proprietary DuoBody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup> technology platform. The majority of Genmab&#x2019;s clinical stage products are based on our DuoBody technology, and we hope that the approval of RYBREVANT is just the first validation of many of the potential for this technology to create effective treatments for patients with cancer,&#x201D; said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. </p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Financial Performance First Half of 2021</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Net sales of DARZALEX by Janssen Biotech, Inc. (Janssen) were USD 2,798 million in the first half of 2021 compared to USD 1,838 million in the first half of 2020, an increase of USD 960 million, or 52%. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Royalty revenue was DKK 2,595 million in the first half of 2021 compared to DKK 1,738 million in the first half of 2020, an increase of DKK 857 million, or 49%. The increase was driven by higher net sales of DARZALEX, TEPEZZA</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and Kesimpta</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> resulting in higher royalties.</span></td></tr></table><a id="_Hlk527456255"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Total revenue for the first half of 2021 was DKK 3,553 million. In addition to the royalty revenue described above, Genmab also recognized DKK 731 million of milestone revenue during the first half of 2021. Revenue for the first half of 2020 was DKK 6,343 million </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">and included the one-time upfront payment of DKK 4,398 million recognized as license revenue from AbbVie Inc. (AbbVie) pursuant to our collaboration announced in June 2020.</span></td></tr></table><a id="_Hlk527456303"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating expenses were DKK 2,234 million in the first half of 2021 compared to DKK 1,775 million in the first half of 2020. The increase of DKK 459 million, or 26%, was driven by the continued advancement of multiple pipeline projects, and the increase in new employees to support the expansion of our product pipeline and building our commercialization capabilities and broader organizational infrastructure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating result was DKK 1,319 million in the first half of 2021 compared to DKK 4,568 million in the first half of 2020. The decrease of DKK 3,249 million, or 71%, was driven by lower revenue as a result of the non-recurring license revenue in 2020 and increased operating expenses.</span></td></tr></table><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Outlook</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is improving its 2021 financial guidance published on February 23, 2021, driven primarily by increased royalty revenue related to the net sales of DARZALEX.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><a id="_4d78a304_37fd_4caa_981e_6b975370e4a7"></a><a id="_7ab37525_b72f_4239_b296_798a7d3d2904"></a><a id="_2e101b06_6dee_4fdb_a032_7465f739db93"></a><a id="_ed6ca4d5_9960_4999_a0c2_bdb55316269e"></a><a id="_20e2a9ce_7b63_4285_8047_bd3af030239e"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Genmab Announces Financial Results for the First Half of 2021 </b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Previous</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">7,300 - 7,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6,800 - 7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(5,500) - (5,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(5,500) - (5,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating result</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">1,500 - 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">1,000 - 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr></table><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Conference Call</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab will hold a conference call to discuss the results for the first half of 2021 today, Wednesday, August 11, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT. To join the call dial </p><a id="OLE_LINK3"></a><a id="OLE_LINK4"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">+1 631 913 1422 (U.S. participants) or +44 3333 000804 (international participants) and provide conference code 78377092.<br /><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investors.</p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Contact:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Marisol Peron, Senior Vice President, Global Investor Relations and Communications </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">T: +1 609 524 0065; E: <span style="color:#029c93;">mmp@genmab.com</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">For Investor Relations:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Andrew Carlsen, Vice President, Head of Investor Relations</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">T: +45 3377 9558; E: <span style="color:#029c93;">acn@genmab.com</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><a id="_2ac28155_17b9_405f_a869_c67bf8a0b169"></a><a id="_0605cb69_7080_4e02_9fd4_37c3dafdbbd9"></a><a id="_3896ab70_00e0_459f_a89f_df84d4f7e098"></a><a id="_57c918f6_18e1_4e22_8682_c1992d54387c"></a><a id="_a126cc5f_d4c3_4594_9722_5f161797a5a2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="TOC"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin:0pt;">M</p></div></div></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">MANAGEMENT&#x2018;S REVIEW</p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#CONSOLIDATEDKEYFIGURES_545330"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">CONSOLIDATED KEY FIGURES</span></a><span style="font-size:11pt;"> </span></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">4</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#OUTLOOK_98518"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">OUTLOOK</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">5</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#KEY2019PRIORITIES_54601"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">KEY 2021 PRIORITIES</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#PRODUCTPIPELINEANDTECHNOLOGYPROGRESSFIRS"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">PRODUCT PIPELINE AND TECHNOLOGY PROGRESS FIRST HALF OF 2021</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#SIGNIFICANTRISKSANDUNCERTAINTIES_402181"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">SIGNIFICANT RISKS AND UNCERTAINTIES</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">15</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#FINANCIALREVIEW_920877"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">FINANCIAL REVIEW</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">16</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><b style="color:#029c93;font-weight:bold;">FINANCIAL STATEMENTS</b></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#COMPREHENSIVEINCOME_677212"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">STATEMENT OF COMPREHENSIVE INCOME FOR THE 2ND QUARTER OF 2021</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">21</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#_STATEMENT_OF_COMPREHENSIVE"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">STATEMENT OF COMPREHENSIVE INCOME FOR THE FIRST HALF OF 2021</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">22</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#BALANCESHEET_971090"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">BALANCE SHEET AS OF JUNE 30, 2021</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">23</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#CASHFLOWS_342842"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">STATEMENT OF CASH FLOWS FOR THE FIRST HALF OF 2021</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">24</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#CHANGESINEQUITY_5054"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">STATEMENT OF CHANGES IN EQUITY FOR THE FIRST HALF OF 2021</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">25</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><a href="#NOTESTOTHEFINANCIALSTATEMENTS_725525"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">NOTES&#xA0;TO THE FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">26</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><a href="#ABOUTGENMAB_779230"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">ABOUT GENMAB</b></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">34</span></p></td></tr><tr><td style="vertical-align:top;width:94.83%;margin:0pt;padding:0pt;"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><a href="#DIRECTORSANDMANAGEMENTSSTATEMENTONTHEINT"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">DIRECTORS&#x2019; AND MANAGEMENT&#x2019;S STATEMENT ON THE INTERIM REPORT</b></a></p></td><td style="vertical-align:top;width:5.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="font-size:11pt;">35</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 3/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="CONSOLIDATEDKEYFIGURES_545330"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt;">CONSOLIDATED KEY FIGURES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2nd Quarter of</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2nd Quarter of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Full Year</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2021</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,972</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,451</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,553</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,343</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,111</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (921)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (775)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,769)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,490)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,137)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (264)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (179)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (465)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (285)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (661)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,185)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (954)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,234)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,775)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,798)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Operating result</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 787</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,497</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,319</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,568</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,313</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net financial items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (365)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (169)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 527</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (409)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net result</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 306</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,378</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,402</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,758</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance Sheet</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cash position*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,875</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,875</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,079</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,179</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,542</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,179</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,542</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,352</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,483</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,683</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,483</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,683</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,143</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Shareholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,252</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,871</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,252</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,871</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,121</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flow Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cash flow from operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 355</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 239</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,540</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,153</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,433</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cash flow from investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,545</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 919</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 966</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 928</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,351)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cash flow from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (240)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (460)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 71</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,477</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,605</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,477</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,605</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,260</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cash position increase/(decrease)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (208)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (178)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,796</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,811</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,108</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Investment in tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (79)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (145)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (107)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (203)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (307)</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial Ratios</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Basic net result per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.68</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 51.88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21.44</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 56.07</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 73.00</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Diluted net result per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.64</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 51.35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21.25</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 55.52</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 72.21</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Period-end share market price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,566</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,220</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,566</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,220</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,463</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Price / book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.36</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.07</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.36</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.07</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.50</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Shareholders' equity per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 306.85</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 274.94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 306.85</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 274.94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 289.71</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Equity ratio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 90</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 86</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 90</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 86</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 90</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,620,740</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,346,580</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,620,740</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,346,580</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,545,748</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Average number of employees (FTE**)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 969</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 614</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 906</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 656</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Number of employees at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,029</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 636</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,029</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 781</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">*&#xA0;&#xA0;Cash, cash equivalents, and marketable securities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;">** Full-time equivalent</p><a id="_Hlk45824573"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 4/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_Hlk77676212"></a><a id="OUTLOOK_98518"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt;">OUTLOOK</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Previous</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">7,300 - 7,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6,800 - 7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(5,500) - (5,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(5,500) - (5,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr style="height:3.7pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating result</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">1,500 - 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">1,000 - 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#x200B;</span><br />Genmab is improving its 2021 financial guidance published on February 23, 2021, driven primarily by increased royalty revenue related to the net sales of DARZALEX.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Revenue</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab expects its 2021 revenue to be in the range of DKK 7,300&#x2013;7,900 million, an increase compared to previous guidance of DKK 6,800-7,500 million, driven primarily by the continued strong growth of DARZALEX net sales. Genmab&#x2019;s projected revenue for 2021 primarily consists of DARZALEX royalties of DKK 5,300&#x2013;5,700 million. Such royalties are based on Genmab&#x2019;s revised estimate of DARZALEX 2021 net sales of USD 5.6&#x2013;5.9 billion compared to Genmab&#x2019;s previous estimate of USD 5.2-5.6 billion. Since the second quarter of 2020, Janssen has reduced its royalty payments to Genmab by what it claims to be Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme in connection with subcutaneous (SC) sales. Given the ongoing arbitration, Genmab has reflected this as a reduction to estimated 2021 revenue. The remainder of Genmab&#x2019;s revenue consists of royalties from TEPEZZA and Kesimpta, reimbursement revenue, milestones for epcoritamab and daratumumab, and other milestones.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Operating Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab anticipates its 2021 operating expenses to be in the range of DKK 5,500&#x2013;5,800 million, which is in line with previous guidance. Operating expenses continue to be driven by the advancement of Genmab&#x2019;s clinical programs, continued investment in research and development, as well as building Genmab&#x2019;s commercial organization and broader organizational infrastructure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Operating Result</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab now expects its 2021 operating result to be in the range of DKK 1,500&#x2013;2,400 million, an increase compared to previous guidance of DKK 1,000-2,000 million, driven primarily by the increase in royalty revenue related to the net sales of DARZALEX.   </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Outlook: Risks and Assumptions</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to factors already mentioned, the estimates above are subject to change due to numerous reasons, including but not limited to the achievement of certain milestones associated with Genmab&#x2019;s collaboration agreements; ongoing binding arbitration of two matters under Genmab&#x2019;s license agreement with Janssen relating to daratumumab; the timing and variation of development activities (including activities carried out by Genmab&#x2019;s collaboration partners) and related income and costs; DARZALEX, Kesimpta, TEPEZZA and RYBREVANT<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>net sales and royalties paid to Genmab; and currency exchange rates (the 2021 guidance assumes a USD/DKK exchange rate of 6.0). The financial guidance assumes that no significant new agreements are entered into during the remainder of 2021 that could materially affect the results. Refer to the section &#x201C;Significant Risks and Uncertainties&#x201D; in this interim report. Additionally, the COVID-19 pandemic could potentially have a material adverse impact on Genmab&#x2019;s business and financial performance, including clinical trials, projected regulatory approval timelines, supply chain and revenues, and cause Genmab&#x2019;s actual results to differ materially from 2021 Guidance and Key 2021 Priorities in this interim report. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The global outbreak of COVID-19 may have long-term impacts on the development, regulatory approval and commercialization of Genmab&#x2019;s product candidates and on net sales of approved products created by </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 5/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab and developed and marketed by Genmab&#x2019;s collaboration partners. The longer the pandemic continues, the more severe the impacts described below will be on Genmab&#x2019;s business. The extent, length and consequences of the pandemic are uncertain and impossible to predict. Genmab has established a COVID-19 response team, led by the CEO, that closely monitors the evolving situation, develops and implements precautionary measures to help limit the impact of COVID-19 at the workplace and on our communities, and ensures business continuity. Genmab is also actively monitoring the potential impact on Key 2021 Priorities and assessing the situation on an ongoing basis in close contact with clinical trial sites, physicians and contract research organizations (CROs) to evaluate the impact and challenges posed by the COVID-19 situation and manage them accordingly. The full extent and nature of the impact of the COVID-19 pandemic and related containment measures on Genmab&#x2019;s business and financial performance is uncertain as the situation continues to evolve. The factors discussed above, as well as other factors which are currently unforeseeable, may result in further and other unforeseen material adverse impacts on Genmab&#x2019;s business and financial performance, including on the net sales of DARZALEX, Kesimpta, TEPEZZA and RYBREVANT, by Genmab&#x2019;s partners and on Genmab&#x2019;s royalty and milestone revenue therefrom.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="KEY2019PRIORITIES_54601"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt;">KEY 2021 PRIORITIES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:23.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:23.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 3.6pt;"><b style="color:#029c93;font-weight:bold;">Priority</b></p></td><td style="vertical-align:top;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><b style="color:#029c93;font-family:'Segoe UI Emoji';font-weight:bold;">&#x2714;</b></p></td><td colspan="2" style="vertical-align:top;width:69.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><b style="color:#029c93;font-weight:bold;">Targeted Milestones</b></p></td></tr><tr><td style="vertical-align:top;width:23.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 3.6pt;"><b style="color:#029c93;font-weight:bold;">Bring our own medicines to patients</b></p></td><td style="vertical-align:top;width:6.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:2.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="vertical-align:top;width:66.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;">Tisotumab vedotin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> &#x2013; U.S. FDA decision on BLA and progress to market</p></td></tr><tr><td style="vertical-align:top;width:23.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 3.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;">X</p></td><td style="vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;">*</p></td><td style="vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;">Tisotumab vedotin &#x2013; JNDA submission in cervical cancer</p></td></tr><tr><td style="vertical-align:top;width:23.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 3.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Epcoritamab<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> &#x2013; acceleration and maximization of development program by advancing expansion cohorts and initiating additional Phase 3 trials</p></td></tr><tr><td rowspan="4" style="background-color:#e5e5e6;vertical-align:top;width:23.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 3.6pt;"><b style="color:#029c93;font-weight:bold;">Build world-class differentiated product </b></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"></td><td style="background-color:#e5e5e6;vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;">DuoBody-PD-L1x4-1BB<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3 </sup>&#x2013; expansion cohort data</p></td></tr><tr><td style="display:none;vertical-align:middle;width:23.16%;margin:0pt;padding:0pt;"></td><td style="background-color:#e5e5e6;vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;">DuoBody-CD40x4-1BB<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup> &#x2013; dose escalation data</p></td></tr><tr><td style="display:none;vertical-align:middle;width:23.16%;margin:0pt;padding:0pt;"></td><td style="background-color:#e5e5e6;vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tisotumab vedotin &#x2013; data in other tumor indication</p></td></tr><tr><td style="display:none;vertical-align:middle;width:23.16%;margin:0pt;padding:0pt;"></td><td style="background-color:#e5e5e6;vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="background-color:#e5e5e6;vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Earlier-stage products &#x2013; progress and expand innovative product pipeline</p></td></tr><tr><td rowspan="2" style="vertical-align:top;width:23.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 3.6pt;"><b style="color:#029c93;font-weight:bold;">Become leading integrated innovation powerhouse</b></p></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;">Operational commercialization model in U.S. and Japan</p></td></tr><tr><td style="display:none;vertical-align:middle;width:23.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="color:#029c93;font-family:'Segoe UI Emoji';font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="font-family:'Times New Roman';">&#x25CF;</span></p></td><td style="vertical-align:top;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further strengthen solid financial foundation </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:1pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1.&#xA0;Co-development w/ Seagen Inc. (Seagen); 2. Co-development w/ AbbVie; 3. Co-development w/ BioNTech SE (BioNTech)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">*Potential JNDA filing timeline postponed to include Phase 3 InnovaTV301 data</p><a id="PRODUCTPIPELINE_610958"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="PRODUCTPIPELINEANDTECHNOLOGYPROGRESSFIRS"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PRODUCT PIPELINE AND TECHNOLOGY PROGRESS FIRST HALF OF 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of the end of the second quarter, Genmab&#x2019;s proprietary pipeline of product candidates, where we are responsible for at least 50% of development costs, consisted of eight clinical stage antibodies. In addition to our own pipeline, there are also 15 products in development by third-party companies, including four approved products, which incorporate Genmab technology and innovation. Beyond the antibodies in clinical development, our pipeline also includes around 20 in-house and partnered preclinical programs. An overview of the development status of each of our products is provided in the following sections. Detailed descriptions of dosing, efficacy and safety data from certain clinical trials have been disclosed in company announcements and media releases published via the Nasdaq Copenhagen stock exchange and may also be found in Genmab&#x2019;s filings with the U.S. Securities and Exchange Commission (SEC). Additional information is available on Genmab&#x2019;s website, <span style="color:#029c93;">www.genmab.com</span>. The information accessible through our website is not part of and is not incorporated by reference herein.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 6/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:250.5pt;"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Genmab Proprietary Products<sup style="font-size:8.25pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> in Development</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"><img src="gmab-20210630xex991d85adb004.jpg" alt="Chart&#xA;&#xA;Description automatically generated" style="display:inline-block;height:250.1pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:485.3pt;" /></sup><span style="margin-bottom:12pt;vertical-align:top;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">1</sup>Product candidates where Genmab has &#x2265;50% ownership. Certain products in co-development, partners as indicated</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen <br /><span style="font-size:10pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Tisotumab vedotin &#x2013; A Next Generation Therapeutic</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">An investigational antibody-drug conjugate (ADC) directed to tissue factor (TF), a protein highly prevalent in solid tumors, including cervical cancer, which is associated with poor prognosis</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on data from the innovaTV 204 (NCT03438396) Phase 2 single-arm clinical study evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent or metastatic cervical cancer, a BLA was submitted to the U.S. Food and Drug Administration (U.S. FDA); potential Japanese New Drug Application (JNDA) filing timeline postponed to include Phase 3 innovaTV 301 (NCT04697628) data </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">U.S. FDA accepted the BLA with Priority Review; under the Prescription Drug User Fee Act (PDUFA), the U.S. FDA set a target action date of Oct 10, 2021</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 3 study in recurrent or metastatic cervical cancer and multiple</span><span style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 2 clinical studies in other solid tumors ongoing</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed in collaboration with Seagen</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tisotumab vedotin is an ADC targeted to TF, a protein involved in tumor signaling and angiogenesis. It is composed of Genmab&#x2019;s fully human monoclonal antibody specific for tissue factor and Seagen&#x2019;s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody and releases it upon internalization, inducing target cell death. Based on its high expression on many solid tumors and its rapid internalization, TF is&#xA0;a suitable target for an ADC approach. Genmab used technology licensed from Medarex to generate the TF antibody forming part of tisotumab vedotin. Tisotumab vedotin is in clinical development for solid tumors. Tisotumab vedotin is being co-developed by Genmab and Seagen, under an agreement in which the companies share all costs and profits for the product on a 50:50 basis. Under a joint commercialization agreement, Genmab will co-</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 7/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">promote tisotumab vedotin in the U.S. and lead commercial operational activities in Japan. Seagen will lead operational commercial activities in the U.S., Europe and China with a 50:50 cost and profit split in those markets. In any other markets, Seagen will commercialize tisotumab vedotin and Genmab will receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the mid-twenties. The companies will continue the practice of joint decision-making on the worldwide development and commercialization strategy for tisotumab vedotin.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2021 Updates</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">May: innovaTV 204 data published in </span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">The Lancet Oncology</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, &#x201C;Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.&#x201D;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">April: The U.S. FDA accepted for Priority Review the BLA seeking accelerated approval for tisotumab vedotin. The BLA requests U.S. FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The FDA has set a target action date of Oct 10, 2021.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2021 Updates</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">February: Genmab and Seagen submitted a BLA to the U.S. FDA seeking accelerated approval for tisotumab vedotin for patients with recurrent or metastatic cervical cancer with disease progression on or after first line standard of care.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The submission is based on the results of the innovaTV 204 (NCT03438396) Phase 2 single-arm clinical study evaluating tisotumab vedotin as monotherapy in this setting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">January: A Phase 3 study of tisotumab vedotin versus chemotherapy in recurrent or metastatic cervical cancer (innovaTV 301 (NCT04697628)) was announced.  </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Epcoritamab (DuoBody-CD3xCD20) &#x2013; Potential Best-in-class Product Candidate</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Proprietary bispecific antibody created with Genmab&#x2019;s DuoBody technology </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Five ongoing clinical studies across different settings and histologies, including a Phase 3 study (NCT04628494) in relapsed / refractory diffuse large B-cell lymphoma (DLBCL) with more studies in planning</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed in collaboration with AbbVie</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Epcoritamab is a proprietary bispecific antibody created using Genmab&#x2019;s DuoBody technology. Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically well-validated target on malignant B-cells. Genmab used technology licensed from Medarex to generate the CD20 antibody forming part of epcoritamab. Epcoritamab is being co-developed by Genmab and AbbVie. The first Phase 3 clinical study (NCT04628494) of epcoritamab in relapsed / refractory DLBCL is ongoing. In addition, Phase 1/2 clinical studies in B-cell non-Hodgkin lymphoma (B-NHL) including chronic lymphocytic leukemia (CLL) (NCT04623541) and in combination with standard of care therapies for B-NHL (NCT04663347) are ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2021 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">June: Updated dose escalation data, including progression free survival, from the Phase 1/2 study of epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NCT03625037) presented during an oral session at the International Conference on Malignant Lymphoma and poster sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 8/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2021 Updates</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">February: &#x201C;Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment&#x201D; published in </span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Blood Cancer Journal</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">January: The first patient was dosed in the Phase 3 study (NCT04628494) of SC epcoritamab versus investigator&#x2019;s choice of chemotherapy in patients with relapsed or refractory DLBCL. This triggered a DKK 245 million (USD 40 million) milestone to Genmab under the collaboration with AbbVie.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoBody-PD-L1x4-1BB (GEN1046) &#x2013; Bispecific Next Generation Checkpoint Immunotherapy</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bispecific antibody created with Genmab&#x2019;s DuoBody technology </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Clinical studies in solid tumors ongoing</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed in collaboration with BioNTech</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoBody-PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab&#x2019;s DuoBody technology. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and profits for the product on a 50:50 basis. DuoBody-PD-L1x4-1BB targets PD-L1 and 4-1BB, selected to block inhibitory PD 1 / PD-L1 axis and simultaneously conditionally activate essential co-stimulatory activity via 4-1BB using inert DuoBody antibody format. Two clinical studies (NCT03917381, NCT04937153) in solid tumors are ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoBody-CD40x4-1BB (GEN1042) &#x2013; Potential First-in-Class Bispecific Agonistic Antibody</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bispecific antibody created with Genmab&#x2019;s DuoBody technology </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 1/2 clinical study (NCT04083599) in solid tumors ongoing </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed in collaboration with BioNTech</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab&#x2019;s DuoBody technology. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody format. A Phase 1/2 clinical study (NCT04083599) of DuoBody-CD40x4-1BB in solid tumors is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2021 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">April/May: Preclinical data was presented at the American Association for Cancer Research Annual Meeting.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">HexaBody-DR5/DR5 (GEN1029) &#x2013; First HexaBody</b><sup style="color:#029c93;font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><b style="color:#029c93;font-weight:bold;"> Program in Clinical Development</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Proprietary antibody therapeutic created with Genmab&#x2019;s HexaBody technology</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Composed of two non-competing HexaBody antibody molecules that target two distinct DR5 epitopes</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 1/2 clinical study (NCT03576131) in solid tumors ongoing</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HexaBody-DR5/DR5 (GEN1029) is a product comprising a mixture of two non-competing HexaBody molecules that target two distinct epitopes on death receptor 5 (DR5), a cell surface receptor that mediates a process called programmed cell death. Increased expression of DR5 has been reported in several types of tumors. The product was created with our HexaBody technology and DR5 antibodies acquired from IDD Biotech. HexaBody-DR5/DR5 is fully owned by Genmab and a Phase 1/2 clinical study (NCT03576131) in solid tumors is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 9/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoHexaBody-CD37 (GEN3009) &#x2013; First DuoHexaBody</b><sup style="color:#029c93;font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><b style="color:#029c93;font-weight:bold;"> Program in the Clinic</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Antibody product created with Genmab&#x2019;s DuoHexaBody technology</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 1/2 clinical study (NCT04358458) in hematologic malignancies ongoing </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed in collaboration with AbbVie</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoHexaBody-CD37 (GEN3009) is a bispecific antibody created with Genmab&#x2019;s proprietary DuoHexaBody technology platform. The DuoHexaBody platform combines the dual targeting of our DuoBody technology with the enhanced potency of our HexaBody technology, creating bispecific antibodies with target-mediated enhanced hexamerization. DuoHexaBody-CD37 is being co-developed by Genmab and AbbVie on a 50:50 basis and a Phase 1/2 clinical study (NCT04358458) in hematologic malignancies is ongoing. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoBody-CD3x5T4 (GEN1044) &#x2013; Promising Novel Product Candidate</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bispecific antibody product created with Genmab&#x2019;s DuoBody technology </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 1/2 clinical study (NCT04424641) in solid tumors ongoing </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed in collaboration with AbbVie</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoBody-CD3x5T4 (GEN1044) is a bispecific antibody created with Genmab&#x2019;s proprietary DuoBody technology platform. DuoBody-CD3x5T4 induces T-cell mediated cytotoxicity of 5T4-positive cells by crosslinking CD3 on T cells with the tumor-associated antigen 5T4 on tumor cells. The broad expression of 5T4 across solid tumors and limited expression in normal cells makes DuoBody-CD3x5T4 a promising novel product candidate. DuoBody-CD3x5T4 is being co-developed by Genmab and AbbVie on a 50:50 basis and a Phase 1/2 clinical study<b style="font-weight:bold;"> </b>(NCT04424641)<b style="font-weight:bold;"> </b>in solid tumors is ongoing. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">HexaBody-CD38 (GEN3014) &#x2013; Latest Proprietary Program in the Clinic</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Proprietary antibody therapeutic created with Genmab&#x2019;s HexaBody technology </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Potential in hematological malignancies; first patient dosed in the first-in-human study (NCT0482479) in March 2021</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed in an exclusive worldwide license and option agreement with Janssen Biotech, Inc. (Janssen)</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HexaBody-CD38 (GEN3014) is a human CD38 monoclonal antibody product incorporating our HexaBody technology. In preclinical models of hematological malignancies, as presented at ASH in December 2019, HexaBody-CD38 demonstrated enhanced CDC and had shown potent anti-tumor activity. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen to develop and commercialize HexaBody-CD38. An Investigational New Drug (IND) application was submitted to the U.S. FDA for HexaBody-CD38 in October 2020 followed by Clinical Trial Application submissions in Europe in November 2020. The first patient was dosed in the first-in-human study (NCT0482479) in March 2021 and the study is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2021 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">March: First patient dosed in first-in-human study (NCT0482479) of HexaBody-CD38.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 10/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Products Created by Genmab or Incorporating Genmab&#x2019;s Innovation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin:0pt;"><span style="font-size:10pt;">In addition to Genmab&#x2019;s own pipeline of product candidates, our innovations are applied in the pipelines of other companies that are running clinical development programs with antibodies created by Genmab or created using Genmab&#x2019;s DuoBody bispecific antibody technology. </span> <span style="font-size:10pt;">Under these agreements, Genmab is entitled to certain potential milestones and royalties.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Approved Medicines</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;"><img src="gmab-20210630xex991d85adb005.jpg" alt="Table&#xA;&#xA;Description automatically generated with medium confidence" style="display:inline-block;height:228.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:485.3pt;" /></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">*</sup>See local country prescribing information for precise indications</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DARZALEX (daratumumab) </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">&#x2013; Redefining the Treatment of Multiple Myeloma</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First-in-class human CD38 monoclonal antibody</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed by Janssen under an exclusive worldwide license from Genmab to develop, manufacture and commercialize daratumumab </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Intravenous (IV) formulation approved in combination with other therapies for frontline and for relapsed/refractory multiple myeloma in territories including the U.S., Europe and Japan and as monotherapy for heavily pretreated or double-refractory multiple myeloma in territories including the U.S. and Europe</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First and only SC CD38-directed antibody approved in territories including the U.S., Europe and Japan for the treatment of certain multiple myeloma indications, known as DARZALEX </span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">FASPRO</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> (daratumumab and hyaluronidase-fihj) in the U.S., and DARZALEX SC in Europe</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SC daratumumab is the first and only approved therapy for AL amyloidosis in the U.S. and Europe </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Net sales of DARZALEX by Janssen were USD 2,798 million in the first half of 2021</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DARZALEX (daratumumab) is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells and is also expressed by AL amyloidosis plasma cells. Daratumumab triggers a person&#x2019;s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 11/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death). Genmab used technology licensed from Medarex to generate the CD38 antibody forming part of daratumumab. Daratumumab is being developed by Janssen under an exclusive worldwide license from Genmab to develop, manufacture and commercialize daratumumab. Under the terms of the agreement, Genmab is entitled to double digit royalties between 12% and 20%. Daratumumab (marketed as DARZALEX for intravenous administration and as DARZALEX <i style="font-style:italic;">FASPRO </i>in the United States and as DARZALEX SC in Europe for SC administration) is approved in certain territories for the treatment of adult patients with certain multiple myeloma indications and is the only<i style="font-style:italic;"> </i>approved therapy in the U.S. and Europe for the treatment of adult patients with AL amyloidosis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the full <span style="color:#029c93;">U.S. Prescribing Information </span>and the full <span style="color:#029c93;">European Summary of Product Characteristics</span><span style="color:#0070c0;"> </span>for DARZALEX (daratumumab) and the full <span style="color:#029c93;">U.S. Prescribing Information</span> for DARZALEX FASPRO<span style="color:#0070c0;"> </span>(daratumumab and hyaluronidase-fihj)<b style="font-weight:bold;"> </b>for all of the labeled safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2021 Updates</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">June: Janssen received approval from the European Commission for the daratumumab SC formulation (daratumumab and hyaluronidase-fihj), known as DARZALEX SC in the European Union, in two indications: in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the treatment of adult patients with newly diagnosed systemic AL amyloidosis and in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor (PI) and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a PI and have demonstrated disease progression on or after the last therapy. The approvals follow positive opinions from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in May 2021. The approvals were based on the Phase 3 ANDROMEDA (AMY3001 / NCT03201965) and APOLLO (MMY3013 /</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">NCT03180736) studies, respectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">June: Overall survival results from Janssen&#x2019;s Phase 3 MAIA (MMY3008 / NCT02252172) study of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) versus Rd alone in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant (ASCT) were presented during the late-breaking oral session at EHA. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">April: Janssen received approval in China based on the Phase 3 LEPUS (MMY3009, NCT03234972) study of daratumumab in combination with bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma. </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2021 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">January: Janssen was granted U.S. FDA approval for the use of DARZALEX </span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">FASPRO</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> (daratumumab and hyaluronidase-fihj) in combination with VCd for the treatment of adult patients with newly diagnosed AL amyloidosis. The approval was based on data from the Phase 3 ANDROMEDA study (AMY3001 / NCT03201965)).</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Kesimpta (ofatumumab) &#x2013; Approved in RMS in the U.S. </b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Human CD20 monoclonal antibody developed by Novartis under a license agreement with Genmab</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Approved in territories including the U.S., EU and Japan for treatment of relapsing forms of multiple sclerosis (RMS) in adults</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First B-cell therapy that can be self-administered by patients at home using the Sensoready</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> autoinjector pen</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Ofatumumab is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops. Genmab used technology licensed from Medarex to generate </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 12/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">the CD20 antibody forming part of ofatumumab. A SC formulation of ofatumumab was investigated in two Phase 3 ASCLEPIOS clinical studies (NCT02792218, NCT02792231) in RMS. The studies compared the efficacy and safety of SC ofatumumab versus teriflunomide in patients with RMS and were comprised of approximately 900 patients each. Based on these studies, Kesimpta (ofatumumab) was approved by the U.S. FDA in August 2020 and the European Commission (EC) in March 2021 for the treatment of RMS in adults. Kesimpta is the first B-cell therapy that can be self-administered by patients at home using the Sensoready autoinjector pen, once monthly after starting therapy. Additional studies with RMS patients are ongoing. Ofatumumab in RMS is being developed and marketed worldwide by Novartis under a license agreement between Genmab and Novartis Pharma AG. Under the terms of the agreement, Genmab is entitled to 10% royalties on net sales of Kesimpta.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the full <span style="color:#029c93;">U.S. Prescribing Information</span> and the full <span style="color:#029c93;">European Summary of Product Characteristics</span> for the labeled safety information for Kesimpta (ofatumumab). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2021 Updates</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">March: The EC granted Novartis marketing authorization for the use of Kesimpta (ofatumumab) in the treatment of RMS in adults with active disease defined by clinical or imaging features. This was preceded in January 2021 by a positive opinion from the CHMP of the EMA recommending marketing authorization in the same indication.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">TEPEZZA (teprotumumab-trbw) &#x2013; First U.S. FDA-approved medicine for the treatment of thyroid eye disease</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Developed and commercialized by Horizon Therapeutics, plc (Horizon) for thyroid eye disease (TED)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First and only U.S. FDA-approved medicine for the treatment of TED</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Also being explored in diffuse cutaneous systemic sclerosis (dcSSC)</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Teprotumumab, approved by the U.S. FDA in January 2020 under the trade name TEPEZZA, is a human monoclonal antibody that targets the Insulin-like Growth Factor 1 Receptor (IGF-1R), a well-validated target. Genmab used technology licensed from Medarex to generate the IGF-1R antibody forming part of teprotumumab. TEPEZZA is being developed and is commercialized by Horizon. The antibody was created by Genmab under a collaboration with Roche and development and commercialization of the product is now being conducted by Horizon under a sublicense from Roche. Under the terms of Genmab&#x2019;s agreement with Roche, Genmab will receive mid-single digit royalties on sales of TEPEZZA. In December 2020, Horizon announced that there was a supply disruption related to the production of TEPEZZA due to U.S. government-mandated COVID-19 vaccine production requirements. Subsequently, in March 2021, Horizon announced its plans to resupply the market beginning in April 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the full <span style="color:#029c93;">U.S. Prescribing Information</span> for all of the labeled safety information for TEPEZZA (teprotumumab-trbw).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">RYBREVANT (amivantamab-vmjw) </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">&#x2013; First regulatory approval for a DuoBody product</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Part of Genmab and Janssen DuoBody research and license agreement</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First U.S. FDA approved product created using Genmab&#x2019;s proprietary DuoBody technology platform</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Under the agreement with Janssen, Genmab will receive royalties on net sales of RYBREVANT</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen&#x2019;s RYBREVANT (amivantamab-vmjw) is a fully human bispecific antibody that targets EGFR and cMet, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmab&#x2019;s DuoBody technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to create </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 13/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:183pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Amivantamab was selected in collaboration between Genmab and Janssen. Subsequent development work was led by Janssen.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2021, Janssen received approval from the U.S. FDA for RYBREVANT for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. This is the first regulatory approval for a therapy that was created using Genmab&#x2019;s proprietary DuoBody bispecific technology platform. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Please consult the full <span style="color:#029c93;">U.S. Prescribing Information</span> for RYBREVANT (amivantamab-vmjw) for all of the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2021 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">May: Janssen was granted U.S. FDA approval for the use of RYBREVANT (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Clinical Stage Product Candidates </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen&#x2019;s bispecific program applying the proprietary DuoBody technology platform accounts for approximately half of the clinical stage product candidates incorporating Genmab&#x2019;s innovation that are in development with other companies. Janssen received Breakthrough Therapy Designation (BTD) by the U.S. FDA for teclistamab for the treatment of relapsed or refractory multiple myeloma in June 2020. Multiple abstracts related to Janssen&#x2019;s DuoBody programs were also presented at the 2021 ASCO annual meeting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="gmab-20210630xex991d85adb006.jpg" alt="Graphical user interface, application&#xA;&#xA;Description automatically generated" style="display:inline-block;height:182.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:485.3pt;" /></p><div style="height:0pt;position:relative;width:100%;"><div style="left:0%;position:absolute;top:0pt;width:671.94pt;z-index:251658240;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:671.94pt;"><div style="left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;width:100%;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">*</sup><span style="vertical-align:super;">UltiMab</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#xAE; </sup><span style="vertical-align:super;">transgenic mouse technology licensed from Medarex, Inc., a wholly owned subsidiary of Bristol Myers Squibb.</span></p></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#x200B;</span><br /></b><b style="color:#029c93;font-size:11pt;font-weight:bold;">Preclinical Programs</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Broad preclinical pipeline of around 20 programs </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Preclinical pipeline includes both partnered products and in-house programs based on our proprietary technologies or antibodies</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Multiple new INDs expected to be submitted over coming years</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 14/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Genmab has entered multiple strategic collaborations to support the expansion of our innovative pipeline, including a broad oncology collaboration with AbbVie</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our preclinical pipeline includes immune effector function enhanced antibodies developed with our HexaBody technology and bispecific antibodies created with our DuoBody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>platform. We are also working with our partners, including AbbVie, BioNTech, Immatics, CureVac N.V. (CureVac) and Bolt Biotherapeutics, Inc. (Bolt), to generate additional new product concepts. A number of the preclinical programs are carried out in cooperation with our collaboration partners.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2021 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">May: Genmab and Bolt entered into an oncology research and development collaboration. The companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt&#x2019;s proprietary Boltbody&#x2122; immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer. The research collaboration will evaluate multiple bispecific ISAC concepts to identify up to three clinical candidates for development. Genmab will fund the research, along with the preclinical and clinical development of these candidates through clinical proof of concept. Under the terms of the agreement, Genmab paid Bolt an upfront payment of USD 10 million and a USD 15 million equity investment in Bolt in June 2021. Bolt is eligible to receive total potential milestone payments of up to USD 285 million per therapeutic candidate exclusively developed and commercialized by Genmab, along with tiered royalties. Genmab will fully fund preclinical and early clinical development of all candidates. If a candidate is co-developed, development costs will be split 50:50 between the two companies, and the companies will be solely responsible for commercialization costs in their respective territories and shall pay each other royalties on product sales.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_SIGNIFICANT_RISKS_AND"></a><a id="SIGNIFICANTRISKSANDUNCERTAINTIES_402181"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="color:#029c93;font-weight:bold;">SIGNIFICANT RISKS AND UNCERTAINTIES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As a biotech company, Genmab faces a number of risks and uncertainties. These are common for the industry and relate to operations, intellectual property, research and development, commercial and financial activities. For further information about risks and uncertainties, which the Genmab group faces, refer to the 2020 Annual Report filed with NASDAQ Copenhagen in February 2021 and the Form 20-F filed with the U.S. SEC in March 2021. At the date of this interim report, there have been no significant changes to Genmab&#x2019;s overall risk profile since the publication of the Form 20-F; however, the full extent and nature of the impact of the COVID-19 pandemic and related containment measures on our business and financial performance is uncertain as the situation continues to develop. See Genmab&#x2019;s Form 20-F for a detailed summary of risks related to our collaborations as well as risks related to the COVID-19 pandemic. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 15/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="SIGNIFICANTRISKSANDUNCERTAINTIES_586492"></a><a id="_Hlk45804376"></a><a id="FINANCIALREVIEW_920877"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt;">FINANCIAL REVIEW</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The interim report is prepared on a consolidated basis for the Genmab group. The financial statements are published in Danish Kroner (DKK).</p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Revenue</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#x2019;s revenue was DKK 3,553 million for the first half of 2021 compared to DKK 6,343 million for the first half of 2020. The decrease of DKK 2,790 million, or 44%, was primarily driven by the one-time upfront payment of DKK 4,398 million recognized as license revenue from AbbVie pursuant to our collaboration announced in June 2020, partly offset by higher DARZALEX royalties as well as milestone revenue from various collaboration partners.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:18.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:18.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">H1 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:18.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">H1 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2,595</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1,738</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 227</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 175</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 731</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 32</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">License revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#x2014;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 4,398</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,553</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 6,343</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Royalties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalty revenue amounted to DKK 2,595 million in the first half of 2021 compared to DKK 1,738 million in the first half of 2020. The increase of DKK 857 million, or 49%, was primarily driven by higher DARZALEX royalties achieved under our daratumumab collaboration with Janssen. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net sales of DARZALEX by Janssen were USD 2,798 million in the first half of 2021 compared to USD 1,838 million in the first half of 2020. The increase of USD 960 million, or 52%, was driven by the continued strong uptake of DARZALEX. Royalty revenue on net sales of DARZALEX<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>was DKK 2,360 million in the first half of 2021 compared to DKK 1,652 million in the first half of 2020, an increase of DKK 708 million. The percentage increase in royalties of 43% is lower than the percentage increase in the underlying net sales primarily due to the lower exchange rate between the USD and DKK in the first half of 2021 compared to the first half of 2020 and the impact of Janssen&#x2019;s continued withholding of a portion of the royalty payments owed to Genmab. Since the second quarter of 2020, Janssen has reduced its quarterly royalty payments to Genmab by what Janssen claims to be Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme in connection with SC sales. Given the ongoing arbitration, Genmab has reflected this reduction in its royalty revenues each quarter. The impact to royalties in the first half of 2021 is estimated to be DKK 146 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">TEPEZZA (teprotumumab-trbw) was launched by Horizon in the first quarter of 2020. In December 2020, Horizon announced that there was a supply disruption related to the production of TEPEZZA due to U.S. government-mandated COVID-19 vaccine production requirements. Subsequently, in March 2021, Horizon announced its plans to resupply the market beginning in April 2021. Royalties, which are based on net sales, amounted to DKK 162 million during the first half of 2021 compared to DKK 77 million during the first half of 2020. The increase of DKK 85 million was driven by the strong uptake of TEPEZZA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Novartis was granted U.S. FDA approval for Kesimpta (ofatumumab) in relapsing multiple sclerosis and Genmab started recognizing royalties on net sales of Kesimpta during the third quarter of 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalties, which are based on net sales, amounted to DKK 72 million for the first half of 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen was granted U.S. FDA approval for RYBREVANT (amivantamab-vmjw) (ofatumumab), a fully human bispecific antibody that targets EGFR and cMet, and Genmab started recognizing royalties on net sales of RYBREVANT during the second quarter of 2021. Royalties for the quarter were not material.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 16/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalty revenue fluctuations from period to period are due primarily to the level of product net sales as well as foreign currency exchange rates. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reimbursement Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement revenue amounted to DKK 227 million in the first half of 2021 compared to DKK 175 million in the first half of 2020. The increase of DKK 52 million, or 30%, was primarily driven by higher activities under our collaboration agreement with BioNTech for DuoBody-PD-L1x4-1BB.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Milestone Revenue</b></p><a id="_Hlk14190762"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Milestone revenue was DKK 731 million in the first half of 2021 compared to DKK 32 million in the first half of 2020, an increase of DKK 699 million, primarily driven by the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">AbbVie milestone of DKK 245 million (USD 40 million) triggered by the first patient dosed in the Phase 3 study of epcoritamab, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">DARZALEX FASPRO milestone of DKK 184 million (USD 30 million) driven by the first commercial sale in the U.S. for patients with newly diagnosed AL amyloidosis,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Janssen DuoBody milestone of DKK 152 million (USD 25 million) driven by U.S. FDA approval for RYBREVANT, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">DARZALEX SC milestone of DKK 125 million (USD 20 million) driven by the first commercial sale in the EU for patients with newly diagnosed AL amyloidosis.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Milestone revenue may fluctuate significantly from period to period due to both the timing of achievements and the varying amount of each individual milestone under our license and collaboration agreements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">License Revenue</b></p><a id="_Hlk77674178"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There was no license fee income during the first half of 2021. License revenue was DKK 4,398 million during the first half of 2020, which was driven by the delivery of licenses for three programs under the AbbVie collaboration.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Financial Statement Note 2 in this interim report for further details about revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Research and Development Costs</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development costs amounted to DKK 1,769 million in the first half of 2021 compared to DKK 1,490 million in the first half of 2020. The increase of DKK 279 million, or 19%, was driven by the continued advancement of epcoritamab and DuoBody-PD-L1x4-1BB under our collaborations with AbbVie and BioNTech, respectively, and the increase in new employees to support the expansion of our product pipeline. During the first half of 2021, Genmab recorded DKK 331 million as compared to DKK 45 million during the first half of 2020 as a reduction to research and development costs for reimbursement related to the collaboration agreement with AbbVie. Pursuant to this agreement, which was entered into during the second quarter of 2020, Genmab and AbbVie share equally in both research and development costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development costs accounted for 79% of total operating expenses in the first half of 2021 compared to 84% in the first half of 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">General and Administrative Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">General and administrative expenses were DKK 465 million in the first half of 2021 compared to DKK 285 million in the first half of 2020. The increase of DKK 180 million, or 63%, was driven by the increase in new employees as Genmab builds its commercialization capabilities and broader organizational infrastructure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 17/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">General and administrative expenses accounted for 21% of total operating expenses in the first half of 2021 compared to 16% in the first half of 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Operating Result</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating result was DKK 1,319 million in the first half of 2021 compared to DKK 4,568 million in the first half of 2020. The decrease of DKK 3,249 million, or 71%, was driven by lower revenue and increased operating expenses as described above.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Net Financial Items</p><a id="OLE_LINK26"></a><a id="OLE_LINK27"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net financial items for the first half of 2021 were a gain of DKK 527 million compared to a gain of DKK 114 million in the first half of 2020. The increase of DKK 413 million was primarily driven by the strengthening of the USD against the DKK on Genmab&#x2019;s U.S. denominated portfolio and cash holdings, partly offset by losses on marketable securities driven by movements in interest rates in the United States and Europe. Refer to Financial Statement Note 4 in this interim report for further details about the net financial items.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Corporate Tax</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate tax expense for the first half of 2021 was DKK 444 million compared to DKK 1,035 million for the first half of 2020. The decrease in corporate tax expense is primarily the result of Genmab&#x2019;s lower net result before tax. The effective tax rate in the first half of 2021 was 24% compared to 22% in the first half of 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Net Result </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net result for the first half of 2021 was DKK 1,402 million compared to DKK 3,647 million in the first half of 2020. The decrease was driven by the items described above. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Cash Position</p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="color:#000000;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Cash Position (DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#xA0;30,&#xA0;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#xA0;31,&#xA0;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 8,398</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 8,819</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 9,477</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 7,260</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Cash position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 17,875</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 16,079</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, cash, cash equivalents and marketable securities (cash position) amounted to DKK 17,875 million, an increase of DKK 1,796 million, or 11%, from the beginning of 2021. The increase was primarily driven by Genmab&#x2019;s operating result of DKK 1,319 million, net exchange rate gains of DKK 573 million due to the strengthening of the USD, and proceeds received of DKK 438 million from the sale of a portion of Genmab&#x2019;s CureVac shares during the first half of 2021, partly offset by cash payments for the purchase of treasury shares of DKK 437 million during the first half of 2021. Refer to Financial Statement Note 3 in this interim report for further details about the sale of CureVac shares. Refer to Financial Statement Note 5 in this interim report for further details about the purchase of treasury shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, Genmab&#x2019;s USD denominated cash, cash equivalents and marketable securities represents 85% of Genmab&#x2019;s cash position compared to 83% as of December 31, 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents included short-term marketable securities of DKK 2,569 million at the end of June 2021, compared to DKK 2,206 million at the end of December 2020. In accordance with our accounting policy, securities purchased with a maturity of less than three months at the date of acquisition are classified as cash and cash equivalents. Refer to Financial Statement Note 3 in this interim report for further details about our marketable securities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 18/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Cash Flow</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Cash Flow (DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">H1 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">H1 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1,540</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2,153</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 928</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> (460)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash provided by operating activities is primarily related to our operating result, changes in operating assets and liabilities, reversal of net financial items, and adjustments related to non-cash transactions. In the first half of 2021, as compared to the first half of 2020, the primary driver of lower cash provided by operating activities was due to decreased changes in operating assets and liabilities related to non-recurring DARZALEX milestones of DKK 1.7 billion achieved in the fourth quarter of 2019 that were received in 2020.<span style="font-size:18pt;white-space:pre-wrap;">  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The change in cash provided by investing activities primarily reflects differences between the proceeds received from sale and maturity of our investments and amounts invested, and the investment in tangible assets. Sales and maturities of marketable securities exceeded purchases in both periods, but to a greater extent in the first half of 2020. For the first half of 2021, investing activities also includes the proceeds from the sale of CureVac shares of DKK 438 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash used in financing activities is primarily related to the exercise of warrants, purchase of treasury shares, lease payments, and payment of withholding taxes on behalf of employees on net settled Restricted Stock Units (RSUs). In the first half of 2021, the primary driver of the cash used in financing activities was&#xA0;related to cash payments for the purchase of treasury shares of DKK 437 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Balance Sheet</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, total assets were DKK 22,483 million compared to DKK 21,143 million on December 31, 2020. As of June 30, 2021, assets are mainly comprised of a cash position of DKK 17,875 million and current receivables of DKK 2,429 million. The current receivables consist primarily of amounts related to royalties and milestones from our collaboration agreements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, total liabilities were DKK 2,231 million compared to DKK 2,022 million on December 31, 2020. The increase in total liabilities of DKK 209 million, or 10%, was primarily driven by corporate tax payable of DKK 186 million and an increase in lease liabilities of DKK 124 million related to the commencement of leases in Japan and the United States.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shareholders&#x2019; equity as of June 30, 2021 was DKK 20,252 million compared to DKK 19,121 million on December 31, 2020. The increase of DKK 1,131 million, or 6%, was primarily driven by Genmab&#x2019;s net result and the issuance of shares related to the share-based compensation plans, partly offset by the purchase of treasury shares. Genmab&#x2019;s equity ratio remained unchanged at 90% as of June 30, 2021 compared to December 31, 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, the total number of employees was 1,029 compared to 636 employees as of June 30, 2020. The increase in employees was primarily driven by the expansion and acceleration of our pipeline, as well as investment in commercialization capabilities and broader organizational infrastructure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:21.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#xA0;30,&#xA0;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#xA0;30,&#xA0;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:21.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">537</p></td></tr><tr><td style="vertical-align:bottom;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative employees*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:21.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 99</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:21.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1,029 </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 636</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">*Includes commercialization capabilities</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 19/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Legal Matter &#x2013; Janssen Binding Arbitration </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on sales of daratumumab (marketed as DARZALEX for intravenous administration and as DARZALEX <i style="font-style:italic;">FASPRO</i> in the United States and as DARZALEX SC in Europe for SC administration). The arbitration first is to settle whether Genmab is required to share in Janssen&#x2019;s royalty payments to Halozyme Therapeutics, Inc. for the Halozyme enzyme technology used in the SC formulation of daratumumab. The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab sales. Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme beginning in the second quarter of 2020 and has continued to do so through June 30, 2021. Given the ongoing arbitration, Genmab has reflected this reduction in its royalty revenues each quarter. The impact to the first half of 2021 royalties is estimated to be DKK 146 million. The impact to the first half of 2020 royalties is not material. The arbitration is also to settle whether Janssen&#x2019;s obligation to pay royalties on sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 20/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_edc66865_cdd7_4cb1_a8e4_0e41840f2c13"></a><a id="COMPREHENSIVEINCOME_677212"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">STATEMENT OF COMPREHENSIVE INCOME FOR THE 2ND QUARTER OF 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><a id="_ede41c12_8ae8_4e58_9041_a75770d0cd1d"></a><a id="Tc_o1g2_GYeLkGYjsHp-RcRjw_1_0"></a><a id="Tc_ew2s-Gyy8kS0J_3nWYBEzg_1_1"></a><a id="Tc_abEUNMgO_kOo9hbPnPHx-Q_1_3"></a><a id="Tc_NE8gYucp00aNGkFefPktBw_2_1"></a><a id="Tc_jbembaemYE-R8ol2wHRu_A_2_3"></a><a id="Tc_DcMpoe6BhkWbNjBx3tInhg_3_0"></a><a id="Tc_gnR0ubTO3UK9TpXRk8GvcQ_5_0"></a><a id="Tc_gkDsLuqtI0Kzc1XlgmSdrA_7_0"></a><a id="Tc_YoDyoESMOUGHZF7vdeZ74g_8_0"></a><a id="Tc_VYC8JLKi8Eq-OrSWauc8kQ_9_0"></a><a id="Tc_bS1r1Y52T0-IPCLyja5cpQ_11_0"></a><a id="Tc_eaZGeK3w3kaz4eyM5v6YMw_13_0"></a><a id="Tc_NH8Ky-L20kCOp6fXUNweJw_14_0"></a><a id="Tc_88ldLJ_n4kmk34st52nEtQ_16_0"></a><a id="Tc_pUvrPRNKnUiouvvx_nk0pg_18_0"></a><a id="Tc_fMQCzWb1pU-dtXOROyZ1ug_20_0"></a><a id="Tc_nsN90eJZtUCG3w5ID6thNg_22_0"></a><a id="Tc_dnPbDeI7yE6v5KsfRoMGow_23_0"></a><a id="Tc_eMvew_em6Ui2_Pik76ltww_25_0"></a><a id="Tc_AUtZnrH-PUqtbNR7w88WLQ_27_0"></a><a id="Tc_qq1b3Y5040WsyGZLMJM3_w_29_0"></a><a id="Tc_I8IR5tqF0EG46mwj4KS7PQ_31_0"></a><a id="Tc_0WGkVLml70ym4cdiRQ0PrQ_32_0"></a><a id="Tc_TepMXe-D6E6VYUf3Bn9tqg_34_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2nd Quarter of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2nd Quarter of</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_G3l5fghIqUyRGsA6ZIBJsg_5_1">1,972</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_bsRKv7xRIEmZ0m0fhXV9Yw_5_3">5,451</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_WBAk2ZlJWUefs129a3QfDA_7_1">921</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_4ojURSR9PUarxRXN3t9J9A_7_3">775</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" id="Tc_-pS-vNlRnkKygyuRwi7Tvw_8_1">264</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" id="Tc_Li01UjMenUa3fey76y6Cng_8_3">179</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_J-dC6YQx7kmoEdsqJM-XNg_9_1">1,185</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_SBeshUgpm0-_afVCfow2Zw_9_3">954</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating result</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_O0cdhBtzaUiGSs6WIdES0Q_11_1">787</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_7tpHnyjMLEuM5Fmo-elm9A_11_3">4,497</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial income</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_LYbnpzvsLUuBR4SEEWUUvA_13_1">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_J9Ti3JfJUUqJ7CRtwT2zhw_13_3">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial expenses</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_Yn2qG_otlUGXqWpVm-IvUA_14_1">430</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_yRQK0l8NtESpn53y-qZ46w_14_3">211</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net result before tax</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_PHJ4Q3XFNkWXkWNlm1941Q_16_1">422</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_9yX5m1YX9U2A9BQSH0Jzag_16_3">4,328</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate tax</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_P-2YEmlGk0WUll6Y69dg2Q_18_1">116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_eOD-2Oy5hUigFrGLe0PHtQ_18_3">950</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net result</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_nwqvuLpFL0Ke-9_1GvuZyw_20_1">306</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_IWyFJXg3RUOn2TeytSuBpg_20_3">3,378</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Basic net result per share</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_NIzpWxvl5E--PtJ4FZrivw_22_1">4.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_gTnGo1IDYkSnoE-HtXwZ0A_22_3">51.88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Diluted net result per share</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_Gn3-Vjih5EuUCFSdR5CZog_23_1">4.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_VqGSQZ6RSUCjAeDixZvJBg_23_3">51.35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Statement of Comprehensive Income</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net result</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_a9Q83SX5A0qU1sgKD9Jc4w_27_1">306</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_1tPjkOcJCkeJ3JwveYyt4Q_27_3">3,378</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income:</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts which will be re-classified to the income statement:</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Adjustment of foreign currency fluctuations on subsidiaries</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="6" id="Tc_S5sJKfb-PUC5WGiD97pVtw_32_1">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="6" id="Tc_ysHKW8yQ-UeiauUyYf4ioQ_32_3">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_bRaOsl1N4kirStPyqr4u2A_34_1">293</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_QXot1pQ7gUWEFIs4BlhSFQ_34_3">3,369</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 21/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_STATEMENT_OF_COMPREHENSIVE"></a><a id="STATEMENTOFCOMPREHENSIVEINCOMEFORTHEFIRS"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">STATEMENT OF COMPREHENSIVE INCOME FOR THE FIRST HALF OF 2021</p><a id="_2cb7c781_c2db_4c11_b83e_5209f5300824"></a><a id="Tc_C-RzFqT9CkyBaQJPyAkqhw_1_0"></a><a id="Tc_roBfFsuQQEKLJpzL77KlVA_1_4"></a><a id="Tc_htchBGmVAk2j-EcKhU5_tw_1_6"></a><a id="Tc_i7EWg5vdJ0WBPTTFH3ppzw_2_2"></a><a id="Tc_vlkfg2F1VE2qoGzG8Lfa7g_2_4"></a><a id="Tc_MjHfm6bI0UKyRrR_uKjfVg_2_6"></a><a id="Tc_ZNj_V36nlUewpc2DV_9bQg_3_0"></a><a id="Tc_zVlCvhFzREarEfUecNYVfA_5_0"></a><a id="Tc_gqTisGNoAUm2BbpBJn-Y_g_5_2"></a><a id="Tc_wQ5Pd1YAyEOa8xMktuPabg_7_0"></a><a id="Tc_i1vy03LEVUmXVAe9XyO77A_8_0"></a><a id="Tc_zNlUY75ZGU2-JRiqxShr3w_9_0"></a><a id="Tc_bPeZDPAq-E6IAL7MKDP0eg_11_0"></a><a id="Tc_7bjeCkeQRkW-TGDtmOVPrw_13_0"></a><a id="Tc_yRbqjm2mSEW44z2eFevzLQ_13_2"></a><a id="Tc_tzRjaD_AbkWKgAb6FSkHng_14_0"></a><a id="Tc_8ia8jE1Ty0KkbE112GpDlA_14_2"></a><a id="Tc_VsdhOKUX1Um-0-zred4bMw_16_0"></a><a id="Tc_ChVHCiwaI0uCr1YmxCUewA_18_0"></a><a id="Tc_AUnnQcXyuUeXt_CPU-ZrIA_20_0"></a><a id="Tc_lOr5AI41aUCxfc55bP2Xgg_22_0"></a><a id="Tc_TJy3Td0bZ0WwbFcfg04L3g_23_0"></a><a id="Tc_5_ituuvb0UiavnFmp4muzA_25_0"></a><a id="Tc_cXKr8DIt0k2VtS2iOmrfZQ_27_0"></a><a id="Tc_GzLHY-LL80yigWtGZ_Y_8Q_29_0"></a><a id="Tc_cdFq-7Kvq0OPTpSz5PlrSw_31_0"></a><a id="Tc_vDeTi4g6_UyZ14NHX6CDFQ_32_0"></a><a id="Tc_FllRw_ak60KiDaPV69ZV1g_32_6"></a><a id="Tc_EnODlWcDAECJxOZxwLSc6A_34_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 30, 2020</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_ONvQSQDSZE6v3c338jHUtg_5_4">3,553</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_aSonAQoFIU-IYGw1DeCKrA_5_6">6,343</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_CR9ZrVgx8kKNKv-QWEtBhg_7_4">1,769</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_EblISj6qgE2b-GuJviBb9Q_7_6">1,490</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" id="Tc_etN26a0wGU2sWKdKwOwyxw_8_4">465</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" id="Tc_k1i-R2BngUeg_YeSa8y5aQ_8_6">285</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_h1xnxh6bh06oFpou9BGXSg_9_4">2,234</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_NisILWz9wEKZJ2xjk3jn6Q_9_6">1,775</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating result</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_6jl44-SCGUSCAydasn6bZg_11_4">1,319</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_Xtk8W8POIEuuGv0iHi71bA_11_6">4,568</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_FqeoFWsNjEWDA2ckucksSQ_13_4">700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_7XBTY5uoxE-AVv8xLOCecg_13_6">119</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_4XvpR67JI0-FvVydRrylWQ_14_4">173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_ZNfID6Qa9UWGD-YdGwRGog_14_6">5</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net result before tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_HNPdivDMMUyNoOWIwQH2BQ_16_4">1,846</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_-YX5Cwh_oUmK0RWI1vJRzA_16_6">4,682</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_U2qsCpZoZUiv8M9pWrBotA_18_4">444</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_hFwIJvffbUex4ljdGoDQ2A_18_6">1,035</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net result</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_bp0TP8B77EWio6kbe-RtKA_20_4">1,402</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_gVprKRc6NkuDth7mvUHQjg_20_6">3,647</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic net result per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_icjUYjPkdEa0qL25Z-lEOA_22_4">21.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_sx7YmSYUY0yfp5p2a499Aw_22_6">56.07</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Diluted net result per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_5PGk-q2VyEW84JfG4naOKA_23_4">21.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_qasvf905fEqlCrlighNvDA_23_6">55.52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Comprehensive Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net result</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_cXcMgffLcESjU7RSoDnstg_27_4">1,402</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_nCdwW0d4y0OwzlWUfEH0GA_27_6">3,647</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amounts which will be re-classified to the income statement:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustment of foreign currency fluctuations on subsidiaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="Tc_G56jq3qNpki338BCKiaUWQ_32_4">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_UBzIFXodSU2cNrTQf78ecg_34_4">1,430</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_6MjgAJF1m0S9MxWIrR85gg_34_6">3,647</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 22/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_757552ce_88fd_40a3_b0ca_5168c8491905"></a><a id="BALANCESHEET_971090"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt;">BALANCE SHEET</p><a id="_64f6d75a_621b_471d_953b_ed66274bcc0e"></a><a id="Tc_OandpGbdZkit-ve8dzqBiA_1_4"></a><a id="Tc__GpjqVAmBUWdq433Swxi3Q_1_6"></a><a id="Tc_jZK1iE8C1UK5E_6N4P_fRw_2_2"></a><a id="Tc_15vrDcZeLkKMTIbFac6wrw_2_4"></a><a id="Tc_bCHOStK3BEunhssv4ot1tw_2_6"></a><a id="Tc_ZVBBwwVQzUCN6fXYmCZIZA_3_0"></a><a id="Tc_dbIspVrAHUijp-oZZIpo4A_4_0"></a><a id="Tc_WbCyes6T2UqiONv8Q-RHnw_6_0"></a><a id="Tc_s-ELeuE09kOIMiISVnz6YQ_7_0"></a><a id="Tc_C3NC8WZQ0Ua9WIuUn3o-fw_8_0"></a><a id="Tc_a2I6HIp3uE23NWGI1nSZew_8_2"></a><a id="Tc_EVkJh4Cu3kGdspgNvNMR6Q_9_0"></a><a id="Tc_rGS6P0S6-USgdZ6BNdRORg_10_0"></a><a id="Tc_jYzmfWOH0kq3i6nC404nfA_11_0"></a><a id="Tc_1PBtDf6WZ0eUCOKhZyk_RA_11_2"></a><a id="Tc_QPbvYnXVHUirZ3_32lV-dw_13_0"></a><a id="Tc_xZhG9iqCFUCcZ151jCp0IA_15_0"></a><a id="Tc_KgLYb7G9uEmAF5PGp-kPXg_15_4"></a><a id="Tc_FYmwFdu0V0iy1a9sn3juKA_16_0"></a><a id="Tc_2T0XMq18B0iAnODy_kuaqw_17_0"></a><a id="Tc__8rWx10HHkmdSa643GR15g_17_2"></a><a id="Tc_672J7Cpf2USzYpgc-xb40w_18_0"></a><a id="Tc_zvbrk65m50WHk5D8poOXyA_20_0"></a><a id="Tc_iTYkAwISaUidjO0Ke5fkNQ_22_0"></a><a id="Tc_GZ26ufeqiEmsAmjP1693IA_24_0"></a><a id="Tc_Y6aBDkVHVkKQi5A6UXmHUQ_26_0"></a><a id="Tc_UggIV4xj0E-SKazs7uUmpg_27_0"></a><a id="Tc_xp8Ft8thWEa1uBFYMs-nfg_28_0"></a><a id="Tc_UTSfgdEcPEadexhDvG-HBg_29_0"></a><a id="Tc_ArZxM9nPj0i_1BD3JryDyg_31_0"></a><a id="Tc_auRYDH1kJkaujMJ6xFAwXA_33_0"></a><a id="Tc_6Pfx-BqybUyn9RipQ9VUJw_34_0"></a><a id="Tc_JeCYc98c8kKs1meG6sW9LA_34_2"></a><a id="Tc_X3Lyop2O7ES-cL2QfnRuVA_35_0"></a><a id="Tc_eJr0ALhouEqCUJQ6ZjMxvw_36_0"></a><a id="Tc_JEh_ph98zkyLLnUPvP5y5g_38_0"></a><a id="Tc_NF9TVqnzDk6jJQh_DTGJew_40_0"></a><a id="Tc_4Kppq7Yqu0-QV9OnxWO37Q_40_6"></a><a id="Tc_JIob_Ugpr0GUfLuPKFdG1w_41_0"></a><a id="Tc_224JONq46UWpr_VpGg8qXQ_41_2"></a><a id="Tc_x5wje1PdwUiiVJwbDxzqqg_42_0"></a><a id="Tc_UaiN77_owke8yfRex6IFQg_43_0"></a><a id="Tc_FNe2Ga0VpkubhehB18AMWw_45_0"></a><a id="Tc_y05kBdd2a0qe1-pVQV317A_47_0"></a><a id="Tc_gScre8GZH0a7xjPq8FJ-Hg_49_0"></a><a id="Tc_InrAk62Ne0GgWKEXLEiylw_51_0"></a><a id="Tc_piQgY0nml0yNHxYQ5s0dBg_51_2"></a><a id="Tc_M0DTl3c-UU2ltGBrZJgshw_52_0"></a><a id="Tc_cyW0yxXUEEGYkdVuUQqdtQ_52_2"></a><a id="Tc_MQUQeSWouEK9rHccVZXyqQ_53_0"></a><a id="Tc_WMPzFjQT2ke6FAh9RW8FhA_53_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#xA0;31,&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="Tc_J-UX7ApV9EeWzJ32A6ZjEg_6_4">297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="Tc_1VjbTfQJiki_h36UjL_RPw_6_6">338</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="Tc_-Qaebtb9s0SFF0blJXyihg_7_4">535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="Tc_AQfX9-IDXkGtO5wi2PiHLQ_7_6">453</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_wqn6WR1qd0OXOEGth9zpRA_8_4">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_xIdvPR5HfkmtOoAHGZxnPg_8_6">283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentReceivables" scale="6" id="Tc_1fsvzoeNDU65vOgaEMcujQ_9_4">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentReceivables" scale="6" id="Tc_2fuMu3mZeESOo_H8gboVuA_9_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="6" id="Tc_4eJB_dhoJUajQHRfgn4Q_w_10_4">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="6" id="Tc_zP3AwUJY_kurCYaXOsnGtA_10_6">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Tc_r47AweIWlEWGd-PVusTNUw_11_4">753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Tc_N2Nq2F2g_Ui8VVeq3Xb95A_11_6">1,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="6" id="Tc_J1jvqoQubkCW7MwKP-YGSQ_13_4">2,179</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="6" id="Tc_AtKphP85qUeRC2OJL8jERQ_13_6">2,352</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Corporate tax receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="gmab:CorporateTaxReceivable" scale="6" id="Tc_bSUFPnt72ku5UAADDJiDOw_15_6">249</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="6" id="Tc_vwwzBNqe_k2c8DAUd9zAag_16_4">2,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="6" id="Tc_FjSuHOajukmPw49VJDx6ng_16_6">2,463</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="gmab:IfrsMarketableSecuritiesCurrent" scale="6" id="Tc_35IEJGrRUUC_xPbihTPKcQ_17_4">8,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="gmab:IfrsMarketableSecuritiesCurrent" scale="6" id="Tc_4U6JHgu6z02WZF043Py4aA_17_6">8,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_TPqPB_wZ1EOn0W2y89J_0Q_18_4">9,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_Nps5GkBwWkeAWx1jHoJ9sQ_18_6">7,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="6" id="Tc_TJSIagr7AUSov7Ke31nbsQ_20_4">20,304</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="6" id="Tc_1NsJm7gcKke7fY7lP3W0Sw_20_6">18,791</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="6" id="Tc_0KQixdyJJUygfOuWKcaF7g_22_4">22,483</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="6" id="Tc_meTowetnB0WJA7FSS4O4Ag_22_6">21,143</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SHAREHOLDERS&#x2019; EQUITY AND LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="6" id="Tc_NpRSr_A8KEad9Cf0s54vWQ_26_4">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="6" id="Tc_dfWBWMgnekypkYWOinZOlg_26_6">66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="6" id="Tc_Tv46WBFduUyeJI3_45KICA_27_4">11,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="6" id="Tc_O-AfiGQs1k63QY_EnnKz9g_27_6">11,894</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherReserves" scale="6" id="Tc_u0tjohH-G0mNPBjY-BvWWw_28_4">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherReserves" scale="6" id="Tc_oTPzVBwcJky_nuXtXHRTAg_28_6">54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Retained earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" scale="6" id="Tc_IpSUGhpRAEatw9cIpzYSCA_29_4">8,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" scale="6" id="Tc_OQr9DgDTBEm05vBkkV7t2Q_29_6">7,107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders' equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_G_Xv53ed1kG7Ui8rwIdV3g_31_4">20,252</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_gJieLR-5zUW2axQg5-qyYw_31_6">19,121</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisions" scale="6" id="Tc_qj_HPx3P8Ui2UEe4uJcsNQ_33_4">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisions" scale="6" id="Tc_e0UDQc_FoEGmN3ml03aDRQ_33_6">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_aA7qedZX5EimuFtUVAiRXA_34_4">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_MFFwi0KPEk6UMoCnosQOoQ_34_6">277</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent" scale="6" id="Tc_E99363rpVECl_Z4TcouLFw_35_4">487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent" scale="6" id="Tc_w5HVWhct9U-FkTQ7ryOYRg_35_6">487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentPayables" scale="6" id="Tc_qsGM5u7IMEeSxEBHwZAiMQ_36_4">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentPayables" scale="6" id="Tc_JNHlyDLqZk6JMkFu2yyOwQ_36_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="6" id="Tc_rrYMvyKpqkiacjZC_AYvdg_38_4">880</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="6" id="Tc_sgfC-0nYekGXN1wEkntopA_38_6">769</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Corporate tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="Tc_DIU8Ay6EoEWI3WC9TRl5kA_40_4">186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_kq7PYqp5KkqD-sygzGWpvQ_41_4">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_-b7BS69lBEuWhmA1di-BHA_41_6">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsCurrent" scale="6" id="Tc_zG-li4xab0uA-2D6l_npfg_42_4">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsCurrent" scale="6" id="Tc_0PJb3hEfO0i_JdTEMx0-wQ_42_6">26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="6" id="Tc_mE4AnD9xiU2-bpKJrXKz4g_43_4">1,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="6" id="Tc_eBLl8dKkaE6WYnGz8oXj4Q_43_6">1,185</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="6" id="Tc_r0f0wynaREmYVe9TFM4nRA_45_4">1,351</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="6" id="Tc_1dlc3e88K0Ksn2YKC1hfPA_45_6">1,253</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="6" id="Tc_wJ2pyXrewUKTqZUCaBwnVQ_47_4">2,231</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="6" id="Tc_C9C5Q6NGVEaO-jcyEzdVuQ_47_6">2,022</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total shareholders' equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="6" id="Tc_MAPAcbLeB0Wcmq9KNk8XAw_49_4">22,483</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="6" id="Tc_WnipAUVPYkG3aVqCuNLTnw_49_6">21,143</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Subsequent events to the balance sheet date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 23/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt;"><span style="color:#000000;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_d3100284_5219_4c2f_9c9a_62862135766f"></a><a id="CASHFLOWS_342842"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">STATEMENT OF CASH FLOWS</p><a id="_cbf12c5d_6216_43c1_8b08_a23d77c9d930"></a><a id="Tc_934mdqKEz0iuHkCS6pLrWA_1_4"></a><a id="Tc_1qNLDUPBj0igYISv0xnL1w_1_6"></a><a id="Tc_zv2cvXb2MUGyp-Ljhg7nJg_2_2"></a><a id="Tc_OFbm9NjI1USqCP4Nd3opEQ_2_4"></a><a id="Tc_U6tBsrTZfUuZJlNnRDCdVA_2_6"></a><a id="Tc_dognCW4_20-YOtg3rtbMAw_3_0"></a><a id="Tc_pnTHgUATdUyRmjKRhgMifA_5_0"></a><a id="Tc_OaANdETqXU-nLFncKT15uw_7_0"></a><a id="Tc_mMogtRpNI0O6VhO1ad24zQ_8_0"></a><a id="Tc_9S45v2kxyUuSlDz85wg56g_9_0"></a><a id="Tc_sx0C3rcUtUiotWIJCzkCww_11_0"></a><a id="Tc__ayDMOugR0GwKcFbWDFyxw_13_0"></a><a id="Tc_nfPe5b81z0mQzfJvwFUvXA_14_0"></a><a id="Tc_KA4oHJsZJEyXBNXK5UBF7A_14_2"></a><a id="Tc_nEwx0XZVAkStTHvGMc-mvg_15_0"></a><a id="Tc_iwGJPtsoHkyyQ51EOpuTSQ_15_4"></a><a id="Tc_p6R-IvIBm0C0gBuvixDRJw_16_0"></a><a id="Tc_v3iEkGA8jEGHVbvo-q4WAQ_18_0"></a><a id="Tc_k2yYmX0ekUmm5z5a_jPfng_20_0"></a><a id="Tc_76j0Y0bl_UeaJdNifUj-wg_21_0"></a><a id="Tc_TxFNxRqv3UKX147f57qg4w_22_0"></a><a id="Tc_TiMT7UbpEkuHAJA_lifFjg_23_0"></a><a id="Tc_JyzaISGEzkeLz2U1nJwHwA_23_2"></a><a id="Tc_rFN9SIbjZU-sbsBxSPc4nw_23_6"></a><a id="Tc_7yUN3RUJdECzCCf23XE8mA_24_0"></a><a id="Tc_506KsizjbUquuElBfpECOQ_24_2"></a><a id="Tc_zbrDnbdSgEuCGBwcWDx5YA_24_6"></a><a id="Tc_xH4e4PCZN0ymhfUa7w6PAA_26_0"></a><a id="Tc_Z2I2X7yOtE6FLZYRxtvPTg_28_0"></a><a id="Tc_88H3KoUlV0uZoVPBe4xi7Q_29_0"></a><a id="Tc_MRte2d6wM0qDvZarI3hnPw_30_0"></a><a id="Tc_xD2LatxcVkm5yGvP2LRG3A_30_6"></a><a id="Tc_zAj7YvZm3Eqxco1v3d1oiA_31_0"></a><a id="Tc_GAHsHEiwK0aTAQ04bluVcA_33_0"></a><a id="Tc_R9RCIhXM-UOu-Kni5OpLUQ_35_0"></a><a id="Tc_LtGi5HXCfESphNyArRU6tg_36_0"></a><a id="Tc_ewOmevffnU6Z3LnY304hwQ_37_0"></a><a id="Tc_Mbg2Umt6aE-OSixfmecfNA_39_0"></a><a id="Tc_nDHBz9r5W0CmII755gRmiw_41_0"></a><a id="Tc_zm7FHCSXvkq-TddlRC-Yjw_42_0"></a><a id="Tc_9uCTwr2ZxE2JgKVYN5I0qQ_43_0"></a><a id="Tc_5BIm8NDfI0-3i8qOAsqSgw_45_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2021</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2020</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net result before tax</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_g1yDMXqQBU6--53kQReQAA_5_4">1,846</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_5pp0_LaIAkW9eAbCfRHpxQ_5_6">4,682</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Reversal of financial items, net</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:ReversalOfFinancialItemsNet" scale="6" id="Tc_XgsCMATuF0ymUneU4AY-FA_7_4">527</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:ReversalOfFinancialItemsNet" scale="6" id="Tc_QBck2waUMkC4HlSAeFGFEw_7_6">114</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments for non-cash transactions</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:TotalAdjustmentsForNonCashTransactions" scale="6" id="Tc_7BB04kuKckusw0jFQIhPLw_8_4">227</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:TotalAdjustmentsForNonCashTransactions" scale="6" id="Tc_beDLsuAIXEObH1eAGhboDw_8_6">182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="6" id="Tc_SQzz-D3ixkK7VGlFcpKFhg_9_4">105</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="6" id="Tc_XNQO-JvBbUOJixkc1YEirg_9_6">2,570</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from operating activities before financial items</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" scale="6" id="Tc_cEgS-eVWYkGJAcVA65H2xQ_11_4">1,441</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" scale="6" id="Tc_Ckwq6vKgs0SF9K2pLkjekg_11_6">2,180</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Interest received</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="Tc_UWa8i3OFW0mPpSTQlckzcA_13_4">107</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="Tc_iIDfbcAB1EW1CQ0a87hs8A_13_6">77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Interest elements of lease payments</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:AdjustmentsForInterestOnLeasePayments" sign="-" scale="6" id="Tc_bg6SSD6QDEaqdBTsQXxvRw_14_4">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:AdjustmentsForInterestOnLeasePayments" sign="-" scale="6" id="Tc_Ixd4HtYKG0m3M7X0whSTgQ_14_6">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Interest paid</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="Tc_-WF47-q50UyHYzAlN7SPuw_15_6">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Corporate taxes paid</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" sign="-" scale="6" id="Tc_14x85DUQDEG89BIa3RSDKw_16_4">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" sign="-" scale="6" id="Tc_c91u1VrFvUWa3iMiPB0mbg_16_6">97</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from operating activities</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="6" id="Tc_WnjYTrSyI0SQ8jQmHijl9A_18_4">1,540</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="6" id="Tc_bi-zfWU7U0Gm9XBffaKKcw_18_6">2,153</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Investment in tangible assets</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="Tc_SgKecu1yl0-VIasbemqG6Q_20_4">107</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="Tc_QA8HYQb7ak6X5OMtFG9ohg_20_6">203</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities bought</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_Q_PggdjwK0Gf0tqdZilVJA_21_4">7,410</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_ntWGIn4TO0uKQ_eLR5Y_QA_21_6">3,006</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities sold</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_ELs5jeBlJEO9dKkIj2MnJQ_22_4">8,137</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_354q6PszVUacWsKQOoxAsg_22_6">4,137</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other investments bought</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_QXYBd2E_q0WOz3HgiK0_8A_23_4">92</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:middle;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other investments sold</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_LQRdBT0rdUyEANvH9X8vig_24_4">438</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from investing activities</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="6" id="Tc_utMFTvOeSka5_O2NEj_9Xg_26_4">966</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="6" id="Tc_2AEK7voHpUmzPiDhQhVsyQ_26_6">928</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:ProceedsFromExerciseOfWarrants" scale="6" id="Tc_aMd5wtdflUuf0beuV_JSIQ_28_4">46</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:ProceedsFromExerciseOfWarrants" scale="6" id="Tc_i3kzwPHgjUywDpfmr7CHXQ_28_6">54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Principal elements of lease payments</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="Tc_8CQY8rtTHk6dncx0BahtaA_29_4">29</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="Tc_bD0_Q32wWEunDXiexGv1hg_29_6">17</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:PaymentsToAcquireTreasuryShares" scale="6" id="Tc_egibv7KKOEWsADD42SDtGg_30_4">437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Payment of withholding taxes on behalf of employees on net settled RSUs</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" scale="6" id="Tc_5Vcu3AgSpE-WSdGpL1Bnww_31_4">40</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" scale="6" id="Tc_kg187EDfn0SA6uaPosA6ww_31_6">18</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flow from financing activities</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="6" id="Tc_XD5844JZjE2B9dlw7-U4RA_33_4">460</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="6" id="Tc_NV_SbNZ_8keyXmlbh-a2xg_33_6">19</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="6" id="Tc_VZte-0OUaUirtYUeLnL4pQ_35_4">2,046</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="6" id="Tc__1UkNYtrj0-uUoiyBXUjiQ_35_6">3,100</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the beginning of the period</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_KxeF8hBQqUC_rNg2kWLqNg_36_4">7,260</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_boDGNdVEsk-xHo_akJVYPg_36_6">3,552</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="Tc_LCls1bvLUUWlZQmNuZyCYw_37_4">171</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="6" id="Tc_ghiCLuqrbUW3YN7ed7W18w_37_6">47</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_IZeUXqpizUag_llEhn-CFA_39_4">9,477</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_9VBi9yvtr0eoHPnr0NVnSA_39_6">6,605</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents include:</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Bank deposits</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Cash" scale="6" id="Tc__oo66pm5r02vlJ9Ju0Hvuw_42_4">6,908</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Cash" scale="6" id="Tc_EtOVQhQsHUqT9yE-i1R1WQ_42_6">3,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Short-term marketable securities</p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" scale="6" id="Tc_pEKNxI3xOkWt6YaUYbCw1Q_43_4">2,569</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" scale="6" id="Tc_l3vMHZo9OEeMNu7z5FZung_43_6">3,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;width:15.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_4biy0v-KzU2duedzNNR4pg_45_4">9,477</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_KbXmF_TWK0uIolCkKr7W3g_45_6">6,605</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 24/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_ef4027c3_7753_4483_ba90_d74fc4d33651"></a><a id="CHANGESINEQUITY_5054"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt;">STATEMENT OF CHANGES IN EQUITY</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_0ffc0122_23f3_4075_a0b3_85e1a547a63f"></a><a id="Tc_TWyzS0K2gEyM-XvZMOuLBg_1_2"></a><a id="Tc_1NgfreMC7U6_yHStRYpm_A_1_4"></a><a id="Tc_pAfd0eI0sE24VIoDMD6n3Q_1_6"></a><a id="Tc_fSzgE3q8AkKC6Lql8Ir6wQ_1_8"></a><a id="Tc_JIlbTE7p406EAa2b8hK9Zw_1_10"></a><a id="Tc_W0wiBeNgBUOFycWFHjJZNA_2_2"></a><a id="Tc_WsPQokxbhESg8GCl2D8tcA_2_4"></a><a id="Tc_xZAa6FL3FUOZ837oJ6cn2Q_2_6"></a><a id="Tc_Ri53KPOr2k-aM3hGTx-aLA_2_8"></a><a id="Tc_m0rNe8wYMkyBCEGiYG_EcA_2_10"></a><a id="Tc_a1BGrqO5ZUO7e3WOThPilQ_3_0"></a><a id="Tc_dDPiQq6MkkexXO1RrdCtqg_5_0"></a><a id="Tc_7BYbdoLSN0uLu8hmHPzWuQ_7_0"></a><a id="Tc_iVBqz4DoUkq7W8nI9Z9Bxw_7_2"></a><a id="Tc_d9ELx3VOwUmVcKYNqcjVwA_7_4"></a><a id="Tc_lUrXx59T8E-sYG9viF0ZLA_7_6"></a><a id="Tc_kAdEFt6dBUm1uKST71E5vw_8_0"></a><a id="Tc_ZONRaWlHe0iQ6IcQOfBN6w_8_2"></a><a id="Tc_KPHWXfxA9UyxFecsDZVp_A_8_4"></a><a id="Tc_R0EKTH_WdkuxC96WNKx30Q_8_6"></a><a id="Tc_pYOZT1oikUyKh2UYh0Rbig_8_8"></a><a id="Tc_4v-1BsJ6wUmxuxJToN9fwg_8_10"></a><a id="Tc_HlhI6erKQ0Wj-V7KhoN4-A_9_0"></a><a id="Tc_k6ZGvGBAhEy-l0akyYRMOw_9_2"></a><a id="Tc_D48X5kI-2kin_exd7U5jJw_9_4"></a><a id="Tc_eKvt7TCObEqeEYU_zXaEWw_9_6"></a><a id="Tc_kiFHk7Em2U-UV7iVyOq4pQ_11_0"></a><a id="Tc_TtUPNBqP8k6ltFZ24-u6EQ_12_0"></a><a id="Tc_MGeSkSazgkWcwabFOzELaw_12_2"></a><a id="Tc_laUi4BBwaEqdyufvJzyMEw_12_6"></a><a id="Tc_3FfZx2xs5UGIycvT6irybg_12_8"></a><a id="Tc_ELHqqJmGEUi-CzzN92yhIg_13_0"></a><a id="Tc_hjIkqDJ1lkmudPGmnBg6dQ_13_2"></a><a id="Tc_GRmK6n5jlkWJpxgi6AJYsA_13_4"></a><a id="Tc_dWtHv6_vm0S-rlMcwHswHA_13_6"></a><a id="Tc_4Jk18Mi-rEu-TwLt9f4JiQ_14_0"></a><a id="Tc_FkN79_lrFUW5Adp-atEwPA_14_2"></a><a id="Tc_YhTy4gR7wUy3jwfr5ROhnw_14_4"></a><a id="Tc_GyatpKfzMUGzk5T1tiSWhg_14_6"></a><a id="Tc_QOM3CuHOtUOhZmgUKMI6cg_15_0"></a><a id="Tc_qVn5F_wOyUWC3ttoIuNnRQ_15_2"></a><a id="Tc_1n28VoEtGkKsOBp1ikUYXQ_15_4"></a><a id="Tc_CVesSOqUfE-CwkeBqNtceQ_15_6"></a><a id="Tc_Hu1F3QASDEOpteQm2sZVkg_17_0"></a><a id="Tc_ti4ZUjq8w027rOjPAlY6ew_19_0"></a><a id="Tc_LAFAjGFLFEy2B6ux8sVXiQ_21_0"></a><a id="Tc_9op8f-ApTE22d3zp8P-wHg_21_2"></a><a id="Tc_HlzndncSmkCsgTUtawd2HA_21_4"></a><a id="Tc_yVor_82uAkacIDeapb0ovA_21_6"></a><a id="Tc_zLlBIq0GzUWopaB-RYu7uQ_22_0"></a><a id="Tc_CNve-YNXlU2UyGf3fOEohw_22_2"></a><a id="Tc_WFABz5TQo0Krczvdh_I8bA_22_4"></a><a id="Tc_5LHTDbFEgEuz8E9jCn064A_22_8"></a><a id="Tc_uK2ptn_VD0SftUoAKerWWw_23_0"></a><a id="Tc_qAG8Avu56kaGg-OdL3a2Vw_23_2"></a><a id="Tc_5fQK56GDl06bbnFwhpLvpw_23_4"></a><a id="Tc_lsBD4wHlHk2xRYxbwtMi1Q_25_0"></a><a id="Tc_7pgYMY-4ZE29EOBLkWfJZg_26_0"></a><a id="Tc_tyHa6yemQEGUHBQYFNzxbA_26_2"></a><a id="Tc_ThOvDBhooUWL8i1Fg1n5Cw_26_6"></a><a id="Tc_wk9Ltg4kPkeiTfqrfCWn-Q_26_8"></a><a id="Tc_FZSy9Mar40Ger6I_SdOdxg_27_0"></a><a id="Tc_vMlR_vGcf0aDNJY7CXOB5Q_27_2"></a><a id="Tc_t4eub4kHOE-PT-TN5SWLCw_27_4"></a><a id="Tc_WqPSszKZ-UaGlHCa8Fis_A_27_6"></a><a id="Tc_W1MR8-PoT0GoexNaBYyTxw_28_0"></a><a id="Tc_5shf0B0Tn0ef-ijRGO8qWQ_28_2"></a><a id="Tc_cZliyfX8A0q3TvaC3xPHjQ_28_4"></a><a id="Tc_Y6y7UmhCskSrYwuzWQvrfA_28_6"></a><a id="Tc_OgBRpQEKB02mXa9vn2j04w_29_0"></a><a id="Tc_9vcgvFxayEqwJzYaWF-sLw_29_2"></a><a id="Tc_pfScyx5owEmSvvpYzrGjxA_29_4"></a><a id="Tc_4R6G1Rzcj0-q5gppm8-kmA_29_6"></a><a id="Tc_J_YwhTsG7kSwW9yVMAjMMQ_31_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Retained</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shareholders'</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">equity</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_p1Fn9MmXZ0mJDu3DNDH-CA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_zlDhUt8ZFkqy8neDNajuCA_5_2">65</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L4KIMTzqKkag3QB7vZbfEQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_FngybefSrEm9tgRswzDdqw_5_4">11,755</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1TQAORpB002CwFlwkSY-8g" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_wA7L9jkGMEiGHzkyF7Pz6Q_5_6">98</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_PAZySbIZoEaim7Pchrrdtw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_emHIsl-g_kaQxGKl60bGig_5_8">2,130</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_WbS3c5lqfUG9iq50CzNoMA_5_10">14,048</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net result</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_8KJr5MuIZUODvBmposPF3g_7_8">3,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_K8KiBhkc5USicxPiWq0u3g_7_10">3,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_3_PfiMQ-4kSjsQ2adoYQYQ_9_8">3,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_UXQyEF-2pUGCrjpsn2B7-A_9_10">3,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Transactions with owners:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L6h4ixqJq0SJo8Qw1UTTOg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_fJwbiQWJT0K6V8s_gqKAcg_12_4">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_9fqMpzKFkE2ta8j1HkadYw_12_10">71</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_fry9e6DqmEqZ5aIHsY1IXw_13_8">98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_fu9sf5Zitk--mQb1Mtwj8Q_13_10">98</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net settlement of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_7UiJBsRSHkOQ2bMQfRZmsw_14_8">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_Kh-er_m-VEa-yZZXHg5YyQ_14_10">18</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tax on items recognized directly in equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" scale="6" id="Tc_37OhZ7ZJukOPJZpoUZp8hQ_15_8">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" scale="6" id="Tc_cfoQMju8JUKKi-k0-bv50A_15_10">25</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_TKZcta72hkC3Gvhut1vakg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_H8jNGZ9sqk-Up-oMhFVOZA_17_2">65</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_A0Jfc6FGgUWtNsve74S7sA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_zLH4niPFdE20GhilErYuqA_17_4">11,826</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_NmzONsVw20-JjLot4LBL5A" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_j0BrSqxR80yI-vhw6_ZJ3A_17_6">98</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_qA8435Q28E6nAiBn6iJsFQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_dPwum3T9RkKk1Am3NWd_LQ_17_8">5,882</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_4qWnMd0kbke1vZuESNCyLg_17_10">17,871</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_mais4ePNskeTkgOGq_-lGA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_cCqq6lx_c0SefjI2gDG5ng_19_2">66</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_CtJaR3tu706WU9cIhYOn4Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_s7_e58ZIIkaPQR67VBfI4A_19_4">11,894</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SgqnYnfln0me5bps_X9-Sg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_aSTzcD9Cs0WVDa44MjktIw_19_6">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_-07AYjBjOk67K2am_lv-cA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_o-M-5W7iKUGE9cd89028Ag_19_8">7,107</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_rzsmHaL3-ku5iok0QKYcqg_19_10">19,121</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net result</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_8Fu0JbcLZUiADoapggZMIg_21_8">1,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_V0NW1i4JKUiWlvz7YL6Tsg_21_10">1,402</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_AXjT64eEiUCHnI3_V_FM8w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="Tc__B5OMuoankeftzWKMgT_Bg_22_6">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="Tc_03uR9Xlkz063dSd0FgvnOA_22_10">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_AXjT64eEiUCHnI3_V_FM8w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_lPf-XXl4-EKQjh-nSi8Z4A_23_6">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_gzOKIcLFt0ez1yHzZsWZPA_23_8">1,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_VH4CsV8qh0yxcvZPJv3fHg_23_10">1,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Transactions with owners:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hGOPQ12jT0ecOSLSOn671A" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_xTWlgcp0XU2ekhK_JhFVeg_26_4">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_QjkoOBKm8EmsmM3BHO9q-Q_26_10">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Tc_dwyGeL1kEU2AjsnJoWEZ5A_27_8">447</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Tc_N7DD3dk3yEuJHJzDYWqsxQ_27_10">447</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_P7T-wJHZKUWjgQ_C67PfGQ_28_8">142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_09d_Jxzf4UST2jTBJXsvlw_28_10">142</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net settlement of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_5s9_edoeA0-W7rSGOQaUzw_29_8">40</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_ZkNfd0MBA0COJmFk0zaAaQ_29_10">40</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4NLivLW-z0mqDErSzXuYzQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_IAJGaw2n_EOBO3z0S0ilyg_31_2">66</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember__pM2AyC5skGhYxOaXLPg1Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_GJa66edFbkaLw_uhTQhl0Q_31_4">11,940</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1qraLfsZLEOjAsD-dxenzg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_WXtQGGvW6USMgcyZ6hmtKg_31_6">82</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fAcxKfHxzk-3GSCXEGeVWw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_sBELu5zTEECOptyYVb3HGQ_31_8">8,164</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_d4rHdeXrR0eSlhtcBeI2EQ_31_10">20,252</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 25/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_2e303f62_a752_4b56_90cb_9b6904691333"></a><a id="_Hlk37693417"></a><a id="NOTESTOTHEFINANCIALSTATEMENTS_725525"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTES&#xA0;TO THE FINANCIAL STATEMENTS</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_xbln6alzgUiXtxou2vVgvg" continuedAt="Tb_xbln6alzgUiXtxou2vVgvg_cont1" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#xA0;1&#xA0;&#x2013; Basis of Presentation</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" id="Tb_K3zYAeaZxki2_LbdBAcTHg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Accounting Policies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS&#xA0;34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#x2019;s external auditors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#x2013; Basis of Presentation in the financial statements in the Genmab 2020 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="gmab:DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" id="Tb_ZOzq5aYqCEKkjliOJntBbQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Management Judgments and Estimates under IFRS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In preparing interim reports, certain provisions under IFRS require management to make judgments (various accounting estimates and assumptions) which may significantly impact the group&#x2019;s financial statements. For a description of significant judgments and estimates, refer to Note 1.3 in the Annual Report.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="Tb_QtvgGqkRokez6zssWOmNiQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information about Geographical Areas</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is managed and operated as <ix:nonFraction unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="INF" format="ixt-sec:numwordsen" name="gmab:IfrsNumberOfReportingUnits" scale="0" id="Narr_Umu-CBkMQEGHdiire9cQBQ">one</ix:nonFraction> business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 26/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_xbln6alzgUiXtxou2vVgvg_cont1"></ix:continuation><a id="_edf90436_79b0_471a_81df_74321ce9636c"></a><a id="Tc_C0hyhQJiH06QiGT2dROcgA_1_2"></a><a id="Tc_Ig5I0Ze9g06ehtZd15qNiA_1_4"></a><a id="Tc_xpy3D1Rnj06NJlRb2RK8-A_2_2"></a><a id="Tc_t3WF2sJhuUybRqRVIzyHOg_2_4"></a><a id="Tc_3KnVm-HJT0af5G-NF3GOQA_3_0"></a><a id="Tc__fhZVx1LhEuz7eWeqSWXDw_4_0"></a><a id="Tc_pjJ3czAjU0WRnfUHRDpcfQ_5_0"></a><a id="Tc_Q3FSh4PRUU-d8iC6Kqj99A_6_0"></a><a id="Tc_RlFK7nv_NkKHVtC9dNZmXQ_7_0"></a><a id="Tc_rTuyw-oVxU6yS34sZpvkRQ_8_0"></a><a id="Tc__66iNre8fkeTNjzGRl-pWQ_8_2"></a><a id="Tc_7oKisNfy1EaABEtSRglUIg_10_0"></a><a id="Tc_k7pV3Y4szUO0mfX4ABZxWw_12_0"></a><a id="Tc_IqOU0BJfOkmejgcOZ-jHrg_13_0"></a><a id="Tc_ssf-98xiw0SvSXNTm5YpqQ_14_0"></a><a id="Tc_2cpx_yhY_EOYGFBfR77wkw_15_0"></a><a id="Tc_Z_LE64jt1EyivetisHK1vg_16_0"></a><a id="Tc_nQvHIFaJIUuR0OlTbVMyRw_17_0"></a><a id="Tc_sY28u1t32063LhqLw8T23Q_18_0"></a><a id="Tc_5sfEmaWJAkGQPzroAPcJmg_19_0"></a><a id="Tc_FbKkKxphHEq92AvkIserCg_19_2"></a><a id="Tc_joQTrU1C-0WSrSl84aYnfg_21_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="Tb_8AI1SxuwNE-Aspx1Zg-huw" continuedAt="Tb_8AI1SxuwNE-Aspx1Zg-huw_cont1" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#xA0;2&#xA0;&#x2013; Revenue</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Genmab enters into license and collaboration agreements that are within the scope of IFRS 15, under which it licenses certain rights to its product candidates to third parties and also may participate in the development of the product candidates. The terms of these arrangements typically include payment to Genmab of one or more of the following: non-refundable, upfront license fees; exclusive designation fees; annual license maintenance fees; additional target fees; development, regulatory and commercial milestone payments; reimbursements for research and development services; and royalties on net sales of licensed products. Each of these payments results in revenue from contracts with customers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on sales of daratumumab (marketed as DARZALEX for intravenous administration and as DARZALEX <i style="font-style:italic;">FASPRO</i> in the United States and as DARZALEX SC in Europe for SC administration). The arbitration first is to settle whether Genmab is required to share in Janssen&#x2019;s royalty payments to Halozyme Therapeutics, Inc. for the Halozyme enzyme technology used in the SC formulation of daratumumab. The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab sales. Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme beginning in the second quarter of 2020 and has continued to do so through June 30, 2021. Given the ongoing arbitration, Genmab has reflected this reduction in its royalty revenues each quarter. The impact to the first half of 2021 royalties is estimated to be DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:ReductionInRoyaltyRevenue" scale="6" id="Narr_0dQZPqNvpkyVeBecQEhZ_w">146</ix:nonFraction> million. The impact to the first half of 2020 royalties is not material. The arbitration is also to settle whether Janssen&#x2019;s obligation to pay royalties on sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#x200B;</span><br />The table below summarizes Genmab&#x2019;s revenue by type and collaboration partner under Genmab&#x2019;s agreements. This information provides the reader additional information regarding the nature, amount, timing and uncertainty of Genmab&#x2019;s revenue and how cash flows might be affected by economic factors.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="Tb_JWKLP42gw0CsIB_FMqPGKA" continuedAt="Tb_JWKLP42gw0CsIB_FMqPGKA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2020</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by type:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_PwANnCyzn0C5MUS8nwx1Sw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_QN57JCYBr0ypJHgXjdZ2gA_5_2">2,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_uqBDRnrgSEiaSoEvBB_vhQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_Tcm55EiVE0uKX6T0_m9Dpw_5_4">1,738</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_Jx4QuMwJkUqCuFfiBGwvYw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_-Tbbof51sEebd_Cy9zZgUg_6_2">227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_D2_7lyccvkaTuObCOVPGJw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_IDUqkEWnNE-Vu__gdGsmAg_6_4">175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_ZaPHCufkHU64vY8arktfIQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_c1crrvqbrESLgxs378sVrA_7_2">731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_m1JCpHXO-kyYxFku-zvTnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_VLqPoMtijk-l6hXovTewRg_7_4">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_n6OJ6Akl1USS7Gay7gozVw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_-Ret4GXh8k6M6mmeHHzJyg_8_4">4,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_k3UtkPI29U6peF4LNRKg0Q_10_2">3,553</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_tEZTnmf5V0ydg5GWM92QyQ_10_4">6,343</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by collaboration partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Janssen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_BPVE7vPNz0u0Ekx3yAqzWw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_wfnkRWlYTU2L7dR6oZWL_Q_13_2">2,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_XoWF9GDwvkauQCs4eAuD6w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_rFAmWSmuGkSmA4zYf_HETw_13_4">1,652</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">AbbVie</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_Tn5RwvlkRUSHrBhAtsMlIw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_mcGH8AyBTUKENWBuSCjukg_14_2">245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_XkMrksxnsESH9AlVnJk8Gg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_NtFS9J7xAk2csCtuCDun-A_14_4">4,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_qY9lpk9pk02Tfs4Fh-iqBA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_NIb0_w2jKU27RjGGBlhZ-g_15_2">162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_rRkDJdMjTUWStzjCszxcAw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_WgxPwL4x1keoEcZg3J0ZMg_15_4">83</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Seagen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_l8NTH0WDpEq0wlqXAMBCwg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_bbFEgiohfk6er6FFH7zhmA_16_2">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_NrXt0j_za0WkwizDvCEL2Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_CMLRH_LJ1UG_YohR_KaAYg_16_4">99</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">BioNTech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_VeITHDP1a0WhA62xDHpgQw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc__gmU_-lL30y4UwSy1lNU2Q_17_2">171</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_i0YAdPafokSkZiDf9ElCYA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_WZlZB8U3yE64Awq5kXB-Sw_17_4">76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_VCedgugRDUuAx52NFUHvig" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_0DcJAfpNbUKw6IxmxLRuTw_18_2">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_r5jbLSw0x0GSS0r6RF8nrA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_b-URIADu_k6ZjHuQJSstgA_18_4">9</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other collaboration partners</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_lb_1v3MJVUOVzAmVqtUJ_Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc__ii2yUQd40yanFrIqGzg2Q_19_4">26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_KZq4jJFw70q7k8E6PZNCvA_21_2">3,553</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_6Hlp_Rj640a9m7yXKXRv_Q_21_4">6,343</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 27/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_8AI1SxuwNE-Aspx1Zg-huw_cont1"><ix:continuation id="Tb_JWKLP42gw0CsIB_FMqPGKA_cont1"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AbbVie Collaboration Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On June&#xA0;10, 2020, Genmab entered into a broad collaboration agreement to jointly develop and commercialize epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 and a discovery research collaboration for future differentiated antibody therapeutics for cancer. Under the terms of the agreement, Genmab received a USD <ix:nonFraction unitRef="Unit_Standard_USD_MZ_DR3Sd-0iNndMFiKqHcQ" contextRef="Duration_7_1_2020_To_7_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_UJmiHgLlu06muPRZ5PWz-A" decimals="-6" format="ixt:numdotdecimal" name="gmab:UpfrontMilestonePaymentReceived" scale="6" id="Narr_7bGOPyswckaGp7D-BuxBtg">750</ix:nonFraction>&#xA0;million (DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_7_1_2020_To_7_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_UJmiHgLlu06muPRZ5PWz-A" decimals="-6" format="ixt:numdotdecimal" name="gmab:UpfrontMilestonePaymentReceived" scale="6" id="Narr_AYNCmaRLBUqCB2qvZNv3NQ">4,911</ix:nonFraction> million) upfront payment in July 2020. Genmab recognized DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_DYo9Pa8mmEeHldxkY2EtIw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Narr_Jw3VVOR7BU-kaVVjagsoQg">4,398</ix:nonFraction> million as license revenue during the first half of 2020 driven by the delivery of licenses for the <ix:nonFraction unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ" contextRef="As_Of_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_YXgvtwoFbEya6zUeGSPkMQ" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfDeliveryLicenses" scale="0" id="Narr_9Tl91u_vGkOHwPLz14r9tA">three</ix:nonFraction> programs described above. Genmab recorded DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_ifrs-full_PerformanceObligationsAxis_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_ilvsRwJsmUW_LnWzSnv9Yg" decimals="-6" format="ixt:numdotdecimal" name="gmab:ContractTransactionPrice" scale="6" id="Narr_XwIYjE6JiE6mmN4rKKiRHA">513</ix:nonFraction> million as deferred revenue related to co-development activities for product concepts and is expected to be recognized as revenue activities are performed, which is estimated to be over a <ix:nonNumeric contextRef="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_eRyWOdr0U0arOAxOzCgi-Q" format="ixt-sec:durwordsen" name="gmab:PerformanceObligationRevenueRecognitionPeriod" id="Narr_leKeuLpOvEel-QJq8acnyw"><span style="white-space:pre-wrap;">seven-year</span></ix:nonNumeric><span style="white-space:pre-wrap;"> period. No revenue has been recognized in the first half of 2021 or 2020 as co-development activities for product concepts have not yet commenced. Refer to Note 2.1 in the Annual Report for further details of the AbbVie collaboration agreement.</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="Tc_nuIu0b3jvUKORfsuV5E5Cg_1_2"></a><a id="Tc_rptG-KuKV0WEM3WGJBQMvw_1_4"></a><a id="Tc_YjJUAV287kuMwHq7rUTgDQ_2_2"></a><a id="Tc_EM0-gB45DUSlPbIPQqz3hg_2_4"></a><a id="Tc_u6MDDLsQGEmhLjOPlONnkg_3_0"></a><a id="Tc_U4QyZ34-S02B-5tMwTlelw_5_0"></a><a id="Tc_WHCi12fv-UaeOnSoSvyyfw_6_0"></a><a id="Tc_ee4y4ywFS0mp7Fa8cqk2Zw_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="Tb_qY-1fCKmg0WdJyGr5FuR0w" continuedAt="Tb_qY-1fCKmg0WdJyGr5FuR0w_cont1" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#xA0;3&#xA0;&#x2013; Financial Instruments</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" id="Group_ad8w6-yWtky-Qg0JD2o2cg" continuedAt="Group_ad8w6-yWtky-Qg0JD2o2cg_2" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June&#xA0;30,&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#xA0;31,&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_HrDvCApT5Uq1RhvNtNXV-g" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_Phk5R8Wm1k6dtGJpYPCITQ_5_2">8,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_c3PLtVVYzU-uGuMkstgoXQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_Es2AWSj3XUGQJwzwk5iJTg_5_4">8,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_EgSoxPtT_kqpSjaUbjg4YQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_pS1BVgHp00ybihN8DzhsuQ_6_2">753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_8tHM7VtXkUuk3JpNpYCVqA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_u7sAy79jvkimWES0dL_6VQ_6_4">1,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets measured at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" sign="-" scale="6" id="Tc_lJspdbsFn0C0CVTqE_8_Cg_7_2">9,151</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" sign="-" scale="6" id="Tc_17Jv5T3dVE2T5HJK-WHqJA_7_4">9,900</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, Genmab&#x2019;s marketable securities were administrated by two external investment managers. The investment guidelines and managers are reviewed regularly to reflect changes in market conditions, Genmab&#x2019;s activities and financial position. During the first half of 2021, Genmab&#x2019;s investment policy was amended to allow investments in debt rated BBB- or greater by S&amp;P or Fitch and in debt rated Baa3 or greater by Moody&#x2019;s.&#xA0;The amended policy also includes additional allowable investment types, none of which were purchased during the first half of 2021.&#xA0; </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#x2019;s current portfolio is spread over a number of different securities with a focus on liquidity and security. Genmab&#x2019;s total marketable securities were invested in EUR (<ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_b1nEv0AoyUCoV8jNBI30Dw" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_fzNwXuevvUyY4iOvlDIfug">10</ix:nonFraction>%), DKK (<ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_OZ08P4IEB0-J1srEa0iG7g" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_gZoAV0DpWkKPvt9sfHqu6A">20</ix:nonFraction>%), USD (<ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_sribKozRAUu_07Nu947Axw" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_vbaRJwrsjU2Olais_YdQmg">69</ix:nonFraction>%) and GBP (<ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_K2gHqglzhkiiSSYKd-yiaA" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_NAQjvd5F7EWqYtALspxykQ">1</ix:nonFraction>%) denominated securities as of June 30, 2021, compared to <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_p0VWrcAFBkKEYD1w7sMfZA" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_m2UnQhRVDEi3CFw1_kbm1w">10</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_FGZXpaWuR0uGlP1dW_5pEQ" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_Yqp4jOk8dUubcvRqCUrrQA">19</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_MCTqYNYF1kymMnq9M9KqFA" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_cVPuwFvPGUm5LmNRrp8tuw">70</ix:nonFraction>%, and <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_qlEizQljAU-i-kzexaRMsw" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_JYOaf0YK2U2ctRh_Is-tCg">1</ix:nonFraction>%, as of December 31, 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, and December 31, 2020, <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2020_To_6_30_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_lu3v55zbDES12yHJmhVJ7g" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Narr_JpdmroW1JEm4ZSehcBB3XQ">99</ix:nonFraction>% of Genmab&#x2019;s marketable securities had an AA rating or higher from Moody&#x2019;s, S&amp;P, or Fitch. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For financial instruments that are measured in the balance sheet at fair value, IFRS 13 for financial instruments requires disclosure of fair value measurements by level of the following fair value measurement hierarchy for: </p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 1 &#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 2 &#x2013; Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 3 &#x2013; Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 28/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="Tc_5XTey43d8kOOotjY2VwUaw_1_0"></a><a id="Tc_gk901owsrUK-GGfzgh_sCA_1_2"></a><a id="Tc_vNG5VIhSmE63SPgiT5MOlA_1_10"></a><a id="Tc_ZsxT_Fxzl0yD7CMryRpq-A_2_0"></a><a id="Tc_J8kaIvMTrEmUuU3r5htHrg_2_2"></a><a id="Tc_Q1e6uT_Fn0en0ls_fETg1A_2_4"></a><a id="Tc_TyuEMChg9kSz90MYx9ieRw_2_6"></a><a id="Tc_x7bNGaeT70WYOQRWAZN0rA_2_8"></a><a id="Tc_HLoaqC89AUCpTWG5FyMpOA_2_10"></a><a id="Tc_F2rTDZTQ7UyKZ5gG5PD4uA_2_12"></a><a id="Tc_Ty0tNYiD60mPin60MN7RzQ_2_14"></a><a id="Tc_V1GCr3AGi0Sy3toPx0KtzQ_2_16"></a><a id="Tc_gl6CpgHoAUaC2PDWVa733A_4_0"></a><a id="Tc_gPDlj_xjfk2yvfk4UWVzFw_4_4"></a><a id="Tc_RSkJMNauwkyVDfoK-MUmUA_4_6"></a><a id="Tc_BhOCx-bMPU24tJ6JKM5G8A_4_12"></a><a id="Tc_se0obFWH60uck8aaqVSK2Q_4_14"></a><a id="Tc_38JfsUPJ2UuZsIrizkxffA_5_0"></a><a id="Tc_VkfJGmAAOkumhBnXpjmoDw_5_4"></a><a id="Tc_TdxZcdtvvUmt3lLtc_LhzQ_5_12"></a><ix:continuation id="Tb_qY-1fCKmg0WdJyGr5FuR0w_cont1"><ix:continuation id="Group_ad8w6-yWtky-Qg0JD2o2cg_2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#xA0;30,&#xA0;2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#xA0;31,&#xA0;2020</b></p></td></tr><tr><td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets Measured at Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_iIgp3bLrT0WdC_XUJJoNxQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_Qk6Qhdv0wUaCFsNhK_Pp8w_4_2">8,398</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_HrDvCApT5Uq1RhvNtNXV-g" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_-lMf9g2QrUy7XeiH9pJMWg_4_8">8,398</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Rqd-AfD3wEytE2ZCSjiHNQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_wYoAc0Jsj0-lk6ryWf8R7w_4_10">8,819</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_c3PLtVVYzU-uGuMkstgoXQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_d95-mP6dE0uWaoPMhDSkHw_4_16">8,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other investments</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Y6PESuh_w0ChCcbF0c5LwQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_6d67PVvhuk6lhlDATV7UEw_5_2">729</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_l6TS3ZYOmUeez0G-_bZVGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_TZrkYUxx6EW4ELEpRWLOzg_5_6">24</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_EgSoxPtT_kqpSjaUbjg4YQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_yx-F5btZGEWQiSmssflNSg_5_8">753</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_DodsJRF0NEOqpd0-8JQNgw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_CKYekYgyQE-07RKvWy2Ibg_5_10">1,067</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_fnkpZL-bskSS4uB8m0uSdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_eXSCtOXTikGAJNkWekBUVg_5_14">14</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_8tHM7VtXkUuk3JpNpYCVqA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_w82KLiuh6k6JEjymaZR8cA_5_16">1,081</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Marketable Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#x2019;s marketable securities (Level 1). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Investments </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other investments as of June 30, 2021 consist primarily of a DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_OY8O9iGctkKqyFaG0cKc5w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr_cXVwP5-w80OpL9OYo4XWgA">650</ix:nonFraction> million investment in common shares of CureVac, compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_oRQeDeA0OUCUPKU1Y5V9-g" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr_9dYcpvRkI0KH86ngb69IuQ">1,067</ix:nonFraction> million as of December 31, 2020. During the first half of 2021, Genmab sold <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_wD9EUBzhJkWAnxVwt1BN_A" decimals="2" format="ixt:numdotdecimal" name="gmab:PercentageOfInvestmentInCommonShares" scale="-2" id="Narr_n61t_wAG6UqTrU4msWFRsw">35</ix:nonFraction>% of its investment in common shares of CureVac. Proceeds received from the sale of shares were DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_wD9EUBzhJkWAnxVwt1BN_A" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="6" id="Narr_LA-1qt14WkCuyJBx7CXtJw">438</ix:nonFraction> million. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the second quarter of 2021, Genmab made an investment in common shares of Bolt. As of June 30, 2021, the investment in Bolt was valued at DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_mh6YfnyyLUOtHNXoweh8Iw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr__OUKyloLjUK-JUT1USR67g">79</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The investments in CureVac and Bolt are recorded at fair value through profit and loss. The fair value of Genmab&#x2019;s investments in CureVac and Bolt are determined using unadjusted quoted prices in established markets (Level 1).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="Tc_cxZDVdA3dEinrihvw3-ITg_1_2"></a><a id="Tc_lERFN8Z9R0SpDvtSTEBf3g_1_4"></a><a id="Tc_uzD5-hqv-U2HtvxXMTeCfw_2_2"></a><a id="Tc_G2w1shGSwUCm7qXeF1xzEA_2_4"></a><a id="Tc_NwVTMICZTUmg3qF-0SqzPQ_3_0"></a><a id="Tc_oAaCsa2iy0-9f_qTnUUlIA_5_0"></a><a id="Tc_q7p1QJMnx0eiA5951FHxaw_6_0"></a><a id="Tc_2g88v6MzLE-nE0yDnP7T2g_7_0"></a><a id="Tc_lDcBoDUOgkSRx-4nxGs-6w_9_0"></a><a id="Tc_QzsjIlXd_Ei4GQ4HfVjVeQ_11_0"></a><a id="Tc_EmaECZsUrUu87fnrnSh_vg_12_0"></a><a id="Tc_94e9o4TblkGSiwinVo7-zQ_13_0"></a><a id="Tc_8CpxKmqB60WuYQ8Zx-DF1Q_14_0"></a><a id="Tc_huRH21CyvU2l8mAnVEBQXA_14_4"></a><a id="Tc_mQ19Hm4tMEWts4vpENbEgw_16_0"></a><a id="Tc_ir_sX8u2GkijAbHU6Ja9wQ_18_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="Tb_7JvthDvMgU-IAZf35TFA_g" continuedAt="Tb_7JvthDvMgU-IAZf35TFA_g_cont1" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#xA0;4&#xA0;&#x2013; Financial Income and Expenses</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock" id="Tb_RVDXSFJt0EOXASrein5m2Q" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2020</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialIncome" scale="6" id="Tc_uHTfWruSRUGsWZKfrnrdUA_6_2">127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialIncome" scale="6" id="Tc_JkVbqLiVVEW24qlMYB4GjQ_6_4">83</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Tc_bTbMQIlo20K56Q8ndAD9Dg_7_2">573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Tc_RN3pXEpbgkyqVZUnLc8azw_7_4">36</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_Cx4LFNUtakSFxVHfbH-OOQ_9_2">700</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_BP6YQBjBkUqCAnewiE6nEw_9_4">119</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialExpenses" scale="6" id="Tc_V1R7H4CeA0eO1O31GMFS5Q_12_2">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialExpenses" scale="6" id="Tc_AQzkN8zffUq_QY6sng4Bqw_12_4">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnMarketableSecurities" scale="6" id="Tc__1lBUSG39U-ZyIgnMjeV7g_13_2">134</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnMarketableSecurities" scale="6" id="Tc_ibgAATHly0SWAZMBFgjINQ_13_4">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnOtherInvestmentsNet" scale="6" id="Tc_CxE_4jYVckqsOPLP8BRRlA_14_2">33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_H2wbAwfOpEqOG84BgGU1pQ_16_2">173</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_q8JQOAjf-EaqSCa-p6_Hyw_16_4">5</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="6" id="Tc_vOygp8gAskurucUjPDVmFw_18_2">527</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="6" id="Tc_-F0J4GVYcEeJFb-pZdVXUA_18_4">114</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign exchange rate gain, net was DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Narr_rrQzvh45TkWMyExm7pxOFA">573</ix:nonFraction> million in the first half of 2021 as compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Narr_igwv8wHHL0Kmz5rCQw8mvg">36</ix:nonFraction> million in the first half of 2020. The increase was driven by the strengthening of the USD against the DKK in 2021 that positively impacted our USD denominated marketable securities portfolio and cash holdings. Refer to Note 4.2 in the Annual Report for further details of foreign currency risk.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 29/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_7JvthDvMgU-IAZf35TFA_g_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on marketable securities, net of DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnMarketableSecurities" scale="6" id="Narr_VhwAAJMs70yJmM1UIHvcxA">134</ix:nonFraction> million in the first half of 2021 was primarily driven by the movements in interest rates in the United States and Europe.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#x200B;</span></p><a id="_Hlk76547909"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_EUeQlQbOJEiOHfBRf5pV5Q" continuedAt="Tb_EUeQlQbOJEiOHfBRf5pV5Q_cont1" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Note&#xA0;5&#xA0;&#x2013; Share-Based Instruments</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Restricted Stock Unit Program</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab A/S established an RSU program as an incentive for all the Genmab group&#x2019;s employees, members of the Executive Management, and members of the Board of Directors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For details of the RSU program prior to changes in 2021, refer to Note 4.6 in the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In February 2021, the RSU program was amended (the &#x201C;2021 RSU Program&#x201D;). Under the terms of the 2021 RSU Program, the Board may decide, in its sole discretion, to accelerate the vesting of the RSUs held by a participant, or accelerate the vesting of the RSUs and make a cash settlement in case of (1) a change of control event as defined in the 2021 RSU Program, if a participant&#x2019;s employment terms are materially changed to his or her detriment during the 12-month period following the change in control event, or if the participant, who is a member of the Board, is replaced by a new board member or such participant's seat on the Board is eliminated due to a reduction in the number of board members, or (2) certain other extraordinary transactions as described in the 2021 RSU Program. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Under the terms of the 2021 RSU Program, in the event an RSU holder separates from the Company under circumstances in which the RSU holder is considered a &#x201C;bad-leaver,&#x201D; such as being dismissed for cause or during the employment probationary period, unvested RSU will be forfeited. RSU holders may maintain a pro rata portion of unvested RSUs if they separate from the Company under circumstances where they are considered &#x201C;good-leavers,&#x201D; such as dismissal without cause or termination of employment due to the Company&#x2019;s material breach of the RSU holder&#x2019;s employment terms, or if the participant is a member of the Board, if the membership of the Board ceases for any other reason than as a result of the participants death. All unvested RSUs will be forfeited in the event of termination of employment due to the RSU holder&#x2019;s death.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr__1MXevknPka3Oh5kWBkXuQ">159,567</ix:nonFraction> RSUs were granted with a weighted average fair value of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw" decimals="2" format="ixt:numdotdecimal" name="gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" scale="0" id="Narr_Kk6KNUWLyEuktonz1aCiSA">2,149.55</ix:nonFraction> per RSU. During the first half of 2020, <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_cvoKNsXHwkePFsaNRDiHew">22,672</ix:nonFraction> RSUs were granted with a weighted average fair value of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw" decimals="2" format="ixt:numdotdecimal" name="gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" scale="0" id="Narr_Tpvinc-LZkCgXpkw4otHCw">1,491.16</ix:nonFraction> per RSU. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Narr_YeShRECSckO_x7BmtFJ-Ig">49,012</ix:nonFraction> RSUs vested, compared to <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Narr_9th6Ap8lEEmBKVJ5XnWdJg">39,438</ix:nonFraction> RSUs during the first half of 2020. Genmab settles RSUs using shares issued from treasury stock. A portion of the settlement is withheld to satisfy individual statutory tax withholding obligations in certain jurisdictions which remain in Genmab&#x2019;s treasury share account.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Warrant Program</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Genmab A/S established warrant programs as an incentive for all the Genmab group&#x2019;s employees, and members of the Executive Management. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For details of the warrant programs prior to changes in 2021, refer to Note 4.6 in the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Warrant Program was amended (the &#x201C;2021 Warrant Program&#x201D;). Under the terms of the 2021 Warrant Program, the Board may decide, in its sole discretion, to accelerate the vesting of the warrants held by a warrant holder in case of (1) a change of control event as defined in the 2021 Warrant Program, if a warrant holder&#x2019;s employment terms are materially changed to his or her detriment during the 12-month period following a change in control event, or (2) certain other extraordinary transactions as described in the 2021 Warrant Program.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 30/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_EUeQlQbOJEiOHfBRf5pV5Q_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the 2021 Warrant Program, if a warrant holder separates from the Company under circumstances in which the warrant holder is considered a &#x201C;bad-leaver,&#x201D; such as being dismissed for cause or during the employment probationary period, unvested warrants will be forfeited. Warrant holders may maintain a pro rata portion of unvested warrants if they separate from the Company under circumstances where they are considered &#x201C;good-leavers,&#x201D; such as dismissal without cause or termination of employment due to the Company&#x2019;s material breach of the warrant holder&#x2019;s employment terms. All unvested warrants will be forfeited in the event of termination of employment due to the warrant holder&#x2019;s death.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="0" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsGrantedDuringPeriod" scale="0" id="Narr_4fJeqvkzfUSvncyMm3MJqA">147,568</ix:nonFraction> warrants were granted to Genmab employees with a weighted average exercise price of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsGranted" scale="0" id="Narr_c2vOP5-kOUyjjn0SGMxRbw">2,189.21</ix:nonFraction> per warrant and a weighted average Black-Scholes fair market value of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfFairValueOfWarrants" scale="0" id="Narr_s1BmQwT6RUadDWmJ7rSwJA">683.79</ix:nonFraction> per warrant. During the first half of 2020, <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="0" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsGrantedDuringPeriod" scale="0" id="Narr_9Un6UoYUAUqCaETRT7Wy1w">49,323</ix:nonFraction> warrants were granted to Genmab employees with a weighted average exercise price of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsGranted" scale="0" id="Narr_C79jpr3JKUWap6oVrmVCHA">1,548.22</ix:nonFraction> per warrant and a weighted average Black-Scholes fair market value of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfFairValueOfWarrants" scale="0" id="Narr_Ft4lDfbt2kaJpiymZpo5Vw">465.70</ix:nonFraction> per warrant.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the first half of 2021, <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="0" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsExercisedDuringPeriod" sign="-" scale="0" id="Narr_bhxKLRhKbEyKI2SJLwzVjA">74,992</ix:nonFraction> warrants were exercised with a weighted average exercise price on date of grant of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsExercised" scale="0" id="Narr_koT2_QzQoE2EgKWBPEGW0A">606.22</ix:nonFraction> with proceeds to Genmab of DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_A_sHaM7Ykki3oxBQqJ10GA" decimals="-6" format="ixt:numdotdecimal" name="gmab:ProceedsFromExerciseOfWarrants" scale="6" id="Narr_FoYoBmZu8UKMP8V_AzWZoA">46</ix:nonFraction> million. The warrants exercised increased share capital accordingly and corresponded to approximately <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants" scale="-2" id="Narr_Ref1xniCT0qs2KKvXkdIAg">0.11</ix:nonFraction>% of share capital. During the first half of 2020, <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="0" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsExercisedDuringPeriod" sign="-" scale="0" id="Narr_GJvVWZVs1E-3hLeYp8JOEg">272,078</ix:nonFraction> warrants were exercised with a weighted average exercise price on date of grant of DKK <ix:nonFraction unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsExercised" scale="0" id="Narr_Wh44cqdXJU-jPpC204bvjw">261.06</ix:nonFraction> with proceeds to Genmab of DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_3MA1mpKA4kSpw8AfLI3utA" decimals="-6" format="ixt:numdotdecimal" name="gmab:ProceedsFromExerciseOfWarrants" scale="6" id="Narr_1Riafqt3YEyzrfVE7nIzOg">71</ix:nonFraction> million. The warrants exercised increased share capital accordingly and corresponded to approximately <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants" scale="-2" id="Narr_c7ai6wt_KkKXaBuDxULdEg">0.42</ix:nonFraction>% of share capital.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Share-based compensation expenses related to Genmab RSU and warrant programs for the first half of 2021 totaled DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="Narr_hKWesDWppUKRbhIayIIMDQ">142</ix:nonFraction> million compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="Narr_dHHl-X9oYUms9eQ9MtuN4w">98</ix:nonFraction> million for the first half of 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#x200B;</span><br /><b style="font-weight:bold;">Share repurchases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In general, Genmab intends to purchase its own shares in order to cover a portion of the obligations in relation to RSUs. Authorization to purchase Genmab shares up to a nominal value of DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_3_31_2016_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_ESq4TWsOUU-_fQutYyImDg" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchaseProgramAuthorizedAmount" scale="0" id="Narr_gzh10mnEBUacniWWSwE_Zg">500,000</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="As_Of_3_31_2016_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_ESq4TWsOUU-_fQutYyImDg" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" id="Narr_pVB2qSfrbkKkd5OBxKt77g">500,000</ix:nonFraction> shares) was given by the shareholders at the annual general meeting in March&#xA0;2016. As of December 31, 2020, a total of <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="Duration_1_1_2020_To_12_31_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_tqrSzrvaIkWs3_xaEgi0Qg" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchasedDuringPeriodShares" scale="0" id="Narr_8EnRA6ciYE-BIyyFJuuDiQ">225,000</ix:nonFraction> shares, with a nominal value of DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_12_31_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_tqrSzrvaIkWs3_xaEgi0Qg" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchasedDuringPeriodValue" scale="0" id="Narr_ArbfLqLhLU293KQKBHDU_Q">225,000</ix:nonFraction>, had been repurchased under the March 2016 authorization. The March 2016 authorization expired in March 2021. Additionally, in March&#xA0;2019, Genmab shareholders authorized the repurchase up to an additional nominal value of DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_3_31_2019_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_YbHFH-aRiUOdag_c24OEXw" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchaseProgramAuthorizedAmount" scale="0" id="Narr_SQLEZFcvRE68U9Ikmuan9g">500,000</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="As_Of_3_31_2019_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_YbHFH-aRiUOdag_c24OEXw" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" id="Narr_WTPFaZCdYE6VQFk8-1RMNA">500,000</ix:nonFraction> shares). A portion of the shares that may be repurchased under this authorization may be used to cover Genmab&#x2019;s obligations in relation to the RSUs. Moreover, in April&#xA0;2021, Genmab shareholders authorized us to repurchase up to an additional nominal value of DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchaseProgramAuthorizedAmount" scale="0" id="Narr_iC7qMpvUCEqlESFiRKmzFg">500,000</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" id="Narr_3JGfKrKVREinipwYRPzUEg">500,000</ix:nonFraction> shares) to cover obligations under our share-based remuneration programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As announced on February 23, 2021, Genmab initiated a share buy-back program. During the first half of 2021, Genmab acquired <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="As_Of_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_XnjM0c4Pf0-AfdDAV6Byxw" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" id="Narr__nYYC6mT9Ead6eTX_SjMUw">200,000</ix:nonFraction> of its own shares, representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA" contextRef="Duration_2_23_2021_To_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_J6YNADjInUKuD19rDW3Jyg" decimals="3" format="ixt:numdotdecimal" name="gmab:PercentageOfShareCapital" scale="-2" id="Narr_wTrXkXuE7ky7St_hAa9Xfw">0.3</ix:nonFraction>% of share capital. The total amount paid to acquire the shares, including directly attributable costs, was DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_2_23_2021_To_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_J6YNADjInUKuD19rDW3Jyg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Narr_pcv7pK2zjkKYqrMPiMuLKw">447</ix:nonFraction> million and has been recognized as a deduction to shareholders&#x2019; equity. These shares are classified as treasury shares and are presented within retained earnings on the balance sheet as of June 30, 2021. There were <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_x8IPZU4fukqM5g_XH7UpIw" decimals="0" format="ixt-sec:numwordsen" name="gmab:IfrsStockRepurchasedDuringPeriodShares" scale="0" id="Narr_fk_gM6C5YkmVFxnDV-bhXQ">no</ix:nonFraction> share repurchases during the first half of 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_S4o242eUzEC8Lsv54F5WNA" decimals="0" format="ixt:numdotdecimal" name="gmab:IfrsTreasuryStockShares" scale="0" id="Narr_a2K4JRu7k0e5xt6g6y9ZTA">299,206</ix:nonFraction> treasury shares were held by Genmab to cover the obligations in relation to the RSU program and to mitigate the dilutive effect of share capital increases resulting from future exercises of warrants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 31/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_LBHecP8Fr0KWZR6kNZQypA" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Note&#xA0;6&#xA0;&#x2013; Related Parties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#x2019;s related parties are the Genmab A/S&#x2019; (parent company) subsidiaries, Board of Directors, Executive Management, and close members of the family of these persons. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab has service agreements with, and has made equity compensation grants to, members of Executive Management in the ordinary course of business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Transactions with Related Parties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, there were no material related party transactions. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Key Changes to Executive Management and the Board of Directors</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, there was one change to the Executive Management team. Effective March 1, 2021, Tahamtan Ahmadi, previously Senior Vice President, Head of Oncology, was appointed Executive Vice President and Chief Medical Officer, Head of Experimental Medicines. He joins the existing Executive Management team of Jan van de Winkel, President and Chief Executive Officer, Judith Klimovsky, Executive Vice President and Chief Development Officer, Anthony Pagano, Executive Vice President and Chief Financial Officer and Anthony Mancini, Executive Vice President and Chief Operating Officer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">There were no changes to the Board of Directors during the first half of 2021. Following Genmab A/S' Annual General Meeting on April 13, 2021, the Board of Directors is comprised of <ix:nonFraction unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ" contextRef="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfIndependentBoardMembers" scale="0" id="Narr_6cavLIjll0q7EpAghH5liQ">five</ix:nonFraction> independent board members, <ix:nonFraction unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ" contextRef="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfNonIndependentBoardMembers" scale="0" id="Narr_Q57DzWSFUkGFL_-9ubH1ug">one</ix:nonFraction> non-independent board member, and <ix:nonFraction unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ" contextRef="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfEmployeeElectedBoardMembers" scale="0" id="Narr_hY-0u5G3v0awzvNC1svBNQ">three</ix:nonFraction> employee-elected board members. They are Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, Jonathan Peacock, Dr. Anders Gersel Pedersen, Peter Storm Kristensen, Dr. Mijke Zachariasse and Rima Bawarshi Nassar, respectively.</p></ix:nonNumeric><a id="_7fe27b19_1751_4b7a_bb77_2b506f02ee89"></a><a id="Tc_Umng6AyHI0mdHHvBaqfJGQ_1_2"></a><a id="Tc_ll4YoRAGqEqDD4D9nnUNtA_1_4"></a><a id="Tc_p1rs8Pldq0WB4e2XwBgTIg_2_2"></a><a id="Tc_-FU3ahmxK0yaUfVbBN6g3A_2_4"></a><a id="Tc_D66jEJDi3kiDVG8ndFO0lA_3_0"></a><a id="Tc__FnrUKZ9G0WL5pgtb3tCNw_4_0"></a><a id="Tc_DbSrfq_RT02hwMvegMZhIA_5_0"></a><a id="Tc_9bGnm-Os-UGjcrioIvqbkQ_6_0"></a><a id="Tc_Bse1X5zhfU6mMUEfQwqeXw_8_0"></a><a id="Tc_Ex_JIfhnz0-6skHTefFz2g_10_0"></a><a id="Tc_sLwKO92CD0qQka8KVBOZCg_11_0"></a><a id="Tc_255dEGZwEkaIstRp3haPvw_12_0"></a><a id="Tc_xMyL3_wtbE6HyBG9veiDRQ_14_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfLeasesExplanatory" id="Tb_6AmNUqZpC0W6-EdC480v9Q" continuedAt="Tb_6AmNUqZpC0W6-EdC480v9Q_cont1" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="color:#000000;font-weight:normal;visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Note&#xA0;7&#xA0;&#x2013; Leases</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Amounts recognized in the balance sheet</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" id="Tb_gfZyy3hs0ES-qDhy_6h5zg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The balance sheet shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#xA0;31,&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember__kp1XyJRaEqpMiDAX0T8vQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_f9QHgL0SM0Kk-fP59gxGSw_5_2">381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_YxEM9iziHkO-obYvfBGHEQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_c-Gi6mOhnEWl34XI15VDkA_5_4">280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_AqtNH3bYz0emLMQ_xHz5lA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_suCV46ulqECwrTJZO8JqaQ_6_2">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_Vnp4zSnt40qzvspJ2EGkFw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_1Uxqn0ep6UuYjVdPkqMc8Q_6_4">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_ELro0N5gp0-McWb5C5sOGg_8_2">384</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_M2BlF71L10CPum_zM54XQQ_8_4">283</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_qD7lQHMDMUGraDYikGeWvQ_11_2">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_sOvKlwlSq0OtzGa6kUIa5A_11_4">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_okNFlfWjS0KbEelnU9CEtg_12_2">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_mRbVNfzm6UqGnDY6RIqjBw_12_4">277</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="6" id="Tc_GQUFYakbI02adtrqyfxAng_14_2">443</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="6" id="Tc_y411eWyEq0q9taYSDZ_3PQ_14_4">319</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the commencement of leases in Japan and the United States with respect to office space. During the first half of 2020, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 32/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_72632c49_b4a9_4d44_8542_2a687d10341f"></a><a id="Tc_Ny8ZdHrfLUuV9RMMgOl4cg_1_2"></a><a id="Tc_OrFrKGRyZkOY_h6lCy1wfQ_1_4"></a><a id="Tc_AbsRTWpkUUawCajBduz0OQ_2_2"></a><a id="Tc_kpHjY26AuU-E18G9HlRjdA_2_4"></a><a id="Tc_P9mhaUoymkmmtMu6CQidhg_3_0"></a><a id="Tc_ranak9hMuU6_kBTeoC2xfg_4_0"></a><a id="Tc_Ny4nyo2mOUeXXuARaRlLPA_5_0"></a><a id="Tc_N90YvUsO9U2gB1jboWxOMg_6_0"></a><a id="Tc_PLgNPlEgakKy0MtXiyP39A_8_0"></a><a id="Tc_L3QDNGLH-E6_b1pZngmnyQ_10_0"></a><a id="Tc_R_LuwNGBnkqz-wM0-mUpbA_11_0"></a><ix:continuation id="Tb_6AmNUqZpC0W6-EdC480v9Q_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">commencement of leases in the United States and the Netherlands with respect to office and laboratory space.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#x200B;</span><br /></b><b style="font-weight:bold;">Significant leases not yet commenced</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During 2020, Genmab entered into a lease agreement with respect to the new headquarters in Denmark with a commencement date in March 2023 and is non-cancellable until March 2038. The total future minimum payments over the term of the lease are approximately DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="gmab:FutureMinimumOperatingLeasePayments" scale="6" id="Narr_zaBgs3NLiUynHtE_5vt-6Q">342</ix:nonFraction> million and estimated capital expenditures to fit out the space are approximately DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ" decimals="-6" format="ixt:numdotdecimal" name="gmab:EstimatedCapitalExpenditureForLease" scale="6" id="Narr_SnVKaOlm5EqD6vTL9sx1CA">40</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During 2019, Genmab entered into a lease agreement with respect to office and laboratory space in the Netherlands with a commencement date in February 2022 and is non-cancellable until January 2032. The total future minimum payments over the term of the lease are approximately DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ" decimals="-6" format="ixt:numdotdecimal" name="gmab:FutureMinimumOperatingLeasePayments" scale="6" id="Narr_QxGoe6bk0kC0PnkvLac_Hw">117</ix:nonFraction> million and estimated capital expenditures to fit out the space are approximately DKK <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ" decimals="-6" format="ixt:numdotdecimal" name="gmab:EstimatedCapitalExpenditureForLease" scale="6" id="Narr_evjC31BJAkm4bZU98FlQ5A">74</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Amounts recognized in the statement of comprehensive income</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="gmab:DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" id="Tb_cT2N_CicWkKuxkR4DPt3wA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The statement of comprehensive income shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#xA0;30,&#xA0;2020</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_arkOpJJSzEOXHp0JsMegrA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_9Pmi9DgmkEWXzbwYn9iIdA_5_2">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_OIs20y9YdUCpESyQhSl9AA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_EwMdiKhVKUuP12b7MmSL0w_5_4">14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8pQrFQMD0keUvx5gLpDr7w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_15KOP0d1Fk2_bhCF6-KDcg_6_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8DR9RGN4mk6fMGFsM-lTeg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_qpVOaQP4iEuMcANQh1P31Q_6_4">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_PvPUO8PM9kSqMJVdTkCLMQ_8_2">26</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_3XlvPkwIKkS66Nq2jlSmBQ_8_4">15</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="Tc_WNG97PBcE0qDBM8Ft10Drg_10_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="Tc_GHJtoR07KkCTRaJrTYE5sg_10_4">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expense relating to short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="6" id="Tc_pR6XP7cou0eI43vCBQjk0g_11_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ" contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="6" id="Tc_A5xegdc_xUaKqK89QXlZ3A_11_4">2</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense is included in net financial items and expenses relating to short-term leases are included in operating expenses in the statement of comprehensive income.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_GFExNk2OZ0K1oTxMoBqFOQ" escape="true"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#xA0;8&#xA0;- Subsequent Events to the Balance Sheet Date</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2021.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 33/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="ABOUTGENMAB_779230"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ABOUT GENMAB</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab&#x2019;s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Interim Report contains forward looking statements. The words &#x201C;believe&#x201D;, &#x201C;expect&#x201D;, &#x201C;anticipate&#x201D;, &#x201C;intend&#x201D; and &#x201C;plan&#x201D; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#x2019;s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab&#x2019;s most recent Annual Report on Form 20-F and other filings with the U.S. SEC, which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; Genmab in combination with the Y-shaped Genmab logo</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; HuMax</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; DuoBody</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; DuoBody in combination with the DuoBody logo</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; HexaBody</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; HexaBody in combination with the HexaBody logo</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">; DuoHexaBody</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;"> and HexElect</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">, UltiMAb</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;"> is a trademark of Medarex, Inc., Kesimpta</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;"> and Sensoready</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;"> are trademarks of Novartis AG or its affiliates. DARZALEX</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;">, DARZALEX FASPRO</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;"> and RYBREVANT&#x2122; are trademarks of Johnson &amp; Johnson. TEPEZZA</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-style:italic;"> is a trademark of Horizon Therapeutics Ireland DAC. </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 34/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;min-height:27.35pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="gmab-20210630xex991d85adb002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2021</b></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="DIRECTORSANDMANAGEMENTSSTATEMENTONTHEINT"></a><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">DIRECTORS&#x2019; AND MANAGEMENT&#x2019;S STATEMENT ON THE INTERIM REPORT</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors and the Executive Management have today considered and adopted the unaudited interim report of the Genmab group for the six months ended June 30, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The interim report is prepared in accordance with IAS 34, &#x201C;Interim Financial Reporting,&#x201D; as issued by the IASB and in accordance with IAS 34 as endorsed by the EU, and additional Danish disclosure requirements for interim reports of listed companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We consider the applied accounting policies to be appropriate and, in our opinion, the interim report gives a true and fair view of the assets and liabilities, financial position, results of operation and cash flows of the group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we consider the Management&#x2019;s Review to give a true and fair account of the development in the group&#x2019;s activities and financial affairs, results of operations and the group&#x2019;s financial position as a whole as well as a description of the significant risks and uncertainties which the group faces, as further described in our 2020 Annual Report and the Form 20-F filed with the U.S. Securities and Exchange Commission in March 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Copenhagen, August 11, 2021</p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Executive Management</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.19%;"><tr style="height:1.25pt;"><td style="vertical-align:bottom;width:17.17%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:19.01%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:18.06%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:19.97%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:25.76%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr style="height:14.7pt;"><td colspan="2" style="vertical-align:bottom;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb008.jpg" alt="A picture containing diagram&#xA;&#xA;Description automatically generated" style="display:inline-block;height:40.73pt;width:81.6pt;" /></p></td><td colspan="2" style="vertical-align:bottom;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb009.jpg" alt="A picture containing text, opener, clipart, tool&#xA;&#xA;Description automatically generated" style="display:inline-block;height:35.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:94pt;" /></p></td><td colspan="2" style="vertical-align:bottom;width:21.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb010.jpg" alt="A picture containing hanger&#xA;&#xA;Description automatically generated" style="display:inline-block;height:38.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:66pt;" /></p></td><td colspan="2" style="vertical-align:bottom;width:19.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb011.jpg" alt="A close-up of a pen&#xA;&#xA;Description automatically generated with low confidence" style="display:inline-block;height:38.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:78.99pt;" /></p></td><td style="vertical-align:bottom;width:20.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb012.jpg" alt="A picture containing sky&#xA;&#xA;Description automatically generated" style="display:inline-block;height:30.97pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:79.8pt;" /></p></td></tr><tr style="height:14.7pt;"><td colspan="2" style="vertical-align:bottom;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Jan van de Winkel</p></td><td colspan="2" style="vertical-align:bottom;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anthony Pagano</p></td><td colspan="2" style="vertical-align:bottom;width:21.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Judith Klimovsky</p></td><td colspan="2" style="vertical-align:bottom;width:19.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anthony Mancini</p></td><td style="vertical-align:bottom;width:20.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tahamtan Ahmadi</p></td></tr><tr style="height:13.95pt;"><td colspan="2" style="vertical-align:top;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(President &amp; CEO)</p></td><td colspan="2" style="vertical-align:bottom;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; CFO)</p></td><td colspan="2" style="vertical-align:bottom;width:21.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; CDO)</p></td><td colspan="2" style="vertical-align:bottom;width:19.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; COO)</p></td><td style="vertical-align:top;width:20.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; CMO)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Board of Directors</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb013.jpg" alt="A close-up of a diagram&#xA;&#xA;Description automatically generated with low confidence" style="display:inline-block;height:33.9pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:55.5pt;" /></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb014.jpg" alt="Graphic" style="display:inline-block;height:28.4pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:97.98pt;" /></p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb015.jpg" alt="Graphic" style="display:inline-block;height:25.81pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:125.4pt;" /></p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Deirdre P. Connelly</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pernille Erenbjerg </p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anders Gersel Pedersen</p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Chair)</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Deputy Chair)</p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb016.jpg" alt="A picture containing text&#xA;&#xA;Description automatically generated" style="display:inline-block;height:33.4pt;width:115.8pt;" /></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb017.jpg" alt="Text&#xA;&#xA;Description automatically generated with low confidence" style="display:inline-block;height:33.31pt;width:69pt;" /></p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb018.jpg" alt="Text, letter&#xA;&#xA;Description automatically generated" style="display:inline-block;height:35.66pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:79.8pt;" /></p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Rolf Hoffmann</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paolo Paoletti</p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Jonathan Peacock</p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb019.jpg" alt="Text, letter&#xA;&#xA;Description automatically generated" style="display:inline-block;height:27pt;width:71pt;" /></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb020.jpg" alt="A picture containing text&#xA;&#xA;Description automatically generated" style="display:inline-block;height:26.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:117.64pt;" /></p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20210630xex991d85adb021.jpg" alt="Graphic" style="display:inline-block;height:21pt;width:120pt;" /></p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Mijke Zachariasse</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Rima Bawarshi Nassar</p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Peter Storm Kristensen</p></td></tr><tr><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected)</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected)</p></td><td style="vertical-align:bottom;width:33.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 60</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 35/35</p></td></tr><tr><td style="vertical-align:bottom;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:bottom;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:bottom;width:37.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gmab-20210630xex991d85adb002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ ,H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#;\;>,]=A\
M37=E:W<EG!;.$5(P 6X!W$]\Y_*NB^'OC:\UNYDTO4V$EPL?F13A0"X& 0P'
M&>1S6UXG\"Z;XFE6Y=WMKP#;YT8!W#L&!Z_SJGHW@>+PI9W][93R7>IM;NL+
MNH 4XR %]20*ZG.DZ=K:GDPH8N.*YN:\;]^GH=IGG%%?.HO;S[3]I^U7 N=V
MXR^80^?K7L_@C6;G6_#B3W?S3Q2-"SXQOQCG\C7*>L='1FO/?B5K][8O;:9:
M2O LT9DED0X9AG 4'MWS^%<9X2N;^+Q18+9RR[Y)@LBAB0R?Q;AZ8R: -WQ7
MXZU.35;BSTV<VMM YCWH!OD(."<GH,^E;7P[\1ZGJTUW9W\K7"PHLB2L/F&3
MC!(Z_P#UC4^K_#:QU+4Y;R&]EM?.8O)&$##<>I'IG\:Z/0O#]CX>LC;62-EC
MNDD<Y9S[_P"% &I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!SVI>"=!U2[:ZGM"DS'+M$Y3>?4@<?C7'^+]?G\/746@:"18V]O&&
M<Q@;BS<XR<_7/4YKU&O._'7@V_U/5%U/3(Q,SH$FBW!2".A&>#QQ^% $OAM[
M;Q[HTD&NP":ZLG $Z_(Q5AP>._!![<"NIT?PUI.A;FL+4)(PPTK$LY'ID]OI
M69X&\-S^'M,F-X5^U7+AG53D( , 9[GD_G74T %%8OB7Q-9>&-/%S=9>1R1#
M"I^:0_T [FN4@U3XAZU&+NRL;.RMG&8UE RP[?>Y_05I&FVK[(YZF)A"7(DV
M^R5ST6BN(T?Q)XF@UJWTG7]%.9R0ES;#Y1@9)/)&/Q!]J[>IE%QW+I58U%=?
MCH%%%%2:A1110 4444 %%%% !1110 4444 %%<YX\DGA\&W\]M<2V\T05E>)
MRI^\ 1D>Q-+X%N);KP5IDLTC22%&!9SDG#L.3^%7R>YS&/ME[;V5NE_QL=%1
M114&P4444 %>6_$/Q'J$>M_V7:7,MO#"BL_E,5+L>>2.< 8XKU*N%\:^"+G6
M[]-1TYXA.4"2QR':&QT(/KVH G^'>NW>KZ7<P7LC32VKJ!*QRS*P.,^I&#S7
M9USO@[PT?#>F21S2+)=3MOE9/NC' 4?3^M=%0!Y1= >)_C MK.-]K8G 0\C"
M#)_-S7J]>5>%_P!W\8-75_O,UQMS_O _RKO_ !%:ZM=Z7Y>B7J6EX'4AW&05
M[@\'^7:MZRUC'R/.P4K0J5+7?,S6JIJ>I6ND:=-?7DFR"%<L>Y] /4D\5Y?K
MU_XW\,RV/V_6XI%N9-JB%%/0C.<H/6M/XOW,B:5IULK$)+,SL/7:O'_H5"H^
M\E?<J>.2ISDHM.-M_/8EM_$WC37XVO=$T>UBL,GRS<-\T@'_  (?IQ[UJ^%O
M&;ZO?S:1JMG]AU6'),?.UP.N,]#WQSQR*RM.^(=E8:9:VD>A:KLAB6,;81@X
M&/6L,ZJVL?$W2M5M-.O;9"R12>;$02>5)XXQ@@?A6GL[W3C8YUB.1QE&HY-M
M7737MIH=CXU\5WGA>33C#;P207+D2-(3E0",X ]B:SY_&/B+5W=_"^A&:R0D
M"YN1@28_N@D?U_"JGQ< ,&C C(,[@C\%KT=$2*-8XU5$4855& !Z 5G[L81=
MM3>U2K7J0YVDK;;ZHY+P?XSEU^YN=-U&T%IJ5L"609 8 X/!Y!!QQ[T>-O%=
MYX7ETXP00207#D2-)G*@$9QCV)K!T'CXS:O_ -<Y/_9*E^+0#)H@(R#.X(/_
M  &JY(^U2MHS)UZJPDY7UB[7^9-<^,_$NJ[Y_#6@M)8(3BXG0DRX[J,CCZ9-
M)9?%**;2?WFGR/K!D\I+.$$B0^H/4#MCDUZ"B+&BHBA44855& !Z"O,?AQ!$
M_B_Q#*T:M)'(P1R.5R[9QZ9P*47"46^78NHJ].I!*?Q7Z:+T)+OQOXMT.6&Z
MUO0X8K"5MN$^\/;.XX.,\$<UZ&+Z)]-%_$'EA,/G*(URS+C(P.YQVKDOBI_R
M)I_Z^8_ZUO>%B!X1TDDX LX\D_[HJ9I."DE8THN<*\J3E=6OJ<K'XR\4:\2_
MAWP^HM<X6>[. WZ@?D33M.\:ZU8>(;?1_%&G16[7)"Q30],DX'<@C/'!XJ_<
M_$'3Q=M9:-87FK31\'[)'\@_'^N,5QWBS5[W5_$6@&\T:XTQHYP$$S9+Y=.G
M Z8_6M8PYG9QLOQ.6K6=-<\:CD[KIIOZ?J=_X]_Y$?5?^N0_]"%<7X;\5:NG
MAJRTGP[H[7MQ;HWGS2#$:$L2 .1DX([BNT\>_P#(CZK_ -<A_P"A"H_AXBIX
M&TTJH!8.6P.IWMR:B+2I7:OJ;U82GB[1E;W?U,+3_B!J=AJ\6G>*M,6R\T@+
M,@*@9XR0201[@\5Z)7!?%FVCD\+P3LH\R*Y4*W<!@01^@_*M71-=D;0-.:1=
MSFUB+,>YVCFE.*E%2BK%4:LJ=65&H[VLTSJ****P.\**** "BBB@#R[QC;7'
MA?QM:>*K>)I+21@)PO9L;6'XKT]Q7H&F:]I>L6RSV-[#*I&2NX!E]BO45=N+
M>&Z@>"XB26&0;71QD,/<5Q5_\+_#LLAEB%W;9/W(I1M'TW UNG&HDI;H\^<9
MX:4IT[.+UMY^1D?%2[MIKG1(8KB)Y(YG+HK@E02F,CMT-:WQ4TF6_P##4=W"
MI9K*3>X _@(P3^'!^F:NZ5\.?#NFRI.+:2YD4AE-R^X _0 #]*ZQE#*58 J1
M@@C@BFYJ#BH]!0P\JT:DIZ<]MNEC \*>(K'6]#M6BN(Q<)$J30E@&5@,'CT]
M#6C_ &UIO]J)IHO83>NI985;+8'7Z5S6H?#'P[=W!G2.XM2QR4MY %_ $''X
M5JZ%X-T3P])YUE;%KC&//F;>X^G8?A4RC"W,KETJE?F5.26F[U_*QRWQ;_U.
MB_\ 7=_Y+7I%9&N^&M.\1+;KJ"R$6[%DV.5Y./\ "M>IE).$5VN:TJ;C6J3?
M6WX(\RT+_DLVK_\ 7-__ &2I?BS]W0_^OAO_ &6NPMO#&FVGB"?6XEE%[."'
M)<E><=OP%+KGAO3O$0MA?K(?L[%X]CE>3CK^5:*HO:)^1S/#R^KSAU;O^)KU
MYG\-O^1J\2_]=/\ VH]>F5CZ1X9T[1+V\N[)91+=G,N]RP)R3QZ<DUG"249+
MN=-:FY5:<ETO^1@_%3_D33_U\Q_UJ/49)XO@XC6Y(?\ L^($KU"G:&_3-=3K
M>B6?B#3_ +%?*YAWA\(VTY'3FI[;3[:UTR+3D3=;1Q"$(_S94#&#Z\52FE%+
MLS.5"4JLW?>-CE?A>+0>#X_L^SSS*_VC'7=GC/\ P'%<YX\U6QN_'&APPW"/
M]DE3SV4Y5"9%.,^H YK?G^&6A?:R\$U_;+(>8X9P%QZ<@G'XU<O? 'A^30X]
M/2V:%(Y!()8V_>%NARQSG(K5.*GS]SD<:LJ'L4DN6WSM\BQX^./ VJ_]<U_]
M"%9OPYUO39?"UIIXNXUN[<,LD3MM;EB01GJ,'M72ZCHEGJ>C'29U<6A55VHY
M!PI! S^ K$OOAUX=O+*WMS;R1&W38DL3X<CKR3D'\16<7%PY7W.FM&I&M[6-
MM(V_$Y[XGZS#J$=EH.GR+<W3SAW2([L'!"KQW);I[5W>FZ/!9:59VCJ&:"!(
MRWJ54#^E9GA_P/HGA^<75M%)+<X^66=MQ7Z8  ^N,UTM*I))*$>A6&I2E)UJ
&F\OP1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gmab-20210630xex991d85adb004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /M!YP# 2(  A$! Q$!_\0
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDXYZ5Z7FI7PI _B;%HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.N!CK70>#[7Q!9:%':^(VTY[J'$<;6&_88U4 ;M_\60>G%"^UZDN^AT-%%%
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M%I%$=2LI+J9I"L(Y95+$\ $<?[!J+3/AKXPUCQ5INL^.O$%I?)IDGF6\%JF
M6R",_(@'(4]#G%8_Q^TQ)]3\/36$VW5KPO8^4APTL;8'/MEB/^!571+U#1MG
M5?!RYUC6M(U/Q)JU[=S+J5XYM8)9F9(8E)X12<*,DCC^Z*],K,\/Z/%H'AZP
MTF#'EVD"Q X^\0.3^)R?QK3IO?02UU8M%%%(92U;_D#WO_7!_P#T$UYM^S]_
MR3<_]?LO\EKTR^A:YL+B!" \D;(I/3)&*\3\/_#OXM>%],_LW1O$FB6MH7,A
M3&_YCU.6A)[>M):-^8FKV+6@JEM^TUKT5D L4EGNF"],E(F)_P"^OYU0\*^(
MO%LOPQ\87NG75[?ZK;W^RW,KM.\:?+NVAB>@).*[SX?_  [?PG/?:KJFH'4M
M=U#_ %]R1@*.I49Y.3WXZ#@8K)\,?#+6M*\(Z[I$^M&PO+Z]-S;W>F3R!HN!
MC=PI/3D>G>BUE;LOU*3N[^?Z'GV@^-0-0TF;3?'.KPZ@)56_L_$DS-;2]-PC
M958)SD9;'7J,5UOQ(\;-%\0+3PU=^(;K0-$CMQ/=W=D&\^1CDA5902!T[>N>
MU3:M\-O&'BZ"QT[Q+>>'OLELZ[M0M(':\E4#&"6&!GOCOZUT'B;P'J;^*=/\
M4^%;VUMM5M(/LSPWJL89X\8&XKR.#^@Z8INSL)=3F_AKXZ>X\7ZOX<AUZ;7-
M*CMC<V-_>[ED&-NY79E!(^;J1_#[UQNM^)M071M1U:/QQK5]K\-P"4T<R?V9
M FX !MR*#QW[G'7K7K>B^#=?GAUV;Q3KS3W.K0/;BULY'^RVB,NT^6K'KTYQ
M^>37()\+?'"^!KKP:-7T1-)WM)%(L<GG3'=O"N>BKNP<C<?K2!6)O''BOQ*/
MASX5U:WDO8;6]CCDU>ZTY0)44JI.T_P9RW/'( SSS4^'/BI;OQM!;:5XRN]0
MTJXA/F6&ORL;Q9 #S&VTHW;@-TSQQFNLF\$^)/\ A#O#UKIVO'3=8T>)4*PR
MR-:W(7 VN.,C@=1W(Q5'3_AUKFI^.+#Q-XG;0[:2P.Z.'1X7'G/V,C/SQ^/X
M56G,^PG\*..U#QY;Z[XTUZ#Q!XTU/PW8:?,UO80::'!D925+N45L_=!P?[W'
M2N\^#WC"]\5^'[V/4;H7=SI]P81=!-IFC/*L1Z]:AE\"^*/#OB?5M6\%W^EB
M#5V\RXM=21\12<G<A3KRS=?7O75^#/#U]X<T);74]9NM6OI',DMQ<2,V"?X4
MW$X4?XFE'1#EOH>?_'W_ (]O"_\ V$/Z"E\4WNO7/QST[0-.UR\T^SN].S*(
MGR%'[QF94.5WD+C<1Q71_$_P1J?C2'1DTV:UB-E=>=+]H=ERN!TPIYIU[X*U
M*Y^,6G>+DFM1I]M9FW>,LWFEB'' VXQ\P[T1\^[_ "!_I^ISOA:[UGPY\8[W
MPE-KFH:KI<EG]HC.H2^;(C8!^]^8P..:J^#'U_XF:AK&OR^*=4TNVM;HP6%K
M8N%C7 R#(I!#\%>#UYKK1X+U(?&(^+O.M?[/-E]G\O>WF[L8SC;C'XUDV'@3
MQ;X3UK5/^$2U32ETC4YC,\=_&[/:L>IC"\-^)'0?6DO/M^O^0=[>7Y''?#N:
M^L_!OQ+F:X9+^$RLTT)*D2!9"64CIS5E?'.OZ=\%/#3VM_+)K.KW<EJ+VY8R
M.@\UQG+9R?NCGH*Z/PM\,M9T'POXPTJXO;2XFUA76VF#MSE7 :3Y>#\P)QGO
M3T^$UQ=_"G3/"]_?10:II\SSPW5OET5R[,.H!(PWMS]*K3KY?\$.FG=FA9>#
M/%N@:_IMWI?BR[U.P8[=2MM9N6DW#CF+"G:>IQQT')%<WXRU=[CQS?6%_P"+
M]2M8(8@++2_#1D:Z+XY,N$VY_P!G=W'3OT5MX;^(&JZOIDOB+Q!9VEC8-N:+
M1GFC:\/'^M)P,<<@<<GBJ,?@#Q;H?C37-5\-ZGI26FM-NF>]C=IK<DDDH%X;
M!8XR<>W%2P1RNB:KJOC'X#^(GU;5;YI]->79,DFQY46($)(?XE.XY'?UI^@6
M=UH?[/5[K=EK6JK<7%L"D9NB([8K.1^Z P4SGGGFNK\&?#34M!\$^(_#.HWE
MK)'J3R>3<0%BP#IMRRD#!X!P">IYJKI_@#QC%\,=2\&WMSHK0^5Y=A+$TH;)
MEWMYA*_E@4Y;.WD-;J_<S-3\8Z]%X)\!Z-IM_)'JOB!(XY=0E_>.@^4%LMU8
M[NO7BK'B&36OA7K&AWL7B35=8TN^N!;7EOJ<WG,"?XD;'R]^/;O6SJ/PPN-3
M\$>&[#[?'9Z[H2(UM=Q*70.N,CD D94'/MT[4C^!O%/BK7=+O/&U_I9L]+D\
MV&STQ'VS/QRY?IT' _2G]KY_@3T^7XF5XAN]>OOCM!X?L=>OM/LKG3@91#)D
M*,,Q9%.5#G;C=CC-2>$;[6M ^+^J^#Y];OM6TX6?VB!K^7S)5;"'[W_ B,=*
MZ&;P7J4GQCM_%RRVO]GQV9MS&6;S=VUAG&W&.?6DB\$:B/B]>>*WGMAIT]E]
MF")(PF#;5&>F!]T\YJ5T^8^_R_0\>G\8ZDUWJ47B?Q/XFT+Q(DK&WC1BMB@'
MW0\:@L1U&0#Q@\U] >#-2N-6\):=>7=]9WUP\7[RYLV)CD(.,C(!!]1@8.17
M#77@;QW'97NBQ:MHVM:3<LQ2?75EEN8 PQ@'D$CL3W["NT\#>$XO!7A:VT6.
MX:X:,L\DQ7;N=CDX'84UL*6]SI:***!A1110 4444 %%%% "5X)\2])77?CE
MH^EN 5N=+>/GW6?!_.O>ZX#5?!&HWWQ@T?Q:DMJ-/LK4Q21L[>:6Q( 0-N,?
M.._K2M=JXT[)GE6FZNWC#3? ?A5SNDL6N)+Q#_#Y*GR\_P# 13_AYXIG\'_!
M+7]5M$5KL:B(H"PRJLR(-Q^G)_"N[\(?"N\\/?$36_$%Q-:/970G%I'&S%T\
MQ\_,"H P,C@FF>%?A'<6GPZUCPKK]Q;$WUUY\<MFS-Y>%7:?F"\@KT]*=]&^
M_P#F&E[=C,U?2O%?AKP''XTC\9:K<:M'''<W-K<2!K1E<C*+'C QNZ^W&*7X
M@^--:F\.>%=7@.IV&@ZA$)M2FTP@31DA<*KG[O?'3-:%QX"\>:MX?@\):KKN
MDC0(MB/<P12?:IHT(VJP/RCH._;O71:]X,U=8-'?PCK3Z=)I4:Q)9SR.;6XC
M P!(H/7WP3S]"!_J);:[G'_#7Q%_:?B>ZTZP\97.I:1<6Q*6VJR/_:$,F.2K
M;-K8Y^ZWOCCG,^%/ATGXG>*S_;.KC^S+W'%S_P ??SR#]_Q\_3/;DFNMT#X=
M:L_CV'Q?XB;1[>ZMHRD5MH\++&[$$;W+<DX8_ISQ4FC^!_$GAOXBZKK&EW.E
MRZ/J]PLMTEQY@F09+$( -N<L>2?PIK=>@G\+1Z%?WL.G:?<WMPVV"WC:61O1
M5&37R[I>O>%]5\+>-9_$&I+!K>M3&2WB,,K[=AWI\RJ0 6.WKT%?07Q!T35_
M$?@V]T?1IK:&YNML;/<.RJ(\Y;[JDY.,?C53P_\ #7PSI?AVPL;[0-(N[N"%
M5FN)+.-S(^/F.XKD\YZU-MRKZ(Y_X>^-S)\%I=4<"6ZT6VEBD0G[QC7*9^J[
M>?K7/Z-IOB;Q#\-=1\8W7BW4_M]U;7$B60=?LGEC<I0QD8R0IP1C&173>%OA
MI>>']>\4V\CV;>%]:1@EM&["2/.>-NW &&8<'LM4+#X>^.=*\.7GA&TUS23H
M$JR+'</$_P!J5'R2@ ^4 DGGDC)(]*):W?=!'2R\SC]+.LV/P"TK7=$O[NWF
MTN^DFFCAE95FB,N"&4'Y@#@\]MU==XB\3WGC#QCX.T3P_J%U:V]U$NI7SVTS
M1MY)&=A*D'H&&/4BNG\#>")]"^')\,:VUO.9!,DWV=B4*N3T) /0^E8WPL^%
M]YX(U#4;[5;N"ZN)$6"U:)F;9"#D@Y P3\O ]*J^I/3S,[QQJ[R^.I-.O_%]
M_8V45N/LVF^'FD:]DEX.9-J$#J>"W3!XYJEX&\5:[J?PJ\8M>ZA>2W.FQSK;
MW,Q*SH/+)&2.=P(]<CUK>G\">*M)^(.J^(?#.H:4(=54+.-01V>'IDH%^]TR
M,D#M[U%X7^&NN:#X6\7Z+<WME<MJRR?9K@,X+,RLN9%V_+U!X+=ZE?"_0K[2
M[7.5L8/$VI_!G_A+I?&6LQWMG%))!%%/MC94D(/F?Q2,<-R3Z#%;6N_$+78O
MA/X9N[29(]9UIUMC<E!\F"0S@=,G _,UT6E^!=4LO@Q+X/DFM#J+V\T0D5V\
MK+NS#G;GHP[56G^%LVI_"S2O#-[>QP:GII\V&Z@RZ+)ECW )&&]JJ5KOM=?\
M$E=/G_P"Q9>#?%N@:_IMWI?BR[U.P)QJ5OK-RTFX<<Q84[3U...@Y(K@]6\>
M6VM>.]<L]>\9:GX;TS393;V46FAU>9U)5F=D5LC(Z'U&.AKN[;PW\0-6U?3)
M?$7B"SM+&P;>T6C/-&]X>/\ 6DX&..0..3Q4%QX%\3>'_%FJZYX+OM+$>K'=
M=6FIH^U7Y.]2G/4L<'U/6EU'T\SG/#GQ3U,?"[Q)?S72ZA?Z/*(;>[:/;YRR
M-MC=E]N3^6:JZMH'B%O@U=>)+GQ9JEW=7UFMQ=6EQ(&MC$Y!VHI'R, 0<@]L
M8KT&P\ W$G@._P##_B'6[O5;G4,M-<RNS>6W!41AB<*I /N?RKEY_A_\0+KP
M3+X0GUO1?[+BCV6\R1R":55.41SC"KP.@)XQS2EU^0X]#L_A=_R3'P__ ->@
M_F:XSQ!_R<QX9_[![_\ H$]>A^#-&N?#W@_2](O'B>XM8!'(T1)4G/8D _I7
M$>._ 7B[5_B!8^)_"^I:=936EH(4>Y)+!LOGY?+92-K]ZINT[BC\#7D,_:"A
MMW^'<<DH7S4O8_))ZY(;./PS6!XN\<W=O?>%O#M]KESH6GS:9#=:E?6RL9R2
MI^52H)'*]0/XO:M-?AAXS\4ZG9OX_P#$UM>:?:2"1;6S3 D/H<(@'IG!.,],
MUTWB_P "W^H>(],\4>&[RVM-9T^/R1'=(3#-'S\K8Y'WFZ>O;%2E;?JPW^2.
M.\#>+O[2\8ZEX/L_%%_K.C7=F[6=_.76Y@?'(WD*Q/4Y]ABH=&\?ZEH/PQ\4
MV.L7\TVO:-</:)+-(6D8R$A&W-R<'<?HHKT'PIX=\2VVMWNN>)]:6>XN%$<6
MGV4D@M(!QRJL>6./3UZYKFO%7PCFU_XDVVNQ7%O'I,KQ2:A;NS!I7CX&% P<
MC Y(ZFF]TNX+JS&\0^(M?\#_  M\.6DVKW*:MJTF;K4+IVGDMT."V,Y.0&4<
M>AQS5#2?'EKHGCC0K30O&>I^)-,U"06][%J0=FA=B KHSJN!EN@]#GJ*]1^(
M'@D>,])MD@N_L6HV,PN+2X*;@KCL1Z'C\A]*S]*\-^-[[Q+9:GXGURUAM;)<
M)9:.\J1W+?WI=V,]N.1].<B?O7$_AL<QX>N%L_C_ .-KIP2D.GB1@/0+$:9X
M1M/$OQ-TB]\2W7BS5=*9IWCL+73Y1'#&%Z;QCY^3CGGCKSQU>C^!M0LOBIX@
M\2W,EH^G:E;"&.)68R#A =PVXQ\IZ$UCZ=X"\:^#XK[2_".L:4=(NY&D3^T$
M?SK4MP=FW(;C'7TZ=:2^%>@=7ZG/R>/=<UGX%ZW>3W<MOK.FW4=J]W;.8V?]
MXGS97&#@D'']:?J-CXKL/AA9>.$\9ZLVIQ6T-PULTH-LT;8 4ICYFPP)9LYY
MJYXP\&6W@?X#:KID,S7$SRQ37%PPP99#*F3CL. ,5#IOA#QIXF^&VBZ&NM:8
MGA^ZMH9)96B?[4B<-Y8'W64'&#P>*>][>16FGS(_&_BK7=3/PXNM)U.XTJ;6
M"/-$$AV;F,0^9<X< L>#3-3B\2Z#\6=.\*V/C+6)+35[822RW<JS/'R^[R\K
MM4_)Q@<9KJ_$OPWN[[4_!!T>6VBL/#LJ&1;AV#LBM&?EPI!.$/7'-7-:\$:E
MJ/Q;T/Q7#-:K86%L8I4=V\TL1)]T;<8^<=QWIJWXL73Y'.>$=4U70/B[K?A.
MYUK4-5TR&T^T1-?R^;*K;8V^]_P(C'3I7$VWQ!C\10:IJ^L>/M4T34Q(W]FZ
M=9K((%4#*^8%0A\DXY.>*]6M? VHP_&/4?%LLMHVFW-IY"Q!F,N=B+R-N,?*
M>_I6+:_#WQGX7@U/1_">L:7'HU_(TBM=K(+BTW#!\LKP3@#D^G:IZ:]ANW0Y
M[Q#X^UG6/@/8ZY%?3VFJ+?+;SSVLAB+E=W/RXZC!(Z5/X\D\3>"]*T7Q;'XK
MU2YO+BXC2ZM)) +4[D+82,# 'RD<Y/.<YKJO%_PZU;6OAK9^&K35OME]#,DL
MMYJ4SDRD;LG.&/4\#L*G^)/@75/&'@_3=(TZ:TBN+:>.1VG=E0A493C"DYR?
M2FOBOYK_ ((DMD^S_P" <7\4-$-U\7/"G_$UU.+^T9 /W=QM-KC:N8>/D)ZG
MKS7M]A:FQTZVM//GN/(B6/SKA]TDF!C<Q[L>YKA?'_@?6->UGP_KF@W5E%J&
MD2%A'>[_ "I!D'DJ">WZ]17<Z?\ ;?[-M_[2^S_;O+'G_9\^7O[[<\X^M"^&
MWJ+7FNSYZ\/^+=5\*_$CQN^E^%KW7C<:@X=;4O\ NMLDF,[4;KD^G2NL\$Z5
MXE\3?$^?QQK>BOHMM';>1!;R@B1SC;R" > 3R0.V*Z7P1X)U+PWXP\5ZO>36
MKV^KW/FVZPLQ95WNWS J #\PZ$UWU"T2]!RUDSY]^''AV_\ $.K>,XH?$.I:
M3:IJ#'_B7.(W>3<^"7QG:!V&,Y]JW_A_XNUZ\^&.ORWFJVQO],F>""_U!R$4
M;5P7;!+8)/4$G@5T_P ._!>I>$KSQ%-J$UK(NI7GVB$0,S%5RQPV5'/S#IFN
M=TKX2:DG@'Q'X=U"_M8YM2O!<P2VY9U7!4@-D#NO:D]K>0UOKW."O_%U_HT&
MBZMH_B_Q%JMY)<*M])<"3^SF8C)2,.J^_&.F3Q78?%;Q)JFD^+[&'4;S7=/\
M+-;AC<:,RQR--D\%SZ<?+GIS3=9^&7CWQ!X7TK2;W5-!C722@MH84E"RA5V[
MI'Q]X#L%QR:[/Q%X:\62:[!K?AW6H5D\GRKC2M1DD>SD./O +T/T';ZY;M;Y
MB1SGPV\5RFT\0/\ \)0FO:;91-<VR7+.+V- "2)-R#<.@W L,_7%<!#X^.J:
M)?:[J'Q"U33_ !(&=[/3+9)!:@+]U&4(5;/3)/<9S7J/A#X:7&G^(=6\0:\V
MF_:]1@-LUEID1CMXT;&[&>23M';UZYK-L_A[XZ\/Z5=>&M U_38]$GE9H[J9
M9%O+96.2$V_*3[Y'?&*.OR [;X?^(Y?%G@C3=8N%5;B9"LP48&]6*DCZD9_&
MNHK/T;3FTG2+2P>[N+QX8PK7%RY>20]V8GWJ_3=KZ"6PM%%%(84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIJ*.MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,W7-#T[Q)I,VEZK;_:+.;;YD>]DS@AARI!Z@5/IVG6
MNDZ=;Z?91^5:VT:Q11[BVU0, 9/)_&K=% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<G(HZV ]!HI%.12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:0MS;V\H#(97DVERIX) &.>E7-4T/PMX?7Q#<C4VTF.\L<WEM:2(FQ 2/-1
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M_OPW^%'_  G>A?\ /:7_ +\-_A71^5'_ '%_*CRH_P"XOY47CV#DK_S+[O\
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M='Y4?]Q?RH\J/^XOY47CV#DK_P R^[_@G.?\)WH7_/:7_OPW^%'_  G>A?\
M/:7_ +\-_A71^5'_ '%_*CRH_P"XOY47CV#DK_S+[O\ @G.?\)WH7_/:7_OP
MW^%'_"=Z%_SVE_[\-_A71^5'_<7\J/*C_N+^5%X]@Y*_\R^[_@G.?\)WH7_/
M:7_OPW^%'_"=Z%_SVE_[\-_A71^5'_<7\J/*C_N+^5%X]@Y*_P#,ON_X)SG_
M  G>A?\ /:7_ +\-_A1_PG>A?\]I?^_#?X5T?E1_W%_*CRH_[B_E1>/8.2O_
M #+[O^"<Y_PG>A?\]I?^_#?X4?\ "=Z%_P ]I?\ OPW^%='Y4?\ <7\J/*C_
M +B_E1>/8.2O_,ON_P""<Y_PG>A?\]I?^_#?X4?\)WH7_/:7_OPW^%='Y4?]
MQ?RH\J/^XOY47CV#DK_S+[O^"<Y_PG>A?\]I?^_#?X4?\)WH7_/:7_OPW^%=
M'Y4?]Q?RH\J/^XOY47CV#DK_ ,R^[_@G.?\ "=Z%_P ]I?\ OPW^%'_"=Z%_
MSVE_[\-_A71^5'_<7\J/*C_N+^5%X]@Y*_\ ,ON_X)SG_"=Z%_SVE_[\-_A1
M_P )WH7_ #VE_P"_#?X5T?E1_P!Q?RH\J/\ N+^5%X]@Y*_\R^[_ ()SG_"=
MZ%_SVE_[\-_A1_PG>A?\]I?^_#?X5T?E1_W%_*CRH_[B_E1>/8.2O_,ON_X)
MSG_"=Z%_SVE_[\-_A1_PG>A?\]I?^_#?X5T?E1_W%_*CRH_[B_E1>/8.2O\
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M[:OF'<?4T;CZFCV<0^N5^Z^[_@GT]_PL3PW_ ,_I_P"_;4?\+$\-_P#/Z?\
MOVU?,.X^IHW'U-'LXA]<K]U]W_!/I[_A8GAO_G]/_?MJ/^%B>&_^?T_]^VKY
MAW'U-&X^IH]G$/KE?NON_P""?3W_  L3PW_S^G_OVU'_  L3PW_S^G_OVU?,
M.X^IHW'U-'LXA]<K]U]W_!/I[_A8GAO_ )_3_P!^VH_X6)X;_P"?T_\ ?MJ^
M8=Q]31N/J:/9Q#ZY7[K[O^"?3W_"Q/#?_/Z?^_;4?\+$\-_\_I_[]M7S#N/J
M:-Q]31[.(?7*_=?=_P $^GO^%B>&_P#G];_OVW^%+_PL'PZ5W"[<KG&?*;'\
MJ^8=QQU-=WI'/PFOB>O]K+S_ -LQ1R1'];KV;NM/+_@GL7_"PO#G_/XW_?IO
M\*/^%A>'/^?QO^_3?X5\^9/K1D^M5[*)R_VIB/+[CZ#_ .%A>'/^?QO^_3?X
M4?\ "PO#G_/XW_?IO\*^?,GUHR?6CV40_M3$>1]!_P#"PO#G_/XW_?IO\*/^
M%A>'/^?QO^_3?X5\^9/K1D^M'LHA_:F(\CZ#_P"%A>'/^?QO^_3?X4?\+"\.
M?\_C?]^F_P *^?,GUHR?6CV40_M3$>1]!_\ "PO#G_/XW_?IO\*/^%A>'/\
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MO_?EO\*/^$]T#_GXE_[\M_A6)M'H/RHVCT'Y4?5(]P_UFQ'\J-O_ (3W0/\
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M[\M_A4.T?W1^5&T?W1^5'L(A_;.([(F_X3S0?^?B7_ORW^%'_">:#_S\2_\
M?EO\*AVC^Z/RHVC^Z/RH]A$/[9Q'9$W_  GF@_\ /Q+_ -^6_P */^$\T'_G
MXE_[\M_A4.T?W1^5&T?W1^5'L(A_;.([(F_X3S0?^?B7_ORW^%'_  GF@_\
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M0O\ GO+_ -^6_P */^$\T+_GO+_WY;_"KVQ?[H_*C8O]T?E1R1#ZW7[K[O\
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M1>/8.2O_ #+[O^"<Y_PG>A?\]I?^_#?X4?\ "=Z%_P ]I?\ OPW^%='Y4?\
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M-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!A"X_]&-6E/<X,?\*,>BBBMCRPHHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"N*U'4C_ZBV_ZXK4=<D=CZ;$?Q/N_(****HP"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH GM/]<?I5ZJ-I_KC]*O5C/<]7"?PPHHHJ3J"BBB@
M HHHH **** );?\ X^$_'^5:-9UO_P ?"?C_ "K0K&IN>G@OX;]1:***@[ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>]=57/>&?#,WAW[3YWB#5]6\_;C^T9Q)Y>,_=X&,YY^@KH:3)"BBB@84444
M)574+ZWTS3KF_NI/+M[>-I9&]%49)JW7*_$>SN;_ .'6NVUH&:=K5BJKU;')
M ^H!%3)V5QQ5V9&E7'C/QA8QZQ;ZG!H.GW +VMNMJLTKQG[K.S9 )'. .XK4
M\.ZAXC@UVYT/Q!"ER(X5GM]4MX3'',"<%6'(5P><#M4NA7\U_P##NPN_#_V6
M2X:Q3[,LS$1APH&UMO(P00<>E8.F^*/&4'C2VT#Q#9:,GVFSEN8VL&D8_)T!
MW'UJG9.Q*=U<Z'4_'GAG1]0:PO\ 5X8KE,;T"L_EY_O%00OXXK0O_$.D:79V
MMW>:A#%;7<JQ03$Y1V8$CYAQC )R>/>O*_AM_P )3<>"5N+/2=#NTO9II+F:
M[N'$LCEV#;P$//&.O0"J5]HLUKX \+Z/J4]C=0_\)3#$JVDWG1K$S/\ N\X[
M9(Q1;6PSU32O&_AO6M2_L_3]5BFNB"RQE67>!W4L &'';-)J'CCPUI5U=6M[
MJL<5Q;,J2Q;&9P67<,* 21CG(R!WK ^($$,&M^")H8TCD76DC#*,$*4;(^AP
M*C\*V-M+\6O'5Y)$KS(;2-68 [5,63CZX'Y"A:_UZ?Y@;L_Q$\)6]C!>R:Y;
MFWG4O&T89SM'!)502HSQR!6O<:[I5MHXU>;4+=-.*!Q<%QL(/3![YKAOACIU
MDLGC0BVCRVOW,)RN?D&"%^GS-^=<WX<OM.@^%/A"&\TN75KY[^7^SK)9=@:5
M)9""Q/&U1ZYHZ?=^(['IND>-_#FNW_V#3M4CENMN\0NCQLP]0' S^%<]8_$&
MTT_Q!XEM?$&J1Q16MZD-I$(\N$\L,>$!8C)ZGIZUB>()M=E\=>"IM5TS3K!3
M?LL(MYS),<H=P)V@;>E;/@FQL7\?>.;QHXWO/MT<1)&2L?E*1^9S^5);_P!>
M1+T.XTW4['5[".^TZZBN;:0926-L@_\ U_:JOB75AH7AG4M4QDVMN\BC^\P'
MRC\3@5RO@)5MO%_C>RM5"Z?%?Q/&JCY5D>,&0#\<9%:'CG_3Y]!T <C4-01Y
ME]88?WK?AE4'_ J'K;S&G^!T.C"]&BV(U*7S;[R$^T.%"[I,#=P.!SFM"D%+
M38EL%%%% PHHHH **** "BBB@#,\06#ZIX<U/3XR%DNK66%3Z%D(_K7.?"W4
MX;SP+I]CQ'>Z;&+.[MSP\4B?+\P[9QFNUKF]7\"^'];OOMUU9%+LC#3V\K0N
MWU*$$_C26EPW.=\6R)KGQ'\*:-9,)9M.G?4+QEY\A N%#'L6)QBL3Q#J4W@W
M5O%^E6N1)KL4=UIBKQFXE(AD ]\E6KTO0_#>D>&[9H-*LH[=7.9&'+.?5F/)
M/UI-3\-:5K.J:=J-]:B6ZTYS);/N(V$X[#@]!U]*+= OU..UAE\*6W@_PQI.
MFV-UJC[H[*:]'[N QH"[Y'.XY[=2:RM6&LQ?%CP3'K6K65U.TERZ6UK;^7Y2
M^40226).3_Z#7HNO^&=)\36L=OJMKYR1/YD;!BCQMZJPP1^%4+3P!X;LKFTN
MH+$BZM9O/CG,K&0M@K\S$Y88)&#D4UO<-EH8_P .(U&K^-I /G;7)5)]@BX'
MZFN8LM7M=%\$>+[B[T^&_5_$MQ%';S@>6TC2*%+9Z '!_"O5=-T2PTB6_DLH
MC&]]<-=7!+EMTA !//3H.!5(>#]#&EZCIC6*R6>HW#W-S%(Q8-(Q!+#/3D C
M'3'%+MZ?Y!_G_F>;_$L>)H_"EM)KVK:5%')=P*MC9VY&]]ZGAV8G  )X KI[
M>)&^.][(R NF@Q!3Z9F;/\JO#X7^$_L4EH^G/*DBJF^6XD=T (("L3E>0.AK
M?CT.PBUV36EB;[>]LMJTA<G,:DL!CIU/7K5(EK^OF<KHP"_&3Q/@8S869/N?
MGI/BYD>#(GD&;2/4+5[OC(\H2C=GVZ5UD.BV-MK=WK$<1%[=QI%,^\D,J9VC
M'08R:M75K!>VLMM<Q)-!*I22-QE6!Z@BIMHBNK_KH8OB74]#L=/L)-4MTNXI
MKN&.TC5%D+2L?D*@GMUR.E<MHNIZYK]WKDGAN/1]&TV&^EADGE@,DTLR\/(P
M! ';KS71:5\/O#>C:C'?6=@?/BSY)DE>18<]=BL2%_"FW?PZ\,7NJ3ZC-IY\
MZ=@\ZI,ZQRMZL@.UOQ% 'DP?S?@5XV<W*W6[6I"9T4*)?WT7S #@ ]>/6O0O
MBK%'%\-RB(%6.YM0@'\.)D'%;C>!/#K:+J6CBQ*6&HS^?<0I(R@OE3D8/R_=
M7@8Z5IZQH=AKVF'3]1A,ML71R@<KRK!EY'/4"JNM/E^@GM;U_$Y'266/XU>(
M4NBHFETZV:SW=3$-V_'_  *L/XI7VG7GAWQ59Z7;;;^V-HVIW*1##(7! )!R
MQ &2.PKT'7?"FC>)/).I6F^6#_53([1R)Z@.I! _&I-+\,Z/HVER:;96,:VL
MV3,K?,92>"7)Y8D>M3;0=]3S_P 5Z1K%YX(F&L^--)BT29$_?)IAQ@L"A7#G
MOC&*T+>$#XWV(D?SGC\,?ZPC!)\X MCMG)K9M?AIX5L[V*ZBTTDQ/YD43S.\
M4;9SE4)VC'L*W/[#L/\ A(AKWE'^T1:_9/,WG'E;MV,=.O?K5)ZW_K8.EC3H
MHHI %%%% !1110 4444 %%%% !1110 4444 %%%% "=J^3_%O_(YZ[_V$+C_
M -&-7UAVKY/\6_\ (YZ[_P!A"X_]&-6E/<X,?\*,>BBBMCRPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N]T?_ ))+??\ 877_ -%BN"KO='_Y
M)+??]A=?_18I%KX9>C.>HHHK4\L**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KI_AY_R/>F?63_ -%M7,5T_P //^1[TSZR?^BVI2V-J'\2/J>C
MO]]OJ:;VIS_?;ZFF]J[%L?)5/B84444R0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** 6YM/_ *BV_P"N*U'4C_ZBV_ZXK4=<D=CZ;$?Q/N_(****
MHP"BBB@ HHHH **** -31OO3?0?UK7K(T;[TWT']:UZXJOQL^ORS_=8_/\PH
MHHK,[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#,U[1X?$&@7NDW$DD<-W$8G>/&X ^F>*A\,>'K;PMX<M-$M
M)998+4,JO+C<<L6YP .];!XH%(#B-$^%^@Z/X6U#P[(9[ZQOYC-*+@C(; 'R
ME0,8V@CO5&+X0Z6QMH=0UC6=2TZU<-#I]U<[H4QTX Z#TS7HU%/S"YRWBGP)
MI/BI[6XG,]K?VG_'M>6C[)8OH?\ &HO#7@#3?#FI3ZJUQ>:EJLR[&OKZ7S)-
MOH#T%=;10M .*G^&]B?&K^*+/4]2L;J5D:XBMI0L<^W'##&2#M&1FJUQ\*=*
M?Q!>ZM::EJM@+]MUY;6EQY<<^<YW8&<')Z'O7?44D!PNE?"W1]'\-ZYH5K=7
MGV35R3(25W1 C&$X_GFK-U\.M-NOAY%X,>[NQ8QA0)@5\SA]X[8Z^U=C2T]P
M.+\2?#C3?$WA;2] NKN[BMM.*&.2(KO;:FP9R".A["F^(?AMIVN^((==BU#4
M=,U../RFN+&;8TB],'@]N.*[6BBXEIH<7X9^&NE>%-6U*^TZZO,:A$(Y897#
MKG^]DC=G.3R>YK$L_@GI.FZ7)8V&NZW:+,2+AX;@*9U/\+ #! Y[=Z]/HH&9
M7A_P_IWAC1H=*TN 16T709R23U)/<FIM:TFVUW1KS2[P$V]U$T3XZ@$8R/<=
M:T**'KN"TV.:\%^#-.\#Z&=+TYY9$:5I7EFQO=CCK@ <  ?A6)J?PGTF]U&^
MN[+4M4TI=0R;V"QGV1W&>NX$'KD]/4UW]%#WN".>_P"$*T'_ (1#_A%OL*_V
M5LV>5DYZYW9Z[L\YZYKD[GX*Z1>:.=,O-<UNYMX\"V66X#"V /1%QCD<<@\5
MZ=10!R>M^ -&U_1=.TZ]$V_3D5;6ZC?;+$5 &01] <=.*@T'X<Z;H^M#6KJ^
MU#5]41=D=UJ,WF-&OHO  ^O6NRQ11?J*VECB];^'-CJ_BM/$<.IZCINH",1R
M/9RA/-48X;(/8 <>E6]*\"V&D^)M;UV&YN7N-7&V9'*[$_W<#/YYKJ:6EH,Y
M+POX#T_PIX6N] L[JYEM[EI&:28J7&]0IQ@ =!Z5<\'>$[3P7H":/8SSSPK(
MT@><C=ECST %=!2T^MQ6"BBB@84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !2$9%+12 P_"OAJU\)Z!#H]G---!$[L'FQN^
M9BQZ #J:+#PU:Z?XHU?7HYIFN-36%98VQL3RUVC;QGGOFMNBG<!:*** "BBB
M@ HHHH *0@$8(R*6J][>06%E/=W4@B@@C,DCMT50,DFDP.5E^'MK#=33:+JV
MIZ*)F+RPV,P$;,>IV," ?H!5O0_!&FZ-J9U5Y[S4-4,?E&\O9C(X3T&> /H*
MPH_B/J]Y"-0T[P-J=UH[#>EV9XT=D_O",\GV]:Z_P_K]CXFT6#5=.D9K>8'
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MREF]<G:!]*J>)?$R^';C1HFM3/\ VG?I9 A]OEE@3NZ<].E;XYH\Q>0M%%%
MPHHHH **** "BBB@ HHHH ***,B@ HHS1F@ HHR/6C(]: "BC-&10 449%&:
M "BC(]:,B@ HHR/6C(H **,BC- !11D>M&1ZT %%&11F@ HHR*,B@ HHR*,C
MUH **,T9H **,BC(H **,BC(H **,T9% !11FC(H **,T9'K0 G:OD_Q;_R.
M>N_]A"X_]&-7UAFOD_Q9_P CGKG_ &$+C_T8U:T]S@QWPHQZ***U/+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *[W1_\ DDM]_P!A=?\ T6*X
M*N]T?_DDM]_V%U_]%BD6OAEZ,YZBBBM3RPHHHH **** "BBB@ HHHH ****
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M,B@ HHR*,CUH **,T9H **,BC(H **,BC(H **,T9% !11FC(H **,T9'K0
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M);_9SB0_=]1[^] T.W#!A)-Q:?9/]8?N>OU]ZU**+L/90[&6FAV\;PL'FS%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAOWMHFNX49(YBOS(IZ@'T.*;:Z98V,,T-K:0PQS2-+*B( '=OO,?4GO1UO\
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M_C1_;FE?]!*T_P"_R_XT<K#VL.Y?HJA_;FE?]!*T_P"_R_XT?VYI7_02M/\
MO\O^-'*P]K#N7Z*H?VYI7_02M/\ O\O^-']N:5_T$K3_ +_+_C1RL/:P[E^B
MJ']N:5_T$K3_ +_+_C1_;FE?]!*T_P"_R_XT<K#VL.Y?HJA_;FE?]!*T_P"_
MR_XT?VYI7_02M/\ O\O^-'*P]K#N7Z*H?VYI7_02M/\ O\O^-']N:5_T$K3_
M +_+_C1RL/:P[E^BJ']N:5_T$K3_ +_+_C1_;FE?]!*T_P"_R_XT<K#VL.Y?
MHJA_;FE?]!*T_P"_R_XT?VYI7_02M/\ O\O^-'*P]K#N7Z*H?VYI7_02M/\
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M8=T7Z*H?VYI7_01M/^_R_P"-']N:5_T$;3_O\O\ C1RL/:P[HOT50_MS2O\
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M7_OV*V:*.9A[&G_*C&_X1/0?^@5:_P#?L4?\(GH/_0*M?^_8K9HHYF'L:?\
M*C&_X1/0?^@5:_\ ?L4?\(GH/_0*M?\ OV*V:*.9A[&G_*C&_P"$3T'_ *!5
MK_W[%'_")Z#_ - JU_[]BMFBCF8>QI_RHQO^$3T'_H%6O_?L4?\ ")Z#_P!
MJU_[]BMFBCF8>QI_RHQO^$3T'_H%6O\ W[%'_")Z#_T"K7_OV*V:*.9A[&G_
M "HQO^$3T'_H%6O_ '[%'_")Z#_T"K7_ +]BMFBCF8>QI_RHQO\ A$]!_P"@
M5:_]^Q1_PB>@_P#0*M?^_8K9HHYF'L:?\J,;_A$]!_Z!5K_W[%'_  B>@_\
M0*M?^_8K9HHYF'L:?\J,;_A$]!_Z!5K_ -^Q3X?#.BV\R30Z;;))&=RLJ $'
MU%:U%',QJC370KW=G;W]LUO=0I-"V,HXR#BLW_A$]!_Z!5K_ -^Q6I=.T5K*
MZ_>5"1]<5YMX,D\;>*_"5AK;^*X[=KI6;RQI\1"X8KZ>U";Z#E3A)WDCMO\
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M>VG?V-X=TZ"(1FWNEO2OV<J1M8$KQTQ^->C-H-E-X;70KI/M%D+=;=ED_B4
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M_P"'-/TF,@BU@6,M_>;'S-^)R?QI+N-G*?&?_DF]W_U\6_\ Z.2N]R%BW,0
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MJ(8RGD7LH9 21\W Z\?J:%M8'O<ZJOD_Q;_R.>N_]A"X_P#1C5]85\G^+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:;\06W_7%:CKFCL?0UTU/5]OR*$VJ1PBY)@N&\AE5ML>=V?[OK[TZ;4HX3=
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M:>0?45_,<Y/J2VYO=UK=-]D"%]L1._=TV^N._I1-J(A>Y4VMT?L\:R-MB)W
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MT1&PKW;T'H:LV-^M_"TJ131A79,2IM.1W^E7,#TI,4: E+JQU%%%(T"BBB@
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M- EVA<1,VXKR1U_"MJF).^H4444#"BBB@ HHHH **** "BBB@ HHHH ****
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M9LA!]DTR8/<>9)AL;U/RC'/0U?VEZ_@1KR^=OQ,7QKKEZ?&ES877BR72+&&
M&VMM*)DNIGP"2Z@<#KQGTK(T'Q1JGB;X&^+CJUPUS-:++"DSKAF78#\WOR:W
MG\$>*]$^(.LZYH7]F7,&K<F2])WVQSU4#KC_  JOX;^''B'1_ /BWP]<M:RS
MZBSFUF63B0D8RPQ\O0'OUJ/LOT+^T8FA:9XIA^#-KXAL?$UQ9M86LD\%E$H$
M31HS$A^[$X->K> _$4GBOP3IFLSH$GN(R) .FY6*DCV)4FO/K7P7\0[+P''X
M/AGTHV<\1CEN&=O,@5B=Z#LPY//'6O3?"OA^#PMX9L-%MW+I:Q[2Y&-S$DL?
MQ))K1M.Y"6B-JBBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $KF_'\\]M\/M?FMBPF2QE*E>H^4\UTE0W-O%=V
MDMM.@>*5"CJ>A4C!%2U=#3L[F)X&@@MO >A1VP B^PPD8'7* D_B235Y[738
M]0N[B*.W74I8 )F7'F,@SMSWQ7(Z;I'C/PC:?V3I"Z?JNEQ9%J;N5HY85SD(
M2/O >M:/AOPOJ%GJ&IZ]K=U'<:QJ"",K$"(X(QTC7/N>3WJI:WL3'2R*'P7_
M .25Z1_O3_\ HYZA=$@^/L8@X-SH3-<JO0XEPI/OVK*\*:7\2_"?ARVT2UTK
M09H;<OMDENGW'<[-S@>K5U/A7PG?66J:AK_B"[CN]9OT$1,2XC@B'2-?QZGO
M3D[RYD-]5_6XSQ5I>NV7AQ],\&V=A! T4@=6RK+N.3L'3)RW7OBK/PXN=.N?
M .E#3$ECMH8O)V3??5U)# ^^X&L>PTCQOX;LI=%TE["]L=[&VO+N1O-@5F)P
MR_QXSQ5G['>?#KX=1PZ6(KZ[@<,YN"1YSN^6P!SDEN!20,[JO._ (\_QOXZN
MY^;P:@D//58E3Y!].M>ACWZUQ>K>&M8T_P 3S^)/"\MM]INXUCO;*YR(Y]O"
MMN'*L!2V8;HZ;4[;3+E(&U*.W=(IEDA,^,+(/ND9[\UQMC_R7C5O^P+#_P"C
M#3YO#WB7Q7JVGR^)?L=EIEA<+<I9VCF0SR+]TNQQP.>*KZUHOC"S^(MUXB\/
M6>F74-Q8QVI6\G9""&)/ 'TH6Z$]5_7<?\:%5?A[-=+Q=6MU;RVS#JLGF*./
MP)KJM0FT;04N/$6H>1;2"$1S73##%!R%]^3TKDSX:\5^+-2T^7Q<VGVNG6,X
MN!8V19Q-(OW2S'L/2JOC/P]XQU?QI:WUG8Z7?:19(#;VMY<,JM+U,C*!R1T&
M?3-/I;S'NRO''J>JVOBSQU<V\ED)]'EM=-MV&)!"JLP=QV);D#M72^%+>W/P
MATJ$@>2^D)OXXYCRW\S4VAMXNU"2YM?%&EZ3;V$D!1?L<S.S$\8(/;!-<_#X
M;\:Z=X??PE92Z>VE[&@AU&1F\Z*%L\;.A8 X!I-:./\ 74$]4S;^%<LDWPPT
M!I22PMMHSZ!B!^@%3_$JYN+3X;Z_-;%A*+1@"O! /!/X FMS1M+@T31K/2[7
M/D6D*Q)GJ0HQDU/>VD%_93VES&)()T,<B'HRD8(ISUO8(:6N8.B2V7A[X>:?
M/%#+):6MA&X2W3>[C8#P!U)ZUCZ-XZ\-ZUXIV0Z7J%MJS6K%9;NS,3-$AR1D
MGIDT:=I/C'PE:II>D_8=6TN+(MOM<ABEA3LA(R& ]:DTKPUKM[XP@\3>(I[.
M.2"U>VBL[1254,>26/6AN[NA)65CS_1=7T7Q5ITFM>(GUZ34;J21H3:Q2^7;
M(&(0)MX.  2?4U9U'5M<UGX=^&%NKB\M=1_X2*&R^TNACD=<N%D(/^R0?J*Z
MO3-#\8>#K:?2- BTZ^TKS'>T:ZD9'MPS9*D#[P!)-2ZGX/UR[T'PW:3:C_:%
M]8ZQ!?W=Q.VW<JEBP4>V0 *%;3MH/_@F=K.AP^"_$_A:]T>YNT:^U$65VDL[
M.LZ,C'+ GJ",YJ*RT!?$WQ.\9V^HW5TVGV[6NVVCF9%9VB^\<>F./K76^+M!
MO=:O_#<MIY>S3]42ZGWMCY K X]3R*-!T&]T[QIXIU6?R_LVI/;M;[6RWR1[
M6R.W-"ZW_K877^O,XCP;X5C\1VFOV.KZC?W-MI6ISZ?9)]H9?*1<$'(/+?-C
M)]*DTO4YM7^#NB7>L>(SIL)G,=Y<DGS)XDD==@(Y!(4<CTKL?!F@7NA-XB-Y
MY>+_ %B>\AV-G]VX7&?0\'BN1M_A[KUIX)\,P1?8WU71+R:X^S3,3#,'=S@G
M'7##G''-'3[BM-3.@O-'TGQ[X;'A635(XKNX:WNQ.)/)F0H2.7ZL",\5HZ+X
M2@\1^.?&DFHW%P;&._14MHI2BF3RERYQU(!&/QK1U#P]XOUO7?#VJWJ:=;Q:
M9?"0V4,A(V$$,Y8CEAQ@8'>G6^A>,="\4^(=5TI-/NK;4[E76VGE*X 0 /D#
M@YR"/I2]?ZV)?]?B7/ %U<VNI^(_#5Q<RW4>CW2"WEF;<WE2)N5">^WD5;^(
MCM<:';:+&3YFL7D5F<?\\R=TG_CBM5CP?X<N=$CU"]U*=)]6U.X^T73QC"+Q
MA47V4<5/?:/=7_C32M1DV?8-/MYB@W?,9WPH./0)NY_VJ;W0+J;Z(J(JJ  !
M@#TIU%% !1110,**** "BBB@ HHHH IZC:/?636Z7$MNS$'S(CAA@YJM<:5)
M.;\C4+F/[4$VA6_U.W^[]>]:3,J*68@*HR2>U9H\2Z$3@:UIW_@4G^--,APC
M+5A-I4DK73#4+E//C5 %;_5D?Q+[FEDTJ1WE;[?<KYEMY  ;[I_OC_:K01UD
M0.C!E(R&4Y!I]%V+V<3+&DR;@?M]S_QZ?9L;N_\ ST_WJ$TF1&A8ZA<MY<!A
M(+??/]\_[5:M%%V'LXF7#I<D369-_<O]G1D8,W^MSW;W%);:3+!]AW:A<R?9
M?,W;V_UV[IN^G:M":>*WA>:>5(HD&YG=@JJ/<GI3/M=OYL47VB+S)E+1)O&7
M ZE1W%%V'LXE&'2)(5M =1NG\AV<EF_UF>S>PH32)52%3J-T?+N#,26^\/[A
M_P!FM-W6-"[L%51DDG  J.WNH+RW6>VFCGA;.V2)PRG!QP11S,/91* T>4 #
M^T;KB[^T_>[?\\_]VA]'D990-1NEWW G!#?=']P?[-:"W,#7#VZS1M/& SQA
MAN4'H2.H!I+>Y@NXO-MIXYH\D;XW##(ZC(HYF'LHE";2)9$NE&HW2>?(LBE6
M_P!7CLOL:+C2))Q?8U&ZC^TE"I1O]3M_N_7O5[[7;_:_LGVB+[3MW^3O&_;T
MSCKC/>E@NH+H.;>>*4(Y1S&P;:PZ@XZ$>E%V'LHE*XTJ2=KQA?W,8N%55"MQ
M%CNON:)-*D<W!%_<KYL(B #?<(_B'O6G4<DJ0Q-)*ZI&HRS,< #N2?2B[#V4
M3/;29"S'^T+D;K7[/C=T/_/3_>I5TF0,A-_<D+;?9R"WWC_?/^U6BCK(BLC!
ME89# Y!%/HNP]G$RX=*DB:V8W]R_DPF,AF_UA/\ $?>DM]*D@:Q+7]S)]F#A
M@S?ZW=W;Z=JU**+L/9Q,JWTB6!+)3J-S(;8N6+M_K=W9OIVHBTB6);8?VC=/
MY,K2$LWWP?X3[5JU%/<PVL+3W$T<,2\M)(P55^I/2B[#V43/&D2A4!U&Z.VZ
M^T9W=1_SS/\ LT'2)2K#^T;KFZ^T9W=!_P \_P#=K4!# $'(]:=1=A[*)DR:
M1*ZS@:C=+YLXE!#?< _A'M1<:1+.MX!J-U']H964JW^JQV7ZUJ$@<FF0S17$
M2RPR))$XRKHP(8>H(ZT78>RB9]QI,DYOB-0N8_M03;M;_4[?[OU[T3:5)*UT
MPU"Y3SXU0!6_U9'\2^]:E%%P]G$S'TJ1VE;[?<KOM_(P&^Z?[X_VJ0:3(&!^
MWW.!:?9L;N__ #T_WJU:*+L/9Q,I-*D1H6-_<L([<PD%OOG^^?\ :I8=*DB-
MH3?W+_9T9&#-_K<]V]Q6G2T78>SB95MI,L'V'=J%S)]E\S=O;_7;NF[Z=J2#
M2)85M =1NG^SR,Y+-_K >S>P[5JT478>RB92:1*J0K_:-T?+N#,26^\/[A_V
M:/['E  _M&Z_X^_M/WNW_//_ ':UJ*.9A[*)D/I$K+*!J-TN^X\\$-]T?W!_
MLU\V^*KE5\::S^YC.R_N%.1U_>-S7U0:^4/%O_(YZY_V$+C_ -&-6E-LX<;"
M*BC/2Y5##F&,^7G.1][/K2)<J@B_<H=A).1][/K5>BM;GF\J+ N5 3]RAVMN
MY'7V/M1]I4 #R4XDW]/T^E5Z* Y46#<J0?W*<OOZ=/;Z4-<JP<>2@W-NX'3V
M%5Z* Y46'N5<2CR47S,$8_AQZ427*N92(8U\S&,#[N/2J]% <J++7*L7/DQC
M<H7@=/<4?:EY_<Q\ILZ?K]:K44!RHL_:ER#Y,?$>SI^OUH%TH*_N8SM7;TZ^
MY]ZK44!RHLI<JAB/DQG8"#D?>SZTB7*H(OW*-Y><Y'WL^M5Z*+ARHL+<JHC'
MDH=A)Y'7V- N5 4>2AP^[Z^WTJO11<?*BQ]I7&/)3_6;^G;T^E!N5(8>2@W/
MNX'3V'M5>B@5D6&N%82_N4&\@C ^[]*[.P4S_#6ZN03&JZIM\I/NG,:<GWX_
M4UPG:N]T?_DDM]_V%U_]%BBY2BN67H81E!W?(O(Q]*#(,GY%Y&*CHK4\VQ)Y
MH_N+]W;_ /7^M'FCCY%X7%1T4@L2"0 K\BG Q]:!*!M^13MS^/UJ.B@+$@D
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M,B;@+>%66/(/8D$X[UI7OC#4(](\*Z;I[VL6K:S:+,T\P BMT$89WV].IX%
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MG>4LH_($T+=7\QO9GH%%%% !1110 4444 %%%% !1110 E?)_BW_ )'/7?\
ML(7'_HQJ^L*^3_%O_(YZY_V$+C_T8U:4]S@Q_P *,>BBBMCRPHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "N]T?_DDM]_V%U_\ 18K@J[W1_P#D
MDM]_V%U_]%BD6OAEZ,YZBBBM3RPHHHH **** "BBB@ KJ_AM_P C_I?_ &U_
M]%/7*5U?PV_Y'_2_^VO_ **>IE\+-\-_&AZH^@J***XSZT**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 2N5^(FHWNG^";_ /LZ&6:^N0+6W6)2Q#2'
M;NXZ8!)S[5U5%)JX)V/.;#X,^&+?2X+6<7KNL063;=NJL<?,< XY.>/>N1N+
M75++X5^+/"!M;J6;2KN-;)O*9O-@:9&3!QSCG..E>Z=J*=W<%I8\M\3:]>^,
MO#3>%;'1K^#5+[9%=>?"5CME# NQ?HW3C'7-.O;^?PQ\5YKM]-O+C2O[&@@E
MG@A+F,B1MIP.OOCGD5ZA11UN+I8X#PU%<^(/B!?>+FLY[2P2Q73[,7";'F&_
M>SE>PSP,UB>/[75M(\27<FB6TT@\3V2V$C1(2(IPRJLC$=!Y;MS_ +->M44M
M-!WW.3\0Z0FF_"S4](L8F9(-*D@B1%R6Q&0, =2:XK5_#K?8?!.O7FCOJ5C8
MZ:MM?V80F1%:-<.%ZDJ1R*]AQ1BGUN+I8\P\/V^B7_BZQD\/^#T@M+97DGU&
MZMVB:-L?*L8/4G)S7I%X"UE.!DDQM@#Z5/12>JL-;W/$[+3[T?!+PG;&SN!/
M'J=NSQ&)MR@7#$DC&1QS79?$JWGN(_"WD0R2^7XALW?8I.U06R3CH!ZUW6**
M>[OYW$M#SB.[E\"^--?N+ZQNYM+UB2.Y@N+6$R[) FUD8#D=,@UJZ3XDU-='
MU?Q!K-E<Q:>)MUC:)!NG$(P-Q4<DL23CL*[*BD,9%()8DD (#J& 88(S4E)2
MTP"BBB@ HHHH **** &D!@00"#V-5/[)TW_H'VG_ 'Y7_"EU"]^P6;7)ADFV
MD?)&,L<G']:K7&L"W:^'V2X?[($)VKGS-W]WUQWIV(<XK1FFB*BA$4*HX  P
M!2UF3:P(GNE^R7#>1&LF57[^>P]Z'U@(TJ_9+@[+;[1PO7_9'^U[468O:1+L
M=I;0RM+';0I(W5U0 G\:6>UM[H 3P12@=!(@;'YU1&L98#['<<VGVK.W_P <
M_P![VI$U@2/"HL[@>; 9LE?N_P"R?>BS#VD30,$)A,!B3R<8V;1MQZ8H\B+>
MC^4F^,81MHRH]!Z50@U<3M: 6EPOVE&<;EQLQV;T-);:R+C[#_H=PGVOS,;D
MQY>W^]Z9[468>TB:; ,I5@"#P0>])'&D,8CC1411@*HP!^%9D.M"9;0_8[E?
MM#LGS)]S'=O04JZT&2%OL=R/,N#!@I]T_P!X^WO19A[6)HK!"DKRK$BR/C<X
M4 M]3WHBBB@39%&D:YSM10!6:-:X!-E<\W?V7[O_ (__ +OO0^M!%D;['<GR
M[CR.$Z_[0_V?>BS#VL32\F+S_/\ *3S=NW?M&['IGTJNVEZ>[EFL;5F8Y),*
MDD_E5:;6A"MTQL[AOL\BQD*GW\XY'J*2XUD6XOB;.X?[(4^ZF?,W?W?7'>BS
M#VL30@MH+9"D$,<2DY*QJ%!/X5A^+="FUO3(GLF6/4K&=;NS=C@"1?X3[,"5
M/L:O7&KBW>\7[)</]F56^5<[]W9?4BB35Q&TX^R7!\J 3<+][/\ "/>CE8>T
MB7#$MS;JEU!&V0"T; , ?ZU)%%%!&(XHTC0=%08 _"LYM8PS#['<';:_:<[>
MO^Q_O>U*NL!F0"TN/GMOM(RO3_9_WO:BS#VD2XEG:QSF9+:%93U<( Q_&I##
M&9A-Y:>8!M#[1G'IGTK/AU<2M;#[)<+Y\32Y9?NX['WHM]8%PUD/LEPGVH.<
MLN/+V_WO3/:BS#VD30$4:RM*(T$C  N%Y('J::;6W99%,$160Y<%!AS[^M9]
MOK(N%LC]CN$^U%P R8\O;_>],XXHAUH2K;G['<KYTK18*?=QW/M19A[6)?6T
MMDF,RV\2RGK($ 8_C3Y88;B/RYHDD3^ZZ@C\C6:-:!5#]CN?FNOLWW.A_O?[
MOO0=: 5C]CN?EN_LWW.O^W_N^]'*P]K$T8XHX(]D$2(HZ*@ %8'A70KC3%U#
M4-1V'5-3N#/<E#D(!\J1@]PJ@#ZYJ])K0C6=C9W)\F80\)][/\0]J+C6A EX
M?L=PYM612%3[^['*^N,T<K#VL35HK,N-8%NU\/LEP_V0(?E7/F;O[OKCO1-K
M A>Z7[)<-Y$:R95?OY[#WHLP=2)IT5F/K 1I%^R7!V6_VC(7K_LC_:]J0:QE
M@OV.XYM/M6=O_CG^][468>TB:E+64FL"1X5^R7 \V S E?NX_A/O2PZN)FM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKJ_AM_R/^E_]M?\ T4]*7PLWPW\:'JCZ"P*,"BBN(^M# HP*** L&!1@444
M&!1@444 &!1@444 &!1@444 &!1@444 &!1@444 &!1@444 &!1@444 &!1@
M444 &!1@444 &!1@444 &!1@444 &!Z48%%% 6# HP*** # HP*** # HP**
M* #%&!110 8%&!110 8%&!110 8%&!110 8%&!Z444!8,"C HHH ,"C HHH
M,"C HHH ,"C HHH"P8%&!110 8%&!110 8%&!110 8%&!110 8%&!110 8%&
M!110 8%&!110 8%&!110 8%&!110 8%&!110 8%&!110 8%&!110 8'I1@44
M4!8,"C HHH ,"C HHH ,"C HHH ,48%%% !@48%%% !@48%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M000:1/.\RJ]ONFBWG+!6Z?3-&G?#..#P7=^'+J_9T-\]W:7,8Q)"=P9"2>K
MYY[YI+S&]]/ZW+]QX$\/6-YI=[8B/2)K2==LD)"^>""#&V?O Y^M<;I$%KH%
MI\2=6T^SABO-/N)_LSJG,8\E3@>V>:ZN+PCKNIZEI\OB;6H+RUTZ87$,%O!Y
M?F2KD*SGOC.<#O4]IX/NK7Q%KDINX)=$UG+W-F\9WARFPX;T.*33_!_H'8Q=
M,\ :'>?#R"6XA$FHW-FMP^HECYWFLN[>&]B?RKFE=O&;?"MM7!E-REY]H#'_
M %NQ!U_WMG/UKK4\#^);?23X>M_$R)H6TPJ3!FY2$C&P/TX'&?2M23P3%%K'
MA*XL)4@L] 2>,0L"2X>,(,'U&,FK5KW_ *ZB7GYF-K>F6?@[QQX8UC3[:.UL
M;EGTJZ2-<*/,)>,_]]Y_.KWA-?[;\<>)/$C<Q12+I5F?]B+F0CV+D_\ ?-2?
M%.XL!X&U&WN+A$O"BR6<88>8TP8&/:.I^8 5M>#]%/A_PII^G2<SQQ;IV_O2
ML=SG_OHFDOR&SE_C#G_A&]*:3_CS76+4W>>GE;CG/MG;7H8QCBJ&M:19Z]I%
MSI=_%YEK<H4<=_8CW!P:Y6+PYXVL[4:?:>*K9K-0$CFN+7=.J?7H3[FDNP,J
M_$J_TV]^%_BE-/EAD:WQ%<"(?=D#KD'WKN=+_P"03:?]<4_D*Y&[^'<"_#J_
M\+:?<E9KWYY;N<;FDE+!F=L=2<55AT'XF0PQQ1^+-("(H5?^)=V'XT+=@]D*
M/^3@3_V+G_M<5Z%7G^M^#O$]QXO@\1Z+KEE:78TY;&;SK8R!L-N8@9XR<5K^
M'=/\96NI&37]=L+ZS,9 BM[3RF#Y&#G/3K36U@>]SJJ*** "BBB@!.U?)_BW
M_D<]=_["%Q_Z,:OK#M7R?XM_Y'/7?^PA<?\ HQJTI[G!C_A1CT445L>6%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5WNC_ /));[_L+K_Z+%<%
M7>Z/_P DEOO^PNO_ *+%(M?#+T9SU%%%:GEA1110 4444 %%%% !75_#;_D?
M]+_[:_\ HIZY2NK^&W_(_P"E_P#;7_T4]3+X6;X;^-#U1]!4445QGUH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F:,US
M4GA%9)7?^U+\;B3@2]*;_P (:O\ T%;_ /[^U5H]SG]I5_D_$Z?-&:YC_A#5
M_P"@K?\ _?VC_A#5_P"@K?\ _?VBT>X>TK?R?B=/FC-<Q_PAJ_\ 05O_ /O[
M1_PAJ_\ 05O_ /O[1:/</:5OY/Q.GS1FN8_X0U?^@K?_ /?VC_A#5_Z"M_\
M]_:+1[A[2M_)^)T^:,US'_"&K_T%;_\ [^T?\(:O_05O_P#O[1:/</:5OY/Q
M.GS1FN8_X0U?^@K?_P#?VC_A#5_Z"M__ -_:+1[A[2M_)^)T^:,US'_"&K_T
M%;__ +^T?\(:O_05O_\ O[1:/</:5OY/Q.GS1FN8_P"$-7_H*W__ ']H_P"$
M-7_H*W__ ']HM'N'M*W\GXG3YHS7,?\ "&K_ -!6_P#^_M'_  AJ_P#05O\
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MPAJ_]!6__P"_M%H]P]I6_D_$Z?-&:YC_ (0U?^@K?_\ ?VC_ (0U?^@K?_\
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M_M'_  AJ_P#05O\ _O[1:/</:5OY/Q.GS1FN8_X0U?\ H*W_ /W]H_X0U?\
MH*W_ /W]HM'N'M*W\GXG3YHS7,?\(:O_ $%;_P#[^T?\(:O_ $%;_P#[^T6C
MW#VE;^3\3I\T9KF/^$-7_H*W_P#W]H_X0U?^@K?_ /?VBT>X>TK?R?B=/FC-
M<Q_PAJ_]!6__ ._M'_"&K_T%;_\ [^T6CW#VE;^3\3I\T9KF/^$-7_H*W_\
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M]J./:N8_X0U?^@K?_P#?VC_A#5_Z"M__ -_:=H]R/:5OY/Q.GR/:CCVKF/\
MA#5_Z"M__P!_:/\ A#5_Z"M__P!_:+1[A[2M_)^)OWEI;:A936=W$DUO.ACE
MC?D,IZ@T^"&*VMXX(4"11J$1!T4 8 _*N=_X0U?^@K?_ /?VC_A#5_Z"M_\
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MRH^T_P#3-/RK4\^\NQ!14_VG_IFGY4?:?^F:?E0%Y=B"BI_M/_3-/RH^T_\
M3-/RH"\NQ!14_P!I_P"F:?E1]I_Z9I^5 7EV(:ZGX;G'C[3/^VO_ **>N<^U
M?],T_*I;?49K299[?$4JYVNO!&1C^1-*2NK%TJCA-2:V9]09'J*,CU%?-O\
MPE6L_P#/]-_WV:/^$JUG_G^F_P"^S6'L/,]G^UU_)^)])9'J*,CU%?-O_"5:
MS_S_ $W_ 'V:/^$JUG_G^F_[[-'L/,/[77\GXGTED>HHR/45\V_\)5K/_/\
M3?\ ?9H_X2K6?^?Z;_OLT>P\P_M=?R?B?261ZBC(]17S;_PE6L_\_P!-_P!]
MFC_A*M9_Y_IO^^S1[#S#^UU_)^)])9'K1D>M?-O_  E6L_\ /]-_WV:V?"NK
M:EK?B6ST^XU"X$4Q?<5<YX1C_,4G1MK<J.:J3Y5#\3WG(HS7F3:?.&(_M.\X
M/_/2D^P3_P#03O/^_E:?5)=SA?$U!.W(ST[(HR*\Q^P3_P#03O/^_E'V"?\
MZ"=Y_P!_*/JDNXO]9Z'\C/3LBC(KS'[!/_T$[S_OY1]@G_Z"=Y_W\H^J2[A_
MK/0_D9Z=D49%>8_8)_\ H)WG_?RC[!/_ -!.\_[^4?5)=P_UGH?R,].R*,BO
M,?L$_P#T$[S_ +^4?8)_^@G>?]_*/JDNX?ZS4/Y&>G9'K1D5R5IX4$]I%*VJ
MWX+J"?WO<U-_PAR_]!6__P"_M8.*74]N%:K**DH;^9T^:,US'_"&K_T%;_\
M[^T?\(:O_05O_P#O[2M'N7[2M_)^)T^:,US'_"&K_P!!6_\ ^_M'_"&K_P!!
M6_\ ^_M%H]P]I6_D_$Z?-&:YC_A#5_Z"M_\ ]_:/^$-7_H*W_P#W]HM'N'M*
MW\GXG3YHS7,?\(:O_05O_P#O[1_PAJ_]!6__ ._M%H]P]I6_D_$Z?-&:YC_A
M#5_Z"M__ -_:/^$-7_H*W_\ W]HM'N'M*W\GXG3YHS7,?\(:O_05O_\ O[1_
MPAJ_]!6__P"_M%H]P]I6_D_$Z?-&:YC_ (0U?^@K?_\ ?VC_ (0U?^@K?_\
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M_M'_  AJ_P#05O\ _O[1:/</:5OY/Q.GS1FN8_X0U?\ H*W_ /W]H_X0U?\
MH*W_ /W]HM'N'M*W\GXG3YHS7,?\(:O_ $%;_P#[^T?\(:O_ $%;_P#[^T6C
MW#VE;^3\3I\T9KF/^$-7_H*W_P#W]H_X0U?^@K?_ /?VBT>X>TK?R?B=/FC-
M<Q_PAJ_]!6__ ._M'_"&K_T%;_\ [^T6CW#VE;^3\3I\T9KF/^$-7_H*W_\
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M?\(:O_05O_\ O[1_PAJ_]!6__P"_M%H]P]I6_D_$Z?-&:YC_ (0U?^@K?_\
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M )'/7?\ L(7'_HQJTI[G!C_A1CT445L>6%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5WNC_P#));[_ +"Z_P#HL5P5=[H__));[_L+K_Z+%(M?
M#+T9SU%%%:GEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=/\
M#S_D>],^LG_HMJYBNG^'G_(]Z9]9/_1;4I;&U#^)'U/1W^^WUIO:G/\ ?;ZF
MF]J[%L?)5/B84444R0HHHH **** "BBB@%N=KIG_ "#;?_KF/Y5<%5-,_P"0
M;;_]<Q_*K8KQY?$S]7P_\*/H@HHHJ38**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .9U7Q]X5T/49-/U/6[:VNXL%XI"<
MC(!';T(JUHOBW0/$3NND:K;7;KR5C;D?@:\I_L+2_$'[1^NV>K645Y;K8)((
MY1D;@D(!_(FJ?Q/\.Z=\.M:\/>*/#D(L&%UY<T,1(5P.>GN P/U%$=4K]1R5
MM%T/?:*X2X\=W4/Q9L_!ZV<)MI[7SS<%CO!VLV,=/X?UIT?CJZ?XMR^#39PB
MV2V\_P"T;CO)VAL8Z=Z";G<FJ]Y>0:?9S7EU*L5O ADDD;HJ@9)->>GXAZYK
MVL:C:>#M#@O[?37,<]S<S^6KMZ)CKT-))XUMO&GPM\43) ]K>VEG<0W=K(<M
M$X1OT.#^1I/:Y27O6-O_ (6KX%_Z&6R_-O\ "NCTS5K#6;-;S3;N*ZMVX$D3
M9%?-O@OQ!\++'PC9VWB32/M&K+YGG2?9BV<NQ7G/]TBNU^!OD6MIXJUB&46^
MA27.^V@=\F)%WDDCMP0/?;566I)[517E=O\ $SQ+K5A=:YH/AB.XT&V9@9)I
MRLTJK]XHHZUL7/Q3T:'X=)XO1'>*0B)+?/S^=_</TP>?3FET'U.KU?6]-T"Q
M-]JUY':6P8*9),XR>@J[#,EQ"DT3!HW4,K#N#R#7@7Q2\1>)M1^'"?V_H$5C
M#>3Q/;R03;]N,G:X/0D?RKN[#QM=:9XPT'PM>6<2V-_IR26MV&.YG"<J1T['
M\Q0M;B>ECT:D8A5+$\#DUQ,7C:ZO?BI-X3LK.*2TM+;SKNY+'<C$<*!T_B7]
M:[.?_CWE_P!T_P J3=HW&M[')_\ "U/ P.#XEL@?JW^%;]CKNEZGIK:E97T,
M]FJEFFC;(  R<^G%?._PN;X<CPW>_P#"7_V=]O\ MC^7]I!W^7L7&,=L[JVO
MA>(O.^(#:.)1X>,3_9M^=I.'QC\/TQ1+1/TN.VOS/3Q\5? Q_P"9ELOS/^%=
M+8:C9ZK:)=V%S%<0/]V2-LBO&O@[X&\,Z_\ #Z*\U31K:ZNFGE0RR*=V >*=
M\-XF\)?&+Q%X/M97;3/*\^&-FSL.$8?HY'X"JMK8F^ESVUF"@DG ')K-T77]
M*\16DEUI%]%>01R&)GCS@, "1^1'YU?N/^/>3_=/\J\F_9W_ .1&U'_L)R?^
MBXZ2U;\AO1'KM9L&O:5<ZU<:/#?12:C;H));=3\R*<<G\Q^=5O%5MK=[X?GM
MO#]U':ZA(55)W&0B[AN/UVYKR3X8:1)H7QL\2Z=+=R7DL-D-]Q)]Z1F,3$_F
M:(ZNPI:*Y[M17G?B3XBW/A#QO:Z=K=E#%H5VA:+4$+$A@/NL.G7^8JWX(\<7
MWBG3M1UN^L8=/T2)V^RS.QWR(N<LV>  /US26UQO0Z75O$.D:$]LFJ7\-JUU
M)Y<(D/+MZ"M2OE[QE?ZCXJ\0Z/XMG+1Z5-J:VFFPL,9C1AE_Q/\ GBOJ$4UM
M=B>]ACNL:,[L%51DDG@"J.D:YIFOV1O=*O(KNV#E#)&>-PZBN5^(GA_7?$4*
M6UGJQL-'2"1[T1C]Y*0/E4>WK6)^S_\ \DV;_K]E_DM):W\AO2WF=._Q1\$1
M2-&_B.S5E.&!)X(_"MK1?$FC^(H7ETC48+Q$.&,39Q]1UKYL\%ZS\/=-75X_
M&&F_:KM[UVA;R#)A/3(/KFNN^%@TK4OBUJVJ>%HC9:$EIL\AFVEV.WHOID$^
MWXTUJ$M#T^[^)7@VQNYK6Y\06<4\+F.1&)RK X(Z>M:6B>*]"\1^8-(U2WNS
M'RPC;D?AUKYXTO5O!&F>//&7_"96'VOS-1?[-^Y,FW$DF[H1CJOY5M>"6T+6
M?C9:WW@R'[!I-O:-]HC;Y/-)## 7/NO_ 'SFB*O8)Z-^1]#T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% %/4M2L](L)K_4+A+>UA&9)7Z*,XY_.N
M;3XI>"'<(OB2R+$X'S'_  J#XN?\DMU[_KBO_H:UD0^,_AF='CBEN])E?R K
M1) "[''('R]:E/<=M#N[_7])TS2/[6O+^&+3\*?M!;*?,<#D>Y%8MM\3/!=W
M<)!#XBLFD<X4;B,GZD5YA<V=W:?L[S)=PR0Q27Z26L,H^:.!KA2H.?S_ !KV
M.[\+Z'J%A):W&DV;12IM8"%0<?4"JMI<F^MC61UD171@RL,A@<@BJFJ:K8Z+
M8M>ZC<I;6R%5:1^@+$ ?F2*XWX47$ZZ)JNC32O*NC:I/8PNYR3&I!7)]LXI/
MC/\ \DVO/^OBW_\ 1R4=5YV#N>@#D4R25(8GDE<(B LS,< #U-*GW!]*X[Q]
MX=NM?TR<2:K-;Z9#:R/+:P?*9W )&YO[O3BID[#CJ=597UMJ5C#>V<RS6TZ!
MXY%Z,IZ$59KEOAK_ ,DV\._]>,?\JZFK:L["6J%HHHI#$KE_B-IEQJ_P]UNR
MM5+3O;%D4=6*_-C\<8KJ:0U,E=6&G9W,+P?JMKK/A'2[VU=61[9 RJ?N,% *
MGT(/%<UXJ\4)K.@>-=(TJ.5Y=-L&#W,9RK.R$E%QW SFM2[^''A^ZNYKB);N
MR:<DRI9W#1(Y/4E1QFMO2- TW0M.^P:=:)#;DDLH&2Y/4L3U)]Z<O>%'W;'/
M6YT;_A42',/]E?V3STV[?+Y_'/ZUB>&[SQQ;> _#2Z/I5A>(;!#*]Y<-&RG)
MVC'^[MK=/PP\,^>6\BX^S%_,-E]H;[/G_<Z?A78(BQHJ(H55&  . *>[;$E:
MR/-;1[R3XQ:5)KT,-O=OH#>3&C[HUF\WYPA/4[<?A4MR+?\ X7JAM=OVS^P)
M/- ]?-7;GWQ^F*Z_7_#.F>)(8H]0A8O"V^&:)RDD1]58<BL_1? >AZ#K/]KV
M<=P;\PM \TLQ=G4L#\V>IX'X4NWS_4=]S@?AE;>*YO!$;:?J6DQ*9IOM,=S
MS2"7>V[S#GK_ $Q4D7AYX_@_.VGZE;:E<Z7?/J5E-:J0BM&^\HN?^!C\:[74
M?AUH&HWT]V5NK9[DYG6UN&B64]RP'4UT-CI=EINFQZ=9V\<-I$FQ8E' %#[K
M<.IPOAZ]B\9?$"Y\0VQWV6F:?';VI/(\Z91(Y'N%V+^-<_\ #*W\63>$G:PU
M'2HB;J?[5'<P,THEWG=O([]/PQ7IGAKPQI?A/3#IVDPM%;M(TI#-N)8^_P"
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ML4BU\,O1G/4445J>6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5T_P\_Y'O3/K)_Z+:N8KI_AY_P CWIGUD_\ 1;4I;&U#^)'U/1W^^WU--[4Y
M_OM]33>U=BV/DJGQ,****9(4444 %%%% !1110"W.VTS_D&V_P#US'\JMBJF
MF?\ (-M_^N8_E5L5X\OB9^KX?^%'T04445)L%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-=M!),Z>6MPA1OE*YYQC.:UO#OA32M;\>>-+S5+=;M4ODBCAD.47,2DMCUY
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M )!MO_US'\JMBJFF?\@VW_ZYC^56Q7CR^)GZOA_X4?1!1114FP4444 %%%%
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MJ"-A_P#GVA ^>4_3H/4FNPKS*/2?&FFZIKNJ?8]*NY;YFQ/-,P:.!1\D8 Z
M#GW)J7L-&Y\*II9_AEH<LTCRR-"V7=B2?G;J374WLTMM87$\,#3RQQLZ0J>9
M" 2%'N>E>:?#=/%%S\)K*'3I;"RE$:_8KB13("N]M^]?7L,5V?AFT\4VIN?^
M$DU.QOMVWR/LMN8MG7=G/7/'Y5<U[S(C\*.-\.WGB:7XPE/$$D<7F:(\\5E
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M110 4444 5KZSAU"PN+*X7=!<1-%(OJK#!_0UYYINF_$/PE8QZ-ID.EZQI\
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M:[U0Q#[):\QQ*@('/=CDDFNSI:*!A1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>0QD9.I'0D=#^-;U% "  #   ]*IKI=DFK/JJVR"^DB$#3_Q&,'(7Z9-7:*
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M[\Y_"NHKC]#\7ZOJVK16=WX-U;387#$W5PR;%P,\XYYZ5V%-@%%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 G:OD_Q;_P CGKO_ &$+C_T8
MU?6':OD_Q;_R.>N_]A"X_P#1C5I3W.#'_"C'HHHK8\L**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KO='_Y)+??]A=?_18K@J[W1_\ DDM]_P!A
M=?\ T6*1:^&7HSGJ***U/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Z?X>?\CWIGUD_]%M7,5T_P\_Y'O3/K)_Z+:E+8VH?Q(^IZ._WV^IIO
M:G/]]OJ:;VKL6Q\E4^)A1113)"BBB@ HHHH **** 6YVVF?\@VW_ .N8_E5L
M54TS_D&V_P#US'\JMBO'E\3/U?#_ ,*/H@HHHJ38**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0@_[[HY6'MJ?\R^\U**R_P#A(M'_ .@A!_WW1_PD6C_]!"#_ +[HY6'MJ?\
M,OO-2BLO_A(M'_Z"$'_?='_"1:/_ -!"#_ONCE8>VI_S+[S4HK+_ .$BT?\
MZ"$'_?='_"1:/_T$(/\ ONCE8>VI_P R^\U**R_^$BT?_H(0?]]T?\)%H_\
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M3)I5BCOH'=CA5#<DT68*M3>BDC1HJ&YN8;2$S3RK'&,99C@#M5+_ (2+1_\
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M?Q/!+<>+-9FBC9XY+Z=D9>0P,C8-:4TSAQM6#BK,PJ*G^Q7/_/%_RH^Q7/\
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M9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\
MONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!
M_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?
M>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$
M(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_
M^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU
M/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:
M/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X
M2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<
MK#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?
M_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[
M[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?
M]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:
ME%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#0
M0@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\
MH(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^
M9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C
M_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+
M1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#
MVU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\
MPD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_
M (2+1_\ H(0?]]T<K#VU/^9?>:E%9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]
MT<K#VU/^9?>:E%9?_"1:/_T$(/\ ONC_ (2+1_\ H(0?]]T<K#VU/^9?>:E%
M9?\ PD6C_P#00@_[[H_X2+1_^@A!_P!]T<K#VU/^9?>:=%9G_"1:1_T$;?\
M[[JW;7MM=Q>;;S)*F<;E.1FCE8*I![-%1O#VD.Y=M/@))R3M[TG_  CFC_\
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M<S#V5/\ E1E_\(YH_P#T#K?_ +YH_P"$<T?_ *!UO_WS6I11S,/94_Y49?\
MPCFC_P#0.M_^^:/^$<T?_H'6_P#WS6I11S,/94_Y49?_  CFC_\ 0.M_^^:/
M^$<T?_H'6_\ WS6I11S,/94_Y49?_".:/_T#K?\ [YH_X1S1_P#H'6__ 'S6
MI11S,/94_P"5&7_PCFC_ /0.M_\ OFC_ (1S1_\ H'6__?-:E%',P]E3_E1E
M_P#".:/_ - ZW_[YH_X1S1_^@=;_ /?-:E%',P]E3_E1E_\ ".:/_P! ZW_[
MYH_X1S1_^@=;_P#?-:E%',P]E3_E1E_\(YH__0.M_P#OFC_A'-'_ .@=;_\
M?-:E%',P]E3_ )49?_".:/\ ] ZW_P"^:/\ A'-'_P"@=;_]\UJ44<S#V5/^
M5&7_ ,(YH_\ T#K?_OFC_A'-'_Z!UO\ ]\UJ44<S#V5/^5&7_P (YH__ $#K
M?_OFC_A'-'_Z!UO_ -\UJ44<S#V5/^5&7_PCFC_] ZW_ .^:/^$<T?\ Z!UO
M_P!\UJ44<S#V5/\ E1E_\(YH_P#T#K?_ +YH_P"$<T?_ *!UO_WS6I11S,/9
M4_Y49?\ PCFC_P#0.M_^^:/^$<T?_H'6_P#WS6I11S,/94_Y49?_  CFC_\
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M*G_*C+_X1S1_^@=;_P#?-'_".:/_ - ZW_[YK4HHYF'LJ?\ *C+_ .$<T?\
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MT?\ ".:/_P! ZW_[YK4HHYF'LJ?\J,O_ (1S1_\ H'6__?-'_".:/_T#K?\
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M*G_*C+_X1S1_^@=;_P#?-'_".:/_ - ZW_[YK4HHYF'LJ?\ *C+_ .$<T?\
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MHR_^$<T?_H'6_P#WS1_PCFC_ /0.M_\ OFM2BCF8>RI_RHR_^$<T?_H'6_\
MWS1_PCFC_P#0.M_^^:U**.9A[*G_ "HR_P#A'-'_ .@=;_\ ?-'_  CFC_\
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MT?\ ".:/_P! ZW_[YK4HHYF'LJ?\J,O_ (1S1_\ H'6__?-'_".:/_T#K?\
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M*G_*C+_X1S1_^@=;_P#?-'_".:/_ - ZW_[YK4HHYF'LJ?\ *C+_ .$<T?\
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M .BQ7!5WNC_\DEOO^PNO_HL4BU\,O1G/4445J>6%%%% !1110 4444 %%%%
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MS<C'>NBTK1[#0M,33M+M4MK2/)2),X!)R>ON31+J3'2QY=^SP /"&K@=!J3
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MK&"TTJ7SHXK4@ESD'''J5&?:O9JK[*0NHM%%%(84444 %%%% !1110 4444
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MS:[+;!$)!G/IZ9H WJ*R]3\0:3HTJ1ZCJ$%J[HTBK*V"RKC)'TR/SJO-XO\
M#UMIUO?S:O:I:W&?)D+\/@X.._4&D!N453T[4[+5K1;K3[J*YMVZ21-D5<I@
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )VKY/\6_\CGK
MO_80N/\ T8U?6':OD_Q;_P CGKO_ &$+C_T8U:4]S@Q_PHQZ***V/+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *[W1_\ DDM]_P!A=?\ T6*X
M*N]T?_DDM]_V%U_]%BD6OAEZ,YZBBBM3RPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "NG^'G_(]Z9]9/\ T6U<Q73_  \_Y'O3/K)_Z+:E+8VH
M?Q(^IZ._WV^IIO:G/]]OJ:;VKL6Q\E4^)A1113)"BBB@ HHHH **** 6YVVF
M?\@VW_ZYC^56Q533/^0;;_\ 7,?RJV*\>7Q,_5\/_"CZ(****DV"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K=7UK9>
M3]IG2(S2B*/<?ON>BCWJ/4=4L-(MS<:A>0VT(ZO*P45R<,W]N_%JZB?YK;P]
M9IL0]/M$X)W?@@P/]XUG>'[6#QA\0/$>J:I&ES;Z1<#3[&WD&Y(R!\[[3P22
M>M):AL=AIGBS0-9N#!IVK6MQ,.=B/\WY4NM>*M!\.RQ1ZQJMM9/*"8Q,^-P'
M7%9'B3P]X=U80J;NTTW4+2=)8KF$HDL94YQVX(R,'UKEOB#J>EZ3\3O"]WJ]
MN;FR%G<AD6W\[)( 'RX.>:.PF=?!\1_!UU<1P0>(["261@B(LG+,3@ ?C6TV
MM:8NM+H[7L(U%XO.6V+?.4SC=CTX-</I?C3P'?ZI:VEIHLB7,TJI$S:04 8G
M@[MO'/>N<\;:)?ZM\7Y[G2)FCU;3=%BO+0 \.ZRD%#[%21^-/L/HSV#4-2LM
M*M3=7]S';P!E4R2' RQP!^)(%6B0!GM7E/C'Q);>*O@^-4MP49KJV2:$_>AD
M$Z!E/T-=MXGT._\ $%O!96^JR:?9L3]K,(_>2KQA5;^'ODTGM<2U=C7L=0M-
M2M_M%E<1SP[V3?&<C<I*D?@016==>+?#]EJ0TZYU>TBNR0/*:0 Y/0'TKDOA
M=)_9GPD$L8)%LUVR@GKMEDQ_*E\$>&-/U7X6V_\ :%K%<W.JP/<7,\B@N[R$
MG.[KD9&/3%#=A];'HH(/(Y!KC/$?A;POXR\1K::G>3RWMK"KO81W)5"FXD,Z
M=^3UK)\*^,GL?@_I.IW2O<W[*;2WASE[B57:-!^.T$GTR:I>"](N=(^+6H+?
MW!N-1NM&CN;N3/!E:4Y"^B@  >PIM>];L*]E_7<[R_\ $7A[PV(;.]U&TL<(
M%CB9L84=..PJ\=7T]=+.J?;(38JF\SALH%]<UB6WAG2=$NM;UO4Y(KE[R4SR
MSW2+B&(* (QG^$8/YUA_#&S2\T'79?LK1Z)J.H3/8V\@P# P ) [*3GBE>_J
M/:QZ&C*ZAE(*GD$=Z=7%_#>^F;1K[1KEVDFT6^EL ['):-3F,G_@) _"NTIB
M%HQ110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 2HY9(X8FEE8)&@+,S'  '4FI*X+Q=<R^)
MM1D\)V,C+:Q1>?JTZ'[L?580?[S]_1?K4MV!([/3]0M-5L8KZPN([BUE&8Y8
MSE6'M5JN+^$O_)+=!_ZXM_Z&U=9>K<R6-PEG(D=TT;"%W&55\?*2.XSBKDK-
MH47=7&G4;0:DNG&XC%ZT1F$&[YM@(!;'ID@?C6;K/C#P]X?NDMM7U>ULYW3S
M%CF?!*Y(S^8-<'X<T*;0OC8T=SJ4^H7=QH+33W$W=C.HP!V  '%0>,=6T?1O
MC3:7.MVK7-J=#*!%MC.0QF.#MP?0\TNWG_P2K;GHVC^+- \02/'I.K6MXZ#+
M+%("1^%0:KXV\-:'?&RU36K2TN0H8Q2OAL'H:\W&K^'O$?Q&\,?\(W:_V;/;
M222SS26_V;S8]N/+"D#<2?RJ36=;T'1/C)K,NNV;744FGVXC"V9N,$9R< '%
M)]!=STS2?$.@^(SYNE:A:7QA/6)@Q3L?<5L5X]HFI:'X@^+6EW?ARW&G1VMG
M-]K5X?LYN@PPJA"!G:><_2O8J?074****!B5S/Q#TVXU;X?ZW96@+7$EJVQ1
MU8CG'XXQ^-=/2<&DU= G9W.4\.ZE)KGP\LY]"N8([LV:(AE7<L,H4 AE'/!!
M&*Y_3=;\96'CZU\/:YJ&EW:W-E+<+]D@*%2O SDUT%[\/M%NKZ2\MVO-.FE8
MM*;"X,0D)[D=,_A5O0_!FB^'[AKNT@DDO&78UU<2&24KZ;C0]7<2T5D><_#&
M#Q9-X(C;3[O1E1YIC<K=1N9?-WMN\S'?^F*HW6DQVG@3PMITFH6>I6K>+(0&
MMLF((S/F,9]"2*]%O_AUH=]?W%TCWUDUT2UQ'9W)B25NY8#N?:K\_@[1I]-T
MK3EMS!::7=1W5M'"VT*Z9(SZCDY]::>MQF#\1% UCP0X ##7(U!'4 H^1^E,
M\)6\?_"U?'EP4'FAK- W< Q9(_E^5=;J^@V6M3Z=-=^9NT^Z6[@V-CYP"!GU
M')XHL=!LM.UG5-5@\S[3J;1M<;FRN47:N!VXH6E_Z["./^&%O"LGC0K$@+>(
M;I#@=0 N!].3^=<IX9U2"R^&'@ZV&E1:EJ=Q?SC3XIGVHDBRR'>3["O6M&T"
MRT'^T#9^9_I]X]Y-O;/[Q\9QZ#@<5CM\.] /ABTT#R[C[-9RM-;RB4B6)V8L
M2K#IRQHZ?=^!5]_Z[G(>(WU__A._!1UN735+:@QA@M0Q=1L.26/;I6WX'2S_
M .$]\=. GVW[=&&/\0C\I<?AG-:4?PYT..ZL[MWO9KVTN%N([F:X+R97.%)/
M\//(&*+SX<:)=ZE>:D)+ZWO;R7S)I[:X*,?E"[>/X>!QZTE_7X$M7_KU,_P%
MM'C'QP+7']GB_B,>W[OF^6/-Q^.,U?\ &G_$PU+P[H(Y%Y?BXG7UB@'F'/MN
M$8_&M[1=$L/#^G)8:; (H%)8\Y+,>2S'N3ZTKZ/:R:_%K+[S=16[6Z9;Y55F
M#' ]25'/M3?3R#N:5%%% PHHHH **** "BBB@ HHHH J:A=P:?IUS>7(/D01
M-))A=QV@9/'?BO/-,\&M+IT.K>!O%%YIUA=K]HBM'420_-SC!Y4>U>ENBR(4
M=0RL,$$<$5Y^/AE/ITDB>'?%6IZ/8R,7^R1A9$4DY(7=T'M2ZCZ'/ZYXOUU_
MA_XTTS4!$NLZ.(H9+FUR$D24@;AZ';N^E='XH\,:%;?"R_@M[2"..TT]IK>9
M% 971-RN&ZYR!S6UI'@C2=*T2]TMEDNUU#<;V6X;<]P2,$L?IT]*QA\-7ELT
MTJ\\2:C<Z&A %@X R@/",_4KQ3>N@)[&5I-W<7_C3P%>79)N9_#\LDI/=BL9
M)KFY78_#[5;0LR6U[XP>VN6!QB)IQNY]#T_&O69?#,$GBC3-;24Q_8+:2VCM
MU4;2KX[]L8Z51MO >G1^'M6T2\DDNK74KR6[<D;61G8-\I'=2!@^U'6_];W(
MM_7R.?\ BCH>EVWA?3IX+:&VDMM0M5B\I0F09%!7CJ,<_A7I9 *D8R,5Y[??
M#&XU6*UBU/Q5J%W%9S1RVR/&H"E3GYL?>..,UZ'1T'U/*- MX4T;XE,D,:LM
M_>*I"@$#R5X'M5^-E7]G<%B /^$>_P#:-;]EX-6QU_5;Z+4)38:H2]SI[1@H
M7*A2P;KR!TK%/PO+:)-H3>)-0;13&T<-F57]V#]T%NK 'G'M4_9MY+\"D[._
MF8,NGVVIZY\*;>[B66$:=+(8V&58K!&1D=^0#^%:<FB::_QZC4V4.P:%]H\O
M8-ID$Q4,1T) )KIHO!L,6H^&;L7DA.@VSV\:[!^]#1A,GT^[^M6SX;B/C@>)
M_M#^:-/-CY&WY<>9OW9]>V*T;5_O)5[6]#S'6IY=%N/BNNEC[.([>R=%B&T(
M7C(=@!T.#76ZSX7T&'X4W5O%:6Z0P:<TL4ZJ RLJ;@X;KG(SFMJ+PA9KK?B+
M4+B0W$>N1PQ3V[K\JK&A3@]\@UB_\*U=[)=)G\2:E+H2\"P(490=$,G4K4/5
M6*NKW_KH<W;QGQ!XE^&$^K()I7TN>=Q(,AG$:$$@^_/UK=\3>'M5M_&$&N>'
M[+3-1,5E]F?3;E@FP%RV].P)S@\<UTUQX7MY?$NC:O'*81I4$L$5NJC:5=0O
M7MC%5M<\'G4M:CUG3M5N=*U-8O(>:%0ZRQYSM93P>>]-O:WG^I*7<R?A[>Z=
M+JNOVT.DW.D:F)HYKVRE(V*67"N@' !Q7?5SWAKPM%H$U[>2WD]_J5\RFYNY
ML OM&%  X  [5T- "T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 3M7R?XM_P"1SUW_ +"%Q_Z,:OK#M7R?XM_Y'/7?^PA<?^C&K2GN<&/^
M%&/1116QY84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7>Z/_R2
M6^_["Z_^BQ7!5WNC_P#));[_ +"Z_P#HL4BU\,O1G/4445J>6%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5T_P\_Y'O3/K)_Z+:N8KI_AY_P C
MWIGUD_\ 1;4I;&U#^)'U/1W^^WU--[4Y_OM]33>U=BV/DJGQ,****9(4444
M%%%% !1110"W.VTS_D&V_P#US'\JMBJFF?\ (-M_^N8_E5L5X\OB9^KX?^%'
MT04445)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"68+G\-V?PJ;VC<+7:1T(O;5IS MS"9A_P LPXW?EUJ26:*",R2R)&@ZL[8
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MM]_V%U_]%BN"KO='_P"22WW_ &%U_P#18I%KX9>C.>HHHK4\L**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KI_AY_R/>F?63_T6U<Q73_#S_D>]
M,^LG_HMJ4MC:A_$CZGH[_?;ZFF]J<_WV^IIO:NQ;'R53XF%%%%,D**** "BB
MB@ HHHH!;G;:9_R#;?\ ZYC^56Q533/^0;;_ /7,?RJV*\>7Q,_5\/\ PH^B
M"BBBI-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 )VKY/\6_\CGKO_80N/_1C5]8=J^3_ !;_ ,CGKO\ V$+C_P!&
M-6E/<X,?\*,>BBBMCRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N]T?\ Y)+??]A=?_18K@J[W1_^22WW_877_P!%BD6OAEZ,YZBBBM3RPHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "NG^'G_(]Z9]9/_1;5S%=
M/\//^1[TSZR?^BVI2V-J'\2/J>CO]]OJ:;VIS_?;ZFF]J[%L?)5/B84444R0
MHHHH **** "BBB@%N=MIG_(-M_\ KF/Y5;%4],_Y!MO_ -<Q_*K@KQY?$S]7
MP_\ "CZ(****DV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)HN@Y9]R_P#V8?\ GXA_[ZH_LP_\_$/_ 'U5#)HR:+H.6?<O_P!F-_S\0_\
M?5=9II\GX>W6GG+%]167S5^X/D QGUKA<FN\T?\ Y)+??]A=?_18I70U&=I>
M]T9B_9O^FB?G1]F_Z:)^=045KH>?:7<G^S?]-$_.C[-_TT3\Z@HHT"TNY/\
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M^@7?_P#?HT?\)G'_ - N_P#^_1KIL#THP/2CFCV#V=;^?\#F?^$SC_Z!=_\
M]^C1_P )G'_T"[__ +]&NFP/2C ]*.:/8/9UOY_P.9_X3./_ *!=_P#]^C1_
MPF<?_0+O_P#OT:Z; ]*,#THYH]@]G6_G_ YG_A,X_P#H%W__ 'Z-'_"9Q_\
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M^$SC_P"@7?\ _?HT?\)G'_T"[_\ []&NFP/2C ]*.:/8/9UOY_P.9_X3./\
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M^?\  YG_ (3./_H%W_\ WZ-'_"9Q_P#0+O\ _OT:Z; ]*,#THYH]@]G6_G_
MYG_A,X_^@7?_ /?HT?\ "9Q_] N__P"_1KIL#THP/2CFCV#V=;^?\#F?^$SC
M_P"@7?\ _?HT?\)G'_T"[_\ []&NFP/2C ]*.:/8/9UOY_P.9_X3./\ Z!=_
M_P!^C1_PF<?_ $"[_P#[]&NFP/2C ]*.:/8/9UOY_P #F?\ A,X_^@7?_P#?
MHT?\)G'_ - N_P#^_1KIL#THP/2CFCV#V=;^?\#F?^$SC_Z!=_\ ]^C1_P )
MG'_T"[__ +]&NFP/2C ]*.:/8/9UOY_P.9_X3./_ *!=_P#]^C1_PF<?_0+O
M_P#OT:Z; ]*,#THYH]@]G6_G_ YG_A,X_P#H%W__ 'Z-'_"9Q_\ 0+O_ /OT
M:Z; ]*,#THYH]@]G6_G_  .9_P"$SC_Z!=__ -^C1_PF<?\ T"[_ /[]&NFP
M/2C ]*.:/8?LZW\_X',_\)G'_P! N_\ ^_1K7TW4QJ5I]H6":$;BNV5<'CO5
M_ ]*3 ]*5UV'&%1/65_D.HHHJ3<**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I#Q17+_$;4[C1_A]K=]:L4GCMB$8=5+$+D?3.:4G97&E=V&7_Q%\/6-W+;
M">>Z>'(E^R0-,(R.H8J,"MK1]<T[7K$7FF727$).TE3RI[@CL?:J7@[2;71?
M"6F65JBJBVZ,S*.78@$L3W)-4[ZRTOP39^(O$]O X>6+[3<1*V$=D4XP.Q/<
MTWIN2O>V.JHKS1+/QM+X97Q+_P )&5U P?:QIH@7[/C;N\LG[V<=_6NOT#Q+
M9ZUX<T[5GEBM_MD"R^6\@!4GJ.>N#D?A18+FY6:VN6*>(H]":1A?R6S72IM.
M/+#!2<].IZ5R_B#5]3U;QC8^%M$U 62/9M?7=[&H=A'NVJJ9XR3GGTK(T^#4
MM/\ C1;V^IW?VQ8="E,5T5"LZ>:I^8#C(/IU&*2W7S&>HT5X_IOBBZ\66TVL
MGQM!H:/(ZV=BH0X16PK2;N23CH.QJQ'XZU.]\+^'_$_V@1Q6VI_8M8BBP8W5
MCY>\>P)5ASWII ]#UBBN.U?5KZ?XB:+H=A<M%;PV\E_J.W'S1_=C4_5LG\*Y
M+3_%-SXM2ZU8^-8="@,SQV5FBH3L5L!I-W.3@\#'!I >F:QKECH-K#<7\C)'
M-/';H54M\[G"CCWK2KQO5/$\OBKX<:5>7/E&[M]?M[6X,7W&=)@-R^Q&#^-=
M/>W^M>)_&^H:#I>I/I5CI,437-Q%&&EEED&Y57/  '6A7U_KH@.]HKS>'7];
MTBY\1^&M3OOM5W9Z6VH6-\$"N\>"/F'3<K#\:H:9'XXOO 5KXG_X2-EOA9+<
M1V7DJ8I5"9&\]=S#G(Q@FCS"W0]7HKRW5_%>MZS<^ CH5V+(:[%.TX9 X4"-
M2>.Y7YL>]&?%MIX]'A-/$CSVMW9?;/MLT*^= %;:RJ!QR<<GIDT[= Z7/4J*
M\TT[Q1J7AJ;QC8ZS>MJ::';Q7<$[J$>171CL;'&<C&:Q6\1ZJGAL^(SXYM#J
M0A^U?V3M3R<;<^5_>SCOZT@LSV6BO,-9\3ZUK.K>!TT&\^Q1:Y:SR3!D#A $
M5LX[E?FQVS5RRFUW1?'<7AR\UN;4;/4K&6:*:6-5E@D3 XQP1SGZTW<#M=/U
M:RU7[5]BG686L[6\I7HLB@97ZC-7J\O^$NFW=M-XBGEU6YGC35[J!H750KN&
M7,AP,[C^7->HT=$+JPHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E?)_BW
M_D<]=_["%Q_Z,:OK#M7R?XM_Y'/7?^PA<?\ HQJTI[G!COA1CT445L>6%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5WNC_ /));[_L+K_Z+%<%
M7>Z/_P DEOO^PNO_ *+%(M?#+T9SU%%%:GEA1110 4444 %%%% !75_#;_D?
M]+_[:_\ HIZY2NK^&W_(_P"E_P#;7_T4]3+X6;X;^-#U1]!4445QGUH4444
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M0:=HFN1:SJ6JWNM7\',$EV>$]#@DY([<UV>IZY!IM_IUB8WFNK^4QQ11XR%
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MM[A!)&X[J1D59I]1+;0Y7Q/X#TCQ-X>MM(D5K5+,J;.2#AH"HP,>V.U<U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"\]GK>O,"$UC4YKB#(QF$'8A_$*3^-=U3ULA=6+1110,**** "BBB@ HHHH
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M;X;^-#U1]!4445QGUH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%/B\':7:^&9]"LVNK6"<[I9X9BL[.2"7,G7<<<FET&=%14<4?E1)&&9@J@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ]2K XH EHKG_#7BBW\2'4O(3R_L5[+:8+ E]F 6X[$GBN@H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 3M7R?XM_P"1SUW_ +"%Q_Z,:OK#M7R?XM_Y
M'/7?^PA<?^C&K2GN<&/^%&/1116QY84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7>Z/_R26^_["Z_^BQ7!5WNC_P#));[_ +"Z_P#HL4BU\,O1
MG/4445J>6%%%% !1110 4444 %=7\-O^1_TO_MK_ .BGKE*ZOX;?\C_I?_;7
M_P!%/4R^%F^&_C0]4?05%%%<9]:%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*075I*$6X@!\FZ4C(=,_D1SBNBH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 )VKY/\6_\CGKO_80N/\ T8U?6':OD_Q;_P CGKO_ &$+
MC_T8U:4]S@Q_PHQZ***V/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,[%.((=:>2,=@7568#\>?QKO:>ZN+R%Q1110,**** #%%%% !1BBB@ HHHH
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MEW0/D74+0OCJ 1C(]QUK0HI-7T!/J><:=J.L^&]%C\/>(?#5YJ\$$?D1W5C
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M.PS$".-<],@,YQ73*ZR*&1@RGH0<T^GV 6BBB@84444 %%%% !1110 4444
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MVO\ Z*>N4KJ_AM_R/^E_]M?_ $4]3+X6;X;^-#U1]!4445QGUH4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !@4444 %%%% !1110 4444 )117.>.]?\
M^$:\&:EJ2'_2%CV6X[F5OE0?F12>P)79YAKEQ=WVNZK\1;8NT&@:A%:0*O\
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M]=_["%Q_Z,:M*>YP8_X48]%%%;'EA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %=[H__));[_L+K_Z+%<%7>Z/_ ,DEOO\ L+K_ .BQ2+7PR]&<
M]1116IY84444 %%%% !1110 5U?PV_Y'_2_^VO\ Z*>N4KJ_AM_R/^E_]M?_
M $4]3+X6;X;^-#U1]!4445QGUH4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTZ33[*:Q-C+9V[V94+]G:(&/ Z#;C&*LT4 (JJBA54*H&  , "EHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F9/#%X\KN
M/$%^H8D[01@4W_A%;W_H8=0_,5U%)5<[.?ZK2[?B<Q_PBM[_ -##?_F*/^$5
MO?\ H8;_ /,5U%%'.P^JTNWXG+_\(K>_]##?_F*/^$5O?^AAO_S%=111SL/J
MM+M^)R__  BM[_T,-_\ F*/^$5O?^AAO_P Q7444<[#ZK2[?B<O_ ,(K>_\
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M+_\ "*WO_0PW_P"8H_X16]_Z&&__ #%=111SL/JM+M^)R_\ PBM[_P!##?\
MYBC_ (16]_Z&&_\ S%=111SL/JM+M^)R_P#PBM[_ -##?_F*/^$5O?\ H8;_
M /,5U%%'.P^JTNWXG+_\(K>_]##?_F*/^$5O?^AAO_S%=111SL/JM+M^)R__
M  BM[_T,-_\ F*/^$5O?^AAO_P Q7444<[#ZK2[?B<O_ ,(K>_\ 0PW_ .8H
M_P"$5O?^AAO_ ,Q7444<[#ZK2[?B<O\ \(K>_P#0PW_YBC_A%;W_ *&&_P#S
M%=111SL/JM+M^)R__"*WO_0PW_YBC_A%;W_H8;_\Q7444<[#ZK2[?B<O_P (
MK>_]##?_ )BC_A%;W_H8;_\ ,5U%%'.P^JTNWXG+_P#"*WO_ $,-_P#F*/\
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MH_X16]_Z&&__ #%=111SL/JM+M^)R_\ PBM[_P!##?\ YBC_ (16]_Z&&_\
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M*.=A]5I=OQ.7_P"$5O?^AAO_ ,Q1_P (K>_]##?_ )BNHHHYV'U6EV_$Y?\
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MH_X16]_Z&&__ #%=111SL/JM+M^)R_\ PBM[_P!##?\ YBC_ (16]_Z&&_\
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MW_YBC_A%;W_H8;_\Q7444<[#ZK2[?B<O_P (K>_]##?_ )BC_A%;W_H8;_\
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M<[#ZK2[?B<O_ ,(K>_\ 0PW_ .8H_P"$5O?^AAO_ ,Q7444<[#ZK2[?B<O\
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M2XW@JQRS<8[^U;/PIL]0M/&7B>VFLK*QTV<"1]-@OXKD6TN<%2JG*Y&[J!T
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MRHIPSJ#Z$T /HI <C.:6@ HII8;@NX9/04!@1E2#@XX- #J*:6"C+, />G4
M%%-SSUZ<&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "=J^3_%O_(YZ[_V$+C_ -&-7UAVKY/\6_\ (YZ[
M_P!A"X_]&-6E/<X,?\*,>BBBMCRPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N]T?_ ))+??\ 877_ -%BN"KO='_Y)+??]A=?_18I%KX9>C.>
MHHHK4\L**** "BBB@ HHHH *ZOX;?\C_ *7_ -M?_13URE=7\-O^1_TO_MK_
M .BGJ9?"S?#?QH>J/H*BBBN,^M"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ'XGGMI;:#6+F,VL<R;7,4:;%<@\C=R>:[JFP0M%%% PHHHH **** "BBB@
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M\]^'6K:G<ZQK^ESZQ_;FFV#Q+:ZEL"EBRDM&2O#%>.?\CT*@$+1110,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.U?)_BW_D<]=_["%Q_Z,:O
MK#M7R?XM_P"1SUW_ +"%Q_Z,:M*>YP8_X48]%%%;'EA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %=[H_\ R26^_P"PNO\ Z+%<%7>Z/_R26^_[
M"Z_^BQ2+7PR]&<]1116IY84444 %%%% !1110 5U?PV_Y'_2_P#MK_Z*>N4K
MJ_AM_P C_I?_ &U_]%/4R^%F^&_C0]4?05%%%<9]:%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKYQ)Y.J&4FU; !\LKG*\9V\5I>&- B\*:-.L]V;BXFE>[O;R0!?,D;EFQV&
M !V J5IJ^PWK]YB?#=S!=^*])4GR++6)3"O9$DP^T?B6_.N^KA_AG:RMI.I:
M[,C*VMW\M[&K#!$).V/_ ,= /XUV]/HKB[BT444#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSMH;>!/NQ0H$5?H!P*GHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 3M7R?XM_Y'/7?^PA<?^C&KZP[5\G^+?\ D<]=_P"PA<?^C&K2
MGN<&/^%&/1116QY84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M>Z/_ ,DEOO\ L+K_ .BQ7!5WNC_\DEOO^PNO_HL4BU\,O1G/4445J>6%%%%
M!1110 4444 %=7\-O^1_TO\ [:_^BGKE*ZOX;?\ (_Z7_P!M?_13U,OA9OAO
MXT/5'T%1117&?6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %.]TVTU!K9[J$2/:S">%MQ4HXR,@@^A(QT(.#5NN;D\96T
M4CQG3=3)5BIQ;''%-_X36U_Z!FJ?^ QJN21S_6J/<Z>BN8_X36V_Z!FJ?^ Q
MH_X36V_Z!FJ?^ QHY)!]:H_S'3T5S'_":VW_ $#-4_\  8T?\)K;?] S5/\
MP&-')(/K5'^8Z>BN8_X36V_Z!FJ?^ QH_P"$UMO^@9JG_@,:.20?6J/\QTU+
M7,?\)K;?] S5/_ 8T?\ ":VW_0,U3_P&-')(/K5'^8Z:EKF/^$UMO^@9JG_@
M,:/^$UMO^@9JG_@,:.20?6J/\QTV/:JU_86VJ6$]C>1^9;3H8Y4W%=RGJ,@@
MUA?\)M;?] S5/_ 8TG_":VO_ $#-4_\  8T<C#ZW1_F.ECC2&)8XT5$0!551
M@ #H!3ZYC_A-;;_H&:I_X#&C_A-;;_H&:I_X#&CDD'UJC_,=/17,?\)K;?\
M0,U3_P !C1_PFMM_T#-4_P# 8T<D@^M4?YCIZ*YC_A-;;_H&:I_X#&C_ (36
MV_Z!FJ?^ QHY)!]:H_S'3T5S'_":VW_0,U3_ ,!C1_PFMM_T#-4_\!C1R2#Z
MU1_F.GHKF/\ A-;;_H&:I_X#&C_A-;;_ *!FJ?\ @,:.20?6J/\ ,=/17,?\
M)K;?] S5/_ 8T?\ ":VW_0,U3_P&-')(/K5'^8Z>BN8_X36V_P"@9JG_ (#&
MC_A-;;_H&:I_X#&CDD'UJC_,=/17,?\ ":VW_0,U3_P&-'_":VW_ $#-4_\
M 8T<D@^M4?YCIZ*YC_A-;;_H&:I_X#&C_A-;;_H&:I_X#&CDD'UJC_,=/17,
M?\)K;?\ 0,U3_P !C1_PFMM_T#-4_P# 8T<D@^M4?YCIZ*YC_A-;;_H&:I_X
M#&C_ (36V_Z!FJ?^ QHY)!]:H_S'3T5S'_":VW_0,U3_ ,!C1_PFMM_T#-4_
M\!C1R2#ZU1_F.GHKF/\ A-;;_H&:I_X#&C_A-;;_ *!FJ?\ @,:.20?6J/\
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M)!]:H_S'3T5S'_":VW_0,U3_ ,!C1_PFMM_T#-4_\!C1R2#ZU1_F.GHKF/\
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M)!]:H_S'3T5S'_":VW_0,U3_ ,!C1_PFMM_T#-4_\!C1R2#ZU1_F.GHKF/\
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MJJ"%5@2/E]<?,>X%:_P[T(^'4UOQ(?"#:1;E"ME:1>?+>2Q YPZ,[#<<+@
MYSVYI+84M]#*/QIUVULKS1;S2(3XS2^%K!:QQOY+@_Q'+9_7G(/3-=UX@\0^
M*]'T;2+:TTF&_P!=OF"3RQQ2"SM>FYG(R0HSW/.">V*\HNO"GCJ]>7XF"VGA
MUU+U9(=*,+>8(!\N-O4\<8QDC)[UT7Q#BUKQ0OA35Y/#^L76A [M2T>*-UF5
M\C(:/@GH<'VZC-'1=PZZ;&[X1^(6LWWCRZ\):ZFD3W$<!E2ZTJ1FBR "5(8D
MYY]L8Z<UYA8^)_"WAOXC^-'\3Z$=56?4'$ ^RQ3>7B1]W^L(QG(Z>E=5X3T>
M]MOC/;ZI#X/O=%T:>R:.!?LV%3Y>LI7(1B0>"<\CUJAI>J>*O _C[Q=>6O@;
M5M5@U&]<QO'%(BX$CD$$1MN!W4^J?D'1_(@\*:AH'BOXV:7J/ARPBT*SM+=B
M\+A(6N&VL,+&IQG#<X[#->A:AXY\0:OXSO?#'@VRT]Y=.4->7NHL_E*Q_@"I
MSGMGU!XXS7(PV_BKXB_$C0-9N_"D_AZUTEQ)+-<!@\@!#!<LJENF  .-QYK5
MBLM:^'7Q%U[6(M!O]8T36F$N=.02S129)(*9SC+-[<CZ4=OF#ZV\CH?"GQ#E
MO[O6M(\1VD>GZQHR&6Y$+%HY(@,ETSR!@C@^H_# L/'7C3Q3H.IZ_8:+IH\/
M(LJ)!+*XNY5 (+*1E21Z$#H1GO3O"_@_5=?\0^*O$^N64FEKK=HUC;VDA_>+
M$552SCL<*O'U]LYOA.Y\5^%/"-WX+E\(ZE<:@AF2TO(4!M6#Y.YI"<#!)..3
MT'%3+5/O8:WT[F#X*\5ZQX+^#UGK&GVUM/9KJ[QWRRHQ98V"X*D,,'J.0>2*
M],\<^.[[2+KPWIWAU+2YOM:G 0SHSHL1Q\V%8'^('/H#7._#?PA=WGP9U+P]
MK%C<64UW+,%CNH61E)"[&PP[$ _A7._!BRU'Q%XQ&I:N-Z^'+)=/@R/NME@!
M[D+N_,5IO*Q"TC?U/H'>!PS#/>O%K/3K;QU\===&N1BZLM%A6.VM9>4!XY(Z
M$9W'\1Z5TWBCX->'/%WB&XUK4+O5([F<*&6"5%0;5"C *$] .]8OB/PUXD\%
M^.F\8>$]/_M6VN;=8;VQ#?O#M &1CKG:IX!YSQ@U"^*[*:TLCKKWX7^$;S5K
M'4DTF.SN+-]Z?8?W"L0<C<$QT([8-<3XCL+/4OVD]'M;^T@NK=],.Z*>,.C8
M$I&0>.M7-.\6_$OQ3XAL4L_"Y\/Z;$_^EOJ",V]3Z;@A/L%'7J<5G>/&U_1?
MC18>)=+\,:CK$%OIXC(MXGVECY@QO"M@C<#TJEHU?S_(6Z9'\;?"ND:!H.G^
M(=#L+?3-0M;Q%#VD8B!!!(.%P,@@'.*[;5_#>B^)[?2O%NKV=U?R6-EY\=A&
MHD2;<F[;Y9'S,3C R,D#-<%K@\;?%V;3](NO"MQX?TB&X$UU+=%MQX(R-RKG
M@G@ \D9Q78^-KOQOX9U33;_PU9-JFAPQ>7<Z9%&"Y(R 00I?H1TSC;SUI;+7
MN/=JQSOPAM[=_&OBZ^@B&D>:P1-&92DL*YR'9".!SP!P,D<<9\R^WZ!X<T7Q
M1X:U?2H=3UR6X=;;4XS'(J9 P?,SE<')('<X.*]6\$Z'XD\0>/-7\:ZUIKZ(
MEU:&UM[9R?,'"C)!P>-O4@9)XKD-/M/&W@_POK'@C_A!Y=1_M!I%74(5+1X<
M;0Q(4@XQD9*X[TO+R&OU/9OASI\NE?#W1;.:ZCN72W!\R)PZ$$E@ PX( (&?
M:NIKD_AOX?O?"_@+3-)U%@;N)6:15;(0LQ;;GIQG''%=95R^(B.PM%%%24%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E&:
M*P/%?BB+POIL4WV:2\O+F9;:SM(R T\K=%R>@[D]A2 W\T5PUS>_$>RM7U%[
M+P_<Q1@R/I\#RB8J.=JR'Y2W_ 0*@\1^/;Q/ VD:]X=A@\[4[J&WC2_C;";R
M0=P4@Y!';/XT >@49KSJYO\ XJZ3;O?75AX9U*"%=SVM@\Z3..^TOQGVK4N?
MB!9GP!#XHTVVDN_M6R.VM<[6:9FV!&/.,-G)]J8'8T5P1\2^*?#VJ:1%XHAT
MF2SU2X6T233S(&MYF!*A@^=P.,9&/I5O6O$>N3^+?^$:\-P6*W,5J+NZN[_<
M8XU+%54*I!+'!/4 4@.RHKE?"/B:\UB[U72=7MH;?5])E2.Y%NQ:*177<CIG
MD C/!Y%=4*8A:***!A125#=7,5G:RW-Q(L<,2%Y'8\*H&23^%*X$U%<%I_B'
MQEXKMQJ6@66EZ=I,A/V:75!(\MPO9PB%=BGMDDUH^'?$FJ7&N7/A[Q#I\5MJ
MD$*W"36KL]O<1DXW*6&5(/&T\TQ'6T5F7OB+1=-NTM;_ %>QM;F3[D4]PB.W
MT!.35JYO[2S6$W5U#")I%BB,D@7S'/15SU)P>!0,LT5FV.OZ/J=U+:V&JV5U
M<1?ZR*"X5V3MR <BFW7B'1; W'VO5[&W^SLJ3>;<(OE,PRH;)X)'(S0!J45E
M7'B70[2T@N[G6=/AM;C_ %,TERBI)_NL3@_A5Z2Y@BMC<R3QI;A=YE9@%V^N
M>F* )Z*R].\1:+K$KQ:9J]C>R(,NEM<)(5'N%)Q6#IOC:'^U_$4&MWFGV%II
MUZEM;RRR"+>#&&Y+'!/)Z8I>0'8T9K,U!KS4-)4Z)>6Z/,4Q=9WA8R1N9.""
MVW.W/&<9XK+\/WMX/$.KZ1+J,NIV]FD+"ZF1 Z2/NW1,8U53@!&Z C?SU%,#
MJ**** "BBB@ HHHH **** "BBB@!*6HIY/)@DEQG8I;'KBL7P;XC/BSPG8ZX
M;7[+]J5CY/F;]N&*_>P,]/2@#>HKF[7Q4;GQ]?\ A?[&%%K9I=?:?-SNW$#;
MMQQ]<UT6X9P3SZ4D ^BFY]31N![BF ZBFY!'!!HW <$B@!:*Q/$/B.#P^VEI
M-"\K:A?1V4>T@!6?/S'/8 ']*V=PP#D8- #Z2H+NX^S64UP!N\I&?;G&<#/6
ML[PMKA\2>%]/UDV_V?[9$)?*W[]GMG S^5 &S13=P/0YH+ =2!]: '45GZQ=
MWMGI5Q<:;8"_O$ ,=J9A%YAR.-QX'&3^%7$9BBEQM)'(SG!H DHIH(/(.:,X
M')Q0 ZBF[AGJ.* P/0YH 6EII8 X)%8'BGQ*?#:Z01:_:/[0U*&P_P!9L\OS
M,_/T.<8Z<9]: .AHK.M[O4)-8O;:?3Q%91+&8+OSU;SR0=PV#E=O'7KFKQ8>
MO/UH ?13=P'>@,#T(_.@!U%-+ =2!03[T .HIH89Z\^E!( Y(% #J*SM9O+^
MRTN2XTS3QJ%TI79;F=8=P+ $[FX& 2??%7R<#DXH =13001G-&X>O/I0 ZBB
MB@!.U?)_BW_D<]=_["%Q_P"C&KZP[5\G^+?^1SUW_L(7'_HQJTI[G!C_ (48
M]%%%;'EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=[H__ "26
M^_["Z_\ HL5P5=[H_P#R26^_["Z_^BQ2+7PR]&<]1116IY84444 %%%% !11
M10 5U?PV_P"1_P!+_P"VO_HIZY2NK^&W_(_Z7_VU_P#13U,OA9OAOXT/5'T%
M1117&?6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% #"0/04M<5>7'_  D'Q,@T@G=8Z' M[.F>'N7)$0(]%4,WU(]*S! _
MQ"\::U:7]Q<+X=T9UM1:02M&+N<C+F0J02%X &<?U2U!GI&0>X-(6 /) KA+
MWX;VNFO!?>#"NBZE%,C,!*_D7$>?F21.0<C/.,YQS6!\2+/P]J/Q*\,VWBEK
M=-+-I<F0W%P84W<8^?([^]'9 >LEE]12\9QWKRS3?"/P;&J6ITZ;1WO5F5K=
M8M89V+@Y7"^:<G/;%8OCDZQ:?&-]:T3,EQI6C1W4ML/^7B'S65T_(Y[]/7%/
MR$>VD@=3^=+D"O-OB'J]IKWPHCU6PE$MK<S6KH>_^N3(/H0<@^XK9\4^&_[=
MUBVN-;O(5\+65N\D]JTS1B2;/#2'@;%4$\GKUH8)ZG8 @].:3(!ZC->8^"+R
MUL=<\3'P_*\WA&T@1XB)&>)+@ F182<Y7&"<' .,=:K^'?!5GXN\%Q^(]7:>
M3Q#J,;W,=\DSJ]L23Y8CP?E51CCO2\Q];'K%(.M</X;\1:[KOPNT[5=-@M[G
M698Q$1<OLCWJY1G;';Y2V!UZ"L[X:0ZG;>)_&4.L:A]OOTN;?S9PNU23%G"C
ML!G ^E5;5KL*]D=CXETS5-6THVND:V^CW!<%KE+=9B5P05PQ&.H.0<C%4O _
M@VQ\#Z --M)GG9Y#+/<2#!E<\9QV'  'M6/\0=6O+V&?POHTQCNY;1[B^N5_
MY=K< _\ CSGY1^)[59\%:=;:O\(='TZ[3?;W&FI&X]BO4>X[&I3T;0WT.U&*
M6N3\ :S<ZKX?DMK^3S-1TNYDL+I_[[QG ?\ X$NT_4FNLIB#%&***!ABBBB@
M P*,"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 2O._'(,?Q'\ W$W_'H+FYB))P!(T8V?CD<5Z)61XB\
M.V'B?2GT_4!((RPDCDB;;)#(IRKHW9A2ZIC1JL0BEF("@9)/2O,OB%K%AK_A
M+P_J.F7 N+277+79*JD XD(/4>HK4G\$^);^U;3=0\=W4VF."DB16,<<\B?W
M3*"?Q(4$U;\2> X=6\*:?H.DW@TB/3YXIK:18?.V&/.."1GGG))]\T/OYH1U
MSE50LQ 4#))["O-_A/>VEEX,EN)[F*WL[O5K@61ED"!PSG:JYZDD' '6IYO
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M.69R\2$DGDG)))J3PQX:M_#-A+#'/+=75S,UQ=W<Y&^>4]6.. .P Z"MRGL
MM%%% PHHHH **** "BBB@ HHHH K7W_'A/\ ]<V_E7COPV'Q'_X5_I7]AMX6
M&F['\G[:+CSL>8V=VWCKGIVQ7LMS&9K:2-2 64@9]Q6!X"\/W7A;P5IVC7TD
M,ES;*X=X"2AR[-P2 >_I0NOR$^AP7AJYURR^*_B2Y\1C3WOX=&25AI^_RBJD
M$??YS6+H7]C^(=!75_$6@>*-1UN]W2_VA;65PRPY8[! R\!5&,8[UZ;;>%;N
M/XD:KXAF>W:PO-/2U6+)WY!YR,8Q^-9.G^&/&GABQDT7P[J.CRZ2&;[+)?K+
MYUJK$G: N5?&>,D?TI+8?7^NQRNI/K>N>#? 4&MF^L=2?6UMY9)%:"?8!(N_
MGD,4[^IS6AK'@S2M*^(WAW2]*^T6&GZO#<+J,%O<.!<K$JLH8[L\G@D<D9&>
M372WG@G4'T_PI;+JCWLFD:@EW=7-[(QDF 5@<=><MP"> .M:6K^'KO4/&_AW
M6XI(1;::ERLR,QWL9$"KM&,=N<D52W_KL3W]#FM"TZV\+_%/4]$T?_0M-GT9
M;PP;BT<<PD*[P">..M<I=VG@FX\/7SPIK/B77$60OK5K;3EA*,D.),[%5>.
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M &%U_P#18K@J[W1_^22WW_877_T6*1:^&7HSGJ***U/+"BBB@ HHHH ****
M"NK^&W_(_P"E_P#;7_T4]<I75_#;_D?]+_[:_P#HIZF7PLWPW\:'JCZ"HHHK
MC/K0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM_PB=Q_T,FL_]_Q_A1_PB=Q_T,FL_P#?\?X4<J[A[>I_)^*.IHKEO^$3N/\
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M]#)K/_?\?X4<J[A[>I_)^*.IHKEO^$3N/^ADUG_O^/\ "C_A$[C_ *&36?\
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M_P 31_PJ'0?^>UQ_WRG_ ,31S1#ZO6_E_$^?.*.*^@_^%0Z#_P ]KC_OE/\
MXFC_ (5#H/\ SVN/^^4_^)HYHA]7K?R_B?/G%'%?0?\ PJ'0?^>UQ_WRG_Q-
M'_"H=!_Y[7'_ 'RG_P 31S1#ZO6_E_$^?.*.*^@_^%0Z#_SVN/\ OE/_ (FC
M_A4.@_\ /:X_[Y3_ .)HYHA]7K?R_B?/G:N]T?\ Y)+??]A=?_18KT;_ (5#
MH/\ SVN/^^4_^)JRGPPTR.R:S2_O%M6?S#""H4MTSC'6CFB-4*UFN7?S/#Z*
M]L_X5/HW_/U=?DG^%'_"I]&_Y^KK\D_PJ_:1.7^S\1V_$\3HKVS_ (5/HW_/
MU=?DG^%'_"I]&_Y^KK\D_P */:1#^S\1V_$\3HKVS_A4^C?\_5U^2?X4?\*G
MT;_GZNOR3_"CVD0_L_$=OQ/$Z*]L_P"%3Z-_S]77Y)_A1_PJ?1O^?JZ_)/\
M"CVD0_L_$=OQ/$Q75?#?_D?]+_[:_P#HIZ]"'PGT8_\ +U=?DG^%2VOPRTZQ
MNDN+74+V&=,[9(RJD9&#R!Z4G.+35S2E@L1"<9N.WF=Y17+?\(G<?]#)K/\
MW_'^%'_")W'_ $,FL_\ ?\?X5ARKN>S[>I_)^*.IHKEO^$3N/^ADUG_O^/\
M"C_A$[C_ *&36?\ O^/\*.5=P]O4_D_%'4T5RW_")W'_ $,FL_\ ?\?X4?\
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MUG_O^/\ "C_A$[C_ *&36?\ O^/\*.5=P]O4_D_%'4T5RW_")W'_ $,FL_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gmab-20210630xex991d85adb005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -)!O8# 2(  A$! Q$!_\0
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MJ"."* )Z*** "BJ,6KZ;/J<NFPZC:27\*[I;5)U,J#CEDSD#D?F*O4 %%%%
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M!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HI*Y;3/B+X4U?Q ="L=6$NIAG0P&"5?F3.X990
M.,'O2 ZFBN;\2>//#7A&X@M]=U06DLZEXT\F20D XS\BG'XUN6=Y!J%E!>6K
M[[>>-98GP1N5AD'!YZ4;@6:***8!114<<B2KN1U9<E<J<\@X(_.@"2BD)P*Y
MG0_B#X6\2:M)I>D:LMU>Q*SM&(I%^53@D,R@'KV- >9T]%)6/XB\4:/X4L8[
MW6[S[+;R2")'\IWRQ!.,*">@- &S12*0PR.AI: "BBB@ HHHH **** "BBL;
M6?%.C>'[O3[35+S[//J,OE6J^4[>8V5&,J"!RR]<=: -FBDKA;GXQ> K.ZFM
M;C7@DT+F.1?LDYPP.".$H [NBL;0/%6A^*;5KC1-2@O$3 <)D,GIN4X8?B*V
M: "BBB@ HHJ*:9((7ED.U$4LQQT ZTM@):*R/#_B32?%.F_VCHUW]JM=YC\S
MRW3YAU&& />M>F%PHHHH **** "BBB@ HHHH **9YB>;Y>]=^-VW/./7%5]1
MU&UTG3KC4+V7RK6VC,LLFTMM4#).!R?PI 6Z*X ?&KX>D@#Q"/QM)_\ XBNE
MF\4:+!X;;Q"VHQ/I*H'-S%F1<9QT4$]>,8I^8=3:HJGIFI6FKZ;;ZA82^=:7
M,8DBDVE=RGH<$ C\:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!X'XVOO#VG?'VWN/%"6SZ6-. D%Q;F=,D/M^4
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M@ !CX]>?R->=_P!AZEJGP%\*7^FVKWCZ9>RW$ELBY+IYTF< =<<?@36SX_\
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MY_&'K!^C*V:MY&1\,?%5IX,^"-UK-W&THCO9%CB4X,CD+A<]OKV -;EYX_\
M''A[2;7Q'X@T'2_["G9-\5I*_P!IMU?[I?=\IZC@=_2N5T3X?ZSKGP(FTAK&
M>TU2'46NH+>Z0PER !CYL=03@],UK^)=4\3>.?"$/A&#PAJMGJ,QB2]N;N(1
MVT80@EE?/S<K^73-4[WT\B(K3[S>\:_$K4M"UWPU;:'8VNHV^LQ[T5]RN^XJ
M$VMG"YW#)(-+;^//$NA>-=.T'QEI^F1Q:K\MG=:<[E0^<;&W\DY*CH.HZ]N/
M^(UK<^'?%WPXLM-B^UW%A&D,,;$+YQ4HH&>V<=?>MC4;?6/B+\1O#MPOA_4]
M)TS0Y?/GFU&+RR[[E.U1DAAE ,@]S1&VGJ_N&_/L7_\ A/O%^H_$/7?"FBZ;
MI,C62AH;BZ:1%1<+DOM)W9+8  %4M!^)'CGQ/:ZG9Z=H6CQZII+L+R:XED$!
MP2 B(/FW':W5L<>]7?"&E:C;?&_Q??SV%U%93Q*(;AX66.0_)]UB,'H>E0_#
M'2-2L-8\?/>:?=VR7-\SP--"R"4;I>5R/F'(Z>HI+X;];#ZV\R_I'Q;M[GX7
M7'B^_L@DUM(;>2VB;B27Y<!2>@.X'G..>M4I?B)XN\/6VEZUXIT?2X]"U&1$
MS92/Y]KO&5,@;@\>GIVKDO"_@/7-7^!NM:,]A<V>I'4OM,$%W$83)M2/CY@.
MO(!Z9JM;>#+35?[+TS3_ (:7MKJ095U*ZU62Y6U0 89HV64;N>>/R/6J^U]P
MNGWGHOB?X@:YI7Q)T[PQI6FV=ZE]9B6/S&9&$A+\E\X" +D_*3P:/#_CKQ&?
M'MQX.\36&FQWWV<SVT]@S^4W&<$-SZ\\=.E4-8T:_P#^&@?#=]!I]TVG6^GM
M&]RL+-$AV3  OT!Y'4]Q4MSI6HM^T5::D+"Z-@NG%#="%O*#;7X+XQGD<4K;
M?/\ 4<M/P.:^'5QXOG^+/B8RR:5)*L\::GO:4A4#-Q!].?O>U>I_$3_DG'B/
M_L'S?^@&N#\.1:IX4^,/B-KO0=4GM-9GC^SWEM;EX4!8G+MG"@;N>_'2O0/'
M=O/=^ =>M[:&2:>2QE6.*-2S.Q4X  Y)J=Z:]!K^(SQ?P=XB^%-G\/+2U\06
MFGS:LL4@G!TUGF8EFP!)LZX(P=W%1^&K:[@_9V\4RRQR1VD]QYEH'[INC!(]
MLC'X&O0OAGX&T8> -)?6?"]B-3"OYIO+!/.SYC8W;EW=,=:VOB;83W7PSUFR
MT^TDFF:%5C@MXRS'#KP%%5/2XH;H\\TWQEXT\+?"[1=:AT;2CH5M!%$Z2S.;
MF1<[=XQA5!./[QYKOM>\9:J-!T2Y\,Z+)?76LJCQ/*CF"U1@#OF91P/F'<=_
M2N8U[2-3F_9RMM,CTZ[>_%I;*;18&,H(D7(V8SQBL7Q9H>N2^'_ 'VC1]3U#
M0K2SA74M-M%;S=X5?O(,-GK],'IFF]6_4%LGY'5^$?B%K-]X\NO"6OPZ1)<Q
MPF9+G296:+@ E3N).>?;ITK(_P"%J>)-:U+54\/0^'8X["5XDLM0N'%W=;>\
M:J0.<=/6L[PEI-W;?&BWU.W\(7NB:-/8M';AK; 7Y>LA7(1B5/!.>GK5/Q%X
M>BN]4U1?%?P_U*34I)";74?#4+F.93T9U+%5;/))&>>GK+Z>@+J>AZE\2AHW
MPYB\3ZGHMW9WDC>2NG7 :-_-R>,L,[< MG'2LP^//%WAK4-'/C+2M+CTW5I1
M"DMA(^^U=N@D#9!_#T/TKE7^&_BS4?@C%I5[O?5+:]^UVUG+("RQ!=HCSG /
M+,!GOBJMAX.T_6=8TFUTKX:WFG!'#:G<ZO)<I'$!C/E$2C>>N/PXQS5)+F$_
MA/H:BD' I:0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI] *Z.CI0@>HM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <5XI\!'Q)XN\/Z\-
M1%N-(D$GD^1O\WY@<;MPV]/0UV@%%+26BL+K<****8PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4GUQ1J!Y)XIN=?O?A%<7OB&,075SJ,,L-ML"M!"9TV(V.K ?CZUOI_R72?\
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M[DRAAAE!'O3?)B_YY)_WR*2W#I89:W,5Y:PW5N^^&9%DC;!&Y2,@\^U3T@
MP*6F(****!A1110 4444 %%%% !1110 5G:W-J%MHMY-I4,4^H1Q,T$4N=KN
M!PIP1U^M:-)28'E/B/QSHOB;P+=Z3]FEG\07ML8?[)%L_G13D=P1P%;G<3VK
MT+P[9W.G>&M+LKQ]]U;VD44SYSN=4 )S]16EY:;MVQ<^N*=3$+1110,****
M"BBB@!*\IOM);X@_$^_*ZG?V-EX=A6WCGL9?+<W$G+X;GHORFO5J0*%)( !/
M7'>E;6X=#Q[Q)X>D^'NM:)XQ36]7U&*&Y6TOCJ%QYQ2WDXR#C@!N<>N*M:;X
MOTOPY\4/&<>JRFWM)WM62[*,8PPA'R,P!P2.1GK@UZNRJPPP!'H:YC0_#MSI
M_C#Q-JMP8&MM3>W:!5)+#RX]K;@1@<^A--?U^ ,X.[$NK:'\2/%20RPV&HV
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M>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%&1ZT9'K0 449'K1D>M
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M44^=D?5:?G][.7_X1C4_^ADO_P!*/^$8U/\ Z&2__2NHHHYV'U6GY_>SE_\
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M *&2_P#TH_X1C4_^ADO_ -*ZBBCG8?5:?G][.7_X1C4_^ADO_P!*/^$8U/\
MZ&2__2NHHHYV'U6GY_>SE_\ A&-3_P"ADO\ ]*/^$8U/_H9+_P#2NHHHYV'U
M6GY_>SE_^$8U/_H9+_\ 2C_A&-3_ .ADO_TKJ**.=A]5I^?WLY?_ (1C4_\
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M.7_X1C4_^ADO_P!*/^$8U/\ Z&2__2NHHHYV'U6GY_>SE_\ A&-3_P"ADO\
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MC(Q4S:5JJLR_\)#>\'':K]A_Q_0_[U6Y?]<_^\:7,SJIING=M[]S$_LO5?\
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M"N]^#OB6SUSP/:V<,26]UIBBVN+<#&".C8_VN3]<TX:J_P#7J.>CL>B4444
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MT?E5CP.B0>.?'<,2A(A>V[A%X 9H@6./<TUYA+1_UV.^HHHH **** "BBB@
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M (^8_P#>J*I;;_CYC_WJ"Z?QHO-]X_6FTYOO'ZTVD=KW"BBB@04444 %%%%
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MUR]T?QE::SJ-O]IUUXI(Y[?.%*C."I_A!PO7D"EUCPQXY\1^#;C0+M]%L(S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO\>'JC6E_P!?)_O&F4^7_7R?[QIE2>Q+=A1110(**** "BBB@ HHHH ****
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MI8[F+SED78648)7C!!;CVS5[P!X+TCXFZQXK\0:Y#+-#+?%;4I*R;<Y)Z=<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOPUXR\2R:-<7ITJU73-1ANUL[=F*R;6&27([#. !WKTJBFM!L6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,GQ1_R*>L?]>4W_ * :^;J^D?%'_(IZQ_UY3?\ H!KYNJH['C9G
M\40HHHJCS HHHH **** "BBB@ HHHH **** "NF^'W_(\Z;]9/\ T6U<S73?
M#[_D>=-^LG_HMJ1I1_B1]2Q-_KY/]XTRGS?Z^3_>-,JCQ9_$PHHHH)"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9/B
MC_D4]8_Z\IO_ $ U\W5](^*/^13UC_KRF_\ 0#7S=51V/&S/XHA1115'F!11
M10 4444 %%%% !1110 4444 %=-\/O\ D>=-^LG_ *+:N9KIOA]_R/.F_63_
M -%M2-*/\2/J6)O]?)_O&F4^;_7R?[QIE4>+/XF%%%%!(4444 %%%% !1110
M 4444 %%%% &UX3_ .1GLO\ >;_T$UH3_P#'Q+_OG^=9_A/_ )&>R_WF_P#0
M36A/_P ?$O\ OG^='4VJ_P"[Q]7^2(Z***9Q!1110 4444 %%%% !1110 44
M44 %:&A_\AJV_P!X_P JSZT-#_Y#5M_O'^5#.C"_QX>J-:7_ %\G^\:93Y?]
M?)_O&F5)[$MV%%%% @HHHH **** "BBB@ HHHH **** +-A_Q_1?[U6Y?]:_
M^\:J6'_']%_O5;E_UK_[QI,[*/\ "^8RBBBD4%%%% !1110 4444 %%%% !1
M110 5+;?\?,?^]452VW_ !\Q_P"]073^-%YOO'ZTVG-]X_6FTCM>X4444""B
MBB@ HHHH **** "BBB@ HHHH L6O5_PHHM>K_A12.NE\*.*TS-Q\:M>DE!W6
MVEVT4.?[K,S-^O\ *H_!T$-[X]\;7=XBR7D=W%;H)!DI"(P5 ST!R35O6H3H
M?Q$TOQ%C_0[^ Z7=MV1BVZ%C]6RN?]H5=UCP3!J6L-J]CJ5]I.H21B*::S<#
MSE'0,""#CUZU*Z?/\S1[G$V']AZ+-\3OMNX:0DL/G)"2#AH^47'3+-C\:I^-
MI=7F^%=TB^%;'2M*BMTVF>XW31J"-NT*/O=.]=MIWPST>PTW7=/DFNKNWUDJ
MUP)WW-N ^\&ZY)^;ZU6N/A?!J.CR:7JGB#5[^U\LI"DTHQ$<8#8 PQ';.:;6
MEO0(Z?B4K^UAOOBEX+:Y42>7I=Q* PS\V%&?UJUK=[9P_$"*#2O#[:KKL-CA
MV:81PVT+-D=01DGT&:Z%/"T"Z[I.K-=3O/IMH]H@.,2!@,LW'7Y>U5=;\$PZ
MIKR:Y9ZI?:7J/E>1)+:,!YL8.0&!!'%/M\_U%'K<Y7PK_:!^,6M)J=I9VL\N
MDQ,\%HY=/OD*6R!EL>W3%<W(BK^S5J9"@$W#Y('_ $^5Z;HO@2RT/Q))KD%Y
M>2W4]M]GN#.^_P X[MV]B><]O3%1V7P^L+73M6TJ2\NKG2=1+DV4C#9"6;<2
MA R.3GK0G:W]=2D[._G^AG?%IU7X>-E@-]U:A?<^<A_D#4,EC;W?Q\62XB60
MV^@!XPPR%8S$9^N"1^)J>Y^%T&H:<EEJ7B#5KV.!D:V$TBGR2K \#&"<#;DY
M.":Z5?#MNOC%_$GG2_:&LA9&+C9M#[\^N<T?\'\B>GW?F<AX6TNR'Q>\<2?9
MHLQI9A,J,+OB); ]RH_*N.U "+X8^/84PL47B=E11T4>=$<#TY->P:?X<M].
M\2ZSKD<\KS:J(!)&V-J>4I48[\@\YK/A\":6ND:]IEPTMS:ZU>27<ZN0"K/C
MA2/0J,=Z:=FGY?Y%.W]>AE_%=U7P?:!F +:E:!1ZGS5/\@:@M;"VN?CIJEQ/
M$LCP:1!Y>X9VEG;)^O'ZU8G^&,-_:PP:EK^K7PMI(Y+8SR*?**,#P,8)(&,G
MG!-=)!X=@@\67?B!9I#/<VT=LT9QM"J201WSS4_U^!+6GW?F<CX*TNQ3XA^.
MI!:Q;EN8 N5!VAHMS8';)YKG--N=(LO &J6VJ64U[;GQ-/;V=A"VWS9?-RD?
MIMR,\\5ZAI7AVWTG6]9U.*:5Y-5DCDD1L;4*)M&/P]:QI?AQI<V@W>ER7%R1
M/J+ZE'.K!9()F;<"A'I1V]/\@_S_ ,SCO&\^MS2^%Y[_ $.PTNW76K41%)]\
MX8MTX  &,YKH-.L+*Y^-NO7,\4<EQ!IUL(@PS@-NW$?D/SJU=?#2'41;2:GK
MNJ7MW:3I-;SS2 ^458'A<;><8)QFK6J> +?4/$MSXA@U6_L=1EBCB66W<#8J
MYR,8Y!XR#Z"GV&_Z^\SM"CCL?C%XCM+)52UEL+>XN$3A5GRP!QV)6M'XB7>D
MVVAVJ:K8S:@9KV)+6RB?:9Y\Y12>F.,G/'%:?AOPO:>&XKDQ2S7-W=OYES=W
M#;I)FQ@$GV]*7Q1X8L_%6F1VEU)+"\,RSV]Q"VUX9%Z,I]1FET0+=GF_C.?7
M)=3\'SW^B6&EPC7+58_+GWS9).5X  7'7\*W]&L+:X^-7BJZFA226&SM%C+#
M.T,ISC_OD5<N/AM!?O9W&I:YJE[>V5S'<6]Q-("8RK X"XV\X&3C-;]EX=@L
M?$^J:ZDTC3ZC'#')&<;5$8(&._.>:8?U^)Y=K+RZ;%\6ET\&+:ELP6/@+OB
M=AZ<9-='XTT71XO@K>1110I;V^GJ]NZ@#D*-I!]^GOFNIM?"EC!JNO7TC/.-
M;$:W$,@!0*B;,#V(ZYKF[SX46=[I,FCRZ_K!TG:1#9^<"D/ICC) [ Y%)K2W
MH-;IG9Z#_P B_IW_ %[1_P#H(K0JO9VRV=E!;(Q988UC!/4@#%6*I[D15E86
MBBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &3XH_Y%/6/^O*;_P!
M-?-U?2/BC_D4]8_Z\IO_ $ U\W54=CQLS^*(44451Y@4444 %%%% !1110 4
M444 %%%% !73?#[_ )'G3?K)_P"BVKF:Z;X??\CSIOUD_P#1;4C2C_$CZEB;
M_7R?[QIE/F_U\G^\:95'BS^)A11102%%%% !1110 4444 %%%% !1110!M>$
M_P#D9[+_ 'F_]!-:$_\ Q\2_[Y_G6?X3_P"1GLO]YO\ T$UH3_\ 'Q+_ +Y_
MG1U-JO\ N\?5_DB.BBBF<04444 %%%% !1110 4444 %%%% !6AH?_(:MO\
M>/\ *L^M#0_^0U;?[Q_E0SHPO\>'JC6E_P!?)_O&F4^7_7R?[QIE2>Q+=A11
M10(**** "BBB@ HHHH **** "BBB@"S8?\?T7^]5N7_6O_O&JEA_Q_1?[U6Y
M?]:_^\:3.RC_  OF,HHHI%!1110 4444 %%%% !1110 4444 %2VW_'S'_O5
M%4MM_P ?,?\ O4%T_C1>;[Q^M-IS?>/UIM([7N%%%% @HHHH **** "BBB@
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MG_R,]E_O-_Z":T)_^/B7_?/\Z.IM5_W>/J_R1'1113.(**** "BBB@ HHHH
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M\4:\!^YU'5'$![/'$-@8>Q(:M;2?!T.C>']0TVVU"Z,]^\DMQ?,096D?@OZ
MX _*MK3-.MM(TVVT^SC$=O;QB.-?0 4?Y6$]?O+M%%% PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,GQ1_R*>L?]>4W_H!KYNKZ1\4?\BGK'_7
ME-_Z :^;JJ.QXV9_%$****H\P**** "BBB@ HHHH **** "BBB@ KIOA]_R/
M.F_63_T6U<S73?#[_D>=-^LG_HMJ1I1_B1]2Q-_KY/\ >-,I\W^OD_WC3*H\
M6?Q,****"0HHHH **** "BBB@ HHHH **** -KPG_P C/9?[S?\ H)K0G_X^
M)?\ ?/\ .L_PG_R,]E_O-_Z":T)_^/B7_?/\Z.IM5_W>/J_R1'1113.(****
M "BBB@ HHHH **** "BBB@ K0T/_ )#5M_O'^59]:&A_\AJV_P!X_P J&=&%
M_CP]4:TO^OD_WC3*?+_KY/\ >-,J3V);L****!!1110 4444""BBB@84444
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M: ))DSJ6CX/('6DBU*UF%OLDS]HW>5P><=:LA$&,*!CIQTH"(,851MZ<=*-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML2222>Y))-);6)>YJ4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1"D7,>&D\I?FZO\ W?K5O-%BE)/86BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )12U#<7$5K"TT
M\BQQKU9C@"@3:2NR6BJSZA:1F4/<1@Q*'DR?NJ>A-!U"S4L#<1@K'YK<]$_O
M?2BS%SQ[EJBJ@U*S) ^T1Y,7G#G_ )9_WOI2C4;1B@6XC)>/S% /5?4>U%F'
M/'N6:*JIJ%I*T(2XC8S M'@_> ZXHCU&SE$'EW,;"?=Y6&^_CKCZ4[!SQ[EJ
MBJJ:E92"(I<QL)6*QX;[Q'4"A=2LV"$7,9#R>4OS=6]/K187/'N32V\,^TS0
MQR;#E=Z@[3ZBI*J_VE9=?M,?^M\G[W_+3^[]:&U*R 8FYC 63RF^;H_I]:5F
M'/'N6J6JCZC9QB4O<QJ(F"2$M]TGH#1)J5G#Y_F7$:^1M\W)^YGIGZT6'SQ[
MEJBJLFHVD1F#W$:F$ R9/W >F:5M0M$:0-<1@QH)'!/13W^E%F'/'N6J*JG4
M;,$@W,>1%YQY_@_O?2@:C:,5 N(R6C\X#/5/[WTHLPYX]RS159-0M)#&$N(R
M94+I@_>4=2*2/4;.4P^7<QMY^3%AOOXZX^E%@YX]RU156/4K.40E+B-A,2(L
M-]\CKCZ4+J5FXC*W,9$CE$P?O,.WUIV%SQ[EK-+FJ@U*R(!%S'@R^2#NZO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_R,]E_O-_Z":T)_^/B7_>/\Z+ZFU7_=X^K_ "17,$1SF->6W'CJ?6AH(FW
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M2N=^6_A'2C^OR$NY/J_BZ/Q#\-?%<D4%S87]C:S17%O*<20OL)'(_F*KZ/\
M$4V7AG3+VZT/4?[&6WB234VQ@': 6*_>VY[_ (URFFR(_AOXK%-0DU >5C[5
M)C=+B%AGCMQQ[5U6J>(=%E^"4GDW$+";2A;16ZL"YE,>Q4V]<[L"AZ7?H):M
M)^9Z3'(LL:R(P9& *D="*?61X6M;BQ\)Z/:7>?M,-E#'+D_Q! #^M:]#5F"=
MU<6BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.JF2::>4DLGSD!5_N@ #IWKE[V6ZU3X;:?I=U=3.;/Q2FFI<EOG9$D*JV?4
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MMQ_P'^M8U;.@];C_ (#_ %I/8Z\#_'C_ %T-JBBBH/H0HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'S_ #HZFU7_ '>/J_R1'1113.(**** "BBB@ HHHH **** "BBB@ K0T/\
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MPA>B?\^Q_P"^S1_PA>B?\^Q_[[-%H]PYJ_\ *OO-G[;:_P#/S%_WV*GKG_\
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M -]FC_A"]$_Y]C_WV:+1[AS5_P"5?>;7VVU_Y^8O^^Q1]MM?^?F+_OL5B_\
M"%Z)_P ^Q_[[-'_"%Z)_S['_ +[-%H]PYJ_\J^\VOMMK_P _,7_?8H^VVO\
MS\Q?]]BL7_A"]$_Y]C_WV:/^$+T3_GV/_?9HM'N'-7_E7WFU]MM?^?F+_OL4
M?;;7_GYB_P"^Q6+_ ,(7HG_/L?\ OLT?\(7HG_/J?^^S1:/<.:O_ "K[S:^V
MVO\ S\Q?]]BC[;:_\_,7_?8K%_X0O1/^?8_]]FC_ (0O1/\ GV/_ 'V:+1[A
MS5_Y5]YM?;;7_GYB_P"^Q1]MM?\ GYB_[[%8O_"%Z)_S['_OLT?\(7HG_/L?
M^^S1:/<.:O\ RK[S:^VVO_/S%_WV*/MMK_S\Q?\ ?8K%_P"$+T3_ )]C_P!]
MFC_A"]$_Y]C_ -]FBT>X<U?^5?>;7VVU_P"?F+_OL4?;;7_GYB_[[%8O_"%Z
M)_S['_OLT?\ "%Z)_P ^Q_[[-%H]PYJ_\J^\VOMMK_S\Q?\ ?8H^VVO_ #\Q
M?]]BL7_A"]$_Y]C_ -]FC_A"]$_Y]3_WV:+1[AS5_P"5?>;7VVU_Y^8O^^Q1
M]MM?^?F+_OL5B_\ "%Z)_P ^Q_[[-'_"%Z)_S['_ +[-%H]PYJ_\J^\VOMMK
M_P _,7_?8H^VVO\ S\Q?]]BL7_A"]$_Y]C_WV:/^$+T3_GV/_?9HM'N'-7_E
M7WFU]MM?^?F+_OL4?;;7_GYB_P"^Q6+_ ,(7HG_/L?\ OLT?\(7HG_/L?^^S
M1:/<.:O_ "K[S:^VVO\ S\Q?]]BC[;:_\_,7_?8K%_X0O1/^?8_]]FC_ (0O
M1/\ GV/_ 'V:+1[AS5_Y5]YM?;;7_GYB_P"^Q1]MM?\ GYB_[[%8O_"%Z)_S
M['_OLT?\(7HG_/L?^^S1:/<.:O\ RK[S:^VVO_/S%_WV*3[;:_\ /S%_WV*Q
MO^$+T3_GV/\ WV:/^$+T3_GU/_?9HM'N'-7_ )5]YO*RNH92"#R".]#NL:%W
M8*HZDG J.VMXK.VCMX5VQQKM4>@IMY9PW]I):W"[HI.&&<9J3;6WF+]MM?\
MGYB_[[%'VVU_Y^8O^^Q6-_PA>B?\^Q_[[-'_  A>B?\ /L?^^S56CW,>:O\
MRK[S9^VVO_/S%_WV*/MMK_S\Q?\ ?8K&_P"$+T3_ )]C_P!]FC_A"]$_Y]C_
M -]FBT>X<U?^5?>;/VVU_P"?F+_OL4?;;7_GYB_[[%8W_"%Z)_S['_OLT?\
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M #['_OLT6CW#FK_RK[S9^VVO_/S%_P!]BC[;:_\ /S%_WV*QO^$+T3_GV/\
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M7_GYB_[[%8O_  A>B?\ /L?^^S1_PA>B?\^Q_P"^S1:/<.:O_*OO-K[;:_\
M/S%_WV*/MMK_ ,_,7_?8K%_X0O1/^?8_]]FC_A"]$_Y]C_WV:+1[AS5_Y5]Y
MM?;;7_GYB_[[%'VVU_Y^8O\ OL5B_P#"%Z)_S['_ +[-'_"%Z)_S['_OLT6C
MW#FK_P J^\VOMMK_ ,_,7_?8H^VVO_/S%_WV*Q?^$+T3_GV/_?9H_P"$+T3_
M )]C_P!]FBT>X<U?^5?>;7VVU_Y^8O\ OL4?;;7_ )^8O^^Q6+_PA>B?\^Q_
M[[-'_"%Z)_S['_OLT6CW#FK_ ,J^\VOMMK_S\Q?]]BC[;:_\_,7_ 'V*Q?\
MA"]$_P"?8_\ ?9H_X0O1/^?8_P#?9HM'N'-7_E7WFU]MM?\ GYB_[[%'VVU_
MY^8O^^Q6+_PA>B?\^Q_[[-'_  A>B?\ /L?^^S1:/<.:O_*OO-K[;:_\_,7_
M 'V*3[;:_P#/S%_WV*QO^$+T3_GV/_?9H_X0O0_^?4_]]FBT>X<U?^5?>/\
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M0"3</4?G1N'J/SJ/[/'_ ':/L\?]VC0"3</4?G1N'J/SJ/[/'_=H^SQ_W:-
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M?\\S^=']E6G_ #S/YT>Z&A;\U/\ GHOYT>:G_/1?SJI_95I_SS/YT?V5:?\
M/,_G1[H:%KS4_P">B_G6AHLT2ZQ;$R(!NY.X>E8O]E6?_/,_G5W2=$L)]4@B
MDB)1FP1N/I2=C;#?QH6[HZ*:XA\Y_P![']X_Q"F?:(?^>T?_ 'T*HR>'-,65
MP(#@,?XC3/\ A'=,_P">!_[Z-3[IZTG.^QH_:(?^>T?_ 'T*/M$/_/:/_OH5
MG?\ ".Z9_P \#_WT:/\ A'=,_P">!_[Z-/W>Y-Y]C1^T0_\ /:/_ +Z%'VB'
M_GM'_P!]"L[_ (1W3/\ G@?^^C1_PCNF?\\#_P!]&CW>X7GV-'[1#_SVC_[Z
M%:^AW5NIGW3QC[O5Q[UR_P#PCNF?\\#_ -]&E_X1[31TA/\ WT:5HFU"M.E-
M3ML=_P#;;7_GXB_[[%'VVU_Y^(O^^Q7 ?\(_IW_/%O\ OLT?\(_IW_/%O^^S
M2Y8]ST/[4G_)^)W_ -MM?^?B+_OL4?;;7_GXB_[[%<!_PC^G?\\6_P"^S1_P
MC^G?\\6_[[-'+'N']J3_ )/Q._\ MMK_ ,_$7_?8H^VVO_/Q%_WV*X#_ (1_
M3O\ GBW_ 'V:/^$?T[_GBW_?9HY8]P_M2?\ )^)W_P!MM?\ GYB_[[%'VVU_
MY^(O^^Q7#VGAS3);J-&A8J3R-YJP_A?2ED8"!L G^,TN6)K''U)1YN7\3L/M
MMK_S\P_]]BC[;:_\_,/_ 'V*X[_A&-+_ .>#?]]FC_A&-+_YX-_WV:+1']>J
M?RK[SL?MMK_S\P_]]BC[;:_\_,/_ 'V*X[_A&-+_ .>#?]]FC_A&-+_YX-_W
MV:+1#Z_4_E7WG8_;;7_GYA_[[%'VVU_Y^8?^^Q7'?\(QI?\ SP;_ +[-'_",
M:7_SP;_OLT6B'U^I_*OO.Q^VVO\ S\P_]]BC[;:_\_,/_?8KCO\ A&-+_P">
M#?\ ?9H_X1C2_P#G@W_?9HM$/K]3^5?>=C]MM?\ GYA_[[%'VVU_Y^8?^^Q7
M'?\ ",:7_P \&_[[-'_",:7_ ,\&_P"^S1:(?7ZG\J^\['[;:_\ /S#_ -]B
MC[;:_P#/S#_WV*X[_A&-+_YX-_WV:/\ A&-+_P">#?\ ?9HM$/K]3^5?>=C]
MMM?^?F+_ +[%'VVU_P"?F+_OL5QW_",:7_SP;_OLT^#PMI+3(I@)!/\ ?-%H
MC6-J-VY5]YUWVVU_Y^(O^^Q1]MM?^?B+_OL5S;>$=&#'_1CU_OFD_P"$1T?_
M )]F_P"^S1:/<U^L5OY5]YTOVVU_Y^(O^^Q1]MM?^?B+_OL5S7_"(Z/_ ,^S
M?]]FC_A$='_Y]F_[[-%H]P^L5OY5]YTOVVU_Y^(O^^Q1]MM?^?B+_OL5S7_"
M(Z/_ ,^S?]]FC_A$='_Y]F_[[-%H]P^L5OY5]YTOVVU_Y^(O^^Q1]MM?^?B+
M_OL5S7_"(Z/_ ,^S?]]FC_A$='_Y]F_[[-%H]P^L5OY5]YTOVVU_Y^(O^^Q1
M]MM?^?B+_OL5S7_"(Z/_ ,^S?]]FC_A$='_Y]F_[[-%H]P^L5OY5]YTOVVU_
MY^(O^^Q1]MM?^?B+_OL5S7_"(Z/_ ,^S?]]FC_A$='_Y]F_[[-%H]P^L5OY5
M]YTOVVU_Y^(O^^Q1]MM?^?B+_OL5S7_"(Z/_ ,^S?]]FC_A$='_Y]F_[[-%H
M]P^L5OY5]YU$4\4V?*E1\==K XHK+T;1;'3&F:UB*%P WS$T5.ATTY3E&[1L
M45XOX@UP:1^T-9R7NH/;Z=%IK22AI"(Q^[DYQTS5;29M4^,OBV34/M5Q8^%M
M-DV1Q12%'G;KS@]^#["DM;&CT/<>U%<[X@\7Z'X/AMXK^=U>3Y8+>%#)*X'H
MHY-2>'/&&C>*+::;3;HDP'$T4JE)(O\ >4].E S>HK@I?C!X1BN&0W-TT"OL
M-VMNQ@SG'W^E5OBO=:-/X1T^XU#6[ZPLY;I&BN-/7>TA*,0."/E(Y_ 46#R/
M1J*Y/6/B'X>\/:Y'HNHW$T=X]N)U B+!E.< $?Q$@\50M_B[X3N;>=UN;E9H
M&VM:M;L)F/7A.IHL".[HKF]%\<Z'K^B7NJV%P[P62L;A&0K)'M!)!7KT!K"_
MX7-X0-C%>)/>/"^=Q2V8^5@X^?\ N]/RH ]!HKSGXC?$A/#W@N#5-$<7,U^,
MVDX0O$ ",DGH#SP#WK1T3X@Z3)X%CU[49YH(H%2&>2XB*%Y=BD[0?O9)XQ1W
M#L=M17':#\2_#OB'5UTJVEN8+YUWQQ7<#1%P!GY<]>A_*NPH 6BBB@ HHHH
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MJR3YB1"Y^7;TW YR:JUA7.QHKAG^(ZRK<7>G:!J-_I-NS+)?P@;#M)#%5/+
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MCI^-=G3:L).X4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW6D7-A=:;JML@E>UN0,E"<!E(X(I@]#J:2BL3Q)XCB\.06,LT#S"[O8K-0A
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MNJH['C9G\40HHHJCS HHHH **** "BBB@ HHHH **** "NF^'W_(\Z;]9/\
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M8Y72[U"5%9X]I/F_WB<<BEGL[?6-#^%%OJ/[V&7:7#G[^(,@'UR0!0_U0_\
M@GI^D^)M%UUY(]+U.WNGC^^L;<CWQ5/3]<N5\7ZAH&H%/,\L7=DZKC?">&4^
MZM^C"N>\86EMI7C7P7>Z=#%!>2WS6CB)0OF0M&=P('4# -3>+V-M\2O UQ%Q
M))+=0/C^)#&#@_0@&FK7%Y'?T444#"BBB@ HHHH **** $K"E\9>'(-1?3Y=
M9M%ND)#1F3H<9QGIFI_$UU<6/A;5KNUS]IALY9(L?W@A(_6N,T/PYHES\%[=
M)[:!UN=+^T3SLH+F1DW,^[KD,3S4MV3?8:6QL:WXL>.Z\*2:1<0S6.K7WE/(
M%W!X]C'Y3VY%;6K>)]$T)T35-2M[5W&561N2/7%>7:7_ ,BM\*/^OP?^BWKH
M_ MG;:KXD\9:EJ,$<]\FK/:+YJABD"*-@ /0')/O56U:_KH2GL_ZZFYXL\2F
MQ^'^I:_HMS!,T4'F02C#H3D5/I_C+0KJ>"P.KVAU!U7,(?DL0#@=L\]*\OUE
M$T_3?BKH]F NF0);S11K]V.21-T@'IR <5U'B[P]HUA\'KG[-;PQ?8K-9[:X
M10'$BX*L&ZY)Q^=*]M>F@[:I?UT.YU77-,T.!9M3OH;6-CA3(V-Q]AWIND^(
M-)UZ&272K^&Z2,[7,;9VGW':N%OM3LY_$>B2'1;G6?$?]E+(T 8"*V1\9=@W
M )88SUJMX7:]3XS:D+S3;?37ET99&M[>0,&Q+@,V.-W6GY"OI<ZSX=Z[?>)O
M!%AJVHE#=3-*',:[5^65E''T45KZMK^DZ%&DFJ7\-JLAVIYC<M]!UKEO@US\
M+M*_W[C_ -'R5%XLT36&\96OB#1(M/U&X@LC;R:=>.!A2^[>OH>WX4YZ2L4U
MJSM-/U:PU>S%YI]W#<6Y_P"6D;9 ^OI66OCGPNU^MD-<LS<,_EA=_5O3/2N*
MTC5M!BLO&2:IIEYH5P(EEU.V#_+M*E0\6.F?YXK'\5-<3?"NZCLO!D6GZ7%:
M@QSW<J+*BC&U@!SN/'YU+8D>BZIKM[:?$+P_HT13['?07,DP*Y;**I7![=35
M_5/%F@:+<K;:EJMM;3$;MCMSCW]*Y"9V?XA^ '<EF;3+HDGJ3Y:5S_@=]=OK
M35]1C\,V.IS7FH3B>XNKA0_#8\O!'   &*?EZ_F).^OI^1Z[+J=C!IQU"6[A
M6S"[_/+C9M]<U3TGQ1HFNRO%I>IV]U(@RR(W('K@UYM:>$-:N? ESI,T]C:3
M0:W]JL+9K@2Q; 0P@;'49S\OTJ[9W[0>-]"'B?PP-*U,F2"SO+&0&"4LO*-C
MKP,CTH6X/8['3];N%\7ZAH&H%/,\L7=BZKC?">&4_P"TK?H171UP/C!C;?$K
MP-<1<22274#X_B0Q@X/T(!KOJ%L-[BT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!36^Z:=2,,@BI>P(\5^&^H>,;+X;P2:-I&GWMK&\[1B6=ED?]XV1C&.N:WO
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M$:NYO'FMZE,%&GWVEQV:L&^;<"V[CZ&I=^6WK^H+=_(S=-N9V^ :W)FD,_\
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M9VRV=E!;*Q98HU0,W4X&.:=]!=2Q1110,**** "BBB@ HHHH **** "BBB@
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M5U>ZU>^@0QVS3J%6$-P2%'<^M4C;_P#"0?%2.Z W67AZW>,-V-S,!D#_ '4
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M 'S_ #HZFU7_ '>/J_R1'1113.(**** "BBB@ HHHH **** "BBB@ K0T/\
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M **** "BBB@ HHHH L6O5_PHHM>K_A12.NE\*,2X\*"XN99O[4OD\QRVU9,
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MA_W]KIZ6CGD'U6EV.7_X0X?]!?4/^_M'_"'#_H+ZA_W]KJ**.>0?5:78Y?\
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MYV/V,.QA?\(T/^@G>_\ ?RC_ (1H?]!.]_[^5NT4<[#V,.QA?\(T/^@G>_\
M?RC_ (1H?]!.]_[^5NT4<[#V,.QA?\(T/^@G>_\ ?RC_ (1H?]!.]_[^5NT4
M<[#V,.QA?\(T/^@G>_\ ?RC_ (1H?]!.]_[^5NT4<[#V,.QA?\(T/^@G>_\
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MF0_=*X;&_P!06QG/>A#.DTKX@:!J^HQ6$,T\-Q,,PK<P-$)?]TMUZ4NH>/\
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M !1110 4444 %%%% !1110!9L/\ C^B_WJMR_P"M?_>-5+#_ (_HO]ZK<O\
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M,BL&\LLH;:?<9H'YFK1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR?[QIE4>+/XF%%%%!(4444 %%%% !1110 4444 %%%% &UX3_P"1GLO]YO\
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M^'M9D2?4='B13<(NT3Q289&([''6KU\GC'PYX1C\3OKGGR6L*37&EF%1#Y0
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M[?2IJ8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &3XH_Y%/6/^O*;_P! -?-U?2/BC_D4]8_Z\IO_ $ U\W54=CQL
MS^*(44451Y@4444 %%%% !1110 4444 %%%% !73?#[_ )'G3?K)_P"BVKF:
MZ;X??\CSIOUD_P#1;4C2C_$CZEB;_7R?[QIE/F_U\G^\:95'BS^)A11102%%
M%% !1110 4444 %%%% !1110!M>$_P#D9[+_ 'F_]!-:$_\ Q\2_[Y_G6?X3
M_P"1GLO]YO\ T$UH3_\ 'Q+_ +Y_G1U-JO\ N\?5_DB.BBBF<04444 %%%%
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M\C/9?[S?^@FM"?\ X^)?]\_SHZFU7_=X^K_)$=%%%,X@HHHH **** "BBB@
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MI;Q00KTCB0*H_ 5-110 4444 %%%% !BC%%% !1110 8HHHH **** "BBB@
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M_P"M?_>-5+#_ (_HO]ZK<O\ K7_WC29V4?X7S&4444B@HHHH **** "BBB@
MHHHH **** "I;;_CYC_WJBJ6V_X^8_\ >H+I_&B\WWC]:;3F^\?K3:1VO<**
M**!!1110 4444 %%%% !1110 4444 6+7J_X446O5_PHI'72^%%FBBB@T"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R?%'_(IZQ_UY3?\
MH!KYNKZ1\4?\BGK'_7E-_P"@&OFZJCL>-F?Q1"BBBJ/,"BBB@ HHHH ****
M"BBB@ HHHH *Z;X??\CSIOUD_P#1;5S-=-\/O^1YTWZR?^BVI&E'^)'U+$W^
MOD_WC3*?-_KY/]XTRJ/%G\3"BBB@D**** "BBB@ HHHH **** "BBB@#:\)_
M\C/9?[S?^@FM"?\ X^)?]\_SK/\ "?\ R,]E_O-_Z":T)_\ CXE_WS_.CJ;5
M?]WCZO\ )$=%%%,X@HHHH **** "BBB@ HHHH **** "M#0_^0U;?[Q_E6?6
MAH?_ "&K;_>/\J&=&%_CP]4:TO\ KY/]XTRGR_Z^3_>-,J3V);L****!!111
M0 4444 %%%% !1110 4444 6;#_C^B_WJMR_ZU_]XU4L/^/Z+_>JW+_K7_WC
M29V4?X7S&4444B@HHHH **** "BBB@ HHHH **** "I;;_CYC_WJBJ6V_P"/
MF/\ WJ"Z?QHO-]X_6FTYOO'ZTVD=KW"BBB@04444 %%%% !1110 4444 %%%
M% %BUZO^%%%KU?\ "BD==+X46:***#0**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_NU;^RV__/"/[^_[@^]Z_7WH-M 008(SEMY^4<MZ_6C0+5/(JR:U81+,SW*
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MX_C"]:M+;0*5(AC!4;5(4<#T'M0MM NS;#&-F0F%'RYZX]*- M4[HJ0ZU87
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M@W"Y%O\ :3_US_O4#6;!F0"Y4EX/M"CUC_O5:^S0?\\8_N;/NC[OI]/:C[-
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M\SI_#ZUZH;6!B288R67:<J.1Z?2C[+;_ //"/[NS[H^[Z?3VHYT'^K_]_P#
M\K$\9( /WD\P<'E?6A9XV* ')==R\'D"O5!:VX((@C!"[1\HX7T^E MH 5(A
MC&T87"C@>@HYT'^K_P#?_ \K2>.3R@C9\W.SCKCK2+<1N(RK9\PD)QUQUKU5
M;6W39M@C79G9A1\N>N/2D%I;KLQ!&-F=N%'RY]/2CG0?ZO\ ]_\  \K6XB8(
M0W#L47CJ?2@7$1 .[@R>6./XO2O51:6X"@01X4[A\HX/K1]DMO\ GA'][?\
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M(BDH(F8K'C^(CK0+^V8(1*,/)Y2^[^E=JMI;KMVP1C:25PHX/M1]DM^!Y$>
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MT^E%T/ZE+^8YE-1M9#$%F!,R&1/]I1U-$6HVDQMQ',&^T;C%C^+;U_*NF%K
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M!G/-+H%CU.BN.N?$^L:AH>@W/AW2Q+<:O&LAEN-WDVBE-Q,A ]3@#C-5=/\
M$?B+3?&MEX>\0_V;<IJ,4DEM<V*LFUHP"RNK$]CUS3MK872YV-GJ-GJ F-G=
M17 AE:&7RG#;'7JIQT(]*M5X]X+E\6S3^*H/#\>FP01:Y=.9[[>WFN6'R*%Z
M8P,L?4<=:] \'>)&\3:/)//;_9;ZUN)+2[MPVX1RH<$ ]QC!'UHZ#>YT5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444A.!2;MJ 45Y/X8U[XG>+-"BUBQ
MG\,16\KNJI/%,'^5BO."1VKIO"GBV_U#6;[P[X@L4LM;LT$N(GW1W$1.!(A]
M,\8[?GA@]#LJ*\_UKQZ_ASP'=ZQ>7^DWNH>9)':I:2GRY")-H')R2H(W >AK
M%OOB5?6%AIMK_;_ABYU._N2K7,3-]GMH@N26&[).00#D"DM0:/6J6LG1=4CO
M+<6TFH65WJ,$<;77V4_*N\;E.W)(!'(SUJW#J-G<W%U;P74,DUJ0)XU<$Q$C
M(##MD<TV(MT5D67B?0M1O6LK+6+&XNESF&*=688Z\ U8U/6=-T:$3:G?VUG$
MQVJ\\H0$^G- R_15:RO[74;9+FRN8KBW?E9(G#*?H14SR+&A=V"J!DDG %&P
M#J*RM.\2:)J]P\&G:M9W<T?+1P3*Y'U -7+34+/4!,;.ZBG$,K0R^4X;9(.J
MG'0CN* +-%<=XQ\?:?X>\*7&K65U9W4HF^SQ)YPPTFX*PXZE<DD>W:MX>(-(
M;2%U7^T[3[ W2Y\X>6><'YNG4$4=+@:E)6=I>O:3K:NVEZE:WHCX<P2A]OUQ
M5:X\7>';6-9+C7-/B1W:-6>X4 LIPPZ]0>#2 VJ*C6XB,'GB1/*V[M^>,>N?
M2L_3O$FB:O</!IVK6=W-'RR0S*[+]0#3 U*6L[4]<TK18TDU/4;6S1SA6GE"
M GVS4BZK8-IC:DM[ ;%4,AN!(-@4=6W=,4@+E%5)-3L8M,.I27<*V(C\TW#.
M FS&=V[IC'>HK[7-+TRSCN[_ %&UMK:3&R664*K9Y&":8&C152PU&SU2U6ZL
M+J&Y@;[LD+AE/XBI;FZ@L[=Y[F9(84&6DD8!5'J30!-169IOB#1]861M-U2T
MNQ']\P3*^WZXJS8:A9ZI9I>6%U%<VTF=DL+AE;!P<$<=: +-%9C>(=&73#J3
M:K9BQ#%#<&9?+W X(W=,YXHA\0Z/=:9+J5OJEI+8P@F2X292BXZY/04M@-.E
MKD? 7C2W\8^'EOC);1W89S-;1RAC"OF,$W?55!SWK8LO$NAZE>O9V6KV5Q=)
MG=#%.K,,=> :IAL:U%9MYKVDZ?)+%>:E:V\D,:RRK+*JE$8X#'/0$@BH&\5:
M FF)J3:U8"Q=MBW'GKL)] V<9J0-BBL'7-89/#@U'2M3TN(2/'Y=S>2?N"I8
M \J>I!P/<BM'4=6L-(MOM.HWL%I!G'F3R!%S]33 O454T_4K+5;5;K3[N&Z@
M;I)"X93^(IU[?VNG6SW-[<Q6\"#+22N%4?B: +-%9^F:UIFLPM+IFH6UY&IP
MS02AP#^%07?B;0["_6QN]8LH+ML;89)U5SGIP30!KTE<Q?:_=V_Q!T?0XQ";
M.\M)YY&()?<FW&#G&.?2M/4?$FB:1<);ZCJUG:32?=CFF5&/T!-(#5I*J76I
M65E;)<W5W## [*BR2. I9CA1D]R34-GKVDZA'<R6>IVLZ6QVSM'*K",_[6.G
M0T :5%9>F>(]&UF1X],U6SO'C^^L$RN5^N#2:EXDT71YDAU+5K.TD<95)YE0
MD>P)I@:E%8>N:G-;VEA/8ZAIL"SW<49DO'.V1&/*ICJY_AJUJ>OZ1HOE_P!I
MZG:6?F?=^T3*F[Z9H TZ*AMKJ&[MTN+:9)H9!E9(V!5A[&IJ "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/'8+> /$(
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MU2[C=IX@Y""0C:,]!U/'<UNV/@.>W\66/B2ZUZXO;^"*2&<RQ*%D1APJ $!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "451?6--
MC<H]_;JRD@J9 "#Z4G]MZ7_T$;;_ +^BGRLS]K#^9%^BJ']MZ5_T$;7_ +^B
MC^V]*_Z"-K_W]%'*P]K3_F1?I:S_ .V]*_Z"-K_W]%']MZ5_T$;7_OZ*.5A[
M6G_,B_15#^V]*_Z"-K_W]%']MZ5_T$;7_OZ*.5A[6G_,B_15#^V]*_Z"-K_W
M]%']MZ5_T$;7_OZ*.5A[6G_,C0I*H?VWI7_01M?^_HH_MO2O^@C:_P#?T4<K
M#VM/^9%^EK/_ +;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R-"BL_P#M
MO2O^@C:_]_11_;>E?]!&U_[^BCE8>UI_S(T**S_[;TK_ *"-K_W]%']MZ5_T
M$;7_ +^BCE8>UI_S(T*2J']MZ5_T$;7_ +^BC^V]*_Z"-K_W]%'*P]K3_F1H
M45G_ -MZ5_T$;7_OZ*/[;TK_ *"-K_W]%'*P]K3_ )D:%%9_]MZ5_P!!&U_[
M^BC^V]*_Z"-K_P!_11RL/:T_YD7Z*H?VYI>?^0A;?]_15_WHM8I2C+9W"BHY
MIXK>(RS2+'&O5F. *J?VYI?_ $$;7_OZ*+,3G&.C9H45G_VWI7_01M?^_HH_
MMO2O^@C:_P#?T4<K%[6G_,C0HK/_ +;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE
M8>UI_P R-"BL_P#MO2O^@C:_]_11_;>E?]!&U_[^BCE8>UI_S(T**S_[;TK_
M *"-K_W]%']MZ5_T$;7_ +^BCE8>UI_S(T**S_[;TK_H(VO_ ']%']MZ5_T$
M;7_OZ*.5A[6G_,C0HK/_ +;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R
M-"BL_P#MO2O^@C:_]_11_;>E?]!&U_[^BCE8>UI_S(T**S_[;TK_ *"-K_W]
M%']MZ5_T$;7_ +^BCE8>UI_S(T**S_[;TK_H(VO_ ']%']MZ5_T$;7_OZ*.5
MA[6G_,C0HK/_ +;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R-"BL_P#M
MO2O^@C:_]_11_;>E?]!&U_[^BCE8>UI_S(T**S_[;TK_ *"-K_W]%']MZ5_T
M$;7_ +^BCE8>UI_S(T**S_[;TK_H(VO_ ']%']MZ5_T$;7_OZ*.5A[6G_,C0
MHK/_ +;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R-"BL_P#MO2O^@C:_
M]_11_;>E?]!&U_[^BCE8>UI_S(T**S_[;TK_ *"-K_W]%']MZ5_T$;7_ +^B
MCE8>UI_S(T**S_[;TK_H(VO_ ']%']MZ5_T$;7_OZ*.5A[6G_,C0HK/_ +;T
MK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R-"BL_P#MO2O^@C:_]_11_;>E
M?]!&U_[^BCE8>UI_S(T**S_[;TK_ *"-K_W]%']MZ5_T$;7_ +^BCE8>UI_S
M(T**S_[;TK_H(VO_ ']%']MZ5_T$;7_OZ*.5A[6G_,C0HK/_ +;TK_H(VO\
MW]%']MZ5_P!!&U_[^BCE8>UI_P R-"BL_P#MO2O^@C:_]_11_;>E?]!&U_[^
MBCE8>UI_S(T**S_[;TK_ *"-K_W]%']MZ5_T$;7_ +^BCE8>UI_S(T**S_[;
MTK_H(VO_ ']%']MZ5_T$;7_OZ*.5A[6G_,C0HK/_ +;TK_H(VO\ W]%']MZ5
M_P!!&U_[^BCE8>UI_P R+]%4/[;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI
M_P R+]%4/[;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R+]%4/[;TK_H(
MVO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R+]%4/[;TK_H(VO\ W]%']MZ5_P!!
M&U_[^BCE8>UI_P R+]%4/[;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R
M+]%4/[;TK_H(VO\ W]%']MZ5_P!!&U_[^BCE8>UI_P R+]%4/[;TK_H(VO\
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M *"-K_W]%'*P]K3_ )D7Z*H?VWI7_01M?^_HH_MO2O\ H(VO_?T4<K#VM/\
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MT4<K#VM/^9&A16?_ &WI7_01M?\ OZ*/[;TK_H(VO_?T4<K#VM/^9&A16?\
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M%'_"*Z%_T#+?_OBM;<-N[(V]<T*ZMDJP8>QHYF'L:?\ *C)_X170O^@7;?\
M?%'_  BNA?\ 0+MO^^*UBZJ0&8 GH":&8*,L0H]S1S/N'L:?\J,G_A%="_Z!
MEM_WQ1_PBNA?] RV_P"^*UFD1,;G49]3BD\Z+_GJG_?0HYGW#V-/^5&5_P (
MKH7_ $"[?_OBC_A%="_Z!=O_ -\5K@Y'!I:.9A[&G_*C'_X170O^@7;_ /?%
M'_"*Z%_T"[?_ +XK9HHYF'L:?\J,;_A%="_Z!=O_ -\4?\(KH7_0+M_^^*V:
M*.9A[&G_ "HQO^$5T+_H%VW_ 'Q6P!@4M%%VRHPC'X58@NK6"\MW@N(EEB<8
M9&&0:S?^$5T/_H&6W_?%;%%%V@E3A+62N8__  BNA?\ 0+M_^^*/^$5T+_H%
MV_\ WQ6S11S,GV-/^5&-_P (KH7_ $"[?_OBC_A%="_Z!=O_ -\5LT4<S#V-
M/^5&-_PBNA?] NW_ .^*/^$5T+_H%V__ 'Q6S11S,/8T_P"5&-_PBNA?] NW
M_P"^*/\ A%="_P"@7;_]\5LT4<S#V-/^5&-_PBNA?] NW_[XH_X170O^@7;_
M /?%;-%',P]C3_E1C?\ "*Z%_P! NW_[XH_X170O^@7;_P#?%;-%',P]C3_E
M1C?\(KH7_0+M_P#OBC_A%="_Z!=O_P!\5LT4<S#V-/\ E1C?\(KH7_0+M_\
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MNA?] NW_ .^*/^$5T+_H%V__ 'Q6S11S,/8T_P"5&-_PBNA?] NW_P"^*/\
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MP]C3_E1C?\(KH7_0+M_^^*/^$5T+_H%V_P#WQ6S11S,/8T_Y48W_  BNA?\
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MIG_/E#_WS5^BB[#E10_L33/^?*'_ +YH_L33/^?*'_OFK]%%V'*BA_8FF?\
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M/90[&5_PC6B_] VW_P"^:/\ A&M%_P"@;;_]\UJT4<S#V4.QE?\ "-:+_P!
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M*VCW?\]2FTG\?WA_X$*(J^CZ W9<RZG4_&+4%\/?#:'0M.7;+?M'86\2]?+
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ML?4O$=KIGB#1]&FBF:?53,(70#:OEIN;=SGITP#6Q0&PM%%% !1110 4444
M%%%% "45F:-KEGKUM/<6+,T4-P]N692N60X; /;/%:>: %HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH R?%'_ "*>L?\ 7E-_Z :^;J^D?%'_ "*>L?\ 7E-_Z :^
M;JJ)XV9_%$****H\P**** "BBB@ HHHH **** "BBB@ KIOA]_R/.F_63_T6
MU<S73?#[_D>=-^LG_HMJ1I1_B1]2Q-_KY/\ >-,I\W^OD_WC3*H\6?Q,****
M"0HHHH **** "BBB@ HHHH **** -KPG_P C/9?[S?\ H)K0G_X^)?\ ?/\
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MWX@M9++^Q 65F)N,6IE*J,9;[PSU^X,,W.&&#GI4W! '(+8Y(&,FD ^BBBF
M4444 9/BC_D4]8_Z\IO_ $ U\W5](^*/^13UC_KRF_\ 0#7S=51V/&S/XHA1
M115'F!1110 4444 %%%% !1110 4444 %=-\/O\ D>=-^LG_ *+:N9KIOA]_
MR/.F_63_ -%M2-*/\2/J6)O]?)_O&F4^;_7R?[QIE4>+/XF%%%%!(4444 %%
M%% !1110 4444 %%%% &UX3_ .1GLO\ >;_T$UH3_P#'Q+_OG^=9_A/_ )&>
MR_WF_P#036A/_P ?$O\ OG^='4VJ_P"[Q]7^2(Z***9Q!1110 4444 %%%%
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M%E+@L"=YW$DDG)YJY=^$-/O?!(\)R2W(L%MH[8.K+YFU,8.<8S\H[4/5?=^
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M_O&F5)[$MV%%%% @HHHH **** "BBB@ HHHH **** +-A_Q_1?[U6Y?]:_\
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M4[8,J3*=T;_>C<'#(WH000?I7+>$,:OX]\6Z\3F.*:/2K<^@B&9,>V]OTI/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^?#4_P#P%-'_  F]C_SX:G_X"FN@HHM'L%ZW\WX'/_\ ";V/_/AJ?_@*:/\
MA-['_GPU/_P%-=!11:/8+UOYOP.?_P"$WL?^?#4__ 4T?\)O8_\ /AJ?_@*:
MZ"BBT>P7K?S?@<__ ,)O8_\ /AJ?_@*:/^$WL?\ GPU/_P !370446CV"];^
M;\#G_P#A-['_ )\-3_\  4T?\)O8_P#/AJ?_ ("FN@HHM'L%ZW\WX'/_ /";
MV/\ SX:G_P" IH_X3>Q_Y\-3_P# 4UT%%%H]@O6_F_ Y_P#X3>Q_Y\-3_P#
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MHM'L%ZW\WX'/_P#";V/_ #X:G_X"FC_A-['_ )\-3_\  4UT%%%H]@O6_F_
MY_\ X3>Q_P"?#4__  %-'_";V/\ SX:G_P" IKH**+1[!>M_-^!S_P#PF]C_
M ,^&I_\ @*:/^$WL?^?#4_\ P%-=!11:/8+UOYOP.?\ ^$WL?^?#4_\ P%-'
M_";V/_/AJ?\ X"FN@HHM'L%ZW\WX'/\ _";V/_/AJ?\ X"FC_A-['_GPU/\
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MPU>L44<R[&7]B4_YF>3_ &M_^?"^_P"_#4?:W_Y\+[_OPU>L44<R[!_8E/\
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1YZ45L+U-%2[';2A)02;/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gmab-20210630xex991d85adb006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *Y!T$# 2(  A$! Q$!_\0
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M_0-US_OQ#_\ ':[7P3X]TOQY9W-UI<%Y#';R"-Q=(JDG&>-K-QS3L!U=%%%
M!16=KFKP:#HMWJMTDCP6L9D=8@"Q ],D#]:C\.Z[;>)="M=7LXYH[>Y7>BS
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MGPYX>\;_  ]O=5TG0]&L]5TF]N#/:W,EZL/V8D8^=3\S8 '"CMUYH]=[?U^
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MN] \-6-U;ZA<M('NKB,_+DX( E4CKWI+1@UH6?%]O#HGQ\\-W6G1+#+>I_I
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M<\.+X5T[2;$^4=EOK7VQ-D:9ZF)@23^%3'_(;_4W?&7B'Q/::=I"V\ECX?\
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M/]I:M_:'F0H\/^C+%Y2;1A/E^]CU-<<WPPU>'X+R>%EN8I]2,GGA=_R!L@[
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MM%S:W$3S1^:B;0$()RQ //I5'Q=X.\0_\+"TSQ-8Z+;:_:PVPA:PN+A(_+8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZW7">./^1N\&?\ 81/_ * :[NA?"A?:8M%%% PHHHH **** "BBB@ HHHH
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MT4M EL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M, HHHH **** "BBB@ HHHH K7%C:74T$UQ:PS2P-OA>2,,T;>JD]#]*LT44
M%%%% !1110 4444 %%%% !1110 4444 %5H;"SMYKB:"T@BEN"&G=(PK2D#
M+$#YN/6K-% %0:;8BP;3Q96XLV!5K<1+Y9!Z@KC'.3^=97_"">#_ /H5=#_\
M%T7_ ,37044 5[2SMM/M4M;.WBM[>,82*&,(BCV X%6*** "BBB@ HHHH **
M** "BBB@ HHHH *S]2T32M:1$U73+*^6,Y075NDH4^VX'%:%% &%!X,\+6UQ
M'/;^&M&AFC8,DD=A$K*1T((7(-;M%% !1110 4444 %%%% !1110 4444 %%
M%% !4%U:6U];O;7=O%<02##Q2H'5AZ$'@U/10!2T_2=.TB P:;86ME"3N,=M
M"L:Y]<* *NT44 %%%% !1110 4444 %075K!>6TMM=013P2J5DBE0,K ]B#P
M14]% $4$$5K!'!!$D4,:A$C10JJH&  !P !6?JND6MY'-="QMY-0%N\4,[1K
MYBA@1M#GD Y]:U**35P6AQO@OPC:V'AC1!K&BV7]L6=NJ&62&.22(@G@.,_H
M:=XGT*\U7QCX6NXK59[*SEN#=EF7"J\1494GG)XX!KL**?5,25E8I:=H^F:1
M$T6F:=:6*.=S);0+&&/J0H&:EM;&TLO.^R6L$'G2&:7RHPGF.>K-CJQP.3S5
MFB@9FWOA_1M2NX[J^TBPNKF/&R:>V1W7'3!(R*T  !@#CI3J*0%6ST^ST^-X
M[*T@MDD<R.L,80,YZL0.I/<U6U#P_HVK2QRZEI%A>R1\(]S;)(5^A8'%:=%,
M1&(T$0C"*(P-H7'&/3%9D/A?P_;Y\G0=,BS*LQV6D8S(IR&X'W@>AZBM>B@8
M4444 %%%% "4M<S-;^+S,YBO=,$>X[08WR!VS3?L_C/_ )_M+_[]/5<OF<_M
MW_(_Z^9U%%<O]G\9_P#/]I?_ 'Z>C[/XS_Y_M+_[]/1R^8?6'_(_P_S.HHKE
M_L_C/_G^TO\ []/1]G\9_P#/]I?_ 'Z>CE\P^L/^1_A_F=117+_9_&?_ #_:
M7_WZ>C[/XS_Y_M+_ ._3T<OF'UA_R/\ #_,ZBBN7^S^,_P#G^TO_ +]/1]G\
M9_\ /]I?_?IZ.7S#V[_D?X?YG445R_V?QG_S_:7_ -^GH^S^,_\ G^TO_OT]
M'+YA]8?\C_#_ #.HHKE_L_C/_G^TO_OT]'V?QG_S_:7_ -^GHY?,/K#_ )'^
M'^9U%%<O]G\9_P#/]I?_ 'Z>C[/XS_Y_M+_[]/1R^8?6'_(_P_S.HHKE_L_C
M/_G^TO\ []/1]G\9_P#/]I?_ 'Z>CE\P^L/^1_A_F=117+_9_&?_ #_:7_WZ
M>C[/XS_Y_M+_ ._3T<OF'UA_R/\ #_,ZBBN7^S^,_P#G^TO_ +]/1]G\9_\
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M[/XS_P"?[2_^_3T<OF'UA_R/\/\ ,ZBBN7^S^,_^?[2_^_3T?9_&?_/]I?\
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M]G\9_P#/]I?_ 'Z>C[/XS_Y_M+_[]/1R^8?6'_(_P_S.HHKE_L_C/_G^TO\
M[]/1]G\9_P#/]I?_ 'Z>CE\P^L/^1_A_F=117+_9_&?_ #_:7_WZ>C[/XS_Y
M_M+_ ._3T<OF'UA_R/\ #_,ZBBN7^S^,_P#G^TO_ +]/1]G\9_\ /]I?_?IZ
M.7S#ZP_Y'^'^9U%%<O\ 9_&?_/\ :7_WZ>C[/XS_ .?[2_\ OT]'+YA]8?\
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M_P!^GH^S^,_^?[2_^_3T<OF'UA_R/\/\SJ**Y?[/XS_Y_M+_ ._3T?9_&?\
MS_:7_P!^GHY?,/K#_D?X?YG445R_V?QG_P _VE_]^GH^S^,_^?[2_P#OT]'+
MYA]8?\C_  _S.HHKE_L_C/\ Y_M+_P"_3T?9_&?_ #_:7_WZ>CE\P^L/^1_A
M_F=117+_ &?QG_S_ &E_]^GH^S^,_P#G^TO_ +]/1R^8?6'_ "/\/\SJ**Y?
M[/XS_P"?[2_^_3T?9_&?_/\ :7_WZ>CE\P^L/^1_A_F=117+_9_&?_/]I?\
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M<6L_W(/^_?\ ]>I]M2_F1I[+$?\ /J7X?YGN=%>&?\+BUG^Y!_W[_P#KT?\
M"XM9_N0?]^__ *]'MJ7\R#V6(_Y]2_#_ #/<Z*\,_P"%Q:S_ '(/^_?_ ->C
M_A<6L_W(/^_?_P!>CVU+^9![+$?\^I?A_F>YT5X9_P +BUG^Y!_W[_\ KT?\
M+BUG^Y!_W[_^O1[:E_,@]EB/^?4OP_S/<Z*\,_X7%K/]R#_OW_\ 7H_X7%K/
M]R#_ +]__7H]M2_F0>RQ'_/J7X?YGN=%>&?\+BUG^Y!_W[_^O1_PN+6?[D'_
M '[_ /KT>VI?S(/98C_GU+\/\SW.BO#/^%Q:S_<@_P"_?_UZ/^%Q:S_<@_[]
M_P#UZ/;4OYD'LL1_SZE^'^9[G17D>G?$'Q!J.BWNIQM:)':.B,C1'<V[TYJM
M_P +/U[TM?\ OT?\:F6(HQWDBH4,3._+2EIZ?YGLM%>,_P#"S]>]+;_OV?\
M&C_A9^O>EM_W[/\ C4_6Z'\Z+^J8O_GS+\/\SV:BO&?^%GZ]Z6W_ '[/^-'_
M  L_7O2V_P"_9_QH^MT/YT'U3%_\^9?A_F>S45XS_P +/U[TMO\ OV?\:/\
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M^-'_  GGB+^_9_\ ?H_XT?7,/_.@^IXS_GS+\/\ ,]9Q1BO)O^$\\1?W[/\
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M_OT]'V?QG_S_ &E_]^GHY?,7UA_R/\/\SJ**Y?[/XS_Y_M+_ ._3T?9_&?\
MS_:7_P!^GHY?,/K#_D?X?YG445R_V?QG_P _VE_]^GH^S^,_^?[2_P#OT]'+
MYA]8?\C_  _S.HHKE_L_C/\ Y_M+_P"_3T?9_&?_ #_:7_WZ>CE\P^L/^1_A
M_F=117+_ &?QG_S_ &E_]^GH^S^,_P#G^TO_ +]/1R^8?6'_ "/\/\SJ**Y?
M[/XS_P"?[2_^_3T?9_&?_/\ :7_WZ>CE\P^L/^1_A_F=117+_9_&?_/]I?\
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M^,_^?[2_^_3T?9_&?_/]I?\ WZ>CE\P^L/\ D?X?YG3T5S'V?QG_ ,_NE?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY+<P:W"T>9X,R1,58;F8-\_WR>@Z59L_AM]C^%LW@K^UM_FAA]L^SXQF3?\
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M/K8#U:BF@_*/I7(7WQ&TVVOKFVL]-U?51:';=3:=:>;'">X+$C)'^SFD!V%
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MY:P)>QF0M_="ALY]J\U^'-]XOO\ PS<W.A66DPF2]N)KB?4C(3<RLY.%"?=
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MSU#3DEAM,"W(D='CQQPZD-^M-L/ _AO2[FVNK'2XX)[8L8Y4=]QW==QSE_\
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M=2&'X&DM+#;O<X_1]+EM_B%>3ZAXK@U+5EL=DUK!II@PG\)9@[#\.M<S@/\
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MS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"<<,(%VL1[;LC\*[RJ&D:5::'I5OIMBA2W@3:H)R3ZDGN2>2?>K]/L M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
M)\7/^1$G_P"NT?\ Z%7S[7T%\7/^1$G_ .NT?_H5?/M>5C?XA[V5_P )^H44
M45QGI!1110 4444 %%%% !1110 4444 %%%% ';^%_\ D0]?_P"N\/\ 6LFM
M;PO_ ,B'K_\ UWA_K6366+WCZ&^7[3]?T"BBBN,]$**** "BBB@ HHHH ***
M* "BBB@ HHHH [6V_P"2?VG_ %^O_P"@UF=JT[;_ ))_:?\ 7Z__ *#69VK7
M$[Q]$88+X9?XF%%%%<YV!1110 4444 %%%% !1110 4444 %%%% '<M_R!M+
M_P"N)_G5>K#?\@;2_P#KB?YU7KV)[KT/FZ6S]7^84445!J%%%% !1110!V^@
M_P#('@^A_F:T:SM!_P"0/!]#_,UHU[E/X$?*UOXDO46BBBM#,**** "BBB@
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M.M#^R=/_ .?&V_[]+_A1_9.G_P#/C;?]^E_PH]T+8CNON?\ F9__  F/A_\
MZ"L'YT?\)CX?_P"@K!^=:']DZ?\ \^-M_P!^E_PH_LG3_P#GQMO^_2_X4>Z%
ML1W7W/\ S,__ (3'P_\ ]!6#\Z/^$Q\/_P#05@_.M#^R=/\ ^?&V_P"_2_X4
M?V3I_P#SXVW_ 'Z7_"CW0MB.Z^Y_YF?_ ,)CX?\ ^@K!^='_  F/A_\ Z"L'
MYUH?V3I__/C;?]^E_P */[)T_P#Y\;;_ +]+_A1[H6Q'=?<_\S/_ .$Q\/\
M_05@_.C_ (3'P_\ ]!6#\ZT/[)T__GQMO^_2_P"%']DZ?_SXVW_?I?\ "CW0
MMB.Z^Y_YF?\ \)CX?_Z"L'YT?\)CX?\ ^@K!^=:']DZ?_P ^-M_WZ7_"C^R=
M/_Y\;;_OTO\ A1[H6Q'=?<_\S/\ ^$Q\/_\ 05@_.C_A,?#_ /T%8/SK0_LG
M3_\ GQMO^_2_X4?V3I__ #XVW_?I?\*/="V([K[G_F9__"8^'_\ H*P?G1_P
MF/A__H*P?G6A_9.G_P#/C;?]^E_PH_LG3_\ GQMO^_2_X4>Z%L1W7W/_ #,_
M_A,?#_\ T%8/SH_X3'P__P!!6#\ZT/[)T_\ Y\;;_OTO^%']DZ?_ ,^-M_WZ
M7_"CW0MB.Z^Y_P"9G_\ "8^'_P#H*P?G1_PF/A__ *"L'YUH?V3I_P#SXVW_
M 'Z7_"C^R=/_ .?&V_[]+_A1[H6Q'=?<_P#,S_\ A,?#_P#T%8/SH_X3'P__
M -!6#\ZT/[)T_P#Y\;;_ +]+_A1_9.G_ //C;?\ ?I?\*/="V([K[G_F9_\
MPF/A_P#Z"L'YT?\ "8^'_P#H*P?G6A_9.G_\^-M_WZ7_  H_LG3_ /GQMO\
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M ,S/_P"$Q\/_ /05@_.C_A,?#_\ T%8/SK0_LG3_ /GQMO\ OTO^%']DZ?\
M\^-M_P!^E_PH]T+8CNON?^9G_P#"8^'_ /H*P?G1_P )CX?_ .@K!^=:']DZ
M?_SXVW_?I?\ "C^R=/\ ^?&V_P"_2_X4>Z%L1W7W/_,\_P#B5KFF:OX/FM;"
M]BGG,L;"-#R0#R:\6^PW/_/%J]S^*=G;6O@B>2WMXHG\Z/YHT"GKZBO!_.E_
MYZ/_ -]&O,Q;I<_O)GM9='%^R?+*._9_YDOV&Y_YXO1]AN?^>+_E47G2_P#/
M1_\ OJCSI?\ GH__ 'U7+>CV9W\N._FC]S_S)?L-S_SQ?\J/L-S_ ,\7_*HO
M.E_YZ/\ ]]4>=+_ST?\ [ZHO1[,.7'?S1^Y_YDOV&Y_YXO\ E1]AN?\ GB_Y
M5%YTO_/1_P#OJCSI?^>C_P#?5%Z/9ARX[^:/W/\ S)?L-S_SQ?\ *C[#<_\
M/%_RJ+SI?^>C_P#?5'G2_P#/1_\ OJB]'LPY<=_-'[G_ )DOV&Y_YXO^5'V&
MY_YXO^51>=+_ ,]'_P"^J/.E_P">C_\ ?5%Z/9ARX[^:/W/_ #)?L-S_ ,\7
M_*C[#<_\\7_*HO.E_P">C_\ ?5'G2_\ /1_^^J+T>S#EQW\T?N?^9+]AN?\
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M47P_9_?_ , .7,?YH?<_\QGVB'^^*/M$/]\4_8O]Q?RHV+_<7\J+X?L_O_X
M<N8_S0^Y_P"8S[1#_?%'VB'^^*?L7^XOY4;%_N+^5%\/V?W_ / #ES'^:'W/
M_,ZQM:TW^RM/C%[%O2(AESRIST-0?VQIW_/W'^=:#6MN='TP_9XLF(DG8,GG
MO5?[-;_\\(O^^!7JR=&^S/ IQQMG:4=WT??U(/[8T_\ Y^X_SH_MC3_^?N/\
MZL?9;?\ YX1?]\"C[+;_ //"+_O@5-Z/9FG+C?YH_<_\RO\ VQI__/W'^=']
ML:?_ ,_<?YU8^RV__/"+_O@4?9;?_GA%_P!\"B]'LPY<=_-'[G_F5_[8T_\
MY^X_SH_MC3_^?N/\ZL?9;?\ YX1?]\"C[+;_ //"+_O@47H]F'+COYH_<_\
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M_2_X4?V3I_\ SXVW_?I?\*/="V([K[G_ )F?_P )CX?_ .@K!^='_"8^'_\
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M^$Q\/_\ 05@_.M#^R=/_ .?&V_[]+_A1_9.G_P#/C;?]^E_PH]T+8CNON?\
MF9__  F/A_\ Z"L'YT?\)CX?_P"@K!^=:']DZ?\ \^-M_P!^E_PH_LG3_P#G
MQMO^_2_X4>Z%L1W7W/\ S,__ (3'P_\ ]!6#\Z/^$Q\/_P#05@_.M#^R=/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M >F-I?Q%5)A_I,^DK<3'U=VW'^=4_BTV$K\OF>QT444#"BBB@ HHHH ****
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MM+3+"TTEY<7#$8_>,V.!_=Q79T4Q'+^%?#MYH>I>(;FYDA=-2OVN81&Q)52
M,-D#!X[9I?"/AV[T&366NI(7^VW\ES'Y3$X5N@.0.?I73T4 ]1:***!A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&^%=$U'3?%?B>]N[
M?R[>]N5>W?>IWJ!C. 21^.*I^)_#FJVWC/2_%7AVT$]R#]GU" 2*GFPG^++$
M#(KO:*25K>0=SSXZ7XB\*^)]2U/1-)35M/U5A--:BY2&6&7&"07^5@?K4L^G
M^+]9\*:^-62%+B]B*V>F1.C" 8Z-)@;F/UQ7>446TL%];GEVJ^%M<BN_#.J1
M:-#K TZT\B;3)9D0HYQ\ZEOD)'2K4&E>*K[XA:3K]_I,%G80V\D'V:*Y61X0
M>=SG@')[+G'K7H]%.X'CO@?4O%EA8ZLFEZ##JMK)J$_DN+Q(3"V[G>&ZKGGY
M<GVKHK'PUXH\/>%5.E75M+K3W1N[R-\".?<<M&&(.WT!XKJ= \/6GARUGMK.
M2=TFG>=C,02&8Y(& .*UZ70'N>:C0M:\3>,=(UB_\-0:"-.<R2SFYCEFN21@
M)F/^'_>/X5)IUAXI\#SW]EI.A1ZWI=Q.]Q;F.\2!X"QR5</U&>XS]*]&HI@<
M!?\ A?Q-KWA(#5;^V_MR.Z%Y;*J@10E3D1Y !88X)K*\26_CSQ3#IEK)X9AL
M8+:\BFN6-_'(9=IZH!T4=>>?:O5** &,@>(QL/E(P17G>EVGB_P7%<Z1INA1
M:S8M*\EG<B]2$Q!CG;(K<X'^SFO1Z*74$>67W@/68O!,=F@2]U:XU6.^N_+<
M*H^?+8+$9 'XFO4ER%&1VI:*8'(WFC:A+\3].UA+?-A#820R3;U^5R<@8SG\
MA5/5]&US1_&4GB?0+&/4ENH%@O+%IQ"YV_=9&;Y?J#BNZQ12 Y31&\6:A?WE
M[K4$6FV31[+;3%=)7![N\BCOZ XKF!X1UP?"Y]'^P_Z>;XS"+S4^YYF[.=V.
MGO7J5%#$<3X_\.:EKF@Z>EA;PW<EG.DTEC.X5+@ ?=)/'Y\5AZWIOB_7ET=H
MO#%OI=G87D<K6BWD;R.!U(VX0 ?4D^E>I4M S@KG3/$/AOQ7?ZQHFEIJ]GJ2
MJ9[47*PRQR 8W O\I!'OFJE]X9\4ZSX3UMM1D']I7SK+;:?]HW16ZJ00@;ID
MXY(XKT>CF@#SJ[TKQ-+<:/XHLM(6'5K*$VUQI<]TG[Z,X^[(I*@]QFK-II7B
M#Q'XLL=;US34TFSTU6^SV9N5FDDD/&]BGR@8[9-=Y13%;0Y'P'HU_HVGZC%J
M%OY+S7\TT8WJV48Y!X)Q^-<IK>@27'Q<MK"$J=.O52_O(@/XXC@$_7^E>KNN
MY&7)&1C(."*P/#_A"Q\/7=W>1W5_>WMT?WES?SF63;G(0'LH]*2W&^OF= ..
M*XBP\-WI\;>)KJ[ML:?J%LD44A=3OX(/ .1^(KN*6BP'F?@CPEKFFP:LVLQ+
MYR0&QL )%;,(S@]3@G(ZU2_X0[7O^%?^'M,-A_IEI?K-/'YR?(@;).=V#QZ$
MUZQ13_X'X"/-O%'@W5]1\<6MQ8Q+_9-ZL8U-MX!'EME< G)STX!K8AT/4$^*
M4^L?9L:<VGK LN]?O@]-N<_IBNQH[TAB]J***8!1110 4444 %%%% !1110!
MPGQ<_P"1$G_Z[1_^A5\^U]!?%S_D1)_^NT?_ *%7S[7E8W^(>]E?\)^H4445
MQGI!1110 4444 %%%% !1110 4444 %%%% ';^%_^1#U_P#Z[P_UK)K6\+_\
MB'K_ /UWA_K6366+WCZ&^7[3]?T"BBBN,]$**** "BBB@ HHHH **** "BBB
M@ HHHH [6V_Y)_:?]?K_ /H-9G:M.V_Y)_:?]?K_ /H-9G:M<3O'T1A@OAE_
MB84445SG8%%%% !1110 4444 %%%% !1110 4444 =RW_(&TO_KB?YU7JPW_
M "!M+_ZXG^=5Z]B>Z]#YNEL_5_F%%%%0:A1110 4444 =OH/_('@^A_F:T:S
MM!_Y \'T/\S6C7N4_@1\K6_B2]1:***T,PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y#5M.N--\=Z;XBLX))H;F+^SK](E+,JD[HY<#LK9!/8-G
MM3]7^&_A#7=7_M34M#@GO206DWNF\C^\JD!OQ!KJZ*0&7J/A_2M6LK6SO+17
MMK65)H(T9HPCI]PC:1T].E7[BWBNK:6WN(UDAE4HZ,,AE(P0:EHHL!@V_@WP
M];>&3X<CTR(Z0<_Z-(S2#EMV<L2<YYZ\5'X<\#>&O"3ROH>E16DDHP\FYI'(
M]-S$D#VKHZ*8!7-:UX"\,>(;XWVIZ4DMT5V/(DCQ&1?1]A&X?[V:Z6B@"O:6
MEM86D5I:01P6\2A(XHE"JJCL *KSZ-87&L6VKRP;KZUC>*&7>PVJV-PQG!Z#
MJ*T**!"50TC1M/T*P%CIMOY%L'9PF]F^9B6;EB3U)K0HH&<JOPZ\)KJ_]J#1
M8?M7F^=C>_EB3^]Y>=F[WQ6SK&B:?K^G-8:G;^?:LRN8][+DJ01RI!Z@5H44
M    P!P*YC5?A[X5UO47O[_2(Y+F3 E=)7C\W'3>$8!_^! UU%%("E_9=A_9
M?]F&RM_L'E^5]F\L>7LQC;MZ8K'T;P%X8\/WPOM-TF.*Y5=J2/(\AC'HF]CL
M'/\ #BNEHI^8>0G6LO3]+T[POHAM--M7CL[</(L,>^5N26;&<L223Q[UJTE(
M#E? ^D7-C87FIZC&8M2U:Y:[GC;K$#PD?_ 5 'US754 8HH$+1113&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PGQ<_Y$
M2?\ Z[1_^A5\^U]!?%S_ )$2?_KM'_Z%7S[7E8W^(>]E?\)^H4445QGI!111
M0 4444 %%%% !1110 4444 %%%% ';^%_P#D0]?_ .N\/]:R:UO"_P#R(>O_
M /7>'^M9-98O[/H;Y?M/U_0****XST0HHHH **** "BBB@ HHHH **** "BB
MB@#M;;_DG]I_U^O_ .@UF=JT[;_DG]I_U^O_ .@UF=JUQ.\?1&&"^&7^)A11
M17.=@4444 %%%% !1110 4444 %%%% !1110!W+?\@;2_P#KB?YU7JPW_(&T
MO_KB?YU7KV)[KT/FZ6S]7^84445!J%%%% !1110!V^@_\@>#Z'^9K1K.T'_D
M#P?0_P S6C7N4_@1\K6_B2]1:***T,PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH YJ:Q\5M-(8M8LUC+'8#;<@=N],_L_P 7_P#0:L__  &KJ**K
MG.?ZM'N_O9R_]G^+_P#H-6?_ (#4?8/%_P#T&K/_ ,!JZBBCG%]6CW?WLY?[
M!XO_ .@U9_\ @-1]@\7_ /0:L_\ P&KJ**.</JT>[^]G+_8/%_\ T&K/_P !
MJ/L'B_\ Z#5G_P" U=111SA]6CW?WLY?[!XO_P"@U9_^ U'V#Q?_ -!JS_\
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M_L'B_P#Z#5G_ . U'V#Q?_T&K/\ \!JZBBCG#ZM'N_O9R_V#Q?\ ]!JS_P#
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M_L'B_P#Z#5G_ . U'V#Q?_T&K/\ \!JZBBCG#ZM'N_O9R_V#Q?\ ]!JS_P#
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M]G+_ &#Q?_T&K/\ \!J/L'B__H-6?_@-7444<X?5H]W][.7^P>+_ /H-6?\
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M]G+_ &#Q?_T&K/\ \!J/L'B__H-6?_@-7444<X?5H]W][.7^P>+_ /H-6?\
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M#5G_ . U'V#Q?_T&K/\ \!JZBBCG#ZM'N_O9R_V#Q?\ ]!JS_P# :C[!XO\
M^@U9_P#@-7444<X?5H]W][.7^P>+_P#H-6?_ (#4?8/%_P#T&K/_ ,!JZBBC
MG#ZM'N_O9R_V#Q?_ -!JS_\  :C[!XO_ .@U9_\ @-7444<X?5H]W][.7^P>
M+_\ H-6?_@-1]@\7_P#0:L__  &KJ**.</JT>[^]G+_8/%__ $&K/_P&H^P>
M+_\ H-6?_@-7444<X?5H]W][.7^P>+_^@U9_^ U'V#Q?_P!!JS_\!JZBBCG#
MZM'N_O9R_P!@\7_]!JS_ / :C[!XO_Z#5G_X#5U%%'.'U:/=_>SE_L'B_P#Z
M#5G_ . U'V#Q?_T&K/\ \!JZBBCG#ZM'N_O9R_V#Q?\ ]!JS_P# :C[!XO\
M^@U9_P#@-7444<X?5H]W][.7^P>+_P#H-6?_ (#4?8/%_P#T&K/_ ,!JZBBC
MG#ZM'N_O9R_V#Q?_ -!JS_\  :C[!XO_ .@U9_\ @-7444<X?5H]W][.7^P>
M+_\ H-6?_@-1]@\7_P#0:L__  &KJ**.</JT>[^]G+_8/%__ $&K/_P&H^P>
M+_\ H-6?_@-7444<X?5H]W][.7^P>+_^@U9_^ U'V#Q?_P!!JS_\!JZBBCG#
MZM'N_O9R_P!@\7_]!JS_ / :C[!XO_Z#5G_X#5U%%'.'U:/=_>SE_L'B_P#Z
M#5G_ . U'V#Q?_T&K/\ \!JZBBCG#ZM'N_O9R_V#Q?\ ]!JS_P# :C[!XO\
M^@U9_P#@-7444<X?5H]W][/+?B%;:Y!X3E?5K^WN;7S4!CCAV,3GCFO'_-LO
M^?>3_ONO=_BW_P B)/\ ]=H__0J^?:\W%U6I[+[CVLNP4)TG[TM_YF6_-L?^
M?>3_ +[H\VQ_Y]Y/^^ZJ45R^W?9?<=_]G0_GE_X$RWYMC_S[R?\ ?='FV/\
MS[R?]]U4HH]N^R^X/[.A_/+_ ,"9;\VQ_P"?>3_ONCS;'_GWD_[[JI11[=]E
M]P?V=#^>7_@3+?FV/_/O)_WW1YMC_P ^\G_?=5**/;OLON#^SH?SR_\  F6_
M-L?^?>3_ +[H\VQ_Y]Y/^^ZJ44>W?9?<']G0_GE_X$RWYMC_ ,^\G_?='FV/
M_/O)_P!]U4HH]N^R^X/[.A_/+_P)EOS;'_GWD_[[H\VQ_P"?>3_ONJE%'MWV
M7W!_9T/YY?\ @3.UT$2/X1UA[9UCM5EB$T;C+.><$'MBL[*?W3^=:?A?_D0]
M?_Z[0_UK)K+$XAIQT6W8VP.70ES^_+?^9_YCLI_=/YT93^Z?SIM%<OUJ7\J^
MY'?_ &73_GE_X$_\QV4_NG\Z,I_=/YTVBCZU+^5?<@_LNG_/+_P)_P"8[*?W
M3^=&4_NG\Z;11]:E_*ON0?V73_GE_P"!/_,=E/[I_.C*?W3^=-HH^M2_E7W(
M/[+I_P \O_ G_F.RG]T_G1E/[I_.FT4?6I?RK[D']ET_YY?^!/\ S'93^Z?S
MHRG]T_G3:*/K4OY5]R#^RZ?\\O\ P)_YCLI_=/YT93^Z?SIM%'UJ7\J^Y!_9
M=/\ GE_X$_\ ,ZJ"*]/@^WD6XB%H;I@L6SY@VWDY]*H[+C_GHO\ WS6Q;?\
M)/[3_K]?_P!!K-K2OB9)K1;+HC'"9;3E&7ORW?VG_F0[+C_GHO\ WS1LN/\
MGHO_ 'S4U%8?6I?RK[D=7]E4_P">?_@3_P R'9<?\]%_[YHV7'_/1?\ OFIJ
M*/K4OY5]R#^RJ?\ //\ \"?^9#LN/^>B_P#?-&RX_P">B_\ ?-344?6I?RK[
MD']E4_YY_P#@3_S(=EQ_ST7_ +YHV7'_ #T7_OFIJ*/K4OY5]R#^RJ?\\_\
MP)_YD.RX_P">B_\ ?-&RX_YZ+_WS4U%'UJ7\J^Y!_95/^>?_ ($_\R'9<?\
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M%7SD?5H_S/[V<O\ 8/%__0:L_P#P&H^P>+_^@U9_^ U=111SB^K1[O[V<O\
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M5U%%'.'U:/=_>SE_L'B__H-6?_@-1]@\7_\ 0:L__ :NHHHYP^K1[O[V<O\
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M5U%%'.'U:/=_>SE_L'B__H-6?_@-1]@\7_\ 0:L__ :NHHHYP^K1[O[V<O\
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MG[0X2WVD$[4!VY)SDX[U-K.A1M\%M.\:W%[?S^(@Z&.^DNY"T:^85"J-V
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MNUY++X1TG5/BM/I=Q;DZ7;:7'BT61E1N>,@$9QVJ7Q#8^#8?$ALM>O+G5!'
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M'_Z%7S[7E8W^(>]E?\)^H4445QGI!1110 4444 %%%% !1110 4444 %%%%
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M,XV'C!'6O.[BSM9](^&;36T,A9D1BZ Y'E$X/J,UOVJ+'\5]?1%"J-)@ 4<
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M+XYO-=OGO8&\B.2(0A=PRY2->!Z%C36MGWL/O\SW<<C-%-3E%^E.H!!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <)\7/\ D1)_^NT?_H5?/M?07Q<_Y$2?_KM'_P"A5\^UY6-_B'O9
M7_"?J%%%%<9Z04444 %%%% !1110 4444 %%%% !1110!V_A?_D0]?\ ^N\/
M]:R:UO"__(AZ_P#]=X?ZUDUEB]X^AOE^T_7] HHHKC/1"BBB@ HHHH ****
M"BBB@ HHHH **** .UMO^2?VG_7Z_P#Z#69VK3MO^2?VG_7Z_P#Z#69VK7$[
MQ]$88+X9?XF%%%%<YV!1110 4444 %%%% !1110 4444 %%%% '<M_R!M+_Z
MXG^=5ZL-_P @;2_^N)_G5>O8GNO0^;I;/U?YA1114&H4444 %%%% ';Z#_R!
MX/H?YFM&L[0?^0/!]#_,UHU[E/X$?*UOXDO46BBBM#,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,S5-%M=5N+"XE:6.XL9Q/!-$0&4XPR\@_*RD
M@C^N*TZ** "BBB@ HHHH **** "BBB@ HHHH **** *>IV*ZGIMS8O/- EQ&
M8VDA8!U!X."0<&GV-E;Z=8P65K&L5O @CC1>BJ!@"K%% "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#<V\5W;2V
M\Z"2&5"CHW1E(P14U%+<#SF'X=^(-)B-CX?\>7NGZ5D[;66RBN&C![)(V"!Z
M>E;=AX'LM+\'7^@6=Q-NO8Y!-=S_ +R221Q@NW3)_+I7544!YG&7W@66Y\-Z
M'I]KJYM;[1RC07GV<."57:<H6Z$=LU>L_"TT'B2\UJXU!9IKJRCM758-@RN<
MO]X]<].WK72T4/42T.(A^':1_#H^$WU)F8,7CO5AVE'W[PP7=V/O3[KP!'/X
M&L/#,5^8A:O%(;@P[C(R-N)*[A@L??\ .NTHIMW"W0YO2/"IT[Q1JFO7%[]J
MGO52.-/*V""-1@*#N.?4GCZ4OC'PLOBS2([1;LV=S!.EQ;W(CW^6ZG.<9&?S
MKHZ*!G"3^ =37Q/?>(=-\3R65_=QQQL/L:R1%57!W*6YYY!!&.>M;7ACPM'X
M>6ZFEO9;_4KV3S+N\F 5I&[ *.%4#H!TKH<44 +1110 4444 %%%% !1110
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M **,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5?<'M:G\S^]G/2^$+.2*6(75ZB,5\L+.?W('9,] >^<T2^$+&0W!$]TGG!0
MLN/+Q_=],]\YKH:*KECV(O+N_O.>?P?8N9B)[M?,C" ++]PC^)?>AO"%BQD(
MGNQO@\D 2GY3_?'^U^GM714E')'L%WW?WG/#PA8[@?/NN(?*P93R?[_^]^GM
M0GA"Q5HF\^[;9&8R&E/SD_Q'WKH<T4<D>P7EW?WG/1>$+&,VY,]V_DJRG=*?
MWN>[>X[8Q20^#[*(6V;B[D,.[<7E/[W/][Z=L8KHZ2CDCV"[[O[S'M]!6VBM
M8X]0OMEO(7 ,OW\]FXY'M3UT4HD2_P!I7Y\NX\_)ER6_V#ZK[5JT5=S/V<;W
M,D:(0NW^TK__ (^OM&?.Y_W/]SVHDT0R)*/[2OU\R<2Y6;!7'\(]%]JUJ*+L
M/90,F?1&F6Z U*_3[0ZOE)L&+'9/0'O2SZ(9C>'^TK^/[24/R38\K;_<],]_
M6M:BCF8>RB94VC&9KD_VC?)YZ*F$FP(\=U]">]#Z.7:8_P!HWR^9;B# E^[C
M^,>C>]:E%%V'LHF5_8Q+EO[1ON;7[-CS?_(G^_[TJZ.5:,_VA?'RX#!@R\-_
MMGU;WK4HHNP]E$RX-&:%K5O[1O7\A&0AY<B3/=O4CL:2#1&@^Q?\3._D^S!P
M=\N?.W?W_7';TK6HHNP]E$R8=%,*VH_M*_?[.[-EYL^;GL_J!VI(]%:(0C^T
MK]O*G,V6FSOS_"WJOM6O11=A[*)D#1#M4?VE?_+=?:<^=U_Z9G_8]J5M%)21
M?[2OQON//R)N1_L#_8]JU:*+L/91[&3+HAE%P/[2OT\Z59,K-CR\?PKZ ]Q1
M<:(;@7@&IW\?VDH?W<V/*V_W./ESW]:UZ*+L/91,J?1C,;L_VC?1_:55<)+@
M18[IZ9[TDFBF1YV_M&^7S81%A9L;,?Q+Z-[UK4478>RB93Z.6:0_VC?#=:_9
ML"7@?]-!_M^]*NCE60_VA?';;?9\&7@_[9_V_>M.BCF8>RB94>C&-K<_VC?-
MY,1B(:7._/\ $WJWO2P:,T+69.HWTGV977#RY\W=W?\ O$=O2M2BB[#V43*M
M]$-NMF#J5_+]E+G,DV?-W?W_ .]CMZ4D>BM$MN/[2OV\F4RY:;/F9_A;U4>E
M:])1=A[*)E+HI58U_M*_.RZ^TY,V2P_YYGU3VI/[%.UE_M*_YN_M.?.Y'_3/
M_<]JUJ*+L/91,F71#*LX_M*_3S9A+E9L%,?PKZ+[43Z(TZ7BC4K^/[2RL#'-
M@Q;>R>@/>M>BB[#V43)GT4SF^/\ :5_']J"#]W-CR=O]S^[GOZTLVC&9[EO[
M1OD\^-8\)+@1X[KZ$]S6K2478>RB9;Z.6:4_VC?#S+;[/@2_=_VQZ/[T?V,=
MX;^T;[BT^RX\WC_KI_O^]:E%%V'LHF6FCE&A/]H7S>5 8,-+P^?XV]6]Z+?1
MS UHQU&]D^S(R$/+GS<]W]2.QK5HHNP]E$R;?1&M_L/_ !,[^3[)OSYDN?.W
M?\]/[V.WI1#HIA6U7^TK]_L\C/EYLF7.>']0,\5K4E%V'LHF3'HAC6$?VE?M
MY5P9\M-G=_L-ZK[4O]BG;C^TK_B\^U_Z[_R'T_U?^S6K11=A[*(W!]Z*=107
MH+1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=7<$$+$!9)) JDGH 3ZUYY\/=!TO7]#O]7U>RMM0OKZZF6>6YC$A"AB @ST
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M %VC_P#0J^?:\K&_Q#WLK_A/U"BBBN,](**** "BBB@ HHHH **** "BBB@
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MD_\  Q/\*Z:BCF78/8U/^?C_  _R.9_M_P 1?]"I)_X&)_A1_;_B+_H5)/\
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M4D_\#$_PKIJ*.9=@]C4_Y^/\/\CF?[?\1?\ 0J2?^!B?X4?V_P"(O^A4D_\
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M/\/\CF?[?\1?]"I)_P"!B?X4?V_XB_Z%23_P,3_"NFHHYEV#V-3_ )^/\/\
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M4D_\#$_PH_M_Q%_T*DG_ (&)_A7344<R[![&I_S\?X?Y',_V_P"(O^A4D_\
M Q/\*/[?\1?]"I)_X&)_A7344<R[![&I_P _'^'^1S/]O^(O^A4D_P# Q/\
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M111_;%3^5?C_ )A_JS3_ .?LO_)?\CM_^%FR?] 1O_ D?_$T?\+-D_Z C?\
M@2/_ (FN(HH_MBI_*OQ_S#_5FG_S]E_Y+_D=O_PLV3_H"-_X$C_XFC_A9LG_
M $!&_P# D?\ Q-<111_;%3^5?C_F'^K-/_G[+_R7_([?_A9LG_0$;_P)'_Q-
M'_"S9/\ H"-_X$C_ .)KB**/[8J?RK\?\P_U9I_\_9?^2_Y';_\ "S9/^@(W
M_@2/_B:/^%FR?] 1O_ D?_$UQ%%']L5/Y5^/^8?ZLT_^?LO_ "7_ ".W_P"%
MFR?] 1O_  )'_P 31_PLV3_H"-_X$C_XFN(HH_MBI_*OQ_S%_JS3_P"?LO\
MR7_(]$_X3?4A#%-_PCK^7*-R'[4O(_*F_P#"=:A_T+K_ /@4O^%5F_Y VE_]
M<3_.J]=\L=)?91Y,,HYE?VKW\O\ (T?^$ZU#_H77_P# I?\ "C_A.M0_Z%U_
M_ I?\*SJ*GZ_+^5&G]C+_G[+\/\ (T?^$ZU#_H77_P# I?\ "C_A.M0_Z%U_
M_ I?\*SJ*/K\OY4']C+_ )^R_#_(T?\ A.M0_P"A=?\ \"E_PH_X3K4/^A=?
M_P "E_PK.HH^OR_E0?V,O^?LOP_R-Z'Q)KMQ$LL7A:1D;H?M:<_I3_[>\1?]
M"I)_X&)_A6KH1_XD\'T/\S6E7HPFI13L>+4P\XS:51Z>G^1S']O^(O\ H5)/
M_ Q*7^W_ !%_T*DG_@8G^%=-15<R[$>QJ?\ /Q_A_D<S_;_B+_H5)/\ P,3_
M  H_M_Q%_P!"I)_X&)_A7344<R[![&I_S\?X?Y',_P!O^(O^A4D_\#$_PH_M
M_P 1?]"I)_X&)_A7344<R[![&I_S\?X?Y',_V_XB_P"A4D_\#$_PH_M_Q%_T
M*DG_ (&)_A7344<R[![&I_S\?X?Y',_V_P"(O^A4D_\  Q/\*/[?\1?]"I)_
MX&)_A7344<R[![&I_P _'^'^1S/]O^(O^A4D_P# Q/\ "C^W_$7_ $*DG_@8
MG^%=-11S+L'L:G_/Q_A_D<S_ &_XB_Z%23_P,3_"C^W_ !%_T*DG_@8G^%=-
M11S+L'L:G_/Q_A_D<S_;_B+_ *%23_P,3_"C^W_$7_0J2?\ @8G^%=-11S+L
M'L:G_/Q_A_D<S_;_ (B_Z%23_P #$_PH_M_Q%_T*DG_@8G^%=-11S+L'L:G_
M #\?X?Y',_V_XB_Z%23_ ,#$_P */[?\1?\ 0J2?^!B?X5TU%',NP>QJ?\_'
M^'^1S/\ ;_B+_H5)/_ Q/\*/[?\ $7_0J2?^!B?X5TU%',NP>QJ?\_'^'^1S
M/]O^(O\ H5)/_ Q/\*/[?\1?]"I)_P"!B?X5TU%',NP>QJ?\_'^'^1S/]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHM%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]#?+]I^OZ!1117&>B%%%% !1110 4444 %%%% !1110 4444 =K;?\D_M/\
MK]?_ -!K,[5IVW_)/[3_ *_7_P#0:S.U:XG>/HC#!?#+_$PHHHKG.P**** "
MBBB@ HHHH **** "BBB@ HHHH [EO^0-I?\ UQ/\ZKU8;_D#:7_UQ/\ .J]>
MQ/=>A\W2V?J_S"BBBH-0HHHH **** .WT'_D#P?0_P S6C6=H/\ R!X/H?YF
MM&O<I_ CY6M_$EZBT445H9A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!0;6=,1BKZA:JRG!!F7(/YTG]MZ5_T$;3_O\ +_C5=_"^AR.SOI=JSL26
M)C')I/\ A$]!_P"@3:_]^Q5>Z<]Z_9?B6?[;TK_H(VG_ '^7_&C^V]*_Z"-I
M_P!_E_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=E^)9_MO2O^@C:?\
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M;7_OV*/^$3T#_H$VO_?L4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH_MO2O^@C:?\
M?Y?\:K?\(GH'_0)M?^_8H_X1/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H(VG_ '^7
M_&C^V]*_Z"-I_P!_E_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=E^)9
M_MO2O^@C:?\ ?Y?\:/[;TK_H(VG_ '^7_&JW_")Z!_T";7_OV*/^$3T#_H$V
MO_?L4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH_MO2O^@C:?\ ?Y?\:K?\(GH'_0)M
M?^_8H_X1/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H(VG_ '^7_&C^V]*_Z"-I_P!_
ME_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=E^)9_MO2O^@C:?\ ?Y?\
M:/[;TK_H(VG_ '^7_&JW_")Z!_T";7_OV*/^$3T#_H$VO_?L4>Z%\1V7XEG^
MV]*_Z"-I_P!_E_QH_MO2O^@C:?\ ?Y?\:K?\(GH'_0)M?^_8H_X1/0/^@3:_
M]^Q1[H7Q'9?B6?[;TK_H(VG_ '^7_&C^V]*_Z"-I_P!_E_QJM_PB>@?] FU_
M[]BC_A$] _Z!-K_W[%'NA?$=E^)9_MO2O^@C:?\ ?Y?\:/[;TK_H(VG_ '^7
M_&JW_")Z!_T";7_OV*/^$3T#_H$VO_?L4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH
M_MO2O^@C:?\ ?Y?\:K?\(GH'_0)M?^_8H_X1/0/^@3:_]^Q1[H7Q'9?B6?[;
MTK_H(VG_ '^7_&C^V]*_Z"-I_P!_E_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W
M[%'NA?$=E^)9_MO2O^@C:?\ ?Y?\:/[;TK_H(VG_ '^7_&JW_")Z!_T";7_O
MV*/^$3T#_H$VO_?L4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH_MO2O^@C:?\ ?Y?\
M:K?\(GH'_0)M?^_8H_X1/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H(VG_ '^7_&C^
MV]*_Z"-I_P!_E_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=E^)9_MO2
MO^@C:?\ ?Y?\:/[;TK_H(VG_ '^7_&JW_")Z!_T";7_OV*/^$3T#_H$VO_?L
M4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH_MO2O^@C:?\ ?Y?\:K?\(GH'_0)M?^_8
MH_X1/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H(VG_ '^7_&C^V]*_Z"-I_P!_E_QJ
MM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=E^)9_MO2O^@C:?\ ?Y?\:/[;
MTK_H(VG_ '^7_&JW_")Z!_T";7_OV*/^$3T#_H$VO_?L4>Z%\1V7XEG^V]*_
MZ"-I_P!_E_QH_MO2O^@C:?\ ?Y?\:K?\(GH'_0)M?^_8H_X1/0/^@3:_]^Q1
M[H7Q'9?B6?[;TK_H(VG_ '^7_&C^V]*_Z"-I_P!_E_QJM_PB>@?] FU_[]BC
M_A$] _Z!-K_W[%'NA?$=E^)9_MO2O^@C:?\ ?Y?\:/[;TK_H(VG_ '^7_&JW
M_")Z!_T";7_OV*/^$3T#_H$VO_?L4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH_MO2
MO^@C:?\ ?Y?\:K?\(GH'_0)M?^_8H_X1/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H
M(VG_ '^7_&C^V]*_Z"-I_P!_E_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'N
MA?$=E^)9_MO2O^@C:?\ ?Y?\:/[;TK_H(VG_ '^7_&JW_")Z!_T";7_OV*/^
M$3T#_H$VO_?L4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH_MO2O^@C:?\ ?Y?\:K?\
M(GH'_0)M?^_8H_X1/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H(VG_ '^7_&C^V]*_
MZ"-I_P!_E_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=E^)9_MO2O^@C
M:?\ ?Y?\:/[;TK_H(VG_ '^7_&JW_")Z!_T";7_OV*/^$3T#_H$VO_?L4>Z%
M\1V7XEG^V]*_Z"-I_P!_E_QH_MO2O^@C:?\ ?Y?\:K?\(GH'_0)M?^_8H_X1
M/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H(VG_ '^7_&C^V]*_Z"-I_P!_E_QJM_PB
M>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=E^)9_MO2O^@C:?\ ?Y?\:/[;TK_H
M(VG_ '^7_&JW_")Z!_T";7_OV*/^$3T#_H$VO_?L4>Z%\1V7XEG^V]*_Z"-I
M_P!_E_QH_MO2O^@C:?\ ?Y?\:K?\(GH'_0)M?^_8H_X1/0/^@3:_]^Q1[H7Q
M'9?B6?[;TK_H(VG_ '^7_&C^V]*_Z"-I_P!_E_QJM_PB>@?] FU_[]BC_A$]
M _Z!-K_W[%'NA?$=E^)9_MO2O^@C:?\ ?Y?\:/[;TK_H(VG_ '^7_&JW_")Z
M!_T";7_OV*/^$3T#_H$VO_?L4>Z%\1V7XEG^V]*_Z"-I_P!_E_QH_MO2O^@C
M:?\ ?Y?\:K?\(GH'_0)M?^_8H_X1/0/^@3:_]^Q1[H7Q'9?B6?[;TK_H(VG_
M '^7_&C^V]*_Z"-I_P!_E_QJM_PB>@?] FU_[]BC_A$] _Z!-K_W[%'NA?$=
ME^)9_MO2O^@E:?\ ?Y?\:5=9TQV"KJ%J6)P )ER3^=5?^$4T#_H$VO\ W[%*
MGA;0XW5TTNU5E(((C'!H]T$Z_5+\38[4UB%!). .]+T&*1E#J58 @C!![U)N
M43K>E@X.HVF?^NR_XT?VWI7_ $$;3_O\O^-5SX4T$DDZ3:Y/_3,4G_")Z!_T
M";7_ +]BJ]TPO7[+\2S_ &WI7_01M/\ O\O^-']MZ5_T$;3_ +_+_C5;_A$]
M _Z!-K_W[%'_  B>@?\ 0)M?^_8H]T+XCLOQ+/\ ;>E?]!&T_P"_R_XT?VWI
M7_01M/\ O\O^-5O^$3T#_H$VO_?L4?\ ")Z!_P! FU_[]BCW0OB.R_$L_P!M
MZ5_T$;3_ +_+_C1_;>E?]!&T_P"_R_XU6_X1/0/^@3:_]^Q1_P (GH'_ $";
M7_OV*/="^([+\2S_ &WI7_01M/\ O\O^-']MZ5_T$;3_ +_+_C5;_A$] _Z!
M-K_W[%'_  B>@?\ 0)M?^_8H]T+XCLOQ+/\ ;>E?]!&T_P"_R_XT?VWI7_01
MM/\ O\O^-5O^$3T#_H$VO_?L4?\ ")Z!_P! FU_[]BCW0OB.R_$L_P!MZ5_T
M$;3_ +_+_C1_;>E?]!&T_P"_R_XU6_X1/0/^@3:_]^Q1_P (GH'_ $";7_OV
M*/="^([+\2S_ &WI7_01M/\ O\O^-']MZ5_T$;3_ +_+_C5;_A$] _Z!-K_W
M[%'_  B>@?\ 0)M?^_8H]T+XCLOQ+/\ ;>E?]!&T_P"_R_XT?VWI7_01M/\
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M &WI7_01M/\ O\O^-']MZ5_T$;3_ +_+_C5;_A$] _Z!-K_W[%'_  B>@?\
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MIHK6[@FE\Z,[(Y QZ^@KPKR)O^>,G_?)KV_XF:+INE>#IKFQLH;><2Q@21H
M0":\3^VW/_/=_P Z\W%^RY];GM9<\7[)\JCOW8SR)O\ GE)_WR:/(F_YY2?]
M\FG_ &VY_P">[_G1]MN?^>[_ )UR_N?,[[X[M'[W_D,\B;_GE)_WR:/(F_YY
M2?\ ?)I_VVY_Y[O^='VVY_Y[O^='[GS"^.[1^]_Y#/(F_P">4G_?)H\B;_GE
M)_WR:?\ ;;G_ )[O^='VVY_Y[O\ G1^Y\POCNT?O?^0SR)O^>4G_ 'R:/(F_
MYY2?]\FG_;;G_GN_YT?;;G_GN_YT?N?,+X[M'[W_ )#/(F_YY2?]\FCR)O\
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MJ'_OX*/MEK_S]0_]_!47]DV'_/I%_P!\T?V38?\ /I%_WS1:CYA?&]H_>_\
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MT";7_OV*/="^([+\2S_;>E?]!&T_[_+_ (T?VWI7_01M/^_R_P"-5O\ A$]
M_P"@3:_]^Q1_PB>@?] FU_[]BCW0OB.R_$L_VWI7_01M/^_R_P"-']MZ5_T$
M;3_O\O\ C5;_ (1/0/\ H$VO_?L4?\(GH'_0)M?^_8H]T+XCLOQ+/]MZ5_T$
M;3_O\O\ C1_;>E?]!&T_[_+_ (U6_P"$3T#_ *!-K_W[%'_")Z!_T";7_OV*
M/="^([+\2S_;>E?]!&T_[_+_ (T?VWI7_01M/^_R_P"-5O\ A$] _P"@3:_]
M^Q1_PB>@?] FU_[]BCW0OB.R_$L_VWI7_01M/^_R_P"-']MZ5_T$;3_O\O\
MC5;_ (1/0/\ H$VO_?L4?\(GH'_0)M?^_8H]T+XCLOQ+/]MZ5_T$;3_O\O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_K]?_P!!K,[5IVW_ "3^T_Z_7_\ 0:S.U:XG>/HC#!?#+_$PHHHKG.P****
M"BBB@ HHHH **** "BBB@ HHHH [EO\ D#:7_P!<3_.J]6&_Y VE_P#7$_SJ
MO7L3W7H?-TMGZO\ ,****@U"BBB@ HHHH [?0?\ D#P?0_S-:-9V@_\ ('@^
MA_F:T:]RG\"/E:W\27J+1116AF%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '@'B3PAI_C;]H"_TG4IKJ* 6"2[K9E5\A4QRRD8Y]*]"\(_"/PQX-
MU$:C9)=7-XH(CFO) YCSUVA549]\9KKQI.G+JC:FNGVHU!DV-=B%?-*^F_&<
M<#BKU):*R!ZL\"T_PEHOB_XX>,+/6[,W,44:O&!*Z%6P@S\I'KWJ/PG%'\)O
MBF_A[4K:![#4CBQU)XE$JAN@+XS@G"D=,X/%>YP:1IMMJ$^H0:?:Q7LXQ-<1
MPJLD@_VF R>@ZTS4=#TG6?+&J:797WE9,?VJW279GKC<#BB.ED)J]SR[XZV$
MME;Z%XOLU_TG2KQ0Q']TD$9]MR@?\"I/@U#+X@UOQ+XZNHRK7]P8+<-U6,<D
M9]/N#_@->LWMA9ZC9M9WMI!<VKX#0SQAT;!R,J>*2PT^RTNT6UT^SM[2V7)6
M&WB6-!DY.%7BG'2XWK8\_N=%^*[>*9+BW\3:4FB&[WI;-&OF"#?G;GR>NWC[
MWXUQGACQ7IWPT\7>--/\1-+;M/<FXM2(F;SAER ,#N&7D\=:]]K/U#0M(U=X
MWU/2K*]>+[C7-NDA3Z;@<4K= ?F>=_ 73+FS\"S7EQ&4&H7;SQ CDI@*#^)4
MU2TK_DYW6_\ L&K_ .@0UZ^JJBA5 "@8  QBJB:1IL>J/JB:?:KJ$B['NQ"H
ME9>."^,D<#C/855_>N'1WZG ^)?'NA>$_B'#!K^@1VZR0;H=<\L2.1C[N F[
M&<C@GMQS7/\ PRDBU_XM>)_$^CPO'H<D8A5BFP2R':=P'OM8^OS#/6O7]0TK
M3M7MQ;ZE86M["#N\NYA61<^N&%2VEE:V%LEM96T-M @PL4*!%7Z <4HZ:A+7
M0L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNH7TUE'HF[9/<-)N828W-D\MCOUKA?!7_$EU/1]?'RPW>H76F7)[?,Y:,_\
M?0(_&A:L'L_D>I^,O'&E^!M-AO=4CN9%FD\M([959R<9)PQ' _K6Y+?P0:8^
MH2L4@2(S,3V4#)KQWXL_\3I/$,_WK?1;2*%/3SI'5F_$*%'XUT?Q(U>*T\&Z
M9H[WD5J=7DBMWEDD$82+@R-N/ XX_&E]F_6X^IU'A+QAIWC+3I;W3H[B)8I3
M$\=RH5U/7H">""#UJTGB"TD\42Z (Y_M<=NMP7('E[2<8!SG/'I7GNCZUH6C
M_%.&VT;5;"ZL-9M%C9;6Y201SQ# X4G&5_,BK&JZ1>:S\8I[>#5+K3[8:9&;
MA[1@DKC<<*'ZK]1S3[$WW/4:*X/PY<7^@^.;OPI=:G=ZC:/:K>6<UXV^9!G:
MRL_5AGIGFN\H'Y"T444 %%%% !1110 E<!-\5K,:A>V=IX6\4Z@;.=H)9;+3
MQ+'N7J 0_P#.N_->,>%/&7_".ZMXHMO^$;\1:IOU>9_-TRP\Y%Z<$[A@^U);
MAT/0/#7CG2_$UU/90P7UAJ$ #2V6H6YAF53T.WD$?0UT]>9:/%JOB3QY+XMF
MT:]T:PMM/:UA2]41SS,3DDH#E0/>L_P>=2C\$2>,=5U[5[N>T6=XK5KL^2RJ
M6"AU_B^IYI]+BZV/7:*\QL_#FO:GX77Q%-XMUB+6Y8?M,<<4X6U0XR(_*QM*
M]B3S44?BF_N%\'^*9+B6.UNV-C?VZR-Y6]ONMMSC.X8S1;6P'J=%>?:EKET?
M'6I7$=Q.-,T#3C)-"DC*DTS#< 0.#@#OZUQ%KXJTO4]$;6;_ .)%[9Z_(AFC
MM8;@I;P-U6,Q;=K#H#G)I#L>\45Y!?\ B?6?$>B>"+K3]2ET^YU"Y:*XDMSA
M6PN&.T\'N1D$9K6>VO\ PCXZT*T@U[5;^SU;S8YX=0N#-M95R&0D?+]!Q3MK
M8.ESLX/$-E=7.IV]MYLTVF\3HD9SNQG:OJ<5:TR^_M/38;S[+=6OFKN\FZCV
M2)[,O8UY9X>T467B'QO=Q:GJIDM6?8'O'(8F/.6&?F(['M4EMKNM7GA3P=H]
MIJ4\-[K /VB_9M\J(HRV"V?F/3/:E'7\ 9ZW17FVH0ZAX U?1[F'7=3U'3;^
MY6TNK?4KCSRK,/E=&/(YZCI5;2=.U3Q1XM\4VUUXCU>UTZUO-L4-G=&-@VT?
MQ=0H_NC ^M,#U*N>\5^+[3PA:VLUU97]XUS+Y44-C$))&;'H2,_A65\.M0U"
M>WU?3=0O9;UM,OWM8[B;'F.@Z;B.I]ZS/BS-=6S>&IK*S^V7*:B#';^8(_,.
M.FX\"D^@+J7(?BKIHNH8]3\/^)-'BE<1K<ZEIQBBW'H"P8XKK)]5$&I6=D+*
M\F%R&87$46Z&/']]L\9[5Y;XWU[Q9J7AQ[37O!4FCZ/)(@O+Z*^CO&BC# DA
M$P?Q[5TU[J+KXR\(PV%],=/FMI#M20A)0%&"PZ'\:8FSO.E**\RT2TU'X@B_
MUBZ\0:OI]HMS)!96VG7'D!%0XW/@?.21WX]JV_ .M:A?PZII>J3BYO=)NVM7
MN-H4S*.58CUQUH0WH=G1110 4444 %%%% !1110 4444 %%%% '.Z[XQTS0K
MN.Q9;J]U&5=T=C8PF:9E]<#@#W8BJ^E>.]/U'55TJZLM2TG4)!F*WU*W\HRC
M_8()5OSK$^'0%YXD\7:E/\UV=0,&2.4C4<+]*[/4M$T[5IK2:^M5FDM)/-@8
MD@QMZ@BDNC8C1JCJ^J0Z-I%UJ5PDC0VT9D=8P"Q ],D#]:\KU?QAINK>,M4L
M-:\776@Z?ISB&&WLYS!).^/F=G R1Z#BHK/Q3_:WA'QCHRZN=8M[&W+6U\WW
MWC8=&/<@]Z7V;E6L[,]/A\01W#Z8(;"_DCU"/S%F6'*0C&?WC9^4G\:V*\TM
M[V[@U?P);17,T<$UJWFQ+(0KX08R!P?QJ+73:1ZG?R>*_B#)IC;O]$LM,U'R
M#%'V+*!N9OKD51*U/4**\?TSQUJB?#">[CU#[7>_;_L%I>RIRP9L*[*<9('K
M72Q^#M>TV6ROM-\5:E=78D4WD6IW)>"9#][:@7Y#Z8Q0,[NJU]=QV%A<7DH9
MHX(VD8+U( SQ4.LW_P#96B7NH%=QMX&DV^I KSB+1-<U+P+<>([CQ'J3:G=6
MCS&V:3-JJ%3\GE 8Z=^N:E]1I:H[>S\50:A::/=6NG:C)!J@RCK"&$ QG,I!
M.T?G6_7D6DWMW;:9\-8(+J>&*<LLT:2%5D&SHP'4?6H-8UN'_A+]4L_%GB;7
M/#["7;IGV:1X+9H\<,652&.>NXXJY*S)6JN>R45Y3X@\6ZEH7@S1H+KQ!9FY
MU&?R6UBW(=%B')<<8W8]L9K*3Q?I&@:UI+Z%XWO=;CN;A8+NSO;@SDAN-Z$@
M%2#V''M26]AO:Y[717G/B3R!KES)XF\<G1K */L5G8ZA]FD(QRS\!F.>P)%9
M'AOQ/K5YX-\5)HVH7&L2Z;+Y>GW4J;II$(SDY W$<XR.:2 ]=HKQOPYJUG?7
M^GMH?CN_?5A(JWVG:Y<N!(#]Y5C9>&';94FL^+]-U3QGJFG:UXNN=!T_3F$4
M4%G.8))WQRS.!G ]!BF![#17G/PW\4C5-2U?1DUAM9MK(J]M?/R[1M_"QXW$
M'O7HM%A)BT444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH X3XN?\ (B3_ /7:/_T*OGVOH+XN?\B)/_UVC_\ 0J^?:\K&
M_P 0][*_X3]0HHHKC/2"BBB@ HHHH **** "BBB@ HHHH **** .W\+_ /(A
MZ_\ ]=X?ZUDUK>%_^1#U_P#Z[P_UK)K+%[Q]#?+]I^OZ!1117&>B%%%% !11
M10 4444 %%%% !1110 4444 =K;?\D_M/^OU_P#T&LSM6G;?\D_M/^OU_P#T
M&LSM6N)WCZ(PP7PR_P 3"BBBN<[ HHHH **** "BBB@ HHHH **** "BBB@#
MN6_Y VE_]<3_ #JO5AO^0-I?_7$_SJO7L3W7H?-TMGZO\PHHHJ#4**** "BB
MB@#M]!_Y \'T/\S6C6=H/_('@^A_F:T:]RG\"/E:W\27J+1116AF%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '+:QK%W+XNTKP[ILWDRNIO;Z7:&
M*6ZG 49!&7;C/8!N^*K^/];U'3=-L=/T2<0ZQJMY':VLA17\L9R[E6X("@_G
M5#PVS3?%_P :/-G=#!8Q0Y/1"C,<?\"K#U74]<U/XM2WFB>'_P"VK?P_;FV"
MM>);K'/*,NP+ Y.WY<"EV^\;T;.T\!:_/XB\)VUS>G_B8P,UM>J0 1/&=K<#
M@9QG'O7&>'/&VO2?%C4M(U2[$NC2W4]G9KY2+Y4L85P"P4$Y4GJ3TI?!NHZM
MI'Q.U/3]:T?^QX_$"?;;:W%TLZ^<@Q)AE Y8?,1[5C2VDK6'C?5K5=UYHWB,
M:C%[B,+O'XH6IW]Y/R_R%;2QVWQ4\3:GX=\,J-#F$6J7#L8G*JVR.-3)(V&!
M!^5<=.]1S>-KZP\!>&KA(EO_ !!K,,$=O&^$5Y60%G;;T4=3C].V+XBNHO%#
M>*=7A826.EZ ]O;MV,LT?F.1]$\L?B:IY%BGPDUBY.W3X;86TCM]U'EMU"$^
MF2*$NC\OU!VM=>9V!T#QX8?M'_";0"[^]]F&EQ_9L_W,_P"LQ_M;L^U;?A;4
M]2U;0H;C5]-?3[]6:.>!@0-RG&Y<_P )ZCZ]ZC\2_P#"7;;;_A%?[$W?-]H_
MM3S<=MNWR_\ @6<^U9GP\\2:OXCL=6_MN*Q2\T_49+)OL2N(VV!>1N)/4GT^
ME"#LR_XET?Q)J<UNVA>*O[$1%(E7^SX[GS#V.7/RXKC_  O-XRN/B%<Z?+XQ
M_M;2-+7%\_\ 9D, :9@<1*5R<C@D@\8Q7=^*M9'A[PKJ>K'!-K;M(@/0MCY1
M^)P*SOAYHAT/P98QS9:]N5^U7;M]YYI/F8G\\?A2CN#V.<^(/Q!U+25GLO#^
MGW+/;31)>:C)$!#!O9?E7=]]CN' Z9_+TH-\@)],UP_Q=_Y$"X_Z^;;_ -')
M4OQ%GU<Z';:?I>GW]S%>R>5>R6**TL4'\04,0-S=,YXYH^S_ %Y"^T96D^.-
M2UWXHQ6-J0GAQ[68P-M7-T\;!6D!QD+DD#'7&:Z/4-9N]'\::?;74N_2M50P
MPY4#R+A 6QGJ0ZYZYY7WK@H]>6V^)N@);>$]<M(+?3)+:.U:WC#A=Z@, )"-
M@QR<Y]JZ?XK$IX?TJ=!^^AUBU>+U#;\?R)H6R_KJ-]3OJ*1?NCZ4M, HHHH
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M;_Q'+?6_E)>:D\\!WJ=Z$#!X)Q]#S53XCZ7K5^FBW6B:9_:,]C>"=X//2'(
M_O.<?SKN:*36R#JV>9:O>_$3Q1I5QHO_  A=MHZ7:^7)>7&JQSA%/7"(,DXK
M2/A.\L?$/A/[)$9;'2[:2&:;>HVY  X)R<^PKNZ*?45CSK3K#Q5X(GO['2="
MCUK2YYWGM76\2!H"QR5</U&>Z_E6WX)\.7FAVE[<ZI+$^IZE<M=7(AR41CT4
M$]<#O7544(;U%HHHH **** "BBB@ HHHH **** "BBB@#@KS1->\->)KW6_#
M=E#J5KJ)#7>G/.(7$@XWHQ^7GN#4<NF^)_&.M:?+K&G+H>DV$HG^SBZ6::X<
M=,E/E51]<UZ!126@'G[:5XA\)^*-3U+1-*35]/U1Q++;+<I!+#*!@D%_E(/U
MS4D^G^+]9\*:^-62%+B]B*V>F1.C" 8Z-)@;F/UQ7>446NK!?6YP*^'=5&L>
M#YS:_N]/MV2Z;S%_=L5 Z9Y_#-9FAZ/XG\+:EJD4'A>TU.:[N7FCU=[R./AC
MP) 07X] #7J-% (\JTSP'KESX*U72-3\J#43J!O+:X#!HY'#;E. <A<\<X-:
MTA\<Z_\ 8M.N=,_L**&57NK^&_5S,%_AC5>0&[[L5W]%- ]2GJ.GQZEI=S82
MD^7/$T3'J<$8S7G7V7Q[I_A.?PK;:%:W12%H(-4^VJD;1XXRA^;=CCTSWKU&
MBE8$>9V?A76HK;P&DEGAM+9C>?O4_=97'KSSZ9K2OY?&5I>:A:3^'K?Q+IEP
MQ:W;[1##Y2G^"17 W#W&:[JBFW<25CRJU^&^K6/A/3S:O:1:U87SW\$ )\E-
MQYB!QTQQG'X5OPWOCK6-1LXWTB/P_9POONY9+F*Y:<?W$"@X'N<&NVHH&>90
M:-XB\.^,=9U"#PQ;:V-0E$L%\;N.)X!C&QM_S #K\N?I3O#WAWQCIZ>*I'DM
MK34]0N%N;:Y0K)"3CE<'+>V2*]+HI(&>6ZSI'B?QH-/L]3\)VFFS6\Z22ZJ]
MW%*0%.3Y84;OF]\5I-I/B'PGXHU'4M$TM-8L-3*R36PN5AEBE QN!?Y2#]<U
MZ!13 YWPP/$TSW=[XB,-N)F'V;3XBK_9U_VI !N8_E71T44 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <)\7/^1$
MG_Z[1_\ H5?/M?07Q<_Y$2?_ *[1_P#H5?/M>5C?XA[V5_PGZA1117&>D%%%
M% !1110 4444 %%%% !1110 4444 =OX7_Y$/7_^N\/]:R:UO"__ "(>O_\
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MXD\9Z+HR#=:Z9(-3O6QP&&1"GU)W-]%KMJ*%T&+1113 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH X3XN?\B)/_UVC_\ 0J^?:^@OBY_R(D__ %VC_P#0J^?:\K&_Q#WLK_A/
MU"BBBN,](**** "BBB@ HHHH **** "BBB@ HHHH [?PO_R(>O\ _7>'^M9-
M:WA?_D0]?_Z[P_UK)K+%_9]#?+]I^OZ!1117&>B%%%% !1110 4444 %%%%
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M1S>0>P?\S.6\SQM_SQT;_OJ2CS/&W_/'1O\ OJ2NIHHYO(/J[_F9RWF>-O\
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M;_OJ2NIHHYO(/J[_ )F<MYGC;_GCHW_?4E'F>-O^>.C?]]25U-%'-Y!]7?\
M,SEO,\;?\\=&_P"^I*/,\;?\\=&_[ZDKJ:*.;R#ZN_YF<MYGC;_GCHW_ 'U)
M1YGC;_GCHW_?4E=311S>0?5W_,SEO,\;?\\=&_[ZDH\SQM_SQT;_ +ZDKJ:*
M.;R#ZN_YF<MYGC;_ )XZ-_WU)1YGC;_GCHW_ 'U)74T4<WD'U=_S,Y;S/&W_
M #QT;_OJ2CS/&W_/'1O^^I*ZFBCF\@^KO^9G+>9XV_YXZ-_WU)1YGC;_ )XZ
M-_WU)74T4<WD'U=_S,Y;S/&W_/'1O^^I*/,\;?\ /'1O^^I*ZFBCF\@^KO\
MF9RWF>-O^>.C?]]24>9XV_YXZ-_WU)74T4<WD'U=_P S.6\SQM_SQT;_ +ZD
MH\SQM_SQT;_OJ2NIHHYO(/J[_F9RWF>-O^>.C?\ ?4E'F>-O^>.C?]]25U-%
M'-Y!]7?\S.6\SQM_SQT;_OJ2CS/&W_/'1O\ OJ2NIHHYO(/J[_F9RWF>-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:59IN6?56N%N6E((^5#*5QSW4].N3QD^(?#J7>H:HGBKX>:C-J<DC&UU'PS
MYBE'9G!<J&)Y)(SSTXYEC74]I\,:S<Z]X?MM0O-,N=,N9 1+:W*,K1L#@_>
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M2"BBB@ HHHH **** "BBB@ HHHH **** .W\+_\ (AZ__P!=X?ZUDUK>%_\
MD0]?_P"N\/\ 6LFLL7]GT-\OVGZ_H%%%%<9Z(4444 %%%% 'H'PG_P"0[>_]
M>W_LPKURO(_A/_R';W_KV_\ 9A7KE?29=_NZ^9\7G/\ O<OE^04445W'EA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <7:^ OLWQ1O/&G]I;OM-N(/L?D8V_*BYW[N?N>G>NSK+;Q%HJ.4?5K$,
M#@@W"Y!_.C_A)-#_ .@O8_\ @0G^-"B[6,W5A?=&I167_P ))H?_ $%[#_P(
M3_&C_A)-#_Z"]A_X$)_C3Y6'M8=T:E%9?_"2:'_T%[#_ ,"$_P :/^$DT/\
MZ"]A_P"!"?XT<K#VL.Z-2BLO_A)-#_Z"]A_X$)_C1_PDFA_]!>P_\"$_QHY6
M'M8=T:E%9?\ PDFA_P#07L/_  (3_&C_ (230_\ H+V'_@0G^-'*P]K#NC4H
MK+_X230_^@O8?^!"?XT?\))H?_07L/\ P(3_ !HY6'M8=T:E%9?_  DFA_\
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M%9?_  DFA_\ 07L/_ A/\:/^$DT/_H+V'_@0G^-'*P]K#NC4HK+_ .$DT/\
MZ"]A_P"!"?XT?\))H?\ T%[#_P "$_QHY6'M8=T:E%9?_"2:'_T%[#_P(3_&
MC_A)-#_Z"]A_X$)_C1RL/:P[HU**R_\ A)-#_P"@O8?^!"?XT?\ "2:'_P!!
M>P_\"$_QHY6'M8=T:E%9?_"2:'_T%[#_ ,"$_P :/^$DT/\ Z"]A_P"!"?XT
M<K#VL.Z-2BLO_A)-#_Z"]A_X$)_C1_PDFA_]!>P_\"$_QHY6'M8=T:E%9?\
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MT?\ "2:'_P!!>P_\"$_QHY6'M8=T:E%9?_"2:'_T%[#_ ,"$_P :/^$DT/\
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M'_@0G^-'_"2:'_T%[#_P(3_&CE8>UAW1J45E_P#"2:'_ -!>P_\  A/\:/\
MA)-#_P"@O8?^!"?XT<K#VL.Z-2BLO_A)-#_Z"]A_X$)_C1_PDFA_]!>P_P#
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MA_X$)_C1_P ))H?_ $%[#_P(3_&NWE9YGM:?=&I167_PDFA_]!>P_P# A/\
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M#_Z"]A_X$)_C1RL/:P[HU**R_P#A)-#_ .@O8?\ @0G^-'_"2:'_ -!>P_\
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M\J,O_A&M#_Z!%C_X#I_A1_PC6A_] BQ_\!T_PK4HHYF'L:?\J,O_ (1K0_\
MH$6/_@.G^%'_  C6A_\ 0(L?_ =/\*U**.9A[&G_ "HR_P#A&M#_ .@18_\
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MH?\ T"+'_P !T_PK4HHYF'L:?\J,O_A&M#_Z!%C_ . Z?X4?\(UH?_0(L?\
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MCF8>QI_RHR_^$:T/_H$6/_@.G^%'_"-:'_T"+'_P'3_"M2BCF8>QI_RHR_\
MA&M#_P"@18_^ Z?X4?\ "-:'_P! BQ_\!T_PK4HHYF'L:?\ *C+_ .$:T/\
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M#V-/^5&7_P (UH?_ $"+'_P'3_"C_A&M#_Z!%C_X#I_A6I11S,/8T_Y49?\
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M7_PC6A_] BQ_\!T_PH_X1K0_^@18_P#@.G^%:E%',P]C3_E1E_\ "-:'_P!
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M%%%% !1110 4444 %%%% !1110 4444 =OX7_P"1#U__ *[P_P!:R:UO"_\
MR(>O_P#7>'^M9-98O>/H;Y?M/U_0****XST0HHHH **** /0/A/_ ,AV]_Z]
MO_9A7KE>1_"?_D.WO_7M_P"S"O7*^DR[_=U\SXO.?][E\OR"BBBNX\L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"D-)TY=4;4UT^U&H,FQKL0KYI7TWXSC@<4E[I.FZE-;S7^GVEU);/O@>>%7
M:)N.5)'RG@=/2KU% %'4='TS6(5BU/3K2]B4[E2Y@64 ^H# TR+0M(@O8;R'
M2K*.Z@C\J*9+= \:?W58#(7D\>]:-% &=!H6D6PO%@TNRB%[G[4$MT'GYSG?
M@?-G)Z^II@\.Z(-+.E#1]/&G,VYK06J>43G.=F-N<\]*U**0&;<Z#H][80V%
MWI-C<6<  BMY;9&CCP,#:I&!@<<4B:!HR74=TFD6"W$47DQRBV0,D>"-H.,A
M>3QTYK3HI@4+'1M+TRUDM-/TVSM+:0DO#! L:,2,'*J,'BC3='TS1X7ATO3K
M2QB=MS):P+$K'U(4#)J_10!2U+2=.U> 0:GI]K>PJV]8[F%95#>H# \\FH=1
M\/:)JYB.IZ/I][Y(VQ_:;9)-@]!N!Q6G10!A6_@WPO:7$=Q;>&]'AGC8.DD=
MC$K(PZ$$+D&KFHZ#H^L-&VIZ58WK1_<-S;)*5^FX'%:-% $<44<$2Q11K'&H
MPJ*,!1Z 5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 (:X_5OA=X+US4&O[_ $&![ESEWCD>+<?4A& )
M]S78T4@,VST73-.TK^R[*RAMK':4\F%=HP>O3N<]>M59O"6A3^'$\/RV"OI<
M8 2!G<[<=,-G=GWSFMNB@#&L?"VCZ;>P7MK:LMS;VWV2.1YY'(BSG;\S'//<
M\^]+:^%]&L]&N=(@L@MA<ES-"9';=OSNY)R,Y['Z5L44>H&&_A+0Y/# \-FP
M']D! GV<2.. <CY@=W4>M6++P]I>GZK<ZI;6NV]N42.64R,Q*H,* "2!CVQ6
MI13N'D4=6TBQUS3)]-U*W%Q9SC;)&21D9SU!!'3M61>^ /#&HLKWFEB:18DA
M61II-ZHGW<-NR",]0<^]=-10!E:)X=TGPY9M:Z391VT3-N;!+,Y]68DEC[DU
MJT44 %%%% !1110 4444 (:X>]^$'@34+V:\NM"\R>9R\C_:YQN8]3@/BNYH
MI 8F@^%-"\,6KVVBZ;#9QO\ ?*9+-]6)+'\31;^%-%M?#\VA0V(73)M_F0&1
MVSN.6Y)SU/K6U138&++X4T6;P]%H+V(_LR(*$@$CC 4Y'S Y_6I-8\-:-X@L
M%LM6TZ&[MT^ZL@Y7Z-U!]P:UJ*0(Y?0/AUX2\,W?VO2-$@@N>TKL\K+]"Y)'
MX5U-%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "F.@=2IS@C!P2/Y4^B@#-T;0].T"Q^QZ9;"" NTA7>S99CDDEB2>:9
MJ?A_3-8N[*[OK7S;BQD\VVD$C(8VZ9^4C/T-:M% ',ZG\/\ PMK.I-J%_I$4
MMR^/,8.Z"3']]5(#_P# @:U-&T+3?#^FC3]+M5M[0,6$08L 2<GJ36C11TL!
MEZ-X>TKP]%/%I5FMM'/*9I K,=SGJ>2?RK*F^'/A*?4Y-0ET6)IY'WR#S'$;
MMZF/=L)^HKJ:6D!SX\%^'ETQ]-73@MF]P+DPK*X'F YR,'CGL./:KVJ:+I^M
M6\-O?V_G10RK-&N]EPZ_=.016C10!B:YX3T/Q((O[6T])WB_U<H=HY$^CH0P
M'MFIM/\ #FCZ7I#:39Z=;QV+ AX=NX/GKNSDMGU.:UJ* .4T_P"'/A/2M0CO
MK31HTGB),6^6218R>Z(S%5_ "M'7?"FB>)1$-6L$N&B.8Y [1NGT=2&'YUM4
M4P,'0_!^@>&[F6?1]-CM))D5)"C,=P'3()QGWZFM>ZM8+RVDMKJ%)H9 5>.1
M058>A%3T4/7<#FM(\!>&-"OQ>Z=I4<5PH(1VD>3RP>R!B0G_  '%17?P[\)W
MVJR:E<:/$]S*VZ7$CJDA]60-M;\0:ZJB@#GAX*\.K87-BNG*EK<S">6%)752
MXZ$ 'Y>G08%7]4T/3M:LH[/4+?SK>.1)43>RX93E3D$'BM&BD!C:[X5T3Q(D
M2ZM8)<&(YCD#,DB?1U(8?@:ETSPYI&C:8VFZ?I\,-H^=\>-V_/7<3DL?KFM6
MBF!R=I\-O"-CJ"7MOHD2S1MOC#2.T:-ZK&6**?H!6X-&L%UIM8$'^GM$(3+O
M;[F<XQG'Z5?HI <]K?@CPYXANTN]3TU9+I5VB:.5X7(]"R,"1[&M/2='T_0K
M!+'3+.*UMDY$<8P,^I/4GW-7Z*>P!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!PGQ<_Y$2?_ *[1_P#H5?/M?07Q<_Y$2?\ Z[1_
M^A5\^UY6-_B'O97_  GZA1117&>D%%%% !1110 4444 %%%% !1110 4444
M=OX7_P"1#U__ *[P_P!:R:UO"_\ R(>O_P#7>'^M9-98O[/H;Y?M/U_0****
MXST0HHHH **** /0/A/_ ,AV]_Z]O_9A7KE>1?"?_D.WO_7M_P"S"O7:^DR[
M_=U\SXO.?][E\OR"BBBNX\L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#FI=)\3-*YC\21HA8E5^Q(<#L,YIO\
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M^*O^AGC_ / %/\:/['\5?]#/'_X I_C7444<[#ZK'N_O9R_]C^*O^AGC_P#
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M^AGC_P# %/\ &C^Q_%7_ $,\?_@"G^-=111SL/JT>[^]G+_V/XJ_Z&>/_P
M4_QH_L?Q5_T,\?\ X I_C7444<[#ZK'N_O9R_P#8_BK_ *&>/_P!3_&C^Q_%
M7_0SQ_\ @"G^-=111SL/JT>[^]G+_P!C^*O^AGC_ / %/\:/['\5?]#/'_X
MI_C7444<[#ZK'N_O9R_]C^*O^AGC_P# %/\ &C^Q_%7_ $,\?_@"G^-=111S
ML/JT>[^]G+_V/XJ_Z&>/_P  4_QH_L?Q5_T,\?\ X I_C7444<[#ZK'N_O9R
M_P#8_BK_ *&>/_P!3_&C^Q_%7_0SQ_\ @"G^-=111SL/JL>[^]G+_P!C^*O^
MAGC_ / %/\:/['\5?]#/'_X I_C7444<[#ZK'N_O9R_]C^*O^AGC_P# %/\
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MK'N_O9R_]C^*O^AGC_\  %/\:/['\5?]#/'_ . *?XUU%%'.P^JQ[O[V<O\
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MK_H9X_\ P!3_ !H_L?Q5_P!#/'_X I_C73T4<[#ZK'N_O9S']C^*O^AGC_\
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M_%7_ $,\?_@"G^-=/11SL/JL>[^]G,?V/XJ_Z&>/_P  4_QH_L?Q5_T,\?\
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MK_A'?#=]J_V?[1]ECW^5OV;N0,9P<=?2J/\ PEA_M_1M+^Q?\A*U:X\SS?\
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MBB@ HHHH **** "BBB@ HHHH **** //+CQ_XDG\0ZGI>A^"O[533Y1')/\
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M5[*![:R@@DE::2-%1I6ZN0,9/UJS110)(****!A1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;_H%:M_X"'_&NCHH]WL'[[^;\#G/^$VMO^@5JW_@(?\ &C_A-K;_ *!6K?\
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M_H%:M_X"'_&C_A-K;_H%:M_X"'_&NCHH]WL'[[^;\#G/^$VMO^@5JW_@(?\
M&C_A-K;_ *!6K?\ @(?\:Z.BCW>P?OOYOP.<_P"$VMO^@5JW_@(?\:/^$VMO
M^@5JW_@(?\:Z.BCW>P?OOYOP.<_X3:V_Z!6K?^ A_P :/^$VMO\ H%:M_P"
MA_QKHZ*/=[!^^_F_ YS_ (3:V_Z!6K?^ A_QH_X3:V_Z!6K?^ A_QKHZ*/=[
M!^^_F_ YS_A-K;_H%:M_X"'_ !H_X3:V_P"@5JW_ ("'_&NCHH]WL'[[^;\#
MG/\ A-K;_H%:M_X"'_&C_A-K;_H%:M_X"'_&NCHH]WL'[[^;\#G/^$VMO^@5
MJW_@(?\ &C_A-K;_ *!6K?\ @(?\:Z.BCW>P?OOYOP.<_P"$VMO^@5JW_@(?
M\:/^$VMO^@5JW_@(?\:Z.BCW>P?OOYOP.<_X3:V_Z!6K?^ A_P :/^$VMO\
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M3:V_Z!6K?^ A_P :/^$VMO\ H%:M_P" A_QKHZ*/=["_??S?@<Y_PFUM_P!
MK5O_  $/^-'_  FUM_T"M6_\!#_C71T4>[V#]]_-^!SG_";6W_0*U;_P$/\
MC1_PFUM_T"M6_P# 0_XUT=%'N]@_??S?@<Y_PFUM_P! K5O_  $/^-'_  FU
MM_T"M6_\!#_C71T4>[V#]]_-^!SG_";6W_0*U;_P$/\ C1_PFUM_T"M6_P#
M0_XUT=%'N]@_??S?@<Y_PFUM_P! K5O_  $/^-'_  FUM_T"M6_\!#_C71T4
M>[V#]]_-^!SG_";6W_0*U;_P$/\ C1_PFUM_T"M6_P# 0_XUT=%'N]@_??S?
M@<Y_PFUM_P! K5O_  $/^-'_  FUM_T"M6_\!#_C71T4>[V#]]_-^!SG_";6
MW_0*U;_P$/\ C1_PFUM_T"M6_P# 0_XUT=%'N]@_??S?@<Y_PFUM_P! K5O_
M  $/^-'_  FUM_T"M6_\!#_C71T4>[V#]]_-^!SG_";6W_0*U;_P$/\ C1_P
MFUM_T"M6_P# 0_XUT=%'N]@_??S?@<Y_PFUM_P! K5O_  $/^-'_  FUM_T"
MM6_\!#_C71T4>[V#]]_-^!SG_";6W_0*U;_P$/\ C1_PFUM_T"M6_P# 0_XU
MT=%'N]@_??S?@<Y_PFUM_P! K5O_  $/^-'_  FUM_T"M6_\!#_C71T4>[V#
M]]_-^!SG_";6W_0*U;_P$/\ C1_PFUM_T"M6_P# 0_XUT=%'N]@_??S?@<Y_
MPFUM_P! K5O_  $/^-'_  FUM_T"M6_\!#_C71T4>[V#]]_-^!SG_";6W_0*
MU;_P$/\ C1_PFUM_T"M6_P# 0_XUT=%'N]@_??S?@<Y_PFUM_P! K5O_  $/
M^-'_  FUM_T"M6_\!#_C71T4>[V#]]_-^!SG_";6W_0*U;_P$/\ C1_PFUM_
MT"M6_P# 0_XUT=%'N]@_??S?@<Y_PFUM_P! K5O_  $/^-'_  FUM_T"M6_\
M!#_C71T4>[V#]]_-^!SG_";6W_0*U;_P$/\ C1_PFUM_T"M6_P# 0_XUT=%'
MN]@_??S?@>;^.]6/B3PQ+I]EIFI"=I$8>9;,!@')YYKRO_A$=<_Z!]Q_WZ;_
M  KZ<I#6-3#TZCNT=5'%XFC&T9?A_P $^9/^$1US_H'W'_?IO\*/^$1US_H'
MW'_?IO\ "OINBL_J5'L:_P!I8S^9?=_P3YD_X1'7/^@?<?\ ?IO\*/\ A$=<
M_P"@?<?]^F_PKZ;HH^I4>P?VEC/YE]W_  3YD_X1'7/^@?<?]^F_PH_X1'7/
M^@?<?]^F_P *^FZ*/J5'L']I8S^9?=_P3YD_X1'7/^@?<?\ ?IO\*/\ A$=<
M_P"@?<?]^F_PKZ;HH^I4>P?VEC/YE]W_  3YD_X1'7/^@?<?]^F_PH_X1'7/
M^@?<?]^F_P *^FZ*/J5'L']I8S^9?=_P3YD_X1'7/^@?<?\ ?IO\*/\ A$=<
M_P"@?<?]^F_PKZ;HH^I4>P?VEC/YE]W_  3YD_X1'7/^@?<?]^F_PH_X1'7/
M^@?<?]^F_P *^FZ*/J5'L']I8S^9?=_P3PC1-.O]/\+ZKITVGWGGW4D;1[8&
M(PN<Y-4/["U7_H'77_?EO\*^B#2?PU,\#0G:Z?WETLTQM*_+-:^7_!/GC^PM
M5_Z!UU_WY;_"C^PM5_Z!UU_WY;_"OH:BH_LW#]G]YK_;>/\ YU]W_!/GG^PM
M5_Z!UU_WY;_"C^PM5_Z!UU_WY;_"OH:BC^S</V?WA_;>/_G7W?\ !/GG^PM5
M_P"@==?]^6_PH_L+5?\ H'77_?EO\*^AJ*/[-P_9_>']MX_^=?=_P3R+P-+<
M>'-3N;F]TV_*20[%\NW8G.0?Z5W?_";6W_0*U;_P$/\ C71"@]JZZ-&G2CR1
M6AYV(Q&(Q$W4G)7]/^"<[_PFUM_T"M6_\!#_ (T?\)M;?] K5O\ P$/^-='1
M6GN]C'][_-^!SG_";6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[O8/W
MW\WX'.?\)M;?] K5O_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!SG_"
M;6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[O8/WW\WX'.?\)M;?] K5
MO_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!SG_";6W_ $"M6_\  0_X
MT?\ ";6W_0*U;_P$/^-='11[O8/WW\WX'.?\)M;?] K5O_ 0_P"-'_";6W_0
M*U;_ ,!#_C71T4>[V#]]_-^!SG_";6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$
M/^-='11[O8/WW\WX'.?\)M;?] K5O_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[
MV#]]_-^!SG_";6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[O8/WW\WX
M'.?\)M;?] K5O_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!SG_";6W_
M $"M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[O8/WW\WX'.?\)M;?] K5O_ 0
M_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!SG_";6W_ $"M6_\  0_XT?\
M";6W_0*U;_P$/^-='11[O8/WW\WX'.?\)M;?] K5O_ 0_P"-'_";6W_0*U;_
M ,!#_C71T4>[V#]]_-^!SG_";6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$/^-=
M'11[O8/WW\WX'.?\)M;?] K5O_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]
M_-^!SG_";6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[O8/WW\WX'.?\
M)M;?] K5O_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!SG_";6W_ $"M
M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[O8/WW\WX'.?\)M;?] K5O_ 0_P"-
M'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!SG_";6W_ $"M6_\  0_XT?\ ";6W
M_0*U;_P$/^-='11[O8/WW\WX'.?\)M;?] K5O_ 0_P"-'_";6W_0*U;_ ,!#
M_C71T4>[V#]]_-^!SG_";6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[
MO8/WW\WX'.?\)M;?] K5O_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!
MSG_";6W_ $"M6_\  0_XT?\ ";6W_0*U;_P$/^-='11[O8/WW\WX'.?\)M;?
M] K5O_ 0_P"-'_";6W_0*U;_ ,!#_C71T4>[V#]]_-^!SG_";6W_ $"M6_\
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+(]Z*=14Z'1J?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gmab-20210630xex991d85adb008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0A"$4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:Q"C)(
M]ZQK;Q7HMY>M:0WT33#MGK346]D)NQMT4F<TM(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K%\4:U'H6@7-X[8<+B/'=CTK:KQGXL:P
M;J\_LT2XBA(++[UT86C[6HD1.7*CS2<3:GJZ1*FZ:X?M[U],>&=#A\/Z'!81
M!<J,NP[FO'_A3H']I>(WU*9-T%L#LS_>[5[Q73F%:\E!=!4XV0M>1?&HM)%I
M\6[Y=V<5Z[7CWQEF07E@F>40M6&"5ZR'/2)U?PSCDB\,B)P=J-A<]Z[:N=\$
MLK^%;)U7&Y,GZUT51BG>M)^9-'X$%%%%8&H4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *:6"@DG '>G5S?C?5QHWA>[G#$2,N
MQ,>IJH1<Y**$W8\9^(>O+JGB6:>)BT47[N*O0/A!H8LM!DU*51Y]TW!_V17C
M]A8RZYJMO80@F25QSZ?6OIW2["/3-,M[*( +"@7BO3QLE3IJDC.FKN[+M%%%
M>4:D-Q*L%O)*WW44L?PKPSP#;+J?CB:>5<G<9/SKU3QYJ7]F>$+V8-M=EV*?
M<UYE\(8GN/$4\Q)VI'7I8/W:,Y^1A6ULCW+%%%%>:;A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>/?&#5]\]OIZMF.,;Y /7M7KLDBQ1-(_"J,FOFCQAJ,VHZG/<L=S3/
MA1Z"N_ 4N:3F^AE5=M#K?@OI"75]=ZI(,M#\B?C7MU<A\.=%_L;PC;*R[99A
MYC\5U]<^)GSU&7%604445@4>9?&/4/*T2VLU.3(^XCZ5#\'+'R]-N;LK@NV
M:X[XH:Q_;'BH6\!8QP'R@/\ :[XKV?PEI::3X<M+= !\@+8[DUZ=3]UA5%[L
MQ?O31NT445YAL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D <D"F":,]
M)%_.BS DHJ/SXC_RT7\Q3PRGHP-%F*XM%%% PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .0\4^/+/PU=K:R1-)*5W'!& /SK(\*^,8O&&O2126Q40#
M?&<\#]:XSXSP/!XBBFR0DT(_2J_P4O%3Q/- _66(XS[5Z,*=-4>9;V(=VSZ!
MHHHKSBPHHHH **** "BBB@ HHHH **** "HYI5AB>1ONJ,FI*YSQMJ0T[PU<
MODAW7:N/6KIP<YJ*ZDR=E<\'\4ZC+JNJR,"6:63:17T%X7TM-'\.V=FB@%(P
M6QW)KQ/P-X>?Q!XD25RIAMWWN#W_ $KZ$ P,"O1S&HM*:Z&=):7%HHHKRS8:
MSA$+L< #)-?-?C+5G\4>+)C%EDW^7$/6O8_B/KXT;PS(L<H6>X^11GG'>O,_
MAEH*ZQXE-U(/W-J-P]VKT<'%0@ZLC&;N[(]B\)Z1_8GAZUM"%WJN6*]S6[11
M7!.3E)R9K%65D%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!*\%^+/A@:=K*:G "(+G._'0-7O=9>NZ):Z_I<MC=*"K=#_ '3ZUM0J
M^SG?H3)7/ ?AMXL'A35VBN%W6MR0KD'[OO7T?'(DL:NC!D89!'>OE'6=&ET7
M6I;"Y4J8G(4GC(KU?X=>/'\Z#0-2ZXVPR_XUUXJAS+VD"8RZ,]:HI*6O.- H
MHHH **** "BBB@ HHHH Q?%5_P#V=X;O)\D,(R%QZU\]^'M+?7/$MI:M\^Z7
M+^PKUKXKZB(-&@M5?#ROR/:J7PET"**QEU>1,SR.40^@KU,._8X9S[F$_>E8
M].CC6*-40 *HP!3J6BO+-R.65(8VDD8*BC))[5\W^-O$4WB#Q([J3)$&,<"B
MO0OBIXR2RM#HUI*1-)_KF7^%?2N+^&GAIM>\0I>.G^B6C;F)_B->CAH*E!U9
M&4KMV/4OA[X5_P"$>T823@?:Y_FD]O:NTI.U+7!.;G+F9HE8****D84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !116?J^KV>BV+W=Y)LC7TZD^U-)MV0-V$UC6K+0[)KJ^EV(.
M@[L?:OGKQ-XOO_$VIEG,GV<'Y(5Z8_K2>*?%=]XQU@PJK&+.V&):]+\#_#6#
M3X$O-7B62X/*QGHOUKU*<(86///<R=Y&!X4^%CZHD5_JQ\J'JL(^\1[U[#8Z
M?:Z= (+2!(HQV48JR %  & *6O/JUYU7>1HE8****R&%%%% !1110 4444 %
M%%% !1110 4444 %)2T4 <SXC\%:7XCB;SX@DQ_Y:*.:\6\4?#S5/#4GFVX:
M>'LZ G'Z5]'TUD5AAE!'H1712Q,Z?FB7$^=/#GQ$UCP[,D%P7>V'6.3K7M.@
M^-=(U^,?9YPDG='(!K/\4?#K3/$1\Y56"?&,J, _6O(=5\%^(O#$_FQ)(4S_
M *R//^%==J&(79D^\MCZ1I:\+T/XNZC9ND&I1B9!P6(YKU31O&6C:X2MI<X<
M?POP:Y*F&J4_,I23.@HI/>EKG*"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ5]!UQ_P\\,?\([H0,J@75P=\GM785>*J<\[+9"@K(6BBBN8L**** "BBB@
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M=-ATK3HK2%0%1<<=S7>G]7I6^U(R^-EZBBBN U"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &,BR+M=%9?0C(KD=<^'&B:TV\Q^0^.L8KL:*J%24/A8FKG
M@^O?"#5+!?.TV9;E0?NC.ZN.6X\0>'9RK"XMW],&OJFJMSI]G>*1<VL4O^\@
M-=D,=):25R>1'BN@?%Z\LE6+4HS,O=OXA7H^E?$7P_JJX6Y,+^D@Q6!K_P '
M]/U&=IK"?[*S=4(^6N"UCX9:_HJ%X5-R!WBS6ML/6\F))K8^A(IXIT#Q.KH>
MZG-25\PZ=XNU_P /MY/G31X/*/V_.O1O#_Q@MY (=5C?=_?4#_&L:F!FE>.H
MU/N>LT5GZ;K6GZM%YEE<I*/0'D5?KC<7%V95[BT444AA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!YK\6-0$5E:V?.6R_P"5;?PWLQ:>#+3Y
M<-*3(WXFN"^+UPTFN01(V=L8!%>L>'8?L_AZQBP 1"M>A67)A8+N8QUG<U**
M**\\V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!*XGXC>)_[#T7R8'(N9_E&.JBN
MJU+4K?2;&2[NF*Q1C)QU->*:)8WWQ"\5SWEV<VL39P3P!Z"NK#4TW[26R,YN
M^B.L^%GAYK:WFU:Y&Z>8 *2.0*],J"UMHK.W2&)0JJ  !4]95JGM)N148V04
M445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F*6B@#G
M->\%:-XA&;RV D'1TX->6:U\&]2M5>;3KA)QGA>0:]VHK>GB:D-$R>5'RM%<
MZ[X1O0Q$]K,.Q[UZCX6^+]M=A8-8'ER$_P"L4<?C7H6M^'=-\06I@OK=7!Z,
M!\P_&O(O%?PANK,_:-$)FC(^9#U!KK56E7TGHQ6:V/:;/4+6_A$UK.DL9[J<
MU:KY<T3Q+K?A>Z=4:1"O6.3I^5>T>%OB7INNQB.Z86]QG&#T-8UL'*/O0U0*
M7<[NBD!!&0:6N,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I">*6JM_<K
M:6$\[YVHA)Q0E=V \2U<GQ%\0XX2-T+W 7CT%>YQ((HD11A5&!7C_P ,K87O
MBB]O)$W^6N58]B37L==^.E[RIKHC&DMV+1117 ;!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !368*I+' '4FE/')KR?XB^.G\XZ'I#L96.V5U_D#6E*DZDK(3=C/\::[>
M>+]=30]);?;*^"5_B->B^$O"=MX6T[R8OFG<9E<'@GVK*^'O@]=!L/M=RJM>
MS#)/]T>G-=Q6^(JJWLX;(F*ZL6BBBN0L**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y7Q-X%TKQ';L'B6&X_AE
M0<_C7@WB3PCJ_A&ZS,K&+/R2KT-?4=4=4TNVU:QEM+J)7CD4CYAG'TKHI8F<
M-.@FKGC'@3XIM8*ECJY>2%FP)"<E:]NM;N&]MDN+=P\3C(9>]?*?B_P_+X7U
MR6S=L@'*D>E>O_!C7VO=&DTR9\R0G<@/7;6E>G%KG0(]4HHHKC&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6,I_\^T#ION>,I\0O%:];8G_ +9&G?\ "S_$>W=]C &<?ZLU[)]F@_YXQ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** &NP1&8] ,FOG>V1M1^($7E#S%^U[SCL,U]
MWT@BL9Y",A4)KQ3X?Q+-X\W\+A&)45Z.!]VG.9C5ULCW2BBBO.-@HHHH ***
M;N'K0 ZDJ,W$*_>E0?5A4+:E8J,F[@'_ &T%-1;Z"NBU2UDR>)-(B;:U]"#_
M +U-/B?1@<?;X>?>K]C4_E8N>/<V**Y^3QIH4?6\'![ U)#XLTF;I.0,9RRX
MI_5ZO\K%SQ[FW17(3_$?18MWEB>7;W1*JS_$NSC3<EA<L,<9&*M82L_LCYX]
MSNJ*\T'Q+O+C)M=*) [-UIT?Q UF1-ZZ/Q]#5_4:W8GVL3TC%%>9)X]\0R1
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MJ7C:TMV$:<5L?(M[ILFE7KV]P'CD0X(85VWA"7PU>2);ZLK++GAMW%>K>,?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5P7PE\(I/<2:Q=Q<1G$(8=_6O::Z<7527LH;$0C=W8M%%%<!J%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*:?+'G;Y0'/M7=4O'#12ZF2UF;M%%%<)J%%%% !1110 4444 %%%% !1110
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M;FW.FL+&'3K..U@0+'&, "K5)2UYC=W=F@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/=E60F*6BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !11VI,CU% "T57DO((@=\@&WK6+<>(+S?LM=
M,F<^K\"KA2E+8ER2.BHKF8KCQ+/U@@BY[U(-*UJ4?O=5V?[@K3V*7Q20N?LC
M<DNH(CB25%/H6K,N?%&D6HR]T&_W!FHX_"UF)/,F>2<X_C:KL.B:=;C$=I&/
MJ,T6HK=MA[QA#QHUQ_QYZ5=2CU(P*QI[WQUJNY;:U%DG8G&:]#6*-!A$51[#
M%.IJM"/PP#E;W9YVO@?Q!>$/?ZXVX]0C'%:L?P\TS<K7,T\Y']]ZZ^BAXJKT
M=@Y$9-MX9TBT'[JS3\1FM*.WAB_U<2+]!4M%8RJ3ENRE%(3%+114C"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /,[HQW/Q<M5;!$:DX/J!Q7IE>3V4WVKXNYC7. V?:O6*[<8
MK."\D8TM;A1117$;!1110 4444 %%%% !1110 4444 %4-7TU=5L)+5W9%88
M.#5^BA.SN!XGK?P3FE$D]G>*')SLP<5Q2_#3Q3OV?V=)[9KZAI*Z%B9]1)6/
M!-'^"VK7 S?SQVP],Y->H^'/ &C>'XE*P+/<#_EM(,FNKHJ98B<E:X6$[4M%
M%8C"BBB@ HHHH *XGQS\/[?Q9 CPF*"\0Y\PC&[ZD"NVHJHR<7= ?(VJ:'JF
MA7C075K("IQDJ<'Z4S^TM7\ORQ+<;<<#GBOK2XLK6[&+BWBE'^VH-5_[#TO_
M *!]O_W[%=:Q?=$\J/G7P?X*U7Q3=;BICA4YDE?C^E?1&C:+9Z%IZ6=G&%11
MR>['U-78;>&W7;#$D:^BKBI:QK5Y5-.@[!1116 PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *:QPI)[#-.J*X<1V\CGH%)X^E"U8F>2^#)1<_$V]D/97
MKU^O*?AS9Q3>*-3OP?G4[=M>K5VX]_O;>1G2V"BBBN(U"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%59]1L[?/G7,28ZY8<5D
M77C+2+9MOF/*?^F2[JN-*<MD3S(Z"EKA)O&VI7?&E:/*X_O2"IY8_&&J1J-T
M5B!UP>3^E:_5I+XFD'-V.SS_ /JJK/J=E;-MFN8D/H6K"M?"UWC=?:M<2O\
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MVI:*R*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2[FEG9L;BS&MJVTNRLT"P6T:8]!5VDJ)5IRW92BD($4# 4#Z4ZBBLR@HHHH
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MX^O.3VJR/B[,W32Q_P!]4O[/K]A^UB>K45Y)_P +<N@W_'A%C/3=4C?&"1"
M=/3D_P!ZG_9]?L+VT3U>DKRT_%W'73E_[[I6^+P0 G3EP?\ ;H>7XA= ]K ]
M2HKRO_A<,?\ SXKS_M4\_%L%=RV2X]WH_L^OV!U8GJ-%>5_\+@&1_P 2XX_W
MJ4_%X9 &GCGI\U']GU^P>UB>IT5Y6GQ>!SNT\<=<-4__  MZU_Y\'_[[%)X"
MNN@_:Q/3**\SD^+4:A2M@,-ZO4+?%J1<9L8^N/OTUE^(["]M ]3HKRT?%Y2Q
M7^S^1VW5"?BW<@C.GI]=U"R^OV#VT3UBBO)3\7IP<?8(_P#OJG#XQ-WTY/\
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M<Y(YK76-8QM154>@%)U:,%[L;^H6D]SA7\*^(M4 .I:MM']V,G J]9_#O1X
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MXD>&MI87A;'8)7'#X/7GE$'4X]QZ_*:EC^#;*@#:F,]\+1[+!_S,+S['1/\
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MX-=S14?6*O<'%,8B+&@1%"J!@ =J?116)04444 %%%% !1110 4444 %%%%
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M.!=L4:H/11BI:SJ8N4O=AHBHP[D2P1( %C0 = !TJ6DQ2URMEA1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ]KFSUI\N#[L=YER3XL>'8QG,Y_X /\ &@_%CPZ!PTQ^BC_&L&?X,(Y;R]1
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JWE];V,!FN)
MB#UK,UWQ38Z%&#.2SGHJXKQ36_&&I:OJ!CMV>=V.%51POTKLH8.51<TM$92J
M=$=UXF^(\4"/# YB!Z8^\?UXKSJTTS6?%NH8MH'\ACR[9Q^==EX7^%TUZJ7^
MNR<M_P LN=WX^E>L6MC;6,(AM84B0=E&*WGB*5!<M)"47+<Y3PM\/-/\/_Z1
M,%N;P]7;D#Z5V8&    *6BO.G4E-WD:I6"BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 GK7D>MWXM_BA8OZ3!3^->N5X?K(%W\4K9%SQ<+G/M7?@5?G]#&
MKNCW&BBBN V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHYIHX(C+*X
M1%Y)8]*-P'Y %<5XK\=0Z+F"VVO-CECT6L+Q5\18E9[6UDV1=-XZM7+:+X>U
M+QQ?"2?=%:+U?'%>C1PT8+GK&,FY:1,R)=6\7W_V:V625F.6<]A[GM7L/A+P
M%IWAF .56>\(^:4C./I6WHVA6&AVB6]G"J!1@MCD_6M.L<1BY5-(Z(N-.,=A
M,4M%%<A84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z5X=*_VCXN
MPJG&+C!KW G KQ'1X1/\70X(P)F;%=V"TC-^1C4^)'M]%%%<)L%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4E&:Q-=\36>AP,9&W2]D!%5"$INT4*4E'5E[4M5
MM-*MC/=2;5].Y^E>,>*_B#>:G*UM;,4AS]Q>X]ZQO$7B;4/$>HK#$7E<]%3I
M7?>"_AFEDRW^L*LLV,K&>@^M>K"E3PL>:IJS%MS.=\(?#FZUF<7VJAH[8'A&
MZM^%>TV=E;Z?;+;VL2QQ(,!5%3JH10J@ #H!3J\^OB)5GKL;1C8****P&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2U*X%M:ESGGTKR#P
M'')?_$>:[528TWL6/O7J/B201::['H%)_2N'^$LP,NI0B/+;]WF?TKT*/NX:
M4EU,'K4/4Z***\\W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6N.\8>+[?1K1XTF
MEQR?2M*5*567+$B<E%79;\1>*[;2(657!D R3V%>*7.H:GXLU VMG&\K2'DC
M_/%):P:KXZU=;6 ,( >6.<*/<U[AX7\(V'ABS$=O&K3G[\I')KTY3IX2/+'5
MF:C*3O(S/"'P_L_#<8GG"3WQZR=0OTKM:**\J=24W>1LE8****D84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R7CF[6'3)$)(/E,:
MR/A':!/#]S=[?FFF/Y"G?$2X$<4FX940[2/<FMWP):+9^$+%05)=-Y*^IKT9
MKEPB\SGAK49TM%%%><= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 E';-%<9XO\4I81F".78O
M\;@_H*UHT959<L29245=C?%7C*WT^W:*"7##JPKR73-(U3QWJY";_)!YD;[J
MBKUOHFH>,=<\BW8BV3'F2'H*]NT+0K/P_IR6=F@"CJV.6->A6G##0]G#<RIQ
M;?-(C\/^'+'P[8);6D8R!\TA'S-]:V***\MMMW9N%%%%( HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#TH \M^)\Z;HH=V'E=5
M%>@Z%9_8-#L[4XS'$ <5Y3XV\W4]:T^VA.9))2R_G7L5K&T-M%&YRRJ 37H8
MOW:4(&%'JR:BBBO/-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "DS17)>,/$\>DVC11R8E/4CM6E*E
M*K/EB3.2BKL@\7>,8=+A\J&3YNC$8X^G->8Z=IVJ^/=9**VRT0Y+G. /3ZU4
MT_3K[QIJ9B3<P!Y;LH]<U[OX?T"T\/:8EG:H !]YN[&O3JRAA(<L-S**<W=D
MNCZ-::)9+;6D850.6[L?>M*BBO)<G)W9L%%%%(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %5-1G%OI\\I_A0X^M6ZY[Q;=
M"WTE8N<S2!.*THPYZBB3-VC<\ZTVX:Z^)5C$%#F'@^@KV6O)_AQ9I<^+M3O2
M0QA&%S[UZQ75CY)U%'L115HBT445PFH4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P/Q OUCGMXLG]U&\
MS8_2N]KQGQY=O=:E>F,DY9;>,>OK7;@(7JW[&-=^[8Z?X56030I]0(_>7,IS
MGT%>@5C>%]-.E>';.T8 .J9;;TR:V:YZ\^>HV:15D%%%%9%!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A(
MYKRKQ[XG\LEHCDJ-L*CU]37;^)]733=-D<2 ,!SS7D?AO2KCQSXF::X)6SA.
MX^GTKT<'",$ZLS"?OOE6QU/PP\,38.O:B-TTG^J##D>]>I5'%$D$2Q1J%11@
M*.U25Q5:KJ2YF;))*R"BBBLQA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%(2 ,F@#$\1Z@+.P$0.'F.W([#N:\9AM9O
M&'BR.P1QY"'GGA5'6NL^(&N 0RS1M\N?)C]_4UI?"_PW_9VEMJ4R?Z1<=,]0
M*]:%L/0YNK.=OGD=[:6L5G:QV\*A8XUPH':IZ**\EN[N="5@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *XWXAZBUMH\=I&Q#7#X;']WO795XWX\UEKO5K@H"4MQY4>>['K79@:7/53>
MR,ZLK1)?A[9'5?$LVHR(&BMUQ&3V->O5RW@'1VTGPQ LBA99?G>NJJ<95]I5
M=MD%*-HA1117*:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** $)P*\3^(&K_:$,:,3+<RX ']T=*]=UB\%EIDTQSD+A<=S7CTU@NN_$
M"TL(E_=P8+D]NYKTL#'E4JC.>J[R43U7PII0T?P[9VH^\$#,?4FMRD "@ <
M# I:\Z4G)MLW2LK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 )534K^/3K":ZE.%C7-6Z\Q^)>N&26+1
M8&(_Y:3$=O2M\-1=6HHD5)<JN<3-%=:U=Q1 [KB_DW/GLM>\Z;8QZ;I\-I$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7&?$PX\)2_P"^M=G7'?$K
M'_")39_O"NC"_P :/J95O@9R_P (4_TN_DX^9!7K->6_")E=M1VC&T(*]2J\
M=K795/X4%%%%<A84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 )7*>,/&$/AVU\N,A[MQE4]/K6CXE\0VWAW2WNIF_>8Q&G=C7
MA$5Y?>+-1=6#/=2M\GL*[L'AE4?//9&-2IRK0DT^RU'Q+KA7=YDTS;G)[#WK
MWO1-'M]$TZ.TMU "CD^IK.\*^%8/#MIR$>Z<?O)!_2NCIXS%>U:A#X4*E3^U
M+<6BBBN W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** $KBOB>&_P"$29A_#(N:[45RWQ!MS<>$
M+L<?+AN:WPSM6CZF=57@SD_@^0LNHH>I537JU>/?"28+K5[#S\T0QBO8:UQZ
MM784G>(4445QF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 E4M4U6TT>R>[O)-D2_F:FN[N&RMWGG<)&@R237@7C#Q1=^);W<C,+4
M<1Q#^==6%PSK2\C.<^70C\1>(+CQ1K+M*KB)>(8Q_A7IW@/P:-%B^W7:+]J8
M84?W165X#\#%'35M2CQ( /+B/;'K7I]=.+Q*4?94]B*=/6[%HHHKS#<****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(>E+10!X5J4+:-\0B<C F#C9Z&O
M<D<.@8=",UX_\2;%K7Q)!=CCS@!QVQ7IOA^]2\TBW<-EB@S7J8Y<]&%3R.:A
MHW$UJ***\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS3'D2*,O(P
M11U)/2@!V:YCQ/XMM]&@,<+J]T>B]<?6L37_ !Z"S6^EM\G1K@]!]*XVQT34
MO$]TQM2=A^_/)G]*]+#X))>TK:(PG5Z1*S3ZGXDO)4=I+F=^%QT%>D^%_A]8
MZ*$N;L+<WP'+GE1]*V/#OABS\/6HCA4/*1\\AZFMRIQ6,YO<I:1"G2>\@Q@<
M4M%%>>;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P?Q-TYKG18[
MI5!:!\D]\5#\-]166TDMB<M&>"?2NVU.R74=.GM7 (D4CFO$M/U/_A&]?$:N
M54-AQ7KX7]_AI4NJ..K[D^8]YI*IZ;J5OJMDEU;,3&W3/45=KR6G%V9UIIJZ
M"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BD) &2<"N9U7QII]@3'"?/E'4+T'
MU-73I3J.T%<ER2W-Z\O8+&W:>X<(B]:\Q\5>+WO"L"%E@)_U0^](*RK[7-4U
M^YE@@#3RM]U%^ZM=;X6\ M9RB]UAUGN!]U.H7\Z]2%&GA%SU=9=CG<I5'[NQ
MB>'_  5=:Q(MS? V]FIXBZ%OK7J-I96]C L-O$L:#H ,58  &!P/:EK@Q&)G
M6?O;&T*:CL%%%%<YH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 E>+?$G0/L.L"_C4>7<<G'8U[36!XPT3^V]"E@5094^=,^M=>"K^RJIO9
MF5:',CG/AI>@Z>\+2@@G(0]0:]"'-?.^C:C<:+J8C+E"3A@>U>]Z9>17EE')
M%('&.3GO71F6'Y9^U6S,<//[#+U%%%>8=84444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'-,[V?XH^'(>DDTG^ZG_ ->LFX^,6G)'^XLI7?W/%8]O\)M2*$2SP@GKS_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%,WCS-G.>M #Z*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *3:,Y[TM% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gmab-20210630xex991d85adb009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X HD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXNS*3N%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'S;.)S@8&2@K:IK&+)6[-6BBBL2@HHHH **** "BBB@ HHHH **** "BBB@
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M  P *6HE-R>I2BEL5[YF33[ED.'6)BI]\&OGWX%'_BM9]PR?LDGX$LIS_/\
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M2/'<?@O1E-N(Y=3N25@B8YVC!S(PSG:.GU--)MV0$7Q#^(MMX,MDMH4$^J7
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M HHHH **** "BBB@ HHHH ***PO&.OIX8\)ZAJI*>9%$1"K'&^0\*/?DC]:
M/#/BGK$_BKXA+IFG.TL=EBUAC#$!IB?F/7&<D+GCI7O/AG0X/#^@6EA#&$9(
MU\T]2SX^8D_7->-_!GPTFI>()M>NCYOV+[A8\F9QDDCO@$_B?:O>ZUJ.UHKH
M1%?:"BBBLBPHHHH ***1F"*68@*!DDG@"@!DTT=O!)/-(L<4:EW=C@*H&22?
M2OESQ5K-]\5/B#%#IL>(6;[)8J<_<R29&]"1ECZ  <XS73?%;XG?VV9?#>@2
M[['.VZN$&?/(_@0]=N>IQSC@XZ]-\&? ;Z/9?\)'J&1=W<>+>(J1Y4?J<]SC
MZ8Y[\;17)'F>_0A^\[=#T+POX<LO"OA^VTJR0*L:@R-WD? #,?<XK9HHK$L*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KG?&7BZQ\':(][='?.^5MK<9S-)C@<=!ZFM36-5MM#T>[U
M.[;;!;1-(W/)P,X'N>E?,FOZ_K7Q(\46C);H)I/W-K:Q9(C0MG+-W//+8'3H
M*N$.;T)E*Q:\/:1JOQ&\<2SWCDO*WFW4RGB&/IM4'MV KZ4TW3;32-.@L+&$
M0VT"[40=N_YDY-9?A'PM:>$M$2PM_GE/S33$<R-_AZ5OT3ES/R"*L%%%%04%
M>>_%'X@-X.TV.WT\P2:I<?P.<F./GY\#WX&??TK7^('C&'P;X<DN_E>]F_=6
ML1;&YSW^@ZFOEO4;R]U;43=7]PT]S<,7DE(SR3G&.PK:C2YW=[&=2?*M-SN?
M@]H8USQ=%<7 <+9DW;D+PS@C:,]N3G\/QKZ6KSSX1>&O[&\,G4)HMMU?D,#G
M_ED!\H_4FO0Z567-(J"L@HHHK(H**** "BH[BXAM+:6XN)4BAB4O)(YPJJ!D
MDGTKAM+^*VD:UXGM]'TZWGD69RJW#853@$Y Z]NXIV8'>T45GZWK-GX?T:ZU
M2^DV6]LA=N0"WHHS@9)P![FD!C^./&VG^"=&-U<D274N5MK8'!E;^BCN?\17
MA?A_P]X@^*GB=]0U"67[#OS-<$G;&A+?)&#^7'U/OCZIJ.J_$7QCYWEM)<W<
MGDVT(/$4>3A?H!R3CU-?37A70(?#/ARTTN+86B0>:ZJ%WOW)Q^6?:NC^%'S?
MX&:?,_(N:3H]AH>GI8Z=;);P+SM08R>Y/J3CK5ZBJFIZG9Z/IL^H7\Z06L"[
MGD<X ]OJ3P!W)KG-!]]?6NF6,U[>SI!;0KODD<X"BOG;QAXRU3XEZ]'HNC12
MKIID"10<@SMG[[XZ 'GG@8R?9FN^(-?^+WB5--T>VFCTR-CY:'@*.[RG[N>#
MC/T'4U[/X'\!Z=X,T\+$!-?R#]]<'DG_ &5]A^OZ5NDJ6KW(UEML6?!/A"U\
M&Z!'80$23MA[B;'^L?\ P';VKI***Q;;=V6%%%%( HHHH **** "BBB@ HHH
MH **** "BBB@ KP;XW:])?\ B"T\.PX\FS43R@#)>5Q\H_!3_P"/?2O=+FXB
ML[2:YG<)#"C2.QZ*H&2?R%?-_A"W7QQ\4OMEXF(KFY>]DCZ?*O*CW_A''O6E
M-;R?0F?8]M^'WAYO#7@ZSLYE NG'G3X_OMV_ 8'X5U%%%9MW*"BBB@ HJKJ&
MHV6E6;W=_=0VUNGWI)7"CZ<]_:O(_%'QQ1&FL_#MFS94A=0N. IZ96/'/MNQ
MSV-5&+EL)M+<]6UC7-,T"R-YJM]#:09P&D;&XX)PHZL< \#)KYY\>_%/4/&,
MG]EZ1%/9Z;SN4-B6?CG?@X"XSQGZGM4&B^$?%/Q#OEO99KAXB?FOK_=MVD\^
M7V/L ,?SKW#PA\.]"\(0(UM;K<7^/WE[,N78]\?W1[#\<]:T]V'FR=9>1Q/P
MR^$KZ9-%K?B.*,W(P]O9GGRFR"'8YQN]N<9Z]J]CHHK*4G)W925E9!1112&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !39)$BC:21U1%&69C@ 4ZO%/C%X_D2>3PMI5P%5DQ?S(<XSG]UGM
MD8S]<548N3LA-V5V<Y\0/'EWXWU+^Q]+RNE)<"*-0W-T^<!CV"Y(P#Z UZI\
M/?AU:>#[075QMN-7F3]Y*1Q$#U1/;W[^U<K\(/ L'V>+Q/?PR+,#MLHVX 4#
M&\COG)Q7LE5.7V5L3%=6%%%%9EA2$A02>@YI:X7XN>(W\.^ KIX'9+F\86L3
M*<%2V23_ -\@TTKNP'@?C+Q%/XW\:W-Z2WV9'\BT3/"Q@\'\>I^M5]%T>36O
M%D.F69W@N(]Z\CJ,GZ9KGE=HE"(3N8=0:^B/@SX'32-)CU^\1_MEU'^Y5P/D
MC/1A_O#'X5VSDJ<+(YXQYW=GJ5M +:UA@4Y$:! ?7 Q4M%%<)T!1110 445Y
MQ\7_ !O+X7T!+'3Y2FIWY*HZ]8HQ]YNGX#ZY'2FDV[(&['%?&7XAPZHC^%M'
M=I$28?:YT;AV4D>4!W^;'/J*V/@Y\/&L8E\1ZQ"1=,!]DA;(\L<Y8CN3QC/3
M&>N*Q/@UX#.I7:^)-6MV-O V;19%/[QP?OY[@$'\<5[_ %I-\JY$2E?4*^=_
MB]XS3Q%J_P#8EC)FPTV0F9B.))@"#CUQDC\S7KWQ#\2Q^%_!M]>;P+F5#!;*
M3@F1N!CZ#)_"OG3PA9)?^*M/%ZZK:13QS7<TC[1@,.K'UX_7I3I1^T^A,WT/
M9_A'X%AT728M>O(O^)C>Q!D5U&84.<8]"P(S^5>FLP52S$!0,DGM7GWB;XQ>
M%_#T6VUG_M2<@A4LW4H#V#/G _ 'Z5Y5?>*?'GQ/NVL-/@E2R+$&&SRL84]!
M))GGCU('M2Y)3?,RKI:(],\8?&31-"CEM=(==3U#;\OE<PH3TW-W]<+GICBO
M,[+2/%_Q9U.2^NI'6V#K\[,4@B&/^6:G/8=N<G)ZYKM/"'P+M+$07/B*X6YF
M1MQM(.8CZ!B1EA[<?C7KUM;06=M';6T*0P1J%2.-0JJ/0 4^>,/@W[BLWN8_
MA7PGIGA'2A8Z=&<D[I9GQOE;U)'Y5NT45BW<L**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#SWXRZQ)IG@.2VBVE]1E%J<\G802V/P7'XUB_ O0D
MM]&O=:9W,D\AMT4CA53J?J23^5<Q\=]9;_A,--L.7BM;,RE ?XW8C\\*M7O!
MOQ>T7PSX-T[2YK#4)KJ)79RBH%):1FX);W]*V47[/3J1=<Q[K2$A5+,0 !DD
M]J\&O/CKK]_($T/0($(SN5]]PW8 X7;C]>H_&HFG?%+X@1^7?23V^GN^3YH%
MM'@=]N S?KVJ?9/KH/F70]DU[QQX>\-Q*VH:C&';(2&']X['_=7./J<"O*-5
M^.6K7DIBT;3;>RC<E(Y+D^;(V> =H( .?J/K6GI/P"M8B&U;7)IA@?NK6(1X
M/?YFW9'X UZ)HW@;PSH!5M.T:UCE4@B9U\R3(.<[FR>H!ZT)PCYCU/%+7X8^
M./%EXVH:LWD-(P;S-1E._G&2J#.,#'!V],5Z5X9^$/A[0_+N+Y#JM\N&\RX'
M[M6_V8^GYY->A44G4D]!**W"BBBH*"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@O+N#3[*>\NI%
MCMX(VDD=NBJ!DF@#F?B'XQC\&^&GNE"O>W!,5K&6QE\'YOH.OY>M>)?#WP3<
M^.M8GO-0ED^QI.9;N?!S,Y.XJI'0G.3Z U5N]2U?XJ>-X8E8#SG,=HA7"P0@
MELGU..I[U](>'-$M_#GA^STJW"[;>,!F QO?JS'W)R?QK5^Y&W5D6YF:2(L<
M:QQJJ(H 55&  .P%.HHK(L**** "O)/V@;"YNO!EE<PQ&2.WO 9<9RH92 ?3
M&<#GUKUNFR1I+&T<B*Z,,,K#((]"*<79W ^:O@_X!/B'6/[4U&%6TZR<%D=3
MB63&57T('4C/ID8//TO3(H8X(Q'#&D:#HJ* !WZ"O-OBC\2KKP;):V.E1127
M\GSN)X69 G.,889.1TJFY5)"244>F45\V_\ "^_%Z'?)9:6%/'-M( "/?S*>
MO[0GB0]=/TD_2.3_ .+JO8S#F1]'T5\Y']H#Q/U73-+V]/\ 5R<G_ONHO^&@
M?%!7BPTG.>OE/C'_ 'W1[&8N='T%KFL6F@:)=ZK?2K';VT>]F/<] /J20![F
MOG'0+74/BS\1A<:FZB( 33*#@)"IQL48Z\@<_6L'Q=\1?$WC"-8=1N(XK-6S
M]FMD*(>GWN26QCOTJKHFB>+;J(G1;#5"LP$;R01NJLI/0MP,?6M(T^17>XG*
M^Q]97>MZ'HD,<=WJ5A91@!8TEG2,8'& "?;]*X;6_CGX4TN22&R%SJ<RY \A
M0L>1_MMV]P#7G5E\!O%-ZP:^NK*U!(+%Y"[8/7[HZC]?6D^(/PPT?P'X5@O5
MO[FZU">X6%%8*JGY6+'')P,#OW]ZB,:=[-W&VS#\<?$*[\=ZC;SS6BV=C:1M
MLMA(9#O/5BV!DG [<8^M)X:^''BCQ9"MQ:6?V>TDQ_I%RQ2,CCD#&6X[@$5/
M\./"">+O$$%E-&R6,">==L#RPS]T>F21^&:^IHHTAB2*) D:*%55&  .@%:5
M*B@N6!$8WU9Y1X>^!&CZ?MEUF]FU&4'/EH/*C_'J3^8^E>HV.GV>EVB6EC;1
M6UN@PL<2!5'X"K-%<TI.6YHDEL%%%%(845CZAXL\/:5.(+_6["WF_P"><EPH
M8<XY&<CD$?@:U8I8YXDEB=9(W 974Y# ]"#0 ^BBL#Q1XRT3PA8FYU6[5&P"
MENA!EDYQ\JYY^OM0E<#?HKD/"GQ&T3Q;<FTM#+!=8+)#, "ZCN,9'X=:Z^FT
MT[, HHHI %%%% !1110 4444 %%%% !116=KVI?V/X>U+4]N_P"QVLL^W.-V
MU2V/TH ^>-;*>,OC1/$B)+')?I:@,=RF.,A6/TPK'%>ZKX \(I)YB^'=.#9!
MX@'4>U>(?!2R&I>.A<RJ&2VBDN,[,CS"0 ,]CAB?P->ZZ_J.O:=+%-IFD0W]
MFB%[@>>5F..T:XP3CGKSTXK6J[-1[$0UU-6VL+.S+&UM(("WWO*C"Y^N*L52
MTO5+36+%+NSDWQMU!X9#W5AV(]*NUD6%%%% !117,^*_'F@^#XU&IW8%RZ[H
M[:,%I&'K@=!GN:$K@3ZKXTT'0M5?3]5ODLY%MOM6^8[49<D84_Q-Q]T<U-X?
M\6:%XIADDT74HKL1D;U *NN>A*L 0/?'KZ5\M^*/%&O?$K7+>Y-@\@0&*VM[
M6-FQDY(XR2W]!7KOP6\":QX<GO=6U>'[*UQ'Y,=NX_>8R"6/ITK65-1C=O42
M=SV"BBBLAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5XQ\;_%;JMMX7L+MD:8%[]$!!\O VJ3CH<GIUQ7K.
MLZK;:'HUWJEXQ%O:Q&1]HY..P]STKYBTRWO_ (B>.=]R7$NHW&^6106$48&0
M/8!0!6E.*;N]D3-NUD>H_!'P\+;3KW7);=D:X80V[.,$QJ!DCV)_E7K55M.L
M+?2].M["T39;V\8CC7V Q^=6:B4N9W8TK:!1112&%%4]3U;3]%LFO-3O8+2W
M7@R3.%&?09ZGV'-1Z/K>FZ_9?;-+NEN(-Q7<H(Y!QT(!H T**** "LR^\/:3
MJ>I6NH7MC%/=VN/)E?.4P<C'X\UIT4 ,DBCE0I(BNAZJPR#5.70])N#F;2[*
M0]<O;H?YBK]% &7'X;T**<3QZ+IR3*<B1;5 PZ]\>Y_.LKQG<:+X=\(WE_=Z
M=9O'"F(8F@!5I"?D&,?WL5U->#_'G7S<ZGIGAJW&YHR+F3']\Y"+UQTR?RJX
M+FE83=E<P?A)X/?Q-XC&HW\&=/L6\QL$J'ESE5![X/)&>./6OI:N8\ ^&4\+
M>$K6R\L+<R 37)&>9"!GKSQ@#\*Z>BI/FE<$K!7SG\=M6EO/&5MI1DQ;V4"N
M%!_C?DD_AMKZ,KX_\<WAU3X@ZY<8&3>O&N!@$)\@/XA:NBKSU)J/30]_^#FA
MII/@2"Y*XN+]VG<E<':#M4?3 S_P(UZ#5+1[./3]%L;*+.R"W2-<J%) 4#H.
ME<?XY^+&A^# UJI_M#5>,6D+X"<_QOR%Z=.3TXQS6;O*19TOB;Q-IGA/1I=2
MU.8)&O$<8Y>9^R(.Y/Z=3@ FO*/#7QNU#5?%$=O=Z?"MC=3I#%%&?GBW' )8
M\-U&>!WKS.6X\4?%/Q0"Q>[O&!$<*';'!&"/P51D9/4GU.*I:GI6M>"/$26U
M_');7D+K+%(A.U\<AE;'//IZ5O"E&UF]3-R?R/LBN3^)FKW6B?#O6;ZR++<"
M$1HZD@Q[V";@1T(#$CW KQ^#X_\ B*&%4GL--GD'&X(Z9]R-QY^E8?B;XP^(
M_$^C7&DW4&G06DX D\F%MQ .<9+''0=JA49WU*YT<1!%<7,@2%"\TG.,_,Q[
M\]Z]2^&7Q(?PO-+IFKS2OII)"H1EK=^YY/"\'('<Y]<^21W4L9!1R"O(8'E?
MQIQ$TTQ8L2[Y+$GJ:ZYP4E8RB['MWC;XYO/ UEX41X=V1)>SQC./^F8SQ]3Z
M\ <&O%[^_O-0E-U>W%Q=3M\IFG9G)]MQST],UZ_\-/@_!K>GV^N>(=_V64![
M>U1BID&>2_'"D#C')!SD<5T'QK\*6\'@6TFT?3(88;&Z5YEMX@NV,JRYX[9*
M_GGM6,9P@^6/WEM-K4Y'X(W%E9>)[R^O[N&"&*Q8!YG"A263N>G&:UM7^.NI
MR:U+'I%K9QZ?$Q"&9&=YL=SR,9] #CU->,PK/<.L$$;O)(PC2-%)+,>  !R2
M<@# [U:U71]5\/SP)JEG/:/*GF1"12"1^/IWJITXN=WU)4G:R/L70]3&M:%8
MZF(FB%U DH1NJY&<5H5\_P#@GXVVF@^';?2]7L;F?[-^[BFM\$E.P8$CD=..
MW;CG6OOVB+! /[/T&XEXZSSK'@YZ84-V[_I7,Z4KV2->9'M5%?,&L_''Q9J;
ML+62#38=VY!!'EL>A9LY^N!GVKT/X6?%&X\0W,VFZ_=6:3A \$C.(S)ZJ!_$
M>_KP?P)4I15V"DF>N45 UY:I,(FN85E)QL+@'/TJC>^)M"TT2&]UBP@,9PX>
MX4$'TQG.:S&:M%5K/4+/481-8W<%S$?XX9 X_,59H **** "O.?C???9/AM<
M0#&;RXA@QGMNWG_T"O1J\2_:$U)5M]#TP [VDDN"<]  %''_  (_E505Y)">
MQH? "Q2/PSJ5]LP\UWY>[U55&!_X\3^->NUY=\!E \"W+C.6OGSGI]Q.GZUZ
MC1/XF"V/&-7UF?PU\>K>WM)"MKJ9@%S"IPA+_+N([MG!S7L]?.$]W+XE_:(3
MR'.V'4EB&[)^2#[P ]#L;\_K7T?535K>@HN]PHHHK,HX3XC?$>T\%V7V>(>=
MJTT9:&(8P@Z;F_7 [XKQ+P[\.O%'Q&:YUQYXHHYIF+W%X[ ROGG: #D#/TR,
M=JY[Q)?W.K>+-0OKY\W,URRN2,;5#;0/H !CZ=3UKV;6?B1X?\ >#;;0O"]U
M;:EJ,< 6-X6#Q(QR6D8@D9SD[?<=JZ.5P2Y=V1=-F7;^/V^%5Y_PA7]G07L-
M@1FX67RV8O\ O"2,')PP],>]>Q^'M>L_$NAV^JV#$P3 \-P58'!!^A!^O6OD
M[3_#OBCX@:G?ZA96LM_=NQEN)BRHNX\XR< 'T7TQ4EIJOC3P+(%635=+ <_N
MID98G?H?E;Y2< \^W%)TT]GJ.[^1]@T5\T6G[0/BJ !9[;3+G!Y9HF5OT8#]
M*Z.#]HQ=A\_PT2W&/+N^OX%./S-0Z4UT'S(]TKE/&OC[2/!>G22W4RRWQ3,-
MFC#S')R 2,\+D<GZ]:\?\4?'O4]3THV6CZ<=*GDXEN/.\QE7T4[1@^_7GC'!
MKR.6X>65I)G:1VY9G;))/.?K5PH-_%H3*:6QWFJ?&/QIJ=V9X]26PA'W8;6-
M0 /<G))Z=?TKT;X2_%*^U_4?[#UZX22Y=2;:8KAG(Y*G'&< D<=C7SV'\QU
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M]:](\*^#-&\(6(M],ME\W!$EU(JF:3)S\S #CVZ5T%%-R;5F 4444@"BBB@
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MO'FE^"-)::Y<27\B'[+:+RTC=B?1<]3^63Q7@WA[P?XC^*.N2ZU>LPMIYO\
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M^OZUT-0D^9LA76B,ZTM/%/Q*\1%II9]1OV^8[F 2%,@$@$[57..!BOH[X?>
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MN/*^(EO&2 )894Y[_+NQ_P".Y_"OIZM:RM,F&P4445D4%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <'\7
M?$S^&O MQY!Q=7[?9(C@':&!+'!_V0WKR17"_L_Z"_VG4M==0(D06D7'5CAF
M[]AM[?Q=:/VB9'-QX=BZ(%N'SZGY!_A79?!*&*+X:VKICS)KB9Y2.[!RHS_P
M%5K7:GZD[R/1****R*"HK@H+64R#*;#N![C'-2TA 8$$9!X(H ^5?@W*D/Q+
MTG=T82J.><F-L5]5U\G_  P,=O\ %72MY6-!=2("1ZJZC\2<#\17UA6U?XB(
M;!1116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!YC\<M!?5/!2:A!"TDVF3><VU<D1$8<^N!\I/;"\^
MHY7X!>++>'[7X8N6V2SS&YM6/\9V ,GUPH;\Z]V=$EC:.10R,"K*PR"#U!KY
MF\<_"G7/"FI/J6@1SW&FQMY\<L!)EML'(SCGY>H8>F>,5K!IQY60T[W1]-T5
M\^^&_CWJ%IY%GKU@MVBMM>ZB.R0+Z[3PQ_$9S7K.F_$CP?J=FMS%K]C"IZI=
M2B%E]<A\?F./>H<)+<I-,ZFL3Q?K$>@^$M3U*1]GE0-L/<N1A0.1W(K#UKXM
M>"]%CEW:O'>S( 1#8CSB_L&'R?FPKP3QMXVU7XBZW"J02QV*.%M;&,ESG^\<
M=7/TX' [DU"FY,&[&K\$=%&I>/8KJ2+=#80O-DG@/]U?KU_,5].UP7PI\%S>
M$?#;F_4KJ-Z_F3(2#Y2CA4R.#W)_WL=J[VBI)2E=;!%604445F,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gmab-20210630xex991d85adb010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- (0# 2(  A$! Q$!_\0
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gmab-20210630xex991d85adb011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" (4# 2(  A$! Q$!_\0
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M 4444 9EY_I>J6]D<^7&/M$GOSA1^>3^ K3HHH **** "BBB@ HHHH ****
M"BBB@!"**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gmab-20210630xex991d85adb012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "2 7@# 2(  A$! Q$!_\0
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M+>U39;P10KZ1H%_E0!C?VMK5V"+'1O)!/RR7C[1^*CFG1:7J]R2VHZL54_\
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MYW8^@Z"L1_B)I4KM%I=O>ZE*.@MX3M)^IJ%M7\;ZIM6PT*UTV-NLMY,78?\
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M1?4 \M4B^'M2U 9UO5I74];>T/EQ_0GJ: +-QK>BZ,/LMOY;39P+2S0,Y/\
MNKTJHTOB36X1]F4:+"Q^]*H>8CZ=!_.MC3='T_2(C'86D4 /4HO)^IZFK] &
M%9>%=/MRDMV)-1NE',]XWF'\ >!^ K=HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &21I*A21%=2,$,,@US<OA!+>XDN='OIM/E8YVJ-T>?I73T4
M<Q#K^H:4WD^(;38N<+>6XW1M_O#J*Z.&:.XA66&17C895E.0:<Z*Z%'4,I&"
M",@U@3V<WA]WO=/5Y++EIK,?P_[2>GTH Z&BJUE>0:A9Q7=LX>&1<J15F@ H
MHJA>ZM:6*'S)-[]!''\S$^F* +]5[F\M[--]Q,D8QGD\GZ#O6#/K%]=(1%LL
M]HRRGYI/P["L>>[MS<HD0DNKQACD^9(?\*=@.@N_$#A5^QVX(8<23MM'X#J:
MY[4M1>5E-[?;D)^XO"CZ <FM&+0M2U*)/M92QC7@!?WDI'U/ _*MG3_#VFZ:
M0T-N'E[RRG>_UR>GX4: <W'IU_J+I]EM!#$.D]Q\H(_W1R?TK7M_"5J95GU&
M>2]E!R WRH/^ C_&NBHI ,CC2) D:*BCHJC %/HHH **0D 9)P*YO6?'.B:.
M3&UR+BX[0V_SM^E '2UDZMXBTW182]W< -VC3EC^%<M%<^,?%$A,<8T73B<A
MV'[UE_'G^57M,^'6E6<_VF]EGOY\YS,WRC_@(_K0!E/X]U'67>#1M-G)Z!E7
M<WYG@?K4MAX7\1:BYGU2[BLMW)5/WLI^IX KO(+>"VC$<$,<2#^&-0H_(5+0
M!S]EX-T:SE:9H&NI3SNN6W_ITK<B@B@39#$D:_W44 ?I23W$-K"TT\J11KU=
MS@#\:QHO$BW\ICTFRFNU''GD;(O^^CUH WJQ[SQ-IMI,+=96NKDG @MEWM_@
M/Q-5FT._U)R^KZE)Y1_Y=+3]VGXG[Q_.M6QTJQTQ-EG:Q0@]2J\GZGJ: ,A'
M\2:L3F.'2+<C@D^;,?PX"U8LO"^GVTIGG$E[<DY,MT=YS[#H*VZ* $  & ,"
MEHHH **BD65MNR0)SS\N2133;(_+EWXQ\S<'\.E !->VUN<2SHA]">?RJM-J
MT4<>^.&XF'_3.,X_,XJG?ZSINDS?9((1/?/]VUMT!<_7'2J,VF^(M<CVW=ZF
MEVS'_4VPW2$>['^E $6J>-Y=/(6/19Y9&.%5I57/Y9Q2>&?$GB+6=3=+WP\E
MG8*#_I'GD\]@ 1S^E;>E^'['24Q$C2RG[TT[;W/X]OPK5Q0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(1D5!?7D=A92W<H/EQ+N;'6JLFO:9%#'*U
MW&5D&5"G)/Y4 9\%C-X?O'FB96L+B4F6(# A)Z$>W8U=O]>LM/*H7,TK=$B^
M8_B>@_&N>UCQ$]SYD2#R[7/#'JV.G%9NGZ;>ZD&%A"BQJ>9)SM4?0<DT[ :=
M[K-Q?A1)(;6VR=ZQ/R1[O65IUPLKO;Z)92W1)PSHI5!]7/!KIK;P?9ATEOY'
MNY%_A;B,?\!_^O70QQ1PQB.-%1 ,!5& *+@<S;^%YKJ,'5+@*#]^"V.U6^IZ
MFM^RT^TTZ$16=M' GHB@9^OK5JBD 4444 %%4=2U:PTBW,^H74<$?JQY/T'4
MUS4GBK6-:/E^&-'+Q9P;V];RXQ]%ZM0!U\T\5M$TL\J11J.7=@ /Q-<M=^.(
M99OLNA6-QJMSZQ(1&ON6-.B\&_;I$N/$-])J,PY$0^2)?HM=-!;PVL0BMXDB
MC7HJ+@"@#BI/#?B3Q'(&U[4Q:69_Y<[0_P S_P#KKHM'\+Z/H2C[!8Q1R=Y2
M,N?^!5L44 %%4-1UBPTJ,/>7*QYZ* 68_0#FL=K[7]:95TZV&FV9ZW5T,R$?
M[,?^- &Y>ZE9Z=%ON[B.('[H8\M]!WK';4]8U48TFR^RPG_EZO!C/^ZG7\3Q
M5C3?#%C83_:I3)>7IZW%P=S?AZ5MT <[#X2M))UN=6EDU2X7D&X.43_=3H*Z
M *%4*H  X %.HH **** "BBB@ HHHH *9(&:-E1MK$$*?0^M/HH SM)TBVTB
MV*1#=-(=TTS??E;U)K1HHH **** "BBB@ HHHH **** "BBB@ HHHH ***@N
MKN"RMVN+F58HD^\S=!0!/5>ZO+>RB\RYF2)/5CBN(E^(-[J1>'PYX>OKIQP9
MIDQ&I^H)S^=5K'PGKVO:FUWXE4V^ !^[G4Y_W0N<=/;K0!9UGQO#>Q36-G 7
MCF0QEB,LV>. *Y?2-%U/3W(O(9K:R8Y6XE0ML'TKU73-"TW1XPME:1HW>0C+
MM]3UK1*AE(8 @]C3N!@Z-H>DVT"SQ2_;6;D3RL&_+ P*CEU:2'QW;Z:4Q!-9
ML0P/!8'/\LU=F\-Z/.VYK&,'_8)3] :FLM&T_3Y/,MK94D(QO)+''U-(#0HH
MHH **Y?Q#X[TCPY=QVDZW-S<NN[R[6$R;><8)' /7C_ZU8']O>+/$]^MK8Z5
M>:18,,M/+%M?;D#.6X[]!S]<4 =MJFMZ?I$)DO+A4('"#EV^@K!36/$6OLR:
M58?V;:'I>78RY'JJ?_KK1TGPGIFELLYA^T7N/FN)V\QR?J>E;U ',V/@NPAF
M^U:E++JEX3DRW9W 'V7H/UKI%544*JA5'0 =*=10 45A^(/%FD^&HXVU":3?
M+GRXX8FD9L8ST&!U[D9YQ6#'XHUOQ'="STG2;[3X6 9KNZ@V?+D E=W'?W-
M'77NJ66GKFYN$0]ESEC]!UK#^V:_KC,EG!_95GG'VB==TKC_ &5Z#\<UHZ5X
M?L=+;SPAFO&_UES,Q=V/U/2M>@#)TWP]8Z<WFX>YNCRUS<'>Y/KGM^%:U%%
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M@Q@ >E &3I_AZTLKC[3,SW=ZW6>?YB/IZ5LT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%-"EQ
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gmab-20210630xex991d85adb013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ &\# 2(  A$! Q$!_\0
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3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gmab-20210630xex991d85adb014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H (H# 2(  A$! Q$!_\0
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-K6S113D)"T444AG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gmab-20210630xex991d85adb015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J ,P# 2(  A$! Q$!_\0
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GH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gmab-20210630xex991d85adb016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ - # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HI
M,C.,\]<4M !1129'2@!:*A-PGVD0 $N5W''11[_7^E34 %-W , 2,GH*&944
MLQ 4#))[5FZ8#>RMJDB8\P;;<'JL6>#]6Z_E32TN!J5#<SQVMN\TAPJ#)]_8
M5+TY-8BRMJ^L*H_X\K3$G_723^$_0=1^!HBKZ@:ML\SVR/<(L<K#+(#D+[9J
M8$$9'(K*OI3?W?\ 94#$* 'NG'\*'HGU;^6?:M15"*JJ % P .U#0#J***0!
M1110 4444 %%%% !1110 4444 %%%5;Z7;$L2_?F;RUP>F>I_ 9-"U BM6/G
MR3RGYIWQ&HYP@Z?3/)_&K]4;=0UY(5^Y$@C'L>N/P&/SJI/?//?FU9!':*@E
M,V_!.&[^QQ5<MWH!J3SQVT+S3.$C12S,>@ K/MV81OJEZIC8K^[C/6-/3_>/
M?\NU0SLVJZE!;D,MK%B=U(QOP?ES[9&0/]G-3W1-Y=10 _NM_/\ M!>3^'0?
MB::5@+%A$XA,\PQ/,=[CT]%_ 5%J$I%S:00RNMQ))N 4\;%.6)'ICCZD5H5S
M=I>S7VIWL\%N_F,WD6\K+\BQKU?/0Y;/'7@4)7;8%K6)3>W$6CPG"R_-=.#C
M9$.2/JW ^AJ[YY>^AM[8IY2)OD(Y^7HH'UZ_A6;"8;2UNKUB\D8R@8G)DVG!
M/N6;^E5O#UM+<Z:59@J32O)</&?O?,<(I[#U_+Z5RKEOV T;N[6[AF;)%A#G
MS7''G$?P+[=B>_0=ZKK.]A8&+*I=,OGW,F,K"#_,\84>U2:G+_I=GIEJB<8D
M9,< +]T?3//T7WJMJJBVA6UC9I'R)9G;K)(>$!_X%SCT6B*V0%S1Q:V5BC&5
M5DN9227?+,_IGN1C%7(]1AG=DMPTSJ2#LZ ^YZ"L+4XKJYM#;V.W[9Y?[H],
M*..#V+$,<^PINAZY]ETY+*?39K62W&S9(53/H>2,_49IN%US=0.@D6_8$QO
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gmab-20210630xex991d85adb017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X '0# 2(  A$! Q$!_\0
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M/-NV @85<DDG X^I%,16-OJ4I!>^C@7NL$()_-B?Y4K::'SYEY>/D]IMG?\
MV<4VXU:-)C;6L;W=R.L<6,)_O,>%_G[&F"RO[PAKZZ\F//\ J+1BH(_VG/S'
M\-M&H%>[BL8Y6BA:\GO",>5#=R;AGIN.["CW/X5I:?#/;V,45U+YLX'S-G/X
M9[XZ9ZG%-M_L%E(MC!Y,4A&X1+@,??W^M4/$UP]M:6<B9XO82^#_  ALG^5/
M?06VIJW%S';",R9_>2+&N!GD]*FK#\0RLLFF!& 87D<C#&<H#M/T^^.:U;FT
MCNO*\S<#%()$96P0P_R1^-*V@[EBBBBD,*2J=W?&&5;>"(SW3#<(P<!1_>8]
MA^I[ U$-.DN1G4;@S9Y\E,I$/;'5OQ)^E%@'R:O91R-$LIFE7K' ID8?4*#C
M\:8U_>NH-OI<IST\Z18_SY)_2KT<,<*!(HU1!T51@#\*@M+M9[!;EQY:X);<
M?NX)!_E3T$5OM&L!"QTZU]D%V<_GLQ0BQZS:V][$\UM,NX(RD97G# ]01D?H
M"*@:>;7%,=F[PZ>>'N<$-,.XC]!_M_EZ@UFZ;2].BM[';%*_[N !0<8'  ]S
MM'XU5NBW$64M]5C.?[0@E'/$EM@^W(8?RK)\1G5?L$*R01O;_:83.]LY$FS>
M,@#KGIT.:Z5,[1NQNQSCUJAKR%]"O=HRRQ%P/=?F'\J47J#6@Z"XTZSTOSH'
MBBLXQCY1@*<X(QZYXQUS[T0:Q8SQS,9Q$8"!,DWR-'GIN!Z9[5EZLJQ76G7T
M2226TTZO-%&N2S!&*,!ZYP/R]*@CTR\DN+EY[)_M4\_G"02@1*NW:H;!W$@'
M:0.N.V:=EU%=D=O<?VA93ZG$P\F!YKGSSR'<*RH%/=57J?7CUI/LUS/HNFVL
MA:2XCL99BK9+Y*[5'U^<C\*MQ^'K@:)_8\DD LXHV1!&"#*><;AT49.<#.?I
MQ6CI5O/\]W=Q&*XD58PA8,41>@)'&223^(IMI;!:^Y@26-U<-->VSW<EK<31
MI"C#+Q+O!9OF&=I(SCM@=NFS<1W%IJ&G^7>W$K33%)$D(VE C$\  #D#G\.]
M;--,:%UD*@NH(5B.1GK_ "%2YW'RV'T445)11N+%WN&N+:Y>WF90K$*&5@,X
MR#]3TQUJ%K36#]W58!];//\ [/6IBDQ3NQ6,*ZU+4],98V@_M*0KNV6T+1M@
M=\DE>O;(/IFH+*".[TR._P!6NHFLE!=( V(4&>"Q/WS]<#VKI*XA94>WNK%[
MDQPI<73J=N?F."@ /WL-(2!Z@5<=42]#K9=0M+>*.62XC6.0X1\\'@GKZ8!.
M?:N:FU!=4U2+4H6C%K!9SM:22(<A]R*9"#T'. /J>XI=)T>]TS2=-\ZR5S9H
MR/;1L&+!Q\V,\<'''IGUJZVD7-\\]V2MJ]SE##(N_$94*<@'[QV@]<# %%HQ
M8:L?975Y'>V]J\WG)YDL9#+EBB9^<L.^=J].];KJKHRL,JP((]15'3=*MM+A
M"0F1V"A/,E;<Q ]_J2?J<UH5#:OH4CF;,SS_ &#2I8W$UC+NG?80NQ,B,@]"
M6^4_]]5TM&*6ANX)6"BBBD,**** "BBB@ HHHH 2L'PY9/';W;W<&V5K^:1
KZ<J-Q"D9]@#GWHHIIZ,74WZ***0PHHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gmab-20210630xex991d85adb018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ (4# 2(  A$! Q$!_\0
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gmab-20210630xex991d85adb019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" (X# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gmab-20210630xex991d85adb020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z /X# 2(  A$! Q$!_\0
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M%&I9F/85B^&KR\U&34[JZ+(IN1'# >D2!%(_X$=W/O3MI<5SH****0PHHHH
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MK$*JF3'?[H"_C7944N=ZCL<;X1T*Y-G'?:O$5?S)9H;1QQ$TDC.7(_O<@#T
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0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gmab-20210630xex991d85adb021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20210630xex991d85adb021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J / # 2(  A$! Q$!_\0
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M:,V.QGGE2;4)4<H=R01C$:GU.>6/U_*EN]%L;Z]2[N(BTJ(8\AB,KG/..O\
M]<UH]Z#3NPL58;"TM\^3;1)NZD( 3]3WJU112&%%%% !1110 4444 %%%% !
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>gmab-20210630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2021 3:41:17 PM-->
<!--Modified on: 8/11/2021 3:41:17 PM-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:ifrs="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full" xmlns:attributeFormDefault="unqualified" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" targetNamespace="http://www.genmab.com/20210630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:gmab="http://www.genmab.com/20210630" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" id="StatementConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>00100 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00200 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00300 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2" id="DisclosureResultsForYearStaffCostsDetailsCalc2">
        <link:definition>40203 - Disclosure - RESULTS FOR THE YEAR - Staff Costs (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2" id="DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2">
        <link:definition>40311 - Disclosure - OPERATING ASSETS AND LIABILITIES - Receivables (Details) - calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2" id="DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2">
        <link:definition>40313 - Disclosure - OPERATING ASSETS AND LIABILITIES - Other Payables (Details) - calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" id="DisclosureFinancialIncomeAndExpensesDetails">
        <link:definition>40401 - Disclosure - Financial Income and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40701 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity" id="StatementConsolidatedStatementsOfChangesInEquity">
        <link:definition>00400 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses" id="DisclosureFinanceIncomeAndExpenses">
        <link:definition>10401 - Disclosure - Finance Income and Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" id="DisclosureFinancialInstrumentsTables">
        <link:definition>30303 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>40201 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails" id="DisclosureRevenueAbbvieCollaborationAgreementDetails">
        <link:definition>40202 - Disclosure - Revenue - AbbVie Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails" id="DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails">
        <link:definition>40301 - Disclosure - Financial Instruments - Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" id="DisclosureFinancialInstrumentsFinancialRiskDetails">
        <link:definition>40302 - Disclosure - Financial Instruments - Financial Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" id="DisclosureFinancialInstrumentsFairValueMeasurementDetails">
        <link:definition>40303 - Disclosure - Financial Instruments - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" id="DisclosureFinancialInstrumentsOtherInvestmentsDetails">
        <link:definition>40304 - Disclosure - Financial Instruments - Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails" id="DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails">
        <link:definition>40408 - Disclosure - Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails" id="DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails">
        <link:definition>40409 - Disclosure - Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details" id="DisclosureShareBasedInstrumentsPart1Details">
        <link:definition>40501 - Disclosure - Share-Based Instruments - Part 1 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details" id="DisclosureShareBasedInstrumentsPart2Details">
        <link:definition>40502 - Disclosure - Share-Based Instruments - Part 2 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details" id="DisclosureShareBasedInstrumentsPart3Details">
        <link:definition>40503 - Disclosure - Share-Based Instruments - Part 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" id="DisclosureRelatedPartiesDetails">
        <link:definition>40601 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10201 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstruments" id="DisclosureFinancialInstruments">
        <link:definition>10301 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstruments" id="DisclosureShareBasedInstruments">
        <link:definition>10501 - Disclosure - Share-Based Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>10601 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10701 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10801 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" id="DisclosureBasisOfPresentationPolicies">
        <link:definition>20102 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationTables" id="DisclosureBasisOfPresentationTables">
        <link:definition>30103 - Disclosure - Basis of Presentation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>30203 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpensesTables" id="DisclosureFinanceIncomeAndExpensesTables">
        <link:definition>30403 - Disclosure - Finance Income and Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" id="DisclosureShareBasedInstrumentsTables">
        <link:definition>30503 - Disclosure - Share-Based Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30703 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="gmab_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="gmab_IfrsMarketableSecuritiesCurrent" name="IfrsMarketableSecuritiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ReversalOfFinancialItemsNet" name="ReversalOfFinancialItemsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" name="CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AdjustmentsForInterestOnLeasePayments" name="AdjustmentsForInterestOnLeasePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ProceedsFromExerciseOfWarrants" name="ProceedsFromExerciseOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PaymentsToAcquireTreasuryShares" name="PaymentsToAcquireTreasuryShares" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" name="PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" name="IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" name="IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_TransactionsWithOwners" name="TransactionsWithOwners" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ExerciseOfWarrants" name="ExerciseOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" name="DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" name="DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_TypesOfRevenuesAxis" name="TypesOfRevenuesAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_TypesOfRevenuesMember" name="TypesOfRevenuesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_RoyaltiesRevenueMember" name="RoyaltiesRevenueMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_MilestonePaymentsRevenueMember" name="MilestonePaymentsRevenueMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_LicenseFeesMember" name="LicenseFeesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ReimbursementIncomeMember" name="ReimbursementIncomeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AgreementsWithJanssenMember" name="AgreementsWithJanssenMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AgreementsWithNovartisMember" name="AgreementsWithNovartisMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_OtherCollaborationPartnersMember" name="OtherCollaborationPartnersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" name="DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" name="DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PropertiesMember" name="PropertiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsEquipmentMember" name="IfrsEquipmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfFinanceIncomeExpensesAbstract" name="DisclosureOfFinanceIncomeExpensesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" name="DisclosureOfFinanceIncomeExpensesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_FinanceIncomeAbstract" name="FinanceIncomeAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_GainsOnHedgingInstruments" name="GainsOnHedgingInstruments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_InterestAndOtherFinancialIncome" name="InterestAndOtherFinancialIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_FinanceExpensesAbstract" name="FinanceExpensesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_InterestAndOtherFinancialExpenses" name="InterestAndOtherFinancialExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_LossesOnMarketableSecurities" name="LossesOnMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsRestrictedStockUnitsRSUsMember" name="IfrsRestrictedStockUnitsRSUsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfWarrantsGrantedDuringPeriod" name="NumberOfWarrantsGrantedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfWarrantsExercisedDuringPeriod" name="NumberOfWarrantsExercisedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_MarketableSecuritiesMember" name="MarketableSecuritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_TripleaRatingMember" name="TripleaRatingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_FairValueAdjustmentOfMarketableSecurities" name="FairValueAdjustmentOfMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" name="FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" name="MarketableSecuritiesNetBookValueInPercentageOfCost" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PercentageOfMarketableSecurities" name="PercentageOfMarketableSecurities" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ForeignExchangeAdjustmentOfMarketableSecurities" name="ForeignExchangeAdjustmentOfMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfWarrantsActivityTableTextBlock" name="DisclosureOfWarrantsActivityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" name="Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" name="WarrantsGrantedFromAugust2004UntilApril2012Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" name="WarrantsGrantedFromApril2012UntilMarch2017Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WarrantsGrantedFromMarch2017Member" name="WarrantsGrantedFromMarch2017Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WarrantVestingPeriod" name="WarrantVestingPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfWarrantsOutstanding" name="NumberOfWarrantsOutstanding" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" name="NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WeightedAverageExercisePriceOfWarrantsGranted" name="WeightedAverageExercisePriceOfWarrantsGranted" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WeightedAverageExercisePriceOfWarrantsExercised" name="WeightedAverageExercisePriceOfWarrantsExercised" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" name="PercentageOfShareCapitalAttributedToExerciseOfWarrants" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" name="IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" name="EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" name="WeightedAverageExercisePriceOfFairValueOfWarrants" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" name="DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_FutureMinimumOperatingLeasePayments" name="FutureMinimumOperatingLeasePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_EstimatedCapitalExpenditureForLease" name="EstimatedCapitalExpenditureForLease" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AmericanDepositorySharesMember" name="AmericanDepositorySharesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" name="DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_CurevacCollaborationMember" name="CurevacCollaborationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsNumberOfReportingUnits" name="IfrsNumberOfReportingUnits" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" name="ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfStaffCostTableTextBlock" name="DisclosureOfStaffCostTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" name="StaffCostsIncludedInResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" name="StaffCostsIncludedInGeneralAndAdministrativeExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" name="StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ResultsForYearAbstract" name="ResultsForYearAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" name="ValuationAssumptionsForWarrantsGrantedTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" name="DisclosureOfCorporateAndDeferredTaxTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfNetResultTableTextBlock" name="DisclosureOfNetResultTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" name="DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_MarketableSecuritiesIncludingInterestReceivables" name="MarketableSecuritiesIncludingInterestReceivables" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_BankDepositsIncludingShortTermMarketableSecurities" name="BankDepositsIncludingShortTermMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PercentageOfRevenue" name="PercentageOfRevenue" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PercentageOfMarketableSecuritiesInvested" name="PercentageOfMarketableSecuritiesInvested" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" name="PercentageOfPossibleIncreaseDecreaseInExchangeRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ReceivablesExPrepaymentsMember" name="ReceivablesExPrepaymentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsCashAndCashEquivalentsMember" name="IfrsCashAndCashEquivalentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_OtherPayablesMember" name="OtherPayablesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_TotalAdjustmentsForNonCashTransactions" name="TotalAdjustmentsForNonCashTransactions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ExpensesRelatedToCapitalIncreaseDecrease" name="ExpensesRelatedToCapitalIncreaseDecrease" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AgreementsWithSeatleGeneticsMember" name="AgreementsWithSeatleGeneticsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AgreementsWithBointechMember" name="AgreementsWithBointechMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_UpfrontMilestonePaymentReceived" name="UpfrontMilestonePaymentReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfPerformanceObligations" name="NumberOfPerformanceObligations" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ContractTransactionPrice" name="ContractTransactionPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PerformanceObligationRevenueRecognitionPeriod" name="PerformanceObligationRevenueRecognitionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfDeliveryLicenses" name="NumberOfDeliveryLicenses" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfTreasurySharesOutstanding" name="NumberOfTreasurySharesOutstanding" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AgreementsWithAbbvieMember" name="AgreementsWithAbbvieMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_WarrantsMember" name="WarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AgreementsWithSeagenMember" name="AgreementsWithSeagenMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_CorporateTaxReceivable" name="CorporateTaxReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_AgreementsWithRocheMember" name="AgreementsWithRocheMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_GainOnOtherInvestments" name="GainOnOtherInvestments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_ReductionInRoyaltyRevenue" name="ReductionInRoyaltyRevenue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_LossesOnOtherInvestmentsNet" name="LossesOnOtherInvestmentsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PercentageOfInvestmentInCommonShares" name="PercentageOfInvestmentInCommonShares" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_BoltBiotherapeuticsIncMember" name="BoltBiotherapeuticsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfIndependentBoardMembers" name="NumberOfIndependentBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfNonIndependentBoardMembers" name="NumberOfNonIndependentBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_NumberOfEmployeeElectedBoardMembers" name="NumberOfEmployeeElectedBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsShareRepurchaseProgramAxis" name="IfrsShareRepurchaseProgramAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsShareRepurchaseProgramDomain" name="IfrsShareRepurchaseProgramDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_RestrictedStockUnitsProgramMember" name="RestrictedStockUnitsProgramMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsStockRepurchaseProgramAuthorizedAmount" name="IfrsStockRepurchaseProgramAuthorizedAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" name="IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsStockRepurchasedDuringPeriodValue" name="IfrsStockRepurchasedDuringPeriodValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsStockRepurchasedDuringPeriodShares" name="IfrsStockRepurchasedDuringPeriodShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_PercentageOfShareCapital" name="PercentageOfShareCapital" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gmab_IfrsTreasuryStockShares" name="IfrsTreasuryStockShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>gmab-20210630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2021 3:41:17 PM-->
<!--Modified on: 8/11/2021 3:41:17 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.genmab.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureResultsForYearStaffCostsDetailsCalc2" roleURI="http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2" roleURI="http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2" roleURI="http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialIncomeAndExpensesDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureLeasesDetails" roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" />
  <calculationLink xlink:role="http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Statements of Comprehensive Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637642932738928049" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637642932738928049" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637642932738938169" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637642932738938169" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_637642932738938169" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637642932738938169" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637642932738938169" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637642932738938169" xlink:to="ifrs-full_ProfitLossBeforeTax_637642932738938169" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637642932738938169" xlink:to="ifrs-full_FinanceIncome_637642932738938169" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637642932738938169" xlink:to="ifrs-full_FinanceCosts_637642932738938169" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637642932738938169" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637642932738938169" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637642932738938169" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense_637642932738948072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637642932738938169" xlink:to="ifrs-full_OperatingExpense_637642932738948072" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637642932738948072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense_637642932738948072" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637642932738948072" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637642932738948072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense_637642932738948072" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637642932738948072" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_637642932738948072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637642932738938169" xlink:to="ifrs-full_Revenue_637642932738948072" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637642932738948072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets_637642932738948072" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637642932738948072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637642932738948072" xlink:to="ifrs-full_CashAndCashEquivalents_637642932738948072" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsMarketableSecuritiesCurrent" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_637642932738958051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637642932738948072" xlink:to="gmab_IfrsMarketableSecuritiesCurrent_637642932738958051" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637642932738958051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637642932738948072" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637642932738958051" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CorporateTaxReceivable" xlink:label="gmab_CorporateTaxReceivable_637642932738958051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637642932738948072" xlink:to="gmab_CorporateTaxReceivable_637642932738958051" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637642932738958051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets_637642932738958051" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_637642932738958051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637642932738958051" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_637642932738958051" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637642932738958051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637642932738958051" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637642932738958051" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637642932738958051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637642932738958051" xlink:to="ifrs-full_PropertyPlantAndEquipment_637642932738958051" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637642932738968046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637642932738958051" xlink:to="ifrs-full_RightofuseAssets_637642932738968046" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentReceivables" xlink:label="ifrs-full_NoncurrentReceivables_637642932738968046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637642932738958051" xlink:to="ifrs-full_NoncurrentReceivables_637642932738968046" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_637642932738968046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637642932738958051" xlink:to="ifrs-full_NetDeferredTaxAssets_637642932738968046" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637642932738968046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity_637642932738968046" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637642932738968046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637642932738968046" xlink:to="ifrs-full_IssuedCapital_637642932738968046" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_637642932738968046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637642932738968046" xlink:to="ifrs-full_OtherReserves_637642932738968046" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637642932738978093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637642932738968046" xlink:to="ifrs-full_RetainedEarnings_637642932738978093" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_637642932738978093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637642932738968046" xlink:to="ifrs-full_SharePremium_637642932738978093" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_637642932738978093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_637642932738978093" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637642932738978093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_637642932738978093" xlink:to="ifrs-full_CurrentLiabilities_637642932738978093" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637642932738978093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637642932738978093" xlink:to="ifrs-full_CurrentLeaseLiabilities_637642932738978093" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637642932738978093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637642932738978093" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637642932738978093" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_637642932738978093" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637642932738978093" xlink:to="ifrs-full_OtherCurrentPayables_637642932738978093" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_637642932738988055" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637642932738978093" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_637642932738988055" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_637642932738988055" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637642932738978093" xlink:to="ifrs-full_OtherCurrentLiabilities_637642932738988055" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637642932738988055" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_637642932738978093" xlink:to="ifrs-full_NoncurrentLiabilities_637642932738988055" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637642932738988055" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637642932738988055" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637642932738988055" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637642932738988055" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637642932738988055" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637642932738988055" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_637642932738988055" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637642932738988055" xlink:to="ifrs-full_NoncurrentProvisions_637642932738988055" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="ifrs-full_OtherNoncurrentPayables_637642932738998046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637642932738988055" xlink:to="ifrs-full_OtherNoncurrentPayables_637642932738998046" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_637642932738998046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637642932738988055" xlink:to="ifrs-full_OtherNoncurrentLiabilities_637642932738998046" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932738998046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932738998046" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637642932738998046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932738998046" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637642932738998046" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637642932738998046" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932738998046" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637642932738998046" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_637642932739008052" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932738998046" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_637642932739008052" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AdjustmentsForInterestOnLeasePayments" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_637642932739008052" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932738998046" xlink:to="gmab_AdjustmentsForInterestOnLeasePayments_637642932739008052" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739008052" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932738998046" xlink:to="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739008052" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637642932739008052" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739008052" xlink:to="ifrs-full_ProfitLossBeforeTax_637642932739008052" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TotalAdjustmentsForNonCashTransactions" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_637642932739008052" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739008052" xlink:to="gmab_TotalAdjustmentsForNonCashTransactions_637642932739008052" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReversalOfFinancialItemsNet" xlink:label="gmab_ReversalOfFinancialItemsNet_637642932739008052" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739008052" xlink:to="gmab_ReversalOfFinancialItemsNet_637642932739008052" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_637642932739008052" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739008052" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_637642932739008052" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637642932739018404" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" xlink:to="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637642932739018404" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637642932739018404" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637642932739018404" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PaymentsToAcquireTreasuryShares" xlink:label="gmab_PaymentsToAcquireTreasuryShares_637642932739018404" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" xlink:to="gmab_PaymentsToAcquireTreasuryShares_637642932739018404" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ProceedsFromExerciseOfWarrants" xlink:label="gmab_ProceedsFromExerciseOfWarrants_637642932739018404" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" xlink:to="gmab_ProceedsFromExerciseOfWarrants_637642932739018404" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637642932739018404" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" xlink:to="ifrs-full_ProceedsFromIssuingShares_637642932739018404" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_637642932739018404" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739018404" xlink:to="ifrs-full_PaymentsForShareIssueCosts_637642932739018404" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637642932739028057" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637642932739028057" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739028057" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739028057" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637642932739028057" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637642932739028057" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739028057" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739028057" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637642932739028057" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637642932739028057" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637642932739038050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739028057" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637642932739038050" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2" xlink:type="extended" xlink:title="40203 - Disclosure - RESULTS FOR THE YEAR - Staff Costs (Details) Calc 2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_637642932739038050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_637642932739038050" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_637642932739038050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_637642932739038050" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_637642932739038050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_637642932739038050" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2" xlink:type="extended" xlink:title="40311 - Disclosure - OPERATING ASSETS AND LIABILITIES - Receivables (Details) - calc2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637642932739048048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637642932739048048" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentReceivables" xlink:label="ifrs-full_NoncurrentReceivables_637642932739048048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_NoncurrentReceivables_637642932739048048" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2" xlink:type="extended" xlink:title="40313 - Disclosure - OPERATING ASSETS AND LIABILITIES - Other Payables (Details) - calc2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherPayables" xlink:label="ifrs-full_OtherPayables" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_637642932739048048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherCurrentPayables_637642932739048048" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="ifrs-full_OtherNoncurrentPayables_637642932739048048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherNoncurrentPayables_637642932739048048" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Financial Income and Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637642932739048048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceCosts_637642932739048048" order="1" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss_637642932739048048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637642932739048048" xlink:to="ifrs-full_NetForeignExchangeLoss_637642932739048048" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LossesOnMarketableSecurities" xlink:label="gmab_LossesOnMarketableSecurities_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637642932739048048" xlink:to="gmab_LossesOnMarketableSecurities_637642932739058204" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_InterestAndOtherFinancialExpenses" xlink:label="gmab_InterestAndOtherFinancialExpenses_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637642932739048048" xlink:to="gmab_InterestAndOtherFinancialExpenses_637642932739058204" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LossesOnOtherInvestmentsNet" xlink:label="gmab_LossesOnOtherInvestmentsNet_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637642932739048048" xlink:to="gmab_LossesOnOtherInvestmentsNet_637642932739058204" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncome_637642932739058204" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637642932739058204" xlink:to="ifrs-full_NetForeignExchangeGain_637642932739058204" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_GainsOnHedgingInstruments" xlink:label="gmab_GainsOnHedgingInstruments_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637642932739058204" xlink:to="gmab_GainsOnHedgingInstruments_637642932739058204" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_GainOnOtherInvestments" xlink:label="gmab_GainOnOtherInvestments_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637642932739058204" xlink:to="gmab_GainOnOtherInvestments_637642932739058204" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_InterestAndOtherFinancialIncome" xlink:label="gmab_InterestAndOtherFinancialIncome_637642932739058204" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637642932739058204" xlink:to="gmab_InterestAndOtherFinancialIncome_637642932739058204" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_637637461730083168" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637642932739068048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities_637637461730083168" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637642932739068048" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637642932739068048" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities_637637461730083168" xlink:to="ifrs-full_CurrentLeaseLiabilities_637642932739068048" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>gmab-20210630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2021 3:41:17 PM-->
<!--Modified on: 8/11/2021 3:41:17 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xmlns="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedStatementsOfChangesInEquity" roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinanceIncomeAndExpenses" roleURI="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRevenueDetails" roleURI="http://www.genmab.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRevenueAbbvieCollaborationAgreementDetails" roleURI="http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsFinancialRiskDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsFairValueMeasurementDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsOtherInvestmentsDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails" roleURI="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails" roleURI="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstrumentsPart1Details" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstrumentsPart2Details" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstrumentsPart3Details" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureLeasesDetails" roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xmlns="http://www.xbrl.org/2003/linkbase" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637642932739078445" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637642932739078445" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AmericanDepositorySharesMember" xlink:label="gmab_AmericanDepositorySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="gmab_AmericanDepositorySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Changes in Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637642932739118046" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_637642932739118046" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="ifrs-full_CashFlowHedgesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CashFlowHedgesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_637642932739128049" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_637642932739128049" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TransactionsWithOwners" xlink:label="gmab_TransactionsWithOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="gmab_TransactionsWithOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ExerciseOfWarrants" xlink:label="gmab_ExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_ExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_ExpensesRelatedToCapitalIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquity" xlink:label="ifrs-full_ChangesInEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_ChangesInEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_PurchaseOfTreasuryShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses" xlink:type="extended" xlink:title="10401 - Disclosure - Finance Income and Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637642932739168045" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637642932739168045" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="srt_ParentCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_637642932739168045" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_637642932739168045" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="gmab_MarketableSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="gmab_TypesOfRevenuesAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_TypesOfRevenuesAxis" xlink:to="gmab_TypesOfRevenuesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember_637642932739178046" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="gmab_TypesOfRevenuesAxis" xlink:to="gmab_TypesOfRevenuesMember_637642932739178046" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_RoyaltiesRevenueMember" xlink:label="gmab_RoyaltiesRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_RoyaltiesRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReimbursementIncomeMember" xlink:label="gmab_ReimbursementIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_ReimbursementIncomeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MilestonePaymentsRevenueMember" xlink:label="gmab_MilestonePaymentsRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_MilestonePaymentsRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_LicenseFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739188048" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739188048" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithJanssenMember" xlink:label="gmab_AgreementsWithJanssenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithJanssenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithAbbvieMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithRocheMember" xlink:label="gmab_AgreementsWithRocheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithRocheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithSeagenMember" xlink:label="gmab_AgreementsWithSeagenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithSeagenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithBointechMember" xlink:label="gmab_AgreementsWithBointechMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithBointechMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithNovartisMember" xlink:label="gmab_AgreementsWithNovartisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithNovartisMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_OtherCollaborationPartnersMember" xlink:label="gmab_OtherCollaborationPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_OtherCollaborationPartnersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithSeatleGeneticsMember" xlink:label="gmab_AgreementsWithSeatleGeneticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithSeatleGeneticsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReductionInRoyaltyRevenue" xlink:label="gmab_ReductionInRoyaltyRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="gmab_ReductionInRoyaltyRevenue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Revenue - AbbVie Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithAbbvieMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="gmab_TypesOfRevenuesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_TypesOfRevenuesAxis" xlink:to="gmab_TypesOfRevenuesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_LicenseFeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637642932739218050" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_637642932739218050" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_PerformanceObligationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember_637642932739228048" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember_637642932739228048" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_UpfrontMilestonePaymentReceived" xlink:label="gmab_UpfrontMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="gmab_UpfrontMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfPerformanceObligations" xlink:label="gmab_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="gmab_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ContractTransactionPrice" xlink:label="gmab_ContractTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="gmab_ContractTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfDeliveryLicenses" xlink:label="gmab_NumberOfDeliveryLicenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="gmab_NumberOfDeliveryLicenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PerformanceObligationRevenueRecognitionPeriod" xlink:label="gmab_PerformanceObligationRevenueRecognitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="gmab_PerformanceObligationRevenueRecognitionPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments - Financial Assets and Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember_637642932739258244" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember_637642932739258244" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_637642932739258244" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember_637642932739258244" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="gmab_MarketableSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="us-gaap_OtherInvestmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="us-gaap_OtherInvestmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReceivablesExPrepaymentsMember" xlink:label="gmab_ReceivablesExPrepaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="gmab_ReceivablesExPrepaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCashAndCashEquivalentsMember" xlink:label="gmab_IfrsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="gmab_IfrsCashAndCashEquivalentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_637642932739278070" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_637642932739278070" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_637642932739278070" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember_637642932739278070" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_OtherPayablesMember" xlink:label="gmab_OtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="gmab_OtherPayablesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Financial Instruments - Financial Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_637642932739298072" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_637642932739298072" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CreditRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="ifrs-full_ExternalCreditGradesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932739308069" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932739308069" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:to="gmab_TripleaRatingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_637642932739308069" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_637642932739308069" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="currency_EUR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_DKK" xlink:label="currency_DKK" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_DKK" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP" xlink:label="currency_GBP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithAbbvieMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_MaximumExposureToCreditRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfMarketableSecurities" xlink:label="gmab_PercentageOfMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_MarketableSecuritiesIncludingInterestReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_BankDepositsIncludingShortTermMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfRevenue" xlink:label="gmab_PercentageOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfMarketableSecuritiesInvested" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfMarketableSecuritiesInvested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Financial Instruments - Fair Value Measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_MeasurementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_637642932739548079" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember_637642932739548079" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtFairValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="gmab_MarketableSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="us-gaap_OtherInvestmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="us-gaap_OtherInvestmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932739558055" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932739558055" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Financial Instruments - Other Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CurevacCollaborationMember" xlink:label="gmab_CurevacCollaborationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_CurevacCollaborationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BoltBiotherapeuticsIncMember" xlink:label="gmab_BoltBiotherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_BoltBiotherapeuticsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfInvestmentInCommonShares" xlink:label="gmab_PercentageOfInvestmentInCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="gmab_PercentageOfInvestmentInCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="gmab_MarketableSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="us-gaap_OtherInvestmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="us-gaap_OtherInvestmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_MeasurementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtFairValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_PurchasesFairValueMeasurementAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40409 - Disclosure - Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_MeasurementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtCostMember" xlink:label="ifrs-full_AtCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtFairValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="gmab_MarketableSecuritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_ExternalCreditGradesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:to="gmab_TripleaRatingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_PurchasesFairValueMeasurementAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesFairValueMeasurementAssets" xlink:label="ifrs-full_SalesFairValueMeasurementAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_SalesFairValueMeasurementAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FairValueAdjustmentOfMarketableSecurities" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="gmab_FairValueAdjustmentOfMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" xlink:label="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" xlink:label="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ForeignExchangeAdjustmentOfMarketableSecurities" xlink:label="gmab_ForeignExchangeAdjustmentOfMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="gmab_ForeignExchangeAdjustmentOfMarketableSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details" xlink:type="extended" xlink:title="40501 - Disclosure - Share-Based Instruments - Part 1 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637642932739628055" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637642932739628055" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637642932739628055" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637642932739628055" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_IfrsRestrictedStockUnitsRSUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_TreasuryShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details" xlink:type="extended" xlink:title="40502 - Disclosure - Share-Based Instruments - Part 2 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromMarch2017Member" xlink:label="gmab_WarrantsGrantedFromMarch2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsGrantedFromMarch2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsMember" xlink:label="gmab_WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WarrantVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsGrantedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsExercisedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ProceedsFromExerciseOfWarrants" xlink:label="gmab_ProceedsFromExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_ProceedsFromExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfTreasurySharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details" xlink:type="extended" xlink:title="40503 - Disclosure - Share-Based Instruments - Part 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsShareRepurchaseProgramAxis" xlink:label="gmab_IfrsShareRepurchaseProgramAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="gmab_IfrsShareRepurchaseProgramAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsShareRepurchaseProgramDomain" xlink:label="gmab_IfrsShareRepurchaseProgramDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsShareRepurchaseProgramAxis" xlink:to="gmab_IfrsShareRepurchaseProgramDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_RestrictedStockUnitsProgramMember" xlink:label="gmab_RestrictedStockUnitsProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsShareRepurchaseProgramDomain" xlink:to="gmab_RestrictedStockUnitsProgramMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WarrantVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfTreasurySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchaseProgramAuthorizedAmount" xlink:label="gmab_IfrsStockRepurchaseProgramAuthorizedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_IfrsStockRepurchaseProgramAuthorizedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchasedDuringPeriodShares" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_IfrsStockRepurchasedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchasedDuringPeriodValue" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_IfrsStockRepurchasedDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfShareCapital" xlink:label="gmab_PercentageOfShareCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_PercentageOfShareCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsTreasuryStockShares" xlink:label="gmab_IfrsTreasuryStockShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_IfrsTreasuryStockShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfIndependentBoardMembers" xlink:label="gmab_NumberOfIndependentBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_NumberOfIndependentBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfNonIndependentBoardMembers" xlink:label="gmab_NumberOfNonIndependentBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_NumberOfNonIndependentBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfEmployeeElectedBoardMembers" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_NumberOfEmployeeElectedBoardMembers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PropertiesMember" xlink:label="gmab_PropertiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="gmab_PropertiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsEquipmentMember" xlink:label="gmab_IfrsEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="gmab_IfrsEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_LeaseLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_AdditionsToRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FutureMinimumOperatingLeasePayments" xlink:label="gmab_FutureMinimumOperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="gmab_FutureMinimumOperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_EstimatedCapitalExpenditureForLease" xlink:label="gmab_EstimatedCapitalExpenditureForLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="gmab_EstimatedCapitalExpenditureForLease" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>gmab-20210630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2021 3:41:17 PM-->
<!--Modified on: 8/11/2021 3:41:17 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DocumentAndEntityInformationAbstract" xlink:label="gmab_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DocumentAndEntityInformationAbstract" xlink:to="gmab_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit or loss [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating result</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net result before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net result before tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income), continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net result</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net result</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net result per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net result per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts which will be re-classified to the income statement:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment of foreign currency fluctuations on subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowHedgesAbstract" xlink:label="ifrs-full_CashFlowHedgesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowHedgesAbstract" xlink:to="ifrs-full_CashFlowHedgesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowHedgesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow hedges [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowHedgesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments of cash flow hedges:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, change in fair value of financial liability attributable to change in credit risk of liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments during the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:to="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification adjustments on cash flow hedges, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments reclassified to the income statement to financial income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentReceivables" xlink:label="ifrs-full_NoncurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivables" xlink:to="ifrs-full_NoncurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other non-current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CorporateTaxReceivable" xlink:label="gmab_CorporateTaxReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CorporateTaxReceivable" xlink:to="gmab_CorporateTaxReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CorporateTaxReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Tax Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CorporateTaxReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Tax Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_CorporateTaxReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsMarketableSecuritiesCurrent" xlink:label="gmab_IfrsMarketableSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsMarketableSecuritiesCurrent" xlink:to="gmab_IfrsMarketableSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Marketable Securities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY AND LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisions" xlink:to="ifrs-full_NoncurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent deferred income classified as non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="ifrs-full_OtherNoncurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentPayables" xlink:to="ifrs-full_OtherNoncurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherNoncurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent deferred income classified as current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReversalOfFinancialItemsNet" xlink:label="gmab_ReversalOfFinancialItemsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ReversalOfFinancialItemsNet" xlink:to="gmab_ReversalOfFinancialItemsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ReversalOfFinancialItemsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The reversal of financial items to the cash flow under operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ReversalOfFinancialItemsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Financial Items, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_ReversalOfFinancialItemsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of financial items, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TotalAdjustmentsForNonCashTransactions" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TotalAdjustmentsForNonCashTransactions" xlink:to="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for total non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Adjustments For Non Cash Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for non-cash transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:to="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow From (Used In) Operating Activities Before Financial Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from operating activities before financial items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AdjustmentsForInterestOnLeasePayments" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AdjustmentsForInterestOnLeasePayments" xlink:to="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Interest On Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest elements of lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate taxes paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in tangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of investments other than investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities bought</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sales of investments other than investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of interests in investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other investments bought</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sales of investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other investments sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ProceedsFromExerciseOfWarrants" xlink:label="gmab_ProceedsFromExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ProceedsFromExerciseOfWarrants" xlink:to="gmab_ProceedsFromExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gmab_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs related to issuance of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal elements of lease payments</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PaymentsToAcquireTreasuryShares" xlink:label="gmab_PaymentsToAcquireTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PaymentsToAcquireTreasuryShares" xlink:to="gmab_PaymentsToAcquireTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PaymentsToAcquireTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow to acquire treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PaymentsToAcquireTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Acquire Treasury Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_PaymentsToAcquireTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:to="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Withholding Taxes On Behalf Of Employees On Net Settled R S Us</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of withholding taxes on behalf of employees on net settled RSUs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange rate adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents include:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, classified as cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Changes in Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retrospective application and retrospective restatement [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENT OF CHANGES IN EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, at beginning of period</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Cumulative Effect of New Accounting Principle in Period of Adoption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in accounting policy: Adoption of IFRS 15</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of stockholder's equity, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Adjusted For Cumulative Effect Of New Accounting Principle In Period Of Adoption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted total equity at January 1, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TransactionsWithOwners" xlink:label="gmab_TransactionsWithOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_TransactionsWithOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TransactionsWithOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TransactionsWithOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions With Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TransactionsWithOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with owners:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through exercise of warrants, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ExerciseOfWarrants" xlink:label="gmab_ExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ExerciseOfWarrants" xlink:to="gmab_ExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for cash</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:to="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses Related To Capital Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses Related To Capital Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses related to capital increases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquity" xlink:label="ifrs-full_ChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInEquity" xlink:to="ifrs-full_ChangesInEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ChangesInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses related to capital increases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfTreasuryShares" xlink:to="ifrs-full_PurchaseOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:to="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from net settlement of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Through Net Settlement Of Restricted Stock Units, Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net settlement of RSUs</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:to="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from tax on items recognized directly in equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Through Tax On Items Recognized Directly In Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax on items recognized directly in equity</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_BasisOfPresentationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ResultsForYearAbstract" xlink:label="gmab_ResultsForYearAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ResultsForYearAbstract" xlink:to="gmab_ResultsForYearAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ResultsForYearAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ResultsForYearAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_DisclosureOfFinanceIncomeExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Income and Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of finance income (cost) [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Income and Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:to="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for Basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description Of Accounting Policy For Basis Of Presentation Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant accounting policies [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xlink:to="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for recently adopted new accounting standards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Standards - Recently Adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Policies and Disclosures</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xlink:to="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for new accounting policy and disclosures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of New Accounting policies And Disclosures [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Policies and Disclosures</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xlink:to="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for Basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description Of Accounting Policy For Judgments And Estimates [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management Judgments and Estimates under IFRS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for segment reporting [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information about Geographical Areas</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for fair value measurement [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for investment in associates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expected impact of initial application of new standards or interpretations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of impact of the adoption of IFRS 16 on the financial statements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenue by type and collaboration partner under agreements</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xlink:to="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for segment disclosures in the financial statements as the group's business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Segment Disclosures In Financial Statements [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of segment disclosures in the financial statements as the group's business activities.</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfStaffCostTableTextBlock" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfStaffCostTableTextBlock" xlink:to="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of staff cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Staff Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of staff cost</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xlink:to="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of fair value of each warrant granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Assumptions for Warrants Granted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of each warrant granted</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xlink:to="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for corporate and deferred Tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Corporate And Deferred Tax [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of corporate and deferred Tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of effective tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:to="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of deferred taxes [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfNetResultTableTextBlock" xlink:label="gmab_DisclosureOfNetResultTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfNetResultTableTextBlock" xlink:to="gmab_DisclosureOfNetResultTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of net result for the year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Net Result [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net result</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Result Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent Company [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of assets [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of offsetting of financial assets and financial liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of marketable securities</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xlink:to="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of finance income and expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of RSUs activity</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfWarrantsActivityTableTextBlock" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfWarrantsActivityTableTextBlock" xlink:to="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of warrants activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Warrants Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of warrants activity</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xlink:to="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of balance sheet information relating to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of balance sheet amounts relating to leases</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xlink:to="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of comprehensive information relating to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of statement of comprehensive income amounts relating to leases</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsNumberOfReportingUnits" xlink:label="gmab_IfrsNumberOfReportingUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsNumberOfReportingUnits" xlink:to="gmab_IfrsNumberOfReportingUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsNumberOfReportingUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsNumberOfReportingUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of business unit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TypesOfRevenuesAxis" xlink:to="gmab_TypesOfRevenuesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TypesOfRevenuesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TypesOfRevenuesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of revenues [axis]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReductionInRoyaltyRevenue" xlink:label="gmab_ReductionInRoyaltyRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ReductionInRoyaltyRevenue" xlink:to="gmab_ReductionInRoyaltyRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ReductionInRoyaltyRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in royalty revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ReductionInRoyaltyRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction In Royalty Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PerformanceObligationsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligations [axis]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_UpfrontMilestonePaymentReceived" xlink:label="gmab_UpfrontMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_UpfrontMilestonePaymentReceived" xlink:to="gmab_UpfrontMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_UpfrontMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash in flow from upfront milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_UpfrontMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_UpfrontMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfPerformanceObligations" xlink:label="gmab_NumberOfPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfPerformanceObligations" xlink:to="gmab_NumberOfPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ContractTransactionPrice" xlink:label="gmab_ContractTransactionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ContractTransactionPrice" xlink:to="gmab_ContractTransactionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ContractTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The identified transaction price under the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ContractTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ContractTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract transaction price</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfDeliveryLicenses" xlink:label="gmab_NumberOfDeliveryLicenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfDeliveryLicenses" xlink:to="gmab_NumberOfDeliveryLicenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfDeliveryLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of delivery license programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfDeliveryLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Delivery Licenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfDeliveryLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of delivery license programs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:to="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from performance obligations satisfied or partially satisfied in previous periods</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PerformanceObligationRevenueRecognitionPeriod" xlink:label="gmab_PerformanceObligationRevenueRecognitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PerformanceObligationRevenueRecognitionPeriod" xlink:to="gmab_PerformanceObligationRevenueRecognitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PerformanceObligationRevenueRecognitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period over which performance obligation revenue will recognize.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PerformanceObligationRevenueRecognitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Obligation Revenue Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PerformanceObligationRevenueRecognitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligation Revenue recognition period</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:to="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Structure, Financial Risk and Related Items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of financial assets [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial assets [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of financial liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at January 1, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of credit risk exposure [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of risks [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_ExternalCreditGradesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExternalCreditGradesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External credit grades [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of credit risk exposure [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_MaximumExposureToCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum exposure to credit risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum credit exposure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:to="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum exposure to credit risk of loans or receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum credit exposure to receivables</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfMarketableSecurities" xlink:label="gmab_PercentageOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfMarketableSecurities" xlink:to="gmab_PercentageOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of marketable securities</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:to="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of marketable securities including interest receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities Including Interest Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities including interest receivables</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:to="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of bank deposits including short-term marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank Deposits Including Short Term Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total value of bank deposits</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfRevenue" xlink:label="gmab_PercentageOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfRevenue" xlink:to="gmab_PercentageOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue (as a percent)</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfMarketableSecuritiesInvested" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfMarketableSecuritiesInvested" xlink:to="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of marketable securities invested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Marketable Securities Invested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities were invested (as a percent)</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:to="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of possible increase or decrease in exchange rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Possible Increase (Decrease) In Exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of possible increase or decrease in exchange rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MeasurementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of changes in fair value measurement, assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Levels of fair value hierarchy [axis]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfInvestmentInCommonShares" xlink:label="gmab_PercentageOfInvestmentInCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfInvestmentInCommonShares" xlink:to="gmab_PercentageOfInvestmentInCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfInvestmentInCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of investment in common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfInvestmentInCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Investment in Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfInvestmentInCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of investment in common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FinanceIncomeAbstract" xlink:label="gmab_FinanceIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FinanceIncomeAbstract" xlink:to="gmab_FinanceIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FinanceIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FinanceIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Income:</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_InterestAndOtherFinancialIncome" xlink:label="gmab_InterestAndOtherFinancialIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_InterestAndOtherFinancialIncome" xlink:to="gmab_InterestAndOtherFinancialIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_InterestAndOtherFinancialIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The interest and other financial income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_InterestAndOtherFinancialIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and Other Financial Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_InterestAndOtherFinancialIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and other financial income</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_GainOnOtherInvestments" xlink:label="gmab_GainOnOtherInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_GainOnOtherInvestments" xlink:to="gmab_GainOnOtherInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_GainOnOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gains on other investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_GainOnOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain On Other Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_GainOnOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized and unrealized gains on other investments, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_GainsOnHedgingInstruments" xlink:label="gmab_GainsOnHedgingInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_GainsOnHedgingInstruments" xlink:to="gmab_GainsOnHedgingInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_GainsOnHedgingInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gains on hedging instruments in fair value hedges.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_GainsOnHedgingInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized and unrealized gains on fair value hedges, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_GainsOnHedgingInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized and unrealized gains on fair value hedges, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange rate gain, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FinanceExpensesAbstract" xlink:label="gmab_FinanceExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FinanceExpensesAbstract" xlink:to="gmab_FinanceExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FinanceExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FinanceExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expenses:</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_InterestAndOtherFinancialExpenses" xlink:label="gmab_InterestAndOtherFinancialExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_InterestAndOtherFinancialExpenses" xlink:to="gmab_InterestAndOtherFinancialExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_InterestAndOtherFinancialExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The interest and other financial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_InterestAndOtherFinancialExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and Other Financial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_InterestAndOtherFinancialExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and other financial expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LossesOnMarketableSecurities" xlink:label="gmab_LossesOnMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_LossesOnMarketableSecurities" xlink:to="gmab_LossesOnMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_LossesOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The losses on marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_LossesOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Losses on Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_LossesOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on marketable securities, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LossesOnOtherInvestmentsNet" xlink:label="gmab_LossesOnOtherInvestmentsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_LossesOnOtherInvestmentsNet" xlink:to="gmab_LossesOnOtherInvestmentsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_LossesOnOtherInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Losses On Other Investments Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_LossesOnOtherInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Losses On Other Investments Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_LossesOnOtherInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on other investments, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeLoss" xlink:to="ifrs-full_NetForeignExchangeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized and unrealized exchange rate losses, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net financial items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer to Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchasesFairValueMeasurementAssets" xlink:to="ifrs-full_PurchasesFairValueMeasurementAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases, fair value measurement, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions for the year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer to level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesFairValueMeasurementAssets" xlink:label="ifrs-full_SalesFairValueMeasurementAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesFairValueMeasurementAssets" xlink:to="ifrs-full_SalesFairValueMeasurementAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesFairValueMeasurementAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales, fair value measurement, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesFairValueMeasurementAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals for the year</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FairValueAdjustmentOfMarketableSecurities" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FairValueAdjustmentOfMarketableSecurities" xlink:to="gmab_FairValueAdjustmentOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of fair value adjustment of marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustment at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustment at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" xlink:label="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" xlink:to="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of fair value adjustment of marketable securities during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Marketable Securities During the Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustment for the period</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" xlink:label="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" xlink:to="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The marketable securities net book value in percentage of cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities Net Book Value in Percentage of Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net book value in percentage of cost</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ForeignExchangeAdjustmentOfMarketableSecurities" xlink:label="gmab_ForeignExchangeAdjustmentOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ForeignExchangeAdjustmentOfMarketableSecurities" xlink:to="gmab_ForeignExchangeAdjustmentOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ForeignExchangeAdjustmentOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of foreign exchange adjustment of marketable securities during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ForeignExchangeAdjustmentOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Exchange Adjustment of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ForeignExchangeAdjustmentOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:to="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WeightedAverageFairValueOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of RSU granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale or issue of treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantVestingPeriod" xlink:to="gmab_WarrantVestingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which the right to exercise an warrant is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WarrantVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant vesting period</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsOutstanding" xlink:to="gmab_NumberOfWarrantsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants held as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:to="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants granted during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Granted During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:to="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants exercised during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Exercised During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:to="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants expired or lapsed or cancelled during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Expired Or Lapsed Or Cancelled During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired/lapsed/cancelled</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Of Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of warrants granted</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:to="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of fair value of warrants during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Of Fair Value Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of fair market value</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:to="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital attributed by exercise of warrants which increase the share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Share Capital Attributed To Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital attributed to exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfTreasurySharesOutstanding" xlink:to="gmab_NumberOfTreasurySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfTreasurySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares that has been held in treasury.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfTreasurySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Treasury Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfTreasurySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares outstanding</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsShareRepurchaseProgramAxis" xlink:label="gmab_IfrsShareRepurchaseProgramAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsShareRepurchaseProgramAxis" xlink:to="gmab_IfrsShareRepurchaseProgramAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsShareRepurchaseProgramAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of the share repurchase program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsShareRepurchaseProgramAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ifrs Share Repurchase Program [Axis]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchaseProgramAuthorizedAmount" xlink:label="gmab_IfrsStockRepurchaseProgramAuthorizedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsStockRepurchaseProgramAuthorizedAmount" xlink:to="gmab_IfrsStockRepurchaseProgramAuthorizedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsStockRepurchaseProgramAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of stock repurchase plan authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsStockRepurchaseProgramAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Repurchase Program, Authorized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsStockRepurchaseProgramAuthorizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of stock repurchase plan authorized</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Repurchase Program, Number of Shares Authorized to be Repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized to be repurchased</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchasedDuringPeriodShares" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsStockRepurchasedDuringPeriodShares" xlink:to="gmab_IfrsStockRepurchasedDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ifrs Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchased shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchasedDuringPeriodValue" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsStockRepurchasedDuringPeriodValue" xlink:to="gmab_IfrsStockRepurchasedDuringPeriodValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Repurchased During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchased values</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfShareCapital" xlink:label="gmab_PercentageOfShareCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfShareCapital" xlink:to="gmab_PercentageOfShareCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfShareCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfShareCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfShareCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsTreasuryStockShares" xlink:label="gmab_IfrsTreasuryStockShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsTreasuryStockShares" xlink:to="gmab_IfrsTreasuryStockShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsTreasuryStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares that has been treasury stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsTreasuryStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ifrs Treasury Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsTreasuryStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury stock shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [line items]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfIndependentBoardMembers" xlink:label="gmab_NumberOfIndependentBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfIndependentBoardMembers" xlink:to="gmab_NumberOfIndependentBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of independent board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Independent Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of independent board members</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfNonIndependentBoardMembers" xlink:label="gmab_NumberOfNonIndependentBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfNonIndependentBoardMembers" xlink:to="gmab_NumberOfNonIndependentBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfNonIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of non independent board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfNonIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Non Independent Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfNonIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of non independent board members</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfEmployeeElectedBoardMembers" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfEmployeeElectedBoardMembers" xlink:to="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employee elected board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Employee Elected Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employee elected board members</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation charge of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to short-term leases for which recognition exemption has been used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to short-term leases</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FutureMinimumOperatingLeasePayments" xlink:label="gmab_FutureMinimumOperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FutureMinimumOperatingLeasePayments" xlink:to="gmab_FutureMinimumOperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FutureMinimumOperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of future minimum operating lease payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FutureMinimumOperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Minimum Operating Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_FutureMinimumOperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum payments</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_EstimatedCapitalExpenditureForLease" xlink:label="gmab_EstimatedCapitalExpenditureForLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_EstimatedCapitalExpenditureForLease" xlink:to="gmab_EstimatedCapitalExpenditureForLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_EstimatedCapitalExpenditureForLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of estimated capital expenditure for lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_EstimatedCapitalExpenditureForLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Capital Expenditure for Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_EstimatedCapitalExpenditureForLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated capital expenditure for lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefits expense</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xlink:to="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of staff cost included in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Staff Costs Included In Research And Development Expense</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xlink:to="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of staff cost included in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Staff Costs Included In General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xlink:to="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of staff cost included in government grants related to research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Staff Costs Included In Government Grants Related To Research And Development Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherPayables" xlink:label="ifrs-full_OtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes Of Share Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AmericanDepositorySharesMember" xlink:label="gmab_AmericanDepositorySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AmericanDepositorySharesMember" xlink:to="gmab_AmericanDepositorySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AmericanDepositorySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for American Depository Shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AmericanDepositorySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">American Depository Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AmericanDepositorySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Premium [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve Of Exchange Differences On Translation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="ifrs-full_CashFlowHedgesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowHedgesMember" xlink:to="ifrs-full_CashFlowHedgesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowHedgesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow Hedges [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowHedgesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow hedges</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restated [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currently stated [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Due To Application Of I F R S15 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in accounting policy: Adoption of IFRS 15</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes Of Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MarketableSecuritiesMember" xlink:to="gmab_MarketableSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MarketableSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for marketable securities .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MarketableSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_MarketableSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_TypesOfRevenuesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TypesOfRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for This member stands for all types of revenues from customers. It also represents the standard value for the 'Types of revenues' axis if no other member is used.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TypesOfRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types Of Revenues [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TypesOfRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of revenues [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_RoyaltiesRevenueMember" xlink:label="gmab_RoyaltiesRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_RoyaltiesRevenueMember" xlink:to="gmab_RoyaltiesRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_RoyaltiesRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for revenue form royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_RoyaltiesRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_RoyaltiesRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReimbursementIncomeMember" xlink:label="gmab_ReimbursementIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ReimbursementIncomeMember" xlink:to="gmab_ReimbursementIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ReimbursementIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for reimbursement income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ReimbursementIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ReimbursementIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement income</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MilestonePaymentsRevenueMember" xlink:label="gmab_MilestonePaymentsRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MilestonePaymentsRevenueMember" xlink:to="gmab_MilestonePaymentsRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MilestonePaymentsRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for revenue from milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MilestonePaymentsRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_MilestonePaymentsRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_LicenseFeesMember" xlink:to="gmab_LicenseFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_LicenseFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for revenue from license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_LicenseFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_LicenseFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fees</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithJanssenMember" xlink:label="gmab_AgreementsWithJanssenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithJanssenMember" xlink:to="gmab_AgreementsWithJanssenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithJanssenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaborative arrangement with Janssen (Darzalex/Daratumumab &amp; DuoBody).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithJanssenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements With Janssen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AgreementsWithJanssenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithAbbvieMember" xlink:to="gmab_AgreementsWithAbbvieMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithAbbvieMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Abbvie.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithAbbvieMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements With Abbvie [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AgreementsWithAbbvieMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AbbVie</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithRocheMember" xlink:label="gmab_AgreementsWithRocheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithRocheMember" xlink:to="gmab_AgreementsWithRocheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithRocheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Roche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithRocheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements With Roche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AgreementsWithRocheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roche</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithSeagenMember" xlink:label="gmab_AgreementsWithSeagenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithSeagenMember" xlink:to="gmab_AgreementsWithSeagenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithSeagenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Seagen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithSeagenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements With Seagen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AgreementsWithSeagenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seagen</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithBointechMember" xlink:label="gmab_AgreementsWithBointechMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithBointechMember" xlink:to="gmab_AgreementsWithBointechMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithBointechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangements with BioNTech.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithBointechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements With Bointech [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AgreementsWithBointechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioNTech</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithNovartisMember" xlink:label="gmab_AgreementsWithNovartisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithNovartisMember" xlink:to="gmab_AgreementsWithNovartisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithNovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaborative arrangement with Novartis (Arzaerra/Ofatumumab).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithNovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements With Novartis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AgreementsWithNovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis (Arzaerra/Ofatumumab)</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_OtherCollaborationPartnersMember" xlink:label="gmab_OtherCollaborationPartnersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_OtherCollaborationPartnersMember" xlink:to="gmab_OtherCollaborationPartnersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_OtherCollaborationPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaborative arrangement with other collaboration partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_OtherCollaborationPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Collaboration Partners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_OtherCollaborationPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other collaboration partners</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithSeatleGeneticsMember" xlink:label="gmab_AgreementsWithSeatleGeneticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithSeatleGeneticsMember" xlink:to="gmab_AgreementsWithSeatleGeneticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithSeatleGeneticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Seatle Genetics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithSeatleGeneticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements With Seatle Genetics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AgreementsWithSeatleGeneticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seattle Genetics</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Top Of Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bottom Of Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PerformanceObligationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Obligations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PerformanceObligationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligations [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Obligations Satisfied At Point In Time [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligations satisfied at point in time</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:to="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Obligations Satisfied Over Time [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligations satisfied over time</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets Category [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets, category [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets At Fair Value Through Profit Or Loss Category [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets measured at fair value through profit or loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets At Amortised Cost Category [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets measured at amortized cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets, class [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="us-gaap_OtherInvestmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestmentsMember" xlink:to="us-gaap_OtherInvestmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Investments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Investments</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReceivablesExPrepaymentsMember" xlink:label="gmab_ReceivablesExPrepaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ReceivablesExPrepaymentsMember" xlink:to="gmab_ReceivablesExPrepaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ReceivablesExPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Receivables Excluding Prepayments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ReceivablesExPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables Ex Prepayments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ReceivablesExPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables ex. prepayments</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCashAndCashEquivalentsMember" xlink:label="gmab_IfrsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCashAndCashEquivalentsMember" xlink:to="gmab_IfrsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Category [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, category [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities At Amortised Cost Category [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities measured at amortized cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, class [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_OtherPayablesMember" xlink:label="gmab_OtherPayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_OtherPayablesMember" xlink:to="gmab_OtherPayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_OtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_OtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_OtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types Of Risks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entitys Total For External Credit Grades [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for external credit grades [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TripleaRatingMember" xlink:to="gmab_TripleaRatingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TripleaRatingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Triple A-rating.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TripleaRatingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Triplea Rating [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TripleaRatingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Triple A-rating from Moody's, S&amp;P or Fitch</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="currency_EUR" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">E U [R]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_EUR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EUR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_DKK" xlink:label="currency_DKK" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_DKK" xlink:to="currency_DKK_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_DKK_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">D K [K]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_DKK_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DKK</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S [D]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP" xlink:label="currency_GBP" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_GBP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">G B [P]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_GBP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GBP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AggregatedMeasurementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedMeasurementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AggregatedMeasurementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated measurement [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AtFairValueMember" xlink:to="ifrs-full_AtFairValueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AtFairValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Fair Value [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AtFairValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Book value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Levels Of Fair Value Hierarchy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All levels of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level1 Of Fair Value Hierarchy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level2 Of Fair Value Hierarchy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level3 Of Fair Value Hierarchy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CurevacCollaborationMember" xlink:label="gmab_CurevacCollaborationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CurevacCollaborationMember" xlink:to="gmab_CurevacCollaborationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CurevacCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to CureVac Collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CurevacCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Curevac Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_CurevacCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BoltBiotherapeuticsIncMember" xlink:label="gmab_BoltBiotherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_BoltBiotherapeuticsIncMember" xlink:to="gmab_BoltBiotherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_BoltBiotherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Bolt Biotherapeutics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_BoltBiotherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bolt Biotherapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_BoltBiotherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bolt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtCostMember" xlink:label="ifrs-full_AtCostMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AtCostMember" xlink:to="ifrs-full_AtCostMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AtCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Cost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AtCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entitys Total For Related Parties [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Payment Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:to="gmab_IfrsRestrictedStockUnitsRSUsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Restricted Stock Units R S Us [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:to="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants granted from August 2004 until April 2012.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted From August2004 Until April2012 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted from August 2004 until April 2012</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:to="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants granted from April 2012 until March 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted From April2012 Until March2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted from April 2012 until March 2017</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromMarch2017Member" xlink:label="gmab_WarrantsGrantedFromMarch2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsGrantedFromMarch2017Member" xlink:to="gmab_WarrantsGrantedFromMarch2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsGrantedFromMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants granted from march 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsGrantedFromMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted From March2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WarrantsGrantedFromMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted from March 2017</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsMember" xlink:label="gmab_WarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsMember" xlink:to="gmab_WarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsShareRepurchaseProgramDomain" xlink:label="gmab_IfrsShareRepurchaseProgramDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsShareRepurchaseProgramDomain" xlink:to="gmab_IfrsShareRepurchaseProgramDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsShareRepurchaseProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of the share repurchase program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsShareRepurchaseProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Share Repurchase Program [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsShareRepurchaseProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ifrs Share Repurchase Program [Domain]</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_RestrictedStockUnitsProgramMember" xlink:label="gmab_RestrictedStockUnitsProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_RestrictedStockUnitsProgramMember" xlink:to="gmab_RestrictedStockUnitsProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_RestrictedStockUnitsProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to RSU program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_RestrictedStockUnitsProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_RestrictedStockUnitsProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Program</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key Management Personnel Of Entity Or Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key Changes to Executive Management</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PropertiesMember" xlink:label="gmab_PropertiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PropertiesMember" xlink:to="gmab_PropertiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PropertiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to properties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PropertiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Properties [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PropertiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Properties</label>
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsEquipmentMember" xlink:label="gmab_IfrsEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsEquipmentMember" xlink:to="gmab_IfrsEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>gmab-20210630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2021 3:41:17 PM-->
<!--Modified on: 8/11/2021 3:41:17 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.genmab.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#StatementConsolidatedStatementsOfChangesInEquity" roleURI="http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureBasisOfPresentation" roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRevenue" roleURI="http://www.genmab.com/role/DisclosureRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstruments" roleURI="http://www.genmab.com/role/DisclosureFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinanceIncomeAndExpenses" roleURI="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstruments" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRelatedParties" roleURI="http://www.genmab.com/role/DisclosureRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureLeases" roleURI="http://www.genmab.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureSubsequentEvents" roleURI="http://www.genmab.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureBasisOfPresentationPolicies" roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureBasisOfPresentationTables" roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRevenueTables" roleURI="http://www.genmab.com/role/DisclosureRevenueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinanceIncomeAndExpensesTables" roleURI="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstrumentsTables" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureLeasesTables" roleURI="http://www.genmab.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRevenueDetails" roleURI="http://www.genmab.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRevenueAbbvieCollaborationAgreementDetails" roleURI="http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsFinancialRiskDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsFairValueMeasurementDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialInstrumentsOtherInvestmentsDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureFinancialIncomeAndExpensesDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails" roleURI="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails" roleURI="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstrumentsPart1Details" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstrumentsPart2Details" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureShareBasedInstrumentsPart3Details" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20210630.xsd#DisclosureLeasesDetails" roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DocumentAndEntityInformationAbstract" xlink:label="gmab_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_637642932739738053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable_637642932739738053" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_637642932739738053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637642932739738053" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_637642932739738053" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637642932739738053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_637642932739738053" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637642932739738053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637642932739738053" xlink:to="ifrs-full_OrdinarySharesMember_637642932739748055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AmericanDepositorySharesMember" xlink:label="gmab_AmericanDepositorySharesMember_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637642932739738053" xlink:to="gmab_AmericanDepositorySharesMember_637642932739748055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637642932739738053" xlink:to="dei_DocumentInformationLineItems_637642932739748055" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentType_637642932739748055" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentRegistrationStatement_637642932739748055" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentPeriodEndDate_637642932739748055" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityRegistrantName_637642932739748055" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentAnnualReport_637642932739748055" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityCommonStockSharesOutstanding_637642932739748055" order="6" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637642932739748055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityWellKnownSeasonedIssuer_637642932739748055" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityVoluntaryFilers_637642932739758218" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityCurrentReportingStatus_637642932739758218" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityInteractiveDataCurrent_637642932739758218" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityFilerCategory_637642932739758218" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityEmergingGrowthCompany_637642932739758218" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityExTransitionPeriod_637642932739758218" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityShellCompany_637642932739758218" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentShellCompanyReport_637642932739758218" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637642932739758218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentTransitionReport_637642932739758218" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637642932739768063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_EntityCentralIndexKey_637642932739768063" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637642932739768063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_CurrentFiscalYearEndDate_637642932739768063" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637642932739768063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentFiscalYearFocus_637642932739768063" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637642932739768063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_DocumentFiscalPeriodFocus_637642932739768063" order="20" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637642932739768063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637642932739748055" xlink:to="dei_AmendmentFlag_637642932739768063" order="21" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Statements of Comprehensive Income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract_637642932739768063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_637642932739768063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_Revenue_637642932739778063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637642932739778063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637642932739778063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_OperatingExpense_637642932739778063" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637642932739778063" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_FinanceIncome_637642932739778063" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_FinanceCosts_637642932739778063" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_ProfitLossBeforeTax_637642932739778063" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637642932739778063" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_ProfitLoss_637642932739778063" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_BasicEarningsLossPerShare_637642932739778063" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_637642932739778063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_DilutedEarningsLossPerShare_637642932739778063" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_637642932739788061" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract_637642932739788061" xlink:to="ifrs-full_ProfitLoss_637642932739788061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637642932739768063" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_637642932739788061" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_637642932739788061" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637642932739788061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637642932739788061" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637642932739788061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowHedgesAbstract" xlink:label="ifrs-full_CashFlowHedgesAbstract_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_637642932739788061" xlink:to="ifrs-full_CashFlowHedgesAbstract_637642932739788061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowHedgesAbstract_637642932739788061" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637642932739788061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowHedgesAbstract_637642932739788061" xlink:to="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637642932739788061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_637642932739788061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_637642932739788061" xlink:to="ifrs-full_ComprehensiveIncome_637642932739788061" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_637642932739798053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637642932739798053" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment_637642932739798053" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_RightofuseAssets_637642932739798053" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentReceivables" xlink:label="ifrs-full_NoncurrentReceivables_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentReceivables_637642932739798053" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NetDeferredTaxAssets_637642932739798053" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_637642932739798053" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets_637642932739798053" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CorporateTaxReceivable" xlink:label="gmab_CorporateTaxReceivable_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="gmab_CorporateTaxReceivable_637642932739798053" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637642932739798053" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsMarketableSecuritiesCurrent" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_637642932739798053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="gmab_IfrsMarketableSecuritiesCurrent_637642932739798053" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_637642932739808219" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets_637642932739808219" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets_637642932739808219" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_IssuedCapital_637642932739808219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_SharePremium_637642932739808219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_OtherReserves_637642932739808219" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_RetainedEarnings_637642932739808219" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637642932739808219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_Equity_637642932739808219" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_637642932739818062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_NoncurrentProvisions_637642932739818062" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637642932739818062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637642932739818062" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637642932739818062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637642932739818062" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="ifrs-full_OtherNoncurrentPayables_637642932739818062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_OtherNoncurrentPayables_637642932739818062" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637642932739818062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_NoncurrentLiabilities_637642932739818062" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions_637642932739818062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_Provisions_637642932739818062" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_637642932739818062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_637642932739818062" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637642932739828062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_CurrentLeaseLiabilities_637642932739828062" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637642932739828062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637642932739828062" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_637642932739828062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_OtherCurrentPayables_637642932739828062" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637642932739828062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_CurrentLiabilities_637642932739828062" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_637642932739828062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_Liabilities_637642932739828062" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_637642932739828062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637642932739808219" xlink:to="ifrs-full_EquityAndLiabilities_637642932739828062" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="ifrs-full_ProfitLossBeforeTax_637642932739838059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReversalOfFinancialItemsNet" xlink:label="gmab_ReversalOfFinancialItemsNet_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="gmab_ReversalOfFinancialItemsNet_637642932739838059" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TotalAdjustmentsForNonCashTransactions" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="gmab_TotalAdjustmentsForNonCashTransactions_637642932739838059" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_637642932739838059" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637642932739838059" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637642932739838059" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AdjustmentsForInterestOnLeasePayments" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="gmab_AdjustmentsForInterestOnLeasePayments_637642932739838059" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637642932739838059" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_637642932739838059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_637642932739838059" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637642932739838059" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637642932739848059" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637642932739848059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637642932739848059" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_637642932739848059" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739848059" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637642932739848059" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637642932739848059" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637642932739848059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637642932739848059" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637642932739848059" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637642932739858082" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ProceedsFromExerciseOfWarrants" xlink:label="gmab_ProceedsFromExerciseOfWarrants_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" xlink:to="gmab_ProceedsFromExerciseOfWarrants_637642932739858082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" xlink:to="ifrs-full_ProceedsFromIssuingShares_637642932739858082" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" xlink:to="ifrs-full_PaymentsForShareIssueCosts_637642932739858082" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637642932739858082" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PaymentsToAcquireTreasuryShares" xlink:label="gmab_PaymentsToAcquireTreasuryShares_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" xlink:to="gmab_PaymentsToAcquireTreasuryShares_637642932739858082" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637642932739858082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" xlink:to="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637642932739858082" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739868064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637642932739858082" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637642932739868064" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637642932739868064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637642932739868064" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637642932739868064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_637642932739868064" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637642932739868064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637642932739868064" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6376429327398680641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_6376429327398680641" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_637642932739868064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_637642932739868064" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash_637642932739878057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract_637642932739868064" xlink:to="ifrs-full_Cash_637642932739878057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_637642932739878057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract_637642932739868064" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_637642932739878057" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Changes in Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_637642932739878057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_637642932739878057" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_637642932739878057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637642932739878057" xlink:to="ifrs-full_ComponentsOfEquityAxis_637642932739878057" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_637642932739878057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637642932739878057" xlink:to="ifrs-full_IssuedCapitalMember_637642932739878057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember_637642932739878057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637642932739878057" xlink:to="ifrs-full_SharePremiumMember_637642932739878057" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_637642932739878057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637642932739878057" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_637642932739878057" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="ifrs-full_CashFlowHedgesMember_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637642932739878057" xlink:to="ifrs-full_CashFlowHedgesMember_637642932739888063" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637642932739878057" xlink:to="ifrs-full_RetainedEarningsMember_637642932739888063" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637642932739878057" xlink:to="ifrs-full_EquityMember_637642932739888063" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637642932739878057" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637642932739888063" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637642932739888063" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_637642932739888063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637642932739888063" xlink:to="ifrs-full_RestatedMember_637642932739888063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637642932739878057" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="ifrs-full_Equity_637642932739888063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="ifrs-full_NumberOfSharesOutstanding_637642932739888063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637642932739888063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637642932739888063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637642932739888063" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="ifrs-full_ProfitLoss_637642932739898083" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="ifrs-full_OtherComprehensiveIncome_637642932739898083" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="ifrs-full_ComprehensiveIncome_637642932739898083" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TransactionsWithOwners" xlink:label="gmab_TransactionsWithOwners_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="gmab_TransactionsWithOwners_637642932739898083" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_637642932739898083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ExerciseOfWarrants" xlink:label="gmab_ExerciseOfWarrants_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="gmab_ExerciseOfWarrants_637642932739898083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="ifrs-full_IssueOfEquity_637642932739898083" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_637642932739898083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="gmab_ExpensesRelatedToCapitalIncreaseDecrease_637642932739898083" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ChangesInEquity" xlink:label="ifrs-full_ChangesInEquity_637642932739908058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="ifrs-full_ChangesInEquity_637642932739908058" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares_637642932739908058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="ifrs-full_PurchaseOfTreasuryShares_637642932739908058" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_637642932739908058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_637642932739908058" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_637642932739908058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_637642932739908058" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_637642932739908058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637642932739898083" xlink:to="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_637642932739908058" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637642932739908058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="ifrs-full_Equity_637642932739908058" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_637642932739908058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637642932739888063" xlink:to="ifrs-full_NumberOfSharesOutstanding_637642932739908058" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637642932739918058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637642932739918058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10201 - Disclosure - Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ResultsForYearAbstract" xlink:label="gmab_ResultsForYearAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_637642932739918058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_637642932739918058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstruments" xlink:type="extended" xlink:title="10301 - Disclosure - Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_637642932739918058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_637642932739918058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses" xlink:type="extended" xlink:title="10401 - Disclosure - Finance Income and Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637642932739918058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="us-gaap_StatementTable_637642932739918058" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637642932739928061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637642932739918058" xlink:to="us-gaap_StatementLineItems_637642932739928061" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_637642932739928061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_637642932739928061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstruments" xlink:type="extended" xlink:title="10501 - Disclosure - Share-Based Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637642932739928061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637642932739928061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRelatedParties" xlink:type="extended" xlink:title="10601 - Disclosure - Related Parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_637642932739928061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_637642932739928061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10701 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_637642932739928061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_637642932739928061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10801 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637642932739938066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - Basis of Presentation (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_637642932739938066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_637642932739938066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_637642932739938066" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_637642932739938066" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_637642932739938066" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_637642932739938066" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_637642932739938066" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_637642932739938066" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_637642932739938066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_637642932739938066" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureBasisOfPresentationTables" xlink:type="extended" xlink:title="30103 - Disclosure - Basis of Presentation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_637642932739948058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_637642932739948058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="30203 - Disclosure - Revenue (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ResultsForYearAbstract" xlink:label="gmab_ResultsForYearAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637642932739948058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637642932739948058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_637642932739948058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_637642932739948058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfStaffCostTableTextBlock" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_637642932739948058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="gmab_DisclosureOfStaffCostTableTextBlock_637642932739948058" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_637642932739948058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_637642932739948058" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_637642932739948058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_637642932739948058" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637642932739958087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="ifrs-full_DisclosureOfDeferredTaxesExplanatory_637642932739958087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfNetResultTableTextBlock" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="gmab_DisclosureOfNetResultTableTextBlock_637642932739958087" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_637642932739958087" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932739958087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932739958087" xlink:to="dei_LegalEntityAxis_637642932739958087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637642932739958087" xlink:to="dei_EntityDomain_637642932739958087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637642932739958087" xlink:to="srt_ParentCompanyMember_637642932739958087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932739958087" xlink:to="ifrs-full_ClassesOfAssetsAxis_637642932739958087" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_637642932739958087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_637642932739958087" xlink:to="ifrs-full_ClassesOfAssetsMember_637642932739958087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember_637642932739968239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637642932739958087" xlink:to="gmab_MarketableSecuritiesMember_637642932739968239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637642932739968239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932739958087" xlink:to="us-gaap_StatementLineItems_637642932739968239" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_637642932739968239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637642932739968239" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_637642932739968239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_637642932739968239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637642932739968239" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_637642932739968239" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinanceIncomeAndExpensesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Finance Income and Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_637642932739968239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_637642932739968239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-Based Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_637642932739968239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_637642932739968239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfWarrantsActivityTableTextBlock" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_637642932739968239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="gmab_DisclosureOfWarrantsActivityTableTextBlock_637642932739968239" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_637642932739978063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_637642932739978063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_637642932739978063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_637642932739978063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsNumberOfReportingUnits" xlink:label="gmab_IfrsNumberOfReportingUnits_637642932739978063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_IfrsNumberOfReportingUnits_637642932739978063" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ResultsForYearAbstract" xlink:label="gmab_ResultsForYearAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932739978063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_ResultsForYearAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932739978063" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis_637642932739978063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932739978063" xlink:to="gmab_TypesOfRevenuesAxis_637642932739978063" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember_637642932739978063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesAxis_637642932739978063" xlink:to="gmab_TypesOfRevenuesMember_637642932739978063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_RoyaltiesRevenueMember" xlink:label="gmab_RoyaltiesRevenueMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637642932739978063" xlink:to="gmab_RoyaltiesRevenueMember_637642932739988069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReimbursementIncomeMember" xlink:label="gmab_ReimbursementIncomeMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637642932739978063" xlink:to="gmab_ReimbursementIncomeMember_637642932739988069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MilestonePaymentsRevenueMember" xlink:label="gmab_MilestonePaymentsRevenueMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637642932739978063" xlink:to="gmab_MilestonePaymentsRevenueMember_637642932739988069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637642932739978063" xlink:to="gmab_LicenseFeesMember_637642932739988069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932739978063" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932739988069" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932739988069" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithJanssenMember" xlink:label="gmab_AgreementsWithJanssenMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_AgreementsWithJanssenMember_637642932739988069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_AgreementsWithAbbvieMember_637642932739988069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithRocheMember" xlink:label="gmab_AgreementsWithRocheMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_AgreementsWithRocheMember_637642932739988069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithSeagenMember" xlink:label="gmab_AgreementsWithSeagenMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_AgreementsWithSeagenMember_637642932739988069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithBointechMember" xlink:label="gmab_AgreementsWithBointechMember_637642932739988069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_AgreementsWithBointechMember_637642932739988069" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithNovartisMember" xlink:label="gmab_AgreementsWithNovartisMember_637642932740098049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_AgreementsWithNovartisMember_637642932740098049" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_OtherCollaborationPartnersMember" xlink:label="gmab_OtherCollaborationPartnersMember_637642932740098049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_OtherCollaborationPartnersMember_637642932740098049" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithSeatleGeneticsMember" xlink:label="gmab_AgreementsWithSeatleGeneticsMember_637642932740098049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932739988069" xlink:to="gmab_AgreementsWithSeatleGeneticsMember_637642932740098049" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740098049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932739978063" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740098049" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637642932740098049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740098049" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637642932740098049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReductionInRoyaltyRevenue" xlink:label="gmab_ReductionInRoyaltyRevenue_637642932740098049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740098049" xlink:to="gmab_ReductionInRoyaltyRevenue_637642932740098049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Revenue - AbbVie Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932740108047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932740108047" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740108047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740108047" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740108047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740108047" xlink:to="gmab_AgreementsWithAbbvieMember_637642932740108047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932740108047" xlink:to="gmab_TypesOfRevenuesAxis_637642932740108047" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesAxis_637642932740108047" xlink:to="gmab_TypesOfRevenuesMember_637642932740108047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637642932740108047" xlink:to="gmab_LicenseFeesMember_637642932740108047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932740108047" xlink:to="ifrs-full_RangeAxis_637642932740108047" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637642932740108047" xlink:to="ifrs-full_RangesMember_637642932740108047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637642932740108047" xlink:to="ifrs-full_TopOfRangeMember_637642932740108047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637642932740108047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637642932740108047" xlink:to="ifrs-full_BottomOfRangeMember_637642932740108047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932740108047" xlink:to="ifrs-full_PerformanceObligationsAxis_637642932740118113" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsAxis_637642932740118113" xlink:to="ifrs-full_PerformanceObligationsMember_637642932740118113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember" xlink:label="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsMember_637642932740118113" xlink:to="ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember_637642932740118113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PerformanceObligationsSatisfiedOverTimeMember" xlink:label="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsMember_637642932740118113" xlink:to="ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_637642932740118113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637642932740108047" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_UpfrontMilestonePaymentReceived" xlink:label="gmab_UpfrontMilestonePaymentReceived_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" xlink:to="gmab_UpfrontMilestonePaymentReceived_637642932740118113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637642932740118113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfPerformanceObligations" xlink:label="gmab_NumberOfPerformanceObligations_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" xlink:to="gmab_NumberOfPerformanceObligations_637642932740118113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ContractTransactionPrice" xlink:label="gmab_ContractTransactionPrice_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" xlink:to="gmab_ContractTransactionPrice_637642932740118113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfDeliveryLicenses" xlink:label="gmab_NumberOfDeliveryLicenses_637642932740118113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" xlink:to="gmab_NumberOfDeliveryLicenses_637642932740118113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods" xlink:label="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" xlink:to="ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods_637642932740128047" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PerformanceObligationRevenueRecognitionPeriod" xlink:label="gmab_PerformanceObligationRevenueRecognitionPeriod_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637642932740118113" xlink:to="gmab_PerformanceObligationRevenueRecognitionPeriod_637642932740128047" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments - Financial Assets and Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_637642932740128047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_637642932740128047" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_637642932740128047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis_637642932740128047" xlink:to="ifrs-full_FinancialAssetsCategoryMember_637642932740128047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsCategoryMember_637642932740128047" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_637642932740128047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsCategoryMember_637642932740128047" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_637642932740128047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_637642932740128047" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740128047" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_637642932740128047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740128047" xlink:to="ifrs-full_FinancialAssetsMember_637642932740128047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740128047" xlink:to="gmab_MarketableSecuritiesMember_637642932740138045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="us-gaap_OtherInvestmentsMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740128047" xlink:to="us-gaap_OtherInvestmentsMember_637642932740138045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ReceivablesExPrepaymentsMember" xlink:label="gmab_ReceivablesExPrepaymentsMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740128047" xlink:to="gmab_ReceivablesExPrepaymentsMember_637642932740138045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCashAndCashEquivalentsMember" xlink:label="gmab_IfrsCashAndCashEquivalentsMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740128047" xlink:to="gmab_IfrsCashAndCashEquivalentsMember_637642932740138045" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_637642932740128047" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_637642932740138045" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_637642932740138045" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_637642932740138045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember_637642932740138045" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_637642932740138045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_637642932740128047" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_637642932740138045" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_637642932740138045" xlink:to="ifrs-full_FinancialLiabilitiesMember_637642932740138045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_OtherPayablesMember" xlink:label="gmab_OtherPayablesMember_637642932740138045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_637642932740138045" xlink:to="gmab_OtherPayablesMember_637642932740138045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember_637642932740148047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_637642932740138045" xlink:to="ifrs-full_LeaseLiabilitiesMember_637642932740148047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_637642932740148047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_637642932740128047" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_637642932740148047" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_637642932740148047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_637642932740148047" xlink:to="ifrs-full_FinancialAssets_637642932740148047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities_637642932740148047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_637642932740148047" xlink:to="ifrs-full_FinancialLiabilities_637642932740148047" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Financial Instruments - Financial Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable_637642932740148047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureTable_637642932740148047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_637642932740148047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637642932740148047" xlink:to="ifrs-full_TypesOfRisksAxis_637642932740148047" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_637642932740148047" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_637642932740148047" xlink:to="ifrs-full_TypesOfRisksMember_637642932740148047" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637642932740148047" xlink:to="ifrs-full_CreditRiskMember_637642932740158104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637642932740148047" xlink:to="ifrs-full_CurrencyRiskMember_637642932740158104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637642932740148047" xlink:to="ifrs-full_ExternalCreditGradesAxis_637642932740158104" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesAxis_637642932740158104" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932740158104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932740158104" xlink:to="gmab_TripleaRatingMember_637642932740158104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637642932740148047" xlink:to="srt_CurrencyAxis_637642932740158104" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_637642932740158104" xlink:to="currency_AllCurrenciesDomain_637642932740158104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR" xlink:label="currency_EUR_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637642932740158104" xlink:to="currency_EUR_637642932740158104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_DKK" xlink:label="currency_DKK_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637642932740158104" xlink:to="currency_DKK_637642932740158104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD" xlink:label="currency_USD_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637642932740158104" xlink:to="currency_USD_637642932740158104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP" xlink:label="currency_GBP_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637642932740158104" xlink:to="currency_GBP_637642932740158104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740158104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637642932740148047" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740158104" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740158104" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740168133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740168133" xlink:to="gmab_AgreementsWithAbbvieMember_637642932740168133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637642932740148047" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="ifrs-full_MaximumExposureToCreditRisk_637642932740168133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_637642932740168133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfMarketableSecurities" xlink:label="gmab_PercentageOfMarketableSecurities_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="gmab_PercentageOfMarketableSecurities_637642932740168133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="gmab_MarketableSecuritiesIncludingInterestReceivables_637642932740168133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="gmab_BankDepositsIncludingShortTermMarketableSecurities_637642932740168133" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfRevenue" xlink:label="gmab_PercentageOfRevenue_637642932740168133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="gmab_PercentageOfRevenue_637642932740168133" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfMarketableSecuritiesInvested" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="gmab_PercentageOfMarketableSecuritiesInvested_637642932740178074" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637642932740168133" xlink:to="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_637642932740178074" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Financial Instruments - Fair Value Measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740178074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740178074" xlink:to="ifrs-full_MeasurementAxis_637642932740178074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis_637642932740178074" xlink:to="ifrs-full_AggregatedMeasurementMember_637642932740178074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember_637642932740178074" xlink:to="ifrs-full_AtFairValueMember_637642932740178074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740178074" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740178074" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740178074" xlink:to="ifrs-full_FinancialAssetsMember_637642932740178074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember_637642932740178074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740178074" xlink:to="gmab_MarketableSecuritiesMember_637642932740178074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="us-gaap_OtherInvestmentsMember_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740178074" xlink:to="us-gaap_OtherInvestmentsMember_637642932740188065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740178074" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_637642932740188065" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_637642932740188065" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740188065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740188065" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_637642932740188065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740188065" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_637642932740188065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740188065" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_637642932740188065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740178074" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740188065" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740188065" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740188065" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_637642932740188065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740188065" xlink:to="ifrs-full_FinancialAssets_637642932740188065" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Financial Instruments - Other Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637642932740198065" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637642932740198065" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740198065" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637642932740198065" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740198065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CurevacCollaborationMember" xlink:label="gmab_CurevacCollaborationMember_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740198065" xlink:to="gmab_CurevacCollaborationMember_637642932740198065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_BoltBiotherapeuticsIncMember" xlink:label="gmab_BoltBiotherapeuticsIncMember_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637642932740198065" xlink:to="gmab_BoltBiotherapeuticsIncMember_637642932740198065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637642932740198065" xlink:to="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637642932740198065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637642932740198065" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_637642932740198065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfInvestmentInCommonShares" xlink:label="gmab_PercentageOfInvestmentInCommonShares_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637642932740198065" xlink:to="gmab_PercentageOfInvestmentInCommonShares_637642932740198065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637642932740198065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637642932740198065" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637642932740198065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Financial Income and Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FinanceIncomeAbstract" xlink:label="gmab_FinanceIncomeAbstract_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_FinanceIncomeAbstract_637642932740208069" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_InterestAndOtherFinancialIncome" xlink:label="gmab_InterestAndOtherFinancialIncome_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637642932740208069" xlink:to="gmab_InterestAndOtherFinancialIncome_637642932740208069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_GainOnOtherInvestments" xlink:label="gmab_GainOnOtherInvestments_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637642932740208069" xlink:to="gmab_GainOnOtherInvestments_637642932740208069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_GainsOnHedgingInstruments" xlink:label="gmab_GainsOnHedgingInstruments_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637642932740208069" xlink:to="gmab_GainsOnHedgingInstruments_637642932740208069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637642932740208069" xlink:to="ifrs-full_NetForeignExchangeGain_637642932740208069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637642932740208069" xlink:to="ifrs-full_FinanceIncome_637642932740208069" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FinanceExpensesAbstract" xlink:label="gmab_FinanceExpensesAbstract_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_FinanceExpensesAbstract_637642932740208069" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_InterestAndOtherFinancialExpenses" xlink:label="gmab_InterestAndOtherFinancialExpenses_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637642932740208069" xlink:to="gmab_InterestAndOtherFinancialExpenses_637642932740208069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LossesOnMarketableSecurities" xlink:label="gmab_LossesOnMarketableSecurities_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637642932740208069" xlink:to="gmab_LossesOnMarketableSecurities_637642932740208069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_LossesOnOtherInvestmentsNet" xlink:label="gmab_LossesOnOtherInvestmentsNet_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637642932740208069" xlink:to="gmab_LossesOnOtherInvestmentsNet_637642932740208069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss_637642932740208069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637642932740208069" xlink:to="ifrs-full_NetForeignExchangeLoss_637642932740208069" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637642932740208069" xlink:to="ifrs-full_FinanceCosts_637642932740218068" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="ifrs-full_FinanceIncomeCost_637642932740218068" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740218068" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740218068" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_637642932740218068" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_637642932740218068" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740218068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_637642932740218068" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_637642932740218068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740218068" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740218068" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis_637642932740218068" xlink:to="ifrs-full_FinancialAssetsMember_637642932740218068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740218068" xlink:to="gmab_MarketableSecuritiesMember_637642932740218068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="us-gaap_OtherInvestmentsMember_637642932740218068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637642932740218068" xlink:to="us-gaap_OtherInvestmentsMember_637642932740218068" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740218068" xlink:to="ifrs-full_MeasurementAxis_637642932740228068" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis_637642932740228068" xlink:to="ifrs-full_AggregatedMeasurementMember_637642932740228068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember_637642932740228068" xlink:to="ifrs-full_AtFairValueMember_637642932740228068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740218068" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740228068" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740228068" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740228068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740228068" xlink:to="ifrs-full_FinancialAssets_637642932740228068" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740228068" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_637642932740228068" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740228068" xlink:to="ifrs-full_PurchasesFairValueMeasurementAssets_637642932740228068" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_6376429327402280681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740228068" xlink:to="ifrs-full_FinancialAssets_6376429327402280681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_637642932740228068" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637642932740228068" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_637642932740228068" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40409 - Disclosure - Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:label="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740238071" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740238071" xlink:to="ifrs-full_MeasurementAxis_637642932740238071" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis_637642932740238071" xlink:to="ifrs-full_AggregatedMeasurementMember_637642932740238071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtCostMember" xlink:label="ifrs-full_AtCostMember_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember_637642932740238071" xlink:to="ifrs-full_AtCostMember_637642932740238071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember_637642932740238071" xlink:to="ifrs-full_AtFairValueMember_637642932740238071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740238071" xlink:to="ifrs-full_ClassesOfAssetsAxis_637642932740238071" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_637642932740238071" xlink:to="ifrs-full_ClassesOfAssetsMember_637642932740238071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637642932740238071" xlink:to="gmab_MarketableSecuritiesMember_637642932740238071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis_637642932740238071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740238071" xlink:to="ifrs-full_ExternalCreditGradesAxis_637642932740238071" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932740248152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesAxis_637642932740238071" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932740248152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember_637642932740248152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember_637642932740248152" xlink:to="gmab_TripleaRatingMember_637642932740248152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637642932740238071" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_637642932740248152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="ifrs-full_Assets_637642932740248152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchasesFairValueMeasurementAssets" xlink:label="ifrs-full_PurchasesFairValueMeasurementAssets_637642932740248152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="ifrs-full_PurchasesFairValueMeasurementAssets_637642932740248152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SalesFairValueMeasurementAssets" xlink:label="ifrs-full_SalesFairValueMeasurementAssets_637642932740248152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="ifrs-full_SalesFairValueMeasurementAssets_637642932740248152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_637642932740328665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="ifrs-full_Assets_637642932740328665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FairValueAdjustmentOfMarketableSecurities" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities_637642932740328665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="gmab_FairValueAdjustmentOfMarketableSecurities_637642932740328665" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod" xlink:label="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod_637642932740328665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod_637642932740328665" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FairValueAdjustmentOfMarketableSecurities" xlink:label="gmab_FairValueAdjustmentOfMarketableSecurities_6376429327403286651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="gmab_FairValueAdjustmentOfMarketableSecurities_6376429327403286651" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_MarketableSecuritiesNetBookValueInPercentageOfCost" xlink:label="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost_637642932740328665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="gmab_MarketableSecuritiesNetBookValueInPercentageOfCost_637642932740328665" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ForeignExchangeAdjustmentOfMarketableSecurities" xlink:label="gmab_ForeignExchangeAdjustmentOfMarketableSecurities_637642932740328665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637642932740248152" xlink:to="gmab_ForeignExchangeAdjustmentOfMarketableSecurities_637642932740328665" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details" xlink:type="extended" xlink:title="40501 - Disclosure - Share-Based Instruments - Part 1 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740338601" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740338601" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_637642932740338601" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_637642932740338601" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637642932740338601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740338601" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637642932740338601" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637642932740338601" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637642932740338601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637642932740338601" xlink:to="gmab_IfrsRestrictedStockUnitsRSUsMember_637642932740338601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740338601" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637642932740338601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637642932740338601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637642932740338601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_637642932740349328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_637642932740349328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_637642932740349328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_637642932740349328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637642932740349328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637642932740349328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_637642932740349328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_637642932740349328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_637642932740349328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_637642932740349328" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_637642932740349328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740338601" xlink:to="ifrs-full_TreasuryShares_637642932740349328" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details" xlink:type="extended" xlink:title="40502 - Disclosure - Share-Based Instruments - Part 2 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740349328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740349328" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740349328" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637642932740358208" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637642932740358208" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637642932740358208" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637642932740358208" xlink:to="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_637642932740358208" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637642932740358208" xlink:to="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_637642932740358208" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsGrantedFromMarch2017Member" xlink:label="gmab_WarrantsGrantedFromMarch2017Member_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637642932740358208" xlink:to="gmab_WarrantsGrantedFromMarch2017Member_637642932740358208" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantsMember" xlink:label="gmab_WarrantsMember_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637642932740358208" xlink:to="gmab_WarrantsMember_637642932740358208" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740349328" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_WarrantVestingPeriod_637642932740358208" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_NumberOfWarrantsOutstanding_637642932740358208" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_NumberOfWarrantsGrantedDuringPeriod_637642932740358208" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_637642932740358208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_NumberOfWarrantsExercisedDuringPeriod_637642932740358208" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_637642932740368445" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_NumberOfWarrantsOutstanding_637642932740368445" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsGranted_637642932740368445" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_637642932740368445" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsExercised_637642932740368445" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_ProceedsFromExerciseOfWarrants" xlink:label="gmab_ProceedsFromExerciseOfWarrants_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_ProceedsFromExerciseOfWarrants_637642932740368445" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_637642932740368445" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637642932740368445" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding_637642932740368445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740358208" xlink:to="gmab_NumberOfTreasurySharesOutstanding_637642932740368445" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details" xlink:type="extended" xlink:title="40503 - Disclosure - Share-Based Instruments - Part 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_637638161275488269" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_637638161275488269" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740378752" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsShareRepurchaseProgramAxis" xlink:label="gmab_IfrsShareRepurchaseProgramAxis_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740378752" xlink:to="gmab_IfrsShareRepurchaseProgramAxis_637642932740378752" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsShareRepurchaseProgramDomain" xlink:label="gmab_IfrsShareRepurchaseProgramDomain_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsShareRepurchaseProgramAxis_637642932740378752" xlink:to="gmab_IfrsShareRepurchaseProgramDomain_637642932740378752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_RestrictedStockUnitsProgramMember" xlink:label="gmab_RestrictedStockUnitsProgramMember_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsShareRepurchaseProgramDomain_637642932740378752" xlink:to="gmab_RestrictedStockUnitsProgramMember_637642932740378752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637642932740378752" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_WarrantVestingPeriod_637642932740378752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_NumberOfWarrantsOutstanding_637642932740378752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding_637642932740378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_NumberOfTreasurySharesOutstanding_637642932740378752" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchaseProgramAuthorizedAmount" xlink:label="gmab_IfrsStockRepurchaseProgramAuthorizedAmount_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_IfrsStockRepurchaseProgramAuthorizedAmount_637642932740388465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_637642932740388465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchasedDuringPeriodShares" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodShares_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_IfrsStockRepurchasedDuringPeriodShares_637642932740388465" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsStockRepurchasedDuringPeriodValue" xlink:label="gmab_IfrsStockRepurchasedDuringPeriodValue_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_IfrsStockRepurchasedDuringPeriodValue_637642932740388465" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PercentageOfShareCapital" xlink:label="gmab_PercentageOfShareCapital_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_PercentageOfShareCapital_637642932740388465" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsTreasuryStockShares" xlink:label="gmab_IfrsTreasuryStockShares_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="gmab_IfrsTreasuryStockShares_637642932740388465" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637642932740378752" xlink:to="ifrs-full_PurchaseOfTreasuryShares_637642932740388465" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637642932740388465" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_637642932740388465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637642932740388465" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_637642932740388465" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_637642932740388465" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637642932740398462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637642932740398462" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_637642932740398462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637642932740388465" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637642932740398462" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfIndependentBoardMembers" xlink:label="gmab_NumberOfIndependentBoardMembers_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637642932740398462" xlink:to="gmab_NumberOfIndependentBoardMembers_637642932740398462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfNonIndependentBoardMembers" xlink:label="gmab_NumberOfNonIndependentBoardMembers_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637642932740398462" xlink:to="gmab_NumberOfNonIndependentBoardMembers_637642932740398462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_NumberOfEmployeeElectedBoardMembers" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637642932740398462" xlink:to="gmab_NumberOfEmployeeElectedBoardMembers_637642932740398462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637642932740398462" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637642932740398462" xlink:to="ifrs-full_ClassesOfAssetsAxis_637642932740398462" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_637642932740398462" xlink:to="ifrs-full_ClassesOfAssetsMember_637642932740398462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_PropertiesMember" xlink:label="gmab_PropertiesMember_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637642932740398462" xlink:to="gmab_PropertiesMember_637642932740398462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_IfrsEquipmentMember" xlink:label="gmab_IfrsEquipmentMember_637642932740398462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637642932740398462" xlink:to="gmab_IfrsEquipmentMember_637642932740398462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637642932740398462" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637642932740408731" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637642932740408731" xlink:to="ifrs-full_RightofuseAssets_637642932740408731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637642932740408731" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="ifrs-full_CurrentLeaseLiabilities_637642932740408731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637642932740408731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="ifrs-full_LeaseLiabilities_637642932740408731" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="ifrs-full_AdditionsToRightofuseAssets_637642932740408731" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="ifrs-full_DepreciationRightofuseAssets_637642932740408731" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_637642932740408731" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_637642932740408731" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_FutureMinimumOperatingLeasePayments" xlink:label="gmab_FutureMinimumOperatingLeasePayments_637642932740408731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="gmab_FutureMinimumOperatingLeasePayments_637642932740408731" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20210630.xsd#gmab_EstimatedCapitalExpenditureForLease" xlink:label="gmab_EstimatedCapitalExpenditureForLease_637642932740418840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637642932740408731" xlink:to="gmab_EstimatedCapitalExpenditureForLease_637642932740418840" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>gmab-20210630x6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:gmab="http://www.genmab.com/20210630"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gmab-20210630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember__kp1XyJRaEqpMiDAX0T8vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_AqtNH3bYz0emLMQ_xHz5lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_YxEM9iziHkO-obYvfBGHEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_Vnp4zSnt40qzvspJ2EGkFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_PwANnCyzn0C5MUS8nwx1Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_Jx4QuMwJkUqCuFfiBGwvYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_ZaPHCufkHU64vY8arktfIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_l8NTH0WDpEq0wlqXAMBCwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_qY9lpk9pk02Tfs4Fh-iqBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_VCedgugRDUuAx52NFUHvig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_BPVE7vPNz0u0Ekx3yAqzWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_VeITHDP1a0WhA62xDHpgQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_Tn5RwvlkRUSHrBhAtsMlIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_DYo9Pa8mmEeHldxkY2EtIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_uqBDRnrgSEiaSoEvBB_vhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_D2_7lyccvkaTuObCOVPGJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_lb_1v3MJVUOVzAmVqtUJ_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:OtherCollaborationPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_m1JCpHXO-kyYxFku-zvTnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_n6OJ6Akl1USS7Gay7gozVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_NrXt0j_za0WkwizDvCEL2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_rRkDJdMjTUWStzjCszxcAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_r5jbLSw0x0GSS0r6RF8nrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_XoWF9GDwvkauQCs4eAuD6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_i0YAdPafokSkZiDf9ElCYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_XkMrksxnsESH9AlVnJk8Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_OY8O9iGctkKqyFaG0cKc5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_mh6YfnyyLUOtHNXoweh8Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:BoltBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_oRQeDeA0OUCUPKU1Y5V9-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hGOPQ12jT0ecOSLSOn671A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L6h4ixqJq0SJo8Qw1UTTOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_l6TS3ZYOmUeez0G-_bZVGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Y6PESuh_w0ChCcbF0c5LwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_iIgp3bLrT0WdC_XUJJoNxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_EgSoxPtT_kqpSjaUbjg4YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_HrDvCApT5Uq1RhvNtNXV-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_fnkpZL-bskSS4uB8m0uSdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_DodsJRF0NEOqpd0-8JQNgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Rqd-AfD3wEytE2ZCSjiHNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_8tHM7VtXkUuk3JpNpYCVqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_c3PLtVVYzU-uGuMkstgoXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember__pM2AyC5skGhYxOaXLPg1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fAcxKfHxzk-3GSCXEGeVWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1qraLfsZLEOjAsD-dxenzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4NLivLW-z0mqDErSzXuYzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_CtJaR3tu706WU9cIhYOn4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_-07AYjBjOk67K2am_lv-cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SgqnYnfln0me5bps_X9-Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_mais4ePNskeTkgOGq_-lGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_A0Jfc6FGgUWtNsve74S7sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_qA8435Q28E6nAiBn6iJsFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_NmzONsVw20-JjLot4LBL5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_TKZcta72hkC3Gvhut1vakg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L4KIMTzqKkag3QB7vZbfEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_PAZySbIZoEaim7Pchrrdtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1TQAORpB002CwFlwkSY-8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_p1Fn9MmXZ0mJDu3DNDH-CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_arkOpJJSzEOXHp0JsMegrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8pQrFQMD0keUvx5gLpDr7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_OIs20y9YdUCpESyQhSl9AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8DR9RGN4mk6fMGFsM-lTeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_AXjT64eEiUCHnI3_V_FM8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_UJmiHgLlu06muPRZ5PWz-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_A_sHaM7Ykki3oxBQqJ10GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_3MA1mpKA4kSpw8AfLI3utA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_eRyWOdr0U0arOAxOzCgi-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2021_To_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_J6YNADjInUKuD19rDW3Jyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-23</startDate>
            <endDate>2021-02-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_sribKozRAUu_07Nu947Axw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_K2gHqglzhkiiSSYKd-yiaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_b1nEv0AoyUCoV8jNBI30Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_OZ08P4IEB0-J1srEa0iG7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_lu3v55zbDES12yHJmhVJ7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gmab:TripleaRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_MCTqYNYF1kymMnq9M9KqFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_qlEizQljAU-i-kzexaRMsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_p0VWrcAFBkKEYD1w7sMfZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_FGZXpaWuR0uGlP1dW_5pEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_wD9EUBzhJkWAnxVwt1BN_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="As_Of_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_YXgvtwoFbEya6zUeGSPkMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_S4o242eUzEC8Lsv54F5WNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_XnjM0c4Pf0-AfdDAV6Byxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-23</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_YbHFH-aRiUOdag_c24OEXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2016_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_ESq4TWsOUU-_fQutYyImDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_tqrSzrvaIkWs3_xaEgi0Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_x8IPZU4fukqM5g_XH7UpIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsShareRepurchaseProgramAxis">gmab:RestrictedStockUnitsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_ifrs-full_PerformanceObligationsAxis_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_ilvsRwJsmUW_LnWzSnv9Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">ifrs-full:PerformanceObligationsSatisfiedOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">
        <measure>iso4217:DKK</measure>
    </unit>
    <unit id="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ">
        <measure>gmab:item</measure>
    </unit>
    <unit id="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_USD_MZ_DR3Sd-0iNndMFiKqHcQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:DKK</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA">
        <measure>gmab:EquityInstruments</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_lachAVH9CEeZhg1Q7RLNrw_2_1">0001434265</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_rZOD-FyHd02Q1btUTgGilA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_7BjP4jCIvUaRrOhjSivKwg_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_K0PRgFc-BEmJkGA7aau2hw_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_qqTsQ23MYUmJaV9f9Q0RAw_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_19P3lYK10U2_hHkCJUFi-w_7_1">Genmab A/S</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_FrVqi3K7m06yn_PA2gcWEw_8_1">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tc_ilA1Dtog2EOMdcDD0DdZkQ_9_1">2021-06-30</dei:DocumentPeriodEndDate>
    <ifrs-full:Revenue
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_G3l5fghIqUyRGsA6ZIBJsg_5_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1972000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_bsRKv7xRIEmZ0m0fhXV9Yw_5_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">5451000000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_WBAk2ZlJWUefs129a3QfDA_7_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">921000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_4ojURSR9PUarxRXN3t9J9A_7_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">775000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_-pS-vNlRnkKygyuRwi7Tvw_8_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">264000000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_Li01UjMenUa3fey76y6Cng_8_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">179000000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_J-dC6YQx7kmoEdsqJM-XNg_9_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1185000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_SBeshUgpm0-_afVCfow2Zw_9_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">954000000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_O0cdhBtzaUiGSs6WIdES0Q_11_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">787000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_7tpHnyjMLEuM5Fmo-elm9A_11_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4497000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_LYbnpzvsLUuBR4SEEWUUvA_13_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">65000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_J9Ti3JfJUUqJ7CRtwT2zhw_13_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">42000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_Yn2qG_otlUGXqWpVm-IvUA_14_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">430000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_yRQK0l8NtESpn53y-qZ46w_14_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">211000000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_PHJ4Q3XFNkWXkWNlm1941Q_16_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">422000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_9yX5m1YX9U2A9BQSH0Jzag_16_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4328000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_P-2YEmlGk0WUll6Y69dg2Q_18_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">116000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_eOD-2Oy5hUigFrGLe0PHtQ_18_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">950000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_nwqvuLpFL0Ke-9_1GvuZyw_20_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">306000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_IWyFJXg3RUOn2TeytSuBpg_20_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3378000000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="2"
      id="Tc_NIzpWxvl5E--PtJ4FZrivw_22_1"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">4.68</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="2"
      id="Tc_gTnGo1IDYkSnoE-HtXwZ0A_22_3"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">51.88</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="2"
      id="Tc_Gn3-Vjih5EuUCFSdR5CZog_23_1"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">4.64</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="2"
      id="Tc_VqGSQZ6RSUCjAeDixZvJBg_23_3"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">51.35</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_a9Q83SX5A0qU1sgKD9Jc4w_27_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">306000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_1tPjkOcJCkeJ3JwveYyt4Q_27_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3378000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_S5sJKfb-PUC5WGiD97pVtw_32_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-13000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_ysHKW8yQ-UeiauUyYf4ioQ_32_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-9000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg"
      decimals="-6"
      id="Tc_bRaOsl1N4kirStPyqr4u2A_34_1"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">293000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_4_1_2020_To_6_30_2020_zZY8nYbMtUG1oAWXkGAUQg"
      decimals="-6"
      id="Tc_QXot1pQ7gUWEFIs4BlhSFQ_34_3"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3369000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_ONvQSQDSZE6v3c338jHUtg_5_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3553000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_aSonAQoFIU-IYGw1DeCKrA_5_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6343000000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_CR9ZrVgx8kKNKv-QWEtBhg_7_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1769000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_EblISj6qgE2b-GuJviBb9Q_7_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1490000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_etN26a0wGU2sWKdKwOwyxw_8_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">465000000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_k1i-R2BngUeg_YeSa8y5aQ_8_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">285000000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_h1xnxh6bh06oFpou9BGXSg_9_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2234000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_NisILWz9wEKZJ2xjk3jn6Q_9_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1775000000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_6jl44-SCGUSCAydasn6bZg_11_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1319000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_Xtk8W8POIEuuGv0iHi71bA_11_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4568000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_FqeoFWsNjEWDA2ckucksSQ_13_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">700000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_7XBTY5uoxE-AVv8xLOCecg_13_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">119000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_4XvpR67JI0-FvVydRrylWQ_14_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">173000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_ZNfID6Qa9UWGD-YdGwRGog_14_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">5000000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_HNPdivDMMUyNoOWIwQH2BQ_16_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1846000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_-YX5Cwh_oUmK0RWI1vJRzA_16_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4682000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_U2qsCpZoZUiv8M9pWrBotA_18_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">444000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_hFwIJvffbUex4ljdGoDQ2A_18_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1035000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_bp0TP8B77EWio6kbe-RtKA_20_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_gVprKRc6NkuDth7mvUHQjg_20_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3647000000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="2"
      id="Tc_icjUYjPkdEa0qL25Z-lEOA_22_4"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">21.44</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="2"
      id="Tc_sx7YmSYUY0yfp5p2a499Aw_22_6"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">56.07</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="2"
      id="Tc_5PGk-q2VyEW84JfG4naOKA_23_4"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">21.25</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="2"
      id="Tc_qasvf905fEqlCrlighNvDA_23_6"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">55.52</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_cXcMgffLcESjU7RSoDnstg_27_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_nCdwW0d4y0OwzlWUfEH0GA_27_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3647000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_G56jq3qNpki338BCKiaUWQ_32_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">28000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_UBzIFXodSU2cNrTQf78ecg_34_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1430000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_6MjgAJF1m0S9MxWIrR85gg_34_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3647000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_J-UX7ApV9EeWzJ32A6ZjEg_6_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">297000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_1VjbTfQJiki_h36UjL_RPw_6_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">338000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_-Qaebtb9s0SFF0blJXyihg_7_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">535000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_AQfX9-IDXkGtO5wi2PiHLQ_7_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">453000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_wqn6WR1qd0OXOEGth9zpRA_8_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">384000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_xIdvPR5HfkmtOoAHGZxnPg_8_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">283000000</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentReceivables
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_1fsvzoeNDU65vOgaEMcujQ_9_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">33000000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:NoncurrentReceivables
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_2fuMu3mZeESOo_H8gboVuA_9_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">20000000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_4eJB_dhoJUajQHRfgn4Q_w_10_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">177000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_zP3AwUJY_kurCYaXOsnGtA_10_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">177000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_r47AweIWlEWGd-PVusTNUw_11_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">753000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_N2Nq2F2g_Ui8VVeq3Xb95A_11_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1081000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_J1jvqoQubkCW7MwKP-YGSQ_13_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2179000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_AtKphP85qUeRC2OJL8jERQ_13_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2352000000</ifrs-full:NoncurrentAssets>
    <gmab:CorporateTaxReceivable
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_bSUFPnt72ku5UAADDJiDOw_15_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">249000000</gmab:CorporateTaxReceivable>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_vwwzBNqe_k2c8DAUd9zAag_16_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2429000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_FjSuHOajukmPw49VJDx6ng_16_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2463000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <gmab:IfrsMarketableSecuritiesCurrent
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_35IEJGrRUUC_xPbihTPKcQ_17_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8398000000</gmab:IfrsMarketableSecuritiesCurrent>
    <gmab:IfrsMarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_4U6JHgu6z02WZF043Py4aA_17_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8819000000</gmab:IfrsMarketableSecuritiesCurrent>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_TPqPB_wZ1EOn0W2y89J_0Q_18_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">9477000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_Nps5GkBwWkeAWx1jHoJ9sQ_18_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">7260000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_TJSIagr7AUSov7Ke31nbsQ_20_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">20304000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_1NsJm7gcKke7fY7lP3W0Sw_20_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">18791000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_0KQixdyJJUygfOuWKcaF7g_22_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">22483000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_meTowetnB0WJA7FSS4O4Ag_22_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">21143000000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_NpRSr_A8KEad9Cf0s54vWQ_26_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">66000000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_dfWBWMgnekypkYWOinZOlg_26_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">66000000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_Tv46WBFduUyeJI3_45KICA_27_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">11940000000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_O-AfiGQs1k63QY_EnnKz9g_27_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">11894000000</ifrs-full:SharePremium>
    <ifrs-full:OtherReserves
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_u0tjohH-G0mNPBjY-BvWWw_28_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">82000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_oTPzVBwcJky_nuXtXHRTAg_28_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">54000000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_IpSUGhpRAEatw9cIpzYSCA_29_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8164000000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_OQr9DgDTBEm05vBkkV7t2Q_29_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">7107000000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_G_Xv53ed1kG7Ui8rwIdV3g_31_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">20252000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_gJieLR-5zUW2axQg5-qyYw_31_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">19121000000</ifrs-full:Equity>
    <ifrs-full:NoncurrentProvisions
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_qj_HPx3P8Ui2UEe4uJcsNQ_33_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_e0UDQc_FoEGmN3ml03aDRQ_33_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_aA7qedZX5EimuFtUVAiRXA_34_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">384000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_MFFwi0KPEk6UMoCnosQOoQ_34_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">277000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_E99363rpVECl_Z4TcouLFw_35_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">487000000</ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent>
    <ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_w5HVWhct9U-FkTQ7ryOYRg_35_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">487000000</ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent>
    <ifrs-full:OtherNoncurrentPayables
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_qsGM5u7IMEeSxEBHwZAiMQ_36_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1000000</ifrs-full:OtherNoncurrentPayables>
    <ifrs-full:OtherNoncurrentPayables
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_JNHlyDLqZk6JMkFu2yyOwQ_36_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1000000</ifrs-full:OtherNoncurrentPayables>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_rrYMvyKpqkiacjZC_AYvdg_38_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">880000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_sgfC-0nYekGXN1wEkntopA_38_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">769000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_DIU8Ay6EoEWI3WC9TRl5kA_40_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">186000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_kq7PYqp5KkqD-sygzGWpvQ_41_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">59000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_-b7BS69lBEuWhmA1di-BHA_41_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">42000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:RentDeferredIncomeClassifiedAsCurrent
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_zG-li4xab0uA-2D6l_npfg_42_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">26000000</ifrs-full:RentDeferredIncomeClassifiedAsCurrent>
    <ifrs-full:RentDeferredIncomeClassifiedAsCurrent
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_0PJb3hEfO0i_JdTEMx0-wQ_42_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">26000000</ifrs-full:RentDeferredIncomeClassifiedAsCurrent>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_mE4AnD9xiU2-bpKJrXKz4g_43_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1080000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_eBLl8dKkaE6WYnGz8oXj4Q_43_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1185000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_r0f0wynaREmYVe9TFM4nRA_45_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1351000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_1dlc3e88K0Ksn2YKC1hfPA_45_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1253000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_wJ2pyXrewUKTqZUCaBwnVQ_47_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2231000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_C9C5Q6NGVEaO-jcyEzdVuQ_47_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2022000000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_MAPAcbLeB0Wcmq9KNk8XAw_49_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">22483000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_WnipAUVPYkG3aVqCuNLTnw_49_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">21143000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_g1yDMXqQBU6--53kQReQAA_5_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1846000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_5pp0_LaIAkW9eAbCfRHpxQ_5_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4682000000</ifrs-full:ProfitLossBeforeTax>
    <gmab:ReversalOfFinancialItemsNet
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_XgsCMATuF0ymUneU4AY-FA_7_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">527000000</gmab:ReversalOfFinancialItemsNet>
    <gmab:ReversalOfFinancialItemsNet
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_QBck2waUMkC4HlSAeFGFEw_7_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">114000000</gmab:ReversalOfFinancialItemsNet>
    <gmab:TotalAdjustmentsForNonCashTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_7BB04kuKckusw0jFQIhPLw_8_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">227000000</gmab:TotalAdjustmentsForNonCashTransactions>
    <gmab:TotalAdjustmentsForNonCashTransactions
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_beDLsuAIXEObH1eAGhboDw_8_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">182000000</gmab:TotalAdjustmentsForNonCashTransactions>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_SQzz-D3ixkK7VGlFcpKFhg_9_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">105000000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_XNQO-JvBbUOJixkc1YEirg_9_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2570000000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_cEgS-eVWYkGJAcVA65H2xQ_11_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1441000000</gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems>
    <gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_Ckwq6vKgs0SF9K2pLkjekg_11_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2180000000</gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_UWa8i3OFW0mPpSTQlckzcA_13_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">107000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_iIDfbcAB1EW1CQ0a87hs8A_13_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">77000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <gmab:AdjustmentsForInterestOnLeasePayments
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_bg6SSD6QDEaqdBTsQXxvRw_14_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-6000000</gmab:AdjustmentsForInterestOnLeasePayments>
    <gmab:AdjustmentsForInterestOnLeasePayments
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_Ixd4HtYKG0m3M7X0whSTgQ_14_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-3000000</gmab:AdjustmentsForInterestOnLeasePayments>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_-WF47-q50UyHYzAlN7SPuw_15_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_14x85DUQDEG89BIa3RSDKw_16_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-2000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_c91u1VrFvUWa3iMiPB0mbg_16_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-97000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_WnjYTrSyI0SQ8jQmHijl9A_18_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1540000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_bi-zfWU7U0Gm9XBffaKKcw_18_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2153000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_SgKecu1yl0-VIasbemqG6Q_20_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">107000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_QA8HYQb7ak6X5OMtFG9ohg_20_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">203000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_Q_PggdjwK0Gf0tqdZilVJA_21_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">7410000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_ntWGIn4TO0uKQ_eLR5Y_QA_21_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3006000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_ELs5jeBlJEO9dKkIj2MnJQ_22_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8137000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_354q6PszVUacWsKQOoxAsg_22_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4137000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_QXYBd2E_q0WOz3HgiK0_8A_23_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">92000000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_LQRdBT0rdUyEANvH9X8vig_24_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">438000000</ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_utMFTvOeSka5_O2NEj_9Xg_26_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">966000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_2AEK7voHpUmzPiDhQhVsyQ_26_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">928000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <gmab:ProceedsFromExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_aMd5wtdflUuf0beuV_JSIQ_28_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">46000000</gmab:ProceedsFromExerciseOfWarrants>
    <gmab:ProceedsFromExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_i3kzwPHgjUywDpfmr7CHXQ_28_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">54000000</gmab:ProceedsFromExerciseOfWarrants>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_8CQY8rtTHk6dncx0BahtaA_29_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">29000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_bD0_Q32wWEunDXiexGv1hg_29_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">17000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <gmab:PaymentsToAcquireTreasuryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_egibv7KKOEWsADD42SDtGg_30_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">437000000</gmab:PaymentsToAcquireTreasuryShares>
    <gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_5Vcu3AgSpE-WSdGpL1Bnww_31_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">40000000</gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs>
    <gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_kg187EDfn0SA6uaPosA6ww_31_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">18000000</gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_XD5844JZjE2B9dlw7-U4RA_33_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-460000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_NV_SbNZ_8keyXmlbh-a2xg_33_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">19000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_VZte-0OUaUirtYUeLnL4pQ_35_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2046000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc__1UkNYtrj0-uUoiyBXUjiQ_35_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3100000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_KxeF8hBQqUC_rNg2kWLqNg_36_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">7260000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ"
      decimals="-6"
      id="Tc_boDGNdVEsk-xHo_akJVYPg_36_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3552000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_LCls1bvLUUWlZQmNuZyCYw_37_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">171000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_ghiCLuqrbUW3YN7ed7W18w_37_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-47000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_IZeUXqpizUag_llEhn-CFA_39_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">9477000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg"
      decimals="-6"
      id="Tc_9VBi9yvtr0eoHPnr0NVnSA_39_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6605000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Cash
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc__oo66pm5r02vlJ9Ju0Hvuw_42_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6908000000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg"
      decimals="-6"
      id="Tc_EtOVQhQsHUqT9yE-i1R1WQ_42_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3602000000</ifrs-full:Cash>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_pEKNxI3xOkWt6YaUYbCw1Q_43_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2569000000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg"
      decimals="-6"
      id="Tc_l3vMHZo9OEeMNu7z5FZung_43_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3003000000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_4biy0v-KzU2duedzNNR4pg_45_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">9477000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg"
      decimals="-6"
      id="Tc_KbXmF_TWK0uIolCkKr7W3g_45_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6605000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_p1Fn9MmXZ0mJDu3DNDH-CA"
      decimals="-6"
      id="Tc_zlDhUt8ZFkqy8neDNajuCA_5_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">65000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L4KIMTzqKkag3QB7vZbfEQ"
      decimals="-6"
      id="Tc_FngybefSrEm9tgRswzDdqw_5_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">11755000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1TQAORpB002CwFlwkSY-8g"
      decimals="-6"
      id="Tc_wA7L9jkGMEiGHzkyF7Pz6Q_5_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">98000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_PAZySbIZoEaim7Pchrrdtw"
      decimals="-6"
      id="Tc_emHIsl-g_kaQxGKl60bGig_5_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2130000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ"
      decimals="-6"
      id="Tc_WbS3c5lqfUG9iq50CzNoMA_5_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">14048000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw"
      decimals="-6"
      id="Tc_8KJr5MuIZUODvBmposPF3g_7_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3647000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_K8KiBhkc5USicxPiWq0u3g_7_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3647000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw"
      decimals="-6"
      id="Tc_3_PfiMQ-4kSjsQ2adoYQYQ_9_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3647000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_UXQyEF-2pUGCrjpsn2B7-A_9_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3647000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_L6h4ixqJq0SJo8Qw1UTTOg"
      decimals="-6"
      id="Tc_fJwbiQWJT0K6V8s_gqKAcg_12_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">71000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_9fqMpzKFkE2ta8j1HkadYw_12_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">71000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw"
      decimals="-6"
      id="Tc_fry9e6DqmEqZ5aIHsY1IXw_13_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">98000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_fu9sf5Zitk--mQb1Mtwj8Q_13_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">98000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw"
      decimals="-6"
      id="Tc_7UiJBsRSHkOQ2bMQfRZmsw_14_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-18000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_Kh-er_m-VEa-yZZXHg5YyQ_14_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-18000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <gmab:IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fZReSt-QmU2eIsPkD19bXw"
      decimals="-6"
      id="Tc_37OhZ7ZJukOPJZpoUZp8hQ_15_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">25000000</gmab:IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity>
    <gmab:IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_cfoQMju8JUKKi-k0-bv50A_15_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">25000000</gmab:IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_TKZcta72hkC3Gvhut1vakg"
      decimals="-6"
      id="Tc_H8jNGZ9sqk-Up-oMhFVOZA_17_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">65000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_A0Jfc6FGgUWtNsve74S7sA"
      decimals="-6"
      id="Tc_zLH4niPFdE20GhilErYuqA_17_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">11826000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_NmzONsVw20-JjLot4LBL5A"
      decimals="-6"
      id="Tc_j0BrSqxR80yI-vhw6_ZJ3A_17_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">98000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_qA8435Q28E6nAiBn6iJsFQ"
      decimals="-6"
      id="Tc_dPwum3T9RkKk1Am3NWd_LQ_17_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">5882000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2020_Wzv8rqVVfESA0EQKZ1uNUg"
      decimals="-6"
      id="Tc_4qWnMd0kbke1vZuESNCyLg_17_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">17871000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_mais4ePNskeTkgOGq_-lGA"
      decimals="-6"
      id="Tc_cCqq6lx_c0SefjI2gDG5ng_19_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">66000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_CtJaR3tu706WU9cIhYOn4Q"
      decimals="-6"
      id="Tc_s7_e58ZIIkaPQR67VBfI4A_19_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">11894000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SgqnYnfln0me5bps_X9-Sg"
      decimals="-6"
      id="Tc_aSTzcD9Cs0WVDa44MjktIw_19_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">54000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_-07AYjBjOk67K2am_lv-cA"
      decimals="-6"
      id="Tc_o-M-5W7iKUGE9cd89028Ag_19_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">7107000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_rzsmHaL3-ku5iok0QKYcqg_19_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">19121000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA"
      decimals="-6"
      id="Tc_8Fu0JbcLZUiADoapggZMIg_21_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_V0NW1i4JKUiWlvz7YL6Tsg_21_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_AXjT64eEiUCHnI3_V_FM8w"
      decimals="-6"
      id="Tc__B5OMuoankeftzWKMgT_Bg_22_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">28000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_03uR9Xlkz063dSd0FgvnOA_22_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">28000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_AXjT64eEiUCHnI3_V_FM8w"
      decimals="-6"
      id="Tc_lPf-XXl4-EKQjh-nSi8Z4A_23_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">28000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA"
      decimals="-6"
      id="Tc_gzOKIcLFt0ez1yHzZsWZPA_23_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1402000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_VH4CsV8qh0yxcvZPJv3fHg_23_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1430000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hGOPQ12jT0ecOSLSOn671A"
      decimals="-6"
      id="Tc_xTWlgcp0XU2ekhK_JhFVeg_26_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">46000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_QjkoOBKm8EmsmM3BHO9q-Q_26_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">46000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA"
      decimals="-6"
      id="Tc_dwyGeL1kEU2AjsnJoWEZ5A_27_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">447000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_N7DD3dk3yEuJHJzDYWqsxQ_27_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">447000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA"
      decimals="-6"
      id="Tc_P7T-wJHZKUWjgQ_C67PfGQ_28_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">142000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_09d_Jxzf4UST2jTBJXsvlw_28_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">142000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_pwfLQAVENE6RQVFD61JwqA"
      decimals="-6"
      id="Tc_5s9_edoeA0-W7rSGOQaUzw_29_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-40000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_ZkNfd0MBA0COJmFk0zaAaQ_29_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-40000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4NLivLW-z0mqDErSzXuYzQ"
      decimals="-6"
      id="Tc_IAJGaw2n_EOBO3z0S0ilyg_31_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">66000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember__pM2AyC5skGhYxOaXLPg1Q"
      decimals="-6"
      id="Tc_GJa66edFbkaLw_uhTQhl0Q_31_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">11940000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1qraLfsZLEOjAsD-dxenzg"
      decimals="-6"
      id="Tc_WXtQGGvW6USMgcyZ6hmtKg_31_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">82000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_fAcxKfHxzk-3GSCXEGeVWw"
      decimals="-6"
      id="Tc_sBELu5zTEECOptyYVb3HGQ_31_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8164000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_d4rHdeXrR0eSlhtcBeI2EQ_31_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">20252000000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_xbln6alzgUiXtxou2vVgvg">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;1&#160;&#x2013; Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS&#160;34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#x2019;s external auditors.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The interim report has been prepared using the same accounting policies as outlined in Section 1 &#x2013; Basis of Presentation in the financial statements in the Genmab 2020 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Management Judgments and Estimates under IFRS&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In preparing interim reports, certain provisions under IFRS require management to make judgments (various accounting estimates and assumptions) which may significantly impact the group&#x2019;s financial statements. For a description of significant judgments and estimates, refer to Note 1.3 in the Annual Report.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Information about Geographical Areas&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_K3zYAeaZxki2_LbdBAcTHg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS&#160;34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#x2019;s external auditors.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The interim report has been prepared using the same accounting policies as outlined in Section 1 &#x2013; Basis of Presentation in the financial statements in the Genmab 2020 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report.&lt;/p&gt;</gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock>
    <gmab:DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_ZOzq5aYqCEKkjliOJntBbQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Management Judgments and Estimates under IFRS&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In preparing interim reports, certain provisions under IFRS require management to make judgments (various accounting estimates and assumptions) which may significantly impact the group&#x2019;s financial statements. For a description of significant judgments and estimates, refer to Note 1.3 in the Annual Report.&lt;/p&gt;</gmab:DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_QtvgGqkRokez6zssWOmNiQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Information about Geographical Areas&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <gmab:IfrsNumberOfReportingUnits
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="INF"
      id="Narr_Umu-CBkMQEGHdiire9cQBQ"
      unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ">1</gmab:IfrsNumberOfReportingUnits>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_8AI1SxuwNE-Aspx1Zg-huw">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;2&#160;&#x2013; Revenue&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Genmab enters into license and collaboration agreements that are within the scope of IFRS 15, under which it licenses certain rights to its product candidates to third parties and also may participate in the development of the product candidates. The terms of these arrangements typically include payment to Genmab of one or more of the following: non-refundable, upfront license fees; exclusive designation fees; annual license maintenance fees; additional target fees; development, regulatory and commercial milestone payments; reimbursements for research and development services; and royalties on net sales of licensed products. Each of these payments results in revenue from contracts with customers.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on sales of daratumumab (marketed as DARZALEX for intravenous administration and as DARZALEX &lt;i style="font-style:italic;"&gt;FASPRO&lt;/i&gt; in the United States and as DARZALEX SC in Europe for SC administration). The arbitration first is to settle whether Genmab is required to share in Janssen&#x2019;s royalty payments to Halozyme Therapeutics, Inc. for the Halozyme enzyme technology used in the SC formulation of daratumumab. The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab sales. Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme beginning in the second quarter of 2020 and has continued to do so through June 30, 2021. Given the ongoing arbitration, Genmab has reflected this reduction in its royalty revenues each quarter. The impact to the first half of 2021 royalties is estimated to be DKK 146 million. The impact to the first half of 2020 royalties is not material. The arbitration is also to settle whether Janssen&#x2019;s obligation to pay royalties on sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;visibility:hidden;width:0pt;"&gt;&#x200b;&lt;/span&gt;&lt;br/&gt;The table below summarizes Genmab&#x2019;s revenue by type and collaboration partner under Genmab&#x2019;s agreements. This information provides the reader additional information regarding the nature, amount, timing and uncertainty of Genmab&#x2019;s revenue and how cash flows might be affected by economic factors.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by type:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,595&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Milestone revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,343&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by collaboration partner:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Janssen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;AbbVie&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Roche&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Seagen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;BioNTech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Novartis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other collaboration partners&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,343&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AbbVie Collaboration Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;On June&#160;10, 2020, Genmab entered into a broad collaboration agreement to jointly develop and commercialize epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 and a discovery research collaboration for future differentiated antibody therapeutics for cancer. Under the terms of the agreement, Genmab received a USD 750&#160;million (DKK 4,911 million) upfront payment in July 2020. Genmab recognized DKK 4,398 million as license revenue during the first half of 2020 driven by the delivery of licenses for the three programs described above. Genmab recorded DKK 513 million as deferred revenue related to co-development activities for product concepts and is expected to be recognized as revenue activities are performed, which is estimated to be over a &lt;span style="white-space:pre-wrap;"&gt;seven-year&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; period. No revenue has been recognized in the first half of 2021 or 2020 as co-development activities for product concepts have not yet commenced. Refer to Note 2.1 in the Annual Report for further details of the AbbVie collaboration agreement.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <gmab:ReductionInRoyaltyRevenue
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Narr_0dQZPqNvpkyVeBecQEhZ_w"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">146000000</gmab:ReductionInRoyaltyRevenue>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_JWKLP42gw0CsIB_FMqPGKA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by type:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,595&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Milestone revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,343&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by collaboration partner:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Janssen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;AbbVie&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Roche&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Seagen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;BioNTech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Novartis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other collaboration partners&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,343&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_PwANnCyzn0C5MUS8nwx1Sw"
      decimals="-6"
      id="Tc_QN57JCYBr0ypJHgXjdZ2gA_5_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2595000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_uqBDRnrgSEiaSoEvBB_vhQ"
      decimals="-6"
      id="Tc_Tcm55EiVE0uKX6T0_m9Dpw_5_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1738000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_Jx4QuMwJkUqCuFfiBGwvYw"
      decimals="-6"
      id="Tc_-Tbbof51sEebd_Cy9zZgUg_6_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">227000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_D2_7lyccvkaTuObCOVPGJw"
      decimals="-6"
      id="Tc_IDUqkEWnNE-Vu__gdGsmAg_6_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">175000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_ZaPHCufkHU64vY8arktfIQ"
      decimals="-6"
      id="Tc_c1crrvqbrESLgxs378sVrA_7_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">731000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_m1JCpHXO-kyYxFku-zvTnw"
      decimals="-6"
      id="Tc_VLqPoMtijk-l6hXovTewRg_7_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">32000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_n6OJ6Akl1USS7Gay7gozVw"
      decimals="-6"
      id="Tc_-Ret4GXh8k6M6mmeHHzJyg_8_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4398000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_k3UtkPI29U6peF4LNRKg0Q_10_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3553000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_tEZTnmf5V0ydg5GWM92QyQ_10_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6343000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_BPVE7vPNz0u0Ekx3yAqzWw"
      decimals="-6"
      id="Tc_wfnkRWlYTU2L7dR6oZWL_Q_13_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2846000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_XoWF9GDwvkauQCs4eAuD6w"
      decimals="-6"
      id="Tc_rFAmWSmuGkSmA4zYf_HETw_13_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1652000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_Tn5RwvlkRUSHrBhAtsMlIw"
      decimals="-6"
      id="Tc_mcGH8AyBTUKENWBuSCjukg_14_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">245000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_XkMrksxnsESH9AlVnJk8Gg"
      decimals="-6"
      id="Tc_NtFS9J7xAk2csCtuCDun-A_14_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4398000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_qY9lpk9pk02Tfs4Fh-iqBA"
      decimals="-6"
      id="Tc_NIb0_w2jKU27RjGGBlhZ-g_15_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">162000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_rRkDJdMjTUWStzjCszxcAw"
      decimals="-6"
      id="Tc_WgxPwL4x1keoEcZg3J0ZMg_15_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">83000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_l8NTH0WDpEq0wlqXAMBCwg"
      decimals="-6"
      id="Tc_bbFEgiohfk6er6FFH7zhmA_16_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">56000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_NrXt0j_za0WkwizDvCEL2Q"
      decimals="-6"
      id="Tc_CMLRH_LJ1UG_YohR_KaAYg_16_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">99000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_VeITHDP1a0WhA62xDHpgQw"
      decimals="-6"
      id="Tc__gmU_-lL30y4UwSy1lNU2Q_17_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">171000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_i0YAdPafokSkZiDf9ElCYA"
      decimals="-6"
      id="Tc_WZlZB8U3yE64Awq5kXB-Sw_17_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">76000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_VCedgugRDUuAx52NFUHvig"
      decimals="-6"
      id="Tc_0DcJAfpNbUKw6IxmxLRuTw_18_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">73000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_r5jbLSw0x0GSS0r6RF8nrA"
      decimals="-6"
      id="Tc_b-URIADu_k6ZjHuQJSstgA_18_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">9000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_lb_1v3MJVUOVzAmVqtUJ_Q"
      decimals="-6"
      id="Tc__ii2yUQd40yanFrIqGzg2Q_19_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">26000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_KZq4jJFw70q7k8E6PZNCvA_21_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3553000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_6Hlp_Rj640a9m7yXKXRv_Q_21_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6343000000</ifrs-full:RevenueFromContractsWithCustomers>
    <gmab:UpfrontMilestonePaymentReceived
      contextRef="Duration_7_1_2020_To_7_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_UJmiHgLlu06muPRZ5PWz-A"
      decimals="-6"
      id="Narr_7bGOPyswckaGp7D-BuxBtg"
      unitRef="Unit_Standard_USD_MZ_DR3Sd-0iNndMFiKqHcQ">750000000</gmab:UpfrontMilestonePaymentReceived>
    <gmab:UpfrontMilestonePaymentReceived
      contextRef="Duration_7_1_2020_To_7_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_UJmiHgLlu06muPRZ5PWz-A"
      decimals="-6"
      id="Narr_AYNCmaRLBUqCB2qvZNv3NQ"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4911000000</gmab:UpfrontMilestonePaymentReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_gmab_TypesOfRevenuesAxis_gmab_LicenseFeesMember_DYo9Pa8mmEeHldxkY2EtIw"
      decimals="-6"
      id="Narr_Jw3VVOR7BU-kaVVjagsoQg"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4398000000</ifrs-full:RevenueFromContractsWithCustomers>
    <gmab:NumberOfDeliveryLicenses
      contextRef="As_Of_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_YXgvtwoFbEya6zUeGSPkMQ"
      decimals="INF"
      id="Narr_9Tl91u_vGkOHwPLz14r9tA"
      unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ">3</gmab:NumberOfDeliveryLicenses>
    <gmab:ContractTransactionPrice
      contextRef="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_ifrs-full_PerformanceObligationsAxis_ifrs-full_PerformanceObligationsSatisfiedOverTimeMember_ilvsRwJsmUW_LnWzSnv9Yg"
      decimals="-6"
      id="Narr_XwIYjE6JiE6mmN4rKKiRHA"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">513000000</gmab:ContractTransactionPrice>
    <gmab:PerformanceObligationRevenueRecognitionPeriod
      contextRef="Duration_6_10_2020_To_6_10_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_eRyWOdr0U0arOAxOzCgi-Q"
      id="Narr_leKeuLpOvEel-QJq8acnyw">P7Y</gmab:PerformanceObligationRevenueRecognitionPeriod>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_qY-1fCKmg0WdJyGr5FuR0w">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;3&#160;&#x2013; Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June&#160;30,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets measured at fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,151&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,900&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2021, Genmab&#x2019;s marketable securities were administrated by two external investment managers. The investment guidelines and managers are reviewed regularly to reflect changes in market conditions, Genmab&#x2019;s activities and financial position. During the first half of 2021, Genmab&#x2019;s investment policy was amended to allow investments in debt rated BBB- or greater by S&amp;amp;P or Fitch and in debt rated Baa3 or greater by Moody&#x2019;s.&#160;The amended policy also includes additional allowable investment types, none of which were purchased during the first half of 2021.&#160; &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab&#x2019;s current portfolio is spread over a number of different securities with a focus on liquidity and security. Genmab&#x2019;s total marketable securities were invested in EUR (10%), DKK (20%), USD (69%) and GBP (1%) denominated securities as of June 30, 2021, compared to 10%, 19%, 70%, and 1%, as of December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2021, and December 31, 2020, 99% of Genmab&#x2019;s marketable securities had an AA rating or higher from Moody&#x2019;s, S&amp;amp;P, or Fitch. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;For financial instruments that are measured in the balance sheet at fair value, IFRS 13 for financial instruments requires disclosure of fair value measurements by level of the following fair value measurement hierarchy for: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Level 1 &#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Level 2 &#x2013; Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Level 3 &#x2013; Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(DKK million)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets Measured at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"&gt;Other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:28.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketable Securities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#x2019;s marketable securities (Level 1). &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Investments &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other investments as of June 30, 2021 consist primarily of a DKK 650 million investment in common shares of CureVac, compared to DKK 1,067 million as of December 31, 2020. During the first half of 2021, Genmab sold 35% of its investment in common shares of CureVac. Proceeds received from the sale of shares were DKK 438 million. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the second quarter of 2021, Genmab made an investment in common shares of Bolt. As of June 30, 2021, the investment in Bolt was valued at DKK 79 million.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The investments in CureVac and Bolt are recorded at fair value through profit and loss. The fair value of Genmab&#x2019;s investments in CureVac and Bolt are determined using unadjusted quoted prices in established markets (Level 1).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Group_ad8w6-yWtky-Qg0JD2o2cg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June&#160;30,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets measured at fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,151&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,900&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(DKK million)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets Measured at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,819&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,819&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"&gt;Other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_HrDvCApT5Uq1RhvNtNXV-g"
      decimals="-6"
      id="Tc_Phk5R8Wm1k6dtGJpYPCITQ_5_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8398000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_c3PLtVVYzU-uGuMkstgoXQ"
      decimals="-6"
      id="Tc_Es2AWSj3XUGQJwzwk5iJTg_5_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8819000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_EgSoxPtT_kqpSjaUbjg4YQ"
      decimals="-6"
      id="Tc_pS1BVgHp00ybihN8DzhsuQ_6_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">753000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_8tHM7VtXkUuk3JpNpYCVqA"
      decimals="-6"
      id="Tc_u7sAy79jvkimWES0dL_6VQ_6_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1081000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_lJspdbsFn0C0CVTqE_8_Cg_7_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-9151000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_17Jv5T3dVE2T5HJK-WHqJA_7_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">-9900000000</ifrs-full:FinancialAssets>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_b1nEv0AoyUCoV8jNBI30Dw"
      decimals="2"
      id="Narr_fzNwXuevvUyY4iOvlDIfug"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.10</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_OZ08P4IEB0-J1srEa0iG7g"
      decimals="2"
      id="Narr_gZoAV0DpWkKPvt9sfHqu6A"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.20</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_sribKozRAUu_07Nu947Axw"
      decimals="2"
      id="Narr_vbaRJwrsjU2Olais_YdQmg"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.69</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_K2gHqglzhkiiSSYKd-yiaA"
      decimals="2"
      id="Narr_NAQjvd5F7EWqYtALspxykQ"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.01</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_p0VWrcAFBkKEYD1w7sMfZA"
      decimals="2"
      id="Narr_m2UnQhRVDEi3CFw1_kbm1w"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.10</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_FGZXpaWuR0uGlP1dW_5pEQ"
      decimals="2"
      id="Narr_Yqp4jOk8dUubcvRqCUrrQA"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.19</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_MCTqYNYF1kymMnq9M9KqFA"
      decimals="2"
      id="Narr_cVPuwFvPGUm5LmNRrp8tuw"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.70</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_qlEizQljAU-i-kzexaRMsw"
      decimals="2"
      id="Narr_JYOaf0YK2U2ctRh_Is-tCg"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.01</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2020_To_6_30_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_lu3v55zbDES12yHJmhVJ7g"
      decimals="2"
      id="Narr_JpdmroW1JEm4ZSehcBB3XQ"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.99</gmab:PercentageOfMarketableSecuritiesInvested>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_iIgp3bLrT0WdC_XUJJoNxQ"
      decimals="-6"
      id="Tc_Qk6Qhdv0wUaCFsNhK_Pp8w_4_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8398000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_HrDvCApT5Uq1RhvNtNXV-g"
      decimals="-6"
      id="Tc_-lMf9g2QrUy7XeiH9pJMWg_4_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8398000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Rqd-AfD3wEytE2ZCSjiHNQ"
      decimals="-6"
      id="Tc_wYoAc0Jsj0-lk6ryWf8R7w_4_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8819000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_c3PLtVVYzU-uGuMkstgoXQ"
      decimals="-6"
      id="Tc_d95-mP6dE0uWaoPMhDSkHw_4_16"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">8819000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_Y6PESuh_w0ChCcbF0c5LwQ"
      decimals="-6"
      id="Tc_6d67PVvhuk6lhlDATV7UEw_5_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">729000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_l6TS3ZYOmUeez0G-_bZVGg"
      decimals="-6"
      id="Tc_TZrkYUxx6EW4ELEpRWLOzg_5_6"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">24000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_EgSoxPtT_kqpSjaUbjg4YQ"
      decimals="-6"
      id="Tc_yx-F5btZGEWQiSmssflNSg_5_8"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">753000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_DodsJRF0NEOqpd0-8JQNgw"
      decimals="-6"
      id="Tc_CKYekYgyQE-07RKvWy2Ibg_5_10"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1067000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_fnkpZL-bskSS4uB8m0uSdw"
      decimals="-6"
      id="Tc_eXSCtOXTikGAJNkWekBUVg_5_14"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">14000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfFinancialAssetsAxis_us-gaap_OtherInvestmentsMember_8tHM7VtXkUuk3JpNpYCVqA"
      decimals="-6"
      id="Tc_w82KLiuh6k6JEjymaZR8cA_5_16"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1081000000</ifrs-full:FinancialAssets>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_OY8O9iGctkKqyFaG0cKc5w"
      decimals="-6"
      id="Narr_cXVwP5-w80OpL9OYo4XWgA"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">650000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_oRQeDeA0OUCUPKU1Y5V9-g"
      decimals="-6"
      id="Narr_9dYcpvRkI0KH86ngb69IuQ"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1067000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <gmab:PercentageOfInvestmentInCommonShares
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_wD9EUBzhJkWAnxVwt1BN_A"
      decimals="2"
      id="Narr_n61t_wAG6UqTrU4msWFRsw"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.35</gmab:PercentageOfInvestmentInCommonShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_wD9EUBzhJkWAnxVwt1BN_A"
      decimals="-6"
      id="Narr_LA-1qt14WkCuyJBx7CXtJw"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">438000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_mh6YfnyyLUOtHNXoweh8Iw"
      decimals="-6"
      id="Narr__OUKyloLjUK-JUT1USR67g"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">79000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_7JvthDvMgU-IAZf35TFA_g">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Note&#160;4&#160;&#x2013; Financial Income and Expenses&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial income:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest and other financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign exchange rate gain, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 573&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 119&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest and other financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss on marketable securities, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (134)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss on other investments, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (173)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 527&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 114&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange rate gain, net was DKK 573 million in the first half of 2021 as compared to DKK 36 million in the first half of 2020. The increase was driven by the strengthening of the USD against the DKK in 2021 that positively impacted our USD denominated marketable securities portfolio and cash holdings. Refer to Note 4.2 in the Annual Report for further details of foreign currency risk.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Loss on marketable securities, net of DKK 134 million in the first half of 2021 was primarily driven by the movements in interest rates in the United States and Europe.&lt;/p&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_RVDXSFJt0EOXASrein5m2Q">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial income:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest and other financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign exchange rate gain, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 573&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 119&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest and other financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss on marketable securities, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (134)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss on other investments, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (173)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 527&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 114&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock>
    <gmab:InterestAndOtherFinancialIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_uHTfWruSRUGsWZKfrnrdUA_6_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">127000000</gmab:InterestAndOtherFinancialIncome>
    <gmab:InterestAndOtherFinancialIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_JkVbqLiVVEW24qlMYB4GjQ_6_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">83000000</gmab:InterestAndOtherFinancialIncome>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_bTbMQIlo20K56Q8ndAD9Dg_7_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">573000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_RN3pXEpbgkyqVZUnLc8azw_7_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">36000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_Cx4LFNUtakSFxVHfbH-OOQ_9_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">700000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_BP6YQBjBkUqCAnewiE6nEw_9_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">119000000</ifrs-full:FinanceIncome>
    <gmab:InterestAndOtherFinancialExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_V1R7H4CeA0eO1O31GMFS5Q_12_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6000000</gmab:InterestAndOtherFinancialExpenses>
    <gmab:InterestAndOtherFinancialExpenses
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_AQzkN8zffUq_QY6sng4Bqw_12_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">4000000</gmab:InterestAndOtherFinancialExpenses>
    <gmab:LossesOnMarketableSecurities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc__1lBUSG39U-ZyIgnMjeV7g_13_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">134000000</gmab:LossesOnMarketableSecurities>
    <gmab:LossesOnMarketableSecurities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_ibgAATHly0SWAZMBFgjINQ_13_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1000000</gmab:LossesOnMarketableSecurities>
    <gmab:LossesOnOtherInvestmentsNet
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_CxE_4jYVckqsOPLP8BRRlA_14_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">33000000</gmab:LossesOnOtherInvestmentsNet>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_H2wbAwfOpEqOG84BgGU1pQ_16_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">173000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_q8JQOAjf-EaqSCa-p6_Hyw_16_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">5000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_vOygp8gAskurucUjPDVmFw_18_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">527000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_-F0J4GVYcEeJFb-pZdVXUA_18_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">114000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Narr_rrQzvh45TkWMyExm7pxOFA"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">573000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Narr_igwv8wHHL0Kmz5rCQw8mvg"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">36000000</ifrs-full:NetForeignExchangeGain>
    <gmab:LossesOnMarketableSecurities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Narr_VhwAAJMs70yJmM1UIHvcxA"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">134000000</gmab:LossesOnMarketableSecurities>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_EUeQlQbOJEiOHfBRf5pV5Q">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;Note&#160;5&#160;&#x2013; Share-Based Instruments&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Restricted Stock Unit Program&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab A/S established an RSU program as an incentive for all the Genmab group&#x2019;s employees, members of the Executive Management, and members of the Board of Directors. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;For details of the RSU program prior to changes in 2021, refer to Note 4.6 in the Annual Report.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In February 2021, the RSU program was amended (the &#x201c;2021 RSU Program&#x201d;). Under the terms of the 2021 RSU Program, the Board may decide, in its sole discretion, to accelerate the vesting of the RSUs held by a participant, or accelerate the vesting of the RSUs and make a cash settlement in case of (1) a change of control event as defined in the 2021 RSU Program, if a participant&#x2019;s employment terms are materially changed to his or her detriment during the 12-month period following the change in control event, or if the participant, who is a member of the Board, is replaced by a new board member or such participant's seat on the Board is eliminated due to a reduction in the number of board members, or (2) certain other extraordinary transactions as described in the 2021 RSU Program. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Under the terms of the 2021 RSU Program, in the event an RSU holder separates from the Company under circumstances in which the RSU holder is considered a &#x201c;bad-leaver,&#x201d; such as being dismissed for cause or during the employment probationary period, unvested RSU will be forfeited. RSU holders may maintain a pro rata portion of unvested RSUs if they separate from the Company under circumstances where they are considered &#x201c;good-leavers,&#x201d; such as dismissal without cause or termination of employment due to the Company&#x2019;s material breach of the RSU holder&#x2019;s employment terms, or if the participant is a member of the Board, if the membership of the Board ceases for any other reason than as a result of the participants death. All unvested RSUs will be forfeited in the event of termination of employment due to the RSU holder&#x2019;s death.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first half of 2021, 159,567 RSUs were granted with a weighted average fair value of DKK 2,149.55 per RSU. During the first half of 2020, 22,672 RSUs were granted with a weighted average fair value of DKK 1,491.16 per RSU. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first half of 2021, 49,012 RSUs vested, compared to 39,438 RSUs during the first half of 2020. Genmab settles RSUs using shares issued from treasury stock. A portion of the settlement is withheld to satisfy individual statutory tax withholding obligations in certain jurisdictions which remain in Genmab&#x2019;s treasury share account.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Warrant Program&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;Genmab A/S established warrant programs as an incentive for all the Genmab group&#x2019;s employees, and members of the Executive Management. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;For details of the warrant programs prior to changes in 2021, refer to Note 4.6 in the Annual Report.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2021, the Warrant Program was amended (the &#x201c;2021 Warrant Program&#x201d;). Under the terms of the 2021 Warrant Program, the Board may decide, in its sole discretion, to accelerate the vesting of the warrants held by a warrant holder in case of (1) a change of control event as defined in the 2021 Warrant Program, if a warrant holder&#x2019;s employment terms are materially changed to his or her detriment during the 12-month period following a change in control event, or (2) certain other extraordinary transactions as described in the 2021 Warrant Program.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2021 Warrant Program, if a warrant holder separates from the Company under circumstances in which the warrant holder is considered a &#x201c;bad-leaver,&#x201d; such as being dismissed for cause or during the employment probationary period, unvested warrants will be forfeited. Warrant holders may maintain a pro rata portion of unvested warrants if they separate from the Company under circumstances where they are considered &#x201c;good-leavers,&#x201d; such as dismissal without cause or termination of employment due to the Company&#x2019;s material breach of the warrant holder&#x2019;s employment terms. All unvested warrants will be forfeited in the event of termination of employment due to the warrant holder&#x2019;s death.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first half of 2021, 147,568 warrants were granted to Genmab employees with a weighted average exercise price of DKK 2,189.21 per warrant and a weighted average Black-Scholes fair market value of DKK 683.79 per warrant. During the first half of 2020, 49,323 warrants were granted to Genmab employees with a weighted average exercise price of DKK 1,548.22 per warrant and a weighted average Black-Scholes fair market value of DKK 465.70 per warrant.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the first half of 2021, 74,992 warrants were exercised with a weighted average exercise price on date of grant of DKK 606.22 with proceeds to Genmab of DKK 46 million. The warrants exercised increased share capital accordingly and corresponded to approximately 0.11% of share capital. During the first half of 2020, 272,078 warrants were exercised with a weighted average exercise price on date of grant of DKK 261.06 with proceeds to Genmab of DKK 71 million. The warrants exercised increased share capital accordingly and corresponded to approximately 0.42% of share capital.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share-based compensation expense&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Share-based compensation expenses related to Genmab RSU and warrant programs for the first half of 2021 totaled DKK 142 million compared to DKK 98 million for the first half of 2020. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;visibility:hidden;width:0pt;"&gt;&#x200b;&lt;/span&gt;&lt;br/&gt;&lt;b style="font-weight:bold;"&gt;Share repurchases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In general, Genmab intends to purchase its own shares in order to cover a portion of the obligations in relation to RSUs. Authorization to purchase Genmab shares up to a nominal value of DKK 500,000 (500,000 shares) was given by the shareholders at the annual general meeting in March&#160;2016. As of December 31, 2020, a total of 225,000 shares, with a nominal value of DKK 225,000, had been repurchased under the March 2016 authorization. The March 2016 authorization expired in March 2021. Additionally, in March&#160;2019, Genmab shareholders authorized the repurchase up to an additional nominal value of DKK 500,000 (500,000 shares). A portion of the shares that may be repurchased under this authorization may be used to cover Genmab&#x2019;s obligations in relation to the RSUs. Moreover, in April&#160;2021, Genmab shareholders authorized us to repurchase up to an additional nominal value of DKK 500,000 (500,000 shares) to cover obligations under our share-based remuneration programs.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As announced on February 23, 2021, Genmab initiated a share buy-back program. During the first half of 2021, Genmab acquired 200,000 of its own shares, representing approximately 0.3% of share capital. The total amount paid to acquire the shares, including directly attributable costs, was DKK 447 million and has been recognized as a deduction to shareholders&#x2019; equity. These shares are classified as treasury shares and are presented within retained earnings on the balance sheet as of June 30, 2021. There were no share repurchases during the first half of 2020. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2021, 299,206 treasury shares were held by Genmab to cover the obligations in relation to the RSU program and to mitigate the dilutive effect of share capital increases resulting from future exercises of warrants.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw"
      decimals="0"
      id="Narr__1MXevknPka3Oh5kWBkXuQ"
      unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA">159567</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw"
      decimals="2"
      id="Narr_Kk6KNUWLyEuktonz1aCiSA"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">2149.55</gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw"
      decimals="0"
      id="Narr_cvoKNsXHwkePFsaNRDiHew"
      unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA">22672</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw"
      decimals="2"
      id="Narr_Tpvinc-LZkCgXpkw4otHCw"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">1491.16</gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw"
      decimals="0"
      id="Narr_YeShRECSckO_x7BmtFJ-Ig"
      unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA">49012</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_jo180pMDiU-Spm6bAxbwzw"
      decimals="0"
      id="Narr_9th6Ap8lEEmBKVJ5XnWdJg"
      unitRef="Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA">39438</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <gmab:NumberOfWarrantsGrantedDuringPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="0"
      id="Narr_4fJeqvkzfUSvncyMm3MJqA"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">147568</gmab:NumberOfWarrantsGrantedDuringPeriod>
    <gmab:WeightedAverageExercisePriceOfWarrantsGranted
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="2"
      id="Narr_c2vOP5-kOUyjjn0SGMxRbw"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">2189.21</gmab:WeightedAverageExercisePriceOfWarrantsGranted>
    <gmab:WeightedAverageExercisePriceOfFairValueOfWarrants
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="2"
      id="Narr_s1BmQwT6RUadDWmJ7rSwJA"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">683.79</gmab:WeightedAverageExercisePriceOfFairValueOfWarrants>
    <gmab:NumberOfWarrantsGrantedDuringPeriod
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="0"
      id="Narr_9Un6UoYUAUqCaETRT7Wy1w"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">49323</gmab:NumberOfWarrantsGrantedDuringPeriod>
    <gmab:WeightedAverageExercisePriceOfWarrantsGranted
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="2"
      id="Narr_C79jpr3JKUWap6oVrmVCHA"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">1548.22</gmab:WeightedAverageExercisePriceOfWarrantsGranted>
    <gmab:WeightedAverageExercisePriceOfFairValueOfWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="2"
      id="Narr_Ft4lDfbt2kaJpiymZpo5Vw"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">465.70</gmab:WeightedAverageExercisePriceOfFairValueOfWarrants>
    <gmab:NumberOfWarrantsExercisedDuringPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="0"
      id="Narr_bhxKLRhKbEyKI2SJLwzVjA"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">-74992</gmab:NumberOfWarrantsExercisedDuringPeriod>
    <gmab:WeightedAverageExercisePriceOfWarrantsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="2"
      id="Narr_koT2_QzQoE2EgKWBPEGW0A"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">606.22</gmab:WeightedAverageExercisePriceOfWarrantsExercised>
    <gmab:ProceedsFromExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_A_sHaM7Ykki3oxBQqJ10GA"
      decimals="-6"
      id="Narr_FoYoBmZu8UKMP8V_AzWZoA"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">46000000</gmab:ProceedsFromExerciseOfWarrants>
    <gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="4"
      id="Narr_Ref1xniCT0qs2KKvXkdIAg"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.0011</gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants>
    <gmab:NumberOfWarrantsExercisedDuringPeriod
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="0"
      id="Narr_GJvVWZVs1E-3hLeYp8JOEg"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">-272078</gmab:NumberOfWarrantsExercisedDuringPeriod>
    <gmab:WeightedAverageExercisePriceOfWarrantsExercised
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="2"
      id="Narr_Wh44cqdXJU-jPpC204bvjw"
      unitRef="Unit_Divide_DKK_shares_zN7gkvHgcEKZQA1XRsDm_Q">261.06</gmab:WeightedAverageExercisePriceOfWarrantsExercised>
    <gmab:ProceedsFromExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_3MA1mpKA4kSpw8AfLI3utA"
      decimals="-6"
      id="Narr_1Riafqt3YEyzrfVE7nIzOg"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">71000000</gmab:ProceedsFromExerciseOfWarrants>
    <gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="4"
      id="Narr_c7ai6wt_KkKXaBuDxULdEg"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.0042</gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Narr_hKWesDWppUKRbhIayIIMDQ"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">142000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Narr_dHHl-X9oYUms9eQ9MtuN4w"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">98000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <gmab:IfrsStockRepurchaseProgramAuthorizedAmount
      contextRef="As_Of_3_31_2016_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_ESq4TWsOUU-_fQutYyImDg"
      decimals="0"
      id="Narr_gzh10mnEBUacniWWSwE_Zg"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">500000</gmab:IfrsStockRepurchaseProgramAuthorizedAmount>
    <gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="As_Of_3_31_2016_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_ESq4TWsOUU-_fQutYyImDg"
      decimals="0"
      id="Narr_pVB2qSfrbkKkd5OBxKt77g"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">500000</gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <gmab:IfrsStockRepurchasedDuringPeriodShares
      contextRef="Duration_1_1_2020_To_12_31_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_tqrSzrvaIkWs3_xaEgi0Qg"
      decimals="0"
      id="Narr_8EnRA6ciYE-BIyyFJuuDiQ"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">225000</gmab:IfrsStockRepurchasedDuringPeriodShares>
    <gmab:IfrsStockRepurchasedDuringPeriodValue
      contextRef="Duration_1_1_2020_To_12_31_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_tqrSzrvaIkWs3_xaEgi0Qg"
      decimals="0"
      id="Narr_ArbfLqLhLU293KQKBHDU_Q"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">225000</gmab:IfrsStockRepurchasedDuringPeriodValue>
    <gmab:IfrsStockRepurchaseProgramAuthorizedAmount
      contextRef="As_Of_3_31_2019_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_YbHFH-aRiUOdag_c24OEXw"
      decimals="0"
      id="Narr_SQLEZFcvRE68U9Ikmuan9g"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">500000</gmab:IfrsStockRepurchaseProgramAuthorizedAmount>
    <gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="As_Of_3_31_2019_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_YbHFH-aRiUOdag_c24OEXw"
      decimals="0"
      id="Narr_WTPFaZCdYE6VQFk8-1RMNA"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">500000</gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <gmab:IfrsStockRepurchaseProgramAuthorizedAmount
      contextRef="As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ"
      decimals="0"
      id="Narr_iC7qMpvUCEqlESFiRKmzFg"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">500000</gmab:IfrsStockRepurchaseProgramAuthorizedAmount>
    <gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ"
      decimals="0"
      id="Narr_3JGfKrKVREinipwYRPzUEg"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">500000</gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="As_Of_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_XnjM0c4Pf0-AfdDAV6Byxw"
      decimals="0"
      id="Narr__nYYC6mT9Ead6eTX_SjMUw"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">200000</gmab:IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <gmab:PercentageOfShareCapital
      contextRef="Duration_2_23_2021_To_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_J6YNADjInUKuD19rDW3Jyg"
      decimals="3"
      id="Narr_wTrXkXuE7ky7St_hAa9Xfw"
      unitRef="Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA">0.003</gmab:PercentageOfShareCapital>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_2_23_2021_To_2_23_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_J6YNADjInUKuD19rDW3Jyg"
      decimals="-6"
      id="Narr_pcv7pK2zjkKYqrMPiMuLKw"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">447000000</ifrs-full:PurchaseOfTreasuryShares>
    <gmab:IfrsStockRepurchasedDuringPeriodShares
      contextRef="Duration_1_1_2020_To_6_30_2020_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_x8IPZU4fukqM5g_XH7UpIw"
      decimals="0"
      id="Narr_fk_gM6C5YkmVFxnDV-bhXQ"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">0</gmab:IfrsStockRepurchasedDuringPeriodShares>
    <gmab:IfrsTreasuryStockShares
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_S4o242eUzEC8Lsv54F5WNA"
      decimals="0"
      id="Narr_a2K4JRu7k0e5xt6g6y9ZTA"
      unitRef="Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ">299206</gmab:IfrsTreasuryStockShares>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_LBHecP8Fr0KWZR6kNZQypA">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;Note&#160;6&#160;&#x2013; Related Parties&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab&#x2019;s related parties are the Genmab A/S&#x2019; (parent company) subsidiaries, Board of Directors, Executive Management, and close members of the family of these persons. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab has service agreements with, and has made equity compensation grants to, members of Executive Management in the ordinary course of business.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transactions with Related Parties&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first half of 2021, there were no material related party transactions. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Key Changes to Executive Management and the Board of Directors&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first half of 2021, there was one change to the Executive Management team. Effective March 1, 2021, Tahamtan Ahmadi, previously Senior Vice President, Head of Oncology, was appointed Executive Vice President and Chief Medical Officer, Head of Experimental Medicines. He joins the existing Executive Management team of Jan van de Winkel, President and Chief Executive Officer, Judith Klimovsky, Executive Vice President and Chief Development Officer, Anthony Pagano, Executive Vice President and Chief Financial Officer and Anthony Mancini, Executive Vice President and Chief Operating Officer.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;There were no changes to the Board of Directors during the first half of 2021. Following Genmab A/S' Annual General Meeting on April 13, 2021, the Board of Directors is comprised of five independent board members, one non-independent board member, and three employee-elected board members. They are Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, Jonathan Peacock, Dr. Anders Gersel Pedersen, Peter Storm Kristensen, Dr. Mijke Zachariasse and Rima Bawarshi Nassar, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <gmab:NumberOfIndependentBoardMembers
      contextRef="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg"
      decimals="INF"
      id="Narr_6cavLIjll0q7EpAghH5liQ"
      unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ">5</gmab:NumberOfIndependentBoardMembers>
    <gmab:NumberOfNonIndependentBoardMembers
      contextRef="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg"
      decimals="INF"
      id="Narr_Q57DzWSFUkGFL_-9ubH1ug"
      unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ">1</gmab:NumberOfNonIndependentBoardMembers>
    <gmab:NumberOfEmployeeElectedBoardMembers
      contextRef="Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg"
      decimals="INF"
      id="Narr_hY-0u5G3v0awzvNC1svBNQ"
      unitRef="Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ">3</gmab:NumberOfEmployeeElectedBoardMembers>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_6AmNUqZpC0W6-EdC480v9Q">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="color:#000000;font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;Note&#160;7&#160;&#x2013; Leases&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;Amounts recognized in the balance sheet&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The balance sheet shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;384&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 283&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 277&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 443&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 319&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first half of 2021, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the commencement of leases in Japan and the United States with respect to office space. During the first half of 2020, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;commencement of leases in the United States and the Netherlands with respect to office and laboratory space.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&lt;span style="display:inline-block;visibility:hidden;width:0pt;"&gt;&#x200b;&lt;/span&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Significant leases not yet commenced&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During 2020, Genmab entered into a lease agreement with respect to the new headquarters in Denmark with a commencement date in March 2023 and is non-cancellable until March 2038. The total future minimum payments over the term of the lease are approximately DKK 342 million and estimated capital expenditures to fit out the space are approximately DKK 40 million.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During 2019, Genmab entered into a lease agreement with respect to office and laboratory space in the Netherlands with a commencement date in February 2022 and is non-cancellable until January 2032. The total future minimum payments over the term of the lease are approximately DKK 117 million and estimated capital expenditures to fit out the space are approximately DKK 74 million.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;Amounts recognized in the statement of comprehensive income&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The statement of comprehensive income shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expense relating to short-term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Interest expense is included in net financial items and expenses relating to short-term leases are included in operating expenses in the statement of comprehensive income.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_gfZyy3hs0ES-qDhy_6h5zg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The balance sheet shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;384&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 283&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 277&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 443&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 319&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember__kp1XyJRaEqpMiDAX0T8vQ"
      decimals="-6"
      id="Tc_f9QHgL0SM0Kk-fP59gxGSw_5_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">381000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_YxEM9iziHkO-obYvfBGHEQ"
      decimals="-6"
      id="Tc_c-Gi6mOhnEWl34XI15VDkA_5_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">280000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_AqtNH3bYz0emLMQ_xHz5lA"
      decimals="-6"
      id="Tc_suCV46ulqECwrTJZO8JqaQ_6_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_Vnp4zSnt40qzvspJ2EGkFw"
      decimals="-6"
      id="Tc_1Uxqn0ep6UuYjVdPkqMc8Q_6_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_ELro0N5gp0-McWb5C5sOGg_8_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">384000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_M2BlF71L10CPum_zM54XQQ_8_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">283000000</ifrs-full:RightofuseAssets>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_qD7lQHMDMUGraDYikGeWvQ_11_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">59000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_sOvKlwlSq0OtzGa6kUIa5A_11_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">42000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_okNFlfWjS0KbEelnU9CEtg_12_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">384000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_mRbVNfzm6UqGnDY6RIqjBw_12_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">277000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA"
      decimals="-6"
      id="Tc_GQUFYakbI02adtrqyfxAng_14_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">443000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Tc_y411eWyEq0q9taYSDZ_3PQ_14_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">319000000</ifrs-full:LeaseLiabilities>
    <gmab:FutureMinimumOperatingLeasePayments
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Narr_zaBgs3NLiUynHtE_5vt-6Q"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">342000000</gmab:FutureMinimumOperatingLeasePayments>
    <gmab:EstimatedCapitalExpenditureForLease
      contextRef="As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ"
      decimals="-6"
      id="Narr_SnVKaOlm5EqD6vTL9sx1CA"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">40000000</gmab:EstimatedCapitalExpenditureForLease>
    <gmab:FutureMinimumOperatingLeasePayments
      contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ"
      decimals="-6"
      id="Narr_QxGoe6bk0kC0PnkvLac_Hw"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">117000000</gmab:FutureMinimumOperatingLeasePayments>
    <gmab:EstimatedCapitalExpenditureForLease
      contextRef="As_Of_12_31_2019_xex72RSubkKykkoK3vKmyQ"
      decimals="-6"
      id="Narr_evjC31BJAkm4bZU98FlQ5A"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">74000000</gmab:EstimatedCapitalExpenditureForLease>
    <gmab:DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_cT2N_CicWkKuxkR4DPt3wA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The statement of comprehensive income shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 15&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expense relating to short-term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_arkOpJJSzEOXHp0JsMegrA"
      decimals="-6"
      id="Tc_9Pmi9DgmkEWXzbwYn9iIdA_5_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">25000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_OIs20y9YdUCpESyQhSl9AA"
      decimals="-6"
      id="Tc_EwMdiKhVKUuP12b7MmSL0w_5_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">14000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8pQrFQMD0keUvx5gLpDr7w"
      decimals="-6"
      id="Tc_15KOP0d1Fk2_bhCF6-KDcg_6_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_8DR9RGN4mk6fMGFsM-lTeg"
      decimals="-6"
      id="Tc_qpVOaQP4iEuMcANQh1P31Q_6_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_PvPUO8PM9kSqMJVdTkCLMQ_8_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">26000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_3XlvPkwIKkS66Nq2jlSmBQ_8_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">15000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_WNG97PBcE0qDBM8Ft10Drg_10_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">6000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_GHJtoR07KkCTRaJrTYE5sg_10_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">3000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      decimals="-6"
      id="Tc_pR6XP7cou0eI43vCBQjk0g_11_2"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">1000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2020_To_6_30_2020_-1q6Ul8Wu0ulQ5yyTADEGg"
      decimals="-6"
      id="Tc_A5xegdc_xUaKqK89QXlZ3A_11_4"
      unitRef="Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ">2000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA"
      id="Tb_GFExNk2OZ0K1oTxMoBqFOQ">&lt;p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;8&#160;- Subsequent Events to the Balance Sheet Date&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2021.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710770353080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Genmab A/S<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001434265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710745852248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Income Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">kr 1,972<span></span>
</td>
<td class="nump">kr 5,451<span></span>
</td>
<td class="nump">kr 3,553<span></span>
</td>
<td class="nump">kr 6,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(921)<span></span>
</td>
<td class="num">(775)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="num">(1,185)<span></span>
</td>
<td class="num">(954)<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(1,775)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">4,497<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">4,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(430)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Net result before tax</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">4,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Corporate tax</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="num">(1,035)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="nump">kr 306<span></span>
</td>
<td class="nump">kr 3,378<span></span>
</td>
<td class="nump">kr 1,402<span></span>
</td>
<td class="nump">kr 3,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic net result per share</a></td>
<td class="nump">kr 4.68<span></span>
</td>
<td class="nump">kr 51.88<span></span>
</td>
<td class="nump">kr 21.44<span></span>
</td>
<td class="nump">kr 56.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted net result per share</a></td>
<td class="nump">kr 4.64<span></span>
</td>
<td class="nump">kr 51.35<span></span>
</td>
<td class="nump">kr 21.25<span></span>
</td>
<td class="nump">kr 55.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="nump">kr 306<span></span>
</td>
<td class="nump">kr 3,378<span></span>
</td>
<td class="nump">kr 1,402<span></span>
</td>
<td class="nump">kr 3,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Amounts which will be re-classified to the income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Adjustment of foreign currency fluctuations on subsidiaries</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowHedgesAbstract', window );"><strong>Fair value adjustments of cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">kr 293<span></span>
</td>
<td class="nump">kr 3,369<span></span>
</td>
<td class="nump">kr 1,430<span></span>
</td>
<td class="nump">kr 3,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowHedgesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowHedgesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710744703800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">kr 297<span></span>
</td>
<td class="nump">kr 338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivables', window );">Receivables</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CorporateTaxReceivable', window );">Corporate tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Receivables</a></td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsMarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">8,398<span></span>
</td>
<td class="nump">8,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">9,477<span></span>
</td>
<td class="nump">7,260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">20,304<span></span>
</td>
<td class="nump">18,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">22,483<span></span>
</td>
<td class="nump">21,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilitiesAbstract', window );"><strong>SHAREHOLDERS' EQUITY AND LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">11,940<span></span>
</td>
<td class="nump">11,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Retained earnings</a></td>
<td class="nump">8,164<span></span>
</td>
<td class="nump">7,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="nump">20,252<span></span>
</td>
<td class="nump">19,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentPayables', window );">Other payables</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Corporate tax payable</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentDeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other payables</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total shareholders' equity and liabilities</a></td>
<td class="nump">kr 22,483<span></span>
</td>
<td class="nump">kr 21,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_CorporateTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Tax Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_CorporateTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsMarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsMarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentDeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of rent deferred income classified as current. [Refer: Rent deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentDeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of rent deferred income classified as non-current. [Refer: Rent deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710755725720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Net result before tax</a></td>
<td class="nump">kr 1,846<span></span>
</td>
<td class="nump">kr 4,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ReversalOfFinancialItemsNet', window );">Reversal of financial items, net</a></td>
<td class="num">(527)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TotalAdjustmentsForNonCashTransactions', window );">Adjustments for non-cash transactions</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Changes in operating assets and liabilities</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(2,570)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems', window );">Cash flow from operating activities before financial items</a></td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_AdjustmentsForInterestOnLeasePayments', window );">Interest elements of lease payments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Corporate taxes paid</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flow from operating activities</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Investment in tangible assets</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Marketable securities bought</a></td>
<td class="num">(7,410)<span></span>
</td>
<td class="num">(3,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Marketable securities sold</a></td>
<td class="nump">8,137<span></span>
</td>
<td class="nump">4,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod', window );">Other investments bought</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod', window );">Other investments sold</a></td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash flow from investing activities</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ProceedsFromExerciseOfWarrants', window );">Warrants exercised</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal elements of lease payments</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PaymentsToAcquireTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs', window );">Payment of withholding taxes on behalf of employees on net settled RSUs</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flow from financing activities</a></td>
<td class="num">(460)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Change in cash and cash equivalents</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">7,260<span></span>
</td>
<td class="nump">3,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange rate adjustments</a></td>
<td class="nump">171<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">9,477<span></span>
</td>
<td class="nump">6,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents include:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Bank deposits</a></td>
<td class="nump">6,908<span></span>
</td>
<td class="nump">3,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents', window );">Short-term marketable securities</a></td>
<td class="nump">kr 2,569<span></span>
</td>
<td class="nump">kr 3,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_AdjustmentsForInterestOnLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_AdjustmentsForInterestOnLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PaymentsToAcquireTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PaymentsToAcquireTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ReversalOfFinancialItemsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reversal of financial items to the cash flow under operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ReversalOfFinancialItemsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TotalAdjustmentsForNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for total non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TotalAdjustmentsForNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710745226216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Share premium [Member]</div></th>
<th class="th"><div>Translation reserves</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">kr 65<span></span>
</td>
<td class="nump">kr 11,755<span></span>
</td>
<td class="nump">kr 98<span></span>
</td>
<td class="nump">kr 2,130<span></span>
</td>
<td class="nump">kr 14,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TransactionsWithOwners', window );"><strong>Transactions with owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity', window );">Net settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity', window );">Tax on items recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2020</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">11,826<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
<td class="nump">17,871<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">11,894<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">7,107<span></span>
</td>
<td class="nump">19,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net result</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TransactionsWithOwners', window );"><strong>Transactions with owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447)<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity', window );">Net settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2021</a></td>
<td class="nump">kr 66<span></span>
</td>
<td class="nump">kr 11,940<span></span>
</td>
<td class="nump">kr 82<span></span>
</td>
<td class="nump">kr 8,164<span></span>
</td>
<td class="nump">kr 20,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from net settlement of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from tax on items recognized directly in equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710748623176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Presentation</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;1&#160;&#8211; Basis of Presentation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Accounting Policies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS&#160;34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#8217;s external auditors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#8211; Basis of Presentation in the financial statements in the Genmab 2020 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Management Judgments and Estimates under IFRS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In preparing interim reports, certain provisions under IFRS require management to make judgments (various accounting estimates and assumptions) which may significantly impact the group&#8217;s financial statements. For a description of significant judgments and estimates, refer to Note 1.3 in the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information about Geographical Areas</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710748628808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ResultsForYearAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Revenue</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;2&#160;&#8211; Revenue</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Genmab enters into license and collaboration agreements that are within the scope of IFRS 15, under which it licenses certain rights to its product candidates to third parties and also may participate in the development of the product candidates. The terms of these arrangements typically include payment to Genmab of one or more of the following: non-refundable, upfront license fees; exclusive designation fees; annual license maintenance fees; additional target fees; development, regulatory and commercial milestone payments; reimbursements for research and development services; and royalties on net sales of licensed products. Each of these payments results in revenue from contracts with customers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on sales of daratumumab (marketed as DARZALEX for intravenous administration and as DARZALEX <i style="font-style:italic;">FASPRO</i> in the United States and as DARZALEX SC in Europe for SC administration). The arbitration first is to settle whether Genmab is required to share in Janssen&#8217;s royalty payments to Halozyme Therapeutics, Inc. for the Halozyme enzyme technology used in the SC formulation of daratumumab. The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab sales. Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab&#8217;s share of Janssen&#8217;s royalty payments to Halozyme beginning in the second quarter of 2020 and has continued to do so through June 30, 2021. Given the ongoing arbitration, Genmab has reflected this reduction in its royalty revenues each quarter. The impact to the first half of 2021 royalties is estimated to be DKK 146 million. The impact to the first half of 2020 royalties is not material. The arbitration is also to settle whether Janssen&#8217;s obligation to pay royalties on sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/>The table below summarizes Genmab&#8217;s revenue by type and collaboration partner under Genmab&#8217;s agreements. This information provides the reader additional information regarding the nature, amount, timing and uncertainty of Genmab&#8217;s revenue and how cash flows might be affected by economic factors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2020</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by type:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,738</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,398</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,343</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by collaboration partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Janssen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,652</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">AbbVie</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,398</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Seagen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">BioNTech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other collaboration partners</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,343</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AbbVie Collaboration Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On June&#160;10, 2020, Genmab entered into a broad collaboration agreement to jointly develop and commercialize epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 and a discovery research collaboration for future differentiated antibody therapeutics for cancer. Under the terms of the agreement, Genmab received a USD 750&#160;million (DKK 4,911 million) upfront payment in July 2020. Genmab recognized DKK 4,398 million as license revenue during the first half of 2020 driven by the delivery of licenses for the three programs described above. Genmab recorded DKK 513 million as deferred revenue related to co-development activities for product concepts and is expected to be recognized as revenue activities are performed, which is estimated to be over a <span style="white-space:pre-wrap;">seven-year</span><span style="white-space:pre-wrap;"> period. No revenue has been recognized in the first half of 2021 or 2020 as co-development activities for product concepts have not yet commenced. Refer to Note 2.1 in the Annual Report for further details of the AbbVie collaboration agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ResultsForYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ResultsForYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710755801720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;3&#160;&#8211; Financial Instruments</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets measured at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,151</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,900</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, Genmab&#8217;s marketable securities were administrated by two external investment managers. The investment guidelines and managers are reviewed regularly to reflect changes in market conditions, Genmab&#8217;s activities and financial position. During the first half of 2021, Genmab&#8217;s investment policy was amended to allow investments in debt rated BBB- or greater by S&amp;P or Fitch and in debt rated Baa3 or greater by Moody&#8217;s.&#160;The amended policy also includes additional allowable investment types, none of which were purchased during the first half of 2021.&#160; </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s current portfolio is spread over a number of different securities with a focus on liquidity and security. Genmab&#8217;s total marketable securities were invested in EUR (10%), DKK (20%), USD (69%) and GBP (1%) denominated securities as of June 30, 2021, compared to 10%, 19%, 70%, and 1%, as of December 31, 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, and December 31, 2020, 99% of Genmab&#8217;s marketable securities had an AA rating or higher from Moody&#8217;s, S&amp;P, or Fitch. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For financial instruments that are measured in the balance sheet at fair value, IFRS 13 for financial instruments requires disclosure of fair value measurements by level of the following fair value measurement hierarchy for: </p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 1 &#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 2 &#8211; Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Level 3 &#8211; Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets Measured at Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,398</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,398</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,819</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,819</p></td></tr><tr><td style="vertical-align:bottom;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other investments</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">729</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,067</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,081</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Marketable Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#8217;s marketable securities (Level 1). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Investments </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other investments as of June 30, 2021 consist primarily of a DKK 650 million investment in common shares of CureVac, compared to DKK 1,067 million as of December 31, 2020. During the first half of 2021, Genmab sold 35% of its investment in common shares of CureVac. Proceeds received from the sale of shares were DKK 438 million. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the second quarter of 2021, Genmab made an investment in common shares of Bolt. As of June 30, 2021, the investment in Bolt was valued at DKK 79 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The investments in CureVac and Bolt are recorded at fair value through profit and loss. The fair value of Genmab&#8217;s investments in CureVac and Bolt are determined using unadjusted quoted prices in established markets (Level 1).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35K<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710793907464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income and Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial Income and Expenses</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Note&#160;4&#160;&#8211; Financial Income and Expenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2020</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 700</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 119</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (134)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (173)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 527</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 114</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign exchange rate gain, net was DKK 573 million in the first half of 2021 as compared to DKK 36 million in the first half of 2020. The increase was driven by the strengthening of the USD against the DKK in 2021 that positively impacted our USD denominated marketable securities portfolio and cash holdings. Refer to Note 4.2 in the Annual Report for further details of foreign currency risk.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on marketable securities, net of DKK 134 million in the first half of 2021 was primarily driven by the movements in interest rates in the United States and Europe.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710748680072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-Based Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Schedule of share-based payment</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Note&#160;5&#160;&#8211; Share-Based Instruments</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Restricted Stock Unit Program</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab A/S established an RSU program as an incentive for all the Genmab group&#8217;s employees, members of the Executive Management, and members of the Board of Directors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For details of the RSU program prior to changes in 2021, refer to Note 4.6 in the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In February 2021, the RSU program was amended (the &#8220;2021 RSU Program&#8221;). Under the terms of the 2021 RSU Program, the Board may decide, in its sole discretion, to accelerate the vesting of the RSUs held by a participant, or accelerate the vesting of the RSUs and make a cash settlement in case of (1) a change of control event as defined in the 2021 RSU Program, if a participant&#8217;s employment terms are materially changed to his or her detriment during the 12-month period following the change in control event, or if the participant, who is a member of the Board, is replaced by a new board member or such participant's seat on the Board is eliminated due to a reduction in the number of board members, or (2) certain other extraordinary transactions as described in the 2021 RSU Program. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Under the terms of the 2021 RSU Program, in the event an RSU holder separates from the Company under circumstances in which the RSU holder is considered a &#8220;bad-leaver,&#8221; such as being dismissed for cause or during the employment probationary period, unvested RSU will be forfeited. RSU holders may maintain a pro rata portion of unvested RSUs if they separate from the Company under circumstances where they are considered &#8220;good-leavers,&#8221; such as dismissal without cause or termination of employment due to the Company&#8217;s material breach of the RSU holder&#8217;s employment terms, or if the participant is a member of the Board, if the membership of the Board ceases for any other reason than as a result of the participants death. All unvested RSUs will be forfeited in the event of termination of employment due to the RSU holder&#8217;s death.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, 159,567 RSUs were granted with a weighted average fair value of DKK 2,149.55 per RSU. During the first half of 2020, 22,672 RSUs were granted with a weighted average fair value of DKK 1,491.16 per RSU. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, 49,012 RSUs vested, compared to 39,438 RSUs during the first half of 2020. Genmab settles RSUs using shares issued from treasury stock. A portion of the settlement is withheld to satisfy individual statutory tax withholding obligations in certain jurisdictions which remain in Genmab&#8217;s treasury share account.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Warrant Program</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Genmab A/S established warrant programs as an incentive for all the Genmab group&#8217;s employees, and members of the Executive Management. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For details of the warrant programs prior to changes in 2021, refer to Note 4.6 in the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Warrant Program was amended (the &#8220;2021 Warrant Program&#8221;). Under the terms of the 2021 Warrant Program, the Board may decide, in its sole discretion, to accelerate the vesting of the warrants held by a warrant holder in case of (1) a change of control event as defined in the 2021 Warrant Program, if a warrant holder&#8217;s employment terms are materially changed to his or her detriment during the 12-month period following a change in control event, or (2) certain other extraordinary transactions as described in the 2021 Warrant Program.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the 2021 Warrant Program, if a warrant holder separates from the Company under circumstances in which the warrant holder is considered a &#8220;bad-leaver,&#8221; such as being dismissed for cause or during the employment probationary period, unvested warrants will be forfeited. Warrant holders may maintain a pro rata portion of unvested warrants if they separate from the Company under circumstances where they are considered &#8220;good-leavers,&#8221; such as dismissal without cause or termination of employment due to the Company&#8217;s material breach of the warrant holder&#8217;s employment terms. All unvested warrants will be forfeited in the event of termination of employment due to the warrant holder&#8217;s death.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, 147,568 warrants were granted to Genmab employees with a weighted average exercise price of DKK 2,189.21 per warrant and a weighted average Black-Scholes fair market value of DKK 683.79 per warrant. During the first half of 2020, 49,323 warrants were granted to Genmab employees with a weighted average exercise price of DKK 1,548.22 per warrant and a weighted average Black-Scholes fair market value of DKK 465.70 per warrant.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the first half of 2021, 74,992 warrants were exercised with a weighted average exercise price on date of grant of DKK 606.22 with proceeds to Genmab of DKK 46 million. The warrants exercised increased share capital accordingly and corresponded to approximately 0.11% of share capital. During the first half of 2020, 272,078 warrants were exercised with a weighted average exercise price on date of grant of DKK 261.06 with proceeds to Genmab of DKK 71 million. The warrants exercised increased share capital accordingly and corresponded to approximately 0.42% of share capital.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Share-based compensation expenses related to Genmab RSU and warrant programs for the first half of 2021 totaled DKK 142 million compared to DKK 98 million for the first half of 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/><b style="font-weight:bold;">Share repurchases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In general, Genmab intends to purchase its own shares in order to cover a portion of the obligations in relation to RSUs. Authorization to purchase Genmab shares up to a nominal value of DKK 500,000 (500,000 shares) was given by the shareholders at the annual general meeting in March&#160;2016. As of December 31, 2020, a total of 225,000 shares, with a nominal value of DKK 225,000, had been repurchased under the March 2016 authorization. The March 2016 authorization expired in March 2021. Additionally, in March&#160;2019, Genmab shareholders authorized the repurchase up to an additional nominal value of DKK 500,000 (500,000 shares). A portion of the shares that may be repurchased under this authorization may be used to cover Genmab&#8217;s obligations in relation to the RSUs. Moreover, in April&#160;2021, Genmab shareholders authorized us to repurchase up to an additional nominal value of DKK 500,000 (500,000 shares) to cover obligations under our share-based remuneration programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As announced on February 23, 2021, Genmab initiated a share buy-back program. During the first half of 2021, Genmab acquired 200,000 of its own shares, representing approximately 0.3% of share capital. The total amount paid to acquire the shares, including directly attributable costs, was DKK 447 million and has been recognized as a deduction to shareholders&#8217; equity. These shares are classified as treasury shares and are presented within retained earnings on the balance sheet as of June 30, 2021. There were no share repurchases during the first half of 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2021, 299,206 treasury shares were held by Genmab to cover the obligations in relation to the RSU program and to mitigate the dilutive effect of share capital increases resulting from future exercises of warrants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710748640072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Parties</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Note&#160;6&#160;&#8211; Related Parties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s related parties are the Genmab A/S&#8217; (parent company) subsidiaries, Board of Directors, Executive Management, and close members of the family of these persons. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab has service agreements with, and has made equity compensation grants to, members of Executive Management in the ordinary course of business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Transactions with Related Parties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, there were no material related party transactions. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Key Changes to Executive Management and the Board of Directors</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, there was one change to the Executive Management team. Effective March 1, 2021, Tahamtan Ahmadi, previously Senior Vice President, Head of Oncology, was appointed Executive Vice President and Chief Medical Officer, Head of Experimental Medicines. He joins the existing Executive Management team of Jan van de Winkel, President and Chief Executive Officer, Judith Klimovsky, Executive Vice President and Chief Development Officer, Anthony Pagano, Executive Vice President and Chief Financial Officer and Anthony Mancini, Executive Vice President and Chief Operating Officer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">There were no changes to the Board of Directors during the first half of 2021. Following Genmab A/S' Annual General Meeting on April 13, 2021, the Board of Directors is comprised of five independent board members, one non-independent board member, and three employee-elected board members. They are Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, Jonathan Peacock, Dr. Anders Gersel Pedersen, Peter Storm Kristensen, Dr. Mijke Zachariasse and Rima Bawarshi Nassar, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710748633032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="color:#000000;font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Note&#160;7&#160;&#8211; Leases</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Amounts recognized in the balance sheet</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The balance sheet shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 280</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;">384</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 283</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 277</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 443</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 319</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first half of 2021, there were additions to Genmab&#8217;s right-of-use assets and lease liabilities related to the commencement of leases in Japan and the United States with respect to office space. During the first half of 2020, there were additions to Genmab&#8217;s right-of-use assets and lease liabilities related to the </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">commencement of leases in the United States and the Netherlands with respect to office and laboratory space.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/></b><b style="font-weight:bold;">Significant leases not yet commenced</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During 2020, Genmab entered into a lease agreement with respect to the new headquarters in Denmark with a commencement date in March 2023 and is non-cancellable until March 2038. The total future minimum payments over the term of the lease are approximately DKK 342 million and estimated capital expenditures to fit out the space are approximately DKK 40 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During 2019, Genmab entered into a lease agreement with respect to office and laboratory space in the Netherlands with a commencement date in February 2022 and is non-cancellable until January 2032. The total future minimum payments over the term of the lease are approximately DKK 117 million and estimated capital expenditures to fit out the space are approximately DKK 74 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Amounts recognized in the statement of comprehensive income</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The statement of comprehensive income shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2020</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 26</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 15</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expense relating to short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense is included in net financial items and expenses relating to short-term leases are included in operating expenses in the statement of comprehensive income.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710744491976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;8&#160;- Subsequent Events to the Balance Sheet Date</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710748731464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock', window );">Accounting Policies</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Accounting Policies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS&#160;34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#8217;s external auditors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#8211; Basis of Presentation in the financial statements in the Genmab 2020 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock', window );">Management Judgments and Estimates under IFRS</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Management Judgments and Estimates under IFRS</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In preparing interim reports, certain provisions under IFRS require management to make judgments (various accounting estimates and assumptions) which may significantly impact the group&#8217;s financial statements. For a description of significant judgments and estimates, refer to Note 1.3 in the Annual Report.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Information about Geographical Areas</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information about Geographical Areas</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710755808056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ResultsForYearAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of revenue by type and collaboration partner under agreements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2020</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by type:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,738</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,398</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,343</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by collaboration partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Janssen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,652</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">AbbVie</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,398</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Seagen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">BioNTech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other collaboration partners</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26</p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:19.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,343</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ResultsForYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ResultsForYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710756034952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory', window );">Schedule of Financial Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,819</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets measured at fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,151</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,900</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:middle;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets Measured at Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:middle;width:26.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,398</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,398</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,819</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,819</p></td></tr><tr><td style="vertical-align:bottom;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other investments</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">729</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 753</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,067</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,081</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section Offsetting financial assets and financial liabilities<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g13A-13F_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710744359576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income and Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfFinanceIncomeExpensesAbstract', window );"><strong>Finance Income and Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock', window );">Schedule of finance income and expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2020</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 700</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 119</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financial expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (134)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (173)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 527</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 114</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfFinanceIncomeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfFinanceIncomeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710745298376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock', window );">Summary of balance sheet amounts relating to leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The balance sheet shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 280</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;">384</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 283</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 277</p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 443</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> 319</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock', window );">Summary of statement of comprehensive income amounts relating to leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The statement of comprehensive income shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2020</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e6e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 26</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 15</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expense relating to short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#e7e6e6;vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance sheet information relating to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of comprehensive information relating to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710786548280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsNumberOfReportingUnits', window );">Number of business unit</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsNumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsNumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710718187416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">kr 3,553<span></span>
</td>
<td class="nump">kr 6,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ReductionInRoyaltyRevenue', window );">Reduction In Royalty Revenue</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">2,846<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">4,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithRocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember', window );">Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember', window );">BioNTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember', window );">Novartis (Arzaerra/Ofatumumab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_OtherCollaborationPartnersMember', window );">Other collaboration partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">2,595<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_ReimbursementIncomeMember', window );">Reimbursement income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_MilestonePaymentsRevenueMember', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">kr 731<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_LicenseFeesMember', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_LicenseFeesMember', window );">License fees | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 4,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ReductionInRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ReductionInRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_OtherCollaborationPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_OtherCollaborationPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_ReimbursementIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_ReimbursementIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_MilestonePaymentsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_MilestonePaymentsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710745625288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - AbbVie Collaboration Agreement (Details)<br> kr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 10, 2020 </div>
<div>DKK (kr) </div>
<div>item</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>DKK (kr)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>DKK (kr)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>DKK (kr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 3,553<span></span>
</td>
<td class="nump">kr 6,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_LicenseFeesMember', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_UpfrontMilestonePaymentReceived', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 4,911<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 245<span></span>
</td>
<td class="nump">4,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfDeliveryLicenses', window );">Number of delivery license programs | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PerformanceObligationRevenueRecognitionPeriod', window );">Performance obligation Revenue recognition period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember', window );">AbbVie | Performance obligations satisfied over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ContractTransactionPrice', window );">Contract transaction price</a></td>
<td class="nump">kr 513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember', window );">AbbVie | License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 4,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ContractTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The identified transaction price under the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ContractTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfDeliveryLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of delivery license programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfDeliveryLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PerformanceObligationRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which performance obligation revenue will recognize.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PerformanceObligationRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash in flow from upfront milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710763532968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial Assets</a></td>
<td class="num">kr (9,151)<span></span>
</td>
<td class="num">kr (9,900)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial Assets</a></td>
<td class="nump">8,398<span></span>
</td>
<td class="nump">8,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial Assets</a></td>
<td class="nump">kr 753<span></span>
</td>
<td class="nump">kr 1,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710744844872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Financial Risk (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk | Triple A-rating from Moody's, S&amp;P or Fitch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | DKK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfMarketableSecuritiesInvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of marketable securities invested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfMarketableSecuritiesInvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExposureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gmab_TripleaRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gmab_TripleaRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_DKK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_DKK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710745635512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value Measurement (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="num">kr (9,151)<span></span>
</td>
<td class="num">kr (9,900)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,398<span></span>
</td>
<td class="nump">8,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember', window );">Marketable Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,398<span></span>
</td>
<td class="nump">8,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">kr 24<span></span>
</td>
<td class="nump">kr 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710745588824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Other Investments (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">kr 753<span></span>
</td>
<td class="nump">kr 1,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember', window );">CureVac</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">kr 650<span></span>
</td>
<td class="nump">kr 1,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfInvestmentInCommonShares', window );">Percentage of investment in common shares</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from sale of shares</a></td>
<td class="nump">kr 438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_BoltBiotherapeuticsIncMember', window );">Bolt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">kr 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfInvestmentInCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment in common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfInvestmentInCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_BoltBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_BoltBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710755732712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Income and Expenses (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_FinanceIncomeAbstract', window );"><strong>Financial Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_InterestAndOtherFinancialIncome', window );">Interest and other financial income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 127<span></span>
</td>
<td class="nump">kr 83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange rate gain, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total financial income</a></td>
<td class="nump">kr 65<span></span>
</td>
<td class="nump">kr 42<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_FinanceExpensesAbstract', window );"><strong>Financial expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_InterestAndOtherFinancialExpenses', window );">Interest and other financial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_LossesOnMarketableSecurities', window );">Loss on marketable securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_LossesOnOtherInvestmentsNet', window );">Loss on other investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total financial expenses</a></td>
<td class="num">kr (430)<span></span>
</td>
<td class="num">kr (211)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 527<span></span>
</td>
<td class="nump">kr 114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_FinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_FinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_InterestAndOtherFinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest and other financial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_InterestAndOtherFinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_InterestAndOtherFinancialIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest and other financial income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_InterestAndOtherFinancialIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_LossesOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The losses on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_LossesOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_LossesOnOtherInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Losses On Other Investments Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_LossesOnOtherInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710755730104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)<br> kr in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>DKK (kr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at January 1, 2020</a></td>
<td class="num">kr (9,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at December 31, 2020</a></td>
<td class="num">(9,151)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at January 1, 2020</a></td>
<td class="nump">8,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at December 31, 2020</a></td>
<td class="nump">8,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at January 1, 2020</a></td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at December 31, 2020</a></td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Other Investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at January 1, 2020</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Fair value at December 31, 2020</a></td>
<td class="nump">kr 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710755819384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)<br> kr in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>DKK (kr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Cost at the beginning of the period</a></td>
<td class="nump">kr 21,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Cost at the end of the period</a></td>
<td class="nump">kr 22,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710748709304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments - Part 1 (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EquityInstruments </div>
<div>kr / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EquityInstruments </div>
<div>kr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">159,567<span></span>
</td>
<td class="nump">22,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested</a></td>
<td class="nump">49,012<span></span>
</td>
<td class="nump">39,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement', window );">Weighted average fair value of RSU granted | kr / shares</a></td>
<td class="nump">kr 2,149.55<span></span>
</td>
<td class="nump">kr 1,491.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_IfrsRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_IfrsRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710755721096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments - Part 2 (Details) - DKK (kr)<br> kr / shares in Units, kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfWarrantsGrantedDuringPeriod', window );">Granted</a></td>
<td class="nump">147,568<span></span>
</td>
<td class="nump">49,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfWarrantsExercisedDuringPeriod', window );">Exercised</a></td>
<td class="nump">74,992<span></span>
</td>
<td class="nump">272,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_WeightedAverageExercisePriceOfWarrantsGranted', window );">Weighted average exercise price of warrants granted</a></td>
<td class="nump">kr 2,189.21<span></span>
</td>
<td class="nump">kr 1,548.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_WeightedAverageExercisePriceOfFairValueOfWarrants', window );">Weighted average exercise price of fair market value</a></td>
<td class="nump">683.79<span></span>
</td>
<td class="nump">465.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_WeightedAverageExercisePriceOfWarrantsExercised', window );">Weighted average exercise price of warrants exercised</a></td>
<td class="nump">kr 606.22<span></span>
</td>
<td class="nump">kr 261.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">kr 46<span></span>
</td>
<td class="nump">kr 54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants', window );">Percentage of share capital attributed to exercise of warrants</a></td>
<td class="nump">0.11%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based compensation expenses</a></td>
<td class="nump">kr 142<span></span>
</td>
<td class="nump">kr 98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">kr 46<span></span>
</td>
<td class="nump">kr 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfWarrantsExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfWarrantsExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfWarrantsGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants granted during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfWarrantsGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital attributed by exercise of warrants which increase the share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_WeightedAverageExercisePriceOfFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of fair value of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_WeightedAverageExercisePriceOfFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_WeightedAverageExercisePriceOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_WeightedAverageExercisePriceOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_WeightedAverageExercisePriceOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_WeightedAverageExercisePriceOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710744732904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments - Part 3 (Details) - Restricted Stock Units Program - DKK (kr)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsStockRepurchaseProgramAuthorizedAmount', window );">Amount of stock repurchase plan authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 500,000<span></span>
</td>
<td class="nump">kr 500,000<span></span>
</td>
<td class="nump">kr 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to be repurchased</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsStockRepurchasedDuringPeriodShares', window );">Repurchased shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsStockRepurchasedDuringPeriodValue', window );">Repurchased values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfShareCapital', window );">Percentage of share capital</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsTreasuryStockShares', window );">Treasury stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">kr (447,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsStockRepurchaseProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsStockRepurchaseProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsStockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsStockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsStockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsStockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsTreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that has been treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsTreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsShareRepurchaseProgramAxis=gmab_RestrictedStockUnitsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsShareRepurchaseProgramAxis=gmab_RestrictedStockUnitsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710787182296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties (Details) - Key Changes to Executive Management<br></strong></div></th>
<th class="th">
<div>Apr. 13, 2021 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfIndependentBoardMembers', window );">Number of independent board members</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfNonIndependentBoardMembers', window );">Number of non independent board members</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfEmployeeElectedBoardMembers', window );">Number of employee elected board members</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfEmployeeElectedBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employee elected board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfEmployeeElectedBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfIndependentBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of independent board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfIndependentBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfNonIndependentBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non independent board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfNonIndependentBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140710718104136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">kr 384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">kr 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_FutureMinimumOperatingLeasePayments', window );">Total future minimum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">kr 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_EstimatedCapitalExpenditureForLease', window );">Estimated capital expenditure for lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">kr 74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=gmab_PropertiesMember', window );">Properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=gmab_IfrsEquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">kr 1<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_EstimatedCapitalExpenditureForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated capital expenditure for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_EstimatedCapitalExpenditureForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_FutureMinimumOperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of future minimum operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_FutureMinimumOperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=gmab_PropertiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=gmab_PropertiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=gmab_IfrsEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=gmab_IfrsEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *Y="U,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "N70M39OSX.>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OI^FZ(J&;B^))07!!\1:2V=U@\X=DI-VWMXV[740?P&-F?OGF
M&YA.1Z%#PN<4(B:RF*]&U_LL=-RP U$4 %D?T*E<3PD_-7<A.473,^TA*OVA
M]@AMT]R 0U)&D8(96,6%R&1GM- )%85TPAN]X.-GZ@O,:, >'7K*P&L.3,X3
MXW'L.[@ 9AAA<OF[@&8AENJ?V-(!=DJ.V2ZI81CJ855RTPX<WIX>7\JZE?69
ME-<X_<I6T#'BAITGOZ[N[K</3+9-RZOFMN)\R]?B>BW:]GUV_>%W$7;!V)W]
MQ\9G0=G!K[N07U!+ P04    " "N70M3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *Y="U-S ]G#IP(  &8(   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME99M;]HP$,=?;Y_"RNO1/ #I@P )Z+IU72?6[D'3M!<F.8)5QV:V,\JWW]D)
M*9-2T[U);.?N?[_S6;Z,ME(]Z#6 (8\E%WH<K(W97(2ASM904GTB-R#PRTJJ
MDAJ<JB+4&P4T=TXE#Y,H2L.2,A%,1FYMH28C61G.!"P4T5594K6; 9?;<1 '
M^X4[5JR-70@GHPTMX![,U\U"X2QL57)6@M!,"J)@-0ZF\<4L=@[.XAN#K3X8
M$YO*4LH'.[G.QT%DB8!#9JP$Q=<?F /G5@DY?C>B01O3.AZ.]^I7+GE,9DDU
MS"7_SG*S'@=G <EA12MN[N3V/30)#:U>)KEV3[*M;?N#@&25-K)LG)&@9*)^
MT\=F(PX<XO09AZ1Q2!QW'<A17E)#)R,EMT19:U2S Y>J\T8X)FQ5[HW"KPS]
MS.129A5NLB%4Y.2M,,SLR+6HJXV[-@H-!K&F8=8(SFK!Y!G!E-Q*8=8:Q7+(
M__4/$:XE3/:$L\0K^*$2)Z0?O2%)E,0>O7Z;<=_I]8]E?) F^?D1K<BU@5+_
M\L08M#$&+L;@6(PONPUT[:'?/>W=>""&+<3P91 +4$S:ZN8$ST@GCU]I7X+7
MKUX=*4+:LJ5>Q>:DW4'!M%$4(3_1LI/,K_,.1$F79!K>>Z!.6ZC3ET#-<<\4
MY7@^<G@D-[#KPO(K15$4#_J#)!UZL,Y:K#.OV+Q2RI;QBND,L7X 5=Y:^M5Z
MO3CI]7TU/&^YSE]VO@[!KG!1=U'YM8X<JSAZNLZB_X)JSOZS6$?D/B<^JH-+
M-O;*3!$IK[$X+3HY_ (KRC5TH80'5W\)JG -3I-,5L+47:!=;9OHM&X=3^9U
M![ZEJF!"$PXK=(U.3O%24'53JR=&;EPC64J#;<D-U_@C ,H:X/>5E&8_L0':
M7XO)7U!+ P04    " "N70M3_ADH72L%  #P%   &    'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;*68;7/B-A#'OXJ&5^U,@RWYD0QA)@&NO;NY]B;IPVO%
M%EB-;5%)0.[;5S;&!GGM8]HW@,U_5_JM5M)*\Z.0;RIC3*/W(B_5PR33>G?O
M."K)6$'55.Q8:?[9"%E0;1[EUE$[R6A:&Q6Y0UPW= K*R\EB7K_[*A=SL=<Y
M+]E7B=2^**C\]L1R<7R8X,GYQ3/?9KIZX2SF.[IE+TS_L?LJS9/3>DEYP4K%
M18DDVSQ,'O']FM0&M>)/SH[JXC>J4%Z%>*L>/J8/$[?J$<M9HBL7U'P=V)+E
M>>7)]..?QNFD;;,RO/Q]]OZAAC<PKU2QI<C_XJG.'B;Q!*5L0_>Y?A;'7U@#
M%%3^$I&K^A,=3]K(GZ!DK[0H&F/3@X*7IV_ZW@3BPL#X@0U(8T!L@Z$6O,;
MN[4%OS'P;VTA: QJ=.?$7@=N135=S*4X(EFIC;?J1QW]VMK$BY=5HKQH:?[E
MQDXOEJ)4(N<IU2Q%+]I\F2S0"HD-6HK"Y%Y6)<6!H8]E(@J&[M#J\V?TPYO\
M$;U)Q$OTA>>Y&7$U=[3I3N7429JFGTY-DX&F/?1%E#I3:%VF+ 7L5^/VX8B]
M8\+0QH*<8_%$1AU^VI=3Y+D_(>(2#/1G>;NY"^'\O];7_[GUJV!X;6)XM3]O
MP%\SWFU*C+CT6Y=^[=(?</G,#JS<,RA33H9!;5BM;8<%GD5D[APNP]\7!7Z
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M'<T\5+FIO/5L6&F6<::$_I5I/S6>\%+RG"V(H@MP17)2SBF8F7 2G('K;]_
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MUY,/^&H;Q[9#;?$79R=]]HSL5!ZD?+0O7_+K2601L9)EQKJ@\/?$MJPLK2?
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M%$#^OZ%4O _4UX/N ];\/U!+ P04    " "N70M3R?9WB<<$   U"P  &
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M[_K_+,*:!HZ.-XTZ&K^&?Y4Q0(<:':1W:-E2(!C,6LTM1].58C"/T_$6.-Z
M.V]<WI-[.F?M+C!-GZHC3@Y7PVY%-YG$4Z(]FAPNO"\4TU9K+-8&)B2+.![_
MW($7]+%B!ISZG4[Z'4 % "H$N=#4A8J) E31;1\R)ATT3--&L\H#250OX:(1
M?*5UTA#=D@:]SUS3W2-A^>@AQFJ4)8TDEZ5#N<7;FPM@+E)B<W/GC5SX0&S%
M+#3*<'>%B4?@%%1F*2K5:@_,42JZ'9A;>U83A-:V4!2X%UK&3 65$CD%8$9P
MC04I@5+L3K11LD[N3,J6BGZ-#@[T!H"BU5XV.;G@PKCHB[[HY(ORRAY!<W,W
M&GIR@%:)Q*5+2CV@*ZZ>C>9$QZD43RM;JWOT4G9XOMY:3@1FS7@KN:O2C?6+
M_HAN-3UR1L_=+^'6S5JC+OW[P:FBE;:[9(?5X8ERUMW,&_/N??.9Z9*:"P(+
M@D:CZ22@0ODW0S>QJO'W]%)9NO7]L*)G%FIG0/\7BIK33YR#X>&V^ %02P,$
M%     @ KET+4PQ@]3KX"0  \B   !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&ULW5IK<]LV%OTK&.UT-YEA]*!>5N-XQD[:;MK)3B;>;#Y#)"1B31(J
M %K6_OJ>"X 4*4N6NTF[,_O%X@.XN/?<UP'HRZW2=R83PK*'(B_-FUYF[>;[
MP< DF2BXZ:N-*/%FI73!+6[U>F V6O#432KR03P<S@8%EV7OZM(]^ZBO+E5E
M<UF*CYJ9JBBXWMV(7&W?]$:]^L$GN<XL/1A<76[X6MP*^WGS4>-NT$A)92%*
M(U7)M%B]Z5V/OK^9T'@WX%]2;$WKFI$E2Z7NZ.9]^J8W)(5$+A)+$CA^[L5;
MD><D"&K\&F3VFB5I8ONZEOZCLQVV++D1;U7^1:8V>].[Z+%4K'B5VT]J^W<1
M[)F2O$3EQOUE6S]V'/=84AFKBC 9&A2R]+_\(>#0FG Q/#$A#A-BI[=?R&GY
MCEM^=:G5EFD:#6ETX4QULZ&<+,DIMU;CK<0\>W6;<2U>W<"NE+TOC=45$+?F
M<F AG(8,DB#HQ@N*3PB:L0^JM)EA/Y2I2+OS!U"JT2RN-;N)GQ3X<U7VV7@8
ML7@8CYZ0-VXL'3MYXZ^QM"-YTDB>.,F34Y*1*6F5"Z96S+A5EFZ5#=_1$L>P
M?%K@/Y05;,K^^I>+>#1ZS4YHSCX)7,O$XO&M5<D=^UQ*RSYJM=:\8#^)LN!+
M=CVX91C'E[E$E*2,E^S3[6>V":.XH2>R3" 1Z<&0YHSG.;.9J"6LM:HV3I?Y
M:\-$L<G53@@3L4(42Z$-F4W#?W@02>6$?. E$IJ4C" ]/1QXH[A.Z>:=U$A.
MI4W?V3H<OV9(-225Y3)OAK?5W6B) 5:Q)./E6AAH[N(CH@(AW!L'WJ0_HU<T
M_;HL*YX#K(W2=K_0^Y+]*):Z0B4*$@[7VA(V, +AS%[02YH:#U_3:#<P(.T>
MCUZ_[ /_E'3 4"MTT1AP."%JH5#P'>Q-9"HB4EC"K48AE%)I$BVH<$5D%$\2
M%#+-81K-O8='9;EN(618)O*4+7>,(^ZTE8G<<,*?_'E^LO,2OQ.8G7"3,2.L
MS9T'22L\<L']8O22!CCHZ3Y!QFN4+'%/ P$7RB%".:VA?VRX7'7U.P@KMZ#'
M#B$/C7 M$8Z[L&A*6&32D%69<)&BI9N45IILHE5'\:N"2A';8+)*$=(Y6D_]
M-FA/5K6U=T!)CT@'OVVF&!;D(8@[,1S1&RTV.4]$P+Y$'UIZSX;QU &3K"WT
M;_"QX):ILA4(D"1RB0K/*9_32CBW0WI:^?X5,"VK6HWV,L;I_R)^R1*AD3TE
M4Y8 $@]6<Z53B$6<X[HTW(DSWET(,KD\[;!]NCP[M(.D$!*^V&0JI]E&  28
M9]A*J\(->ZL*(+)CE1.?2)U4!8H5RI%+[6TF 5V=F$$,D(+K#%)&4SVKTW+)
MTU>YX/="1R$C/?"P<RG(^TBI0AHJHE3D$EY14.MVY+2"$$5@R0DHPLT'4@0M
M*7<@@+392I3)I:N8*R'QM-]2TKC$)E+DG,%)'H/MN$ 5(G<"P+8X$X)OUZ#T
M/)"V\++P$REC6L $6-9*U;B81\ $2#BQ#IN!L^UA(3=3, 9=6]"$V&QIUF1Q
MG;!L"8*()5H5W.-R,M]/Y-]3J>?O0OQG<M-M+XE T3*^GP$[GP[0RKBL0V!2
M=<<# _I6SVPM3,G!;=9GU_!RUU&/'-^->9+U'.R.@!*6K'/NW3XR5U(;RS*>
MKTB@[U>CZ2*:SN9!*0H#9&!)^I S8=S645+*$3@?#9FMN-3LGN>5J][O?OF%
MQ=%HLNA/IQ3B)*C_Y*)$QN)H-H^_:LU1-%F,^J/9?LUG&CQ91,-16-L[)$+
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MG_:8]E_8_8U5&_=5>ZFL586[S 1'@-$ O%\I9>L;6J#Y-X>KWP!02P,$%
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MXW$/BJ\%1@+;H !Y;G"0=A_!P>HJ>_0?4$L#!!0    ( *Y="U-*(%2PM 0
M .$.   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;,57;4\C-Q#^*U8J
M5:T$278WD  A$A"N/:YW0L==^]G9G<U:>.W%]A+27]\9[PN!O$ J72LD8GMG
MGIG',YZQQPMM[FT&X-A3+I4][V3.%:>]GHTSR+GMZ@(4?DFUR;G#J9GW;&&
M)UXIE[VPWS_NY5RHSF3LUV[-9*Q+)X6"6\-LF>?<+"]!ZL5Y)^@T"U_%/'.T
MT)N,"SZ'.W#?BUN#LUZ+DH@<E!5:,0/I>><B.+T<D+P7^%/ PJZ,&3&9:7U/
MDX_)>:=/#H&$V!$"QY]'N (I"0C=>*@Q.ZU)4EP=-^@?/'?D,N,6KK3\2R0N
M.^^,.BR!E)?2?=6+WZ'F<T1XL9;6_V>+2C:(.BPNK=-YK8P>Y$)5O_RIWH<5
MA5%_BT)8*X3>[\J0]W+*'9^,C5XP0]*(1@-/U6NC<T)14.Z<P:\"]=SD#T!*
M=MQSB$4KO;C6NZSTPBUZQ^RS5BZS[%HED+S4[Z$/K2-AX\AEN!/PIE1=%O4/
M6-@/@QUX44LL\GC1'L1>  U:H($'&NR]0[OU?OYI%/:C,_9%.V!#1M,@.&,5
M'+O(=:F<Q;R.]5R)OR%A0C&7 >:8Y"H&5IW);VLK-M,+ZR53+?%,"35GO$63
MW-&"TTQZ0Z>L\6/?7PP(^(!,(89\!H9%P<&:%$5K==)GOTP_?<),E1(/W:]O
M6O%5X%"GAZ4%QJT%9'%KL.88)W";HE' PE&?73^4HL!:X%B$?^^E\$T[+IG9
M8"(:#1#W_4@^:DP*/A-2>,]>2UR5QI!_1R=L$&+0U6%<KWA;P^&>7LLUBX,!
M<@].6KEI:7RH*1.$L8YE7*9,ISXF![1N@"WH'T\203704E[\!BKG,Y^.PS.[
M<7>X2C;8]\F%>8H89#/6.08$4X,XHM4JWRB+;WC!E0<AN>]*D-:=0V6+U<UE
MB&0+K,J$I--44&H7/(;N3DK]_Y/2.I&&WA<@K_" )EO)>=M\I@UWVBP;KDT8
M[P2>?Y3C:+,VJ+1C2SSJC3_)ZYA7VU'19N@L[@C5#S3):Y9\;J#B\=HI<EIA
MM\RPA3^4W*"RIS@E-'-?R?.7>Y$@99+YS$V<D?7(DQ+D*B8Z52>)#"4P+$-"
MMG+1J.LKF/,IG9:NQ-!A%Q-YF;."+PG<,OV(Q87<0E=RVG<:US0HU$5A])/
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MAT\B/Z0&!H8$\'NJ\9I=3\A ^ZJ=_ -02P,$%     @ KET+4YR,<Q0J @
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M'J4-,.<S(?3:L1<T_QK&OP%02P,$%     @ KET+4Q$KO"[  @  NP<  !D
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MT]X_*[ AP>]WQN Y"*U>'VKU!U!+ P04    " "N70M3O-E6KC\$  !A$P
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MKXW,'!@59#RO[NR'"T0+$(YZ *$#A,\!80\@<H#H.8#V &('B(^=(7& Y%C
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M\!7J@!+#E_%"VE]TJ&S3U$/97BI>UF"MH*2L^B>O=2): ,WC!H0U(.P"XC.
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M3H^*K.JI66^,7+G!,Y.&QIA;YO2C064=Z'PAI=EN;(#VUS7Z!U!+ P04
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MR;&\X4?"])L=%SE6^E;L WD4!*<6E&<!"L-QD&/*!LNY??8@EG->J(PR\B"
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ KET+4U5'EA4Q P  5A8   \
M  !X;"]W;W)K8F]O:RYX;6S%F-]/VS 0@/\5*T^;-)8F@?)#%&D4V"JA4=&)
MU\E)KL3"L3O;+8R_?I>$#K=+3WLQ/+5V7/?+Q7>?G=-';1YRK1_84RV5'465
M<XN3.+9%!36WG_4"%%Z9:U-SATUS']N% 5[:"L#5,DX'@V%<<Z&BL]/U7%,3
M^PWMH'!"*^QL.NX$/-K7ZTV3K805N9#"_1Y%[7<)$:N%$K5XAG(4#2)F*_WX
M31OQK)7C<E88+>4H2KH+=V"<*/[IGC60/WANVQ['\UN.(*-H., )Y\)8UXYH
MY^?(N (<W+663E\)Z<!<< =?C5XNA+IOIL&[B+W;:..P_NR">&+^)XQZ/A<%
M7.AB68-R71P-R 90V4HL;,04KV$4K8<PKDIVJ1P&B4U4-Q6.;>X4_WI2=G?M
M$->+H3D1>,%,RA8\'.08VUJ*$O^]9+,&HOF!97K.QKI>>) I 9F^(>0YEUP5
MP-H58#W C #,WB^*W%8>Y#X!N?]^D!7WU^,! 7D0%O*<6]$B30U8'+J=*D,"
M;1@6[196H);@P1P2,(=A8:Z$PBP07&))L<ZTP_UD."+0CMX"#1"LT#5TU>\)
MY[/@ QX3@,=A 6<5-["'*PWSH#]ZR8"JR(/0ZTRV*3KEZ,:-F"6D* *;XAKX
MYA-,*",D@94P6^86?BT;O5ZNMI\>98(DL IZ"QC[,,7*6VP]3<H%26 9O!0S
M]@$W3A+L1Y^+*O])X/K?6]=Z*2D3)(%50)2XAM7'I!R1!)9$E[*]T:/\D 06
MQ(X4N0#'A=S$I"R1!-;$WQ3I 4LI0:3!!=&![;$O>8['&=RI2\ES;;I ^IB4
M,-+ PNA/Y3WVTN]CDF>+P"8A,7^F/B;EE32P5W9B<F'8G5]R4LHK:6"O[,*\
M<148-O$Q*<VD;ZB9GA+N8U*>20-[9LP7PB'D#"-9N*6!3^R5_'8CA2C/I($]
M0V)NIA#EG32P=W;L^W%U-EOMC;I)>2=]G^-)A[D1S8RR4!;80C1FYF-2%LH"
M6VCK--5K\XSR3Q;8/^M-6A\7^4JK%4Z\?H]9PEPH*+_CG!;["RZ+J6'-1W=6
MVS]H-E/SI91C[+M1UYJ7Z]>BZU>Z9W\ 4$L#!!0    ( *Y="U/@/0E7: $
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MPY)WZNW\H[9N[GFN<?]W4NW'=^V\_;1\WEQ\*A/.&HX.C[]02P,$%     @
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M4$L! A0#%     @ KET+4SD1]M%+!0  N!8  !@              ("!2Q
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *Y="U-3#+D>
MS04  )T7   8              " @<P5  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "N70M3-M=:RY $  #,$@  &
M@('/&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ KET+
M4\GV=XG'!   -0L  !@              ("!E2   'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( *Y="U-!7_$'808  $T/   8
M      " @9(E  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "N70M3+U*.C:,&   @%   &               @($I+   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ KET+4P^K)HZ< P  Q D  !@
M             ("! C,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( *Y="U,,8/4Z^ D  /(@   9              " @=0V  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ KET+4UA4#=NG!
MU@H  !D              ("! T$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "N70M32B!4L+0$  #A#@  &0              @('A
M10  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *Y="U.<
MC',4*@(  /,$   9              " @<Q*  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ KET+4VK6NKWK!   2@P  !D
M     ("!+4T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Y="U/%O'[=QP$  +0#   9              "
M@99>  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ KET+
M4[S95JX_!   81,  !D              ("!E&   'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "N70M3N$(@!9D#  "^#0  &0
M        @($*90  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( *Y="U,&!;*ND0(  +<'   9              " @=IH  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ KET+4V1/([<M P  0@T
M !D              ("!HFL  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "N70M3\9 D5@X#  !"#   &0              @($&;P
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *Y="U/8I(28
MRP(  (@(   9              " @4MR  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ KET+4R<8\F)> P  J@L  !D
M ("!374  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "N
M70M3#I<# =0"  #("0  &0              @('B>   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *Y="U/X.MNG&P(  ),$   9
M          " @>U[  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ KET+4]9CLHRU @  Q@8  !D              ("!/WX  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "N70M3/%^.;;,#   .
M#   &0              @($K@0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( *Y="U/0*/;T2@,  .T*   9              " @16%
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ KET+4T@0
M5\\Y @  (P4  !D              ("!EH@  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " "N70M3D0PA>2@$  "=$   &0
M    @($&BP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M *Y="U-'G)%S$P,  "P1   -              "  66/  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ KET+4Y>*NQS     $P(   L              ( !
MHY(  %]R96QS+RYR96QS4$L! A0#%     @ KET+4U5'EA4Q P  5A8   \
M             ( !C),  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *Y=
M"U/@/0E7: $  $H4   :              "  >J6  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *Y="U,<F@E=C $  .<4   3
M          "  8J8  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     I "D
*%@L  $>:      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>98</ContextCount>
  <ElementCount>228</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Finance Income and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses</Role>
      <ShortName>Finance Income and Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Share-Based Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstruments</Role>
      <ShortName>Share-Based Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>20102 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureRevenue</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Finance Income and Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinanceIncomeAndExpensesTables</Role>
      <ShortName>Finance Income and Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureLeases</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureRevenueTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Revenue - AbbVie Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails</Role>
      <ShortName>Revenue - AbbVie Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Financial Instruments - Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Financial Instruments - Financial Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails</Role>
      <ShortName>Financial Instruments - Financial Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Financial Instruments - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails</Role>
      <ShortName>Financial Instruments - Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Financial Instruments - Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Financial Income and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails</Role>
      <ShortName>Financial Income and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40408 - Disclosure - Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails</Role>
      <ShortName>Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40409 - Disclosure - Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails</Role>
      <ShortName>Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Share-Based Instruments - Part 1 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details</Role>
      <ShortName>Share-Based Instruments - Part 1 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Share-Based Instruments - Part 2 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details</Role>
      <ShortName>Share-Based Instruments - Part 2 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Share-Based Instruments - Part 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details</Role>
      <ShortName>Share-Based Instruments - Part 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureRelatedParties</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gmab-20210630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureLeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" original="gmab-20210630x6k.htm">gmab-20210630x6k.htm</File>
    <File doctype="6-K" original="gmab-20210630xex991d85adb.htm">gmab-20210630xex991d85adb.htm</File>
    <File>gmab-20210630.xsd</File>
    <File>gmab-20210630_cal.xml</File>
    <File>gmab-20210630_def.xml</File>
    <File>gmab-20210630_lab.xml</File>
    <File>gmab-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gmab-20210630xex991d85adb002.jpg</File>
    <File>gmab-20210630xex991d85adb004.jpg</File>
    <File>gmab-20210630xex991d85adb005.jpg</File>
    <File>gmab-20210630xex991d85adb006.jpg</File>
    <File>gmab-20210630xex991d85adb008.jpg</File>
    <File>gmab-20210630xex991d85adb009.jpg</File>
    <File>gmab-20210630xex991d85adb010.jpg</File>
    <File>gmab-20210630xex991d85adb011.jpg</File>
    <File>gmab-20210630xex991d85adb012.jpg</File>
    <File>gmab-20210630xex991d85adb013.jpg</File>
    <File>gmab-20210630xex991d85adb014.jpg</File>
    <File>gmab-20210630xex991d85adb015.jpg</File>
    <File>gmab-20210630xex991d85adb016.jpg</File>
    <File>gmab-20210630xex991d85adb017.jpg</File>
    <File>gmab-20210630xex991d85adb018.jpg</File>
    <File>gmab-20210630xex991d85adb019.jpg</File>
    <File>gmab-20210630xex991d85adb020.jpg</File>
    <File>gmab-20210630xex991d85adb021.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gmab-20210630x6k.htm gmab-20210630xex991d85adb.htm": {
   "axisCustom": 3,
   "axisStandard": 10,
   "contextCount": 98,
   "dts": {
    "calculationLink": {
     "local": [
      "gmab-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "us-gaap-eedm-def-2020-01-31.xml",
      "srt-eedm1-def-2020-01-31.xml",
      "gmab-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gmab-20210630x6k.htm",
      "gmab-20210630xex991d85adb.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gmab-20210630_lab.xml",
      "doc_full_ifrs-en_2020-03-16.xml",
      "dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gmab-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "local": [
      "ref_ifrs_12_2020-03-16.xml",
      "ref_ifrs_16_2020-03-16.xml",
      "ref_ias_2_2020-03-16.xml",
      "dei-ref-2020-01-31.xml",
      "ref_ifrs_17_2020-03-16.xml",
      "ref_ifrs_6_2020-03-16.xml",
      "ref_ias_38_2020-03-16.xml",
      "ref_ias_34_2020-03-16.xml",
      "ref_ias_19_2020-03-16.xml",
      "ref_ifrs_5_2020-03-16.xml",
      "ref_sic_29_2020-03-16.xml",
      "ref_ias_24_2020-03-16.xml",
      "ref_ias_33_2020-03-16.xml",
      "ref_ifrs_2_2020-03-16.xml",
      "ref_ifrs_4_2020-03-16.xml",
      "ref_ias_20_2020-03-16.xml",
      "ref_ias_36_2020-03-16.xml",
      "ref_ias_12_2020-03-16.xml",
      "ref_ias_37_2020-03-16.xml",
      "ref_ias_40_2020-03-16.xml",
      "ref_ifrs_1_2020-03-16.xml",
      "ref_ifric_2_2020-03-16.xml",
      "ref_ias_8_2020-03-16.xml",
      "ref_ias_29_2020-03-16.xml",
      "ref_ias_41_2020-03-16.xml",
      "ref_ias_1_2020-03-16.xml",
      "ref_ias_16_2020-03-16.xml",
      "ref_ias_27_2020-03-16.xml",
      "ref_ifric_5_2020-03-16.xml",
      "ref_ifrs_15_2020-03-16.xml",
      "ref_ias_10_2020-03-16.xml",
      "ref_ifrs_8_2020-03-16.xml",
      "ref_ifrs_3_2020-03-16.xml",
      "ref_ias_23_2020-03-16.xml",
      "ref_ifrs_13_2020-03-16.xml",
      "ref_ias_21_2020-03-16.xml",
      "ref_ias_7_2020-03-16.xml",
      "ref_ifrs_7_2020-03-16.xml",
      "ref_ias_26_2020-03-16.xml",
      "ref_ifrs_14_2020-03-16.xml"
     ]
    },
    "schema": {
     "local": [
      "gmab-20210630.xsd",
      "xbrl-linkbase-2003-12-31.xsd",
      "xl-2003-12-31.xsd",
      "xlink-2003-12-31.xsd",
      "negated-2009-12-16.xsd",
      "dei-2020-01-31.xsd",
      "xbrl-instance-2003-12-31.xsd",
      "xbrldt-2005.xsd",
      "nonNumeric-2009-12-16.xsd",
      "numeric-2009-12-16.xsd",
      "full_ifrs-cor_2020-03-16.xsd",
      "us-gaap-2020-01-31.xsd",
      "us-roles-2020-01-31.xsd",
      "srt-2020-01-31.xsd",
      "ref-2006-02-27.xsd",
      "srt-types-2020-01-31.xsd",
      "srt-roles-2020-01-31.xsd",
      "country-2020-01-31.xsd",
      "us-types-2020-01-31.xsd",
      "currency-2020-01-31.xsd",
      "reference-2009-12-16.xsd",
      "deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 375,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 8,
    "total": 8
   },
   "keyCustom": 46,
   "keyStandard": 182,
   "memberCustom": 20,
   "memberStandard": 15,
   "nsprefix": "gmab",
   "nsuri": "http://www.genmab.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": null,
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.genmab.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Share-Based Instruments",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstruments",
     "shortName": "Share-Based Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Related Parties",
     "role": "http://www.genmab.com/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Leases",
     "role": "http://www.genmab.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Subsequent Events",
     "role": "http://www.genmab.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Revenue (Tables)",
     "role": "http://www.genmab.com/role/DisclosureRevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Finance Income and Expenses (Tables)",
     "role": "http://www.genmab.com/role/DisclosureFinanceIncomeAndExpensesTables",
     "shortName": "Finance Income and Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Leases (Tables)",
     "role": "http://www.genmab.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:IfrsNumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:IfrsNumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_0xSHWmYa2EKhiZpS5BggIg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Revenue (Details)",
     "role": "http://www.genmab.com/role/DisclosureRevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "-6",
      "lang": null,
      "name": "gmab:ReductionInRoyaltyRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Revenue - AbbVie Collaboration Agreement (Details)",
     "role": "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
     "shortName": "Revenue - AbbVie Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_7_1_2020_To_7_31_2020_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_UJmiHgLlu06muPRZ5PWz-A",
      "decimals": "-6",
      "lang": null,
      "name": "gmab:UpfrontMilestonePaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Financial Instruments - Financial Assets and Liabilities (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_lu3v55zbDES12yHJmhVJ7g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "gmab:PercentageOfMarketableSecuritiesInvested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Financial Instruments - Financial Risk (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
     "shortName": "Financial Instruments - Financial Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2020_To_6_30_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_lu3v55zbDES12yHJmhVJ7g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "gmab:PercentageOfMarketableSecuritiesInvested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_2h_43Y6ufkqH88hsbM9lnA",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Financial Instruments - Fair Value Measurement (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
     "shortName": "Financial Instruments - Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_iIgp3bLrT0WdC_XUJJoNxQ",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Financial Instruments - Other Investments (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
     "shortName": "Financial Instruments - Other Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_OY8O9iGctkKqyFaG0cKc5w",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gmab:InterestAndOtherFinancialIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Financial Income and Expenses (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails",
     "shortName": "Financial Income and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gmab:InterestAndOtherFinancialIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40408 - Disclosure - Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)",
     "role": "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
     "shortName": "Capital Structure, Financial Risk and Related Items - Fair Value of Other Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_12_31_2020_geU0cp50AkaTzgTmfdbvoQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Assets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40409 - Disclosure - Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)",
     "role": "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
     "shortName": "Capital Structure, Financial Risk and Related Items - Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Share-Based Instruments - Part 1 (Details)",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details",
     "shortName": "Share-Based Instruments - Part 1 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_nQh5z87pHkSqE1RrAuryiw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EquityInstruments_PHtLf5OtaUWbEqn6zU_LxA",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Balance Sheets",
     "role": "http://www.genmab.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gmab:NumberOfWarrantsGrantedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Share-Based Instruments - Part 2 (Details)",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details",
     "shortName": "Share-Based Instruments - Part 2 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gmab:NumberOfWarrantsGrantedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_gBEfsOR66kGnhKj5abwmUQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gmab:IfrsStockRepurchaseProgramAuthorizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Share-Based Instruments - Part 3 (Details)",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details",
     "shortName": "Share-Based Instruments - Part 3 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_4_30_2021_gmab_IfrsShareRepurchaseProgramAxis_gmab_RestrictedStockUnitsProgramMember_PDAUOhgwQ0yvM3nvN935yQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "gmab:IfrsStockRepurchaseProgramAuthorizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:NumberOfIndependentBoardMembers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Related Parties (Details)",
     "role": "http://www.genmab.com/role/DisclosureRelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_4_13_2021_To_4_13_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_jmeuxIJJ2EuJyYHukSDhcg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:NumberOfIndependentBoardMembers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_O6Zc31pSUkWFYJxuD7qMHQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Leases (Details)",
     "role": "http://www.genmab.com/role/DisclosureLeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_6_30_2021_POjOV2xKpkGFh6WblnXCnA",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": "-6",
      "lang": null,
      "name": "gmab:ReversalOfFinancialItemsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_p1Fn9MmXZ0mJDu3DNDH-CA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Changes in Equity",
     "role": "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_p1Fn9MmXZ0mJDu3DNDH-CA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_-_iwip_IpUGAdc7yUYbMQQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Basis of Presentation",
     "role": "http://www.genmab.com/role/DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Revenue",
     "role": "http://www.genmab.com/role/DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Financial Instruments",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Finance Income and Expenses",
     "role": "http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses",
     "shortName": "Finance Income and Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20210630xex991d85adb.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_JFidCS0VKES7E_0ogSPmiA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 35,
   "tag": {
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_DKK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "D K [K]",
        "terseLabel": "DKK"
       }
      }
     },
     "localname": "DKK",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "E U [R]",
        "terseLabel": "EUR"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "G B [P]",
        "terseLabel": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S [D]",
        "terseLabel": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r193",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_AdjustmentsForInterestOnLeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Interest On Lease Payments",
        "terseLabel": "Interest elements of lease payments"
       }
      }
     },
     "localname": "AdjustmentsForInterestOnLeasePayments",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_AgreementsWithAbbvieMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Abbvie.",
        "label": "Agreements With Abbvie [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AgreementsWithAbbvieMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithBointechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangements with BioNTech.",
        "label": "Agreements With Bointech [Member]",
        "terseLabel": "BioNTech"
       }
      }
     },
     "localname": "AgreementsWithBointechMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithJanssenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaborative arrangement with Janssen (Darzalex/Daratumumab &amp; DuoBody).",
        "label": "Agreements With Janssen [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "AgreementsWithJanssenMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithNovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaborative arrangement with Novartis (Arzaerra/Ofatumumab).",
        "label": "Agreements With Novartis [Member]",
        "terseLabel": "Novartis (Arzaerra/Ofatumumab)"
       }
      }
     },
     "localname": "AgreementsWithNovartisMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithRocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Roche.",
        "label": "Agreements With Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "AgreementsWithRocheMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithSeagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Seagen.",
        "label": "Agreements With Seagen [Member]",
        "terseLabel": "Seagen"
       }
      }
     },
     "localname": "AgreementsWithSeagenMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithSeatleGeneticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Seatle Genetics",
        "label": "Agreements With Seatle Genetics [Member]",
        "terseLabel": "Seattle Genetics"
       }
      }
     },
     "localname": "AgreementsWithSeatleGeneticsMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AmericanDepositorySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for American Depository Shares.",
        "label": "American Depository Shares [Member]",
        "terseLabel": "ADS"
       }
      }
     },
     "localname": "AmericanDepositorySharesMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_BankDepositsIncludingShortTermMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of bank deposits including short-term marketable securities.",
        "label": "Bank Deposits Including Short Term Marketable Securities",
        "terseLabel": "Total value of bank deposits"
       }
      }
     },
     "localname": "BankDepositsIncludingShortTermMarketableSecurities",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "stringItemType"
    },
    "gmab_BoltBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Bolt Biotherapeutics, Inc.",
        "label": "Bolt Biotherapeutics Inc [Member]",
        "terseLabel": "Bolt"
       }
      }
     },
     "localname": "BoltBiotherapeuticsIncMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items.",
        "label": "Cash Flow From (Used In) Operating Activities Before Financial Items",
        "totalLabel": "Cash flow from operating activities before financial items"
       }
      }
     },
     "localname": "CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_ContractTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The identified transaction price under the contract.",
        "label": "Contract Transaction Price",
        "terseLabel": "Contract transaction price"
       }
      }
     },
     "localname": "ContractTransactionPrice",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_CorporateTaxReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Tax Receivable",
        "label": "Corporate Tax Receivable",
        "terseLabel": "Corporate tax receivable"
       }
      }
     },
     "localname": "CorporateTaxReceivable",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_CurevacCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to CureVac Collaboration.",
        "label": "Curevac Collaboration [Member]",
        "terseLabel": "CureVac"
       }
      }
     },
     "localname": "CurevacCollaborationMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for Basis of presentation.",
        "label": "Description Of Accounting Policy For Basis Of Presentation Policy [Text Block]",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for Basis of presentation.",
        "label": "Description Of Accounting Policy For Judgments And Estimates [Policy Text Block]",
        "terseLabel": "Management Judgments and Estimates under IFRS"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for recently adopted new accounting standards.",
        "label": "New Accounting Standards - Recently Adopted",
        "terseLabel": "New Accounting Policies and Disclosures"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of balance sheet information relating to leases.",
        "label": "Summary of balance sheet amounts relating to leases"
       }
      }
     },
     "localname": "DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition.",
        "label": "Capital Structure, Financial Risk and Related Items"
       }
      }
     },
     "localname": "DisclosureOfCapitalStructureFinancialRiskAndOtherItemsAbstract",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "stringItemType"
    },
    "gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of comprehensive information relating to leases.",
        "label": "Summary of statement of comprehensive income amounts relating to leases"
       }
      }
     },
     "localname": "DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for corporate and deferred Tax.",
        "label": "Disclosure Of Corporate And Deferred Tax [Table Text Block]",
        "terseLabel": "Schedule of corporate and deferred Tax"
       }
      }
     },
     "localname": "DisclosureOfCorporateAndDeferredTaxTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfFinanceIncomeExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Finance Income and Expenses"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpensesAbstract",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "stringItemType"
    },
    "gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Schedule of finance income and expenses"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpensesTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinanceIncomeAndExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfNetResultTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net result for the year.",
        "label": "Disclosure Of Net Result [Table Text Block]",
        "terseLabel": "Schedule of net result"
       }
      }
     },
     "localname": "DisclosureOfNetResultTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for new accounting policy and disclosures.",
        "label": "Disclosure Of New Accounting policies And Disclosures [Policy Text Block]",
        "terseLabel": "New Accounting Policies and Disclosures"
       }
      }
     },
     "localname": "DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfStaffCostTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of staff cost.",
        "label": "Disclosure Of Staff Cost [Table Text Block]",
        "terseLabel": "Schedule of staff cost"
       }
      }
     },
     "localname": "DisclosureOfStaffCostTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfWarrantsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants activity.",
        "label": "Disclosure Of Warrants Activity [Table Text Block]",
        "terseLabel": "Summary of warrants activity"
       }
      }
     },
     "localname": "DisclosureOfWarrantsActivityTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "stringItemType"
    },
    "gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholder's equity, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Equity Adjusted For Cumulative Effect Of New Accounting Principle In Period Of Adoption",
        "terseLabel": "Adjusted total equity at January 1, 2018"
       }
      }
     },
     "localname": "EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_EstimatedCapitalExpenditureForLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated capital expenditure for lease.",
        "label": "Estimated Capital Expenditure for Lease",
        "terseLabel": "Estimated capital expenditure for lease"
       }
      }
     },
     "localname": "EstimatedCapitalExpenditureForLease",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_ExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of warrants exercised.",
        "label": "Exercise of Warrants",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_ExpensesRelatedToCapitalIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses Related To Capital Increase Decrease",
        "label": "Expenses Related To Capital Increase Decrease",
        "terseLabel": "Expenses related to capital increases"
       }
      }
     },
     "localname": "ExpensesRelatedToCapitalIncreaseDecrease",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_FairValueAdjustmentOfMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value adjustment of marketable securities.",
        "label": "Fair Value Adjustment of Marketable Securities",
        "periodEndLabel": "Fair value adjustment at the end of the period",
        "periodStartLabel": "Fair value adjustment at the beginning of the period"
       }
      }
     },
     "localname": "FairValueAdjustmentOfMarketableSecurities",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_FairValueAdjustmentOfMarketableSecuritiesDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value adjustment of marketable securities during the period.",
        "label": "Fair Value Adjustment of Marketable Securities During the Period",
        "terseLabel": "Fair value adjustment for the period"
       }
      }
     },
     "localname": "FairValueAdjustmentOfMarketableSecuritiesDuringPeriod",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_FinanceExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Financial expenses:"
       }
      }
     },
     "localname": "FinanceExpensesAbstract",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_FinanceIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Financial Income:"
       }
      }
     },
     "localname": "FinanceIncomeAbstract",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_ForeignExchangeAdjustmentOfMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of foreign exchange adjustment of marketable securities during the period.",
        "label": "Foreign Exchange Adjustment of Marketable Securities",
        "terseLabel": "Foreign exchange adjustments"
       }
      }
     },
     "localname": "ForeignExchangeAdjustmentOfMarketableSecurities",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_FutureMinimumOperatingLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of future minimum operating lease payments.",
        "label": "Future Minimum Operating Lease Payments",
        "terseLabel": "Total future minimum payments"
       }
      }
     },
     "localname": "FutureMinimumOperatingLeasePayments",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_GainOnOtherInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gains on other investments.",
        "label": "Gain On Other Investments",
        "terseLabel": "Realized and unrealized gains on other investments, net"
       }
      }
     },
     "localname": "GainOnOtherInvestments",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_GainsOnHedgingInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gains on hedging instruments in fair value hedges.",
        "label": "Realized and unrealized gains on fair value hedges, net",
        "terseLabel": "Realized and unrealized gains on fair value hedges, net"
       }
      }
     },
     "localname": "GainsOnHedgingInstruments",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Ifrs Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "IfrsCashAndCashEquivalentsMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Axis]"
       }
      }
     },
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative [Domain]",
        "terseLabel": "Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Domain]"
       }
      }
     },
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Ifrs Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Ifrs Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Change in accounting policy: Adoption of IFRS 15"
       }
      }
     },
     "localname": "IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equipment.",
        "label": "Ifrs Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "IfrsEquipmentMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsMarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.",
        "label": "Ifrs Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "IfrsMarketableSecuritiesCurrent",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsNumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of business unit"
       }
      }
     },
     "localname": "IfrsNumberOfReportingUnits",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_IfrsRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Ifrs Restricted Stock Units R S Us [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "IfrsRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "ifrs Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "IfrsShareRepurchaseProgramAxis",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_IfrsShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Ifrs Share Repurchase Program [Domain]",
        "terseLabel": "ifrs Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "IfrsShareRepurchaseProgramDomain",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsStockRepurchaseProgramAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Ifrs Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Amount of stock repurchase plan authorized"
       }
      }
     },
     "localname": "IfrsStockRepurchaseProgramAuthorizedAmount",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Ifrs Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Number of shares authorized to be repurchased"
       }
      }
     },
     "localname": "IfrsStockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_IfrsStockRepurchasedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "ifrs Stock Repurchased During Period, Shares",
        "terseLabel": "Repurchased shares"
       }
      }
     },
     "localname": "IfrsStockRepurchasedDuringPeriodShares",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_IfrsStockRepurchasedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Ifrs Stock Repurchased During Period, Value",
        "terseLabel": "Repurchased values"
       }
      }
     },
     "localname": "IfrsStockRepurchasedDuringPeriodValue",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsTreasuryStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares that has been treasury stock.",
        "label": "ifrs Treasury Stock Shares",
        "terseLabel": "Treasury stock shares"
       }
      }
     },
     "localname": "IfrsTreasuryStockShares",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from net settlement of restricted stock units.",
        "label": "Increase Decrease Through Net Settlement Of Restricted Stock Units, Equity",
        "terseLabel": "Net settlement of RSUs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from tax on items recognized directly in equity.",
        "label": "Increase Decrease Through Tax On Items Recognized Directly In Equity",
        "terseLabel": "Tax on items recognized directly in equity"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_InterestAndOtherFinancialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest and other financial expenses.",
        "label": "Interest and Other Financial Expenses",
        "negatedLabel": "Interest and other financial expenses"
       }
      }
     },
     "localname": "InterestAndOtherFinancialExpenses",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_InterestAndOtherFinancialIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest and other financial income.",
        "label": "Interest and Other Financial Income",
        "terseLabel": "Interest and other financial income"
       }
      }
     },
     "localname": "InterestAndOtherFinancialIncome",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_LicenseFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for revenue from license fees.",
        "label": "License Fees [Member]",
        "terseLabel": "License fees"
       }
      }
     },
     "localname": "LicenseFeesMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_LossesOnMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The losses on marketable securities.",
        "label": "Losses on Marketable Securities",
        "negatedLabel": "Loss on marketable securities, net"
       }
      }
     },
     "localname": "LossesOnMarketableSecurities",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_LossesOnOtherInvestmentsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Losses On Other Investments Net",
        "label": "Losses On Other Investments Net",
        "negatedLabel": "Loss on other investments, net"
       }
      }
     },
     "localname": "LossesOnOtherInvestmentsNet",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_MarketableSecuritiesIncludingInterestReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of marketable securities including interest receivable.",
        "label": "Marketable Securities Including Interest Receivables",
        "terseLabel": "Marketable securities including interest receivables"
       }
      }
     },
     "localname": "MarketableSecuritiesIncludingInterestReceivables",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for marketable securities .",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_MarketableSecuritiesNetBookValueInPercentageOfCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The marketable securities net book value in percentage of cost.",
        "label": "Marketable Securities Net Book Value in Percentage of Cost",
        "terseLabel": "Net book value in percentage of cost"
       }
      }
     },
     "localname": "MarketableSecuritiesNetBookValueInPercentageOfCost",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_MilestonePaymentsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for revenue from milestone payments.",
        "label": "Milestone Payments Revenue [Member]",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentsRevenueMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_NumberOfDeliveryLicenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of delivery license programs.",
        "label": "Number of Delivery Licenses",
        "terseLabel": "Number of delivery license programs"
       }
      }
     },
     "localname": "NumberOfDeliveryLicenses",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfEmployeeElectedBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employee elected board members.",
        "label": "Number of Employee Elected Board Members",
        "terseLabel": "Number of employee elected board members"
       }
      }
     },
     "localname": "NumberOfEmployeeElectedBoardMembers",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfIndependentBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of independent board members.",
        "label": "Number of Independent Board Members",
        "terseLabel": "Number of independent board members"
       }
      }
     },
     "localname": "NumberOfIndependentBoardMembers",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfNonIndependentBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non independent board members.",
        "label": "Number of Non Independent Board Members",
        "terseLabel": "Number of non independent board members"
       }
      }
     },
     "localname": "NumberOfNonIndependentBoardMembers",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of performance obligations.",
        "label": "Number of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfTreasurySharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares that has been held in treasury.",
        "label": "Number of Treasury Shares Outstanding",
        "terseLabel": "Treasury shares outstanding"
       }
      }
     },
     "localname": "NumberOfTreasurySharesOutstanding",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants exercised during period.",
        "label": "Number Of Warrants Exercised During Period",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercisedDuringPeriod",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants expired or lapsed or cancelled during period.",
        "label": "Number Of Warrants Expired Or Lapsed Or Cancelled During Period",
        "negatedLabel": "Expired/lapsed/cancelled"
       }
      }
     },
     "localname": "NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsGrantedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants granted during period.",
        "label": "Number Of Warrants Granted During Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "NumberOfWarrantsGrantedDuringPeriod",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants held as of the balance sheet date.",
        "label": "Number Of Warrants Outstanding",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstanding",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_OtherCollaborationPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaborative arrangement with other collaboration partners.",
        "label": "Other Collaboration Partners [Member]",
        "terseLabel": "Other collaboration partners"
       }
      }
     },
     "localname": "OtherCollaborationPartnersMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_OtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for other payables.",
        "label": "Other Payables [Member]",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherPayablesMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs).",
        "label": "Payment Of Withholding Taxes On Behalf Of Employees On Net Settled R S Us",
        "negatedLabel": "Payment of withholding taxes on behalf of employees on net settled RSUs"
       }
      }
     },
     "localname": "PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_PaymentsToAcquireTreasuryShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire treasury shares.",
        "label": "Payments To Acquire Treasury Shares",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "PaymentsToAcquireTreasuryShares",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_PercentageOfInvestmentInCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of investment in common shares.",
        "label": "Percentage of Investment in Common Shares",
        "terseLabel": "Percentage of investment in common shares"
       }
      }
     },
     "localname": "PercentageOfInvestmentInCommonShares",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of marketable securities.",
        "label": "Percentage of Marketable Securities",
        "terseLabel": "Percentage of marketable securities"
       }
      }
     },
     "localname": "PercentageOfMarketableSecurities",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfMarketableSecuritiesInvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of marketable securities invested.",
        "label": "Percentage of Marketable Securities Invested",
        "terseLabel": "Marketable securities were invested (as a percent)"
       }
      }
     },
     "localname": "PercentageOfMarketableSecuritiesInvested",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of possible increase or decrease in exchange rate.",
        "label": "Percentage Of Possible Increase (Decrease) In Exchange rate",
        "terseLabel": "Percentage of possible increase or decrease in exchange rate"
       }
      }
     },
     "localname": "PercentageOfPossibleIncreaseDecreaseInExchangeRate",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue.",
        "label": "Percentage of Revenue",
        "terseLabel": "Revenue (as a percent)"
       }
      }
     },
     "localname": "PercentageOfRevenue",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share capital.",
        "label": "Percentage of Share Capital",
        "terseLabel": "Percentage of share capital"
       }
      }
     },
     "localname": "PercentageOfShareCapital",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share capital attributed by exercise of warrants which increase the share capital.",
        "label": "Percentage Of Share Capital Attributed To Exercise Of Warrants",
        "terseLabel": "Percentage of share capital attributed to exercise of warrants"
       }
      }
     },
     "localname": "PercentageOfShareCapitalAttributedToExerciseOfWarrants",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PerformanceObligationRevenueRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which performance obligation revenue will recognize.",
        "label": "Performance Obligation Revenue Recognition Period",
        "terseLabel": "Performance obligation Revenue recognition period"
       }
      }
     },
     "localname": "PerformanceObligationRevenueRecognitionPeriod",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gmab_ProceedsFromExerciseOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the exercise of warrants.",
        "label": "Proceeds From Exercise Of Warrants",
        "terseLabel": "Warrants exercised",
        "verboseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfWarrants",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_PropertiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to properties.",
        "label": "Properties [Member]",
        "terseLabel": "Properties"
       }
      }
     },
     "localname": "PropertiesMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ReceivablesExPrepaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Receivables Excluding Prepayments.",
        "label": "Receivables Ex Prepayments [Member]",
        "terseLabel": "Receivables ex. prepayments"
       }
      }
     },
     "localname": "ReceivablesExPrepaymentsMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ReductionInRoyaltyRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in royalty revenue.",
        "label": "Reduction In Royalty Revenue"
       }
      }
     },
     "localname": "ReductionInRoyaltyRevenue",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_ReimbursementIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for reimbursement income.",
        "label": "Reimbursement Income [Member]",
        "terseLabel": "Reimbursement income"
       }
      }
     },
     "localname": "ReimbursementIncomeMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_RestrictedStockUnitsProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to RSU program.",
        "label": "Restricted Stock Units Program [Member]",
        "terseLabel": "Restricted Stock Units Program"
       }
      }
     },
     "localname": "RestrictedStockUnitsProgramMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ResultsForYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Revenue"
       }
      }
     },
     "localname": "ResultsForYearAbstract",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "stringItemType"
    },
    "gmab_ReversalOfFinancialItemsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reversal of financial items to the cash flow under operating activities.",
        "label": "Reversal Of Financial Items, Net",
        "negatedLabel": "Reversal of financial items, net"
       }
      }
     },
     "localname": "ReversalOfFinancialItemsNet",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_RoyaltiesRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for revenue form royalties.",
        "label": "Royalties Revenue [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltiesRevenueMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for segment disclosures in the financial statements as the group's business activities.",
        "label": "Schedule Of Segment Disclosures In Financial Statements [Table Text Block]",
        "terseLabel": "Schedule of segment disclosures in the financial statements as the group's business activities."
       }
      }
     },
     "localname": "ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of staff cost included in research and development expenses.",
        "label": "Staff Costs Included In General and administrative expenses"
       }
      }
     },
     "localname": "StaffCostsIncludedInGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "monetaryItemType"
    },
    "gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": 3.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of staff cost included in government grants related to research and development expenses.",
        "label": "Staff Costs Included In Government Grants Related To Research And Development Expenses"
       }
      }
     },
     "localname": "StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "monetaryItemType"
    },
    "gmab_StaffCostsIncludedInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of staff cost included in research and development expenses.",
        "label": "Staff Costs Included In Research And Development Expense"
       }
      }
     },
     "localname": "StaffCostsIncludedInResearchAndDevelopmentExpense",
     "nsuri": "http://www.genmab.com/20210630",
     "xbrltype": "monetaryItemType"
    },
    "gmab_TotalAdjustmentsForNonCashTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for total non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Total Adjustments For Non Cash Transactions",
        "terseLabel": "Adjustments for non-cash transactions"
       }
      }
     },
     "localname": "TotalAdjustmentsForNonCashTransactions",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_TransactionsWithOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Transactions With Owners",
        "terseLabel": "Transactions with owners:"
       }
      }
     },
     "localname": "TransactionsWithOwners",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_TripleaRatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Triple A-rating.",
        "label": "Triplea Rating [Member]",
        "terseLabel": "Triple A-rating from Moody's, S&amp;P or Fitch"
       }
      }
     },
     "localname": "TripleaRatingMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_TypesOfRevenuesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Types of revenues [axis]"
       }
      }
     },
     "localname": "TypesOfRevenuesAxis",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_TypesOfRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for This member stands for all types of revenues from customers. It also represents the standard value for the 'Types of revenues' axis if no other member is used.",
        "label": "Types Of Revenues [Member]",
        "terseLabel": "Types of revenues [member]"
       }
      }
     },
     "localname": "TypesOfRevenuesMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_UpfrontMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash in flow from upfront milestone payments.",
        "label": "Upfront Milestone Payment Received",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontMilestonePaymentReceived",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of each warrant granted.",
        "label": "Valuation Assumptions for Warrants Granted [Table Text Block]",
        "terseLabel": "Fair value of each warrant granted"
       }
      }
     },
     "localname": "ValuationAssumptionsForWarrantsGrantedTableTextBlock",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_WarrantVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which the right to exercise an warrant is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Warrant Vesting Period",
        "terseLabel": "Warrant vesting period"
       }
      }
     },
     "localname": "WarrantVestingPeriod",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "durationItemType"
    },
    "gmab_WarrantsGrantedFromApril2012UntilMarch2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants granted from April 2012 until March 2017.",
        "label": "Warrants Granted From April2012 Until March2017 [Member]",
        "terseLabel": "Warrants Granted from April 2012 until March 2017"
       }
      }
     },
     "localname": "WarrantsGrantedFromApril2012UntilMarch2017Member",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WarrantsGrantedFromAugust2004UntilApril2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants granted from August 2004 until April 2012.",
        "label": "Warrants Granted From August2004 Until April2012 [Member]",
        "terseLabel": "Warrants Granted from August 2004 until April 2012"
       }
      }
     },
     "localname": "WarrantsGrantedFromAugust2004UntilApril2012Member",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WarrantsGrantedFromMarch2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants granted from march 2017.",
        "label": "Warrants Granted From March2017 [Member]",
        "terseLabel": "Warrants Granted from March 2017"
       }
      }
     },
     "localname": "WarrantsGrantedFromMarch2017Member",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Member]",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WeightedAverageExercisePriceOfFairValueOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of fair value of warrants during the period.",
        "label": "Weighted Average Exercise Price Of Fair Value Of Warrants",
        "terseLabel": "Weighted average exercise price of fair market value"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfFairValueOfWarrants",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "gmab_WeightedAverageExercisePriceOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants exercised during the period.",
        "label": "Weighted Average Exercise Price Of Warrants Exercised",
        "terseLabel": "Weighted average exercise price of warrants exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsExercised",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "gmab_WeightedAverageExercisePriceOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants granted during the period.",
        "label": "Weighted Average Exercise Price Of Warrants Granted",
        "terseLabel": "Weighted average exercise price of warrants granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsGranted",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement.",
        "label": "WeightedAverageFairValueOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement",
        "terseLabel": "Weighted average fair value of RSU granted"
       }
      }
     },
     "localname": "Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement",
     "nsuri": "http://www.genmab.com/20210630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions to right of use assets"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "terseLabel": "Corporate taxes paid"
       }
      }
     },
     "localname": "AdjustmentsForIncomeTaxExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated Measurement [Member]",
        "terseLabel": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r49",
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All Levels Of Fair Value Hierarchy [Member]",
        "terseLabel": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r23",
      "r104",
      "r105",
      "r108",
      "r166",
      "r170"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "periodEndLabel": "Cost at the end of the period",
        "periodStartLabel": "Cost at the beginning of the period",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AtCostMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on cost. Cost is the amount of cash or cash equivalents paid or the fair value of the other consideration given to acquire an asset at the time of its acquisition or construction, or, when applicable, the amount attributed to that asset when initially recognised in accordance with the specific requirements of other IFRSs."
       }
      },
      "en-us": {
       "role": {
        "label": "At Cost [Member]",
        "terseLabel": "At Cost"
       }
      }
     },
     "localname": "AtCostMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AtFairValueMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "At Fair Value [Member]",
        "terseLabel": "Net Book value"
       }
      }
     },
     "localname": "AtFairValueMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic net result per share"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r132",
      "r156",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom Of Range [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Bank deposits"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r20",
      "r82",
      "r101"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]",
        "terseLabel": "Cash and cash equivalents include:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowHedgesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow hedges [abstract]",
        "terseLabel": "Fair value adjustments of cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowHedgesMember": {
     "auth_ref": [
      "r64",
      "r138",
      "r139",
      "r141"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Hedges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash Flow Hedges [Member]",
        "terseLabel": "Cash flow hedges"
       }
      }
     },
     "localname": "CashFlowHedgesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r68",
      "r83"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash flow from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r68",
      "r83"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash flow from investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r83"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Cash flow from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities",
        "terseLabel": "Transactions with subsidiaries"
       }
      }
     },
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInEquity": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in equity",
        "negatedLabel": "Expenses related to capital increases"
       }
      }
     },
     "localname": "ChangesInEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r109",
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables",
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r60",
      "r109",
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes Of Assets [Member]",
        "terseLabel": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables",
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r175",
      "r183",
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes Of Share Capital [Member]",
        "terseLabel": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Amounts which will be re-classified to the income statement:"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r34",
      "r90",
      "r92",
      "r93",
      "r98"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CreditRiskMember": {
     "auth_ref": [
      "r145",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit Risk [Member]",
        "terseLabel": "Credit risk"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r162",
      "r178",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency Risk [Member]",
        "terseLabel": "Currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r24",
      "r93",
      "r94"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails",
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r25",
      "r93",
      "r96"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "terseLabel": "Corporate tax payable"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "terseLabel": "Depreciation charge of right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for investments in associates. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for investment in associates [text block]",
        "terseLabel": "Other Investments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "terseLabel": "Information about Geographical Areas"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "terseLabel": "Schedule of impact of the adoption of IFRS 16 on the financial statements"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted net result per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCreditRiskExposureLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of credit risk exposure [line items]"
       }
      }
     },
     "localname": "DisclosureOfCreditRiskExposureLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCreditRiskExposureTable": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the credit risk exposure."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of credit risk exposure [table]"
       }
      }
     },
     "localname": "DisclosureOfCreditRiskExposureTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of deferred taxes [text block]",
        "verboseLabel": "Schedule of components of the deferred tax asset"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r144",
      "r151",
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of revenue by type and collaboration partner under agreements"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Schedule of Result Per Share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [text block]",
        "verboseLabel": "Schedule of marketable securities"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [line items]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Financial Income and Expenses"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r144",
      "r151",
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Summary of RSUs activity"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets and financial liabilities [text block]",
        "terseLabel": "Schedule of Financial Assets"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Schedule of share-based payment"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Nature of Business and Accounting Policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Instruments"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r76",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Exchange rate adjustments"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r41"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForExternalCreditGradesMember": {
     "auth_ref": [
      "r152",
      "r161",
      "r186",
      "r189",
      "r192"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entitys Total For External Credit Grades [Member]",
        "terseLabel": "Entity's total for external credit grades [member]"
       }
      }
     },
     "localname": "EntitysTotalForExternalCreditGradesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entitys Total For Related Parties [Member]",
        "terseLabel": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r23",
      "r28",
      "r89",
      "r91",
      "r104",
      "r105",
      "r108"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total shareholders' equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND LIABILITIES"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [Member]",
        "terseLabel": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Share-based compensation expenses"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "terseLabel": "Expense relating to short-term leases"
       }
      }
     },
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExternalCreditGradesAxis": {
     "auth_ref": [
      "r152",
      "r161",
      "r186",
      "r189",
      "r192"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "External credit grades [axis]"
       }
      }
     },
     "localname": "ExternalCreditGradesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Financial expenses",
        "negatedTotalLabel": "Total financial expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Financial income",
        "totalLabel": "Total financial income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeCost": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "totalLabel": "Net financial items"
       }
      }
     },
     "localname": "FinanceIncomeCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r143",
      "r148",
      "r149",
      "r152",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "periodEndLabel": "Fair value at December 31, 2020",
        "periodStartLabel": "Fair value at January 1, 2020",
        "verboseLabel": "Financial Assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial Assets At Amortised Cost Category [Member]",
        "terseLabel": "Financial assets measured at amortized cost"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial Assets At Fair Value Through Profit Or Loss Category [Member]",
        "terseLabel": "Financial assets measured at fair value through profit or loss"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial Assets Category [Member]",
        "terseLabel": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r154",
      "r155",
      "r175",
      "r183",
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial Assets [Member]",
        "terseLabel": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "negatedLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r159",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial Liabilities At Amortised Cost Category [Member]",
        "terseLabel": "Financial liabilities measured at amortized cost"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial Liabilities Category [Member]",
        "terseLabel": "Financial liabilities, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r154",
      "r155",
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial Liabilities [Member]",
        "terseLabel": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Income Statement"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r37",
      "r44",
      "r45",
      "r46",
      "r55",
      "r102",
      "r165"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income), continuing operations",
        "negatedLabel": "Corporate tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of application of IFRS 15."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase Decrease Due To Application Of I F R S15 [Member]",
        "terseLabel": "Change in accounting policy: Adoption of IFRS 15"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Change in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTerseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInWorkingCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of warrants, equity",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r17",
      "r62"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r18",
      "r103",
      "r167"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "verboseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "verboseLabel": "Shares issued for cash"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued Capital [Member]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Key Management Personnel Of Entity Or Parent [Member]",
        "terseLabel": "Key Changes to Executive Management"
       }
      }
     },
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [abstract]",
        "terseLabel": "Lease Liabilities"
       }
      }
     },
     "localname": "LeaseLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "auth_ref": [
      "r81",
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease Liabilities [Member]",
        "terseLabel": "Lease Liabilities [Member]"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "auth_ref": [
      "r49",
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Level1 Of Fair Value Hierarchy [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "Level1OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level2 Of Fair Value Hierarchy [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Level3 Of Fair Value Hierarchy [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "Level3OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r49",
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r23",
      "r104",
      "r105",
      "r108",
      "r166",
      "r171"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MaximumExposureToCreditRisk": {
     "auth_ref": [
      "r150",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum exposure to credit risk",
        "terseLabel": "Maximum credit exposure"
       }
      }
     },
     "localname": "MaximumExposureToCreditRisk",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The maximum exposure to the credit risk of loans or receivables. [Refer: Loans and receivables; Credit risk [member]; Maximum exposure to credit risk]"
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum exposure to credit risk of loans or receivables",
        "terseLabel": "Maximum credit exposure to receivables"
       }
      }
     },
     "localname": "MaximumExposureToCreditRiskOfLoansOrReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r65",
      "r66",
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "NetDeferredTaxAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeGain": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Foreign exchange rate gain, net"
       }
      }
     },
     "localname": "NetForeignExchangeGain",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net loss arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange loss",
        "negatedLabel": "Realized and unrealized exchange rate losses, net"
       }
      }
     },
     "localname": "NetForeignExchangeLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r24",
      "r93",
      "r95"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Non-current"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails",
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r25",
      "r93",
      "r97"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentProvisions": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current provisions",
        "verboseLabel": "Provisions"
       }
      }
     },
     "localname": "NoncurrentProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentReceivables": {
     "auth_ref": [
      "r19",
      "r27"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeReceivables",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other non-current receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "NoncurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedLabel": "Forfeited/Cancelled"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Number of shares, at end of period",
        "periodStartLabel": "Number of shares, at beginning of period"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "negatedTotalLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r31",
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary Shares [Member]",
        "terseLabel": "Ordinary shares [member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r7",
      "r33",
      "r39",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability": {
     "auth_ref": [
      "r26",
      "r39"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to changes in the fair value of financial liabilities attributable to the changes in the credit risk of those liabilities. [Refer: Other comprehensive income; Credit risk [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, change in fair value of financial liability attributable to change in credit risk of liability",
        "terseLabel": "Fair value adjustments during the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r26",
      "r39"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Adjustment of foreign currency fluctuations on subsidiaries"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherPayables",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "verboseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentPayables": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherPayables",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current payables",
        "verboseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherNoncurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherPayables": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesOtherPayablesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other payables"
       }
      }
     },
     "localname": "OtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Other reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "negatedLabel": "Costs related to issuance of shares"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Principal elements of lease payments"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PerformanceObligationsAxis": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Performance obligations [axis]"
       }
      }
     },
     "localname": "PerformanceObligationsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PerformanceObligationsMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Performance Obligations [Member]",
        "terseLabel": "Performance obligations [member]"
       }
      }
     },
     "localname": "PerformanceObligationsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for performance obligations satisfied at a point in time. An entity satisfies a performance obligation at a point in time, if the performance obligation is not satisfied over time. [Refer: Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Performance Obligations Satisfied At Point In Time [Member]",
        "terseLabel": "Performance obligations satisfied at point in time"
       }
      }
     },
     "localname": "PerformanceObligationsSatisfiedAtPointInTimeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PerformanceObligationsSatisfiedOverTimeMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for performance obligations satisfied over time. An entity satisfies a performance obligation over time, if one of the following criteria is met: (a) the customer simultaneously receives and consumes the benefits provided by the entity\u2019s performance as the entity performs; (b) the entity\u2019s performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced; or (c) the entity\u2019s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. [Refer: Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Performance Obligations Satisfied Over Time [Member]",
        "terseLabel": "Performance obligations satisfied over time"
       }
      }
     },
     "localname": "PerformanceObligationsSatisfiedOverTimeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "verboseLabel": "Proceeds from sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Shares issued for cash"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investments accounted for using equity method",
        "terseLabel": "Other investments sold"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investments other than investments accounted for using equity method",
        "terseLabel": "Marketable securities sold"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r32",
      "r74",
      "r90",
      "r92",
      "r93",
      "r166",
      "r169",
      "r176",
      "r185"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net result",
        "totalLabel": "Net result"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r136",
      "r166",
      "r169"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Net result before tax",
        "totalLabel": "Net result before tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r38",
      "r57"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating result"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r16",
      "r48"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Provisions": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities of uncertain timing or amount."
       }
      },
      "en-us": {
       "role": {
        "label": "Provisions"
       }
      }
     },
     "localname": "Provisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedLabel": "Investment in intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of interests in investments accounted for using equity method",
        "negatedLabel": "Other investments bought"
       }
      }
     },
     "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of investments other than investments accounted for using equity method",
        "negatedLabel": "Marketable securities bought"
       }
      }
     },
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Investment in tangible assets"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "PurchaseOfTreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart3Details",
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchasesFairValueMeasurementAssets": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in the fair value measurement of assets resulting from purchases of those assets. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchases, fair value measurement, assets",
        "terseLabel": "Acquisitions",
        "verboseLabel": "Additions for the year"
       }
      }
     },
     "localname": "PurchasesFairValueMeasurementAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r132",
      "r156",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r132",
      "r156",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [Member]",
        "terseLabel": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax": {
     "auth_ref": [
      "r40",
      "r140",
      "r142",
      "r187"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments related to cash flow hedges, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification adjustments on cash flow hedges, net of tax",
        "negatedLabel": "Fair value adjustments reclassified to the income statement to financial income"
       }
      }
     },
     "localname": "ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement, assets [abstract]",
        "terseLabel": "Financial Assets"
       }
      }
     },
     "localname": "ReconciliationOfChangesInFairValueMeasurementAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RentDeferredIncomeClassifiedAsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of rent deferred income classified as current. [Refer: Rent deferred income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Rent deferred income classified as current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "RentDeferredIncomeClassifiedAsCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of rent deferred income classified as non-current. [Refer: Rent deferred income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Rent deferred income classified as non-current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "RentDeferredIncomeClassifiedAsNoncurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "auth_ref": [
      "r11",
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements of foreign operations recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve Of Exchange Differences On Translation [Member]",
        "terseLabel": "Translation reserves"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r5",
      "r15",
      "r85",
      "r86",
      "r88",
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Restated [Member]",
        "terseLabel": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r28",
      "r42"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r10",
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r5",
      "r85",
      "r86",
      "r88"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Revenue": {
     "auth_ref": [
      "r1",
      "r2",
      "r35",
      "r93",
      "r99",
      "r136",
      "r164",
      "r168",
      "r172",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue.",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from performance obligations satisfied or partially satisfied in previous periods"
       }
      }
     },
     "localname": "RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails",
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Treasury shares issued"
       }
      }
     },
     "localname": "SaleOrIssueOfTreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SalesFairValueMeasurementAssets": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in the fair value measurement of assets resulting from sales. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sales, fair value measurement, assets",
        "negatedLabel": "Disposals for the year"
       }
      }
     },
     "localname": "SalesFairValueMeasurementAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Share premium"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share Premium [Member]",
        "terseLabel": "Share premium [Member]"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Sharebased Payment Arrangements [Member]",
        "terseLabel": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term investments, classified as cash equivalents",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Equity"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "STATEMENT OF CHANGES IN EQUITY"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]",
        "terseLabel": "Statement of Comprehensive Income"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Comprehensive Income"
       }
      }
     },
     "localname": "StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r132",
      "r156",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top Of Range [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueAbbvieCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r19",
      "r27"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeReceivables",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivables": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureOperatingAssetsAndLiabilitiesReceivablesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables"
       }
      }
     },
     "localname": "TradeReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, assets",
        "terseLabel": "Transfer to level 3"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, assets",
        "negatedLabel": "Transfer to Level 1"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r28",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r137",
      "r146",
      "r147",
      "r178",
      "r179",
      "r180",
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r137",
      "r146",
      "r147",
      "r178",
      "r179",
      "r180",
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types Of Risks [Member]",
        "terseLabel": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart1Details",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsPart2Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Parent Company [Member]"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Investments [Member]",
        "terseLabel": "Other Investments"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureCapitalStructureFinancialRiskAndRelatedItemsFairValueOfOtherInvestmentDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinanceIncomeAndExpenses"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r1": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r10": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r100": {
   "Clause": "viii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r101": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r102": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r103": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r104": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r105": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r106": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r107": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r108": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r109": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r11": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r110": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r111": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2020-01-01"
  },
  "r112": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2020-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r113": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r114": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r115": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_116_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r116": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "119",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r117": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r118": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r119": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "C8",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C",
   "URIDate": "2020-01-01"
  },
  "r12": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r120": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2020-01-01"
  },
  "r121": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2020-01-01"
  },
  "r122": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r123": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r124": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r125": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r126": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r127": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r128": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r129": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2020-01-01"
  },
  "r13": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r130": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2020-01-01"
  },
  "r131": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r132": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r133": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r134": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r135": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r136": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2020-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r137": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r138": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r139": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_24B&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r14": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r140": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_24C_b_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r141": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_24C&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r142": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24E",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_24E_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r143": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r144": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r145": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r146": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r147": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r148": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r149": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r15": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r150": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35K_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r151": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r152": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r153": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r154": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r155": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r156": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r157": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r158": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r159": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r16": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r160": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r161": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r162": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2020-01-01"
  },
  "r163": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Offsetting financial assets and financial liabilities",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS07_g13A-13F_TI",
   "URIDate": "2020-01-01"
  },
  "r164": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r165": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r166": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r167": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r168": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r169": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r17": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r170": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r171": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r172": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r173": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r174": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r175": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2020-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r176": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r177": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r178": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r179": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r18": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r180": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r181": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r182": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r183": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2020-01-01"
  },
  "r184": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r185": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r186": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "4",
   "Paragraph": "39G",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39G_a&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r187": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_23_d&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r188": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_a&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r189": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r19": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r190": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r191": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "9",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_9_a&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r192": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "IG24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2020-01-01"
  },
  "r193": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r194": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r195": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r196": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r197": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r198": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r199": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r20": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r200": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r21": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r22": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r23": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r24": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r25": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r26": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r27": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r28": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r29": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r3": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r30": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r31": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r32": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r33": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r34": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r35": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r36": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r37": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r38": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r39": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r4": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r40": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "92",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_92&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r41": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r42": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r43": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2020-01-01"
  },
  "r44": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r45": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r46": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r47": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r48": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r49": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r5": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r50": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2020-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r51": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2020-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r52": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r53": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r54": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2020-01-01"
  },
  "r55": {
   "Clause": "viii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2020-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r56": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r57": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2020-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2020-01-01"
  },
  "r58": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r59": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2020-01-01"
  },
  "r6": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r60": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r61": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r62": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r63": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r64": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "39",
   "Paragraph": "86",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=39&code=ifrs-tx-2020-en-r&anchor=para_86_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r65": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r66": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2020-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r67": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r68": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r69": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r7": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r70": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r71": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r72": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r73": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r74": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r75": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r76": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r77": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r78": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r79": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r8": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r80": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r81": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r82": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r83": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r84": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2020-01-01"
  },
  "r85": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r86": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r87": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r88": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r89": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r9": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r90": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r91": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r92": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r93": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r94": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r95": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r96": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r97": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r98": {
   "Clause": "ix",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r99": {
   "Clause": "v",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001558370-21-011244-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-011244-xbrl.zip
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M&3GI7BGO :9UF_2G[?J%*:(V]!9%*G5VI98NUZ3?:]UC,M*W@9J[.74G#A^
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M8<7T_OV(_?L1@"\M_A6]WCJ!LYB:V HP)$& _.%H@6E(&0KV10[%=HW N([
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M;!L[U/I-9CT5X&=;R\ZLN1VEAW3<#&L;I*5[4@JFS/=NM$E=FJ?0Q'U/;P3
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MQJB4#'X@P&RSZ8"_?NF<M*_'VX.MEH+-I>WW[" \) 86NPO\;4#W%9=HF/7
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MM09W?@+%0I-;6Z<.TF%!QE=8](E/S<K-8L\"[E#OBAW\D(M>=6%FU@-IK+6
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M[JRC^T!?^?ZXQQ5S%WX4^7NSL*MNBS[R:B 6@Z^B(>KXJ[.W\SJ]E(DG"H?
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M@)VCC.WO7$CZ& 3,<]Z([Y&=K!T=DA?F0HY+UFP/GZS9P0]Y4NOBB7I?0E@
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M97UE\B97RD".E.,3B-D%='T\Q7/MAQ';&&0+F:M3-CQ.R*YA"XJ=";Q",S]
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MM*,KKG,S]]D)2:;_O4Z?I9MX>45NY,^)]I1NRSSVJA)"=P)#.5=;J+NQ0EF
M%%*ZD1*!6S?ZDWM2MDU4=Y!+3U>62P)3'A<([:)S2JXX'?.O.*5-]K9MMO<Z
MTW:BN_>32_@RWGI.92BV('T7N Q4OEA^2%Q">+]#1F7Y(2\ K2O[P#'6FC=W
M\ HN$4IL5O&VW?OB^].?>.O.B;DIJ6D49:JAU;HS/(/#HOO 7Z$@>KO'DT#\
M:M;?:V=%R5,O4,,HULBA5+7"@,Z6!V>^B/P9!IF,)?9FIU#0*&X(@:M[KR2E
MQ L*GGT**2[@D.*;[]F;_*HV<EZ(4X'-#&IIH^@ACE#511'H9@-OY6]20.2X
M@&\Z:(7-XH<H0,Z]$:/H,?9>4.($&MFVO_;PKO2S'WP/R<T]/.U&;U]1M-A+
MT"E=WR@2U<%<]_)*R=0$B%D[4UQF= H%C>**$#BMMU6D*<%XTO#:#U9^@.6
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M)L%F7!JO5?<T@M,,0 8J.8V0A0S+ \"(-,K:\MM7%-@.68S\:06!Q0@QXM<
MJ'P%JBS$%E40@=8['X#2^F1%0_+&8QG'N<*YB9OH-4RG4E41=.:4,PW2P^O(
M6!KQ,P37?LAYPX5=I4-DDI-!W5FJ1?O%5#"363$E4M:_3U%!*=VD6^P>&]6(
M")H+FK6H2D$_^2,;;WX#]$1NY*R#-^I4*%+%=,)4ED%=+VT)(Z1OE_ 9@1>)
M3K18^.X4"^G)>D7AQ+M""\N=36:WRY7KOR'RHV\H>D11Y*+IP^-W'ETJM=<E
M+JD3D&:_*J!K3&+*J.DLR,OX?-@_/S6*A$KDH<HQ"MU-M7]UE?Z4:7+C\'8V
M0S8>V;>O]L+RYN@!#ZCK^&^\>RJ*O@"0M_+.+;W24/2.#WC6:GB N*5\DH"F
MZ%1]A3 C2/JK(-JC"*2'GMA#9\(8<TS^5&C+"'*IPJWUXF\'S-*@?=21P:9H
MK948IEMO?X4/R"S1Y2)T#,BN9H2QJ0"Q*\_\$)EPJ9&7SL6P?W;1- $JJ)/%
M"BHZK:=ZTCF\-*;07/A!A'NYS,3YY)*_"TXVDNV8RR@5@CC,.>#A\]@F:[NQ
MEW\EM22;[:E4-MOD$SW'ZVT_TN*DMGF!2:6V954%8WB8?7TB;PA4P!C7 VA8
MQ!5:L"05D'*F+8 A)=?^<N5[B7%()?+J<#8TU.*MTCA;<]35B3C@=BD^CER8
MIND+OZ+E,PJ86J>4!:AR"551_;:"(#4L2Z%P(CX*O@_0TEDO2RBQ7]0\1@AB
MU+!4A$*(!ZRTX 7M_(,WS@Q#0IY-_(-Q@ETW5FD)6R3;,8]**@2@(>09"L\V
M#J3?T!3/U"5DHA7."VR(]X8G+6>,,$I5)X( :?& 2"8!-+VU I)/H(P8].+F
M44,"IX9[ME#(L;GYQJ5$MI!Y1"A%I^%8#HKZ\2 (_'"%2) /&JU6KF,GNO.F
MN5_AF7>S%>3N;"NV!Y!4JK:^*B7"62-#W!L70GANUNC)STA@,AM_?G@<G)5M
MFZ6: <@DE0P0"96J(""#=^.I5*?E>ZM,L0ZR2$  !F_1V=;^#J\1:4]T2-4%
MR"=5\UM5]+"N'NM>8)<LK5O%#[Y>V2MLG3-/2X(MOZV)<9W,DMM"DW6$;:Y'
M[GTP^<&L83AEY' KFIEX+%)U\6Z,(5ZOEVOBJ'S9!JY_0S_3I#08XGW@>+:S
M<M'8NX][-)F-I@DFVD6K>BT:R2-=<M$Z::FZR)>Z0.(W%^(41VKIIK!Y<[FG
M6T@:W-4@+_KMWJMESI"[(GE)D:?8#:"3,-"N)(.,4V<2EV^ %L@+\8A*'I1A
M$H15P7"Z2,'NS,T3"=YTCS*2; &2#9'U+G3FX6)RPW[RT\/?HZUHZ"6-U+4L
M7JTW1P"M,XH^]*=%X*_GB_W,:27N',EVP'!,EA<BYQ!5L&N]K2+]L"5K@R64
MA+ LZUXKM2V#3.OE#TBV@X2\;B(/^-&_FU(&,$$&F2*WR0L*GGV-*X;T/<KP
M ;GQJZ1^&L9<-&STT2Y6UP#-U\>KU7L!Z/EBQCVQ_9U&OEQ.9I?]8?]LV#:.
MR&'3G"$-T/YS]Y@"-]]>>06C."(%4G.6,T#F@[&@CF5#+GI.TPQR6>G+[DRX
MC1E%,F4"T.K]4+5'8:#=9A%,O @DZ"=P[/AZLV__^.XYC!VNDC8-H),^.6CU
MM$A'A<JQZLEZG7BQ^^D!V?[<<_X'36^< -F1^\98_-1MSG N519!2J-+&#2"
M%%;5)$D.%E:EF :M2!6E*ZC*/,+(X=[X8OO:2*0M@\N-$]JNCS<2Z,H*G9 \
M*+UKZ$-.<8QT+8,^_J]WU-NUA/\1-T:RLQ2:TY*8A3$%4P QTJF4%X<R@G="
MGLQV'<:C([V_D"8CMMQ=CIS;UY5K>:23[$F@7K/Y,3%H>(4AH/;\6-< 7M'A
M#,N->Z;?&CR@%^2MD: %.-ZW +L&#CGF\59B[<;/I?P7L@+><&>5A#C24UF2
MG./Q&^>XH_'B^7H=1OX2+T!EQ[A,@[!&-U_![(%=&['6\]8#3.];*S;VL,S6
ML1D3'-TG^Z-[VUHOWUS+$J]E&4(34&GZ-?$&(-J5&W*QWR6/&,S\8)E.E?XZ
MHB&1-3$5VP9C;:J3A&V$5,I$\Q+C8!8IC9X;>=/-0:F@53IE62742YKLX1U;
M+]/H(=<A^YQ)<6[ZPUN:2%2N;E5F5O@<@U^'1W/+6L5&Y1/"<^OF)T>)#1D<
MG0QB8.F/=_ML6M9&>B$PH[J:<LB(E@"F.S&? M7=,>[JL@OFD1X/^^<-Y9"7
M4 1'>WQ<3 U"G,5I%):=K4O: */\ZN-7'>YVIFK>H8Y]FE=6_'B5[%;@;'_2
MC9L[BMLS9S/PA()E2%*#^][4B0^K4E]P]OQ[1$(ZYTD""9F-0O7&(9H?7L^E
M=PVBC8$Q2'KHPS98M034=A]&&D)Y;P791PM+3-8YS3<9M]/;-=1F4Y4Y4;]"
MT4^$O+R<Y&R3>&L0C5&FKV_R3E%J7>BF1E;]/!^IN  .\UB*/E,2/V M:D(N
M]DW(MG[++$?V6"Q]QILXT^]0&")4:BD$:T.T#$EG96W"7BV UD!*I>S1+P:U
M[>/^<?T<HK_7N)';%XE]SY"R[]FVU-LVU3)CD%7_-ZS&. F'X\T3/*,9UM(#
M6OE!G'<CCDV16DO(-@G1;+#[+6M*A%K*C[D3/.;.FS8O]4G"MCG59=)V.T2)
M4KGW7<<6W=<<]P?]8Z&HJ]Z_;!K^?YT)P&*=RJ#0#IQ5,E%F4@H1^;SA*9.E
ME+<GK(4K_*4?U..:VJV"&?4R 50ZL<.ZW'X@/]IZN;2"-_P79^XY,\>VO*@@
M44=^ 2O=:BNYJ!/[8=S]FBW; [)1%OPC"6>V@FD8YT[#>_[Z9D[R$ZWDV<$$
MH35]HO1;M )!#OD<?>G0&GG379E0A&.U6FPQI=3CUIHY0!F#2H;2OZ^G\R3&
MRIO>XEW'THK$>*2@W1:S21=ZK8D3 >6I*1/@(XKEM]VR"BW*JK?92B;J0]Z5
M#(QE<OML.<$?EKM&7^-,$/$1L HFEK1K.!NKH(>5Y;%!1E:-&Z_7KNF,K(!>
M:XZ$%C%R[+V@,"(B&WNC,/2Q&"-.#J%JS1G./PG06G,J-','.HXN%O/)G_0'
M_1-!GWS2;'<\\@<R 22$ER22&2]7%GDZ8.PY$;:<N3?>\ 9[ZY*98'9CMF'F
M)/ $34/MS^1'SVGKKDSK%T;[8Q7C"Z=2YN-XWWRDS31E,,R\3XW_;LWG <EK
M%[-3^?WJ.A^ 91JJWK=6+@%81X*,X?)H+]!T[9*SI\2ID7':CCU*(HEX5'-=
MF36;;!N;M&%NQS%>]O0RLF:S:S^,RCDB4*V5/*B*"]:+F0Q=$R=3(O P7"_C
M+A*!;!+%?R'_1]-RY5=IIY5L4 84UI-@ J;@V@]6?H"-'3D&3+OX9+W*&0:A
M1EI)##4HX1YNU;COO9U(D[?TMH\589$\8"&1E)EX*G6=G:N#Q2<53>;E?C;L
M#R] LTL;YLX<8>62GVQ'HWP8&ZMRVQBE )VBPR;=3X3D0UJB1#1R,Q:C6MMT
M7@N7UH,<Z3"> ]VYL +/\>;A/0KBZ\[2-RW8]=O&'34 VWXL0SL!E7*LGNP[
M5JD9[+2[6=]3V>F"3 G;F,SP3A&E5!'#7=8*&/NA(SU=-?2ZLEV%&]*$R/XX
M]U\^39&3['SP7XH;'ORCO^[0W')OO8@\)_[J%$_R*"6@*[.2.G9*%D6L,-F5
MM,Z2KMWX2\OQ* K+_AJ,MD3EFM=$*10-!QP*7 YA$&7<#?A?12WB'_UU'\N*
MO(EL>6]?$4F=7U FHQ0HG99J:*=0&3B@]*IV KYV+6R-PHU1HEA=;EDPVM=C
M?^6Q<\ZH #XL4T!%'?<EI0$R0%17 GJ&;!087INO5O #183<C\A>8\HYB*[8
MDM)YT.?#XY-+8(KE**?@NI%$V;AJ@:6*!:%\E79=$CCS,!J*'<_*9C*;83&0
M\-_,9C*UA-YT^Y,[QWIVW'@DR#KG:GT!#+,D.5"V\U8OE,.$3\(B+V]@2R=$
M%FO+5$+6@:\HTJK!QX]8+Q-(^9Q/63YGZOL$307XPGRHH&IGY<X7!9H ,[ZK
M)SY7!EO1E.(R8V,.G/)<:C2?[8]F1N)S0\Z0WC.@BZ=.C!\+Q7#^1,Y\$:'I
M",]=UAR/+1383HCN \<F&\])M$!!\B)IC8>5E'T-C&W30T#VXD:O! ^3F5#A
M3+H)H!V1P#;\%;E)E%^[ QQ3(1&MEQ,.,+\FN8.E)M2+_0DU::7%\R? Y-H"
MX__*<LEZ\'&!4)1YF2[.!N]X\R<_HUUALU"IT?S8N$B>YVY9<FV-DM"^ %=Z
M96&)>[7 >XLX6%H1JZJU:B2M%(I"T>S3Q,:.<G,]>613;!HZ%7Z[OO<O:;O=
M2=G Z- 8DSA909-;O6G.KN^>$Q4/B$I*@QF5TOGU)#')!,AIST<@-SK8[[HW
M-A[>,Q+$U^7%8UJK-0UK=!XL"P$;N\ H5K4Y?\(UPFUG:6%5K&)@M*9='063
M+"H+ 2VJ6@T7NL2.HJ$6!*-)*?'RM<)!UGC0#&NV\=\LEYRWIQC86J27S(,=
M8K!-GA^)ZZ.@2 EP8#6)G.7S&C>:)+(C9U\<9;(*FZ)/*7P:O)-J@A4=%^&)
MPD.IH[9\D/)K&*+<"B U)$Q1HN$[QR:GTY\1;_[<*V2('L5P:4AFHLQ-<.V[
M6%$D'8?S@K+'*-XT\Z_XF.UI87GYXHQ5KXIVP1#DT,MD;<(3N+F@:EU=%P/U
MLIG"EL&02Z_&%3.+(SNH*\H1'J))^CDR&/_=\D*L6?8TQ2EN%F4XJBR01E8D
M[6#"Z/GYQ>$L0MFEWWD@)!&H^Y$\C ??7@BS(%/XG00B H&Z8\FC>$367'Q.
MR)9^9X&01*#N?O(PKGS'BY"]$"5"OOP[%01EHB&#HP8R?/-?K"!R. X-7OD,
M\--^_W+8/^TB&01DHB'%HA(RQ(+(",'W[C$4#W^&38BR.ETE126Y:'BL2\_*
M(7+1%^2AR+&%;06M5E?)45$R&A(N&A%P<L=( Z"Z>3!T/:!O]B R5+1C4I8W
M5A_/2P7%I'!I3=/8R:<,C:'51-2*2U$/:+JV2<?&7A+P\):"I8<(, IWE2(5
MI-+BP/,45N*KS"U!M^L.V5#;8U:H[5$/?^8/!_5RW^EM/Z0_%E=-2B$*U;),
M8\3R2M>&,@VU);Z77(+ X[&AS&L5R:$QYG<G#QVI;=L=+M$L5[0K7&^X1"N)
M=<!PB6;)I5?CNL,EA+@%R+^EY)#< ,)P%%GED!P^#91<;NG6-"0J"QWI@W5?
M;@$PA$7%R]=*"X=B[>AJ>,KC=+&@/C%<C:M.HY>43$S<E.W;$F!4?D#+*RH&
MCEL=8,[V&$M9JO9L(8"JY^N#J<&.#O,G?X5'!!% B=:+!:%J7LS&2^(RF !7
M?H2MGA@'*&5-H8$HM,:#BS6F)T-!G";(L]'DV762Z9+_:@N[2EYX@^%@8%:J
M 3Z;).7""5,%N$B@@RLQ';Q* +DBJ4!Q#G 0&SS)T&7QB/\(9PZ:CJ)[$KX[
M]IX<QK7[.DVUAEZ<[HH33%H2W:7=Y 4%]1F7;Z6C9!,0@L$KI_9%3L)@Y@%7
M9!IER+E7HMJO_GV%1>A%Q10>#\A&SLLN:BCKH"VI8AHK^*HJ.'FKR$9KJ*)T
M$H3V1\EVB'-U1:0U#;QT@#;#1&TRG](7##0+Q:_15;)4%8V&F\_JD[1L1/,4
M6%YHQ1'!\:L:-'JPRG::&%)"T7 +6CTE-E2_02Z>>X.W] "6:S&*93M-"2FA
M:+@+#7T54[:##<CE4,=RW;?MS\9X4*$7QU^'N++C3X76/"J^D]?9,813E>96
M2-H$RKD#KGKC1L608L3;#7_NQ>\+);VEF3RI!KI*'T62TG %_*"7C[8/ F>>
M)=M_-CCS6K#<5:23_:S_V]9S+QUF?YY\-G[3-//AQIX)R#V58JV<R'(?<;_M
M*"N^!R?\@0451^;&]!-][+1*BU!FS/VG0/-$$K]YQ*P-QCPII +GK60I,>BX
M^J&/+-=6A.:X6R3&LFAA>'$#)?7 $$2%1FG\J(*_7<PHH$H!OY4<M7%K 61%
M%3W2^""/V^!3VZ(@H^UK\T^+P%_/%_>!/W.B27#GAQ6))=,F0-K)TT6 =+5E
MTB5*CI;D6:\03:_],*K*04XCW2&=K! ,#B.X=BTL%-FE%*<20!8I7D?)@M=Q
M!^Y@9D?.OH U)-)*$[ CD*<EUO,T5O #183NC\A>![$_A/,T#;-T'O0)!GW6
MM(;%E5/PW4FB;%RU:A+?)%X%[P6%46P#J2S@%S:$!!5 -KX>8&8+(T%$\5/U
MMZ_W 5JEKRWQ7A7CU3!$PU610DWH/L;2N+;"Q<B;DC]N_UYC8"Y?T65U3%)U
M):R-IVT_L,<T<R(B[S8M5 9(G@/X3D6$T*ZKV#1HLHX&9E6 )*FL5N[N0$X"
MH-:3^NE4TXTEVA) LE7DARC5Y,5A,//VM_O"TUU938#,TNW?DICH6G*=F :M
M@@D":VNJZ5#4U$"V*;PG3NZMMWC_5_*J2;X80.U*ZJ2P.Q+%V+@J]0W_.V3A
M/@D/?7KQO-!.(7BY*Q.C$M;&O6#-!:3=2=V?Y;8 D$9JUQ/U)*'CHNO!#L]$
MC\U:R &^U@1.SWC:KCOGL!Z$D7Z5X[ K4*FU9[<X4P:\[EQTF1#'(_<#TK)9
MXIPW'$!/0H%E ^;WWNXH#Y@GGWD/CP<='G^-J>Q$I-.WKZOX9^+!\8RZ8"S)
M04+C9830KO#G3=YA#(WOXRH6!$. ^AJC:5\(;GM5799#=:\H0'4+J:A,M^5;
M51-]&;O144*$8L&\H,Z&@_XI)!IPM$GU6HN@,YD&:]Q]SWX3(<)>4<.H((;/
M8/?5+=X5!!A+,BB^!-:TY-2+50$@,52N#*1@MRN,^];#6\&W\,G'Z^?/?D!#
M6F(FA%L 2!(IQ5*940M\X_,,ZXF<P%FYR'K RO#FG =R]HM!U'$M%14.Q40A
M-ZY9:O1W&$29R&_\KV+4-_[1=EJD3 3%7P/4=GVS+P125[Q>N-%9B.R/<__E
MDYWV)-';YE]%O6U^_M?(==.^D]09M/</>47!Z%-(!SN526,",3SKZOKV^P-+
MM_A78'0IK1R*7EEXC-#CS>^_L_2(?V64'EEX0.RQZNKQ^^,-2X_X5T;ID86G
M\9LP*O3XY>J>I4?\*Z/TR,+3^"67UC\U;LAB6*]T= 0#&_&6^/EP<-)0>EB]
M&E?,+([L&E\:'O0M\;83AJ/( F4D)=(X#9H*][B3"CWEU =#-#V^_3I2:%?0
MZ5?KU5FNEULQ^3NX3(YPZK2.%WQ=TK@ABU[K^RN @E(Y<IG,[GS+"R=!)H]"
M%7;1VNDVXX0ETHJG6.Y18!-MS;'@:)EU:(NALCK&\J,Z>JTOKJCB @W-V+/=
M]=3QYF,/?QR%$=N>5&K#;*XHD48KGF:YLKP?-PB+R(EV"!\7?A ]H6 I:EGD
M6S&;/XKD >LE%X&9*'V*H6SR28N9S0%1P)R72F JF6X<23XW^BN5HG7STKD8
M]B^ .X"5+C^X4CC,JR4*.7+OAZ&#\6'C%Y";SC<H^7/LW;[:"^++>K"B4CLA
MUDIW>%-#'BF#AD:]>[/):?X5"P&7(3^4O;UW(GQ[#W^L%W^ME_G<^RT^T+?X
M: R9S)*+T1*/W92U L8"'>;1FTKB:-?%KPPT;D!_H1P8(JC4'-7/)H"[71H?
MI:_6H6D&6TGH/J<.0":(Z(RF:UF4!A\99MY1*:-&L21 0L@JEDH.(9P&4T+S
MPQX@B*)G#I$60KMNABE_X ,$%:251M.\.-C&#<=!'_@ H6%QY0@<FD!6+= '
M/H;#_CF<U)<2)*@ $L2]!5VY+U^0&V;FR]\<%& 5+&@7 T6K 62*GK5!!3&T
MZPF D>NR,9;M+<KK B1*!952-QP5P8.:;C28FD$%(I55!,BBJNIG&AE9^*;S
MZ+@JCS@5N\ C6?BF+WU.JO*(4[$+/)*%#^+*:+,G>7=R6<)%6@+(-#T+;362
M:=>K) _(]O'FUG5B!4YFUW'H1#CV: )(W5OT@W,E;;:8:WQ6T/BF6D[M.F14
MDK<>!$-4ZU' 35Q;_X>-3BJZP60CDTY%(Y/B#_4R7WH/2JH8E*3I[CLMTDA=
MP_EA<=F<<5 <?*190CHFCM9GW6B:/?K4K9A73-$)T$KZ(JH1*3G:3BVFQA4S
MBR.[QEV/#")>8]O^8MD9&+['/@QGES:+,!Q%%B@C*1&H-+CRW>C*\8DPK!5:
M1XY-[KZQB< KWU4J2,ND<3<RRR;4$!?+GZ>N8;/H);SJT2<[6#D3]#EP=KOL
MD6W[:R]"T\]^\#UTO/GMWVO<VZ\H6OC%:Y#2]6'Q4Q]M:%Z?.B+2_*ZAJ@UA
M]D[?#NX82VZY]+W'!59':0(/5KWN4:>>:+1:+NFKM?HLUWW@VPA-P\]8.>,P
M7&,Y38*IXUG!&Y5P$C6[1[FZPE%T:,NR4V<']7CCWR(LW-O7%?)").GGQC+A
M^;E)VSW+F_8VK8/P;2<]1$GW-CT3=6.75%8RP>2^P>L8M6".LL=]3-E+(!YE
M(<%OYP1Q< )>.U59$C;9@S;^[\) HKKC^%5@J4M<Z$7'60646A,&JEKM?<%[
M_XE7/ ZD*9I>TA#]2H"#M2;CJ#6<>+^AZ3Q."K8]DF5IEEK8(.6*X].:50]0
MGL]O*,);5^3,M_E9ONR?N)05;S]#*B'4FCT/D$<I)]"2@"!DRH0O TQ5$CSR
M?EU](O 7W")[ 4916$JMO>@6@B=PH5O[LGO34:F%]Z82+*7)B%YT\<U%6G?Y
M?9D,32])0K$W."\5Z?[.CZ^L>Z+93'GEC=&X-,BZB_(#*[NXT<!+#YZN*<6-
M4[4HQKK+\Q)- W**[Z]'B:PD%NBDN D\J82Q[A)=M470ODB_]L/2H/VD4%Y>
M RRO88LY48JL[AH]SX0GZE(='AV2%3&1BMB^C92$18Q*RWQ9=*J\/516'"#U
M;%D8^P-R"6OC<\/M[9?)K##;RAZ+#8O'8FDW>MM^_/_,21GI2GQ.EG:F%_<F
MG[;6G^U=%0%QFM;&FR+-7WK5E;X6E$UJ/GUMP8BUY)ZA_N1#3=)$I5YI;*D@
M!AW7/LQ(/@2#*!542F-&5?"-A^RW/=D'#!9553_3R,C"-YA'>O/HPN"/GNE*
M6@@"QRZ )BO5>71A4$%::>S]MPC8Q@W'(?/HPM"PN'(*[GI)E(VK%F8>W?:2
MH +(QF\!PGZ)Y?@8 A?TS/XBN 52XP*:\'6^Q *#"2(ZHVX_)5&"FAH4DT31
M2RPP""&K6"HYA' :3 DHZ2)A4$K/;*-&,N_I(E6ESVL7U_BLH/%-M9RT7A@Z
M@\-9%8DF87!+-0,$_"@ZF;-"F"[3Q\@*(LBW$IX"RPLQK'"RQJ.7[:LNH9=<
M,QUEGP(A:8[-!43,^S46A14BZN//)6P4J-M1"E:5C-:+?(!8IVXZ'72!3D)B
M4'3!+YE0;SW05FMKXL=>Y->?345:Z:@EJR\C5?<-^38-1K@J[:A)-E#U4DV@
MZJXKO5U?WN-3W^-3B]ZIDV'_HJ%9%&)\:BJ.=@4@*CG4:Y (*C4G?:@GKG%
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MJ:M<+!\';N/O"Q<9M@X#<[]=QZ*YS3;"2]?RG? J=/O9)=-"POZ,::N:8 C
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M2<IM#.[/%N^KAB0_ WC!F*18NK^SP:W?H?R2WJ:56S%A1WF+9 2 =\@Q212
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M?6=P7"P4<9TFEQI7M1BO8%4K5!HX6I2QI1%IX:43MY3AJRDK^9'K&]*R;2=
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MX=G*V,30\4S?=&QBVKK+J,>.#@PF?CO< LVX]S&*^=P\&R]1;"B\A+(1=S]
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M[XY"UII*NI7!J.(6,W=!3:4HJ(!%-DS)[0U8-(NJ$(+:/W8MX%!M:FIM5?1
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M7(&TI,CC"(1DG]U\NSS/:TV@/@QZ8.IRI$,'DZS$4/L413X:/-I"P& ,PR;
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M4:8HJFIJZXX[='@Q,YD5Y8,JL('S'D<DZ3]A)>-3-D*B\^IZT8Q$.I.<;JH
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M"=' :AO,!Q'R>8$M7J)8J 6.8KK1,9:3DVZUXE#%H9Q#0Z4F%#_O"[V0KA9
MH<#RS:'%0GY:$">^GIF1::/:&(5+Z3U6@N!$4E_2.@SK?BL152(J&>@\:DW
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MF_LC);'-TY4]]I?Q$60K3@:3%X7?R"X&_$"4$0,Q?.)0E#>![_%#PRF9+GQ
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M*%F5':BR U5V8);QW2H[,.-D5]F!2R9[YC-W5':@R@Y4V8';PSX\.U KJO1
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M#WBD0--J^_J!TR$$32=R:;A(I^O V/$^DZI3EL0^IH1-5%J),)"B-A![HE:
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M%:>B0?.BR/EHN+DQ;>/Y4JW@^?40=EI2+1Y7BU%VH"\+2$5**!<U41K32_@
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M=ZS&U 3UM $0CH:(X:R#"^YY%#D9W,1PWA!^I:Y(4:6\=)T3MAWI4NR9&G)
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M&SCVQ2@TG1A1_9.X$,A$W]>8:U!3]$$0<0)8RHE@)D"B!HDK62>N6O4L7BX
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M8]3>,@9BBTL 8G<(^JTE $JVE6$Z TX@UQ+E3&N%;%5EMS*=QB4 N 0@\24
ME-N<+QIJ-;\ 5::ZW8#AWF5;"/VX! #[;?%1;;@$(/$E *\/=75GP(9J]G'&
M(Y@6]C,9*8]D93@NJ)_W?6\;]LXQ$$F<(\&V%MO:"[.UPA(*I^L0D#OJC-CJ
MAD&, 6&#E&HHCJ-/=* 1KD5 BWPPP?!9AV,);(RC*-#8&"?!& O:W'/<X^$?
M&J<!=T6HGFT#4]T3$\-372]HWR0LJ,F\L:-KNF+K>)YC[#O5_?#GR7EO<-Q;
M!VYCXK?RJC/%G(*"/ID A ?@-,RN#>EE^/O\03B0-/!KPZX!XIQJ;3).-:4\
MUR_IA6QZU7.W,N,7X5(,[F9/;);T')+QY?=<?:%D[)URK9_9MU(2T!5/V@\G
MK&ZUD&2@EG?<\!YCI^[R(KG+"-PN*4[K6JYBA.9$\>EWA,[_OMHW##%^(;9L
MW%8:CD'5V85N=]SF?FVS'BW(C#_RF\Z>NGGX&#S^#EZ4Q."K'<'WB4%K8+G4
MJI6>2GVQ6''8G#'K%%M(#(+S</[4K0O)$_SE*F,#G"<+Z2_,PE^^U[1%Q<)J
M^N;?_\(_CA]4#:#82*9F?VNZLS*4_4^?C(?O.LH/XW\]_/<L@">=OF8X^*.#
MR)'D'VA'CY[[Y&$I%1C&2^;LR1-^ETR9!RK1[(.8$:_RD?H '_WWN;?<@8Z!
M5MM05@[X>?S+8[[Q\.$'HBV57<H71O.XR90!)NY/Q7.MXP]\91'\Y*"6@C6/
M]-1AC:]E?.I".EO>X4-/R>G:QZT>MD %='B?:\7PURS_FIEXQ.]'S[?@,R>&
MM3T2\OCO%%+2/\<V4!:I+:3<WRO+T9$P_[0!"OLVX-DS#]CSO_BX5!E#->ZY
MX)-Q\VZ9_PA6 F$[_/DNFQ889^Z:IS'9STUV)GV=I3#9/X_L'PSDWM0VGV@;
M@B>6@+E4QH3P5^<#;N?[1/33]]H%QD_B?UF.2$,_C:#3:/SVQ_;\)KX_8\^O
MYS61-ZB8>T(P31CNJD'/E&E=$SSYR_'_^6%34^!'QI9&Y.S]= H(EHD^?(K*
M[BE\LC&$3U.!U*:IOU#';VS00G$\2>2M%3!G</LFT;LB"DCOV(OHHV:[W5Y/
M?25Y#2.W&"(FWVO[^H6F2)I@,AGVNT/&7S:HZ,__\S]/_(63M.$AL_$HI#M&
M:S[MIR 5N"/*Q 7V3\78*GOGP*MT]OH^=?CS/CF"HCZ"(F&H]P?QZ._H]4X"
M213<//)2G@0OAX\]C5^./WS#+3K$1:ZU>F<0^N7I&Y\0]$-0J2^GA&.K__R8
M0D%)H70BR3/D#NRR64K+<(HV)DGZ>KZ:_B 4P_WG1PDZAC-=_?$\5-9-0S<A
MCPQ+71PYQ[+7691F"&+ !Q(>G<5KDGOL+][3$)&+?" -1UVS2%I^$']]23KB
MA";C$.@S\%<A*:X*#(AM?4FTP<JR791<\HN8BKKMN$19,2:HL )1]2'E\TH2
MXSD,3RCS"#\L=TVRP7X5/Q4E=[I"5[P5ZUVY493SC=MF6RR+]4ZE)R+(*\=U
M]\L:Q2>+*G7X3['8:'?+8K'2[AP^=$_LHYS2637+_/VKI*?"Z/@R+^XW2S2*
MQ)/M$L%^";AA NZ80%ON$F7AIHB6!B1?W=.&5L=I-9VA9)76QC*K4I0\SC!
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MHAC/?-#68-_B0N*9Y'=D1^*=HQ@)G:V#^_N-SR7JLV]X9ZS?$L/Y>-F\R"$
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M2(]3):^ZT7/C; NBG4=H9[/D)]Y!\/UN1PF8P%8,W^M0M*5NZHYK^XU%V/'
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M7-B15VQ]CDNT6[B #W,>9^QQQCY15AUG[-\N/^BXB@N64#42UH3(6\N5#6;
M=/0-("J'&??)J.O#D7:R[-8E1-HOO/2G01F;G@AS-7YVY@*U$(Z;,.=QW(3C
MID09+QPWO1TWX<8G;,$NE^&X\2F<:HEN?%('ZNUT,KE1Q<Y<2K<[5L%TW*E,
MIW'C$VY\BIZL?&OCDYG7MGU28_=D8WMG]*6)6"9+ I(5W/B4( L: ;6 G:GH
M00&G W Z *<#+BD=T'!GP(;NR./ST^".\)\X/Y $D_;VRW\J">+,;6S&$F/&
MOC?4C0H5$F[7+MU;QX$;A@(.W+#%PX%;0@W<:ZZLL(1BZSH$9)4Z([:Z81!C
M0-@@I1J*X^@3'6B$:Q$PO#O$<_!9AXI9'-DEPN;AR Y'=I=GYW!DEWS#)VAS
MSW&/S1WHUD2X24+U;!N8ZIZ8&)[J>L&U#80%:>*-'5W3%5L'3B(4':[-Q3%=
M5&*Z.)5MQ+V*R3^,>=++%K2RU8';F/C7UZ@SQ9R"@CZ9 *0+@=,PNS:DGN'O
M,Z2>H\3Q\S6SKJ\6.L-D<OF:KDC]ELP$(Z8R>-K#Q=8X$3X5*!9W[ER>C<#>
MP:5R'D?"V++AP#>R]NRU%%?7<A4CM%0G,1F^""1ZHM<['P6J)!,:%QPJ)[H;
M*"2$#KOR.'=7*0XLK2/1:MWNMB;I#%"G,L,>VH(8$K<%X9 Y,D+SU6U![Q,:
M_G8^%:I%:DEVLK>[?L5N9[BI+S0?Z0_ZRU7&!OATH(<B.UAXO^X>:33\T7N1
M_L7[C,[.?%6!-O!;OK>F;_[]+_SC^$'5 (J-%,+L;TUW5H:R_^D#X!E+&'\O
M\-^S0+#H]#4#A>^H+TCR#[2C1\]]\K"4"@SC)<O]Y F_2[/, \EH]JA>7]&M
M]PA\+P']][EW4@(%"1T40UDYX.?Q+X^9R,.''XBV5'8I7XV8]X@WP,3]J7BN
M=?R!K^F"GQQT:K#FD9(]K/%5I$]=2&?+.WSH*3E=^[C5PQ:H@ [O"[H8_II]
MU>%^Q.]'S[?@,R>&M3T2\OCO%+(P/\<V4!:I+:3<WRO+T9$:^FD#E"3?@&?/
M/&#/_^+C4F4,;9#G@D_&S8>TU<>$[?#GNPQRX()PUSR-R7YNLC/IZRR%R?YY
M9/]@BN=-;?.)MB%X8@F82V5,"']U/N SOT]$/WVO76#\)/Z7Y8@T]# ).HW.
M!S^VYS?Q_1E[?L5GAU^!_%C%W!.":<+(7@UFA)K6-<&3OYP9/#]L:@K\R-C2
MB)R]GTX!P3+1AT]1V3V%3S:&\&DJD-HT_1?#Q0@M%,>31-Y: 7,&MV\2O2NB
M@/2.O8@^:K;;[?745Y+7,.:,(6+RO;:O7VB*I DFDV&C$.S^DD%%?_Z?_WGB
M+YQD2 ]IF4<AW3%:\VD_!:G '5$F+K!_*L96V3O'U'KV^C[A\_,^L\/X(2<)
M0[T_B$=_1Z]W$DBBX.:1E_(D>#E\[&G\<OSA&V[1(2YRK=4[@]"SG (\CL/U
MY91P;/6?'U,H*"F4-B5YAMR!739+:1E.T<8D25_/5],?A&*X__PH0<=PIJL_
MGH?*NFGH)N218:F+(^=8]CJ;A5\3Q( /)#PZBWX*+(2&B%SD VG\XS.T6^*O
M\^0FQB'09^"O0I)S%510H"^)-EA9MHO28GYG1%&W'9<H*\8$%9HBJCXDJUY)
M8CR'X0EE'N&'Y:Y)-MBOXB?1Y#27YCA:!7(F,]%DEE08>4RJBLQ1?$;-L%DJ
M2W((_,KQ$SGA1JCGQ4Y9%+MR-DV16?+P^WL*'X63SJI9YN]?I3<51KPG&N>P
M%<+?BT^GPTOQ[(37TIPB\S0UEMDTI<E9CAG+0.-Y.LV.594$3UZJJ\H-Q=16
MI;$V6NAN:@,RVMTZIPLRA?+O3U?*I=5\W1.6.:FOK5F&Z6QW.M."*_GG*^>C
M&J6+F3PEU3A1YNML4YZTMS(MT\]74MS&+J@C<+.HW78KXZ*B\EL;K3SY]G&^
MW.BX-28G>N;,<3:LY5(N6GGR[:->+K?=]EIW4K[.3P;#97Y4&0DR(Y//5VKC
MBK/JV4)9TN>KE#4:5586*\CLZ<K^.+\'#M^EI;7>J&\RK52[;&YE_G2EDQ)O
M@">2V46C<JM7.CWSCA^VY/3IRCQ3SV?ZHQ8I*=E^Q9-,QDI-MG+F=*5"5_AR
M9<5X(LW4^Z4*979& *T\H:?86U1G;-YC%B7-64WKF_IMFV_)V=-GVJ4.WR0[
M?$KJ3+41GZMK[49[*E/DZ=+Y\&XYZ3?*Y&+-Z+R99TG6G$"(4*=+J6;.+4SX
M_H@$4KY1FXWV"[GM+SW9:JLYW@S-00\2WQXQ,D,;O92VE:D0/NU&LU)67^>+
M4EX=014WSZ_("GPJ=[JT-KT9CM.EK"<NA2+7+*U2B^9@BI:>(*HX7&Z+FD?V
M2'U/*5G'9.9>#3XUA*ETEQS<KJE,CM0%LU'8RPM/6<.]AG!5SMC]'466RXNE
MUE%XEBFU*6Z*EIY0@$_3U71^-:&ESMUP-553NS%+PJ>&(.!N,[87/+?DR'YY
MP14R*ZLQV LR'<(MO3M<"-M*1Y%T;=X@:X";+.HM=,7CR=+2B.:]"5CKXM(1
MEO,FQ6<92%<Z1 "&O)(K+'KEWJ+6TCF!EP;+L@2?&D(L:3JM]-C=G!13G9IR
MYZ0]:;GR)_V=,G:5*;H9=]87%<K+%8>W3LJ<P*4A%)"ZG<E4$]6FJ&A@-RML
M2JER#BX-@;9@CW:W6;,Y)W69RA68JKTO[*<R$X)7Q6L/"V5J45THWORVRN^*
MPG8 =44("/GF9)?*K?=C:6]FV_JJE>U)U2TZ=#E96@7YH9J%=F11<Z@E*/%.
M/WLCH*4G&!@P-WMK13?28B>EWM"MB=GV>G!I"+1!U2:%FYGEB>N\5&WQH_GM
M;@,W$,*"JCB35[-LYFZQO[DQI>:FR>TA")D0NM:+V6YO;=X5%OR\VIK)A6ZI
M"G4+&X(LMK9:K=/#M4>F6KULP]SU&TRZA9:>Z.!JQ1I#(*QLLB1-;KQFK:B5
M*/C4$!;0-%MMU-<L+_57MMQ;E::9]:"%EIX0:\=MYX!J:EM)UWO5[;BPNUNO
MIS(; FU)T>OIM&QM%R"SG[3!CJ\46W!I"&.+=4"7%+*W6GCC&9CEJ(QPVX=[
M#6'!GN06.4VC%7(-J-2JU^HQ5!H:C!!H3SNJ#3*E49E4TKMY<YTI5E-EN($0
MO%9,6UCP=!V0I6F_)@YN1'UO;*$K<KITI;>F0])<&N2^7MX-6YQ#:E *N!!B
MW9*%KL&H*4FB#;>4LT?5J3.#3PTAEKKOD_O=0!+%TG"A]3RIM=;<%EIZ^M26
MU *=/@1A+6N75;4W&NS7<&D(7?NWS;OBO-6E%X O"K-LNY\IS@2T]/C4SSIB
M><?YR6>>EG#T-<]>9/[X/44,9\CBOUS2D7FU2A+SY7OXDKUFL+Q$D"]07C!?
M(L@7BKU.8\9$D#%88*+)%RPP7\N8C_9PO.4@?Q<1,F&YU7,5[[_NFW[R$=EG
MSJ[Y@CDV;WF$W]W,^)2N9T/(E]+DFQ'R:7T>;^GZ\].IZID@>'F&O/K$^S43
MC8?XL[T 5+ < _O >NJ$]=AL1MYL?JZA^"8B!=;T^YIX/EF3U"WW\[IIOU:'
M1A,^GVQJXP2LH'P$X^8LS8.QA,>O%R!_N7W.O&&>_RS4:@1\J*%;YG\NSKB>
MTY9BFL17&T;#:":<6AA!T8]HOY$H<;.LKT]Y[W3$;N?S(I(OSP._]J:?EI[Z
M:D/Y<>?N:=8I\CKKUSD5&U/U1M_.!;,PH9R*FM['&<]/)0D.P1+M0.. Z\NF
M!6*X)#VZ.A\JHF9DW_*"*J:KF%,=U?HKC@/<S[D?!(=1.(S"893_SE]^!X?@
MR(W)HV&AS<:\T:-WM=6B5)SQ_;%A#O+F[PP+?5 1@J\A_$LXNC/%+%F6AN[5
M"YF"6$U)@[2PZF5%T+^K,K3 C^;B%.X27:J1#1N!F& L8\B&0I:B4=NG/ZMS
M"B1277&DL%"Z=]/N<J*--U;KS)BE>O-Q=]*JZ@M=GC&\-+^1VTW41XX&=S*O
MW003-Z/?M*T5W-_^BE@9BND2D'T$6'OZ"HV"P@X =@ BP"GL $3& 3BJBR92
M%H*IB4=5$:)$4RT%C-UQUB$[Q2(Y-JJ#O3Z;RFED^#DT,@P;_HN'ZE<:_H]@
M56A-!ME4I3!8E-P&M]7IIEZ^0>-@H,%G.29!!K^-.)VR)BG/P7%^',Q\.M%Z
M$=OVR-AV7S-8$Z@7@D I1$UNUR;?;U-KC6P,&F+)G67O5FU!SB"3SJ!ACMBD
M7SQ"O]*DOP.BNXJV:;:Y\F2Q=!N64"Z-=F9S"B'*HSM<$V7)@0KT#9K-@RUX
MI"TX#M2QJCRW,:];INK9-@3G(S41ENF<.)L["]0+$L]M&E-%O%6].9I$B2SZ
M:]HR@?#%*#V[07\O3.F)=^LQRQ$0.PU++F>F8ZOG"1"FR*J'W3T75Z-> !,
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MFQ.7)+?)+1:]M$NW$(K]8:T4^=K@X:@Y!M&OP\#E;+B<[2+JDV*3N,#E;%&
M"T9%5&WJ[S44H0.&&?P[L)W_ZU^EXNX3TCF$9Y^\^NYX]LFEQ_S)FGTB^KHK
M)( JR8,-QP"-6I32DIZQMQ6MQTQ13!=,::6YL-3_I8L%1G^\,@DOPG]:U<%-
M.\7=27U:V;6F7&J]'V[11E"-0/:*HO%XUHO.*GP32>*59O@^W"1>E' B N,'
MSS[!LT_@%S1M"[V?9>*"@$BG%W!!0-243D3.2K\POJ];YN%.J0<M$1+NK.=R
MN;ECFAE)IR41L%Y5=>HMF6'\0W]\X(]!^J5A^#M1"DBIT%+EHB66EG5F:9",
M4FC[*(5!>9(J_6Z X@#"T!7?9]%QV7ZT#7LZT?H06_,(6G-?0]P\*(@0;:D(
MZ3701@-.U)=>T95Z@MX>"#+#(IO.9' 9'P;KN:SZ.]!Z6RQN=;+6%!>\=&OE
M3<MI-:P60BL:-IZ.4[G>6R M@ F 9-$(&VR Z8$8&/?HE\[$*S&.\YA)3WM'
M1+]_:2^!Z1Y56<54K27(&XKCZ!,=:(+SH/Q#E+V8S3(\8Z]Z8MZ01VQ7M;R;
MXE9F..2:L)G7E#T6!NS3?&OKP2^#?LN5>_V9ZF:E5''1;:7M?6/8GB+0\V^!
M/FX>3C!S8*7LE;&!DQ?13E[@4XG$%VW%SK7P]<>CI/!!D80=7#BE6\Y+5VY%
MT-F)N?)V).BW,&STQP:&E6@E&. 8QY%S%]X/Y&J];.P+-^O1@J_>+HH>O=\W
MMCZ0^=>!'#7?(/I^,$Z6X&3)1<2'L4F6X!K!*, %HR*J-O43+FB'SD/JX(4\
M+2S 78N1,IVX:Q%W+2:C;^L\=1"O'BK;]O!VLZ^MU@M=4>>CO"P,-]I49H+9
MA9FP2<27+B)8$N*587BO*#C323Y%FD.P* WJU%9<F*ZU$I HH(%(?!9W,UYR
MVN&;2!*O/,3WX2;QHH0S%1@_N)L1=S/"+\A;]LJR%1<0KK([UA#$P/SB$@)<
M0A 9_1.1H]4O3 'D@Z"GJ^P>Q3WY%XNO"A4I(^QYT1+[%::?SW;;!K<09);T
MZP0R^'[!>P/PY=C,?AB;OFVCV C?0(\;^A)ET'!#'[9BY[1B[^B/6JS3S>%Z
MQ=46ZT+*V4_O2OW5IB6S_CP^+BQ]EV $8Z">/<_\?J2FQNE<A\\:.='KSY8"
MI>FI7%E 2$5U[J]=&!4WJXX;^2X^)XQ3>$G/^$9$MW];(]_+,?5=*67H[$X9
MDYZ0H@N\(9NKR51F:7]$<"Q#ZNBKQTO!^_<U\;T,>+)9'3,S<=(@=;FJ=<7;
M'9G:MA#@^3< 'S?/!C?PQ2=9@;/OB:]9BIU+X>N/_)M-3TN1%<Q"=J=+=&J\
MJE7M0>V.A1Z$/W:0NB)#*_02C' ,Y,CY"N]$,LC=&!FMME!$OC\T2W<9:S!G
M6PC)J'WOBLIP,?(.HN\%XS0)3I-<1'08FS0)+HR+ EPP*J)J4S^AA0^W[T7?
M;.+V/=R^EXRFI3-4/;S>NT=.R.W>5-KB<M@#V6[QEC7;@LQR06Z X=ZZ@.T2
M)00+0KRR"^^2!$HS5 9D,C6RYICTL):G9I.F+PE^;H'F&-R\=\D)AV\B2;PR
M$-^'F\2+$LY18/S@YCW<O/>^+ ;.7D37Y.+L!<Y>)"-H^\+LQ>O!VK9*K_8#
M&VRE6G<]DO)*;FOV6C*;]HLBKV@&IRUPVB+N:8O712"?S7,MOE[JB4HC-5?W
MXIW6\WP10&625R0=U@.2U'P%3D_@]$1TB70)X25.3V#\X/0$3D^\+SWAS!0;
MS.!/@.W\7P*L/4@) CI@.&\185N,\Q8X;Y&,J.T+\Q:BK\L$4WOC(EZA*:CC
M&Y C^^IRG:W5%YF!L)79K)_ H*_8S%O'S9<H)%@6XI7!>*<P]$U])4B]YG!1
M8I3>.N_5;[JF+PPHE4%=42RNO<#)#9S<B"21<'!ZT<$IQ@W&S24D-3HH8Y$:
M*P[0"-UT7-M;0FV-AS9$.O_ Q4!/7<Y\OA=>[0)F:B244W'3X6U@*"[4WRO%
MQM.!HZZ[>:P1XJ<1,*?BPJFXZ>Z.-W; VD.=V6@,K.L0KD6X,T",%4,Q54 X
M,P!<0H,*'NOU*.OU#-86\=,6F%-QX92OU_]RT02M3\^AO9P/HN[7W1^ST:OW
MET=]1:X/;2 LB?5->XH+[9[O,[H[>[20^JUTI*9O_OTO_./X8-4 BHT4PNQO
M37=6AK+_Z<O3,RXQ_O;@OV?!E]+I:P9*YU%?D.0?:,>/GOOD82D5&,9+Q1U/
MGO")*I)FCXKDK00O]0$^^^]S7\<2'+:KEF$H*P?\//[E,5]Y^/ #T9;*+N6?
M29OW0F" B?M3\5SK^ -?%08_.>C<8,TC)7Q8XZ>W?>I".EO>X4-/R>G:QZT>
MMD %='B?'\SPURS_FAEXQ.]'S[?@,R>&M3T2\OCO%+(P/\<V4!:I+:3<WRO+
MT='Y]D\;Y2KT#7CVS /V_"\^+E7&CF5X+OADW'Q(@7U,V Y_OO^Z+)J[YFE,
M]G.3G4E?9RE,]L\C^P>C[C>US>>ZS_"))6 NE3$A_-7YZ(UV;XKHI^^U"XR?
MQ/^R')$F:9*@T_1'0LOWX?N+G?J_T46L2PB7/2&8IN69*D"GBH1I71,\^<O)
MFO/#IJ; CXPMC<C9^^D4$*A@*^KP*2J[I_#)QA ^3052FV;^8K@8H87B>)+(
M6RM@SN#V3:)W1120WK$7T4?-=KN]GOI*\EJUEC%$3+[7]O4+39$TP60R;!1R
M![]D4-&?_^=_GO@+)T7TAQ+?1R'=,5KS:3\%J< =428NL'\JQE;9.P=>I;/7
MS+%X^.=]E3#CYQ9(&.K]03SZ.WJ]DT 2!3>/O)0GP<OA8T_CE^,/WW"+#G&1
M:ZW>&82>I6[H<<)%7TX)QU;_^3&%@I)"E?8DSY [L,MF*2W#*=J8).GK^6KZ
M@U ,]Y\?)>@8SG3UQ_-063<-W80\,BQU<>0<RUYGT>VV00SX0,*CL^CGR$)H
MB,A%/I"&HZY9)"T_B+_.DX0:AT"?"4M<_/BW@K+H^I)H@Y5ENZCBVC_J*.JV
MXQ)EQ9@0UH1 5'VH@GXEB?$<AB>4>80?EKLFV6>JZ"A*=%;-,G__*G5"<S0O
MZX>G\OL;62C%KS*7-0:^/)UA98ZFLC*KTA,9OHXB\W2&IRF&2_/\!,FP<OQ$
M7NB4BS>-?D=F6/@Y^O#+\U+E.8@Z7:$KWHKU+M$H$FB'A+_%QR^JCB<4K7(:
M?#.*EUE&I>3,F,S("LUHZ;2:U;(,^>1%NZJ<9=BEMJZ)=Z3NE1?Y#K^ZL?N"
M[-]Z^G0EM:[?%*1F;D[JTV&ELR%WY@VUE?U;)Y^NO-O0ZF8PIF^ETGZ5NIG/
MIFFS.I5IF7Z^LE$<+[/U>862.NM\DZUKC+426S)]^NT2[^8<NSN:2-ZH:M3-
M=B&O]029/OUVS9J:^3XKTV1JV'"GC.V.;X6MS,@G[[XRN^6I)'0U:=]>SFOM
MV?16GP@R=[JRH0AU3>RN!U+*O"F::JU+<=Y63I^N7-Y:4[>]JE?(!M^;-2A%
MH]F[EIPY79GML-R&7NSVDM<Q"G<9;COE^*F</5WI[,@\8ZN2*^F6VZ]4\W>+
M_!92GCI=*BO[PFW#F[;)TK:F%L?]0G&_@TM#WMZ<- $WSE!WY+)U-ZENMD5I
M,X"<9T^7U@36*E>=457<#W+U08V3<L6TO_2$HZ:XW9&#44]8=-QN>5.Z55/+
MS52F0HBJ;TO5INM8Y<5^W^(HL;'RNIT66GK"_17?3E4VE=R2S)/3G+?1=X5V
M%;X6?_K4#:.+BY*0F8NE<F^\L5)KMB_ IX9P8$'OA\L!"1;2<LG=<8H\;TY,
MB%/R=&F:GY-#<FS($E"J6EV?2//4%BX-84%W5ZSOVNL-(]4&%)N><.GUE-W*
M-!VR5+_MIJ7Q2EQX9:$JR(8^*<[A4T.X5=W?*95.2;Q;@)L[6J+,ZK:\%=#2
M$Q;8Q7JV4QG/1U+*&3NY7:>ILN86+3V1E?1>JC-MJ:J)^;M\?D(S S&SA$\-
MP0!'\C6HN.9C:>UYHI&;K,1\HX66GFS@;FP7S+'6F8I>OI3;JOW"CAOZ3SW9
MP*[, K:9']7)_7(VD93TEF\*<&D(8T=TA1ZD]PU7Y(LWHV%[YVZ:74BL$,9F
M,F6F9DE&C_1&5J^9 ^Q.3\.]ALC6;=L%M,9O;\EU83-2[ HS,YM;U"1XLG17
MH&\4=Z?V%DMN7]HTZ9MVB1'0TE,-*,S3P\UHR8CKG6I1&T:C+%U W58G3RT)
M9:<LZML:J72%%LF.#:^GPJ4A&&AGV_G*;'";DAI>JF;J7&-U([5D)D2V;MR2
MSI4'^8G86<WJ>\%N0P4ZE9D0NH)M8PDVDXDI\2/FQAPR)#O;PJ>&*+?;\926
MEBZOB*E&1]]-ED"=U.%>0^AJ%LJYNZS-]<G\LE))<]RTO=2WZ)+BDZ5WRW2Q
MG.\,-HMUJJMI1CN?&LZWZ-:_4YWIY;M;FQ[M1+HZK?6&=:Y"KOU;@$[QFJLL
M,_7"I$*F&#VS;@C.NC/=HJ&^QZ6?=7CQCI.)SSR'X)AKEKO(S.R[>Q3.<2QQ
M3;U:$X"9< 8F9*[YRSR1BQ(3L"1$@ D4=\VF,1>P*& F0%'(8E&(S$'VF^[J
M=Q$A&Y9_^]QNWW<IA:2__UM.6G1&*6!$?-]0R/=Y,;]+F>R'H<(3M_#3,X<0
M30UHF-,?>_\W;7%T&(K-6K2@G7WK]<>A7Y"'6QW;^EM?\?(\PM^83?C(W'W?
MX+&/2\2KD\?J%NJJ^S@9+AD>OV/[X@2<JF>"@!(,>17\):A,P%#Y#$UR,)[Q
M1\2OE[-^N95]"QM_%FHU C[4@%'\?SZE*?(,#N&G!4/GF7T5KP#Q7"/2+@ G
MT8P1(T$:#)>(!9K?2(&HV<P(1Z98/K#9Q3C!9A?#!9O=I)G=#Z8QGJ7Q@$O8
MP/$,EQB#B64#PE5V4<SK_8YS<?&'ES%,\W\#OZ-I_YXEVR)V84C!LQ7T')F2
MJ>#ZG*[UZ"Z=:E'7\AVR5Q,[:5$FK6FGN=1_YRZ=IFU-=/?&<IR<KZZZRB[D
M]I IM2_<#M:MG,2G4ARS:+5!2T -/.R/?ZFK#,O_[D4ZWV+E?WDT>UR-?+R@
M3SZ&/BFGJ#4O&9F^1WI&B]OONT)!+$V_'/K<:D7*-TI%6/2S0!CG)^WR:M>"
MT.=__,M>\9G/O@+X@I,*2;6#V.^Y+'Y'T^_Y5.N7&$UPR>[ ]Q$@:D;QK9"_
M#>#V',5 ,R$FNJF8*GPRH;M@Z5P1)G C">WH(!D;N>3Q.YI&[JT(YX0PQ)^Q
M#.#1S)^?1ZW4F!2/.JF"5%(=N"&!S&#JY&^%KE<D]TO)!!(K#%-%04ZC&)ZC
MTR=AS$>J<+"]CD+X?GYP?TV(_@O@;N74!;U5I-M%GBT;'0$42T41S8V!43I%
ML:^!.VZ^B*#-/<?U;\;SIU;!UTJIBC,C7!L^+WB_C]R[E%0#A1V2R^)W/!V2
MDY1K/ \4?)7=M5S%>*2>BI9=M\P\U$W=1ZHI1'NG<SF277@U=>$Y6W)>;%5F
MS9NMG$&N"1WBFD02[=@SB1#*O] Q^664CT'AQO&$RD!LC,L4$$JSL55 *$<^
M2N@Y0EQ=E/Q,,:? (723L%8 <<:<$HKC .BR0,82AJ[X"/_8!9%)-5S84;DL
M?B>B:RT"P>=7ET943-4&B@,*(/AOQ>Q;]@*2-*^L=!=]XD3%=UIW=ZD"H^\6
MM72O9!355:TX0Z-&49T$R>$<RR=Y,E@,SE<F\0MB,*BW&JGJ)C>6&E4H"RHU
M%'4;B0'T=.@K+DW&*1\3,8\@@081.T"7Q>]H9FJB;OJPZ<?E$!&)[U\M"T69
M$ (-]",FMK5\G " IG[C!_W'UHAGI121K1F.CA!@<Y@\?H>8P_3WF\-XU8I_
MX:D&TF=%J,Z*4)M)#M J9N.HTH1[C194D#\]J0X)C%1QVDF!7G^X*%4%M2?P
M7)G>M= %(WXC!<M2N)$B#JY"O(3C"P]#/E,X\HOMFM_4I@[9*69K].IF,0>+
M*1(./VU 94[3!LEMM<"F$[M*F-\7F#G G14)\ \BA(BH&<6W<@O^O9S 05,4
M5*!ODC4*&INYF"HS;.8B6.3U]04 @2IJ'S11WE <1Y_H0!.<D# G)*21^DI&
M9QK%/KELKCK=EJ$N[E0!W1+J%P3@RL;(6_+(@?[KC_M_%_1ZI3 9JT*.$OM4
MOD4JF?3,R?B@AW%\^C7,Q]97 08(&C*L"6&@(@EBI>S]GT12H*,COU_MO7Q\
MLG8:<RRF_L<)86):@>@G5I\6F!\53<.\0=JE>5 N4/E"2L#'AE6;3_E.I\"W
M"J*RUG)=IS78;=I;=)4X=#U.YS7A2L2X>1[GA_L7GB/\-MPK.XTMN\-:B5PR
MM^D!N9UUNM,6@CMT.I@XU1N^V^E8*3I.CN#DR*7Q.Y[.R6F<Z+\JQ?X=299B
MPYM\PWL:\S>A1?EXO)_J%]ET:LV1TKX\O!.,>KK3]*"G&8Q(3)+IS5OVRH(4
M\8<Z P=;8&R!+Y'?OU.PB#NWSG=^\3RH4JTE&G(K[E; =,!KT13%[C)<06I!
MNY+)YBH*T^X4:E"E\_Y$!IP\P&V,L?-Q?ET8U"SE43V[N)'Z"J/?ZLT<N1Q/
MD3! _R;[ZN"TJ#DX$7,.$F@;L2]T6?R.9O-&U.T?MO]Q*D!,=+WA[_8R1K8_
M)SIHQW8O>?Q.9@X@6GU;7YT?.#9O.:]V;X5$1'US/NS:G7V%[+0R\]:RK,^-
MK"!3F:"-D6/?ZM2*D-A$WTO XA*-#,(OB\M83]U-^E):(DO+[" WF2BUFKI%
MXA(T-G*G]0G);6Q,3']3=/0$]J^2Q^\+R"LD1A-$WX6("0%^#Q%1LY)O%_)M
M0' B@08E0^]GJH\-<)B3'$F@1P?7V.0EC]_Q+.P[(4SLRP::GJW.% <T)DT;
M93S=?=-03%<P-7'MZ2NDL!X7B05J[*T8J#.M =6C]@:9ZE449PR6ZQ+?@F_P
M4B<DKBF(FJF/GB1\^0W17R$)+2%3'K;&:67!#[C&K5LL9:W9%$D"R@:0B>I5
MN%7L!7 5Y-8X4/SMP_1'RX/0B:1\1T><L8>3/'YC#R=J'LY##.8TW!FPNS/%
M?/0S054AMUR@%2U;<B#-D=YW][? G5E:F&Z7F].I-M_6R-*$=-?:2#=Z54&F
M_?F.Z2N6>G7R?83D OLY49*'\_DYGRP/IMLO54RVVR"]6DL&-VUN"/T?) ^H
M*_.*)%]M1$Z&M^-8!FX2P;[.I?$[GKY.XF98P<!5!4#SSZP[4#L[GZ[CQ1N'
MFX.<414;6:VVJ,SI6[/:DFD:^3R9*XK!4ZYB[_(D;LK5UXL%P[%KONG<]21%
M[3NU5L/:"<X4B07JBGU#+-[V?)806@:(BN?C$XS0'ZB%<SQ1\'L^/OV*P1R+
MJ>>2["Q-,)_ J?Q6<F8PS&FT**_)?N..*4_U&BEG8##J#^/,XJ[6)+HIIT-6
MXF]:<4(!&]98<BR9%U]?6,K@HU;WIM76<EW2UJ2]*-0WY>P@L]%A'.3/H629
M#$X.7%R7R"]9Y?AT..#\<-3--SX/B(3Q3UI#0UR!$.'WCU?_0J+;%3XR*$$_
M5D+B00G8[ETVO_&@A/A'Q"&=W^^K]?;<VV)WTP"=A<+)#;HNSN7L  :__AS%
M+']:_119)1E]'P$+2S2.UG]96&A!K*4W5GDE+>^:>F'6FO6<?0L)"YJS2(=E
MBI(Z) &;5NQ*87[C%$)L@!#A]\<IA,BD$/J*;2OH"!OL@*WJ#K[<&5NQB^-W
M-*W8A9QR^Y?-/3[@%@^:J#$Y*J>0R$2YU;BMJTT,R9N08^#UY&JG B,3?]XA
M&Q;%1Q#EEVRB(X?N+[Q*\</HUIG%W;99GLZE_;:PFBSM=+X\\-$-XV[N] *G
M^/H?35LW57VE&/C"9NR18(\DWA[)"6'B7_!^4$&-B7_M[8VN^,S4@?-XRDQ1
M-Q6HQ=Y(IF;RK6'&=KOE!:^9ZH[,*3-7$60ZZ]_@E,7%[K'W6<Z/_R]OROM$
M_(\+I-QBZ&U?],S"0 >[TH9"4Y:RR*FA8G5ITYM>S:%/!ODRK@TIY]E[PIDI
M-L#.#'9F+HW?V)GY_OS*08]W+4%=>[H-N@>MU/&54HBV!E-]O$G7:@VQ[PB%
M DMW"FYIBC;G-PG@Z9#Q=U?BV 7PIN4-@(X,[U9W9S/+0-]^N!P:BNP8S!1C
M@GX-EBO#VH/@QR9P"0>XK@$THMV1L)7&5OK2^)W,JL@D6O'&I/^@VKI(LS7,
MG*_7&A/QJ-4:9AVXG4"E(8T68N*YGNHQPK2S$E/]CE9:W5 Y<[N5&7\T8LB%
M4=C")ZT,,BD)BZ^0CL64RJ3%PL0D.P+O*4W+$?A .E"ZXK3T,<+IBHAY#PDT
MGMA9NBQ^1S.E$75[B/T!7/<8D3S!1UHG)\?C#=PZB>W>9?/[0I($KW>#Q3.#
M\&H[6/@)+B06?'A(;#0H<!F6K8[F(IW+:L8VG9+8MB S3%!]&9HZB*B^C+Z[
M$%VYN?@NRO<5/M1[<F=<'\F9!=@/EL9XEE+HW11)"\HDG!;^X";*J"F)Z+PN
M=JJ2Q^\+2":<F(.X(B/Z[D),"/![B(B:4?R]=,-,,:< W3BMHL0#=(."OX"U
MIV^@+^&W0$34?8X._+%E3!Z_HVD9XQ46?74VH6*JJ)80%$#PWXJ) B7!U-!_
MQ <5E@/PH4"<3(#J-B;B3O6U7EMQ0:#_PB*GWL@%*;(A*9)NNT,)W)@W[*HE
M,YS?,G%%AC9Z1E131L-P1L25B)<(?75FX2M%2*:D17WHVG,RY4F6OL\-I+GN
MBY!_WR-%GB;KHIU_>,O5RK_D0Q&*2[@S0(P!_*R)CG-0=P;\P0I^A87G7F#W
MZM+XG1#WZK/5O^#(C8E,T:C6RU?X4R"1ZHHCA872O9MVEQ-MO+%:OYE*/E7O
M(=J[M@/%S"S76DMYV:Y/Z47_9EV?R@P?W%Y-AQRU1!+7EYPVB1B>J:R\ [LT
MW>YXXT5MOUA8-6936^[/@N>Q52C5M9[H+%*[LB4KBVIOV/3Q['LC''=ZYU=\
M/9&C@T9 ;Q(0BC;W#A>V1%)$HR.1V-5('K^363B2D!%<#XK\E=BR\4)0&G;!
M5-YPJ/'F1I+ZQJBUK'NC?7ZXE9DT\EJH-(5]EJ17AIS0)Z:-);\K&2]64$UG
M>O[&6]MCJ<\,ZVF@I?M4QA<1=!=UK(9A1,Q[2*#QQ,[29?$[FGF9J!M%[!3$
MJ?[C@LL]WCJ@ /!WSXXF(GJF&1WP8S.8/'Y?2,[@K$?;02[X(8/0;,P;/7I7
M6RU*Q1G?'QOF(&_^;G/)NY($E1&0!NN5?B<I4]DPQ)F9RA<%F?''86:OV/1I
M$!19/1A]KP#+PWOD@93[=YN,O>[U)F)'(,56;41Y=>EWNT;>)0_97D[/[C>N
M30*KW#1MLMXS.[X\\#_^Y:]XDHM9H4;$/(0$&DCL$%T6OW%>(+) B/#[X[Q
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MMN.A$!/F30!6T!W7PTJ2J:+#FT_+4EX(8CPGPQ/('-$/DTP0S':]4AB=$BE
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M WLL(V(-?:T:>DO!.^EAIAN]$C'(S_D%$9B+!ZZ>S06?;>&/QP5>T^V):K#
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MQ\:0G!1?]A"693#WW-#6TUT,K.9 WLTP!L>J ;YN_Y:CN21H],VW0 ;*/19
M[VX2SN-Z$"2/$R$#$IIN__LD*1M1&@.=]:"I.(1 2$Z36S4W.4W'VZ=2 ,K3
M<U+@+,WM9']G"\^0&B $;.6("$Q0!7YMWESRP,3;E45:DJUU\"R><EP/,7=
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M.'J82P._0_A%LT4J S$YY]M? /SA8LY,FT9:$?RQO.PL<H+CM*'>.%/!=!/
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M:!AY!X68#'7H?^\\QP?'D4C9-FWGQ_]#4!DY0__[)U+B)$SS1&PTH%#=7A3
M'&X-@ *;_A<[' 3 MJ ()?4.'MN.2A="2^CBO(81MX="<CWXPJQIR\8!*YU^
M_J%;J'@$WWS@N@[0K>2,:O\:SI>.^+*'<8<3+]0[@L!7>A AF4I0W[/L>GN
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MR'W.!:$+PM>L+\B%*5C% SP?N-'H[;[V.':@\IFF(*KRPT-]S+>>0;/'6#;
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MKO=+>R'3^8Q +((;5A:Z!G$H<)6<D-Q4,F9Z1)"&MF!8.($7B-.U:9WKA>6
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MHN+M2U/$O@%Z GKV,@S3GTT1ODMRWI*0-IXCIN6TFC")3]<7)NF^.]VQ=Z?
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M"5.G^DZB96JTPDW2=+<>DK%5P99DBY8+.(1DN 4!M.#!2U*BI-1GQ&7*$V8
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M]\C^FR(,D2WAG\\$JC\? HIL#P'%=P@YQ&(TGO>9"-"IXB?ZR1+><#(4_7)
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MKC=_'6FRM+GWZZ_9:G&(,/S5LP;*G_\/4$L#!!0    ( *Y="U-#25=G= P
M #4-   @    9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C P,BYJ<&>=DG<T
MW(L2QW]K=1(]41=1HR4ZT>)B-\M%B%C=U:)=7:+$)2*('CW9B!J]A2B)$F6Y
M6M2575F$740+V5678)^\>LX[[X_WWG?.]Z^9,V<^,T.9H2P"K(90.!0 40$
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M#3T,(HKF1"[GP$G&2Z)*>#'23[2_DOUW8(__+[)_@OV+"P<P@T'GQP.S 3K
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M]D7/3ON;4^*^ V3X)XN-IJ_,%$K=6NV)9QKC)2.VU";>UU$&,#[4-P^M</D
M==$9P<)!/]QW0/%-#F<9TOTTH.N:XPP2-B7,E9B%XIG'15@@=87:B_M"A^^R
MW>$V&QZ>THMD#5[\ 5A(%F95138XR?)NU!>;*\W0Y#DNN(56:\W@@#(CU<_
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M)T^6#*C=YAVYNJR\/W44V$R.QCGW/O1ULTI8 ;2QDKVY_P/LUUH')H)JB9!
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MJ_[.R:&_G" J%<)>^32)^;38_GEB:Z388C<KO<^EYF4&ATNY[\B:G/XRH[_
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MGKKZIWV,M_%HMEWO :DZ&^0GV21&8'';!/00_?%FZ-*$N;94XRC K<<P7*H
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M?\#5B;3)K2LX/(R]L=9'XZCZVYD%EWA*VUA[D2'#45+7"<:0ERL&4DZ1VK"
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M:*R2^:EB[[A'%TADUZ.Q&HJ^:C8@!%B8T[S 6"<,U/I49*5%@T*TQ%6@XV8
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M3/I6\MU*E;WUL=$6K&X(YQZ@,^<<--$@6S X>6#ZHBGPD92ZIZV!3E(*#S[
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M0X$C#YS2Q9S61\22(OUF*1KG@BG#2^>=V.$$G_RS<X#:L1$H>W3#2'!W+C[
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M0(1D!)5X0.BH[=+?CH007_Q*('H+G)UEK<=^1@B)D+_S0#G/>T3^F95WK*N
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MW5&:12;^6(G6?$3ZZ\#)=\2)>[%* 7P<TL5TJ7\JTE4/%+$\TFB>M\;^WM!
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MG9!\@A*/ZX,YZ1TYUY)D5HZU+K]6])K%-&&[+?H4XTM>_,BZ9);'P&JV]Y8
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MWIE!HR[EW;?4_!UE(]1^H8#[Y6H>I(T6A:T 8M]9MHO3'@TTZ(#?\B5RJ.$
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M.,?^Z.AOM;XF-ZFO<AY"J;UIO?66^!O)%\<[]ZR\G:0L*0S%6^VZLQ EY3@
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M9^:8)NB&ZNG"YS!1L]BNW#$-]-F\G]*_ Q)E>8[2#JGX?O$)<YM!+726]B!
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MIM%JIS:,,XK]B3C %0L<X(<F#H#%#NF(]4#,M8Z!Q%G=% 5&V%M#., 7& Z
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MYTX5G2K[AP3E9(]!S+3%BA/DRHV60V;];T(R7N$ C=1_M#%*7_'S&LM6"P[
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M;K;U*K>ET=>T_N4C5>15'&"%Q0WO%UA/TJN#,:8IIR$'&T$\[%W>WX"8B]O
M[44Z0RCVG0L4M1>>JU@!R3\ 1B8G1<I(NX6/LN"M-6D9<YKVU_,=RKL0'28'
M[/$.?&5M*^1&7\0!#HAK\/;UT>L=Y.3J%&2Z0SR'<Q9;HH*5<7>6A5&0MNNX
MJH#,26"YT^_6KF*V'9[_8I/O@_1!-J2Y'6P*5,?_BR#,+EOI_9]X_Q]!]!^
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M<L@\8-SGV&TQMKFY^<FZZ1&#LUCE:;='$LE4N=7+@("CY\WEV"L[SY*)!VN
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M03N@<>LNCN+3^P8</?WS=Q&*_OA*^E/J<(N3K,/YJGR6FL&)37"B7V$FW%4
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M<,:PP#ZNDG(]9@<;/QNJYFB9^IBX=9=._NWR3[_YTPJA%E^R/#N%5//XVA5
M!X31WS'.,L@&1OHDBQ@A3$+H/$!4_ ?\U;A=C=5Q @^H6Z\ PBT(P)<^/!X)
M8P/MEC!,C-)/N?W7=A/5<R Y.4HZ<=CZ5$>GGB]N8H<-KW^8(:;S_<>(9PPN
MFTG#.6\ K0\?5$W'MX](/<#]-9&:V5,MQBC 2M(BN+.G,4:.%XAK6]\4R/.H
M\0UK.NTA1#2Z1W_/09NI.L[*M/S!H^FO *XAL<(!5Q\:<B2]0KCRJ+T=WRX1
M975#4;-A.[<"0(1KO9@C?7@7);!D!.P2?MD\]J-5QSH[3 J*$-PJ$B'_4<K^
MI;O>#_S65Z-HD]S )FF@ZMUN344)%0=ED+9#3XG+PH-=D[;7&RF$=5/V;LDO
MMD^T!]Q/59ST+-R,^K%=H4[28IO-B[$BH%)"*=#2#!Z@=9=]M;&R*"VRX#[9
M+9^U8AN=4U*$\JFP[Z32@WVBHJS[=/FMSE$]U4[N]8F3S;1(-LW'Y:6\0KEL
M&[J/Z,IIIZI%:&Z"V*P\Z(SGD2GVXF33>T]#/N%&G.,NA8M=V[9M9:67OB7>
MCA\:I4B#>;-:DC"3C9=8^!\!5J=91,\M:RJ-)9>'L&1@5P \?:7<^7EAJN?C
M1HR=W1*<^SIX0])S4<D?2@TM",@TAB/(C3#R$S*W3^KG!O/Q"EI0"B616=G!
MW(LWG7<'0#H12!V)RK$B?]IY [[V 1L7#\?[9)]AOFE>Z[$IEZ"LL"47^"U#
MK]%K8WGZ-FJ@QWV?N<1[+7PS@!$9!_K>DZYF+.9'O)=_/5V6*3W?@HHT"6N\
M1LA*"H>:O>+9\K::'>^%#56B5 -P#+:2WGLS=G_F7(-<2!(-,G M<JW@2]!Z
M:_$5?U!12(%(>:*\)Q8"7R*#+&Q$QV:L$3-*KR#XAMUCCP1[MS!,)R.O (%6
M8XV/..KN5.>E$AK,4%2Z3MTJ_$;JK)[,_]6,F%-)OK()K)+1&*)65XM("&T$
MZ*\M3<YHC)4P-43=Q7:@( Q#[)^K(RL&>*D<52K',R8MX9_XW\N<"'A8U'(3
M^;:+O^)/>;PC/WX,U5\2IU(",>9DU#LT7>;G%"WOC'SK[+/E/XA2$7LMY3[.
M9_K\']_F_ZPH_V-HPG^,&I7W^?KP"O!;V*C=_ZZPT?\T[N'OC["O"]M$4P=\
M.\WQ,[\"C-C+&U"HHAG\5&0"FA<TE':5?[\8A9NM%/@J7H_,_%>OC7UPYM?U
MI?R<@&_\"^@Z\*IVE^<!,O&\F0:I=B3Q<]WZ_^G8]C\*I='E2M)4IX$1D1"9
MW5'>[<OY[NXSW24&\0[<A3C+;Z?-(HCXTAR<[7 Q3%FV6X5V%]1KEF2T$-7"
M776DFKRO)N+[ +JZN7,S97/U'M!PPA'?L -&0X.,E9]@,/"L!J7GZ:D\:E>H
M\W?M7;PG(Z^0FR:>W3>$,;=1>OL*\-ZQ)+-!+G:@IJ[.*MCS,!C30S)062;;
MW!,].*6%C(45"ZBWU%:5Q8^N9G$9/>3N"^1VV=;RIT^6E!FK9G=401RON%1B
MV.=TCL0Q?+Q9(G3,QQS^I*K)8(GS71H"UTG!^MRM0Q["7JU@?\LJ5RC==NIX
M6$52N:=5'"\8/6_@YWTN-RIE/79AV+R&26L_!)1?]W7,WTY2Z5K.WW1\,FR3
MI.@AH/TRBC&DW\(7/Q&P#B]I[VMOP;?C3&NHK!K)J OJZ*)3K-.F#!2W+20J
M2J4N57MCX4A 2WM$/\A[7OI9+/5X7)P.Q+6 XC+24:QS9%KRT8G2G0[4[$])
M-23?0*FY+-VJ"9SJJ(F6<W/2TU]S[W1?-%NC1X)%"6P15P!*2>?%+P9#. \\
M1OA$:AVJ(%NTSJQ5T3[X2TU7 &0 -DV'VZ4=CIS>5X+VR^<P?W(9O[Q9L<Z1
M7M>#[RLQ,Q:^J:,5O)QXALB&=OHNTOILE/[<05-798<(JP%N*OOS(UI<*S&0
M#"RYT!CUV,="T":K,8*FJ );%&?) (\'9I3?7!<V[\<QEU87+'UCV;KW(7V)
MLN#YJ*.[B+[VH24DV-<,;[_# 'A_Z_436_9P0WY@I)QVZZF%(/5Q/Y+CU* )
MF9]G:+O/8 (:-:L+[B_O:K14)Y;=;,!@.(_5@S('B2H(O$'1.#KB9=5,7NP[
MV.U]38O^\6,9+ZJO0?"XT%L3S>(8J4'1P"[$)*S))ABES5IVEKMFHCWH61!
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M.02B;4F8^TPWYN>YZ\D>BPOX"[8!4!U]L2*(%ZZY^9;,<QE)Y.3Q \ ;P%,
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M,NSTR\1B<[(?,[QAHQ(U*]W6,!J )>/C-/%/:H?LDI)2ZR6/PQK+-U.X_=B
ML-5E9)_>.,J$U_*I??I8\=N';-62"F DA1D:PS#U/>\NILS('F\+X?9/AKHJ
MK'U8#5ST)4N2:3VT@4!R[1I8=E1"USPM! %\<V2D_(.:%CI1((>;ZOV8Q) [
MU4FB!*R#<$B_ MRE0/IT0&U-3#J(!EP/Y2I8B)LWF//-QK%A'+N\%X[!4+MZ
MB^SCZNJ%4/OUFV>GLBO?[UP!3)V_ZD@YYLUXJBPEA&9-FI/4U'>ZC^D;R3Z-
M,'L>$=1 [1)&7'(%* D%EG:.ER&J^^/K5TNR<W'$'.5J!(@,'&=C<D:UXAKR
MZ:DGHD$(C$Z(/UE(YXBG)?_HBYMZ(:D?0C'6S8VW\)U3,I.&4F"B4DM@$L\0
ME=ESHY:0^38'0/O H]EUQSR,B+$J&FIK9]]'E1">=P'4235]9E5G,;+WK6_X
M!'>[;%A[5/JY7LKD+$Q)IDTUTXI%H,F,Z%IM'Y<R1.+3V, T2VO$'?P ?&J^
M+DNROB_F*1K@1\RZ\83.H)59R_O4LI;NHA&$J$*2,87:D>/4]^=NT*4E')^N
M:!4XY.-=FA#YC1+@2MWT%6#ZCLDE9;7V!,?II=2)QL&E@CYSI,6G[<EYVFJP
M<N.(ED7=P<H"V8=/%16I:7Q?KX5)7-L$[=*^O.\D?JP'E%X!Y Z<DR^$7=>I
MXR*+;1+(ASXT,VZ>O'/K/#?*Z&Z9MX]P1BX3QSJ@\:]M D;&QBF^TFJ<EP^@
MJHUT&DRS#P/-MC"KY:?4JJT<M]/G0&C1+RKCC4+V6=-X<F[?LCRQ_'*#M#4V
M(_CE=FX#E1"6U==/G![I8S!:O.NX5N7S12#P%4*>-##K&)/YH(C'@C@DTI\<
M*NG(UZCZPZA 4L3!LR>F5EL\,QMD>^VUZOD*73_[F9:U3]#J!!]TUL(1C_\#
MHVW(?>1[DPY #7JR?H$V+G'2,&_Z!AH@3&-[!#T<"DYPA\\C<Q5B+ Q6ISAR
M#^YV>)F74%"'3#;A1X4/^^E6_3>E@V+\^Y1<_R_,@CP^YJ.1^MM%Y]7T&6OJ
M_>LY-?'1+YM><5QJQH K%-=6HV'/0>'S@LU?XDV,19N9_$M#T _\[EV38FK[
M+X2H_G<6S*B?_W:X))U>OM.YMG$#"WS]@]FX8 .O)OF,Y-GF\NDB>  8-_8#
M,=<UD"'M_N)5R-Q\S]SVR9,G"4\96*>X.=G*;YS)'<O[);QIM%@:NF\#+05S
M%)/,*/LA] U,0^S>S41U .4?5?F&L"\<#P\W(*C+4FF.=N\Z9AMQ&-!P[7I"
M#<R^GA]C'.1*+8D9HH=)R>^;?'>MKCB\#:&0M,,4XYE/7KHVP#V#_.EM4GC@
M*_P0C;8;@2"##Z)ET@^M@-*7K'B8;?./5<(CEP9>LHM^V,46#%0,G0'< APX
M =:"BIO-FS@/6*V%<\/$F4VV2:'^+4SA63\,*7PT(:$\\L\&3<3*WR''7!=(
MMZCID&[+D6QZ!S.:(\5[M$FZW202U:V"Q]^3(+F>*MW4&./'FO#JIJC,["T>
MLE&V#[XY-6:H'L=6K6)2V-Q)]&+ _39>Q!P(>J3!.]C"ZFAA7T"0HWNXK[#3
MHM)9=;FZC:1D[M@G0R[+P<6"XL&+N>-%9H>B#6D#(?T1*BK/95%L!C".7)OL
MKF5[,[4Y_(J24YV:1_Q>L@TS #^YR\?-E"/^7$B3YY"1HQDC2GV)!JO/6P.'
M7&:QJ>J@3+A*1[$R162 -L*^4\-6>)9IWAH&9)7NN&4%?WBN)5!83K-FL<'C
MN=V=0I+:5>;Y<7-G@%YO$_$BATF3X67O>A[=%S=$X!&*,KQ3M8-\:W3V\@WB
MX,GG61.:O4.PAC9O*:ZO!#SEG3/,[Y'K=I/8CZXF5,R.)W$O\\J>%_.6[>I0
M.Y8!3-Y3G2+[PN[U99YA]$'B!?HA8P"K,O1D&.2G++D4%;E4S :K>FT[3^NG
M+K0>.MOUY-E#DUN1$<(1B*%JUX-M*"2XT0]&G'(N#4>7F\>C)<W,76X#"'M>
M:QSR27:ED"*CESDQN[*,H39E?(69-!S+[*XR9&*?<&/!^M/(\LP\I )EY?<R
MX\WG=].=O&5KU6^<]J*<Y4\:#HF_5!PPC* D"Y#OEOD+[>T#Z*S)G]P4>F5H
M%_,*2^B<:.&TM;BO)=2?HK&L\9WLE-V>&TWE]V%)BM7$.!PG(/8W)&=ZW\M%
MM;QYBU*^#_I[E@Y9 CBI>>OHVT;XJ?#]=F'M=*KCJ"#[V^->/^CVOGVC/19_
MCW:5%WY]AL]Q_A7<*L*F"2<<)]8JY2C)YOGN]4JB]=8E !CIS=@<E VU==G2
M/KDGXR-XN;+UAL>?;[4%'HC<;CT/6H0SKF:=&\WFJ-EX@&=C-U-;_8E'/.]W
M&'-63#KRM1!O,]F4Z%A7!%62TY@H8RIJ&2]-MR/IKP"/5"@"IE6OE:&Z%@&A
M%'7"A1S26^$68=-<C0/Q'0%SV:S45H+OA9O&Q,A<F)&!?L*SFC'QH3QCWI4A
MNG)Z%_O]GCOU)G<\,8VH.6.[J;D:@OUT^KC:;@'=[TG0?/M*X"+GD.IX0#'"
MMX :Y.GQCC"Y9X' VVQX,>(+=*33EUD#.#@X!RYZ8*#$K*<X>E \),FX/(]%
M,N7B=(DR!U[=.-I@RYQJONGIN@$9RNQRAZ9'1M;&KZ]PSHBZYA]QOH-+P+M/
M)>O9[^3G=4>^1EL>R:E]>,XUDV,##)Y_=R%W_KGE(3NL FD $[)74U>P6;Q7
M$:7I]0*!?!. O8",+4:&MWDWQRV%&_3F#I\6Z4"]Z*T9S.BW@*IB()(AV$)4
M]4PRJ0)":^#S<)47<>9!*.=3M3<$S7>$=I1<FY_"':J7P0]UH;;899[*0Z=1
M1&K-:RK/1? 74HLU_!IBXN)27T@NXGGH-XSPF5 BOZA[5M5)]H+,L7[@RON?
MYHN:^HM7KQB+<GN&=_1TG[_?X*C&DWA9645TT[1:R]?<.^;&%>!XJM!3H55X
M, Y4XBFI0V,-SQXQ PDKWPJ]B^D@''$%>.H'PNP. .R,R;]'2M]-N1BB-JVK
MH_!MI%RF+W$?U5Y3\B*FSCOVD^R:IQYAW\T:KPY7,*_%_&[U\>7)LB#]&%W%
ML1%&QP+1R]%CYB:!>HM*V5Y*SHO\+[2^\[6L 3P*CO">]@_ININDPJ_F#?1(
MG_JE]W$GV ]\Z_'>J"JF[G@^=E]Y=%<=.BKZZ0//&[G>[3TEHBU%U_+5A<I6
MC';R6JH[6:T$%Y9Q/9XRG2G,P[X&RX]@"WC\%96VRI:/0@_*&3YO;L>>Z>2@
MZ.!1Q8N7&*J5$TM10KE--A]E:)VK"J(6) W]4V$F8>(/$?@M;K!M>YZ=\[CM
MH<05;4:/<F.4T_C,U"I:2KQF3P<^F>U6Y.M2/=ZH9PKER&+'==?^@G6H_- <
MXH_C'R<_98S #T*$=',C SIVBQ08WEH\DSUH%<(,VSH"WO(<,D1,)B^9D _9
M/!R[<4!;3;OGX#R6RPQ\4T J_@ 9G>G[;.IX"'?&9HU*6IE\24I(;2P"H7$2
M=\$EWD+_B"]2QA#9!NM;(-M42N-]5OS5Y^YAUA  DB-[!6!J?K]KS..X"*;V
MA'3I2V<NZQ695HUF'V:&C0<:KE Z;VE:09N2"G>R.#)&I!X$_],S;D&#:-(K
M0-:\9S?:,>E R=W:W&R<#D#H_^:^\0=#]H60XP4"9,P50!_>;F DD4_L,R .
M0[7,1XEV.KR)'B=7</*ATCH._N+A8B%V]+1J<G2_QDN0!8FF\=6A@('/GOA?
MVW\EVL!SEO'\=,_PSGFZ,3<:PA['ER]SY*T"N^_Z=L<;FHJ4+6.(L8EO*R)R
MPA$$)I-58N3=Z"D-!3<-L>G0T@1J AKU %:0\Y%%:KAL]&8]WL%+1_;J+V88
M!$TQTVQ'])!J$8-Q=E&-I06DS&I#,#N-@EN"&B>MB;AQ/@'S1_%#_YLQ! 2>
MJ5W"Z"]YR H1$38J?A5Q/'&H"H]OQUZ#0-I12?QVFS]Y<WW,UK945;R7;N6W
MS9C.4]XB^L$CG-IE)-625DT*4)AO_"'KT^^!^^_"MF%5-< [H].[%T+#[:F*
M7F*VJ8&^&'? ,(-+$=7R8+;PM=HPR]! ?5)W* ]ZD_B9M;&@"B[-G= =I9"X
M$ZY"LN: RF6:K?.]F9Y<;^U&^Y6WOCJ'5FKP SUFI ?LC)'QZ[14C _L64E2
MG4]?8N-CS!#>9.Y1H6)JZQW=!ECFL\:G5,A;J=EN?$IS->^KM'_F%GF:$9._
M!8UK!F?-;>DHU>#HZNL15$2DKLIMW)S=]/;;"50HQ-&;Q;T33_P*2,0Z2I=Q
M2PH[S13P%% J-E*$TEC&XZ=R.#1*E0G<])T!B? :%MF?*I1O.0\MZZ.IKGV(
M+\I3#JZ1QI)Y-MLW^^SS=[#D!G$=,!$>WW:5YQZ63E"1GEB$0-%3)VR.55>
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MF??$M],;1-$.7X$%B#W7WZS]I",SN&Z!OR\QC%XUE3B33>?;G,QJ>#3H-G/
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MZA6@2:;V':'",]&G)?1=XN6%Z"N [X_KP&K)<'EC[PJP-Y2%(7EQ72930*X
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M1G&NKBV2&3I$$>UY!7B:9ZC3YI#&8'WM'KE-YT\VWVX7&SZU<U)KW/YY[3!
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MV $D!++L]!?*S[R:EG"46H0TJ797W/_J9!797Y%DZMPRW(VX C#'76!:MZX
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MB>=5,0_6LG(6P41S=7'TVN[?EJ0@I,_(^R0L_(JS2GK3S=O)V_32%?ON(SN
MX%MO#+W4N* ,Y>RJ.BKD>S3E L291B[,6K14IBVNSJ[1/LI]2R@+YKN]G9\&
M)UED'0SK33<!)-G'$,8KY)L,CX*8=B1P,[^/OR+$7E.@ "AQFY?:8[\GDC>4
M%45]C3:*]DU#'#Z"UQI4M:>070OV%]WGS]&Z6'W;[FJ*GJ>COA_;BW^8(".Y
MV_LHOBTV+-)(-GH0)T?X$#W,K#[8H325:G-#=BU6M,"/CY#\;4@;3V'",(K@
M"(QN46I[N%+V9_/;3Q+IF&;YXV_B765W]W;SZ.(.GE^E::2DF5X*8-^IH; 3
MDK_[RVVQF( 4*A9\2+;JV,^HHLDBU#! 0MC6+1\\W >?4J$/Q+FO43'_J8SQ
MXA/1>CE3V/:?WZS^Z[]!_4\6S"36]NHA3@V$;2^[H60M@C\G!]QM$5<ZM^&5
M'K*^ROP)??EEPODMZ-B_:QZ8Z$U;-^W$>N7YHV5<W@AH=**$@4Z/7IYA:?O:
MHK=)15,5TB@7WOT5^;F$^D;=['8R?,"*L%UH*<+IPW*\)SBK-ER_\]%::[4J
M)V_W1@W_*L5ACS"U-F QLU[4$2X7V"3J;65[SGD6?X.0)G\W=@]HKJ)LC:2B
MG;%V!@4U3!=EZ1>7^Y@.CX%03TAHM^5H_*]4;14B6:NB*L*NUMN]T:<\-=;(
M16U\0AI@*8E4)I].4VL.7/1R)7\OGAWI!K>GNFJUV#XW)XN_L5"_UNT+6T:F
M7/FS82PM>J;?\:E/9=KFC&AFUA4=A;7@3E0SE4/5GV@N&#;95_8$ X/L7F-<
M\HTKPLQKKH6F?K7X.2%($@_(>SKR,H8X$JEC,F0@B5TKH>ZRU:ODT4@YOA_P
M)H60$)86=.,11L<O<DKQVTE,X54%G/N>0HR#T/G-'J';6MFKF4]"V++DI_M>
M+.PV3!F38YJQR,JWX=WV$*-%H2GC\&$\-BL))24%%+^)UOQSF&5X0'5-$EQ]
M@>*M;N@^H#^CF4.LAC&SB4>V"F':?>H*@^(M;FL+#XYIM5NF=N%DKT;<>3EV
MNXBAC399KQWHG0QH3V5-GGT$G9GG6 TU1O=22O:?=?-M,OUR)R0\K0T$<I9
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MG"_S:1\SGC<$1WORO-P^%[DI"@\W6WJ++XM@QL95JDX ZEJUHAL?+[K41I:
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MAQR0*R>Q#LCG?2KB]=8;1Q&=C#"HK=(GT[:H::C)8PZ;D:FH._G<&ON>815
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M\9>9TP<HA]##K8>^S$/?-F$L@8Q73KSB>6-P=*=X< &[CUTEB<%NQNQ5*.K
M+7LJKZ\Q'!O*2 2[FV,Q+:^6G_"J= 9H>Q;CMU3G-!\]#PWRW(258TK72HT,
M%,&VMPV^!?1)J>M^O.7<Q="H+VY6T/K>6XZ.$69>:$?'%1[R$*[O3:9T^]T
M\755)3]A_#!X?!9R5V>DCJ?X5M]I=@WVDQ/></<N"VG1PUIS5<*F1\^98Y[#
M4KQ:C@M0+.>C=&FI2#1Q\C3>@YLR3(C4FOG6<VU\86'^8^Z-]%-)F"JXA=C=
M&G&R*28UY H3:ST4)&:QS9]0!FH?2LW9SPXJB$R0J!N^K1S<J^<R0QFG%'MX
MM7UNE;C%P;(Z;+U-2/E!FJDU#,>X(-M&XF::>L.(MVSA^VY0XWA&Z;!%M.F+
M9[Z.!A>S5[9-S8_,#3VL.Q/T\69HJT?+O,)%=?MJU_E88"Z#I/Y*3&\:Q+9.
M;7%6!4L)'9XX\?;2XI"5R'>M@\)5M/A[",KJ[PZK!3@%P2D"A8 I[].)L!=@
MPUZO[2G_X7SJC[*, 7]F&?LO9QD;P-S))0EI$ F![,><AMAT,ST7SQ0^OB:K
M,53B4'=QH=YS6"_:@7_ZZ9R)GHGR3HL%QTG7^,#E<5K:=8Z<47YPE;=UKD>H
M:F3?;3YSZ#73G S69U7=M&Q3"P5$3D:4[;#Z11*(*YYFRP(Q,)]6URN@.;M&
M,@HTOF!"=BD);)EOYZG31FR_04V4.ZSR:?20F>\>C6[4TT[C_0Q$:]89H*4=
MZ802^MK0>9KBM'P&L+7?.70P?#K;X;PQ4\^LAMQZG:U@,>SB(/%9IAD,M@A+
M:Y?*&:F3S )ST:\GR@;NRA'(N-K'Q.'GT[]HOR+EF5Q>/M92",[/*TMJ_F@H
MUYP5<[M<6QO?GV"1KN0226=/\R26=._<.CIJI.>@A!R73*ZL^@5$R:5129\!
M&L"ZNGJPHT:JJ"NM3&^>XIGWLB=O3H_1KC"POTXE1UWH7VEF G^9>SW9.C&]
M*"3HY:FO6EJHR%3Z@9:I!^:96X*H!8FU"QY?^@0FHJ*&]R)GIA3$"UCP+Y$1
M=#@-L"8C:NBG13LU7LI K2&N9!\<8]N*,X+OXS#(PZ@G?.+S[.!C!VZ';IL]
MLN+W'T@^DF-;,]UP[K5W<-F41P05D@3V<N0I9HN+QHXO?%N>3UH\:;R+L<YK
MK-=#0L+*4J[,)[L=P_:H$H,BR2<-)Y2ODQ5FW) RSG/$I=DP#K4TL\R=Y((%
M9E-5; RQ,9.F'^.T2TL$9DW;$>8/Y.CV>+X==[Y5PQ\:\?8)+[N!,@FLERE(
M5*L_%+DB_ZE.+F+ALZT1C6F&NW4SPZOID)RY@2,V1M 9H*30Y)2,HY823U P
M?HQ\2AJ,ISEU;;@K.M!6@>;BJ\4YISY-=X>0SG?=\R5T-C605T\U'WUA%<+:
M'_*I0'C>=0Q=\ <"*#UP:9A2'##L=.EHK^RD(RXZ<@>F\0<$S?'B+L\4>WSN
M<51X#.DFBI :T5!:FD5)KQ/L%9U4+0[ML6<-NJ 3=<TXP+:,7X>%CW0^J*<-
MY5ETUHI(!NO%&J)@GX%-QSTW&=NC*80V.N>-]I]XJ$DSTB.7*E(M=JUIXY<A
M1QM\,?VSH>3H)Q5K$_#[5"%LZ7]Z!/YG)83GU[C)D+]&&_]8?H@Y_O5^<9Y_
M1NU[)#/1=TI_C5@V59<%T'P?T^W.^IU^=7PE)J"#C)S":='-&-T<#WWIX:OJ
M05O"*P)#@U*4]OPGH+L='!Q7;&"P)_3F(;<FWDNDP?3/6=YC:_^5]B]QTZ1O
M>.-,"<2O>8VQ,[6JX;=[5MIFM#!8[&I+\O3>F<GDFL0Y _B-Z9VS9GSS78!?
M#_9ILGY1Y*^!L(03#6HH"";"\U?G+CC#'SAW?;_ZB^GGU5__U:+6$ME2_4Z<
M0ZRK5URVB.V)@KIPTRE[&C+$$/JEN^@,,(O"4GH75O=LKD-9$1&Y\=40](,M
MR54+.'0;?0:X+#E/7G4&R(C5.P,T+F#8EHQ:)T>P:NT,LES/9I&OI_Y&@P+:
MPGJ^,LO<_G0&@':BU3_7!E<68-)"1!.5OE]A\ALB9X"7J@O8(!5K[!D@$ID5
MYT[BH'DD2>%*H?,],WI*YRE1XL#I&8!I7AYSTYUICQ<L>8B!!@(+J[SLTKK1
M6?F9U= _D_'Q+S(RQ7W/U?[/I:SX1<H0_:7&/Q,2\HN0_#I<?R*DYW<A"S+_
M12!5*'M^)]3OR-_98IS)V_%E6[<I-L"2BD4>TPJDG6 E6R)_0UY$Q_%@7S(6
M):\I^Z]V#$?\[W3\D7J$UA2H7FT1HSXR:%CYHX9,OR'^K'C^KX83\A/ GP#^
M!/ G@'\',/\7 %?^3O".EQI1'\25HJ]DO?2E:8?06TJ(>:>2B([3^U'ZRG,)
M0D(*\L?+]V,G;XT<%'T]_48<#%P)T#7YS5K%H[A_-T>Q?8*GL?>?PUFL-37P
MLW]^&OB_ X#2);$8O=^<5NR=4XQ-.WKW%TT^+J-5,J?46'8-I[HYPXRF_<EZ
MG[,D.R?FC[N*H!CA[Q7E41+NB B.54GT8U$2S,$YDP;-,\#K+"SEU8 S *A8
M<OO-&0!A=Y3I=&I<N8-E'4A6;_?!_YZF^?Q;-76,Z? S%,4/;<GX ETI[SS=
M2<.H  =)"N%8D[:CW1#ADO3S+=JC5<G=B07LD1KV=N3ON"3>V/><[4&G23C)
M4^XQ8>XPX&.]#*&S[&> ML'?\7!^(%%B< 0E7^EG0S2<BQ8H<TY[ !QYLB2)
M3I3\D4F$3?#H!I0;X7W4#M3Y D7FNS =;9Y;@7?>&8!<_K=,^JX=UT.6,&II
MPEDAQR2_5=KF=TQ$,IET8)C&U[LK%$XFYY+]J#33[[CPRZSO-R:@)+S_'%N;
MY5<^?X$VI? W'QLE<K\3H#2-B+_K6V(?]S;5:%KO/?\,99=^'GB$3?@CF%6U
M^ZZX1,C! /KQL1#FU,A7\;OMYPTVKJQO[*@A"P^B1:"?4 R-Y&VK)?;G9-6R
MH .C8XMIY_9WQX<>ZUO<R'*.-RA;YD22=!(EKOJ_I90U\4#R/T#HH8X6<O;O
M!UDE]YD(]\S/ -PZ)C'00&4PLD?U8XURJ-'] ]IA,8NP]]'1 5V,;Y(1PSK\
M.?YM]YV2(F:LG__S,:T-+*S^=O)SVODY;_\$\"> /P'\">#_[P"&<'P/2=?X
MNXZP<"$U!XGA+J_)PJRJRG>.)TEK>]E#1DJ!>I5%#KN29^/_"U!+ P04
M" "N70M3H^>ZC3*M 0"U.P( (    &=M86(M,C R,3 V,S!X97@Y.3%D.#5A
M9&(P,#4N:G!G[+L'5%3-LBB\R2!)<A(&!0$E2<Z,B(" @&3)(I*32(XC("!9
M0$#)DG/..4?)43(,&8$9X@##S.,[]WSGW'_=<^][]ZYUW_^_]Y\]JU8WW5U5
M7;6[JJN:WN@Y]"IP5TE>41[ P 0 C-L?@%X 9 %\7%P\7!Q\/#P\ @+\.T24
MQ$2$A$1TY!2DE(ST("9&^GOWF%EYV)D?<+'<N\<A\HCK"9^@H""(74Q*E%^2
M1T"0_P\B& 0$!$2$1+3$Q+3\]^_=Y_]//^AV@ P?2Q'W' OC 8!)AH%%AH'N
M!D"W\\3!^,L#_/7!P,3"QL'%PR>X0W@[H.8N@(F!A86)C86#@XU]V^M[VP]@
MD^&0W^>3P:50-\5[X$3)[Q_S Y_E644'E<8XC%7@[8< @CO4-+1T] _9V#D>
M/184$A81%1.7?2XGK_!"44E32UM'][6>OMD[<PM+*VL;9Q=7-W</3Z_ 3T'!
M(9]#PV+COL8G)'[[GI29E9V3FY=?4%A955U36U??T-C9U=W3V]<_,#@Q.34]
M,SOW:WYM';JQN;6]L[L'/SXY/3N_0%Q>_2$7!H"%\>?S#^4BNY4+$QL;"QOO
M#[DP,-W_&$"&C7.?#Y=<1AW/U(GB ;\_/N6SF!\5'00L AHPJK<?QN]0LPJN
M/83_(=I?)/M?$RS@OR39WP3[NUSS !$6QNW+PR(#P,#%%>=7.%XWA !AH($:
MF7%UK%RR(_>$6,:C-,<VM:*F#K#6V3\AU;W/I4!Z8>O;=&3\DG9=-U_V1/PH
MN=V(HW+#.#(P_P*]X\WJ61[!>Z@%Y9;KY_,^K2H3EZJM!AL1/NV6\5("!I1
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M5:<=[OU(;R&_$B/XLDH"?#U":1NY&HO+<'IYX61#<JYEJ&_3X?]1-404?1A
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M4XRAL$6L+F=%ZJ2B7M$J9R21N1MUDS9ZC#>L0<R>U+Z5WO/E, +=JFZ&H)L
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M89L'1Q?G0RZNOX=]5HQQN14*=H#WLZ/HF?%GFB@_V-]HQAP!2[4J)@@)]K@
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M=2+;\YHU[&X/I_TOK*:AY=G.EQ)?0*Z+&K5Z0U)W (VVHR@6L9.@**>LDFS
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M#7?5=-/SZK!^2.\O-TQYK]P!?,18[5Y_P.^18;4V/N9I%LOI6%U\-"!?EZ!
M"XZ2C644P#\,?&@YB^)Y7U,YO6>!YV97MCC@X4(Y2\L;^" 7X,C5&^"]O7VH
M!,=2PB43)YVM[K#U*MLE:=3')1?CAZVYTF&^PB,SYFJGG[X#7-.YY_9@P239
M<C8^^_]ZV7=TYK"<E3KLN:NG4\9.TV5;N@L]2*[KH<M7)/PD=7'L47!]_Q0*
MO8FZM&::*2Q!-A_@509+UHUY"AM8 RS\(HPN5=6/38"J*J.^5(56IF>R";#;
M@ZO(IJ;>8_H?:(&%=8 U@&GC*Q9M2^#"-=.$/>\%N&(_VE2,^LT\[TG#S>3;
M$];X#/0^C/BL*:AU,OZ.KD8!$$NDV_:I5-2-O : X+!;1>1WG#RBA_X["W-P
M78C@BB5DNL@S0.]K%SFO\+>G8RF_![" :2R$J_$M'1CJ!D'Q.I[NT($N:$$3
MY7AM3RXE5U]T= 0=!K93ELNPDJ4M-6;MI%O*U%XME;1"6Q*&RY 9K3IW#,!1
M$I.Z?LCMHZIQP]#L3B-3H"O%0'+RVT"N^N:FS#0%>K.IA2.%<H_5GA1;MW)4
M;/?T:+,[-+]/3PRNY?J.>QAM'=,7V*Z54UU:K(D6!'_\4^/CPP\ *L!/!R>Q
M,F>!5D!=ND'35!F?G_J[M!-.Z/AOXV(N=$"<9$>O4X1=2F<FDTKMS#Z[/<<X
MCCT^T:\4[(_[K_2?/V'S>*XPPC<[)J>(-[AQRHFA Q=FC"]DW]\HW6'  2W@
M8I1HN&_%?XV?B8 4H$SG56;X<+075)R< C!>OV>8_T*GEHW 9&+B:Y)!J_K5
MUHGU,,961,E,NV:<D;Z_H,,E3%["2X[B.V5&H(PU/.O1>"T%.S_%I_J)3Q,D
M=DG=B1?.4GG&16(=Z'$N!F+L !=ODJ_[K@;*?FIZ\XN*ZFE<3YI:XGC*C+=,
M P'HH@A6%;VQ?;=]XL-W+=AV![E<_>"5E7/,:;!5WJGFPY;A=P$/=):VB1LM
M;G.+#%0LF5)MBT0#]:46(ZJ#)G9.BWD=,*#6:953!X>'IP8RSWJ)ND]^1KWS
M#KX'=O@CVZ(<X(\R]GLKHE4GJJ9_&*_%D9-IJ+<[QU1)M_F]5/:-:*25Q\"-
M$'O]I )M!^H/PJWP\ @H@3N&X!L8#9M;=:SL4[ZZ?9#3BGA8UIBY>)M:"D_C
M30EU&Y]]3\3H</A,$JVE!\>=]P,FDT0@KP<B$+% [=;R,]724G8P9K7SP'2N
MG]XE;1R)%PIJEK-PL'5AJ\HC435@"8M*CH8 G/&(:F0>5,7:KN[:JA L[_:S
M%<#.2']Z]E,0,CK*D8V(@ZW%J2%CI^R&EV067GQ"TUX:R. 74JN.PL8>0Y]5
M%=!Z^A%K\NF=XU:'8DOB"Y??!%ZM6GSY9#H?%]3#[=0M+=&I*#)34S_)EZE[
M>38,$]H_L&?$'DNB7>'@#W3D=DK<->@F/"/KA4O@@3B;%;Q@C]V4WO6J-<A/
M#-=^Y^A6_0+HP*#FR3@A[;9!>702BY/798EHI5D?F!_;V]O3^-:TG:>6.D<\
M$WL/\I&:N);+5RB ?[B($\)^+6]N,O8]1I*Z-MQD!4N;3T3O1E%SBB_\\_"N
M1ENZ]Z]% 0#@_K$JN1.JO3GE<KT#X,Y;+]%/\]5OII;S23Y.HJ!0_ZU6"HDZ
MPA/*542<UB6";,DSN >/X-5R]"7K=E*18+OVD].ASV-IQJ?$_S:']G]_PP82
M!O05E@7,?%^^1*M(+]VA^:=^26[5VJ< PGOZ7B+:_B>B^U\S)Z8&9Y005[=R
MF0*[3+>1-K+? \)IU+K^+@58C@,J$F_6WI>(ZER_OV?=3_[$W_F;_PWW'T$
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MH<N?$RD\ J.2@G8J3W[1ZT1?DV!F4+@]X.IM^"G2A+/M[4=6P3MF.MT<@',
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MF2YRZH#*IT=0MC ''0WI+UHHE_R1U_*O(I&R&1(^Q7!D*PDY&232#QNF1U3
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M\&'QTH*#QS(DB%@:AN@9PHB'\40&>W80&Y$-Y^OC7%+T37(Z:I!8CN9]?AE
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M!$3N5R:"HLAWE[X9NO+T]GCE+U$IH ,EB.SXI6(.3945M%AA?52WF&-_)?5
MFEC^LE$"+D'_<8@YB;"6V%*JN_VZ4E;J0C=)F\)0WA)+>*60CC0C JFM*WPY
M^OIH"-X;N_UL#W0<^&GX KH1+(T[HY#$&2!XB$((?)#PB@16G98V7QE5B)$A
M0O#066R:KT?YQ7(=4B/NQN<I5?) J")X)>J'=E0:,)';5*:E-200-\62!</^
MLYGJO^<!*S.MWF(+^YK-A )R&N'],CNK#<9X170HGZA#;?:%GE!PR&FX#9SG
MMXGB#Y ERC_0*0?S^@.#;YP8=83?VE\&+]O<H.Y<TTCQ]#[&K@S &^K60*UI
M\)S\S;L0 "0V1N(ZX_>/=+Y?>AS#^!QM<GV&X34<VP(FH:C5B547(S6TOW"+
MT4/SH2PS)OLPX"&PSB^6;!0I]!1GP"/4,??@R'W7U7@&:X<H9$OAIJ>T7:"7
MA&]7< <H88'BW9!'+V06N<S )='$I5[[<@X@%"Y /-K.;ZH25*B =T2SQ6C7
MB;XR&C0:M7:\T2N#_-P^M&IT)V:]9_,RP*CU42O\F.TEG1=>7T-./=:0Z==/
MS#3*ZW0[$N4Q> HS__"B.Z7[)I9N08K+-G]S#SIPV;L\+8EX&V!&\YL$.36N
MZ?ID%?N>&%AO4&LRL[!$,U5;EAWM]@N_$G9]OXS9#,Y7:\,J #Q.0>I%US.4
M;L-A(7%_I%/$33]<J9*7>.J&WP.O6D&NH\=W\$QSDX]GL74_!0%H4!Y^Z1ZX
M<X;D]4CAYQP#"X!W0)6!&/&;]('?)KA"U"9?4+BS-)$ZUDO7HWY3E?QI#CC'
M,KY5HTM0#, ^_SMWTQW*6V&-85PRYZ.Y]PZW<($$P]57H_MA= ]=@NO2DME_
MAP0>2!P.U>P+-6:*_1$@ *1=\O0]O4[D\ZD+2FJZGLM0 [IC<,:6?UOZRHNQ
M'Z^_/?W>_J'\/#_($8-FV9]_(K\S?)OZ+]+_CA-E]W$"?KI/P]4P6*K$1QAC
MDAV=Q? [*1 @%.M^H>WYYLX_ AZ&]?[V#]%?<7'_I^,MR/Y&S=UY4VDM\RXB
MI PQ^%A TGB7#]57@ )K]F)0'+ ]Y2_;>Q3.DJ>P6P'*A&PI @$R7'KU[P-D
MR-$F]YM>RCI3?9D27==Y'EBEM7M_5QK*FZXV<>@,X?M&8:LMG4'ZR_:KS.29
M5Z4WNW]0(NUMJ5RZ>C(];F@F,2;@'KAO2P-:E68>^#ZF@I^1'WY<#G!1Y80.
MFJG:_(YEJKU!Z#W.O=9&Y$.FBV@/*P*%'T87-5K\S0^R@/"(T#PE\M!\]2G2
MJ?K8IM 0@P=(7004]8.46?3>T&_OQO?ZFRK:]RE1[Z@?Y.;*]SG"-%XL'XB*
M@M'SP76SF;/Y _?V4PB3*@U_2S+)@?E5K^OZ@$<_4HKGAPYWZ"S'8;/O'UX@
M=Q<'%8\V15_@5 ;$R) ONZX0/TA>KS!5B7/H-*P+@RK<:WPGN!W5ER$_=>]'
M+H-%:B=) IOA=RNT9TOKVGQF9HY\\6.#)/_R#AZX%-HSN.J3$?V3XG#T4X]U
MJ..F.)@W4>_KXA;P>7Z@NGKY"+H@E>KO];4V;ACX*%E?+PU+ZL7AQX3SVK,(
M2AT4_C%:)PPJ(4%3I?H8W_NY-#'-= L>M6?LW0DDH+'&#1L@G-_Z;% 6W-RA
MV=M''7:WJ.Q$9RF!E^) 6_!T.S?Z'^X,:@SZ:0T*I!^DYO7 >& '\6?'X0;!
MPY.E_WXL6"DSD-G7M]@5'NC85/OEF& @(Y:Q6!S63SIN;C8L^41X?B/#-!FT
MG/AE%*>!\K<.1$%WWS$_7*!$7]TOM1)\K$8S_' RC0@%C@8A#0\V*+Q,-@L!
M7>0Y//']=\\023#!Q\(%E31S3!5O(2&KE@VLD*N<JSWPSRZ^<FBL=N:^0;[\
M_[",?^EJK>'/3:Z4GPM;1X]%3CMLN!H:DD&^MV=:/BKA"9&3!4^TBO0+3YV2
M)9S-A(P1TSP7;O,%\WH@0S44PF7M'NKC!8F#ER%\MEB.Z.Z6;CL_DEK6@8O&
MT<_181 "'333@F;#$<@(Q<#G(KA!'B?9-*E;"*,(8?K#LJ6\%CP&^3 (4>_0
ML\;%M7CTTU/]B\C1A&$^$@1F6BRE)+]$^XY>B-R8N>\T?"\)P>=I>UW%$M1=
MK3YMLHDI'T8<HZ1TYYVH'+Q:[OT/OI#&6<&._HD!K]$Z?EFWQ1\SJU4SCTG9
M#\Y)'3S;C0J-S)]]K:-QZ8===MVRZ57]_3"TU,1FIW&'5$:M>0^-?9;24A9Q
M%D?D<NC[-R6.!D&YZT?96:F+)<\N*?#AN]Y\/H"2MJP?I4">RF6\%U*48(('
M\^<8 [1!R\^HP>MJ]FA' .(SJH92A>=[HZI;4!KT,L#1G7GZA[5?7WX"?#[T
M"OYBT'3S>QO//A-5A Y> &.ZD$A;&-*I^(:12,0[F(]&:$C4T0):@9O'N>$*
M,T!)6/KE0]*)8A#+B5CQZOF<_=FO4*T$;\$1XM*WRMD]4F^\@J7Y!6@6MJZ$
M@?AZ4E@XG77%;9\8,2-,LCCJQYP)IN/XX8M&9V)699K4A:V%\6\7FOXQDI.M
M;Y+I5]SVB!]D0#@Z)R;RTRB'NC\HYUPHUM!4.7/9T;GKJQH(Z@5'UR757I'>
M):9N2CIPWKL\-YES)VH@@P'I(93?S__;Q+. _#*AU@Q,I%.%DU3^%UW,U-WE
MOBX>+G7,,WT:][$7:&>4,=[^;,($PT><90$HE"U?K=O1D".9X*$W'#]PVW0:
MZ;H3>D(;R-0*>I2G@G'>LG(C>)>)-7T?$JH4#3I"?\7ANW96HL529;6X&'#E
M ;ZDSI_JU4>_#&[I'E9.MC9_>!*C70^DI.A?*8EBB"&#%;?<MV[^X?WYE+(I
MZA<X%0'G.>@'C0XH[8 .XT!O,D#F*^8H#ATX%UW92)JYD+V.T?OJU@L4;-(S
M=[4(W0R0@\G'<V)M8['H(7@LF9%56O[K1^G!4J4^S7*3=QFI^;K?:?$W)$!&
MDG4D9$S3)A?X5;B6^7Y3%?E5L.D^ )07^V-\<#&Z,!]-\)"H8QOO(W'P5C>#
MSM; 4N]A<>79'P7J\GTZ"MJ#Z/Q=.A*(TJ,)Y\\SI7J6_NC.UKGA]PW38R'Q
MJ>XO)CD.3\ZKM1N#8BYD+B#QWOK.AN,]*;I=U[^S42=)F\A]-C+LM#D8W]YH
M2)+0WIKB^[DU<(@;=@K,/.ZJ,EQ28(0B<?H98A4!V,%=\I5WM>NK]5'##W<8
MT HW7X_P"P'UCB6 H!82K[/*(!>9V,B#QU@V#W]B*<;28G<%4X^Q(9EC71G$
M20TS,2N-,N)P1S#NJ#$G]9+SD;Z6VL?Q96XA-.0333'F[,MLXC/)4M7X,9@7
M4OJ( 7$9/42-T=%$;W]Q1[(V^MWK9!%8B84' I9+B<>H;<3ZW9K]Y'N)8;;(
MJQFYTEC&7Y^[,\)Z&WS@>5#A-3@WFK:Q>VUH2_ S %-R.+^LEEA@27ZX@(PU
MO^XA<O%/PIA@D'[<PBT(GZK4U?W;C-$8@5FF[B=QQLRGH5^X],@_<>4Q:JL,
MZ^WO[<TFN1JDY]=_ZJ5<WJ<7?TX1F)W8@G^U2=IL*KA@MIE]74I5T)E.5]Z]
MA#\7FAOTG/5\-2HS&G)&3.W=0):$J=[B"N?EB!+9U#-64O/9)XLB6(ZK7=1:
MIG.?2?8;L3[S$V,Y0P]SSMIPM]W:SYM^&7LWQS;N'Y4N/DTAWO296+-\1CW^
MS!OOQNZ9JVU,$-Q\&:@LNV];AJXQ7MJ6.2[LA[)\_N&8_U6LU4#C4XG5W2 ^
MQ2QHCL/+(Q/Q'5-S)@R+ 0DLC4\!PBZ7[W,+AO@D*F\HZ@9(?H@Q,3*^KPJ)
M:2*M@U^Y"%"&9?/%_2* )46>(UPRY6W'!8JS#C(QEZZK*#WK+O"/6?JRS:.7
MVZSI@4$7^=!S+A]5U)SS'--Y<[F1U?H&$T^PG$]*YT2<T_"Y*%M@U0>9_:CO
M1]_Q"EQ<E +6(B?7]TY2V<1A',?2"\@HYJ_J56#;P;JJVE,;6N1GN=9&9-V(
M)1^QAY<YQBGD/:=UT>4W$'(OV6E .I<$Y.=>;(E^-]Z!3+I1Q\6-MR D;(R3
M[]-K4:,72BDOFB!9XH$%O:<OZH7,6D=7@GT6&_:5\E,8:_-B;2PZ!B/QW)]C
M@$C&"^07$6";!$B_SQLKX=V"&D;3!POR[W:9R6#Z&01KJ6= (:#S:#8G#Q%_
MT_.5^UB'5_DM*+\W:C\=4=#O T<HYL*9DBK*PN56N^[WH_D/Q:AM*F-B%6,4
M_>P/^U?&*1HH[:!5'Q/JQ9Y8QG[_=#$G5W56;6WR-!36.*<@\UG%5$THO\C+
M7*>#G)M>2U :Z01.)NGIUI 3_056J-G<V.M4;1_CFJ#X*"?*XX*$K)ZB2>WN
MP(+MTP=:N;45QK/92YP58]0#1PDDFTKU%6#G$*2'8J^?9#$X)TE SP) _2Y,
M+-]'\RQO0:X*\.K#Y87XFQ>V!85Z*6KK/2$=:I2L/R1^NJF?B4H(%G9(5@L4
M+JY=O=X;:[,"/^KUN@[,&]!0[[*D8"X*Z;CYD+MV"T*7BO*VZ9[*1Y6]:5=W
M")62*O:P\U IG)T"LD^@5:RISPWA69Z\3)@,B9+ "!6GI(^*0="TY;:F4O8B
M,8[V)SE'3K2B. F< ?5<F%5YDC:I>NM:F"\9<\F1^=2K3F^L&(KS?)I"/.A$
M7]$>ARR8J/N3(JZ=1#E>ON&0@3))[S\$W907OE9Z]Y^T;9V"545'S/4#=LK7
M )PD!^XU[A'418P_<!<R6S_OSY3WV"NM&V0)V3O2B:.26!!;CWU]>9I?OD_4
MNX\BC7R.N,P4S>PRG3 5$,>Q](UW+,)!1Z3.<\'\BXMVJLC;_/3R)H>H&RU(
M3U\#ZV:[6$$F>(R1O<^O<8H#A>*3^1.&W U!-P>!^7V%([OM&Z'16]"8_$#F
M<!Y$7\6,&;(0T; A3I=+FDR5$;J(A_UF,/W].-GN.TZ6-?AZQR0/%\;TL]PF
M2Y/8[1KM#9[L4*/,\-#.PZ_8[C4@V$RGE5V]FA$!0J,+S9'A'Z97<K'&&I'G
M$QBO<B:.04L"P_GY-5X7B7,H:7K6K"V/5NI*,F?%5IYT'X/VE0(=W?U=!#/.
M#%3WO$X"#2.54?/ )N1M7W5](RKIG8YVU0]=Q >?CDZ)FQ"_^U%):L!4P:0S
M4VMF;S.5>/0@QFB?8%':;TP+O:K$CY="0(/S9=!J6#?&(_X:LZO<Y/T^WZEF
M+=PD>>]'534HQ5/?H20ZQ>V"#$G-=8TJI1%7+Y>NE48XM0S'3@@"N'97H(?!
M;4C*BHOJ576R^9-0LUF]H*1TR1QNHD\'[9VH2\$LC70Q1MC7-E7,/IZ:9PG9
MZTFH?(*+])I,L\[U<D+>TZ40C5P2WEL0ZJ;6E[0-BTT>]LC,!]>]P_0O+N'P
M"XD1"O=N00MJ58_4%2L?DLQ_R8?P*B4UW\#O<WS$%S0?+)C\T63=S=BB#R.X
MVWAEEW],::)CWI2$9K"O[6^;S[QE"=;3Y51_FR?YIK9KYZAITL2^O8$LKOF&
M,$SAT\-8<"Q-LY@8GB.VM'2^%0G28&K_#?6&DX:@U1BXU(=4CC7L+#YV^*P-
M?M*-1&/JRT%/E%)G[65U#)RQL[NFZ-S%FEW(!HZU!G^=LH4XC^M9J)"J6QHW
M=B!DD39S?R=E80D& 9*76JWZDM?7[JGG%)$RX=(NLI$;VEZ TXV_&6,Y(YVA
M)I42[RH<6$E9L.TK-%_*.4O\VY7POEW*XU5U<Q3H"]23J![RXY33XZLOUV[4
MJ>+9XVU6C.GUE9*>@U01KTE;N+-G!BF8R1^!\1F@(.4X!YWOL52E>S==N[*>
MVSR1:<:5K-JUF#0A8W:O[2;5@S.L:_1SG9>0R1=.@G.DR=6UZX>TOK82AIA_
MS1';LD \SC1PAIF\1M4K;RQM4.*(LM!XM/'AJX @G>IN/F-&$/Y.BI\XEW"H
M4$:#QW$ASSY'B,[\+H:#NGP_9+2WX)AB:.?]E\^QW ]6OF1-(K E/ND_VL41
M:,S?C-QTM&?*Y*]S>T_=X<=:KNC*HQ_8 @'FB1M0Y052]-Y%KG+[V(>?QS>L
M56E>O5T)"&#ILXY=HX@@"TR/&$$748V>?W!< +O 7ETVQ <VTS-ZH[8]Z!A@
MI?Y(1+J>.5#&1(![K])[)P8HP<T$!JRMT2@0Z\H)%2YU0\'$7M,[D$((<WA]
MQC!KUGR9'#SL0=;R2-F:F4 ?XW6.=+PCY(7W56GL3_EF)P[/0F1IZ1I-FOJR
MD$X(_N-0#]9&HYV&M/U"OE#4)QH. B?\K"V3B97,4>0<A0SJ2(+4O2C2+X=U
M!L/L\+=#-5XCD76S&>IR"?4\T F8=QJV&SNQ#^@VL7^XE>0 ?@IIU""AAQXC
M)&GO136?%5*'!/;VO#*"1>OA2PM)LH0NJ4]6^&:>F2]*>^H.Y(=V;P=;FUM]
MW2M)]K>8YIT?VGS/*/VJ>I@AS\^_MM8!Z7J.0RCF0G>X71C=,6.LNWU[8HFD
MNI!MS]LWTZ%YL]6IO=XX:BA!SEDLU$V81=3K<5IE=EX2SNMK+X.%0L2):2WC
M&M?1-.Y8/%VXUT0Z]B'Q1X]J2"QH[4A^YD]I3\QZ7U).XQ*ZG48\=7&UE J3
M+_(]Z70U#6SL;I%(WKG9U:H[*J3'B8J<I>TW=^&>[Q450[0IUB:B@U+66MB#
M'.F;^LHU]]R]CWJ5V]U8&X89=6I"&148R%Z&X"/DB9&D+R6=@ 4:Q[[&K!T:
MVW&<PLPZ3SE\,Z\E[,J!KB'VJO<ZY.]$3C+N5/#)+D@F*"'EQNA+?9@Z#29Z
MX_:R,HM^_/%1'YRTD?7\-9,DX;GYMO #N479+Q9<Y_7MS]W"&17;3XL;_R=>
M\ ,G_2]NB@;_XW?9\?U20;]G8"Q%DG=_E9/^\<:ER3^NO2*7$&P-SOY@_GNE
M[Z\;EXHD##=46++@AW^U>H10ZY_<8#0X^XNUR3:V'+DWNZ3*YV0\-*DQK7^Y
M(UI*RBVHPWCJ>NDJ5^!O=_:>K#4#*90D:_3WO%K@UVKD".IBYKO-T(0^W2W]
MJK AJ23=(]U4&2E-/@8FR!ZW(#5IG4+8*X=;D"9R#DUJ\@7:O]-S";!)HWS8
M"XUH6OZ]ZB+E==4(Y!@2U;PO*5"'AR<%/Q^AHD9"J,7+R_0W!JA0?ZHKR#SI
M&+EB3=T<!%/E?FNRV7>%ACAJIV!=:J.LG7 :V9IDJK?PO#S1<QAZ*!J_?6$0
M.YSJ0:MBI,2C%4>2I&="A&/Y"0>+E.9AJ,-IY]7FB[$F ?S21/'\(TFNY:_/
M/V 6[-39]=H W!"^P1\P*U.Q<3P:IQB:GUI1+[G*KOS&S_*F<>^;5TX+!/DD
MRIQ'+4O,OI F^1W(:0F[' S24S^S%RU3SZ@<2O;1;"V:?JB!B/[R@70%XM6&
MZ !;)YOTEG*);]D VI>M5I<X># TPW! ",O<)@[YU2BA2:W*ZB=\#+&!+X\[
MK-)=Z2H*%Q)PM4)IV:4XD#+]=]C\NV[8\V<CO^++G%F+?F36^?*V,I!91Z5
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M""ZLF^!/X?0'7HZ;Z#/0A12<^"OM0<\5PT1MB-FU/=T<_K9;'3/,^.$Z[CG
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M,BOHO7&DN-!!1GF6WT"I<P3K GF:OV>1KE49R((YQ(E)1;Q6S_N(+D2H!+I
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M^#F>O#@'9%@8DF,>MX4I,"$.TKZW"?@&V1E&(BR<#!^= ]XXJZ)66BEJ<OO
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MY)T1Q('CE*\6J9-EXI%R(HFZ@#(T82]*@Z%EAT#'W&7/+4A_A&,%29%U^L5
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MF_X-5?(']M#LAW"2&[++%M&$N!ODB!O&0OF[KCC2U@$^'Q,NL%L5UL6^:B>
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M&(*=2##,E#-\K,)_K&N%/6\DPBWG*U G%GC!$ XUR.^TFGM3:GH7$MCM,:[
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M[?E)-^6QUAG&R1H5-_ S0DC^HQF%\"T $?E$1[C),!%W5V"Q<J&FJD;E'41
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M#D%+G)M^ZT;]$X9^=D>&AGY:8S23]VP2)TLN S*3Y[2P,\];P'W(&-MQR"T
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MG,U"J=\Z('@DAW#-GK0@'IG2S7@-?**)71/?W7WQP'SV2>W8CJ/+QQMJ\KG
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M5+B'Q".]3"JC'A?AD\V(P90-7G<KP/833]Y)4U0P[*1[[NZ/BOQ0[J87$A
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M[Q-],6\,1+8D[Z\\#CE8?MU.^*V.5'=2!97/":;M5C#+GYM#%Z.7T:56IA,
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M)L^#\Q>(OT#\!>(O$'^!^ O$WX%X]YL(6<%;/X&<62^@9B:Y\#Q=S+B.'/I
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M/S._(]RSD);5]@SVVBS (ZB+-B:CI'#_14CAQBW@(<@-N.6,?^WT/)K@Q)[
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M,LQ6$H1J!(E#==Q:)SF_#6V*R_[V#\E>UU$*9RU_K99;@+JPR 7!M:^S6$$
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M[3*W N'0*VY\U\E]KX^8FMI&%6^/E4\;"'QZHCOJ[^7C&M)XFWK:4TB0I*M
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M@%6KO/C'MJF6@R/0]T^D/"P&>0><'UR_B@1Q<Q_<!M#X_^'RBR/?:KKEI^.
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M=2+5:3(/BM:1,S4F9THFO!ARG8@*DK,=[95'F>S&U2&PXG"\\D%=-FE\,YS
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MJB,B&:QN92O< G%AJ3\ATOB ?3Z5N:!&E?E:&X176>YR-VGX_P!02P,$%
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M)?$AND$+SX['K4\NF8Q26WGUYU18I"+7CK0%.[PV@+F9:B=M+2+,:.PA"P;
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M)+-8]#:SF*O59@/3VK,TD?>2"VK0>D;#3'(X!A!:>Z7$8AVY.+6BF<I.4O5
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MZDX)(.XH?#ZNZG-<>M$%OZZ];W[BJ_MZ(XB,X6J/LW3SF]^"@$*TMNP$SVY
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M3,]4-RPI>WTEBJYR$49B]*7%40DGHF9A.?G=M$)SY+SF".KF4KWKL+ZMOH^
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M,[ZY1O86"R]W@7K<UJ$N,X3E7"5YWL]4PF*D-*:8C#[ZFR/RW'2\:*-.*C
M+&Y[TLD2JY Z(L%G+1G7+>7#%3UDGXM0;[^R!$PE/56M&DX'@2#53YACK=D3
MIN,._ :&##Y5UTND2.@5O4JO#'XI:OY<8QN7ZUNI8-1.,P5RK=L]IFC))E),
MUUB6(;C4J&C+GE@--EIRK,1]8CR;]V)EKLN=3I0=9Y],:I>Y%^9C@+X#K/?*
M69-B?NKT4*KDQ=.88P!U.\/!4V]V#,#LR8\'XYZ['Q8C:!0"3[BE.TR!X[8\
M5ROHMCVAZG1>SV7V@VQD)G62K2=D!G98[\@RI+)_6UBAW>V&CPR.[Q(E2![J
M-F)GENI@E,25^^<]BMSO,(!*IJD%'_&QJ@AS^@^(5WKM#Q/.!36BOHS;>RWV
MLFN,;E<:U+-B5[8RUDD55S^<X.$A>I4$5<5<.L<"FH1P@Q\/@U\_<YW^Z/LA
MLX)![NEOUQ]^-\?=1#BAGRAC %LPR#FY]X6)K+<A!A!#"CG?84 'F$B/QT>@
MF?8L(:V^G^3)=*DV_FC?FZXY  -8D1O'$FJ0&</VPM_? $C@=3^G6;U0'S_Z
M=9?JR1_N4MDWKZ1-0<:Q#=>%/DS!=G[WL[)]C^&)V3ND)9J-3$/>*=7OCR9N
MQ_D#W"&L*"%H%^,B$90?K/E\"9*J6_K2JU1N;>/5I<D:MKULWM\2V4RO__V<
MOV\ LD*,-X !".@+[6HA20XJFT-X-6PR0@>^_T<F-UJ (9O+I?DVUY?M0*ZW
M9YZTO^G'U4C<"M1"CKF,F) (?G IYNE1"3. C; G ($7$8_8)TEE(\(C>JYO
M4]07:\E7CKY^P,-J:UY3]E']VN!M*K6'/5]EN#@9H[;\]9V+LY-,#*#6!4@&
MS2JDSV+JU58^#^E4'_L'*^+IK6769C61_.ITH&Q$5T!7J+>T::!)Q:9.'\\#
M'D5<SL1XL2,IXK$Z;PVY$8J@7]:;*! )J?O5*K J2)G[NV]GI2S5(@#6;V?A
MG<(6+&;^/M+QF=FV4 X$<>2/+_*X^RL$R5</+22(<B?LO&9)4,;%IS"^NERM
M?Z3/.6\0LAENT\"Z6.\UVAC4=J[B9H=^V9>@$8(#<1>>@<_52DFW=1CCI3P;
M/O*Y)04"UM;$K@TF(!A!+^%L(H2CLOU<:=F>W'0;!(N",D'47NYNVTT<E54C
M8.OZ!/0R30,L6>ZK&A('9[^HL#1 _+[[GG)MQ?Y.^3K"H.<DMM1O;>65*'?<
M?+9G -F)VV-1547@N+?4,E?_;1MQ_<VQJ8]\71Y6/!14I$J=%/*\!]&*U][8
M##8P>?G@A? VR-.^,7'WN\9OT,:>Q/WI.4=A?>;#;I9( :-9N@WGS[L>#I\1
M,U R#. ]'\SK62!#&1UX)VPUB:\:$G]ZNK-,)S!7+6F^.'TF305<["=NM4CL
M#AT3FBMX8IIGGL#H,P"JS$AQNY[33I&P86U-"+,COR<OKS%Q)729^F()]X/0
M3O1@^IC<MQWK/)\"45)!\X.B_+>3)B>R_5M&HV3O83J2%^C;J=9J^U+9"7&%
M,,_9QO'IU40O%C?-A ?KR,T@4?C <_V H- &L'2J>:&-QGJR9>5W-Q&UTQ")
M/JWHX#L9\/Q7#'9'=IQ^7>[U3T:$TFXCM4VK#@6G)3KKZATWA<G49_?5U+^K
M/P*5;<C+.]R$SNDEO+C'SZ3!XC[S@4Y!E@K%^2K0@1X_>!XYW(%F-#R[,]-E
M?;.+@-&H2+%J.ZJU_MNG+%N=9/IX<,[$)Z#[';MWCNKY[+7LL3Z;E])?N/_D
MH=K_S866O:/_C 0[/91@X[=U[<,=G^N_][C&.B+(H,9X#.#F><"/^U!9?W@?
M"OW[+?MB,/Z/5"6E&,"X.Z388DRO<7D=G+@C8S* ]3#+4K?_Z#Y4914&$ NQ
MQ0!,L$W3QZSMAO_Y'^-W&GQ( O$7$Y%)&O+D?:Y_Z/1[(%]I@%AYV,]&/3__
MY',;0W8;B5.R*XXA/PC@?OJ;7P:G8R6F)_Z$MH*!)/ZQFS]>J[Z@^&T,S=(H
MGQ'*)?<?^<8>AU2=PH9/:; I%^#,JO=Z75X$?8>8&#M1:Q+WP0Q4REP?C+EN
M?W=4#K=(^Q:UG2J#]K9OWL.J$:"]Y#35['(J<RB  2SR80&_O&Z*VI#Y^Y];
MBA?LZAA &@WXXJAY4?%$+0T#D!:>/]V M*;54;2[F3AAYQ 9]!V&'\QTB/OB
M_O$G#%*.]99GB!_WZ8%H,HC%!@9PN/SC)GXBBN/T\43DUBYDS1H#:/V1M/[\
M5LO9CSOC44'8[L.%!]=GF!1W0R&G(?/9V#!,YG>4O#Z]4OQ5Y.;?Q&1$K6/]
M4E<;!G!$[G]8S/"S@E@ZD+_3D1JH8JZ[2#O[,+^?A(2@WWWV=8;\QE[V;"SJ
M9^U^AQ+]N@')K$\_ZCL&@%3QEL$ 9/5DQ'\"2>X/08IRY@[>;8*CK=Q0;-(,
MV'Z7Q9#*\#?F+IF7<;D80']$]>6YR7[F[XC\'5R)?R :]0_F@^CN80P WCF-
MON1%:OR.S"S^2XG26@S@0^I/> +_"5O(G\76]!_8DOTY;#& _Q^X+6=C0?\[
MP87\!F[1S^!^^A/@RORKX [\"7#3?@)4\1_L;7[?S7]':#>@C&Y\!@/XWO]3
M;\W\:<#(_"\.F'_3J#^-\=^-&.*_K/J75?^RZE]6_<NJ_PVMNH=4D?R!JY*,
MN*-[M6R"_).1!9[VZU2;JL98=)KAG?,_P-$L^6!:=&O2X!V1+$FDS%/C=5:3
MPA\6XI_72%:PC #RM?K%JINIK7/>('BHJ!_G=!O9W+:I))Y%17_TDSA^0[ #
MQU?%AQB X3^!K^V50U'Z[^ME_VJD^5=O^<L'_&75OZSZ7\2JDAC DDYMCAV:
M.'FL]803SM_9*B@93<S68+ M(G/843B#YIR<UD?>\^#>60I!K:-M!CBW-KE:
M4!L0>"8&,*_0\-T@NW^/S>N%LX-O]\$WB1/(&O"$)NULZ<@G$(YV;U[5\, :
MM%\1 VC*.\2* 8W" 'QTN==/K"$\$F>96 E8+PC[40C(MZC/6!SZ*5$%O.(F
M9]@.=CI*[]Q\B-5GKX!7L8+(T.U0<?=OQ#& > 8S+.10WK/GQG^K)?F;3,^-
MHZQH:_;6HG[@FOBK&AC ?>DVK'$E30[R&OY6[1^"-=)_%W.8[V7X843>B=<0
M>!CZ^?] ? U/J23'Y>9DF1_3C,EO8N?]ID;&/ZK]6+U*,:#/,XZ\'JYV001]
MX6B+YM_$UOB;'O)_JY79EXCVE+D\EE\_,>N)1-M<]J/Z>MJ&6$O]*PM?3"A*
M#K4/=L[J$<#)4\H:N;3:'BDO^+@J7DFU"@(][*;SI/[6?2R4P#K0\!K:.7%W
MN1']0M&W']4Q,??+*_!3E30M!?7\$H/%"YF&O=7OD%\EYW,5R::A&8IC'QF,
MV[1I8JBX:$OD^Y7M[UIE('W[]X@,NWZU%:6YIT99(R>_CRJ5=$[8#W)B3@S_
M K11Q(9"YU%6][&@Q7DR;] V>O]_A9'X5]YBW1;7L0AQ_(!Z:YO#KT:-()D=
M$HBW3G&#1MJ5J:_F<DR-;_3R^H2/^K.MMM5W>5?U==V]"G/+-\W?1YKU\+Q0
M=,-VBJ1^F-PE0G&*"8W,W3;!5E+H0"^AM0/V+]/F,0# Y@\1&7Z(F&83=+$4
M]:.R^D3SC,FWB+#+#E3>#UDQ@ 4\'G/4 -:-A5\\D9DG\\E@V OU_4'G^:L?
M).5_(_8#B: ?2%C_8)>Y<QL#\-8ZX3VE/,A\B0$X0.[_  7KSZ[T)&$ @M)P
MM+GT(/%I!\,/SFEED)KF>!K*B[ S#6\9ZU,,X,L/)#YAD: Z"88T<?S*^?)7
MH7Z5[P?VS6B XYI,+W'M'^GYW(1X\A+K>G%^P(WUIGUEE<4B%USJX<8=C?>8
M$B7S^^6>05[9SA^>,L#U"4&OG7T>7D(?)(6PFW;#&W4OA)I1^V%H)/EF]V#3
M]WW.+AIK6RRHI\>,Z(D?'FQ7IB]J)T(&[;N,VNR:Q+HD^'N3TR^9VU@'<]C*
M>['P?"[*RK8GXE=#?\, IJDAJ,NNL\'+LA^N<P:2JG?!_2\,R'P2YM'N\EBX
M;OTTT'7_')>?QZ) YB!*^]/T1G073^[5&CQ&Z,?D1JP[#/K-'2J$Y4QT9WWI
MM7ZM1LS&M.E3*(?%XN\3@'&'M-H3[UGMX)/('? DUA'(_4_. \520W]-/7\%
M%']9]?\-JTK\=E*!Q32-.!0F$3)TMY*#7OGN/0XIY85;]3]3R%85[A0A2GC#
MQ?DMYNXU:NP2-;BI&"MVCT10,9F]]-'S=7NPP+W3#BCM\.NYH8MV:NWB[^[S
M!*<QG5LQ,?'<,2TY!LB>UE,WDNEI]S@EJ(?>/7GR(Y6^KG2 L'*)Q))UVQ[^
MG(TT(X+VW/C2Z-6<AL-)B *5UBW7P.E./+L.I.R/J[RG4,)!;V6GG->CL8J_
M&%YF: 0JZW%.T8"O*-HQEY1^TAPVG]Q,R"RTG9*OJ1G9VWF5;C7!6OO!7'/N
MPTM<=YEXCX[QCHLJV(B0#WNK+G504!$;GVI>2GN8*"-I63202%$&RL6\;%QF
M7XIB'A(R>+B$7__5\M$RP95(->*:[#7!RK*=I]\VJ908P]]Q@MXCV-MOH 2$
MXS(F;./LSE=1=J;E@;(,/9=K+XD&6W8FX.0*/4OQ,TUBP][L>>[&RVK-=016
MAZ_CWYMPFNK:Q=R+%E]Q.\JU?Z4.A,;:E/"V0:5_I(;I3-X+@E3X]E_^,NT[
M"-\]]'WE,YL)7K-C($(I^1N,HM2M75X^L#^B,&/M3G-WT5RH$HYH=I(Z'U([
MCYP^HQLE7TW;K^&)A+H@%BX.%\W8^G=D8&PHZ]=[["4"G4ZAW<C&I1T[46])
M0=$5<554S+?J9[/W\3/4GCQQP;DK)DE[H84S95-"K(/T]\I\L7Y234\3CU(N
MH""QY9O-M)_RA-5,ASM]]#S70K$B;JE"VG71=*."RLX^5MV2X]6@@-2G#E]=
M )#;J/4912=Y#Z'$3FYUG<^CKP7[KQO.5B7MG$14?\TK>ZNVT^%HX'\0("4^
M'-1INXL2G4+'+UQL%8M/7SVWY=%DPG&(SHQCXQ<#N&1)V'DVDG=LSI,*-@JT
MN-(S1^*'^>5M&TAH Y19PD5-7KE)HH44E9!Q'KSAW T"2[P$O1DFQD\LJV1
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MY&/'E,W-0\RQ:RHWC5C=43/.<R1O(<C;0B,:2K=,)ET9)B&3@=_FM^E-XD_
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MS;SM[, (LY29&@%7.M&>\,4\ANWCYX3+D"7I/ZO+=D:<K-0?=2O_<P_ ?O?
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MH VS=E1&Q^-*N]<K/=*#;$CG,2RP!']"T4]-2T!]32Z& 9T2W* 1@?6I>)5
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M[CBKTM:4N;3D$#]U+6ZYR9,!!LI-TMND2WON@;:?B37(8M/[3E^BG7?&)<#
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MNO/I>&BHQ7#.&HZHHF(DO/H[B,_J7G)D4)9=2=ZN2EKF K.CQ'/R[>Q3NK"
M>/AJKWNCCK?XZ://+F_[I:UMC2.U# (=U&CIKASD0NG[SB0RO!G+JVMNFT2]
M>;=T>E5-DG;;N%!%]:768>!'Y=JXPA$4HAQ5EGLSQ&OUX2URFY^W[R4#^ >
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M=E2JYNGZ_+RE7LP)\X0^;Z/N/B%6?>4@;[E2P^)@ZC)K(*HL-.>Q<19+JN"
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M@7>H(^> 7A!_J=6_?@^>D@QJNCK"6=^,;S[?J6SE@J]__[&E]]?NM]RA@'/
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M*1+! ? J[AKM2D/0SSY#^BE@.QP0E,B?L-X( _Y-%' D&8(WX3'_,3/L1S3
M.?,N_  HXDT>@P.TPBD46">H@?'^P"76M1[@\2D_)A$3-8.EL<W8O^" N<R*
M46/]":7-ZZSHS3#\(.%=_< \ W.6B%7%*CG@32T&.CDOCKT0C;T5_0-"T59U
MI<,VT*)1]''H204(Z]^- ]S$>\*_8;+L4Q/\4'5@VK#%0WAG_HP#=$$Z]T%H
MM8/K))J09BFL?K8S*Y2??3</!VAV*X#TU^$ :"K8G-8?A?.+X+[E@T9F+(^$
MHLP@UD>[>)E*V&LE]['!<+SNN;]-CG-2P\ 5 PCFBM%.\=H=?QC_HF+&6#<>
MXLZ_=3'7"0863W@H]!LT?$""][17ZT_P4[D;?DQO0YJCT8^AY">T1GC=$C'<
M4F%R>-;R9Q&PWYU4/!-UJ]Z)LILV..>%?>BF5=\J"#O]CPG=>D4)R_%[9;M<
MPXA;N50;GE"!O0B$%DMZQD]APD.C/TW98*$-I5^/JU\P_U^""7'P_!O*.ZIV
M#@8):UQ+.]]C%+>H%TXUF%^F/Q;LE8(K*= :A!0^A;7_E@$Q)AQB5G)[J(KM
MS!T9EMNVR=$^;<LM'J.(4,2KF'9SY7E!OIT<2M6@EW0680A4?I0([+R5HS5#
MCH=0A\BTQLW/W)(2G$#A<U&R/O!@WP<#(=4HA[:8"SR')SIUT<SR4703)Q3H
MD1DZ&]:=C*]9K73*"7*,-<.EBIY[$680@6] J?ABS?4S2$RVX='!(M:B4 5E
M>B_\RR=T;8DH>WZWTZ%;A!)K,B/'BTATQS<?N(.#U.1$A]!Y&@62<^N!PD:R
M5H8<(PV\I])CUE*B,^/VL$H6H'"WTK%JDR(=!:)NFP9=W>;>)+M3&IYE])72
M6CML,.=P;45GF<]SZ@O]%_9<N2IL%7ONS$'A^KO@P$"=V2LH'S\(DKJZU2:#
MH EFYKYW[Y;:0[V+V@%B"_&1RA>6(P3EH/FS9=?6=:/JD65$Z$2-$%3EOEWU
MZI7F-C)Y#OYO D1RDP<YT\DDY6ZH^:_:B!8=>@<S!;](#RI ,WG9]*12C>Y^
MN,U[!]ZLVNJ8%R%:Y(R%G6;L;&''&J3.ZR"T2[&GX9"BWN8-U6G?>V^_79>O
M]3*N*"-H4O1FP0%4T'RCH]U?O44;TY#3>FU6#+G-^V]-"YB;XK7[03Z,^__5
MM^><\JIJ0-=!^TXR,E $%A"F':8&L<F\T[+ALJ.$.5]70FLTV*!D>MC#@F7L
M]IVM5#L"93++'XIV8AB7OSP$KF[-XP"*HF Q1S1D7JMV*%N';93'H#1+/MB*
MHL;7>Q8'D/*1%DA(+%\5 =^<93;' 70'^+9$B:.E=+8MWNB9E%+KOQ0 ,%U9
M$IEA7C>=6PR>L]QV:U1Z$OMM//=N0?[WY_2!YYH+<J#@?<R]B6.60OVH>I1P
M,PO]R(LA-S^C#7C,RQ[6\5S?\T*23]DS#XHC'^ZUI5\6TTTO+.THL:IX_-:@
M==2*0+YA5HIJ[=P:HV@X_YO04'\!SRCU+!NI#\FCPW:#F[Z'CSBUZ>D(9=2'
MK2Q[<8"6)O&=Y7"2H <C)G6>QYZ'GR58ZG4(HGW!\H:J>38)T[?0M<;NKNL]
M5WQLQ-7)<L\%(O><5FC?/GV>7GM8\A[*2HGNT!O)&CAX-2#2(^8.?:8]P)F
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M^$19SZU+M56>T!06ZACI0T=R3EQ9G"[69;_T-_S-EEP?E,*4\M>/L !49OT
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M>.PTA;)7-"5:][8FW!+LRL$/ 0B?LWU0*SL[I39<[?,^2T0^PTX,PE;8K7
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MO'<N^MT;T2-D^UZ[YK>& _P8W^F< $-<5?9K7L0]@EJP+;QO!]TJPP&:;W_
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MCYNS2>33B #_^ZL13X3K/\+A3F,Z^H8/Z;,#Q6("#]A(4$_6Q7& <=V;6Q_
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M?_T$'V7I6V3]W$'Q'X=[U<PN:!.XCB?<9_B^J>O^\RG2(SI+X*NO$ YP#9\
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MJ'@5=%V]^K4Q<=%@QB]J[LMJ1O=@D._+C$=P<I0']@%Q],EQ%0XPT*6!4<@
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M[*YA7\&NZS]%:H@#2: _)0QN7"Q)7KI4Q4UKW\GBD\"_Y5<N8CP'B*_N5,M
M,C9BW2.X;4M:\ NW[WFFF*[8L +;Z?<8[FMNNM-()&1%Z;6E*WWD2L6P3?%@
M#!I'DQIBC&(F;-L)W_W42:8.>[2,D4.D0XU:R\*Z,G7[KIRV6*T^JS/1)?O8
M=DF^U#VRR')>=.<'.C#V,^9&T$@S7M>4[I85[7W%;U<E0@^8SK+A#=97<7*
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M\O?A?LQ28]6W;.9Y0 K]HQ) OEQMAV].#4[W6&^TTM!Q3\7/O3'P03+GI1M
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MF8*O))_W+1^G4E^WV?U&@&G/K=/"E'V5%$A;K=0;B8ISF4]X]93Q%K(*4?A
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M*1-]^6[FOGMYU?[^T9MEP+U&@].Y@4.=D&,4[QG:]-!V$ZB=A-O8N9><]B\
MW*(6\%#E<X KO53\*='_C?:,S95QZ9*GQV,S#OK_LO3O_^U;FP$9?\,<PHHX
MQBA6,8F#(5[ (SZ4_'[A85D2+IOQ#4<9 WM!+0&5C.T,Q'U>5;FDKA+&*5QV
M!%[2K6W-V"WJ/UD&XMUYJY4X''[=E!O%K^$R#X5 D;YCC\X!>QBW/]21+\C"
MY4A77'0W/&!'8N?"#G:9:LX!>=9GWS5RZ3%]/HZEE>Y%CFQ+W>KM_6\%>V_>
M+K?I<8;]LD&W?W0V9/435O&E8LK"GO-^FG_$*ST0RW]D_[DSZDZ)H_#_WX^
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MOB*;B^5%>9F%7EPCWHB^DR"U^.J6,WK+Z=NC[TMH[)(K2I:Y:"(.:V326_=
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M^ 04]^]3<#^E?LK]'[YN6@'$][">WI/$Q* 'W"'&P"3&N.D$T-W^3VR,?[D
M_WIAW,'$PKZ+<P\7#_^V0=4#P!T,3,P[6)C8V%A8MY]ZWWX.P"+&?OB42^SN
M(Q5C''H'$N[/T5GW&-Z6MY&JCNPSOC1Q],7%(R.GH*1ZQL3,POJ<AY>/_Y6
MH+B$I)2TC*S<>S5U#4TM;1U3LP_F%I96UD[.+JYN8'</OR_^ 8%!P2$QL7'Q
M"8E?DY*S<W+S\@L*BXJ_5U165=?4UM6W=W1V=??T]O6/CHU/3,*GIF<0R*7E
ME=6U]8U-U,'AT?')*?KL_ ^[, "8&/]V_5F[B&_MNH.%A8F%\X==&'?<_FA
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MIPZU+@S2(;G*'9=D-G.'^[,QHYC#?L;/-5LE]<%R1R0L"W, !'@'=G[U3R.
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MS#CMS3ON-SS<P:E(=.IL07"@/@_IV+4+?O,R7.(/Q^NAC[T!*)1,-P:UK,5
M%ND3^]]PE4.>BS0H77MGGMC5(2.1&8_+WY3+X=T RB=S8[MHV7%7<6J[1=?2
M//ECZ0S9(<\-GPN9FBQM2,.M;@##E9QF%^F,0DI+JABT[L.YSMTH\O )UXQ*
MVQL U&7W#B/F%Q6TLJG2+N?*O[87M>!8^Z2(A)#G8'//FT'*53,>@5M3<:&R
M1[@&^S8(86/Q8Y4W-5^H@V)%=\?.CT2CA%-VP:*7C NOUD*A@I=Q&;,^O#>
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M"?!B+=U\^+BV+ \XC1I&Z*<:X*/"K/'F^@O&?L#TQX[0/+.O=LI^LEF^X-)
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M$"(NXHHN^'4\REO=6!,4JAO;P)"=;!A@P$W%5%RM^4XR=9'U1*1JQP>XOVS
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M14]1=/Y&?1Q1\Z&J5>3I&V15;^]J0DBWJJ.;J5S;GTXO5Z@\DG46P3IE+TY
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MB-W9R"Q'5X2;TZB4!'RRCQ#*=PPQOJNH*O&5,E'KB=ZF]3I5Y-2\?E/#@V&
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MY]Y)+#F*>K(LK1M^%P#5S'MXI;X>Y*XZH@:%/[P9\DV!=417<UNB0J)T8#1
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M\A&#SU C^H-SN=-6I?67*BNDUM&9$BKV,%JNP[.7Q0OO^6LPMNYQ[:,>FF
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M<ZK0:>#H04'5_)KR2%[P9.38R@$H(.G^<%S0VXC[9VSDJ>)H>&"=#$W26X?
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M*K3PQ^^<>V^_'N>^V_><'OVZ>]7X_MI[U-AS[3F_^<VYYGZ8?U@'$*DH*"L
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M(67@;,^+5VED6OWJ.: Y#D;%$*Y_N%\[5?/(GES_2:?7RFXQ]0(87L>KX?
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M&"])3#-'+KMHWD5S[WHU [+@5Z/:;!#Q@GPY-TX.^A(E%_]OY>%(._PBJ>0
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MUAC:S.=GT#8?AO"Z0R#)GOMU>0@I>B=\F=STD]PUD7^;W=81L*>=$QE4LG9
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MZ;7)!3YGL:0.[II(+0+-"'N_5K2 _3M02P,$%     @ KET+4Z]Z3T$O!0
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MD )!%E9%0S8AQT#VQ$)A):-&#A&GB0LW'N14-@[Z()I4=)%+3,7DH>I'D-?
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M!B86Z-+,6,#4I4$0\_^_"0!02P,$%     @ KET+4^>&U_I*%   X18  "
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ML;VOOOJ_AK]]F.\4).[X U!+ P04    " "N70M3Q\[VO#<%  #:!0  (
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M<OF^DUNJFE]?AM5.#VKGYEZ\Y.A1VDP/W+(7,@S&;#I;1IPF%QBU7KY[+K5
MK=LVCEK][(N7;IQ^8J2K_*U"BJGJFY_5K:^Y=:KEI5KA42 <"$<##5F[IV(!
M*H'6#4A030')V'?>K@L7@U*OQVMFT1^S%"R+9^@[HDSNK N/-M!:_*UGZB!J
M2^RY)I S>P?1;U:[:'%)SZ8AYGW?["T-KYQ/3B8Q3I?;\Q>KX>3\6_7D\9N+
MN-<;)5WDP=&V\7L#P=4V9Y_H_S+AXW.ES]:*MI97KU.@V%[?A<#GU_".H"B[
M)E^B*ST+;>=X)*A_VAT6;G9PA*?ED!.AZ6C_GOQY.F$?<+\^V9659$[HE"Z0
MCWQ5Z;<CT]9E]&)DM%UE,UV[(CEJM^QVE_BD:@:])[RB@,5#!T@9'"U_\,[U
M?'! $\KJ7D7\GEIC[]!G"X<A^C330V=]@AT782"ID13GUGLMJB]D6&\#1\ Y
M3^R,LZZK(E*\XAI'XN_.%-[G3<$9W*J!UK(T?XQ%F'KB&S%1LTSPRP0C>U7A
MO$UHV!V/T9SQ<7/:*D(9D95F:B@?.$_KU9.)0-AK_.2],N%6G<Q93W=)U.W-
MQ"V)MA.&+)-54CC]HP4$N1KG;J5G+S%(68JNW%/S/%K0#8\UQ\OCBD[L+*GC
M>*LS,B,)'-+[>[:OS]><2ABN;&-$+(^?%%NZD.CFTMLE\&7OAU+9IQ1R)=-#
MR2+FB7MH>FVX1XGR;D]8X]$^FP"6+ X]MT.<C@_O5[MA^WVL$&"ST;RW9)UG
M3?)C!RZRW6VM.7@K- EW*LT_^)U3"DUE'6NK+"47/K,;HOJAX+1+_1ITI@JJ
M7#V0Y5W>8617H_3)OC^,$C[\DW;Z8V<&]RU+R@"(EXAOU(K6+;2+_K 76X19
MV12V0-BU=2IH[]T.",R?//=QK+UT2QO7D[^*U4EBEWNB\T](^J3  EU&S.9"
MJ;D>PGFO_4^1YL<N$2^_H&_S JW#ZN#?AU[0,,0W,,R?5TVT*U).!L.)%^;F
M([N? =+'S7)EI\>TE>J&5RI/Q)$'QE26[]8M3L%9A2'[0$/H$?8&D[&HFU3!
M4O0N D/K&GWK14,B*9.)6QOO%^S=5F<S4L-O^8W]FJ->U Q)%\/7MOGV^O<Q
MDLU75YXSQ;P?&?N1M^\[N5L2K4+\PBLO]9GCR^5E5:HMR%ZDOJ;23-1Z#=QA
MPRKG 7&N3'X(?+.$1)?N(-XF76/+G9D'V;Z@MMV J1:T!G[G5KUK-JK_8\.R
M"X=WUF6)6]3,Y%V<I(2*%'O1]3@/IE'C=4-MOO9]QZZBZSXL;=DT)8TIG^FP
M<F3[8IE(.:TZ0NWO&6DIE<)+X\'>CB74WY'81]RB]2H"_JKN=%)R>Z8D5UU1
M2CTK")DAFO?4K"+!!)G'GZEOTGWMXY)H+P;=*A%EV=]W_<KDST!1M+=;PEZ(
MH_P&ILQP1\2CG]J;]ZH,6ENOMVO<8KB4+K[72C$W);8<_DC)N1KN-Z.>Z./"
M.UH=\#SYJ?MJY)46C,^F\/BWVQ4L%8Y6B<%@B&$LQ75KBU5__%38-SWGG&@M
MIM)-X%]J-PTV4Z9FJ6_C= !^.JI=QC(D;8+E^=NV5 ?U#966S>C(S&:H ?^C
MP/LC?P!02P,$%     @ KET+4Y(=("3P!P  J0@  "    !G;6%B+3(P,C$P
M-C,P>&5X.3DQ9#@U861B,#$V+FIP9YV5>33;:QK'?TE((F((H:*Q4[$5D2XT
MC257[$5+J'*KHHI;"6*YU>G@*BU5&JU6M;6T=E(W)2B#:-5VJVTNBH:+0;5:
M+5)+8\FE9^;.'S-SSLQ\W_/]Z_F^[WD^YSGG><7#X@E SHGB2 % 8   ;1]
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M2I08!-8DY6EY(U)9B_%!QL7_K;@LB3IQ=&4?[2O9GP.+_;_(_@#[-]<0@(*
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M8ZD5/#MD%[E_V;DL,O ?#A$-_@-02P,$%     @ KET+4Y&EG*27!@  / <
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MV^YV]SQXV-O7/S X-CXQ.?5TFC?SXN7"J]=\P>+2F[7W']8WA)N_;VWON4
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M?L[7\YHK,,%9Y[A3Q330 >WQ9PHNXOT+4$L#!!0    ( *Y="U/?*R_A2 L
M  0,   @    9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C R,"YJ<&>=EG<T
MW L6QW]C,(PARNC#Z$9OHR:>%CW$"&*(D(A.H@^R0M28)R,(B5$2+;I']!+1
M1<TCPRCA:1$D1!<EF95WWNY[NV?_V-WO/=^_[CWWW,^Y?]Q+F:3, \PF!L8&
M (@* $!G 5!F #V CI860DM#!X% Z.GIH# X(XR! <;-RG8.SL>#Y.?C02 $
M1&3%!82DA1$(E*J$M+P"&HU&BJMKJBE>D%5"*_YH J*GIX<QP+@8&;D4!1&"
MBO^S*.T "QV@ 7P'@X0 *A80F 5$Z0:09W/2@'X7\(= 5&!J&EH('3V4X:R@
MCAF@ H'!5-1@&AIJZK-L^%D>H&:A8154T*%EP]R "/G!%>\GY]()ZU9WL%N.
M;HDHW?2/HH=R<')Q\XB*B:,D)-'**JIJZAIZ%_4-#(V,3:Y86=M<M<7:.=]R
M<75S]_ ," P*QH6$AD7'Q,;%/TC IZ0^3DM_\C2#F)=?4/BBJ+BD]&5-;5U]
M0V-3<V=7=T]OWYO^@;%WI/$)\N34],+BTO*'E8^K:^O;.[M[^P>'7X^.?W"!
M ##H'_J/7"QG7%34U&!JR \N$!7N1P$+-8V@ BVK#@9RPX]-2/$^'5PW.;>Z
M@UY8R7*+_:;_*)1#!+T@NOT#[7>R_PXLZO\B^R?8GUS3  P,.EL>F 70 @Z/
M4<4K1#4A#Y>@BYAT5S6J2)&"<N,+VJXWB0Z/R173.COZ%""<_W7DAO5RIEW*
M)@-VGU>*^R/3J#[<P,"I<797%=E]WMJ_+:]I= 7?Y<-[Q;GQ:]P64I\@K[7'
M4^B,*[4+:0I,D(NH%? *SKGJ'E77(( 2#3E/".G3,91[>FV].*_4,'BXQ,Q]
M5#%&/^B>;_O'G[H*C08#,?H _ ^+<N<K1TN95GHJSNA+]179M?4[,,%VF$J>
M;1*^%Q%(HGZ\I+JW(:)SE^EL!P4#5B#)JCG!Z,2K%(!/J)G'!SOICBJ6D[4<
M&;F;H6;D[,&[2FNFTKLA5RZSN?2&$))N#:GDHM+*%I >)<8M+DK9BN2XT<,]
ML4\/V']>*!L<-C S7U]]*='$T@5:8Z6VU)HWQ/VTMU'8$_ \#R\!0^7A@;]Z
MA%0G5J.@<X?AFL.0'\(Y4A.;Y"39RJ-DIM8\+G9BU?[A2H'?-\[7)-)NSX$/
M]DZZ4*=M-VN55B"525:82Z:671NA\O[CJ'.Z$G.#.M#2XEPK *)-XX\CRYMM
MLYEB;SW4K\C:*>, \^)+3G<I (&X=L<I97W,2#@CUXU+47P.?&'IUZ57OELA
M7N83%_S*N1>'.# SW>P!<:*F\N+?C[Y)KLW8] @7-8X7-&67[SUFNZ06^O:X
M,6 ]XL$)M*[0PW?-5U$8G6HTLT(TMS/H$R$K%]LV1"WSM#UI]# 9:*C7_F!M
M#!YV].L-KW%PF/VL8L,Z9]+5GP"+(2Q-ISH.:%D.\WW*WGI(:N#G^TYZ]71E
M$RMKOKO36S"/.@#.C=0*DM%'/F)-7K$$-7OOV!&5%##LFU7TGK*LS'DJUVSV
M9]^JBRB 6X0[0\&)K-&N$BDZ,=R?KD<VK=3^$X>C9_T<V]U>O<HQ:!8BJ3/M
MZ:9C7O7E!TX:+[$&B1;#R]P)()S/3>W]#HNBV<@*(D\5@SZ\+UE8=[/#.E3:
M''@.FXVPT+B=C'[C)\68S*P4I[G]63$"NORY,BC<9A0]S&KDO9&OFS+<,"1Y
MSG^6(<>X3V^N_G6=M]RI%?LO%4,JO@M6;^1WC-?V,!0@R>;P6.9AM59S%/NQ
M)'[LM'2"E#W$R'2\:S[NO#67"V-X21ZJ)8)B0TBQTU>K@8H@]D'W;=.RKWF?
MNED%"6-J9MF/A#,X@U=25XV N]!U3Y?&T=1%MYU6F;(WH5,N2A%+<9GYQGSQ
M,8%'XC[),Y,&(WU5MKV7UZYX';R\_O6N95TLSE2YH#KON%H7^.85-1YT5.<#
M,=M:R:1>7%RA2U_(,-FP*&M2/Q2\O&1-M^LNME%2M]"0Z9#^R;99[D!"9)=#
M=54W$=7W?/DD15,JH(O^(90W^K!R:O/MMSK_I1T89,&,)$,VV?)YSS$O-_4Y
M2U9M67"E?"WNO..YJ>KSSOAQ^K=.S!C5< L9NGV^L'?F+?CQPWZEQ]+%2M78
M3MJ?9AZPOQAB,54 0"G&:]=Q^1>.>TM>]$OHR>9*C%?J>-=:B(U2.\^(VG\B
MXKJUF&5&DNX6>EBVO&^O$'W7.VEK >Y"'B3T2I1>]42I-^<D&.>$KZ>-E+FY
M@(T#- QLY-"Y6BJ:\1$FRY:FO=LV"7[2OQQ\:BI,L7<ZLK_KQPTM"/[H00'"
M\N2]<>>GM76X(<K)%9X5S@=>ID%8N2]<A:T^[^ZG.W^&:*6)18>0%1QTWQFB
MZC,'KB;E\NI\+[@';W*HY)SH'384J>[,_!"DSS<Y;\-. ? "<>L./W6*MY)L
M,)PIK8!)7+]F)"3UJY5-&R+G^')=2%1$G9&QE'>K/K]?^WZOQ@GQ;_7CL?UN
MV^E)B&&XXF#@NF_GM+#8.9*??3"9(<@'L5I9NB3HX&M(NB+C75&>QV(WTP=E
MNL_)[@S/;@8:"ZRA\L]!JQ+N!0I2O%W3MXZ#*I:N)1_\W-)?B82HP28QSPYU
M)\9%.<?: VPTLL+:TLHF/8<1BAW2!S51OBK(YO<'J"YBQ];).K_HUL.L>UB.
M^N %G8BCL P05&N6FBK<Z*#RB>,8.IIQI";4&5XS8U_SQ7L'S@KB[CCU),=+
M\U[:6LEV7:LWJAB]%J:B^%N)<I$BIEEL^NEU9/4K4J"/QMCF[$9@BY?MHKL(
MU]UXB]:&O*V0]7N/B9?CIY>Z[=KR(]@8K%ONU-AKG);KEF8H_+89^?IAL)7E
MQS!"'^\"'W1YJB^\K-OZM-\U;K2/!9VB]$3XY'VD)G!8I!<0E!=RQ9IY>NAP
MVQ2G^GXAHR#8YJU?'&2KLA./V-SL[,NP=R>_6TT_U AD^FB>HKX02OLN9.#D
M&; ;O8O(,>59%]KNQ6_3>K@2S+?1T@CDI9O-=F;YZNUOON@]4YE/PVO<?GZ<
M4MLYX2ZP-*@D.Q$1_DK[>(+S <:Y+?V+;4/C,Y/[8(%H44-(:+*A.->Q$QEK
M>UTX=I_%K4#V(LY_,ROI:/&I*S()O%W(6:Q)P!GCU=$QMA=DW7+F:T?&NJOS
ME!#S;"- ^])8@0.4 IAF?%&VX3SVK(YX>1$;VQ:6A6P#P/N++57R&AA\$6:/
M4P)N>?%@=)">D4W@%DI-BJ#PU8KG>CY3Q0O[WV9N[\AR#B56=4B&(;L#K@(@
M7PA_&H)9WX=*A]H#892+879"[5'5H!Z1E>\4SIDM#0Z;?U"9UKF#4'F]D9K2
MMR62-#C6[&GB45?5(.D9O($K=)@1GR-R)H:;)&.)LL..'395\2Z[WC%,$0F\
MMR>0%CH52V-5SC4MHW7G,\H75#DXO5U"6"+="[5"GVA:-R=/GECD1 :D1\"^
M#WI!*ZLU'%!2HMW.L/X=(#\G4N!TW8L"Q*-\B&03DDAM?>;/C_U:!]36PW(,
M(M@<!E3V&6L3"3'^$OOWIG&O>@8(E[X*,>I^GO-Z8NDX"ZH7PWPHUU/GU3[\
M2#0ZY5;.)J5Z-,\.5SVZT6#P4H$"W.?WVW PS$;FW)AK<[+H41K1<-LK\0PO
MJ.=+[ID-X5DYN=+0VK)-\[[-#GV+&AK,E@+B4_KT6<KZ CK]-@68POE/&4J6
MOGD ZL=$&H3Q9^SWW!G5RR)68;EY5.,WT*[-(:;],D,OL"*//K1E[%$ 'G(>
M/GT&YY06A4<]OZ$/MP"=F=;\E>OQPW(.P0 86>'H>XY=]C*R\M?76Y+C<%QA
MWK=_.?\2A?!'W3!"_%CVG]_+7VVCHM*'<=#N?.UEFR@EYQL3)W54K!6+_;<G
M@C+U=U!+ P04    " "N70M3]Q5?#-L'  "*"   (    &=M86(M,C R,3 V
M,S!X97@Y.3%D.#5A9&(P,C$N:G!GG91Y--1['\=_LYEAQK6$AIB8,8BZB6D8
MKES)($_,1+:*&)4EQ#!9DBPA6UE&BZV&K!&:889N)6(DA*ELV2)E2;A(RCST
M;/\\YSS+^WO>?WW>YW,^K_,]YRWL$XX"DH?)EF0 ! 8 T.8#A(. *8 0$8&+
MP!!P.%Q4%"&&DA%'(9$H>>EM$C)*"CLQ2@J*BLJJOZHK8W?C%!4U]';MUMY'
M(!!VJI.,]'5^^U67H+.U!"0J*HI"HM#BXF@=%445G?]9PJ> % +0!+Y 0%@
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M_<^&"_O_"E!+ 0(4 Q0    ( *Y="U-,9M-(;Q(  #S1   1
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M2P$"% ,4    " "N70M35P%G',)* 0#9:1( '0              @ %?]@
M9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8BYH=&U02P$"% ,4    " "N70M3
M0TE79W0,   U#0  (               @ %<00( 9VUA8BTR,#(Q,#8S,'AE
M>#DY,60X-6%D8C P,BYJ<&=02P$"% ,4    " "N70M3:CRBF>X! @#*Z (
M(               @ $.3@( 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C P
M-"YJ<&=02P$"% ,4    " "N70M3H^>ZC3*M 0"U.P( (
M@ $Z4 0 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C P-2YJ<&=02P$"% ,4
M    " "N70M3RR]YS,5H 0#/*@( (               @ &J_04 9VUA8BTR
M,#(Q,#8S,'AE>#DY,60X-6%D8C P-BYJ<&=02P$"% ,4    " "N70M324K9
M/ ^#   7_P  (               @ &M9@< 9VUA8BTR,#(Q,#8S,'AE>#DY
M,60X-6%D8C P."YJ<&=02P$"% ,4    " "N70M3KA,@)HHX  !9/P  (
M            @ 'ZZ0< 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C P.2YJ
M<&=02P$"% ,4    " "N70M3-/&C0[D%  "%!@  (               @ '"
M(@@ 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C Q,"YJ<&=02P$"% ,4
M" "N70M3KWI/02\%  #]!0  (               @ &Y* @ 9VUA8BTR,#(Q
M,#8S,'AE>#DY,60X-6%D8C Q,2YJ<&=02P$"% ,4    " "N70M3YX;7^DH4
M  #A%@  (               @ $F+@@ 9VUA8BTR,#(Q,#8S,'AE>#DY,60X
M-6%D8C Q,BYJ<&=02P$"% ,4    " "N70M3Q(5.\_$%  "4!@  (
M        @ &N0@@ 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C Q,RYJ<&=0
M2P$"% ,4    " "N70M3Q\[VO#<%  #:!0  (               @ '=2 @
M9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C Q-"YJ<&=02P$"% ,4    " "N
M70M31,>^*D0'  #C!P  (               @ %23@@ 9VUA8BTR,#(Q,#8S
M,'AE>#DY,60X-6%D8C Q-2YJ<&=02P$"% ,4    " "N70M3DAT@)/ '  "I
M"   (               @ '450@ 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D
M8C Q-BYJ<&=02P$"% ,4    " "N70M32EM"7!L'  "Z!P  (
M    @ $"7@@ 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C Q-RYJ<&=02P$"
M% ,4    " "N70M3D:6<I)<&   \!P  (               @ %;90@ 9VUA
M8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C Q."YJ<&=02P$"% ,4    " "N70M3
M_:^P^5L'   6"   (               @ $P; @ 9VUA8BTR,#(Q,#8S,'AE
M>#DY,60X-6%D8C Q.2YJ<&=02P$"% ,4    " "N70M3WRLOX4@+   $#
M(               @ ')<P@ 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C R
M,"YJ<&=02P$"% ,4    " "N70M3]Q5?#-L'  "*"   (
M@ %/?P@ 9VUA8BTR,#(Q,#8S,'AE>#DY,60X-6%D8C R,2YJ<&=02P4&
/ !D &0!4!P  :(<(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
